FRANCHISE DISCLOSURE DOCUMENT

AmerisourceBergen Drug Corporation
A Delaware Corporation
1 West First Avenue, Conshohocken, PA, 19428
(610) 727-7000
www.AmerisourceBergen.com

The franchise offered ("GNP Premier Program") is for one or more retail outlets properly licensed as a retail pharmacy offering prescription services, over-the-counter health and beauty aids, and complementary services under the trade name of **Good Neighbor Pharmacy®** ("GNP Premier Pharmacy"). This offering is being made to pharmacies operating under a distribution agreement with us that sign a GNP Premier Agreement (Exhibit B).

The total investment necessary for an existing pharmacy to begin operating a GNP Premier Pharmacy franchise, depending on your pharmacy's existing fit-out, equipment and inventory, ranges from $43,797 to $556,405, which includes between $1,797 to $279,497 which must be paid to us or our affiliates.

For a start-up pharmacy, the total investment necessary to begin operating a GNP Premier Pharmacy franchise ranges from $278,797 to $575,205, which includes between $81,797 to $165,297 which must be paid to us or our affiliates.

This Disclosure Document is required by law and summarizes certain provisions of your GNP Premier Agreement and other information in plain English. Read this Disclosure Document and all accompanying agreements carefully. You must receive this Disclosure Document at least 14 calendar days before you sign a binding agreement with, or make any payment to, the franchisor or an affiliate in connection with the proposed franchise sale. **Note, however, that no governmental agency has verified the information contained in this document.**

You may wish to receive your Disclosure Document in another format that is more convenient for you. To discuss the availability of disclosures in different formats, contact your account representative or the Good Neighbor Pharmacy program at 1 West First Avenue, Conshohocken, PA, 19428. You can also e-mail programs@amerisourcebergen.com.

The terms of **your franchise agreement with us** (the "**GNP Premier Agreement**") will govern our franchise relationship. Do not rely on the Disclosure Document alone to understand your contract. Read your entire contract carefully. Show your contract and this Disclosure Document to an advisor, like a lawyer or an accountant.

Buying a franchise is a complex investment. The information in this Disclosure Document can help you make up your mind. More information on franchising, such as "A Consumer's Guide to Buying a Franchise," which can help you understand how to use this Disclosure Document, is available from the Federal Trade Commission. You can contact the FTC at 1-877-FTC-HELP or by writing to the FTC at 600 Pennsylvania Avenue, NW, Washington, D.C. 20580. You can also visit the FTC's home page at www.ftc.gov for additional information. Call your state agency or visit your public library for other sources of information on franchising.

There may also be laws on franchising in your state. Ask your state agencies about them.

Date of Issuance: December ~~19, 2024~~18, 2025

How to Use This Franchise Disclosure Document

Here are some questions you may be asking about buying a franchise and tips on how to find more information:

QUESTION	WHERE TO FIND INFORMATION
How much can I earn?	Item 19 may give you information about outlet sales, costs, profits or losses. You should also try to obtain this information from others, like current and former franchisees. You can find their names and contact information in Item 20 or Exhibit D.
How much will I need to invest?	Items 5 and 6 list fees you will be paying to the franchisor or at the franchisor's direction. Item 7 lists the initial investment to open. Item 8 describes the suppliers you must use.
Does the franchisor have the financial ability to provide support to my business?	Item 21 or Exhibit E includes financial statements. Review these statements carefully.
Is the franchise system stable, growing, or shrinking?	Item 20 summarizes the recent history of the number of company-owned and franchised outlets.
Will my business be the only Good Neighbor Pharmacy business in my area?	Item 12 and the "territory" provisions in the franchise agreement describe whether the franchisor and other franchisees can compete with you.
Does the franchise have a troubled legal history?	Items 3 and 4 tell you whether the franchisor or its management have been involved in material litigation or bankruptcy proceedings.
What's it like to be a Good Neighbor Pharmacy franchisee?	Item 20 or Exhibit D lists current and former franchisees. You can contact them to ask about their experiences.
What else should I know?	These questions are only a few things you should look for. Review all 23 Items and all Exhibits in this disclosure document to better understand this franchise opportunity. See the table of contents.

What You Need To Know About Franchising *Generally*

Continuing responsibility to pay fees. You may have to pay royalties and other fees even if you are losing money.

Business model can change. The franchise agreement may allow the franchisor to change its manuals and business model without your consent. These changes may require you to make additional investments in your franchise business or may harm your franchise business.

Supplier restrictions. You may have to buy or lease items from the franchisor or a limited group of suppliers the franchisor designates. These items may be more expensive than similar items you could buy on your own.

Operating restrictions. The franchise agreement may prohibit you from operating a similar business during the term of the franchise. There are usually other restrictions. Some examples may include controlling your location, your access to customers, what you sell, how you market, and your hours of operation.

Competition from franchisor. Even if the franchise agreement grants you a territory, the franchisor may have the right to compete with you in your territory.

Renewal. Your franchise agreement may not permit you to renew. Even if it does, you may have to sign a new agreement with different terms and conditions in order to continue to operate your franchise business.

When your franchise ends. The franchise agreement may prohibit you from operating a similar business after your franchise ends even if you still have obligations to your landlord or other creditors.

Some States Require Registration

Your state may have a franchise law, or other law, that requires franchisors to register before offering or selling franchises in the state. Registration does not mean that the state recommends that franchise or has verified the information in this document. To find out if your state has a registration requirement, or to contact your state, use the agency information in Exhibit A.

Your state also may have laws that require special disclosures or amendments be made to your franchise agreement. If so, you should check the State Specific Addenda. See the Table of Contents for the location of the State Specific Addenda.

Special Risks to Consider About *This* Franchise

Certain states require that the following risk(s) be highlighted:

1. **Out-of-State Dispute Resolution**. The franchise agreement requires you to resolve disputes with the franchisor by mediation, arbitration, or litigation only in Pennsylvania. Out-of-state mediation, arbitration, or litigation may force you to accept a less favorable settlement for disputes. It may also cost more to mediate, arbitrate, or litigate with franchisor in Pennsylvania than in your own state.

   ~~———~~Certain states may require other risks to be highlighted. Check the "State Specific Addenda" (if any) to see whether your state requires other risks to be highlighted.

AmerisourceBergen

GOOD NEIGHBOR PHARMACY

ADDENDUM TO AMERISOURCEBERGEN DRUG CORPORATION
DISCLOSURE DOCUMENT
FOR THE STATE OF MICHIGAN

THE STATE OF MICHIGAN PROHIBITS CERTAIN UNFAIR PROVISIONS THAT ARE SOMETIMES IN FRANCHISE DOCUMENTS. IF ANY OF THE FOLLOWING PROVISIONS ARE IN THESE FRANCHISE DOCUMENTS, THE PROVISIONS ARE VOID AND CANNOT BE ENFORCED AGAINST YOU:

(A) A PROHIBITION ON THE RIGHT OF A FRANCHISEE TO JOIN AN ASSOCIATION OF FRANCHISEES.

(B) A REQUIREMENT THAT A FRANCHISEE ASSENT TO A RELEASE, ASSIGNMENT, NOVATION, WAIVER, OR ESTOPPEL WHICH DEPRIVES A FRANCHISEE OF RIGHTS AND PROTECTIONS PROVIDED IN THIS ACT. THIS SHALL NOT PRECLUDE A FRANCHISEE, AFTER ENTERING INTO A FRANCHISE AGREEMENT, FROM SETTLING ANY AND ALL CLAIMS.

(C) A PROVISION THAT PERMITS A FRANCHISOR TO TERMINATE A FRANCHISE PRIOR TO THE EXPIRATION OF ITS TERM EXCEPT FOR GOOD CAUSE. GOOD CAUSE SHALL INCLUDE THE FAILURE OF THE FRANCHISEE TO COMPLY WITH ANY LAWFUL PROVISION OF THE FRANCHISE AGREEMENT AND TO CURE SUCH FAILURE AFTER BEING GIVEN WRITTEN NOTICE THEREOF AND A REASONABLE OPPORTUNITY, WHICH IN NO EVENT NEED BE MORE THAN 30 DAYS, TO CURE SUCH FAILURE.

(D) A PROVISION THAT PERMITS A FRANCHISOR TO REFUSE TO RENEW A FRANCHISE WITHOUT FAIRLY COMPENSATING THE FRANCHISEE BY REPURCHASE OR OTHER MEANS FOR THE FAIR MARKET VALUE AT THE TIME OF EXPIRATION, OF THE FRANCHISEE'S INVENTORY, SUPPLIES, EQUIPMENT, FIXTURES, AND FURNISHINGS. PERSONALIZED MATERIALS WHICH HAVE NO VALUE TO THE FRANCHISOR AND INVENTORY, SUPPLIES, EQUIPMENT, FIXTURES, AND FURNISHINGS NOT REASONABLY REQUIRED IN THE CONDUCT OF THE FRANCHISE BUSINESS ARE NOT SUBJECT TO COMPENSATION. THIS SUBSECTION APPLIES ONLY IF: (i) THE TERM OF THE FRANCHISE IS LESS THAN 5 YEARS; AND (ii) THE FRANCHISEE IS PROHIBITED BY THE FRANCHISE OR OTHER AGREEMENT FROM CONTINUING TO CONDUCT SUBSTANTIALLY THE SAME BUSINESS UNDER ANOTHER TRADEMARK, SERVICE MARK, TRADE NAME, LOGOTYPE, ADVERTISING, OR OTHER COMMERCIAL SYMBOL IN THE SAME AREA SUBSEQUENT TO THE EXPIRATION OF THE FRANCHISE OR THE FRANCHISEE DOES NOT RECEIVE AT LEAST 6 MONTHS ADVANCE NOTICE OF FRANCHISOR'S INTENT NOT TO RENEW THE FRANCHISE.

(E) A PROVISION THAT PERMITS THE FRANCHISOR TO REFUSE TO RENEW A FRANCHISE ON TERMS GENERALLY AVAILABLE TO OTHER FRANCHISEES OF THE SAME CLASS OR TYPE UNDER SIMILAR CIRCUMSTANCES. THIS SECTION DOES NOT REQUIRE A RENEWAL PROVISION.

(F) A PROVISION REQUIRING THAT ARBITRATION OR LITIGATION BE CONDUCTED OUTSIDE THIS STATE. THIS SHALL NOT PRECLUDE THE FRANCHISEE

FROM ENTERING INTO AN AGREEMENT, AT THE TIME OF ARBITRATION, TO CONDUCT ARBITRATION AT A LOCATION OUTSIDE THIS STATE.

(G) A PROVISION WHICH PERMITS A FRANCHISOR TO REFUSE TO PERMIT A TRANSFER OF OWNERSHIP OF A FRANCHISE, EXCEPT FOR GOOD CAUSE. THIS SUBDIVISION DOES NOT PREVENT A FRANCHISOR FROM EXERCISING A RIGHT OF FIRST REFUSAL TO PURCHASE THE FRANCHISE. GOOD CAUSE SHALL INCLUDE, BUT IS NOT LIMITED TO:

(i) THE FAILURE OF THE PROPOSED TRANSFEREE TO MEET THE FRANCHISOR'S THEN CURRENT REASONABLE QUALIFICATIONS OR STANDARDS.

(ii) THE FACT THAT THE PROPOSED TRANSFEREE IS A COMPETITOR OF THE FRANCHISOR OR SUBFRANCHISOR.

(iii) THE UNWILLINGNESS OF THE PROPOSED TRANSFEREE TO AGREE IN WRITING TO COMPLY WITH ALL LAWFUL OBLIGATIONS.

(iv) THE FAILURE OF THE FRANCHISEE OR PROPOSED TRANSFEREE TO PAY ANY SUMS OWING TO THE FRANCHISOR OR TO CURE ANY DEFAULT IN THE FRANCHISE AGREEMENT EXISTING AT THE TIME OF THE PROPOSED TRANSFER.

(H) A PROVISION THAT REQUIRES THE FRANCHISEE TO RESELL TO THE FRANCHISOR ITEMS THAT ARE NOT UNIQUELY IDENTIFIED WITH THE FRANCHISOR. THIS SUBDIVISION DOES NOT PROHIBIT A PROVISION THAT GRANTS TO A FRANCHISOR A RIGHT OF FIRST REFUSAL TO PURCHASE THE ASSETS OF A FRANCHISE ON THE SAME TERMS AND CONDITIONS AS A BONA FIDE THIRD PARTY WILLING AND ABLE TO PURCHASE THOSE ASSETS, NOR DOES THIS SUBDIVISION PROHIBIT A PROVISION THAT GRANTS THE FRANCHISOR THE RIGHT TO ACQUIRE THE ASSETS OF A FRANCHISE FOR THE MARKET OR APPRAISED VALUE OF SUCH ASSETS IF THE FRANCHISEE HAS BREACHED THE LAWFUL PROVISIONS OF THE FRANCHISE AGREEMENT AND HAS FAILED TO CURE THE BREACH IN THE MANNER PROVIDED IN SUBDIVISION (C).

(I) A PROVISION WHICH PERMITS THE FRANCHISOR TO DIRECTLY OR INDIRECTLY CONVEY, ASSIGN, OR OTHERWISE TRANSFER ITS OBLIGATIONS TO FULFILL CONTRACTUAL OBLIGATIONS TO THE FRANCHISEE UNLESS PROVISION HAS BEEN MADE FOR PROVIDING THE REQUIRED CONTRACTUAL SERVICES.

THE FACT THAT THERE IS A NOTICE OF THIS OFFERING ON FILE WITH THE ATTORNEY GENERAL DOES NOT CONSTITUTE APPROVAL, RECOMMENDATION, OR ENDORSEMENT BY THE ATTORNEY GENERAL.

ANY QUESTIONS REGARDING THIS NOTICE SHOULD BE ADDRESSED TO:
DEPARTMENT OF ATTORNEY GENERAL
CONSUMER PROTECTION DIVISION
~~670 LAW BUILDING,~~ G. Mennen Williams Building, 5th Floor
525 W. ~~OTTAWA STREET~~Ottawa Street
LANSING, MICHIGAN 48913
Telephone (517) 373-7117

AmerisourceBergen

GOOD NEIGHBOR PHARMACY

TABLE OF CONTENTS

Page

~~ITEM 1 THE FRANCHISOR AND ANY PARENTS, PREDECESSORS, AND AFFILIATES.....2~~

~~ITEM 2 BUSINESS EXPERIENCE.....10~~

~~ITEM 3 LITIGATION.....11~~

~~ITEM 4 BANKRUPTCY.....14~~

~~ITEM 5 INITIAL FEES.....14~~

~~ITEM 6 OTHER FEES.....16~~

~~ITEM 7 ESTIMATED INITIAL INVESTMENT.....19~~

~~ITEM 8 RESTRICTIONS ON SOURCES OF PRODUCTS AND SERVICES.....23~~

~~ITEM 9 FRANCHISEE'S OBLIGATIONS.....28~~

~~ITEM 10 FINANCING.....30~~

~~ITEM 11 FRANCHISOR'S ASSISTANCE, ADVERTISING, COMPUTER SYSTEMS AND TRAINING.....30~~

~~ITEM 12 TERRITORY.....34~~

~~ITEM 13 TRADEMARKS.....35~~

~~ITEM 14 PATENTS, COPYRIGHTS AND PROPRIETARY INFORMATION.....36~~

~~ITEM 15 OBLIGATION TO PARTICIPATE IN THE ACTUAL OPERATION OF THE FRANCHISE BUSINESS.....37~~

~~ITEM 16 RESTRICTIONS ON WHAT THE FRANCHISEE MAY SELL.....38~~

~~ITEM 17 RENEWAL, TERMINATION, TRANSFER AND DISPUTE RESOLUTION.....39~~

~~ITEM 18 PUBLIC FIGURES.....44~~

~~ITEM 19 FINANCIAL PERFORMANCE REPRESENTATIONS.....44~~

~~ITEM 20 OUTLETS AND FRANCHISEE INFORMATION.....47~~

~~ITEM 21 FINANCIAL STATEMENTS.....64~~

~~ITEM 22 CONTRACTS.....65~~

~~ITEM 23 RECEIPTS.....65~~

~~EXHIBIT A STATE ADMINISTRATORS AND AGENTS FOR SERVICE OF PROCESS~~

~~EXHIBIT B GNP PREMIER AGREEMENT~~

~~EXHIBIT C TABLE OF CONTENTS OF GNP MANUAL(S)~~

~~EXHIBIT D LIST OF CURRENT, TRANSFERRED & FORMER FRANCHISEES AS OF SEPTEMBER 30, 2024~~

~~EXHIBIT E FINANCIAL STATEMENTS AND CENCORA GUARANTY~~

~~EXHIBIT F STATE SPECIFIC ADDENDA TO AMERISOURCEBERGEN DRUG CORPORATION DISCLOSURE DOCUMENT~~

ITEM 1 THE FRANCHISOR AND ANY PARENTS, PREDECESSORS, AND AFFILIATES.....2

ITEM 2 BUSINESS EXPERIENCE.....11

ITEM 3 LITIGATION 12
ITEM 4 BANKRUPTCY 16
ITEM 5 INITIAL FEES 16
ITEM 6 OTHER FEES 18
ITEM 7 ESTIMATED INITIAL INVESTMENT 22
ITEM 8 RESTRICTIONS ON SOURCES OF PRODUCTS AND SERVICES 26
ITEM 9 FRANCHISEE'S OBLIGATIONS 31
ITEM 10 FINANCING 33
ITEM 11 FRANCHISOR'S ASSISTANCE, ADVERTISING, COMPUTER SYSTEMS AND TRAINING 33
ITEM 12 TERRITORY 37
ITEM 13 TRADEMARKS 38
ITEM 14 PATENTS, COPYRIGHTS AND PROPRIETARY INFORMATION 39
ITEM 15 OBLIGATION TO PARTICIPATE IN THE ACTUAL OPERATION OF THE FRANCHISE BUSINESS 40
ITEM 16 RESTRICTIONS ON WHAT THE FRANCHISEE MAY SELL 41
ITEM 17 RENEWAL, TERMINATION, TRANSFER AND DISPUTE RESOLUTION 42
ITEM 18 PUBLIC FIGURES 47
ITEM 19 FINANCIAL PERFORMANCE REPRESENTATIONS 47
ITEM 20 OUTLETS AND FRANCHISEE INFORMATION 51
ITEM 21 FINANCIAL STATEMENTS 73
ITEM 22 CONTRACTS 73
ITEM 23 RECEIPTS 74
EXHIBIT A STATE ADMINISTRATORS AND AGENTS FOR SERVICE OF PROCESS
EXHIBIT B GNP PREMIER AGREEMENT
EXHIBIT C TABLE OF CONTENTS OF GNP MANUAL(S)
EXHIBIT D LIST OF CURRENT, TRANSFERRED & FORMER FRANCHISEES AS OF SEPTEMBER 30, 2025
EXHIBIT E FINANCIAL STATEMENTS AND CENCORA GUARANTY
EXHIBIT F STATE SPECIFIC ADDENDA TO AMERISOURCEBERGEN DRUG CORPORATION DISCLOSURE DOCUMENT

ITEM 1
THE FRANCHISOR AND ANY PARENTS, PREDECESSORS, AND AFFILIATES

The Franchisor is AmerisourceBergen Drug Corporation. To simplify this Disclosure Document, AmerisourceBergen Drug Corporation is referred to as “ABDC”, “we”, “us” or “our”. “You” means the person or legal entity who buys the franchise, the franchisee (called a “Customer” in the agreements). If you are a corporation, limited liability company, partnership or any other type of legal entity, certain

provisions of the GNP Premier Agreement (defined below) also will apply to, and be binding upon, certain of your owners (referred to as your "Principals").

AmerisourceBergen Drug Corporation

We are a Delaware corporation, formed on June 24, 1985. We do business only under our corporate name, ~~including~~ "**AmerisourceBergen Drug Corporation**~~", "AmerisourceBergen~~", and the names "**Good Neighbor Pharmacy**" and "**Elevate Provider Network**." Our principal business address is 1 West First Avenue, Conshohocken, PA, 19428. Our agents for service of process are listed in Exhibit A. We have offered franchises since 2009. We have not conducted business nor offered franchises in any other line of business.

Our parent company is Cencora, Inc. ("Cencora"). Cencora is a Delaware corporation, formed on March 16, 2001 as AmerisourceBergen Corporation (and changed its name to Cencora, Inc. on August 30, 2023) in contemplation of the August 2001 merger of AmeriSource Health Corporation ("AHC") and Bergen Brunswig Corporation ("BBC"). In August 2001, AHC and BBC became subsidiaries of Cencora. AHC and BBC continued as subsidiaries of ~~AB~~Cencora until October 2002, at which time BBC was merged with and into AHC. AHC was the survivor and was renamed AmerisourceBergen Services Corporation ("ABSC"). ABSC survives today as a subsidiary of Cencora.

Cencora is one of the largest global pharmaceutical sourcing and distribution services companies, helping healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain. More specifically, we distribute a comprehensive offering of brand-name and generic pharmaceuticals (including specialty pharmaceutical products), over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers located in the United States and select global markets, including retail chain and independent pharmacies, mail order pharmacies, acute care hospitals and health systems, physician practices, medical and dialysis clinics, long-term care and other alternate site pharmacies, and other customers. We also provide pharmacy services to certain specialty drug patients. Additionally, we furnish healthcare providers and pharmaceutical manufacturers with an assortment of related services, including reimbursement and pharmaceutical consulting services, niche premium logistics services, claim management services, and pharmacy management, along with retail strategies and front-end management, marketing and advertising services, digital media tools, and educational opportunities.

Our Predecessor and Affiliates

We acquired a substantial portion of our assets from Bergen Brunswig Drug Company ("BBDC"), which merged with and into AmeriSource Corporation ("ASC") in October 2002. ASC was the survivor, under the name AmerisourceBergen Drug Corporation (us), and we acquired BBDC's assets pursuant to the merger. In Puerto Rico, we operate through our wholly owned subsidiary, J.M. Blanco, Inc. ("Blanco"), a Delaware corporation, which maintains the same principal business address as us. In 2012, we acquired World Courier Group, Inc., which operates in over 50 countries and is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. In February 2015, we acquired MWI Veterinary Supply, Inc. ("MWI"), a leading animal health distribution company in the United States and in the United Kingdom. MWI sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. MWI also offers its customers a variety of value-added services, including its e-commerce platform, technology management systems, pharmacy fulfillment, inventory management system, equipment procurement consultation, special order fulfillment, and educational seminars. In June 2021, we acquired a majority of the Alliance Healthcare business from Walgreens Boots Alliance. Alliance Healthcare is one of the largest pharmaceutical wholesalers primarily in Europe and also

operates retail pharmacies and provides manufacturer services in certain of its countries of operation. In January 2023, we acquired PharmaLex Holding GmbH, a leading provider of specialized services for the life sciences industry. In January 2025, we acquired Retina Consultants of America, a leading management services organization of retina specialists.

Although ~~Customers~~customers may, from time to time, choose to do business with our affiliates, other than Blanco, such business would not be connected with the GNP Premier Agreement.

~~Our predecessors, parents and affiliates have not previously offered franchises in any line of business.~~Our affiliates, Alliance Healthcare Romania SRL and Alliance Healthcare Nederland B.V., make available pharmacy franchise offerings under the Alphega® brand in Romania and the Netherlands, respectively. Alliance Healthcare Romania SRL, which was incorporated in Romania and maintains its principal place of business at 7 Amilcar C. Sandulescu Street, 6th District, Bucharest, 060859 Romania, has made its pharmacy franchise offering available since September 1, 2016. As of the close of its 2025 fiscal year, there were 652 franchisees participating in Alliance Healthcare Romania SRL's pharmacy franchise offering. Alliance Healthcare Nederland B.V., which was incorporated in the Netherlands and maintains its principal place of business at Kempkens 2200, 5465 PR Veghel, Netherlands, has made its pharmacy franchise offering available since 2002. As of the close of its 2025 fiscal year, there were 77 franchisees participating in Alliance Healthcare Nederland B.V.'s pharmacy franchise offering. Except as described above, our predecessors, parents and affiliates do not provide products or services to our franchisees as part of the franchise relationship.

Our Legacy Voluntary Program

From 1982 until July 2019, we offered independent community pharmacies a license to operate under the Good Neighbor Pharmacy trade name ("Voluntary Pharmacy") on terms substantially different than those contained in the GNP Premier Agreement. As of July 2019, we no longer offer new independent pharmacies the opportunity to sign up as Voluntary Pharmacies; however, a significant number of legacy Voluntary Pharmacies continue to operate. As part of the Voluntary Pharmacy program, we provide products and services to independent community pharmacies, regional retail chain pharmacies and other healthcare providers, including hospitals, physician offices and clinics and other alternate care facilities. Voluntary Pharmacies did not sign the GNP Premier Agreement, which we began offering in 2009. As of September 30, ~~2024~~2025, there were ~~182~~157 Voluntary Pharmacies and 2,~~286~~204 GNP Premier Pharmacies (for a total of 2,~~468~~361). *See* Item 20.

Description of the Franchise

We grant franchises for GNP Premier Pharmacies that operate under the "Marks," which include (i) the "Good Neighbor Pharmacy" and related service marks, (ii) the "Elevate Provider Network" service marks, (iii) the elements and components of a GNP Premier Pharmacy's trade dress, and (iv) any and all additional, different or replacement trade names, trademarks, service marks, logos and slogans that we adopt from time to time to identify the GNP Premier Program and products and services that can be offered by a GNP Premier Pharmacy or the GNP Premier Program, including Available Programs. Though ~~there are~~we do not currently ~~none operational~~own or operate any GNP Premier Pharmacies, we reserve the right to own and/or operate GNP Premier Pharmacies.

ABDC, as a pharmaceutical distribution services company, delivers medicines and other products to thousands of retail customers on a just-in-time basis, which are then dispensed or sold to patients and consumers. We also provide business coaching services to help those customers who are GNP Premier Pharmacies improve their businesses and focus on their strengths. GNP Premier Pharmacies offer other retail products and services, including traditional drug store categories such as vitamins, cough and cold, first aid, and analgesics. Some GNP Premier Pharmacies carry home healthcare products, such as canes, walkers and other durable medical equipment.

We offer GNP Premier Agreements that grant to eligible ~~Customers~~customers the right to convert one or more existing or start-up pharmacies to each become a GNP Premier Pharmacy at a designated site ("Pharmacy Location"). The GNP Premier Agreement is attached to this Disclosure Document as Exhibit B. If you currently operate a pharmacy, we assume that you have an existing location, inventory, equipment and other items necessary to operate a pharmacy at the time you sign the GNP Premier Agreement. You have the right to terminate the GNP Premier Agreement at any time on 60 days' notice without cause.

To be eligible to participate in the GNP Premier Program, you must meet our minimum requirements ("Premier Minimum Requirements"), including having a computer system for pharmacy management that allows participation in our InSite ~~program~~ from ABDC~~.~~ program and related Available Programs. For stores whose existing pharmacy management system does not enable participation in our ~~program~~InSite from ABDC program and related Available Programs, we estimate it would take two to four months for a store to plan, evaluate, purchase and install the required system. *See* Items 8 and 11.

You must operate your GNP Premier Pharmacy and utilize Available Programs in accordance with the GNP Premier Agreement and the standards we establish ("Standards"). The Standards are described in our manuals and other directives to you, whether on paper or electronic form ("GNP Manual"), which we revise and supplement from time to time. The Standards pertain to, among other things, purchases of prescription pharmaceuticals, over-the-counter products, including our GNP private label products ("GNP Private Label Products"), health and beauty care products, signage and layouts, equipment, specifications for products and services, training, methods of inventory control, advertising and marketing programs and information technology, all of which we may improve, further develop or otherwise modify from time to time.

GNP Premier Program

Among other things, the GNP Premier Agreement, which we began offering in 2009, provides an integrated bundle of programs and services ("Available Programs"), including programs and services ~~for no additional~~ fee such as Elevate Provider Network, InSite from ABDC, Claim Reconciliation, and Business Coaching. See description of the Available Programs under "Description of Available Programs" below in this Item, and in Term Sheets 1-10 of the GNP Premier Agreement (each, a "Term Sheet"). You must participate in certain Available Programs after your GNP Premier Agreement becomes effective and you may, from time to time, elect to enroll in others optional Available Programs, some of which have additional fees. *See* pages 3-4 and Term Sheets 1-10 of the GNP Premier Agreement (Exhibit B to this Disclosure Document). Term Sheets 1-10 of the GNP Premier Agreement describe Available Programs we currently offer or provide to you.

Terms and conditions for each Available Program are provided on applicable Term Sheets, which are agreed to as part of the GNP Premier Agreement (see Term Sheets 1-10 which are attached to the GNP Premier Agreement). In addition, you will sign a Data Authorization to the Master Program Agreement (which is attached to the GNP Premier Agreement), which we then provide to one or more of your designated system vendors and our Program Partners (as defined in Term Sheet 2) as authorization to enable us to receive your Pharmacy Data (as defined in the Data Protection Provisions; *See* Exhibit A to the GNP Premier Agreement).

You may be required to fulfill certain prerequisite conditions before the services offered in ~~such~~an Available Program are made available to you. For an Available Program that is Optional, you may (i) enroll during the Term by submitting applicable information required to set-up your participation and requesting that ABDC begin providing such Available Program and (ii) disenroll by requesting that ABDC discontinue providing such Available Program, pursuant to the terms of ~~such~~the corresponding Term Sheet. All Term Sheets incorporate provisions of the GNP Premier Agreement, including, without limitation, its respective Exhibits, by reference.

The following is a short description of the Available Programs. Also see Items 6, 8, 9 and 17 of this Disclosure Document for more information about the Available Programs.

The table below lists the Available Programs you must participate in under the GNP Premier Program. See Item 11 and relevant Term Sheets for more detailed descriptions.

Required Programs	Term Sheet
Elevate Provider Network® We will enter into agreements on your behalf with Payors (as defined in Item 16) that offer pharmacy benefit plans to their members. Individual Payors process and pay covered service claims you submit. We receive centralized payments from Payors and disburse your funds to you ("Central Pay"). We provide help desk service and in general facilitate your participation in managed care networks to gain access to patients. *Additional fees may apply for Network Providers that: (i) process more than 10,000 claims in a month; (ii) use alternative, approved switch service providers for Elevate Advanced Features; and/or (iii) elect to receive optional and/or enhanced Elevate Advanced Features services (e.g., enhanced reporting, etc.).*	Term Sheet 1
Elevate Advanced Features *(Included with Elevate Provider Network®)* ABDC, together with Program Partners, has assembled a suite of data-driven services designed to assist you with your healthcare operations including treatment, payment, and healthcare operations activities. We will collect your Pharmacy Data directly from you and indirectly from Program Partners supporting or participating in the Available Programs, including without limitation your designated pharmacy system vendor, designated point-of-sale system vendor, designated reconciliation service provider, Change Healthcare (a part of Optum® ["Change Healthcare"]), or other switch service provider approved by ABDC in writing, EnlivenHealth (f/k/a FDS AMPLICARE, Inc.) ("EnlivenHealth"), Retail Insights and Outcomes Operating, Inc. (f/k/a Prescribe Wellness) ("Outcomes"). *Additional fees may apply for Network Providers that: (i) process more than 10,000 claims in a month; (ii) use alternative, approved switch service providers for Elevate Advanced Features; and/or (iii) elect to receive optional and/or enhanced Elevate Advanced Features services (e.g., enhanced reporting, etc.).*	Term Sheet 2
Pre & Post Edit Solutions (PPE) *(Part of the Elevate Advanced Features)* ABDC, together with our Program Partner Change Healthcare, offers pre- and post-edit and other claim services. Your pharmacy must use Change Healthcare as its pharmacy switch for routing claims to Payors (as defined in Term Sheet 1). You must contract directly with Change Healthcare for pharmacy switching services (or indirectly through your pharmacy management system vendor). Change Healthcare captures your claim transactions and furnishes a copy to us for use in those programs designed to aid your pharmacy in its treatment, payment, and healthcare operations activities. Optional services offered by Change Healthcare through ABDC include payer compliance re-billing and electronic medical claims billing for immunization services.	Term Sheet 2A

Required Programs	Term Sheet
Claim Reconciliation Services *(Part of the Elevate Advanced Features)* ABDC, together with our Program Partner EnlivenHealth, extend our Central Pay services to include a self-service claims reconciliation solution through the use of a web-based portal so that your pharmacy staff can match claims to actual payments and generate various receivables reports. This program is designed to aid your pharmacy in its payment and healthcare operations activities. EnlivenHealth also offers an optional "Concierge Service" for an additional monthly fee. Customers may enroll in the optional service directly with EnlivenHealth. ~~This program is designed to aid your pharmacy in its payment and healthcare operations activities.~~ ~~An optional concierge service is offered by EnlivenHealth.~~	Term Sheet 2B
InSite from ABDC *Pharmacy Management System Data* We operate a proprietary data analytics system used to measure and compare pharmacy performance by organizing and analyzing detailed prescription and other business transaction data. Certain data is collected directly from you and other data indirectly with the collaboration of your designated system vendors and in cooperation with our Program Partners, including without limitation Change Healthcare (or other claims switching services provider approved by ABDC in writing), EnlivenHealth, Outcomes, and Retail Insights. We manage your data under the terms of our Data Protection Provisions (Exhibit A to the GNP Premier Agreement). Optional programs include InSite for Point-of-Sale System Data and the Five-Star Rebate Program.	Term Sheet 3
First to Shelf® *Front-End Products* We will auto-ship to your pharmacy certain newly launched front-end products that we anticipate will be important products in the category. These products are often private label products or Rx-to-OTC switch items. You must promptly display the products.	Term Sheet 5

Optional Programs

The following optional programs are available to GNP Premier Pharmacies, subject to the fees and conditions outlined in the following table and described in further detail in the relevant Term Sheets attached to your GNP Premier Agreement. You may (i) enroll during the Term by submitting applicable information required to ~~set-up~~activate your participation and requesting that ABDC begin providing such Available Program and (ii) disenroll by requesting that ABDC discontinue providing such Available Program, pursuant to the terms of ~~such~~the corresponding Term Sheet. See Item 11 and relevant Term Sheets for more detailed descriptions.

Optional Programs	Term Sheet
Five-Star Rebate Program We offer the Five-Star Rebate program to recognize high performance in CMS Star Measures and to encourage continuous performance improvements. Based on pharmacy performance measures, your pharmacy will be eligible for a rebate of up to 100 basis points (1.00%) on your overall net purchases of rebateable PRxO Generics®. ~~The~~Unless agreed upon otherwise as between ABDC and your buying group (if any), the quarterly rebate is issued as a credit by us. As part of the program, you provide your consent to extract dispense usage data from your Pharmacy Data and make it available to our sales team to assist you in optimizing your purchase performance with ABDC. Requires participation in Elevate Advanced Features (Term Sheet 2). Further eligibility conditions apply (see Term Sheet 4) and may differ based on buying group affiliation; consult with your buying group for more details. No additional fees.	Term Sheet 4
Pre & Post Edit Solutions (PPE) *(Part of Elevate Advanced Features)* Customer may choose to participate in Change Healthcare's payer compliance re-billing and electronic medical claims billing for immunization services (where ABDC has signed network agreements with applicable Payors). Additional fees apply at the following negotiated pricing. Fees: Payer Compliance Claims: $1.00 per successful claim MedRx Immunization Claims: $1.00 per successful claim Other Services: Prevailing rate	Term Sheet 2A
Claim Reconciliation Concierge Services This optional service is provided directly by EnlivenHealth who will assign a reconciliation analyst to you. This analyst will conduct those tasks normally handled by you or your staff in our self-service model. The analyst will regularly provide you reports on the state of your third-party receivables. You will sign a service agreement directly with EnlivenHealth to enroll in the optional Concierge program. Fees: $199/month for optional Concierge Services (No fee for self-service)	Term Sheet 2B
Outcomes ~~PCS Solution (formerly PrescribeWellness~~Patient Care Services~~)~~ Outcomes makes available its Outcomes ~~PCS~~Premium Solution (as defined in Term Sheet 2C) offering real-time analytics and ongoing management tools designed to assist subscribing pharmacies in improving, among other things, patient health outcomes, patient adherence, and clinical services. The Outcomes ~~PCS~~Premium Solution is currently made available through Prescribe Wellness functionality but will be transitioned to ~~OutcomesOne~~Outcomes Premium. Subscribing customers will sign a service agreement directly with Outcomes to access certain modules or offerings available via this optional program. Applicable fees to be paid by Customer may vary and are dependent upon the manner in which Customer enrolls in the Outcomes ~~PCS~~Premium Solution and applicable Outcomes ~~PCS~~Premium Solution modules chosen by Customer. If Customer enrolls in the Outcomes ~~PCS~~Premium Solution directly through Outcomes, Customer will pay Outcomes' prevailing rates. Alternatively, if Customer enrolls in the Outcomes ~~PCS~~Premium Solution through ABDC and satisfies all applicable requirements (see Term Sheet 2C), Customer will pay the following rates, which may be increased by up to Five Percent (5%) annually, for the following Outcomes ~~PCS~~Premium Solution modules: ~~OutcomesOne~~Outcomes Premium ~~(formerly PEC):~~: $49/store/month ~~OutcomesOne~~Outcomes Premium + Vaccine: $129/store/month ~~OutcomesOne Complete~~Outcomes Premium + Vaccine + Engagement: $249/store/month	Term Sheet 2C

Optional Programs	Term Sheet
EnlivenHealth Patient Care Services EnlivenHealth makes available its ~~Amplicare Clinical~~Treat Solution (as defined in Term Sheet 2D) offering real-time analytics and ongoing management tools designed to assist subscribing pharmacies in improving, among other things, patient health outcomes, patient adherence, and clinical services. Subscribing customers will sign a service agreement directly with EnlivenHealth to access certain modules or offerings available via this optional program. Applicable fees to be paid by Customer may vary and are dependent upon the manner in which Customer enrolls in the ~~Amplicare Clinical~~Treat Solution and applicable ~~Amplicare Clinical~~Treat Solution bundles chosen by Customer. If Customer enrolls in the ~~Amplicare Clinical~~Treat Solution directly through EnlivenHealth, Customer will pay EnlivenHealth's prevailing rates. Alternatively, if Customer enrolls in the ~~Amplicare Clinical~~Treat Solution through ABDC and satisfies all applicable requirements (see Term Sheet 2D), Customer will pay the following rates for the following ~~Amplicare Clinical~~Treat Solution bundles: ~~Clinical (includes care opportunities and medication therapy management):~~Essentials: $100/store/month ~~Clinical Plus: $249~~Workflow: $100/store/month ~~Premium: $349~~All-In: $185/store/month ~~Platinum: $409/store/month~~ **Additional transaction fees may apply based on the bundle chosen, as provided under Customer's direct agreement with EnlivenHealth respecting the ~~Amplicare Clinical~~Treat Solution*.	Term Sheet 2D
InSite for Point-of-Sale System Data We also accept the data from your point-of-sale system to measure and compare the performance of the front-end of your pharmacy to your peers. Certain data is collected directly from you and other data indirectly with the collaboration of your designated system vendors and in cooperation with our Program Partners, including without limitation Change Healthcare (or other claims switching services provider approved by ABDC in writing), EnlivenHealth, Outcomes, and Retail Insights. We manage your data under the terms of our Data Protection Provisions (Exhibit A to the GNP Premier Agreement). No additional fees.	Term Sheet 3
Planogram Services We regularly publish and update schematic diagrams, known as "Planograms," which specify the optimal layouts of traditional drug store front-end product categories. Planograms are designed based on industry and consumer research to increase product sales. If you enroll in Merchandising services, our team will implement the planograms as part of their scheduled visit in your store. No additional fees.	Term Sheet 5
Retail Product Zone Pricing We regularly publish and update suggested retail prices, based on competitive zones, for traditional drug store front-end products. Prices are set based on industry research. You will pick a specific price zone which is tied to targeted competitiveness. No additional fees.	Term Sheet 5
Front-End Support Kit *Monthly in-store promotional materials* As an integral component of the Good Neighbor Pharmacy program, ABDC provides in-store promotional materials in reasonable quantities in a monthly kit for you to promptly display in-store, consistent with directions from ABDC in Program Guides.	Term Sheet 5

Optional Programs	Term Sheet
Merchandising Services A Retail Merchandising Specialist visits your pharmacy periodically to match pharmacy product choice and placement to category Planograms which you maintain between visits. You must substantially comply with Planogram layouts and stock substantially all Planogram products. Requires participation in InSite for Point-of-Sale System Data. No additional fees.	Term Sheet 5
Digital Marketing We provide a set of interrelated programs designed to assist you in promoting your pharmacy through the use of digital marketing channels. Programs include a website, mobile application, social media resources, pay-per-click digital advertising and local listing management all designed to attract patients and other consumers and build loyalty. ~~No additional fees.~~*Additional optional digital advertising services, such as ad hoc digital marketing campaign opportunities, may be made available via separate enrollment form(s) and subject to additional terms, conditions, and fees (which may vary based on options selected).*	Term Sheet 6
Business Coaching Using the data received by InSite as well as additional financial and operational information you provide, a ~~business coach~~Business Coaching Associate (as defined in Term Sheet 7) will assess your pharmacy's current state, help identify opportunities to enhance performance and make recommendations to you based on industry best practices. The recommendations are intended to be able to be implemented in a relatively short period of time and without significant capital investment. No additional fees.	Term Sheet 7
Pharmacy Data Services You may select which system data services you wish us to provide for your installed systems, including on-line order processing and item catalogs with price updates for your pharmacy management and point-of-sale systems. No additional fees.	Term Sheet 8
Unsaleable Returns To assist pharmacies in recovering the value of unsaleable products, we provide pharmacies with a comprehensive solution for disposal including all processing, shipping, and destruction costs. Premier pharmacies are eligible for onsite assistance and pre-funding based on the estimated recoverable value prior to returning the products. No additional fees.	Term Sheet 9
Statement of Work Services (Form) You may request that we provide other services that are beyond Available Programs. The Special Project Form, when agreed upon by the parties, would describe the terms and conditions under which those extra services will be provided. Fees: Determined on a case-by-case basis.	Term Sheet 10

The General Market

We consider the market for pharmacies to be very well developed. GNP Premier Pharmacies offer most of their products and services to all types of consumers on a walk-in, retail basis. Some GNP Premier Pharmacies also serve long term care, assisted living, or similar facilities. Sales of prescription products are restricted by law to patients with a valid prescription. Sales of some products, both prescription and OTC, such as vaccines or cough and cold remedies, are generally seasonal.

Industry Specific Regulation

You must comply with all federal, state and local laws relating to the offer and sale of prescription medicines, as well as regulations adopted by state pharmacy boards and the U.S. Food and Drug Administration and U.S. Drug Enforcement Administration, including laws and regulations relating to whom prescription pharmaceuticals may be sold and the storage, security and disposal of prescription pharmaceuticals. You must comply with regulations under the federal Health Insurance Portability and Accountability Act of 1996, as amended, ("HIPAA"). *See*, for example, HIPAA Business Associate Agreement, Exhibit B of the GNP Premier Agreement (which is Exhibit B of this Disclosure Document).

Development and operation of your GNP Premier Pharmacy will also be subject to compliance with applicable zoning and environmental regulations as well as federal and state employment and health and safety laws, including minimum wage laws governing some of your employees. Some of your GNP Premier Pharmacy's personnel may be paid at rates related to the federal minimum wage and, accordingly, further increases in the federal, state or local minimum wage will affect your labor costs. There may be other laws or regulations affecting your GNP Premier Pharmacy.

We are not aware of any laws or regulations that would apply to a GNP Premier Pharmacy differently than those that already apply to you if you operate an existing pharmacy or that will apply to you if you are opening a new start-up pharmacy. We recommend that you check with your state and local agencies to determine which laws apply to the operation of a GNP Premier Pharmacy in your area. You should consider these laws and regulations when evaluating your decision to participate in the GNP Premier Program.

Competition

You will compete with other GNP Premier Pharmacies. You will also compete with other independent pharmacies and chain pharmacies in a variety of locations, ~~including~~such as grocery and mass merchandisers and in some instances, hospital and clinic facilities. With respect to non-pharmaceutical products, you will compete with grocery stores, drug stores, discount stores and similar retail outlets.

ITEM 2
BUSINESS EXPERIENCE

President and Chief Executive Officer: Robert P. Mauch

Mr. Mauch has been President and Chief Executive Officer of the Company and a member of the Board since October 2024. Prior to that, he served as Executive Vice President and Chief Operating Officer from October 2022 to September 2024. He served as Group President from February 2019 to September 2022. He served as Group President, Pharmaceutical Distribution & Strategic Global Sourcing from June 2017 to February 2019. He served as President, AmerisourceBergen Drug Corporation from February 2015 to June 2017. Mr. Mauch served as Senior Vice President and Chief Operating Officer, AmerisourceBergen Drug Corporation from March 2014 to February 2015. He was Senior Vice President, Operations, AmerisourceBergen Drug Corporation from April 2012 to March 2014. He was Senior Vice President of Sales and Marketing, AmerisourceBergen Drug Corporation from April 2011 to April 2012. He was Senior Vice President, Alternate Care Sales and Marketing, AmerisourceBergen Drug Corporation from May 2010 to April 2011. Mr. Mauch has been employed by the Company or one of its predecessors for over 25 years~~.~~.

Executive Vice President and Chief Financial Officer: James F. Cleary

Mr. Cleary has been Executive Vice President since March 2015 and became Chief Financial Officer in November 2018. He served as Group President, Global Commercialization Services & Animal Health from June 2017 to November 2018. He previously served as President, MWI Animal Health from March 2015 to June 2017. Prior to joining the Company, he was President and Chief Executive Officer of MWI Veterinary Supply, Inc. from June 2002. Mr. Cleary has been employed by the Company or one of its predecessors for over 25 years~~.~~.

Executive Vice President and Chief Legal Officer: Elizabeth Campbell

Ms. Campbell has been Executive Vice President and Chief Legal Officer since September 2021. She served as Senior Vice President and Deputy General Counsel from June 2020 to August 2021. Prior to that, Ms. Campbell served in a variety of roles within the Company's legal department with increased responsibility, including serving as Chief Litigator and Chief Compliance Counsel. Ms. Campbell has been employed by the Company for ~~14~~15 years.

Executive Vice President and President, U.S. Pharmaceutical and Animal Health: Rich Tremonte

Mr. Tremonte has served as EVP & President of U.S. Pharmaceutical and Animal Health at Cencora since October 2022. Prior to this role, Mr. Tremonte served as EVP & President of Community & Specialty Pharmacy at Cencora beginning September 2018 and President of Strategic Global Sourcing from June 2017 until September 2018. This included leading global offices in Ireland and Switzerland.

Senior Vice President, Community & Specialty Pharmacy and Marketing Retail Executive Vice President: Franklin Harris

Mr. Harris has served as our Senior Vice President, Independent Community & Specialty Pharmacy Field and Inside Sales since July 2020. Mr. Harris joined Cencora in 1997 and has held roles within CSP sales, Strategic Global Sourcing as well as internationally where he worked within the Walgreens Boots Alliance Development Sourcing Group as the AmerisourceBergen Secondee. Mr. Harris is located in our office in Conshohocken, Pennsylvania.

Senior Vice President~~, Community & Specialty Pharmacy Solutions~~ and President, ~~Good Neighbor Pharmacy: Jennifer Zilka~~Community Retail & Long-Term Care: Tim Cernohous

~~Ms. Zilka~~Mr. Cernohous has served as Senior Vice President~~,~~ and President of Community ~~& Specialty~~Retail and Long-Term Care Pharmacy ~~Solutions and President, Good Neighbor Pharmacy Since October 2021.~~since February 2024. Prior to ~~her current~~this role, ~~Ms. Zilka~~Mr. Cernohous served as ~~Senior Vice President of Good Neighbor Pharmacy Field Programs and Services since March 2018 and the Vice President of Good Neighbor Pharmacy Business Coaching and Pharmacy Ownership~~ SVP, Commercial Advancement and Operations at Cencora within the Health System and Government Services business unit. Before joining Cencora in 2023, Mr. Cernohous led Ambulatory Pharmacy Services ~~from 2015 until March 2018~~at Essentia Health located in Duluth, Minnesota.

ITEM 3
LITIGATION

Cencora, our parent, is one of the largest global pharmaceutical sourcing and distribution services companies. As a result, at any given time, Cencora and its subsidiaries may be involved in lawsuits, administrative proceedings, government subpoenas and investigations which may be viewed as

ordinary and routine. Such matters may allege or involve, among other things, fraud, unfair practices or comparable allegations.

Other than the matters below, at this time, we do not view these matters as material to prospective franchisees. Cencora's audited financial statements describe certain of these matters. *See* Note ~~13~~12 and Note ~~14~~13 of Exhibit E to this Disclosure Document. Further, Cencora may have been involved in matters in which it was alleged to have violated antitrust or securities law or to have engaged in fraud, misrepresentation or similar behavior which may be considered other than routine in nature, but which we do not believe, at this time, are material to a prospective franchisee.

United States ex rel. Michael Mullen v. AmerisourceBergen Corporation, et al., Civil Action No. CV-10-4856 (E.D.N.Y); United States ex rel. Omni Healthcare Inc. v. AmerisourceBergen, et al., Civil Action No. CV-12- 1178 (E.D.N.Y); United States ex rel. Daniel Sypula and Kelly Hodge v. AmerisourceBergen Drug Corporation, et al., CV-13-10439 (E.D.MI.). In these three related cases, Cencora settled civil claims pertaining to a formerly operating subsidiary of AmerisourceBergen Specialty Group, LLC's alleged violation of the False Claims Act, 31 U.S.C. §3730(b). Cencora paid the sum of $625 million to settle the cases without any admission of liability.

In re: National Prescription Opiate Litigation, Case Number 1:17-md-02804 (N.D. Ohio). A significant number of counties, municipalities, and other governmental entities in a majority of U.S. states and Puerto Rico, as well as numerous states and tribes, filed lawsuits in various federal, state and other courts against pharmaceutical wholesale distributors (including Cencora and certain subsidiaries, such as ABDC and H.D. Smith), pharmaceutical manufacturers, retail pharmacy chains, medical practices, and physicians relating to the distribution of prescription opioid pain medications.

Starting in December 2017, more than 2,000 cases were transferred to Multidistrict Litigation ("MDL") proceedings before the United States District Court for the Northern District of Ohio (the "MDL Court"). Since then, several cases filed by government and tribal plaintiffs that were selected as bellwether cases in the MDL have been resolved through trial or settlement. Following trial in two consolidated cases in the United States District Court for the Southern District of West Virginia ~~federal court~~, the ~~court~~Court entered judgment in favor of the defendants, including Cencora. The plaintiffs filed an appeal of the ~~court's decision on August 2, 2022, which remains pending.~~Court's decision in the United States Court of Appeals for the Fourth Circuit on August 2, 2022. On October 28, 2025, the Fourth Circuit issued its opinion in the case, vacated the District Court's judgment, and remanded the case back to the District Court for further proceedings consistent with the Fourth Circuit's opinion.

On July 21, 2021, Cencora announced that it and the two other national pharmaceutical distributors had negotiated a Distributor Settlement Agreement that, if all conditions were satisfied, would result in the resolution of a substantial majority of opioid lawsuits filed by state and local governmental entities. The Distributor Settlement Agreement became effective on April 2, 2022, and as of September 30, ~~2024~~2025, it included 48 of 49 eligible states (the "Settling States") as well as 99% by population of the eligible political subdivisions in the Settling States. The Distributor Settlement Agreement requires ~~the Company~~Cencora to comply with certain requirements, including the establishment of a clearinghouse that will consolidate data from all three national pharmaceutical distributors. The States of Alabama and West Virginia and ~~its~~their subdivisions and Native American tribes are not a part of the Distributor Settlement Agreement, and ~~the Company has reached separate agreements with those groups. The State of Alabama also did not participate in the Distributor Settlement Agreement and was pursuing a case against the Company (and another national pharmaceutical distributor) in Alabama state court. On February 28, 2024, the Company and another national distributor executed an agreement with the State of Alabama and all its participating subdivisions to resolve opioid related claims. Pursuant to the agreement, the two distributors will pay approximately $245 million, including attorneys' fees and costs, to the State of Alabama and its participating subdivisions, of which the Company's portion is 50%. On~~

~~July 1, 2024, the Court entered a Final Consent Judgment and Dismissal with Prejudice pursuant to the terms of the settlement agreement. In Maryland, a trial commenced on September 16, 2024 in a case filed by the Mayor and City Council of Baltimore~~Cencora has reached separate agreements with those groups. ~~. On November 12, 2024, the jury returned a verdict finding ABDC (and another national distributor) liable for public nuisance and assessing approximately $274 million total in compensatory damages, approximately $74 million of which was assessed against ABDC. A second phase of the trial is scheduled to commence on December 11, 2024 related to the City of Baltimore's request for an abatement remedy, which will proceed as a bench trial. While the judgment is not yet final, the Company is evaluating next steps, including a possible appeal. The $74 million is a component of the Company's $4.9 billion litigation liability as of September 30, 2024 as described below.~~

The MDL Court selected four cases filed by third-party payors to serve as additional litigation bellwethers. On May 31, 2024, the MDL Court severed and stayed these four cases against ~~the Company~~Cencora and the two other national pharmaceutical distributors, pursuant to ongoing settlement discussions to resolve litigation filed by a putative class of third-party payors. On August 29, 2024, ~~the Company~~Cencora and two other national pharmaceutical distributors entered into a proposed class action settlement agreement to resolve the opioid-related claims of a proposed settlement class of third-party payors. Pursuant to the agreement, ~~the Company~~Cencora recorded a $93.0 million litigation expense accrual in Litigation and Opioid-Related Expenses (Credit), Net in its fiscal 2024 Consolidated Statement of Operations. ~~On September 3, 2024, the~~The MDL Court granted a motion for preliminary approval of the proposed class action settlement~~. Federal law imposes additional requirements before the class settlement can become final, including notice to class members,~~ on September 3, 2024. Following a time period for submission of any objections ~~to the settlement~~ or requests to be excluded from the settlement, ~~and~~ the MDL granted final approval of the settlement during a fairness hearing~~, among other procedural steps, as described in the MDL Court's~~ held on January 13, 2025 and entered a final approval order on January 15, 2025. On February 13, 2025, the sole objector to the settlement filed a notice of appeal of the final approval order. A settlement agreement with the sole objector was entered into on June 12, 2025. On June 16, 2025, the MDL Court ruled that it would approve the settlement with the sole objector if remanded for that purpose. On July 25, 2025, the United States Court of Appeals for the Sixth Circuit granted a motion for limited remand. The MDL Court approved the settlement with the sole objector on August 8, 2025. The class action settlement became effective as of September ~~3, 2024 order. The MDL Court has scheduled a fairness hearing for January 13~~9, 2025.

In Maryland, a trial commenced on September 16, 2024 in a case filed by the Mayor and City Council of Baltimore in the Circuit Court for Baltimore City. On November 12, 2024, the jury returned a verdict finding ABDC (and another national distributor) liable for public nuisance and assessing approximately $274 million total in compensatory damages, approximately $74 million of which was assessed against ABDC. A second phase of the trial began on December 11, 2024 related to the City of Baltimore's request for an abatement remedy and proceeded as a bench trial. On June 12, 2025, the Court issued a ruling on the defendants' post-trial motions relating to the first phase of the trial. The Court upheld the jury's finding of liability, but granted the defendants a new trial on the extent of damages to correct certain errors and due to the excessive nature of the jury's damages award. In the alternative, the Court granted remittitur, through which the Court reduced the compensatory damages assessed against ABDC to approximately $14.4 million. The Court issued its ruling regarding the City of Baltimore's request for abatement on August 8, 2025, assessing approximately $28 million against ABDC for abatement measures, bringing the overall monetary award assessed against ABDC to approximately $42.5 million. On August 14, 2025, the City of Baltimore informed the Court that it would accept the reduced damages award as reflected in the Court's post-trial ruling, in lieu of a new trial. On September 2, 2025, the Court entered final judgment. In October 2025, ABDC (and the other national distributor) filed a notice of appeal to the Appellate Court of Maryland, and the City of Baltimore filed a notice of cross-appeal. In November 2025, both the City of Baltimore and ABDC (and the other national

distributor) filed petitions for a writ of certiorari (bypass) with the Supreme Court of Maryland. If the Court grants the petitions, then the appeal will proceed directly in that Court, instead of in the Appellate Court. The $42.4 million is a component of Cencora's $4.3 billion litigation liability as of September 30, 2025, as described above.

On September 26, 2024, ~~the Company~~Cencora and two other national pharmaceutical distributors entered into a proposed class action settlement agreement to resolve the opioid-related claims of a proposed settlement class of hospitals. ~~The Company~~Cencora recorded a $120.9 million litigation expense accrual in Litigation and Opioid-Related Expenses (Credit), Net in its fiscal 2024 Consolidated Statement of Operations, representing ~~the Company's~~Cencora's expected share of the potential class action settlement. ~~Pursuant to these settlement discussions, a case in Alabama that involved up to eight plaintiff hospitals, and that was scheduled to begin trial on July 8, 2024, has now been severed and stayed as to the Company.~~ On October 30, 2024, the United States District Court for the District of New Mexico granted a motion for preliminary approval of the proposed class action settlement. ~~Federal law imposes additional requirements before the class settlement can become final, including~~Following notice to class members, a time period for submission of any objections to the settlement or requests to be excluded from the settlement, and a fairness hearing~~, among other procedural steps, as described in the Court's October 30,~~ on March 4, 2025, the Court granted final approval of the settlement and entered a final approval order. The settlement became effective on April~~2024 order. The Court has scheduled a fairness hearing for March~~ 4, 2025.

~~In January~~ Cencora's~~2024, the Company prepaid the net present value of a future obligation as permitted under its settlement agreements. The discount on the future obligation resulted in a $0.1 billion reduction of its accrued litigation liability. The Company's~~ accrued litigation liability related to the Distributor Settlement Agreement, including the State of Alabama and an estimate for nonparticipating government subdivisions (with whom ~~the Company~~Cencora has not reached a settlement agreement), as well as other opioid-related litigation for which it has reached settlement agreements, as described above, was $4.3 billion as of September 30, 2025 and $4.9 billion as of September 30, 2024~~ and $5.5 billion as of September 30, 2023.~~. The $4.~~9~~3 billion liability will be paid over ~~14~~13 years. ~~The Company~~Cencora currently estimates that $~~630.2~~416.0 million will be paid prior to September 30, ~~2025~~2026, which is recorded in Accrued Expenses and Other on ~~the Company's~~Cencora's Consolidated Balance Sheet. The remaining long-term liability of $~~4.~~3.9 billion is recorded in Accrued Litigation Liability on ~~the Company's~~Cencora's Consolidated Balance Sheet. While ~~the Company~~Cencora has accrued its estimated liability for opioid litigation, it is unable to estimate the range of possible loss associated with the matters that are not included in the accrual. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. ~~The Company~~Cencora regularly reviews opioid litigation matters to determine whether its accrual is adequate. The amount of ultimate loss may differ materially from the amount accrued to date. Until such time as otherwise resolved, ~~the Company~~Cencora will continue to litigate and prepare for trial and to vigorously defend itself in all such matters. Since these matters are still developing, ~~the Company~~Cencora is unable to predict the outcome, but the result of these lawsuits could include excessive monetary verdicts and/or injunctive relief that may affect ~~the Company's~~Cencora's operations. Additional lawsuits regarding the distribution of prescription opioid pain medications have been filed and may continue to be filed by a variety of types of plaintiffs, including lawsuits filed by non-governmental or non-political entities and individuals, among others. ~~The Company~~Cencora is vigorously defending itself in the pending lawsuits and intends to vigorously defend itself against any threatened lawsuits or enforcement proceedings.

Since July 2017, Cencora has received subpoenas from several U.S. Attorney's Offices, including grand jury subpoenas from the U.S. ~~Attorney's~~Attorney's Office for the District of New Jersey ("USAO-NJ") and the U.S. ~~Attorney's~~Attorney's Office for the Eastern District of New York ("USAO-EDNY"). Those subpoenas requested the production of a broad range of documents pertaining to Cencora's distribution

of controlled substances through its various subsidiaries, including ABDC, and its diversion control programs. Cencora produced documents in response to the subpoenas and engaged in discussions with the various U.S. Attorney's Offices, including the Health Care and Government Fraud Unit of the Criminal Division of the USAO-NJ, the U.S. Department of Justice Consumer Protection Branch and the U.S. Drug Enforcement Administration, in an attempt to resolve these matters. On December 29, 2022, the Department of Justice filed a civil complaint (the "Complaint") against Cencora, ABDC, and Integrated Commercialization Services, LLC ("ICS"), a subsidiary of Cencora, alleging violations of the Controlled Substances Act. Specifically, the Complaint alleges that Cencora negligently failed to report suspicious orders to the Drug Enforcement Administration. In the Complaint, the Department of Justice seeks civil penalties and injunctive relief. This Complaint relates to the aforementioned and previously -disclosed investigations. On March 30, 2023, Cencora filed a motion to dismiss the Complaint in its entirety on behalf of itself, ABDC, and ICS. On November 6, 2023, the United States District Court for the Eastern District of Pennsylvania granted in part and denied in part the motion, dismissing with prejudice all claims for civil penalties for Defendants' alleged violations of the suspicious order reporting requirement prior to October 24, 2018, but otherwise denying the motion. On December 18, 2023, Cencora, ABDC and ICS filed an Answer and Affirmative Defenses to the Complaint. On ~~January 23,~~ July 15, 2025~~2024~~, the Court entered ~~a~~an Amended Scheduling Order setting the fact discovery deadline as ~~January 9~~June 12, 2026 and the expert discovery deadline as ~~September 18, 2026~~January 15, 2027. Cencora denies the allegations in the Complaint and intends to defend itself vigorously in the litigation.

In addition to the above-referenced matters, please see Cencora's SEC filings, which disclose additional lawsuits not directly related to the franchise offering or franchise system involving the manufacturing, administering, prescribing, distributing, or storing of pharmaceutical products where Cencora has been named as a defendant.

No other litigation information is required to be disclosed in this Item.

ITEM 4
BANKRUPTCY

No bankruptcy information is required to be disclosed in this Item.

ITEM 5
INITIAL FEES

Premier Agreement

Although we do not charge you an initial franchise fee, you may have to pay us or our affiliates for certain goods or services upon signing the Premier Agreement as described in the "Start of GNP Premier Program Billing" subsection below (existing store) or prior to your store's opening date (start-up store).

Initial Inventory of Pharmaceutical and Front-End Products

For an existing pharmacy, no incremental inventory may be required other than the requirements for GNP Private Label Products described below. Accordingly, the low-end estimate for this cost for an existing pharmacy is $0. Depending on your existing inventory of pharmaceutical and front-end products, we estimate in certain cases an existing pharmacy may be required to expend up to $25,000 for an initial inventory of these products. For a start-up pharmacy, we estimate that before your opening

date you will pay us $~~75~~50,000 to $~~125~~150,000 for an initial inventory of pharmaceutical and front-end products.

GNP Private Label Products

For an existing pharmacy that is already stocked with a broad selection of GNP Private Label Products, we anticipate little or no additional expenditure for GNP Private Label Products will be required. However, if you are a start-up franchisee or your existing pharmacy does not currently stock a broad selection, you must place an order for GNP Private Label Products with us in quantities you determine are reasonable to meet anticipated consumer demand. We estimate this amount may be $0 to $1,200 for existing stores that have regularly stocked GNP Private Label Products. We estimate that a store with no or minimal existing inventory of GNP Private Label Products may place an order ranging from $5,000 to $12,000 (see Item 7 and Item 8), depending on the size of the store, front-end categories carried, the number of facings, and the market where it is located.

Interior and Exterior Signage

We provide complimentary signage packages to all new franchisees that, when applied according to our standards, meet our minimum requirements (for an existing Voluntary Pharmacy converting to a GNP Premier Pharmacy we may provide only a partial package as compliant signage may already be installed). To encourage you to enhance the appearance of your GNP Premier Pharmacy and further apply the Good Neighbor Pharmacy trade dress at your location, we offer new franchisees a one-time purchase match of up to $2,500 per location to order additional or enhanced signage and other trade dress that meets our specifications within 180 days of signing the Premier Agreement (the "Purchase Match Amount"). We will match your initial purchase, dollar for dollar, up to $2,500 for qualified expenses which meet our specifications. For example:

- If you spend $1,000, you will get a $1,000 match
- If you spend $2,500, you will get a $2,500 match
- If you spend $3,000, you will get a $2,500 match

To obtain the Purchase Match Amount, you must place your signage order within 180 days of signing the Premier Agreement and order through our approved vendor (currently GoodNeighborPharmacySigns.com) or submit pre-approved estimates and copies of paid invoices, along with photos of the installed trade dress to the Good Neighbor Pharmacy department in our Conshohocken, PA office via email to programs@amerisourcebergen.com. If you terminate the Premier Agreement for any reason other than an uncured default by ABDC prior to the end of the first full twelve (12) month period that the Premier Agreement is in effect, you will pay ABDC, in addition to any other amounts or damages that may be owed to ABDC under any other agreement and not as liquidated damages, an amount equal to the Purchase Match Amount.

Typically, all signage must be purchased from an approved vendor. From time to time, ABDC will pre-purchase signage from the approved vendor to facilitate delivery of signage, in which case you may be billed for signage originally purchased by ABDC from this outside vendor. The cost of the various signage and trade dress available for purchase from our approved vendors and according to our specifications will range between $0 and $25,000 depending on your choices. Since our complimentary signage package meets our minimum requirements the low estimate on expenses is $0.

Leasehold Improvements

If you have an existing pharmacy, depending on the design and layout of your pharmacy, you may not need to incur any additional leasehold costs. If you do need to incur leasehold costs, these improvements vary substantially based on the location and condition of your existing pharmacy.

If you are opening a start-up pharmacy, the cost of leasehold improvements will vary based on the size and existing configuration of the premises as well as local factors such as wage rates and availability and price of materials. These costs may also vary if the landlord agrees to incur the costs and allocate them over the term of the lease.

Our pharmacy transformation services group can, at your option and upon the execution of a corresponding agreement, evaluate your existing pharmacy, recommend improvements and manage the project for you for a base fee ranging from $1,500 to $3,000 depending on the applicable services tier chosen. Additional fees may apply.

Optional Available Programs

At this time, ~~there are no initial fees for~~certain Available Programs in which you elect to participate may require the payment of additional fees, as described in Term Sheets 1-10 of the GNP Premier Agreement (Exhibit B to this Disclosure Document).

Start of GNP Premier Program Billing

ABDC invoices any monthly fees, such as the Premier program fee, and initial fees (applicable to optional programs and promotional material) in arrears (typically on the 25th of the month~~).~~), which such fees may be prorated as applicable. Typically, you will pay on the same terms on which you pay for other goods and services purchased from us or as we mutually agree (such as by the 10th of the following month).

Release from Claims

As part of your consideration for entering into the GNP Premier Agreement with us, you, your owners and affiliates agree to release us from any and all claims in connection with offering ABDC's Voluntary Pharmacy program. This release does not apply to any claim related to this offer of the GNP Premier Agreement.

The fees described above are uniform as to all customers who sign the GNP Premier Agreement and such fees are fully earned when paid and not refundable.

ITEM 6
OTHER FEES

Type of Fee	Amount	Due Date	Remarks, Definitions and Caveats
GNP Premier Fee	$599	Monthly	If you are an existing pharmacy, you will begin paying this fee in the month after you sign the GNP Premier Agreement. If you are a start-up pharmacy, you will begin paying this fee the month after you open for business. We may increase the monthly fee upon 120 days' notice.
Claim Reconciliation Concierge Services	$199/month	Monthly	$199/month for optional Concierge Services (No fee for self-service)

Type of Fee	Amount	Due Date	Remarks, Definitions and Caveats
Outcomes Patient Care Services (Outcomes ~~PCS~~Premium Solution)	~~OutcomesOne~~Outcomes Premium ~~(formerly PEC):~~: $49/store/month ~~OutcomesOne~~Outcomes Premium + Vaccine: $129/store/month ~~OutcomesOne Complete~~Outcomes Premium + Vaccine + Engagement: $249/store/month	Monthly	Subscribing customers will sign a service agreement directly with Outcomes to access certain modules or offerings available via this optional program. Applicable fees to be paid by Customer may vary and are dependent upon the manner in which Customer enrolls in the Outcomes ~~PCS~~Premium Solution and applicable Outcomes ~~PCS~~Premium Solution modules chosen by Customer. If Customer enrolls in the Outcomes ~~PCS~~Premium Solution directly through Outcomes, Customer will pay Outcomes' prevailing rates. Alternatively, if Customer enrolls in the Outcomes ~~PCS~~Premium Solution through ABDC and satisfies all applicable requirements (see Term Sheet 2C), Customer will pay the rates listed in this table, which may be increased by up to Five Percent (5%) annually, for the applicable Outcomes ~~PCS~~Premium Solution modules. Customer may not concurrently enroll in the Outcomes ~~PCS~~Premium Solution and EnlivenHealth ~~Patient Care Services~~Treat Solution via ABDC.

Type of Fee	Amount	Due Date	Remarks, Definitions and Caveats
EnlivenHealth Patient Care Services (~~Amplicare Clinical~~Treat Solution)	~~Clinical (includes care opportunities and medication therapy management):~~Essentials: $100/store/month ~~Clinical Plus: $249~~Workflow: $100/store/month ~~Premium: $349~~All-In: $185/store/month ~~Platinum: $409/store/month~~	Monthly	Subscribing customers will sign a service agreement directly with EnlivenHealth to access certain modules or offerings available via this optional program. Applicable fees to be paid by Customer may vary and are dependent upon the manner in which Customer enrolls in the ~~Amplicare Clinical~~Treat Solution and applicable ~~Amplicare Clinical~~Treat Solution bundles chosen by Customer. If Customer enrolls in the ~~Amplicare Clinical~~Treat Solution directly through EnlivenHealth, Customer will pay EnlivenHealth's prevailing rates. Alternatively, if Customer enrolls in the ~~Amplicare Clinical~~Treat Solution through ABDC and satisfies all applicable requirements (see Term Sheet 2D), Customer will pay the rates listed in this table for the applicable ~~Amplicare Clinical~~Treat Solution bundles. Customer may not concurrently enroll in the Outcomes ~~PCS~~Premium Solution and EnlivenHealth ~~Patient Care~~Treat Services via ABDC. Additional transaction fees may apply based on the bundle chosen, as provided under Customer's direct agreement with EnlivenHealth respecting the ~~Amplicare Clinical~~Treat Solution.
Special Projects	Varies	As incurred, 15 days from invoice date, or as otherwise agreed	We will charge for time and materials or at a fixed price, as negotiated, for any special projects not covered by a Term Sheet or other agreement.
Optional/Enhanced Services	Varies	As incurred, monthly, or as otherwise agreed	We make available certain optional, enhanced services (e.g., enhanced Elevate Advanced Features reporting, etc.) at specified rates.

Type of Fee	Amount	Due Date	Remarks, Definitions and Caveats
Indemnification Costs	Varies	As incurred	As more fully specified in Items 7 and 8, you must carry liability insurance that covers ABDC and its affiliates as additional insureds and if we or our affiliates are threatened with liability due to operation of your GNP Premier Pharmacy you must pay for the cost to defend us.
Late Fee	Lower of 0.05% per day (18%/360) or maximum rate permitted by law	As incurred	Payable so long as the respective payment remains unpaid.

Explanatory Notes

In addition to the initial fees in Item 5, and except as described above, all fees are uniformly imposed by and payable to us. All fees are non-refundable. We must provide 60 days' prior written notice to change fees on any Available Program and, you may terminate with 60 days' prior written notice.

Typically, you will pay on the same terms (such as weekly or semi-monthly) on which you currently pay us for other goods and services you purchase; otherwise, payments are due 15 days from invoice date unless noted otherwise above.

ITEM 7
ESTIMATED INITIAL INVESTMENT

A. Existing Pharmacy

Type of Expenditure	Amount	Method of Payment	When Due	To Whom Payment is Made
Leasehold Improvements[(a)]	$0 to $50,000	As arranged	As agreed	Third Party Contractors
Leasehold Improvement Management Services[(a)]	$0 to $1,500	As arranged	As agreed	ABDC
Furniture, Fixtures, and Equipment	$0 to $50,000	As arranged	As agreed	Third Party Vendors
Pharmacy Management System Hardware and Software[(b)]	$0 to $15,000	As arranged	As agreed	Third Party Vendors
Point of Sale System Hardware and Software[(c)]	$0 to 35,000	As arranged	As agreed	Third Party Vendors
Interior and Exterior Signage[(d)]	$0 to $5,000 (interior) $0 to $20,000 (exterior)	As arranged	As agreed	ABDC or Approved Vendors
Fees for Optional Goods and Services[(e)]	$0 to $1,908 (3 months)	As arranged	As agreed	Vendors
Insurance[(f)]	$1,500 to $5,000	As arranged	As agreed	Third Party Insurance Company
Opening Inventory[(g)] (exclusive of GNP Private Label Products)	$0 to $250,000	As arranged	Net 10 days after semi-monthly billing	ABDC
GNP Private Label Products[(h)]	$0 to $1,200	As arranged	As agreed	ABDC
Pharmacy and Business Licenses[(i)]	$500 to $3,000	As arranged	As agreed	Licensing Authorities

Additional Advertising and Marketing[j]	$0 to $15,000	As arranged	As agreed	Vendors
Additional Funds – 3 months[k]	$40,000 to $50,000	As arranged	As agreed	Vendors
GNP Premier Fee – 3 months	$1,797	As arranged	As agreed	ABDC
Total[l]:	**$43,797 to $556,405**			

B. Start-Up Pharmacy

Type of Expenditure	Amount	Method of Payment	When Due	To Whom Payment is Made
Real Property Lease/Leasehold Improvements[a]	$50,000 to $110,000	As arranged	As agreed	Third Party Contractors
Leasehold Improvement Management Services[a]	$0 to $1,500	As arranged	As agreed	ABDC
Furniture, Fixtures, and Equipment	$25,000 to $75,000	As arranged	As agreed	Third Party Vendors
Pharmacy Management System Hardware and Software[b]	$0 to $15,000	As arranged	As agreed	Third Party Vendors
Point of Sale System Hardware and Software[c]	$0 to 35,000	As arranged	As agreed	Third Party Vendors
Interior and Exterior Signage[d]	$0 to $5,000 (interior) $0 to $20,000 (exterior)	As arranged	As agreed	ABDC or Approved Vendors
Fees for Optional Goods and Services[e]	$0 to $1,908 (3 months)	As arranged	As agreed	Vendors
Insurance[f]	$1,500 to $5,000	As arranged	As agreed	Third Party Insurance Company
Opening Inventory[g] (exclusive of GNP Private Label Products)	$75,000 to $125,000	As arranged	Net 10 days after semi-monthly billing	ABDC

GNP Private Label Products[(h)]	$5,000 to 12,000	As arranged	As agreed	ABDC
Pharmacy and Business Licenses[(i)]	$500 to $3,000	As arranged	As agreed	Licensing Authorities
Additional Advertising and Marketing[(j)]	$0 to $15,000	As arranged	As agreed	Vendors
Additional Funds – 3 months[(k)]	$120,000 to $150,000	As arranged	As agreed	Vendors
GNP Premier Fee – 3 months	$1,797	As arranged	As agreed	ABDC
Total[(l)]:	**$278,797 to $575,205**			

Explanatory Notes to Charts A and B.

a) Real property lease, leasehold improvements, furniture, fixtures and equipment. If you have an existing pharmacy, depending on the design and layout of your pharmacy, you may not need to incur any additional leasehold costs. If you do need to incur leasehold costs, these improvements vary substantially based on the location and condition of your existing pharmacy. Our pharmacy transformation services group can, subject to execution of a corresponding agreement, evaluate your existing pharmacy, recommend improvements and manage the project for you; additional terms and conditions apply. If you are opening a start-up pharmacy, the cost of leasehold improvements will vary based on the size and existing configuration of the premises as well as local factors such as wage rates and availability and price of materials. These costs may also vary if the landlord agrees to incur the costs and allocate them over the term of the lease.

b) Pharmacy Management Systems. Pharmacy management systems enable the prescription dispensing process including patient profiles, clinical screening, inventory replenishment, claim submissions and connectivity to e-prescribing networks. As discussed above, you must participate in InSite from ABDC, a proprietary pharmacy performance analytics system that measures pharmacy performance using data from your pharmacy management system. If your existing system is from one of the participating industry vendors with whom we have agreements to facilitate your participation in InSite, we anticipate you will incur minimal or no expense. The above estimate is for start-up pharmacies and for existing pharmacies that need to purchase or replace computer hardware, software and related services from a participating vendor.

c) Point-of-Sale Systems. Point-of-sale systems enable retail checkout processes such as UPC scanning, credit and debit card processing, inventory replenishment, and sales reporting. Use of a point-of-sale system is not required under the GNP Premier Agreement but is highly recommended. As discussed above, we offer you optional participation to upload your sales transaction data into InSite from ABDC, a proprietary pharmacy performance analytics system that measures pharmacy performance using data from pharmacy management and point-of-sale systems. Uploading your sales transaction data into InSite may be required for participation in certain front-end retail programs such as merchandising services. If your existing point-of-sale system is from one of the participating industry vendors with whom we have agreements to facilitate your participation in InSite, we anticipate you will incur minimal or no expense. The above estimate is for start-up pharmacies and for existing pharmacies that

need to purchase or replace computer hardware, software and related services from a participating industry vendor.

d) Interior and Exterior Signage. We provide complimentary signage packages to all new franchisees that meet our standard, minimum requirements at the time of application (for an existing Voluntary Pharmacy upgrading to a Premier Pharmacy we may provide only a partial package as compliant signage might already be installed). Therefore, we anticipate that you will have minimal or no initial expense for signage. The above estimates are provided in the event that you wish to further enhance the appearance of your location with Good Neighbor Pharmacy exterior signage and/or interior trade dress. In the event you choose to purchase or replace exterior signage, your costs will depend on the physical features of your location and whether you have architectural, municipal or lease restrictions on the signage you can use. In all cases, you must meet or exceed our specifications for your signage unless you are restricted by local ordinance or lease provisions from meeting our specifications. While such expenses vary widely, for purposes of comparison, we estimate you may spend up to $5,000 if you choose to purchase additional interior trade dress and up to $20,000 if you choose to enhance your exterior signage. For additional information on signage and trade dress, see Item 5 above.

e) Optional Goods and Services. The low-end estimate assumes you do not enroll in any optional programs while the high-range estimate assumes you will choose to enroll and pay fees for optional products and services. See Item 6.

f) Insurance. If you have an existing pharmacy, we anticipate you will incur no incremental expense for required insurance coverage. For start-up pharmacies, the amount in the table represents our best estimate of the annual premiums in the marketplace to provide the coverage/limits for commercial general liability and professional liability insurance that meet our requirements. See Item 8 for a more detailed description of insurance requirements. Costs for insurance may vary substantially based on the geographic location of your pharmacy.

g) Opening Inventory. If you have an existing pharmacy, we anticipate you will incur modest incremental expenses (from $0 - $25,000) to meet our recommendations which may include categories carried, adjacencies and number of facings of product on your shelves. For start-up pharmacies we estimate a range of $~~75~~50,000 to $~~125~~150,000 or more depending on ~~the size of your~~ location ~~to stock a reasonable supply of~~, demographics, pharmacy type/specialty, expected growth rate, front-end size, and ~~prescription products~~customer needs.

h) GNP Private Label Products. If your pharmacy is an existing Voluntary Pharmacy, we anticipate you will incur little or no additional investment ($0 - $1,200) in GNP Private Label Product inventory. If you are a start-up pharmacy or an existing pharmacy with no GNP Private Label product on your shelves we estimate an investment of $5,000 to $12,000 so that, as you reasonably determine based on your experience, you can carry a representative assortment to meet consumer demand, taking into account, among other things, your Pharmacy's size and market. Any such initial inventory that is purchased from us will typically be on terms that are the same or substantially similar to those that would be available to you whether or not you are a GNP Premier Pharmacy.

i) Pharmacy and Business Licenses. You must obtain certain business licenses and occupancy permits to operate a retail pharmacy. If you have an existing pharmacy, we assume you have all required licenses and, as such, will have minimal or no incremental expenses. For start-up pharmacies we estimate a range of $500 to $2,500 to obtain the licenses under state and federal law required to operate a pharmacy as well as permits. The costs will vary by state

and may be impacted by local ordinances. We assume that licenses or other fees for pharmacists, pharmacy technicians or other employees are not your expenses.

j) Advertising and Marketing. If you have an existing pharmacy, you may feel you have no significant need for "new business" advertising in which case we have estimated no expense at the low end. In addition, we will expend certain amounts on advertising (see Item 11) to promote the Good Neighbor Pharmacy franchise system generally. However, we recommend that both start-up pharmacies and existing pharmacies also promote a grand opening for their new GNP Premier Pharmacy. Amounts for such promotions vary widely based on the extent to which you advertise and the media you elect to use. Accordingly, we have estimated $15,000 at the high end. Advertising is suggested as a best practice regardless of when the pharmacy opened.

k) Additional Funds. For start-up pharmacies and for purposes of comparison, we estimate that a typical pharmacy would incur the following on-going expenses over a three-month period of operation: phone ($2,000-$3,000); other utilities ($15,000-$20,000); rent ($30,000-$35,000); security ($2,000-$3,000); trash/waste removal ($500-$1,000); legal, accounting and other professional services ($6,000-$7,000); office systems ($6,000-$7,000); and miscellaneous/other ($58,500-$74,000); for a total of $120,000 to $150,000.

l) Total Initial Investment. These figures are an estimate of your total opening and operating expenses for the initial three months of business. They are based on the experiences of pharmacy owners that have operated pharmacies over more than 10 years.

We do not offer, directly or indirectly, any financing arrangements for your initial investment in connection with the GNP Premier Pharmacy franchise relationship. To our knowledge, costs and expenses described above are not refundable.

ITEM 8
RESTRICTIONS ON SOURCES OF PRODUCTS AND SERVICES

To ensure that the quality of the products and services you offer under our Marks is consistent, the furniture, fixtures equipment, and signage used in connection with your GNP Premier Pharmacy, must meet the Standards we establish as contained in the GNP Premier Agreement and GNP Manual. We modify Standards (including those for vendors) by revisions to the GNP Manual and other periodic written directives to you. If your pharmacy is an existing Voluntary Pharmacy, we expect that you will have already acquired and installed a significant amount, if not all, of such items. We formulate and modify these Standards based on research, industry trends, guidance from regional and national advisory boards and our general business plan.

Restrictions on Programs

To be eligible to sign the GNP Premier Agreement and thereby participate in the GNP Premier Program, you must meet the Premier Minimum Requirements, which necessitate that you: (1) be an existing pharmacy or a start-up pharmacy; (2) have a Prime Vendor Agreement (PVA), or other applicable distribution agreement, with ABDC (where permitted by applicable law); (3) be willing to immediately implement the GNP signage requirements described below in this Item; (4) utilize a pharmacy management system from one of the participating industry vendors that enables connectivity with our ~~programs~~Available Programs; (5) immediately enroll in Elevate Advanced Features and InSite from ABDC (which requires you to sign our Data Authorization to the Master Program Agreement and GNP Premier Agreement (see Exhibit B) to initiate our cooperation with your participating vendor); (6) unless otherwise approved by ABDC in writing, utilize Change Healthcare as your switch vendor (or immediately initiate the transition to Change Healthcare) to activate the capture and upload of your Pharmacy Data to InSite; *See* Items 1 and 11 and also Exhibit B. Additionally, you must comply with

prerequisites or other qualifications for the specific Available Programs you select, including any base Available Programs for which other Available Programs are enhancements, maintain the on-going obligations for those Available Programs as stated in the GNP Manual and applicable Term Sheets, and remain in compliance with our Standards, also as described in the GNP Manual. Where equipment, software and other items we determine are necessary for Available Programs you select, such costs are your responsibility. Certain third-party vendors utilized in the provision of Available Programs may pay ABDC a fee for pharmacies that enroll in additional program offerings by such vendor. You may only use the Available Programs at Pharmacy Locations that are covered under a GNP Premier Agreement.

You must comply with the Elevate Provider Network℠ program terms (Term Sheet 1 of the GNP Premier Agreement, which is Exhibit B to this Disclosure Document), under which we will assist you to participate in and obtain payment from Payors (as defined in Item 16) that offer pharmacy benefit plans to their members. Under the Elevate Provider Network program, only we may negotiate and enter into ~~contracts~~Payor Contracts (as defined in Term Sheet 1 of the GNP Premier Agreement, which is Exhibit B to this Disclosure Document) with Payors on your behalf (unless you contract directly or through another pharmacy services administration organization ("PSAO") that we approve) to provide covered services for all Payors with which ABDC has contracted so that we may promote the capabilities of all GNP Premier Pharmacies to Payors. Except as noted in the preceding sentence, you will not appoint any other PSAO or any other party to act as your contracting entity for ~~agreements~~Payor Contracts with Payors (although you may always contract directly). We regularly, as a course of business, add, discontinue and revise arrangements with Payors, typically in response to changes by Payors, and Payors regularly add, discontinue and modify pharmacy benefits plans and other related requirements. As applicable, we or the Payor will, to the extent permitted, give you notice of any such material changes and an opportunity to accept such new provisions or to withdraw from the affected Elevate Document (as defined in Term Sheet 1 of the GNP Premier Agreement, which is Exhibit B to this Disclosure Document) or the Elevate Provider Network.

Restrictions on Systems

You must use a pharmacy management system from one of the participating industry vendors that enables connectivity with our programs and: (1) sign our Data Authorization to the Master Program Agreement (Exhibit E of the GNP Premier Agreement which is attached to this Disclosure Document as Exhibit B) to initiate our cooperation with your participating vendor; and (2) have the capture and upload of your data to InSite in full operation. *See* Items 1 and 11 and also Exhibit B.

While use of a point-of-sale system is optional, some Available Programs require use of a point-of-sale system from one of the participating industry vendors that enables connectivity with InSitePOS (managed in conjunction with our Program Partner Retail Insights) and to have the capture and upload of your data to InSitePOS in full operation. We may add, discontinue or modify arrangements with participating industry vendors.

Restrictions on Signage and Trade Dress

Each Pharmacy must be identified as a participating "Good Neighbor Pharmacy®" as ABDC designates. At each pharmacy location, within 90 days after signing the GNP Premier Agreement, you must remove any and all non-GNP pharmacy-franchise-related signage and/or trade dress (if applicable) and install GNP signage and trade dress that meets our Standards. Our current signage Standards require: (i) at least one "GOOD NEIGHBOR PHARMACY" identification window decal; (ii) at least one "GOOD NEIGHBOR PHARMACY" logo, which is available in both standard and customized interior and exterior versions; (iii) "GOOD NEIGHBOR PHARMACY" member plaque; and (iv) any other signage required by ABDC, as set forth in the GNP Manual.

We provide complimentary signage packages to all new franchisees that when applied according to our standards meet our minimum requirements. If you are an existing Voluntary Pharmacy we may provide only a partial package as compliant signage may already be installed. You may purchase additional GNP signage which is typically purchased from an approved vendor that is not affiliated with ABDC. However, in order to facilitate administration, ABDC generally pays for signage ordered from its approved vendor and then invoices the pharmacy for such signage. ABDC may also pre-purchase signage from the approved vendor to facilitate delivery, in which case ABDC will also bill the pharmacy for signage purchased by ABDC from this outside vendor.

The GNP Manual describes Standards for appearance, placement and visibility of signs. You must keep the signage in good repair at all times. As discussed above, if you do not yet have required signage, you must do so within 90 days of signing the GNP Premier Agreement and should immediately begin taking necessary steps, such as initiating and pursuing permits and approvals. We may modify signage requirements and at that time you must comply with such modifications at your expense. You may not vary from any of the signage Standards unless we have approved the change in writing before you use any non-compliant signage. Variations and exceptions are reviewed and approved by the Good Neighbor Pharmacy department before use.

Restrictions on Internet Marketing

You may promote your GNP Premier Pharmacy and sell products using the Marks on the internet in accordance with the GNP Premier Agreement, GNP Manual and Standards, so long as you clearly identify your business and comply with all applicable laws. Specifically, you cannot identify your store as a Good Neighbor Pharmacy store without also clearly indicating the full name under which you are licensed or do business, as well as your geographic location. We do not require that you get our prior approval for any internet domain name, home page address or internet content. We may restrict use of an internet domain name, vanity URL, home page or other web address that includes a Mark (or require a separate license for such use), limit your use of hyperlinks or require use of hyperlinks or other material (including required links to the MyGNP Website) and restrict use of material in which any third party has any interest. However, your website, including any use of Marks on or in connection with it, must comply with applicable Standards, and you must modify or discontinue your website if we notify you that any use or material is disapproved. *See* sections 1(c), 8(a), and 8(b) of the GNP Premier Agreement (which is Exhibit B to this Disclosure Document). You are solely responsible for accuracy of content you provide on the internet.

Restrictions on Products

As a GNP Premier Pharmacy, except where prohibited by law, you must purchase from us brand and generic prescription (“Rx”), over-the-counter (“OTC”) and health and beauty care (“HBC”) products and GNP Private Label Products pursuant to a distribution agreement such as a prime vendor agreement (“PVA”) or other buying arrangement through an approved group purchasing organization or retail buying group. Typically, distribution agreement terms are the same or substantially similar to those that would be available to you whether or not you are a GNP Premier Pharmacy. We will provide access to electronic catalogs of such products, which are typically updated daily. You must place orders using one of our then-current order systems, with purchases subject to terms in your distribution agreement or as otherwise agreed, including terms for payment, credit, liability, risk of loss, shortages, delays and compliance with law. All such orders will be at our standard then-current wholesale prices under your distribution agreement. You may purchase new products, including Rx and GNP Private Label Products, as they are available.

You must accept delivery of AutoShip products from us, sent without a corresponding order from you, and promote them as required in the Front-End Solution Program terms, Term Sheet 5 of the GNP Premier Agreement (which is Exhibit B to this Disclosure Document). “AutoShip” is a service that we

provide to make you more competitive and includes certain new market break items, line extensions, GNP Private Label Products, Rx-to-OTC switch and other OTC products. You must promote the products to consumers using promotional materials we have provided and display them according to our schematic diagrams ("Planograms").

Additionally, you are required to support national advertising programs, for example by stocking products and providing services that are featured. Also, you must use shelf sign kits, shelf talkers and other promotional material that we provide, display advertising circulars in your GNP Premier Pharmacy and comply with Planograms.

Restrictions on Approved Suppliers

Purchases of GNP supplies and services are often restricted to approved vendors. In general, vendors we approve are those who demonstrate, to our continuing reasonable satisfaction, their ability to meet our Standards. All vendors we approve must have adequate quality controls and the capacity to supply the needs of GNP Premier Pharmacies promptly and reliably over an extended period of time at a competitive price. Currently, we are an approved supplier of brand and generic prescription ("Rx"), over-the-counter ("OTC") and health and beauty care ("HBC") products and GNP Private Label Products pursuant to a distribution agreement such as a prime vendor agreement ("PVA") or other buying arrangement through an approved group purchasing organization or retail buying group. Except as otherwise disclosed in this Item, neither we nor our affiliates are currently approved suppliers.

We may designate other specific vendors and suppliers in the future. Let us know if you desire to purchase supplies or products from a supplier that is not already approved and we will evaluate the need to do so. Our prior written approval may take up to 90 days or more after we receive all requested information, including information regarding the supplier's fiscal strength, demonstrated customer service, product quality, product safety and market presence. We do not charge any fees related to obtaining alternate supplier approval. If GNP determines that a previously approved alternate supplier of GNP supplies and services no longer demonstrates to our satisfaction their ability to meet our Standards, such alternate supplier will be removed from our list of approved vendors.

We may receive revenue from the sale of items to GNP Premier Pharmacies and expect to contract with vendors that may provide volume discounts, rebates or other benefits based on aggregate purchases of supplies and products by GNP Premier Pharmacies. We expect to receive payment from third party vendors on the sale of certain logoed items (such as shirts and key chains) to GNP Premier Pharmacies. The payment from third party vendors on the sale of certain logoed items should not exceed 25% of the cost to acquire such logoed items. These items will not be offered for resale, and you are not required to buy them. However, if you choose to purchase these items, they must meet our ~~trademark standards.~~Standards. We anticipate that most such benefits we receive based on your purchase of products and supplies related to the GNP Premier Program will be used to enhance and promote Available Programs or otherwise used to benefit GNP Premier Pharmacies generally. In certain cases, we may allocate such benefits directly and proportionally to participating GNP Premier Pharmacies and we may deduct our expenses to administer and coordinate suppliers. We reserve the right to receive revenue from the sale of items to you by others. In the GNP Premier Agreement, you assign to us for collection and for our account promotional and advertising allowances related to the GNP Premier Program and all related products and services. Additionally, ABDC charges outside reconciliation service vendors a data interchange fee (typically a monthly flat fee per location, currently $55.00) as compensation for our consolidating remittance advices from multiple Payors into a single, consistent format. Except as described above, as of the date of this Disclosure Document, no third-party vendors are providing rebates, discounts or other benefits to us based on required purchases by GNP Premier Pharmacies from any third-party vendor, and there are no agreements in effect which would require them to do so.

Restrictions on Insurance

Because operation of each GNP Premier Pharmacy reflects on other GNP Premier Pharmacies and the goodwill of the GNP Premier Program, we expect that you and all other GNP Premier Pharmacies will use your best efforts to operate with diligence and vigor, and maintain the highest possible ethics, as well as maintain your Pharmacy and personnel in a manner that are a credit to the community and reflect the high standards and quality of the GNP Premier Program, including, without limitation, interacting with and treating all customers and ABDC personnel in a respectful and professional manner. However, with such interdependence, there is some increase in the risk that we, you, or other GNP Premier Pharmacies could be sued as the result of actions for which we are not responsible. As such, each GNP Premier Pharmacy must carry commercial general liability and professional liability insurance in the amounts and on terms required by Payors, with minimum requirements described in note (f) of Item 7. We anticipate this is comparable to insurance already in place for most existing pharmacies and, as such, there will be little or no incremental expense. Such insurance will be underwritten on an occurrence basis, covering activities and errors and omissions of your GNP Premier Pharmacy and your personnel, in each case naming ABDC and our affiliates as additional insureds and requiring at least 30 days' written notice to ABDC if such insurance is cancelled or coverage is reduced. You will provide ABDC with a copy of such policies upon request. Any pharmacist or other health care professional providing covered services who is not separately insured by policies with similar coverage and limits must be covered on your insurance. *See* Section 4(l), Elevate Provider Network program terms, Term Sheet 1 of the GNP Premier Agreement (which is Exhibit B to this Disclosure Document).

Licensing Requirements

As a condition to being a GNP Premier Pharmacy, including as a condition to providing any covered services to persons covered by Payor pharmacy benefit plans, you must be fully licensed at your Pharmacy ~~location~~Location. If you have an existing pharmacy, we anticipate all such licensing would already be in place and, as such, there will be little or no incremental expense. If you have a start-up pharmacy, please review our estimated licensing costs for start-up pharmacies provided within Item 7.

Other

None of our officers own any interest in any Payor (other than those times we function as the Payor) or other approved vendor.

We have not arranged any purchasing cooperatives for our franchisees, and, except as described above, we do not negotiate purchase arrangements with suppliers for your benefit. We also do not provide material benefits to our franchisees, such as renewal or granting additional franchises, based upon their purchases of particular products or services and their use of certain designated suppliers or vendors.

During fiscal year 20252024, our parent company, Cencora, had revenues of $~~293,958,599~~ 321,332,819,000, which includes parts of its business other than ABDC. The US Healthcare Solutions Division of Cencora, which includes ABDC, had revenues during fiscal year 20252024 of $~~265,339,427,000.~~290,982,022,513.13. ABDC's revenues during fiscal year 20252024 were $~~252,075,459,882~~277,303,688,430.26, of which about $0.~~46~~51 billion (approximately 0.18%) was derived from sales of products and services to Voluntary Pharmacies and about $~~7.89~~8.32 billion (approximately 3.~~13~~00%) was derived from sales of products and services to GNP Premier Pharmacies.

We estimate that the purchases described above may be nominal (5% or less) of the cost to open a GNP Premier Pharmacy for an existing Voluntary Pharmacy. Typically, for purposes of comparison, the cost to purchase inventory for a community pharmacy can range from approximately 65% to 80% of ongoing operating expenses. We estimate that the ongoing required purchases of GNP Private Label

Products will be nominal (1% or less of total operating expenses for a GNP Premier Pharmacy), as determined by you in your reasonable discretion based on your general business experience.

ITEM 9
FRANCHISEE'S OBLIGATIONS

This table lists your principal obligations under the GNP Premier Agreement and its exhibits and Term Sheets. It will help you find more detailed information about your obligations in these agreements and in other items of this Disclosure Document.

Available Program Term Sheets

Key:	Elevate Provider Network	Term Sheet 1
	Elevate Advanced Features	Term Sheet 2
	Pre and Post Edit Solutions	Term Sheet 2A
	Claim Reconciliation Services	Term Sheet 2B
	Outcomes ~~PCS Solution~~ Patient Care Services	Term Sheet 2C
	EnlivenHealth Patient Care Services	Term Sheet 2D
	InSite from ABDC	Term Sheet 3
	Five-Star Rebate	Term Sheet 4
	The Front-End Solution Programs	Term Sheet 5
	Digital Marketing	Term Sheet 6
	Business Coaching	Term Sheet 7
	Pharmacy System Data Services	Term Sheet 8
	Unsaleable Returns	Term Sheet 9
	Statement of Work-Services (Form)	Term Sheet 10

Obligation	Section In GNP Premier Agreement	Item In Disclosure Document
a. Site selection and acquisition/ lease	Not Applicable	7, 11, 12
b. Pre-opening purchases/leases	Not Applicable	7, 8, 11
c. Site development and other pre-opening requirements	Not Applicable	5, 6, 7, 8, 11, 12
d. Initial and ongoing training	Term Sheet 1, Section 4 Term Sheet 2B, Section 4	7, 11
e. Opening	Not Applicable	5, 7, 11
f. Fees	Section 2, Summary and Signature Pages, Section 9(c), Exhibit E and; All Term Sheets Section 2, except: Term Sheet 5, Sections 2, 3, 4, 5, 6 and 7; Term Sheet 6, Section 2, 3, 4 and 5; Term Sheet 8, Sections 3, 4; and Term Sheet 9	5, 6, 7

Obligation	Section In GNP Premier Agreement	Item In Disclosure Document
g. Compliance with standards /GNP Manual	Sections 4, 5, and 8, Exhibit E, HIPAA Business Associate Agreement, Sections 2, 3; Term Sheet 1, Section 4; Term Sheet 2A, Sections 3, 6; Term Sheet 2B, Section 3; Term Sheet 2C, Section 3, Term Sheet 3, Sections 5, 7; Term Sheet 6, Section 10;	1, 8, 11
h. Trademarks and proprietary information	Sections 1(a), 1(d), 3(a), 4(k), 10; Term Sheet 1, Sections 4, 7; Term Sheet 2A, Sections 3, 5, 6; Term Sheet 2B, Section 3, 5; Term Sheet 2C, Section 3, Term Sheet 3, Sections 3, 5, 6;	13, 14
i. Restrictions on products/services offered	Section 1(d), 4(a), 4(g), and 4(h); Term Sheet 1, Section 4	11, 16
j. Warranty and customer service requirements	Not Applicable	Not Applicable
k. Territorial development and sales quotas	Not Applicable	12
l. Ongoing product/ service purchases	Sections 4(g), 6	8
m. Maintenance, appearance and remodeling requirements	Sections 3, 4(a)-(d), 4(l), 5	5
n. Insurance	Term Sheet 1, Section 4;	7, 8
o. Advertising	Sections 5, 8 and 9; Term Sheet 5, throughout	5, 6, 7, 11
p. Indemnification	Paragraph 6, Provisions, Exhibit C; HIPAA Business Associate Agreement, Paragraph 6; Term Sheet 1, Section 4; Term Sheet 7, Section 7; Term Sheet 8, Section 8	6
q. Owner's participation/ management/staffing	Section 4(e)	15

Obligation	Section In GNP Premier Agreement	Item In Disclosure Document
r. Records/reports	Paragraph 2, Provisions, Exhibit C Term Sheet 1, Sections 3, 6; Term Sheet 2A, Section 4	8
s. Inspections/audits	Paragraph 1, Provisions, Exhibit C; Term Sheet 1, Section 6;	11
t. Transfers	Section 11	17
u. Renewal	Section 7(a) Term Sheet 1, Section 9	17
v. Post-termination obligations	Section 13, Paragraph 5.2, Provisions, Exhibit C; Term Sheet 1, Section 9;	17
w. Non-competition covenants	Not Applicable	17
x. Dispute resolution	Paragraph 2, Provisions, Exhibit C; Section 15; Term Sheet 1, Sections 3, 4 Term Sheet 2A, Section 4 Term Sheet 2B, Sections 3, 7	17

ITEM 10
FINANCING

We do not offer direct or indirect financing other than the payment terms included in your ABDC distribution agreement. We do not guarantee your note, lease or any other financial obligation.

ITEM 11
FRANCHISOR'S ASSISTANCE, ADVERTISING, COMPUTER SYSTEMS AND TRAINING

Except as listed below, ABDC is not required to provide you with any assistance.

Pre-Conversion

After you execute the GNP Premier Agreement, but before you operate as a GNP Premier Pharmacy:

We will make accessible to you the GNP Manual, in electronic format, which contains our Standards. (Section 2(c) of the GNP Premier Agreement, which is Exhibit B to this Disclosure Document). The GNP Manual is currently ~~97~~94 pages long, and the table of contents is attached to this Disclosure Document as Exhibit C.

Computer Systems

Computer hardware and software systems, which range in cost from $0 to $55,000, include a required pharmacy management system and an optional point-of-sale system. Pharmacy management systems enable the prescription dispensing process including patient profiles, clinical screening, inventory replenishment, claim submissions and connectivity to e-prescribing networks. Point-of-sale systems enable retail checkout processes such as UPC scanning, credit and debit card processing, inventory replenishment, and sales reporting. While capability, features and the type of data generated and stored on such systems vary among vendors that provide point-of-sale systems that meet program requirements, typically data includes a master file (items a store sells and their prices, including sale or other special prices), transaction information (item sold, its price, and how it was paid for, such as cash, credit card, etc.) and inventory information (number of units ordered, received, sold and on-hand). We will not have independent access to the information stored in your system. However, Select Vendors and participating vendors may have access to your system and directly or indirectly coordinate the transmission of certain information to us, subject to applicable law and agreements, including the Data Protection Provisions and any HIPAA Business Associate Agreement.

System vendors typically provide regular maintenance updates under support contracts which typically range from $2,000 to $5,000 per year depending on your system's size and the options you select. The costs associated with maintenance updates and support contracts are subject to the terms you negotiate with your system vendor.

Post-Conversion

After you become a GNP Premier Pharmacy, we will make accessible to you additions, modifications and supplements to the GNP Manual as they become available in electronic format. *See* Section 2(e) of GNP Premier Agreement. Additionally, we will provide the following services and assistance to you.

Our Assistance with Available Programs

We will provide Available Programs, including any optional programs that you select, consistent with applicable Term Sheets, industry standards and applicable laws, and subject to our right to modify or discontinue any particular Available Program (see GNP Premier Agreement, Section 3(a) and Paragraph 1 of Provisions, Exhibit C).

1. Elevate Provider Network (See Paragraphs 3(a)-(g) of Term Sheet 1 to the GNP Premier Agreement, which is Exhibit B to this Disclosure Document).

- Negotiate Payor Contracts on your behalf for paying and processing covered claims;
- Provide a help desk during normal business hours;
- Publish newsletters and other communications to assist in claim submission;
- Assist you in investigating Payor problems;
- Promote your GNP Premier Pharmacy to Payors;
- Offer direct deposit to your account for payments from Payors through our central payment service;
- Offer claim reconciliation service to you or alternatively, provide consolidated electronic remittance advices (RAs) to your selected outside vendor for reconciliation; and

- Update pharmacy plan specifications received from Payors.

2. Elevate Advanced Features (See Term Sheet 2, 2A, 2B, 2C, and 2D to GNP Premier Agreement).

- Collaborate with your designated system vendors and our Program Partners for the transmission of your business data to InSite from ABDC as necessary to facilitate your participation in PPE Solutions, Claim Reconciliation Services, ~~and~~ the Outcomes ~~PCS~~Premium Solution, and the ~~Amplicare Clinical~~EnlivenHealth Treat Solution.

3. InSite from ABDC Program (See Term Sheet 3 to GNP Premier Agreement).

- Collaborate with your designated system vendors and our Program Partners for the transmission of your Pharmacy Data to InSite from ABDC to facilitate your participation in Available Programs;

- Provide you with reports, studies, analyses and other compilations about your business performance, including various benchmark comparisons from our proprietary pharmacy performance analytics system, InSite; and

- Protect your ~~business data~~Pharmacy Data pursuant to the Data Protection Provisions.

4. The Front-End Solution Programs. Provide products, materials, marketing support and merchandising services with respect to non-prescription brand name and GNP Private Label Products we supply, as described under Advertising in this Item 11. *See* Term Sheet 5 to GNP Premier Agreement.

5. Digital Marketing. Provide an overall strategy to attract and engage patients and consumers online. Includes the following programs: MyGNP Website, MyGNP Mobile App, Digital and Social Media Marketing, and Local Listings Management. *See* Term Sheet 6 to the GNP Premier Agreement.

6. Business Coaching Program. Provide certain recommendations related to increasing your Pharmacy's performance through our representative, including gathering data, ~~report~~reporting and ~~present~~presenting our findings and recommendations to you by various means, ~~guide~~guiding you in implementing the recommendations, ~~provide~~providing on-going coaching, and ~~help~~helping to set goals for your Pharmacy. *See* Term Sheet 7 to GNP Premier Agreement.

7. Pharmacy System Data Services Program. Furnish certain system data services to assist with pharmacy computer applications, including pharmacy management and point-of-sale systems. Such system data services include electronic order entry and confirmation and catalog and price updates for prescription pharmaceuticals and OTC products, via on-line downloads or access to our secure website. *See* Term Sheet 8 to GNP Premier Agreement.

8. Unsaleable Returns. Provide quarterly on-site assistance including the processing of returns, packing and shipping of returned products, printing inventory manifest and requesting 222 forms and issue monthly checks based on the ERV before the product is returned to the manufacturer. See Term Sheet 9 to the GNP Premier Agreement.

Our Assistance with Ordering ABDC Products

We will provide access to electronic catalogs for our brand and generic prescription pharmaceuticals, over-the-counter, health and beauty care and our GNP Private Label Products, which we typically update daily. *See* Section 4(f) of GNP Premier Agreement.

Our Assistance with Site Selection

We do not offer any site selection services.

Our Assistance with Training

GNP Premier Pharmacies will be owners and operators of an existing or start-up pharmacy and, as such, we do not currently offer any initial training.

Our Assistance with Advertising and Promotions

The GNP Premier Agreement, the Front-End Solution Programs Term Sheet and Digital Marketing Term Sheet and (Term Sheets 5 and 6, respectively) describe advertising and marketing assistance that we provide and your obligations. The GNP Premier Agreement contains provisions regarding advertising on the internet. The Front-End Solution Program terms describe the various types of merchandising support that we offer to you (see Item 1 for a description).

Under the Front-End Solution Programs, we provide: (i) automatic shipment (without your order) of certain over-the-counter ("OTC") products to facilitate your prompt stocking of products to meet anticipated consumer demand (First To Shelf™); (ii) a set of schematic diagrams ("Planograms") with periodic updates showing recommended layout of specific product categories; (iii) periodic suggested retail prices for a broad range of health and beauty aids, OTC and other non-prescription products, based on various factors (Retail Product Zone Pricing Service); (iv) optional merchandising assistance; and (v) a point-of-sale data analytics system used to measure and compare the performance of pharmacy front-ends (InSitePOS from ABDC).

We are not obligated to conduct advertising, nor to spend any amount in connection with advertising in your area or territory. We do not currently require you to join a regional advertising cooperative or contribute to an advertising fund.

You may use your own advertising materials (including internet advertising, as described in Item 8), so long as the materials comply with our Standards.

Our Assistance with Advertising Council & National Advisory Boards

We do not currently have a franchisee advertising council that advises on advertising policies. We may form one in the future, but we have no obligation to do so. If we do, we will have the right to determine how its members are selected and the scope of its authority as well as the right to change or dissolve the franchisee advertising council.

We currently have a national advisory board consisting of owners/operators of GNP Premier Pharmacy owners. The number of members on the national advisory board may vary between 5 and 18, but currently includes ~~11~~10 members. Members of the national advisory board provide us with advice and recommendations on issues related to the ~~Good Neighbor Pharmacy~~GNP Premier Program and its administration, participate in design of new and modified programs and value-added services, including Available Programs, make presentations to peers on the GNP Premier Program and related services, recommend new business opportunities for us and community pharmacies, and otherwise assist us. National advisory board members are nominated and selected by ABDC and agree to participate actively in the GNP Premier Program and comply with certain standards. Typically, they serve a 3-year term but may resign at any time and extensions may be offered. Advisory board members are not paid, although we may reimburse their expenses to attend in-person meetings in some circumstances.

Our Assistance with Internet Capability

We engage in advertising on the internet for consumers and control its design and contents, which we plan to maintain but may discontinue it at any time. *See* GNP Premier Agreement, Section 8(c).

We may establish and maintain a portal through which GNP Premier Pharmacies may communicate with each other and through which we may disseminate updates and supplements to the GNP Manual and other Confidential Information ("GNP Portal"). We will establish policies and procedures and other terms of use to address issues such as: (i) restrictions on the use of abusive, slanderous or otherwise offensive language; (ii) restrictions on communications that endorse or encourage breach of any agreement, including a GNP Premier Agreement; (iii) confidential treatment of materials contained in the GNP Portal; (iv) password protocols and other security precautions; (v) grounds and procedures for suspending or revoking your access to the GNP Portal; (vi) a privacy policy governing our access to and use of electronic communications that franchisees post on the GNP Portal; and (vii) compliance with laws, including antitrust laws and HIPAA. Your right to access the GNP Portal will continue until your GNP Premier Agreement's expiration or termination. To increase usefulness of the GNP Portal, you must allow us to use, publish and copyright photographs of your GNP Premier Pharmacy and your statements with or without identifying information for editorial, promotional, advertising or other purposes, at any time and in any medium, including advertising on the internet for consumers and the GNP Portal. We plan to maintain the GNP Portal but have the right to discontinue it at any time. *See* GNP Premier Agreement, Section 8(d).

ITEM 12
TERRITORY

GNP Premier Agreement

Under the GNP Premier Agreement, we grant you the right to operate one or more GNP Premier Pharmacies under the Marks and our GNP Premier Program, each at an approved Pharmacy Location specified in the GNP Premier Agreement. Your use of the Marks or any element of the GNP Premier Program in the operation of a business at any other address or in any other channel of distribution without our express prior written authorization will constitute willful infringement of our rights in the Marks and the GNP Premier Program. We do not permit the relocation of an approved Pharmacy Location. In the event that you would like to change your approved Pharmacy Location or open an additional franchise, you must complete the same approval process used to establish your currently approved Pharmacy Location(s). Additionally, you must be in good standing with our wholesale distribution business and in compliance with the standards set forth by this Disclosure Document and the Premier Participation Agreement. We do not grant you any options, rights of first refusal or any similar right to obtain additional franchises under the GNP Premier Agreement.

You will not receive an exclusive territory. You may face competition from other franchisees, from outlets that we own, from other channels of distribution or competitive brands that we control.

You will have no competitive protection at all. We reserve rights to do any of the following without compensation to you, regardless of proximity to or competitive impact on you:

(i) Allow others to establish and operate GNP Premier Pharmacies, Voluntary Pharmacies or other businesses, and do so ourselves;

(ii) Offer and sell the GNP Premier Program and related products and services to other customers;

(iii) Establish, operate, offer and sell other businesses, goods and services, or allow others to do so, including those that are the same, similar or different and using some, all or none of the Marks; and

(iv) Advertise and promote the sale of any products and services in any area and advertise and promote franchises for other GNP Pharmacies.

We do not impose any restrictions on your right to use other channels of distribution in connection with the GNP Premier Pharmacy franchise relationship~~.~~ except as specified otherwise herein.

We have no obligation or duty to insulate or protect your revenues from erosion as the result of your GNP Premier Pharmacy's competition with other GNP Premier Pharmacies, with Voluntary Pharmacies or with other pharmacies not affiliated with us to whom we may provide goods and services.

ITEM 13
TRADEMARKS

We have registered the following principal Marks on the Principal Register of the United States Patent and Trademark Office ("USPTO"):

Mark Name	Registration Number	Registration Date
	4205108	9/11/2012
	4209193	9/18/2012
GOOD NEIGHBOR PHARMACY	1516842	12/13/1988
GOOD NEIGHBOR PHARMACY	5726298	4/16/2019
GOOD NEIGHBOR SCRIPT	5927822	12/3/2019
ELEVATE PROVIDER NETWORK	5115412	1/3/2017
LOCALLY OWNED. LOCALLY LOVED.	5449413	4/17/2018
MY GNP	7154791	9/5/2023
YOUR PARTNER IN DIABETES CARE	2937589	4/5/2005
DIABETES SHOPPE	2953807	5/17/2005

We filed all required affidavits and renewals for our trademark registrations related to Marks and for those classes of the Marks that are still in use and know of no superior prior rights or infringing uses of Marks that could materially affect their use.

You must notify us of any infringements of, or challenges to, the Marks that come to your attention and actively cooperate with us in the investigation of any infringement or challenge. We have the right to control any administrative proceedings or litigation involving the Marks and will take whatever action we deem appropriate.

Although we are not contractually obligated to defend the Marks, we intend to do so vigorously. We will defend and indemnify you against third party claims of infringement or unfair competition arising from your authorized use of the Marks that comply with the GNP Premier Agreement and Standards. Your indemnity of us will include an infringement claim arising from use that is not authorized or is not compliant. *See* Exhibit C, Paragraph 6, of the GNP Premier Agreement.

You may not use “GOOD NEIGHBOR PHARMACY”, “ELEVATE PROVIDER NETWORK” or any other Mark, or any abbreviation, acronym or variation as part of your corporate or other legal name without our express and written consent, and you must comply with our instructions in filing and maintaining trade name or fictitious name registrations. You must sign any documents we require to protect the Marks or to maintain their continued validity and enforceability. In addition, you may not directly or indirectly contest the validity of our ownership of the Marks, or of our rights in the Marks.

You may use the Marks in connection with advertising on the internet, subject to your compliance with the GNP Manual, our Standards and applicable law. Although we do not require that you get our prior approval for any internet domain name, vanity URL, home page or other web address or internet content, we may restrict use that includes a Mark (or require a separate license for its use), limit your use of hyperlinks or require use of hyperlinks or other material (including required links to our advertising on the internet for consumers), and restrict use of material in which any third party has any interest. You must discontinue any use if we notify you that any use or material is disapproved. You are responsible for the accuracy of all content.

Upon expiration or termination of your GNP Premier Agreement for any reason, you must immediately discontinue the use of all the Marks. You must take appropriate action to remove the Marks from your GNP Premier Pharmacy location and online presence.

There are no currently effective determinations of the U.S. Patent and Trademark Office, the Trademark Trial and Appeal Board or the trademark administrator of any state or any court, nor are there any pending infringement, opposition or cancellation proceedings involving the Marks. Nor is there any pending material federal or state court litigation regarding our use or ownership rights in the Marks. If we modify or discontinue the use of the Marks, you must promptly comply with and adopt all such modifications at your own expense.

ITEM 14
PATENTS, COPYRIGHTS AND PROPRIETARY INFORMATION

Neither we nor our affiliates currently own any required patents or registered copyrights that are material to the franchise. There are no pending patent applications that are material to the franchise.

The GNP Premier Program and its components, the contents of the GNP Manual and all of the employee training materials and computer applications developed by us or in accordance with our Standards and any confidential information that we impart to you with respect to a GNP Premier Pharmacy's operation or management, whether through the GNP Manual, Confidential Information, or otherwise (collectively, “Trade Secrets”) belong exclusively to us or our licensors, if applicable, and the ideas and information in the GNP Manual are our sole and exclusive property.

You and your Principals must hold the elements of the GNP Premier Program, the Trade Secrets and the contents of the GNP Manual in strict confidence, must not disclose any Trade Secret or any operating or management procedure to any person other than your Designated Manager (as defined in the GNP Premier Agreement) and your employees who must receive disclosure to understand their job duties, and you must instruct and routinely remind your employees that the GNP Premier Program, the Trade Secrets and the contents of the GNP Manual are confidential and may not be disclosed or appropriated. You may not disclose any element of the GNP Premier Program, any of the Trade Secrets or the contents of the GNP Manual, or make the GNP Manual available, to anyone who is not actively and regularly involved in your GNP Premier Pharmacy's management, including, if you are a business entity, a shareholder, director, officer, partner, member or manager (other than your Designated Manager) who is not actively managing your Pharmacy.

You and your Principals must not use any element of the GNP Premier Program, any of the Trade Secrets or the operating, management or marketing procedures in the GNP Manual in connection with the operation of any establishment or enterprise other than your GNP Premier Pharmacy, and must promptly discontinue use of the GNP Premier Program, the Trade Secrets and the operating, management and marketing procedures in the GNP Manual upon the expiration or termination of your GNP Premier Agreement.

You and your Principals must not, without our prior written consent, copy or permit any person to inspect, copy or reproduce any part of the GNP Manual and any other printed, graphic or audio/visual item designated by us as containing Trade Secrets or otherwise permit their use or inspection by any person other than you, your Designated Manager and your employees who need to be disclosed to in order to perform their job duties, and our authorized representatives.

All employee training materials (including videos, presentations, audio or web-based video programs) and all computer programs developed by us or by following our standards contain information, embody procedures or facilitate business practices that are proprietary to us and fall within the parameters of our Trade Secrets.

You must notify us of any infringements of or challenges to the copyrighted materials that come to your attention and actively cooperate with us in the investigation of any infringement or challenge. We have the right to control any administrative proceedings or litigation involving the copyrighted materials and will take whatever action we deem appropriate.

Although we are not contractually obligated to defend the copyrighted materials, we intend to do so vigorously. We will defend and indemnify you against third party claims of infringement or unfair competition arising from your authorized use of copyrighted material that complies with the GNP Premier Agreement and Standards. Your indemnity of us will include an infringement claim arising from use that is not authorized or is not compliant. See Exhibit C, Paragraph 6, of the GNP Premier Agreement.

If we modify or discontinue the use of any copyrighted materials, you must promptly comply with and adopt, at your own expense, all such modifications.

You, your GNP Business ~~Coach~~Coaching Associate and certain of your employees are bound by confidentiality provisions (see Item 17) concerning the proprietary information and may be required to enter into a confidentiality agreement (see Item 15).

If you develop or suggest an innovation or improvement that we decide to incorporate into the GNP Premier Program, either temporarily or permanently, the innovation or improvement will become our Confidential Information and property without compensation to you.

ITEM 15
OBLIGATION TO PARTICIPATE IN THE ACTUAL OPERATION OF THE FRANCHISE BUSINESS

You must appoint a Designated Manager to be your primary contact with us to administer and coordinate our relationship. As explained in Item 11, we do not currently offer any initial training, other than continuing education courses offered at our annual trade show and optional education available on Good Neighbor Pharmacy University. In the future, we may offer other training, at our option, with or without a fee.

Your Principals will be bound by certain provisions of the GNP Premier Agreement. Your “Principals” include each of your officers and directors and those of any of your affiliates and anyone with a direct

or indirect interest in you or your affiliates, the GNP Premier Agreement or the assets, revenues or income of your GNP Premier Pharmacy, each as we may determine. If the franchisee is a business entity, the Designated Manager is not required to have any equity interest in the franchisee's business. By signing the GNP Premier Agreement, you agree your Principals will be bound by provisions relating to confidential treatment of our Trade Secrets and use of our copyrighted material.

You also must ensure that your Designated Manager, other employees and other representatives are aware of their obligations and do not disclose any ABDC Confidential Information.

By signing the GNP Premier Agreement, you and your Principals agree to be bound by a HIPAA Business Associate Agreement (in Exhibit B of the GNP Premier Agreement, which is Exhibit B to this Disclosure Document, or as we may agree otherwise) in connection with Available Programs, such as Elevate Provider Network, Elevate Advanced Features, Pre and Post Edit Solutions, Claim Reconciliation Services, ~~Outcomes PCS Solution, EnlivenHealth Patient Care Services,~~ InSite from ABDC and Business Coaching, that involve access to protected health information. A HIPAA Business Associate Agreement requires that we, you and your Principals to comply with the federal Health Insurance Portability and Accountability Act of 1996, as amended, relating to privacy of protected health information, which describes the uses and limits of use on the covered health information.

ITEM 16
RESTRICTIONS ON WHAT THE FRANCHISEE MAY SELL

GNP Premier Pharmacy franchisees must participate in the Elevate Provider Network, our program that provides access to pharmacy benefit plans of Payors and provides for the processing and payment of covered claims you submit through the program (or through another pharmacy services administration organization ("PSAO") that we approve) in connection with your provision of covered services for all Payors with which ABDC has entered into Payor ~~contracts on behalf of pharmacies in the Elevate Provider Network. A "Payor" is an entity that has entered or will enter into a Payor Contract~~ Contracts (as defined under Term Sheet 1 of the GNP Premier Agreement, which is Exhibit B to this Disclosure Document) ~~with ABDC~~on behalf of pharmacies in the Elevate Provider Network. A "Payor" is an entity that has entered or will enter into a Payor Contract with ABDC in connection with applicable covered services to be provided by participating Network Providers thereunder, such as: (i) a pharmacy benefit manager, health plan, or other third party that sponsors or administers prescription drug programs ~~or~~, health benefit plans, clinical services plans or programs, and/or is primarily responsible for processing and paying pharmacy claims; (ii) a prescription drug discount company; and/or (iii) a workers' compensation processing company. Additionally, From time to time under one or more Elevate Document (as defined under Term Sheet 1 of the GNP Premier Agreement, which is Exhibit B to this Disclosure Document), ABDC may also be a Payor that contracts with GNP Premier Pharmacies as part of providing its pharmacy benefit plan administration services~~..~~. Payor Contracts typically require you to provide certain covered services to eligible persons covered by a Payor's pharmacy benefit plan specifications. These services include dispensing pharmaceuticals or devices to eligible persons and providing such other services for which you accept any co-payment and compensation from a Payor as full payment.

If you offer products and services described in a Term Sheet, you may do so only if you comply with the Standards and the GNP Manual, and acquire all equipment, software and other items required for the services covered by the selected Term Sheet. You may sell products and services on internet websites only as we authorize in the GNP Manual or otherwise.

A Term Sheet only applies to a GNP Premier Pharmacy's authorized Pharmacy Location covered under a GNP Premier Agreement. You may not enroll for one ~~GNP Premier~~ Pharmacy~~,~~ Location and then use

Available Programs in another store even if you also own or control such other store unless it is otherwise permitted to do so.

You must comply with all laws, including maintaining all licenses and other required approvals and reporting or reflecting discounts, rebates and other price reductions relating to cost reports or claims submitted to federal or state healthcare programs. You must retain and make available upon request any invoices and related pricing documents.

You must feature the GNP Private Label Products as your preferred alternative to national brands~~,~~ and use your best efforts to promote and sell GNP Private Label Products. You must periodically order a representative assortment of GNP Private Label Products, as you determine is reasonable to meet anticipated consumer demand, based on your experience, taking into account, among other things, your Pharmacy's size and market. You must also accept automatic delivery of promotional and new products (see Item 8), and participate in the special promotions and new product introductions for those products.

We have the right to change the products and services without limitation, and you must promptly comply with the new requirements, unless you exercise your right to terminate the GNP Premier Agreement.

We regularly, as a course of business, add, discontinue and revise arrangements with Payors, typically in response to changes by Payors, and Payors regularly add, discontinue and modify pharmacy benefits plans and other related requirements. As applicable, we or the Payor will, to the extent permitted, give you notice of any such material changes and an opportunity to accept such new provisions or to withdraw from the affected Elevate Document (as defined in Term Sheet 1 of the GNP Premier Agreement, which is Exhibit B to this Disclosure Document) or the Elevate Provider Network.

ITEM 17
RENEWAL, TERMINATION, TRANSFER AND DISPUTE RESOLUTION

THE FRANCHISE RELATIONSHIP

This table lists certain important provisions of the GNP Premier Agreement, its exhibits and certain of the Term Sheets, including those for Elevate Provider Network and Business Coaching. You should read these provisions in the agreements attached to this Disclosure Document.

Available Program Term Sheets

Key:	Elevate Provider Network	Term Sheet 1
	Elevate Advanced Features	Term Sheet 2
	Pre and Post Edit Solutions	Term Sheet 2A
	Claim Reconciliation Services	Term Sheet 2B
	Outcomes ~~PCS Solution~~Patient Care Services	Term Sheet 2C
	Enliven Health Patient Care Services	Term Sheet 2D
	InSite from ABDC	Term Sheet 3
	Five-Star Rebate	Term Sheet 4
	The Front-End Solution Programs	Term Sheet 5
	Digital Marketing	Term Sheet 6
	Business Coaching	Term Sheet 7
	Pharmacy System Data Services	Term Sheet 8
	Unsaleable Returns	Term Sheet 9
	Special Projects Form	Term Sheet 10

Provision	Section in Premier Agreement	Summary
a. Length of the term	Signature Page and Section 7(a)	Five years. Generally, Available Programs continue until GNP Premier Agreement terminates.
b. Renewal or extension of the term	Section 7(a)	Automatic renewals for 2-year terms, unless we or you give 120 days' notice of intent not to renew.
c. Requirements for franchisee to renew or extend	Section 7(a)	Automatic renewals for 2-year terms if in compliance with program requirements, unless you or we give notice to terminate or not renew. However, as noted in paragraph (d), you may terminate anytime without cause on 60 days' notice. When renewing you may be asked to sign a contract with materially different terms and conditions than your original contract.
d. Termination by franchisee	Section 7(b)	Termination without cause on 60 days' prior written notice to us. (subject to state law)
	Paragraph 5, Provisions, Exhibit C	Termination without cause on 60 days' prior written notice to us; Termination for cause for reasons described in 17.h below. On written notice to us, for Bankruptcy (as defined in Paragraph 5), failure to pay continuing 5 days after written notice, or failure to perform any other material obligation continuing for 30 days after written notice.
e. Termination by franchisor without cause	Section 7(b)	Termination without cause on 60 days prior written notice to you.
f. Termination by franchisor with cause	Sections 7(c), 7(d) and 11 Paragraph 5, Provisions, Exhibit C	You or a Principal (as defined in Section 7(c)(ii)) commits any one of several listed violations; and as provided in Section 5, Provisions.

Provision	Section in Premier Agreement	Summary
	Section 4(i) Term Sheet 1, Section 9	We may terminate if you designate another PSAO as your primary contracting entity without our prior written approval. We may terminate if you default under the Elevate Provider Network Term Sheet, a Pharmacy Addendum or Payor contract, and do not cure after 30 days written notice; we or the Payor may terminate without notice or cure if you provide substandard, inferior, contaminated or adulterated drug products, violate laws relating to drug products, your licenses are revoked or suspended or you or your employees are barred from providing Medicare, Medicaid or other health care services or you commit any act or omission for which a Payor may terminate any Pharmacy Addendum or contract you have signed with a Payor; or you are insolvent. Termination by us ends all Payor relationships for your GNP Premier Pharmacy.
g. "Cause" defined – curable defaults	Term Sheet 1, Section 9(b)	Any failure to perform, in any material respect, your obligations under Elevate Documents.
	Paragraph 5, Provisions, Exhibit C	On written notice to you, for Bankruptcy (as defined in the Paragraph 5), failure to pay continuing 5 days after written notice, or failure to perform any other material obligation continuing for 30 days after written notice.
	Term Sheet 1 Section 9(a)	We may terminate if you fail to cure a default under any of the Elevate Documents 30 days after written notice.
h. "Cause" defined – non-curable defaults	Section 7(c)	Breach of confidentiality, abandonment, conviction/guilty or no contest pleas to certain crimes or any other conduct any of which may adversely affect our goodwill, another GNP Premier Pharmacy or our Marks.
	Paragraph 5, Provisions, Exhibit C	On written notice, for Bankruptcy as defined in Paragraph 5.

Provision	Section in Premier Agreement	Summary
i. Franchisee's obligations on termination/non-renewal	Section 13	Discontinue use of the Marks, Copyrighted materials, the GNP Premier Program and Trade Secrets, and remove Trade Dress, cancel advertising and cease using all Available Programs, except as mutually agreed.
	Paragraph 5, Provisions, Exhibit C	Pay all amounts due, return Software, equipment and material, including GNP Manual.
	Term Sheet 1, Section 9(e);	Customer must discontinue use of all signage, Marks and trade dress.
j. Assignment of contract by franchisor	Section 11 Paragraph 8.3, Provisions, Exhibit C	You consent to our assignment of all or part of our obligations under the GNP Premier Agreement and to the grant of a security interest by us or our affiliate. We may assign with notice to you. We may assign all or part of our obligations to an affiliate or for financing or securitization purposes without notice to you.
k. "Transfer" by franchisee – defined	Section 11	Includes transfer of contract or assets or any change in control (including sale of 25% or more of your assets or equity).
l. Franchisor approval of transfer by franchisee	Section 11	We may terminate if you do not have our prior written consent.
m. Conditions for franchisor approval of transfer	Section 11	You must promptly notify us of changes in ownership, name, form or state of business, and your intent to sell, close, move or modify your operations.
n. Franchisor's right of first refusal to acquire franchisee's business	Not Applicable	Not Applicable.
o. Franchisor's option to purchase franchisee's business	Not Applicable	Not Applicable.
p. Death or disability of franchisee	Not Applicable	Not Applicable.
q. Non-competition covenants during the term of the franchise	Term Sheet 1, Section 4(f)	We are your exclusive PSAO (unless you contract directly or through another pharmacy services administration organization ("PSAO") that we approve to provide covered services for all Payors with which ABDC has contracted). (subject to state law)

Provision	Section in Premier Agreement	Summary
r. Non-competition covenants after the franchise is terminated or expires	Not Applicable	Not Applicable. (subject to state law)
s. Modification of the agreement	~~;~~Section 4(g); Section 8.6, Provisions, Exhibit C; Section 5, Master Program Agreement, Exhibit E; Term Sheet 1 Section 5	Except for unilateral modifications by us permitted by the GNP Premier Agreement, the Master Program Agreement (Exhibit E of the GNP Premier Agreement), and its other Exhibits and Term Sheets, no modification except in writing signed by both parties. We may amend the GNP Premier Agreement, Master Program Agreement, and/or other Exhibits or Term Sheet if we determine it is appropriate or, respecting modification to applicable Elevate Documents, a Payor amends pharmacy plan specifications. We, or, respecting modification to applicable Elevate Documents, Payors, will give you notice and you may withdraw to the extent permitted under the affected documents if you don't agree.
t. Integration/ merger clause	Paragraph D	Only the terms of the franchise agreement and other related written agreements are binding (subject to state law). Any representations or promises made outside the disclosure document and franchise agreement may not be enforceable. Notwithstanding the foregoing, nothing in any agreement is intended to disclaim the express representations made in the Franchise Disclosure Document, its exhibits and amendments.
	Term Sheet 1, Section 5	Payor Contract controls if in conflict with the Elevate Provider Network Term Sheet.
u. Dispute resolution by arbitration or mediation	Section 15(c)	At ABDC's option, all claims or disputes which are not first resolved through the internal dispute resolution procedure will be submitted first to mediation to take place at ABDC's then-current corporate headquarters under the auspices of the American Arbitration Association ("AAA"), in accordance with AAA's Commercial Mediation Rules then in effect. (subject to state law)

Provision	Section in Premier Agreement	Summary
v. Choice of forum	Section 15(e)	Any actions arising out of or related to this Agreement must be initiated and litigated to conclusion exclusively in the state court of general jurisdiction closest to ABDC's then-current corporate headquarters. (subject to state law)
w. Choice of law	Paragraph 8.6, Provisions, Exhibit C; Section 15(a)	Pennsylvania law governs, subject to applicable state law.

A provision in the GNP Premier Agreement that terminates the agreement on your bankruptcy may not be enforceable under Title 11, United States Code Section 101.

ITEM 18
PUBLIC FIGURES

We do not currently employ any public figure or celebrity in our management.

ITEM 19
FINANCIAL PERFORMANCE REPRESENTATIONS

The FTC's Franchise Rule permits a franchisor to provide information about the actual or potential financial performance of its franchised and/or franchisor-owned outlets, if there is a reasonable basis for the information, and if the information is included in the Disclosure Document. Financial performance information that differs from that included in Item 19 may be given only if: (i) a franchisor provides the actual records of an existing outlet you are considering buying; or (ii) a franchisor supplements the information provided in this Item 19, for example, by providing information about possible performance at a particular location or under particular circumstances.

Background

This Item sets forth certain historical data pertaining to GNP Premier Pharmacies performance vs. industry statistics, GNP Premier Pharmacies participating in certain options programs as against non-participating GNP Premier Pharmacies, and GNP Premier Pharmacies own year-on-year performance for the measurement periods set forth in each of the notes below. The GNP Pharmacies are substantially similar to those offered in this Franchise Disclosure Document, where GNP Pharmacies participate in certain optional programs, those Pharmacies are noted and compared to those that do not participate. Information is what is reported to us from our franchisees for all GNP Premier Pharmacies that participated in the various programs for the time-period stated. We have not audited this information, nor independently verified this information. Written substantiation of the data used in preparing this information will be made available upon reasonable request. The information is for the periods set forth in the specific notes set forth below.

Clinical Services

1. Premier members administer on average ~~39~~41.4% more vaccinations.

This is based on comparing Independent Premier Members (1,~~915~~740 stores) and Independent Elevate Only members from (~~1,018~~964 stores) during the months of ~~November 2023 – July~~September 2024~~.~~ ~~–~~ August 2025. Premier members averaged ~~40~~53 vaccinations per month (min: ~~6~~9, max: ~~151~~244) compared to Elevate only members who averaged ~~29~~37 vaccinations per month (min: ~~6~~11, max: ~~95~~143) in the same period. ~~36~~28% of Premier customers were above average (~~681~~484 out of 1,~~915~~740 customers) with a median of ~~26~~28.

Elevate Members

2. Elevate members experienced 5.~~1~~0% year-over-year growth compared to 1.~~3~~2% for the independent class of trade and 2.~~5~~3% for the overall retail pharmacy market (August 2025~~2024~~).

Based on information licensed from IQVIA: RXInsight dated August 2025 for the period of August 2023 – September ~~2022 - August 2023~~ 2024 vs. September ~~2023 - August~~ 2024 ~~reflecting estimates of real-world activity. All rights reserved. Specifically, AmerisourceBergen has a limited release to cite~~ August 2025. IQVIA's Custom GNP Retail Prescription Report ("IQVIA Data") ~~in marketing disclosures. Such IQVIA Data may contain adjusted and unadjusted prescription performance~~ measures ~~for~~ AmerisourceBergen's GNP Pharmacies in the Independent Class of Trade, in addition to benchmarks to the overall Independent Class of Trade and the Overall Retail Segment (Chain, Mass Merchandisers, Food Stores and Independents~~)."~~) and is based on information provided to IQVIA by the pharmacies.

Five-Star Rebate

3. PRxO Generics five-star rebate: $~~781.79~~926.94 average payout of Q2 ~~2024~~2025 scoring 4.5 and higher.

~~Additional 0.25% rebate with Five Star Safety Net;~~ 1% maximum rebate. ~~591~~776 stores participating full Q2 2024, 50~~.1~~% above average, median $~~522.65~~738.54. Highest performing member $~~5,988.61~~7,113.98 and lowest $5.03.

4. ~~60~~68.6% higher proportion of Premier customers achieving 4.5 or greater star rating compared to non-Premier in Q2 2025.~~2024~~

~~591~~774 customers achieving 4.5 or greater five-star ratings participating full Q2 ~~2024~~2025, 50~~.1~~% above average, median $~~522.65~~738.56. Highest performing member $~~5,988.61~~7,113 and lowest $5.03.

5. 99.~~8~~7% higher rebate earned for Premier customers compared to non-Premier customers across all payout tiers in Q2 2025.~~2024~~

~~Additional 0.25% rebate with Five Star Safety Net;~~ 1% maximum rebate. 2,~~666~~284 stores participating in PRxO Generics five-star rebate for full Q2 2025, 37.6~~2024, 36.2~~% above average, median $~~391.73~~440.53. Highest performing member $~~5,988.61~~9,560.51 and lowest $5.

~~6. 2.3% average increase in pharmacy sales~~

~~Results are based on a comparison of 1,624 Premier accounts working with a business coach from Aug 2022 through Aug 03~~2024. Measured by Cencora, these numbers reflect best estimates and projections. Results are not guaranteed and may vary by individual facility. 49% above average. median 1.8%. Highest performing member 3,293.4% and lowest -98.4%.

~~7. 3.2% increase in the average number of patients per pharmacy~~

~~Results are based on a comparison of 1,624 Premier accounts working with a business coach from Aug 2022 through Aug 2024. Measured by Cencora, these numbers reflect best estimates and projections. Results are not guaranteed and may vary by individual facility. 45.9% above average. median 24. Highest performing member 1,890 and lowest -4,984~~.

Front-End Purchases

~~8~~6. 9.~~1~~2% Increase in front-end purchases (YOY)

Average performance for GNP Pharmacies (October 1, ~~2023~~2024 - September 30, 2025~~2024~~) All 2,~~111~~148 Pharmacies participating full year FY ~~23~~2024 & FY ~~24~~2025, 48% above average, median ~~8.0~~7.9%. Highest performing Pharmacy +~~3371~~21,708.6% and lowest -~~91.53~~286.15%.

Pharmacy Quality Performance

~~9~~7. GNP Premier Pharmacies complete, on average, ~~219~~121% more medication therapy management ("MTM") services per month~~.~~".

This is based on comparing Independent Premier Members (2,~~253~~282 stores) and Independent Elevate Only members from (~~2,091~~1,579 stores) during the months of ~~November~~ September ~~2023 – July~~ 2024~~.~~ – August 2025. Premier members averaged ~~80~~145 MTMs completed per month (min: ~~6~~14, max: ~~184~~359) compared to Elevate only members who averaged ~~25~~86 MTMs completed per month (min: ~~2~~9, max: ~~59~~163) in the same period. ~~32~~29% of Premier customers were above average (~~712~~667 out of 2,~~253~~282 customers) with a median of ~~$31~~93.

~~10~~8. GNP Premier Pharmacies earn on average ~~of 339~~252% more on enhanced services dollars per month.

This is based on comparing Independent Premier Members (~~1,982~~2,313 stores) and ~~Independent~~pharmacies only participating in Elevate ~~Only members from (1,512~~Provider Network (2,624 stores) during the months of ~~November~~ October~~2023 – July~~ 2024~~.~~ – September 2025. Premier members averaged $~~31~~25 Enhanced Services dollars earned per month ~~(min: $6, max: $49)~~ compared to Elevate only ~~members~~pharmacies who averaged $7 Enhanced Services dollars earned per month ~~(min: $1, max: $14)~~ in the same period. ~~15~~21% of Premier customers were above average (~~294~~491 out of ~~1,982~~2,313 customers) with a median of $0.

9. GNP Pharmacies earn 28% more dollars in the Humana MAPD performance Quality Improvement Program.

This is based on comparing Independent Premier Members (1,184 stores) and independent Elevate Only members from (503) stores during the months of January 2024 – July 2025. Premier members captured an average of $4,471 Humana MAPD Quality Improvement Program performance dollars compared to Elevate only members who averaged $3,192. (min $1,000, max: $378,000) in the same period. 25% of Premier pharmacies were above average (305 out of 1,184 customers) with median of $12,764.

Unsaleable Returns

10. $9,021~~11. $8,370~~ per year in unsaleable returns recouped.

Average performance of participating Good Neighbor Pharmacies (October 1, 2024~~2023~~ – September 30, ~~2024~~2025). All 1,~~709~~569 Pharmacies participating in the stated time-period, 50% above average,

median $5,529977. Highest performing pharmacy returned $1.3M0M in product and the lowest returned $1.

Using a Business CoachCoaching Associate

11. 2.9% increase in the average number of patients per pharmacy

Results are based on a comparison of 1,540 pharmacies working with a business coaching Associate from August 2023 through August 2025. 40.7% above average. median was a 2-patient increase. Highest performing member increased patients by 4,445 and lowest -1,523.

12. 12. Premier membersPharmacies working with a Business Coaching Associate dispense 65%91 more prescriptions on average per month.

This is based on comparing IndependentGNP Premier Members (2,232Pharmacies (1,540 stores) working with a Business Coaching Associate and Independent Elevate Only members from (1,729 stores) during the months of NovemberAugust 2023 – July through August 2025.2024. Premier members working with a Business Coaching Associate averaged 3,963 scripts91 more prescriptions per month (min: 1,335, max: 4,966low: -924.4 per month, high: 1,446.5 per month) compared to Elevate only members who averaged 2,401 scripts per month (min: 870, max: 3,010) in the in the same period. 4043% of Premier customer were above average (890 out of 2,232 customers) with a median of 3,438 achieved an increase of 91 or more prescriptions a month with a median increase of 20 prescriptions per month.

13. GNP Premier Pharmacies working with a Business Coaching Associate in Humana's Quality Improvement Program increased their payout by an average of $5,220.

This is based on 399 same store GNP Premier Pharmacies working with a Business Coaching Associate participating in the Quality Improvement Program comparing January 2024 - July 2024 vs. January 2025 – July 2025. The average dollar increase was $5,220 (min: $179,501 decrease, max: $50,747 increase)128 (32.1%) of the participating pharmacies had payouts that exceeded the average. The median increased payout was $4,474.

Private Label

14. GNP Premier Pharmacies make 141126.5% more private label product purchases per month.

This is based on comparing measured GNP Premier Pharmacies (2,368092 stores) and pharmacies only participating in Elevate Provider Network (2,1421,935 stores) during the months of November 2023 – July September 2024. – August 2025. Measured GNP Premier Pharmacies averaged $866903.74 in private label product purchases per month (min: $817773.49; max: $9101,195.13) compared to measured Elevate-only pharmacies, who averaged $360398.92 in private label product purchases per month (min: $334360.44; max: $384456.08) in the same period. 3534% of GNP Premier Pharmacies measured were above average (830706 out of 2,368092); median of $628651.

14. Pet Meds

15. GNP Premier membersPharmacies have 59110.7% higher pet health purchases per month.

This is based on comparing IndependentGNP Premier MembersPharmacies (1,111478 stores) and Independent Elevate Only members from (443715 stores) during the months of MaySeptember 2024 –

~~July~~ August 2025~~2024~~. Premier members averaged $~~118~~65.92 in pet health purchases per month (min: $~~116~~52.83, max: $~~118~~76.27) compared to Elevate only members who averaged $~~74~~31.28 in private label purchases per month (min: $~~64~~27.05, max: $~~83~~38.48) in the same period. ~~47~~42.1% of Premier customers were above average (~~522~~622 out of 1,~~111~~478 customers) with a median of $~~102~~48.50.

Merchandiser

16. GNP Premier Pharmacies that placed all shelf talkers were 25% higher than those that did not place any shelf talkers.

This is based on GNP Premier Pharmacies that participated in shelf talkers (1,240 stores) from December 2024 - July 2025 compared to GNP Premier Pharmacies that did not place any shelf talkers. Median sales for participating pharmacies were $532 (min: $1, max $13,786.48). 408 (33%) participating pharmacies exceeded the average. 53% of pharmacies that placed at least 1 shelf talker exceeded the median figure.

Some outlets sold these amounts. Your individual results may differ. There is no assurance you will sell as much.

Other than the preceding financial performance representation, we do not make any representations about a franchisee's future financial performance or the past financial performance of GNP Premier Pharmacies. We also do not authorize our employees or representatives to make any such representations either orally or in writing. If you are purchasing an existing GNP Premier Pharmacy, however, we may provide you with the actual records of that pharmacy. If you receive any other financial performance information or projections of your future income, you should report it to the franchisor's management by contacting Michael Nachman at (610) 727-7000, Cencora, 1 West First Avenue, Conshohocken, PA, 19428, Attn: Michael Nachman, Esq. (Legal Department), the Federal Trade Commission, and the appropriate state regulatory agencies.

ITEM 20
OUTLETS AND FRANCHISEE INFORMATION

We did not offer franchises for the operation of GNP Premier Pharmacies prior to 2009 but, since 1982, have permitted Voluntary Pharmacies the opportunity to operate using the Good Neighbor Pharmacy trade name. As of July 2019, we are no longer offering new independent pharmacies the opportunity to operate as Voluntary Pharmacies, though the legacy Voluntary Pharmacies described in the Tables below continue to operate. Tables 1 and 3 are broken out to describe Voluntary Pharmacies and GNP Premier Pharmacies separately to provide information on both our franchises and the legacy Voluntary Pharmacy program. Please note that our fiscal year ends September 30.

TABLE NO. 1

VOLUNTARY PHARMACIES
SYSTEMWIDE OUTLET SUMMARY
FOR FISCAL YEARS ~~2022~~2023 TO 2025~~2024~~

Outlet Type	Year	Voluntary at the Start of the Year	Voluntary at the End of the Year	Voluntary Net Change	Outlets that Converted to Premier	Outlets at Year Start Including Premier	Outlets at Year End Including Premier	Net Change including Premier

Licensed	20222023	259240	240199	-1941	411	25152412	24972515	103-18
	20242023	240199	204182	-3617	60	24972515	25012476	-1421
	20252024	204182	182157	-2225	0	25012476	24682361	-33115
Company Owned	20222023	0	0	0	0	0	0	0
	20242023	0	0	0	0	0	0	0
	20252024	0	0	0	0	0	0	0
Totals	20222023	259240	240199	-1941	411	25152412	25152497	103-18
	20242023	240199	204182	-3617	60	25152497	25012476	-1421
	20252024	204182	182157	-2225	0	25012476	24682361	-33115

GNP PREMIER PHARMACIES
SYSTEMWIDE OUTLET SUMMARY
FOR FISCAL YEARS 20222023 TO 20252024

Outlet Type	Year	Premier at the Start of the Year	Premier at the End of the Year	Premier Net Change
Franchise	20232022	22752153	22982275	12223
	20232024	22982275	22972294	22-4
	20242025	22972294	22862204	-1190
Company Owned	20232022	0	0	0
	20242023	0	0	0
	20252024	0	0	0
Totals	20232022	22752153	22982275	12223
	20242023	22752298	22972294	22-4
	20252024	22972294	22862204	-1190

TABLE NO.2

TRANSFERS OF OUTLETS FROM FRANCHISEES TO NEW OWNERS (OTHER THAN THE FRANCHISOR)
FOR FISCAL YEARS 20222023 TO 20252024

State	Year	Transfers
Alabama	20232022	0
	2024	3
	2025	1
Alaska	2023	0
	2024	0

State	Year	Transfers
	2025	0
Arizona	2023	0
	2024	1
	2025	0
Arkansas	2023	1
	2024	5
	2025	1
California	2023	0
	2024	31
	2025	7
Colorado	2023	0
	2024	0
	2025	0
Connecticut	2023	0
	2024	0
	2025	3
Delaware	2023	0
	2024	0
	2025	0
District of Columbia	2023	0
	2024	0
	2025	0
Florida	2023	0
	2024	11
	2025	1
Georgia	2023	0
	2024	4
	2025	2
Guam	2023	0
	2024	0
	2025	0
Hawaii	2023	0
	2024	0
	2025	0
Idaho	2023	0
	2024	1
	2025	0
Illinois	2023	0
	2024	2
	2025	1
Indiana	2023	0

State	Year	Transfers
	2024	0
	2025	3
Iowa	2023	0
	2024	1
	2025	1
Kansas	2023	0
	2024	3
	2025	1
Kentucky	2023	0
	2024	6
	2025	2
Louisiana	2023	0
	2024	6
	2025	0
Maine	2023	0
	2024	2
	2025	0
Maryland	2023	0
	2024	3
~~Alaska~~	~~2022~~2025	0
Massachusetts	2023	0
	2024	~~0~~3
~~Arizona~~	~~2022~~2025	0
Michigan	2023	0
	2024	~~1~~10
~~Arkansas~~	~~2022~~2025	0
Minnesota	2023	~~1~~0
	2024	~~5~~0
~~California~~	~~2022~~2025	~~4~~0
Mississippi	2023	~~0~~1
	2024	~~3~~1
~~Colorado~~	~~2022~~2025	~~0~~1
Missouri	2023	0
	2024	~~0~~5
~~Connecticut~~	~~2022~~2025	0
Montana	2023	0
	2024	0
~~Delaware~~	~~2022~~2025	0
Nebraska	2023	0
	2024	~~0~~1
~~District of Columbia~~	~~2022~~2025	0

State	Year	Transfers
Nevada	2023	0
	2024	01
Florida	20222025	10
New Hampshire	2023	0
	2024	110
Georgia	20222025	10
New Jersey	2023	0
	2024	416
Guam	20222025	01
New Mexico	2023	0
	2024	0
Hawaii	20222025	0
New York	2023	0
	2024	04
Idaho	20222025	0
North Carolina	2023	01
	2024	13
Illinois	20222025	01
North Dakota	2023	0
	2024	20
Indiana	20222025	0
Northern Mariana Islands	2023	0
	2024	0
Iowa	2022	2
	20252023	0
	2024	1
Kansas	2022	0
Ohio	2023	0
	2024	3
Kentucky	2022	0
	2023	0
	2024	6
Louisiana	2022	1
	2023	0
	2024	6
Maine	2022	0
	2023	0
	2024	2
Maryland	2022	0
	2023	0
	2024	3

State	Year	Transfers
~~Massachusetts~~	~~2022~~	~~0~~
	~~2023~~	~~0~~
	~~2024~~	~~3~~
~~Michigan~~	~~2022~~	~~0~~
	~~2023~~	~~0~~
	~~2024~~	~~10~~
~~Minnesota~~	~~2022~~	~~0~~
	~~2023~~	~~0~~
	~~2024~~	~~0~~
~~Mississippi~~	~~2022~~	~~0~~
	~~2023~~	~~1~~
	~~2024~~	~~1~~
~~Missouri~~	~~2022~~	~~0~~
	~~2023~~	~~0~~
	~~2024~~	~~5~~
~~Montana~~	~~2022~~	~~2~~
	~~2023~~	~~0~~
	~~2024~~	~~0~~
~~Nebraska~~	~~2022~~	~~3~~
	~~2023~~	~~0~~
	~~2024~~	~~1~~
~~Nevada~~	~~2022~~	~~0~~
	~~2023~~	~~0~~
	~~2024~~	~~1~~
~~New Hampshire~~	~~2022~~	~~0~~
	~~2023~~	~~0~~
	~~2024~~	~~0~~
~~New Jersey~~	~~2022~~	~~0~~
	~~2023~~	~~0~~
	~~2024~~	~~16~~
~~New Mexico~~	~~2022~~	~~0~~
	~~2023~~	~~0~~
	~~2024~~	~~0~~
~~New York~~	~~2022~~	~~0~~
	~~2023~~	~~0~~
	~~2024~~	~~4~~
~~North Carolina~~	~~2022~~	~~2~~
	~~2023~~	~~1~~
	~~2024~~	~~3~~
~~North Dakota~~	~~2022~~	~~0~~
	~~2023~~	~~0~~

State	Year	Transfers
	2024	0
~~Northern Mariana Islands~~	~~2022~~2025	~~0~~2
Oklahoma	2023	0
	2024	0
~~Ohio~~	~~2022~~2025	~~2~~0
Oregon	2023	0
	2024	0
~~Oklahoma~~	~~2022~~2025	0
	~~2023~~	~~0~~
	~~2024~~	~~0~~
~~Oregon~~	~~2022~~	~~0~~
	~~2023~~	~~0~~
	~~2024~~	~~0~~
Pennsylvania	2023~~2022~~	~~1~~0
	~~2023~~	~~0~~
	2024	4
	2025	0
Puerto Rico	2023~~2022~~	~~0~~13
	~~2023~~	~~13~~
	2024	2
	2025	0
Rhode Island	2023~~2022~~	0
	~~2023~~	~~0~~
	2024	0
	2025	0
South Carolina	2023~~2022~~	0
	~~2023~~	~~0~~
	2024	7
	2025	4
South Dakota	2023~~2022~~	0
	~~2023~~	~~0~~
	2024	1
	2025	0
Tennessee	2023~~2022~~	0
	~~2023~~	~~0~~
	2024	4
~~Texas~~	~~2022~~2025	~~1~~3
Texas	2023	13
	2024	11
~~Utah~~	~~2022~~2025	~~0~~3
Utah	2023	0

State	Year	Transfers
	2024	0
	2025	0
Vermont	20232022	0
	2023	0
	2024	1
	2025	0
Virgin Islands	2022	0
	2024	0
	2025	0
Virginia	2023	0
	2024	5
	2025	3
Washington	2023	0
	2024	1
	2025	2
West Virginia	2023	0
	2024	0
Virginia	20222025	02
	2023	0
	2024	5
Washington	2022	0
	2023	0
	2024	1
West Virginia	2022	0
	2023	0
	2024	0
Wisconsin	20232022	0
	2023	0
	2024	0
	2025	0
Wyoming	20232022	0
	2023	0
	2024	0
Totals	20222025	200
Totals	2023	29
	2024	159
	2025	45

TABLE NO. 3

OUTLETS STATUS SUMMARY
FOR FISCAL YEARS 20222023 TO 20252024

We did not offer franchises for the operation of GNP Premier Pharmacies prior to 2009 but, since 1982, have permitted Voluntary Pharmacies the opportunity to operate using the Good Neighbor Pharmacy

trade name. As of July 2019, we are no longer offering new independent pharmacies the opportunity to operate as Voluntary Pharmacies, though the legacy Voluntary Pharmacies described in the Tables below continue to operate. For purposes of comparison, the following list summarizes the number of Voluntary Pharmacies in recent years, by state. Other than stores that became GNP Premier, we do not have records to indicate whether stores that discontinued being Voluntary Pharmacies did so because we terminated them, they ~~choose~~chose to not renew, or they went out of business, were sold or otherwise discontinued operations. We have not purchased or operated any GNP Premier Pharmacies.

VOLUNTARY PHARMACIES
FOR FISCAL YEARS ~~2022~~2023 TO 2025

~~2024~~

State	Year	Outlets at Start of Year	Outlets Opened	Converted to GNP Premier	Termination Non-Renewal, and Other	Reacquired by Franchisor	Reverted from GNP Premier	Outlets at End of Year
Alabama	2023~~2022~~	3	0	0	~~0~~1	0	0	~~3~~2
	2024~~2023~~	~~3~~2	0	0	~~1~~0	0	0	2
	~~2024~~2025	2	0	0	0	0	0	2
Alaska	2023~~2022~~	0	0	0	0	0	0	0
	2024~~2023~~	0	0	0	0	0	0	0
	~~2024~~2025	0	0	0	0	0	0	0
Arizona	2023~~2022~~	0	0	0	0	0	0	0
	2024~~2023~~	0	0	0	0	0	0	0
	~~2024~~2025	0	0	0	0	0	0	0
Arkansas	2023~~2022~~	1	0	0	0	0	0	1
	2024~~2023~~	1	0	0	0	0	0	1
	~~2024~~2025	1	0	0	0	0	0	1
California	2023~~2022~~	~~17~~15	0	~~0~~2	~~2~~1	0	0	~~15~~12
	2024~~2023~~	~~15~~12	0	~~1~~0	~~1~~0	0	0	~~13~~12
	~~2024~~2025	~~13~~12	0	0	1	0	0	~~12~~11
Colorado	2023~~2022~~	1	0	0	0	0	0	1
	2024~~2023~~	1	0	0	0	0	0	1
	~~2024~~2025	1	0	0	0	0	0	1
Connecticut	2023~~2022~~	1	0	0	0	0	0	1
	2024~~2023~~	1	0	0	0	0	0	1
	~~2024~~2025	1	0	0	0	0	0	1
Delaware	2023~~2022~~	0	0	0	0	0	0	0
	2024~~2023~~	0	0	0	0	0	0	0
	~~2024~~2025	0	0	0	0	0	0	0
	2023~~2022~~	0	0	0	0	0	0	0

District of Columbia	2024~~2023~~	0	0	0	0	0	0	0
	~~2024~~2025	0	0	0	0	0	0	0
Florida	2023~~2022~~	~~6~~5	0	0	~~1~~2	0	0	~~5~~3
	2024~~2023~~	~~5~~3	0	0	~~2~~0	0	0	3
	~~2024~~2025	3	0	0	~~0~~1	0	0	~~3~~2
Georgia	2023~~2022~~	1	0	0	0	0	0	1
	2024~~2023~~	1	0	0	0	0	0	1
	~~2024~~2025	1	0	0	0	0	0	1
Guam	2023~~2022~~	9	0	0	~~0~~1	0	0	~~9~~8
	2024~~2023~~	~~9~~8	0	0	~~1~~5	0	0	~~8~~3
	~~2024~~2025	~~8~~3	0	0	~~5~~0	0	0	3
Hawaii	2023~~2022~~	1	0	0	0	0	0	1
	2024~~2023~~	1	0	0	0	0	0	1
	~~2024~~2025	1	0	0	0	0	0	1
Idaho	2023~~2022~~	0	0	0	0	0	0	0
	2024~~2023~~	0	0	0	0	0	0	0
	~~2024~~2025	0	0	0	0	0	0	0
Illinois	2023~~2022~~	~~1~~0	0	0	~~1~~0	0	0	0
	2024~~2023~~	0	0	0	0	0	0	0
	~~2024~~2025	0	0	0	0	0	0	0
Indiana	2023~~2022~~	0	0	0	0	0	0	0
	2024~~2023~~	0	0	0	0	0	0	0
	~~2024~~2025	0	0	0	0	0	0	0
Iowa	2023~~2022~~	2	0	0	0	0	0	2
	2024~~2023~~	2	0	0	0	0	0	2
	~~2024~~2025	2	0	0	~~0~~1	0	0	~~2~~1
Kansas	2023~~2022~~	~~3~~1	0	~~1~~0	~~1~~0	0	0	1
	2024~~2023~~	1	0	0	0	0	0	1
	~~2024~~2025	1	0	0	0	0	0	1
Kentucky	2023~~2022~~	~~3~~2	0	1	0	0	0	~~2~~1
	2024~~2023~~	~~2~~1	0	~~1~~0	0	0	0	1
	~~2024~~2025	1	0	0	0	0	0	1
Louisiana	2023~~2022~~	~~60~~59	0	0	~~1~~2	0	0	~~59~~57
	2024~~2023~~	~~59~~57	0	0	2	0	0	~~57~~55
	~~2024~~2025	~~57~~55	0	0	~~2~~4	0	0	~~55~~51
Maine	2023~~2022~~	1	0	0	0	0	0	1
	2024~~2023~~	1	0	0	0	0	0	1

	20242025	1	0	0	0	0	0	1
Maryland	20232022	2	0	0	0	0	0	2
	20242023	2	0	0	01	0	0	21
	20242025	21	0	0	10	0	0	1
Massachusetts	20232022	0	0	0	0	0	0	0
	20242023	0	0	0	0	0	0	0
	20242025	0	0	0	0	0	0	0
Michigan	20232022	5	0	0	01	0	0	54
	20242023	54	0	0	1	0	0	43
	20242025	43	0	0	10	0	0	3
Minnesota	20232022	0	0	0	0	0	0	0
	20242023	0	0	0	0	0	0	0
	20242025	0	0	0	0	0	0	0
Mississippi	20232022	109	0	0	10	0	0	9
	20242023	9	0	0	0	0	0	9
	20242025	9	0	0	06	0	0	93
Missouri	20232022	65	0	0	10	0	0	5
	20242023	5	0	0	01	0	0	54
	20242025	54	0	0	10	0	0	4
Montana	20232022	0	0	0	0	0	0	0
	20242023	0	0	0	0	0	0	0
	20242025	0	0	0	0	0	0	0
Nebraska	20232022	0	0	0	0	0	0	0
	20242023	0	0	0	0	0	0	0
	20242025	0	0	0	0	0	0	0
Nevada	20232022	32	0	0	1	0	0	21
	20242023	21	0	0	10	0	0	1
	20242025	1	0	0	0	0	0	1
New Hampshire	20232022	0	0	0	0	0	0	0
	20242023	0	0	0	0	0	0	0
	20242025	0	0	0	0	0	0	0
New Jersey	20232022	64	0	0	21	0	0	43
	20242023	43	0	0	10	0	0	3
	20242025	3	0	0	0	0	0	3
New Mexico	20232022	1	0	0	0	0	0	1
	20242023	1	0	0	0	0	0	1
	20242025	1	0	0	0	0	0	1

New York	20232022	1918	0	13	03	0	0	1812
	20242023	1812	0	0	31	0	0	1511
	20242025	1511	0	0	40	0	0	11
North Carolina	20232022	6	0	01	0	0	0	65
	20242023	65	0	10	0	0	0	5
	20242025	5	0	0	01	0	0	54
North Dakota	20232022	0	0	0	0	0	0	0
	20242023	0	0	0	0	0	0	0
	20242025	0	0	0	0	0	0	0
Northern Mariana Islands	20232022	3	0	0	0	0	0	3
	20242023	3	0	0	0	0	0	3
	20242025	3	0	0	0	0	0	3
Ohio	20232022	76	0	0	1	0	0	65
	20242023	65	0	0	1	0	0	54
	20242025	54	0	0	10	0	0	4
Oklahoma	20232022	4	0	0	0	0	0	4
	20242023	4	0	0	01	0	0	43
	20242025	43	0	0	10	0	0	3
Oregon	20232022	0	0	0	0	0	0	0
	20242023	0	0	0	0	0	0	0
	20242025	0	0	0	0	0	0	0
Pennsylvania	20232022	5	0	0	0	0	0	5
	20242023	5	0	0	0	0	0	5
	20242025	5	0	0	01	0	0	54
Puerto Rico	20232022	32	0	01	012	0	0	3219
	20242023	3219	0	0	122	0	0	2017
	20242025	2017	0	0	32	0	0	1715
Rhode Island	20232022	0	0	0	0	0	0	0
	20242023	0	0	0	0	0	0	0
	20242025	0	0	0	0	0	0	0
South Carolina	20232022	0	0	0	0	0	0	0
	20242023	0	0	0	0	0	0	0
	20242025	0	0	0	0	0	0	0
South Dakota	20232022	3	0	01	01	0	0	31
	20242023	31	0	10	10	0	0	1
	20242025	1	0	0	0	0	0	1
Tennessee	20232022	43	0	0	10	0	0	3

	20242023	3	0	0	0	0	0	3
	20242025	3	0	0	0	0	0	3
Texas	20232022	3027	0	12	23	0	0	2722
	20242023	2722	0	20	32	0	0	2220
	20242025	2220	0	0	28	0	0	2012
Utah	20232022	0	0	0	0	0	0	0
	20242023	0	0	0	0	0	0	0
	20242025	0	0	0	0	0	0	0
Vermont	20232022	0	0	0	0	0	0	0
	20242023	0	0	0	0	0	0	0
	20242025	0	0	0	0	0	0	0
Virgin Islands	20232022	1	0	0	0	0	0	1
	20242023	1	0	0	0	0	0	1
	20242025	1	0	0	0	0	0	1
Virginia	20232022	1	0	0	0	0	0	1
	20242023	1	0	0	0	0	0	1
	20242025	1	0	0	0	0	0	1
Washington	20232022	0	0	0	0	0	0	0
	20242023	0	0	0	0	0	0	0
	20242025	0	0	0	0	0	0	0
West Virginia	20232022	0	0	0	0	0	0	0
	20242023	0	0	0	0	0	0	0
	20242025	0	0	0	0	0	0	0
Wisconsin	20232022	0	0	0	0	0	0	0
	20242023	0	0	0	0	0	0	0
	20242025	0	0	0	0	0	0	0
Wyoming	20232022	1	0	0	0	0	0	1
	20242023	1	0	0	0	0	0	1
	20242025	1	0	0	0	0	0	1
Totals	**2023**2022	259**240**	**0**	411	1530	**0**	**0**	240**199**
	2023**2024**	240**199**	**0**	60	3017	**0**	**0**	204**182**
	2024**2025**	204**182**	**0**	**0**	2225	**0**	**0**	182**157**

As noted above, we did not offer franchises for operation of GNP Premier Pharmacies until 2009. The above table reflects only Voluntary Pharmacies, and the following table reflects only GNP Premier Pharmacies, showing the number of stores at the beginning and end of each year and how many opened, were terminated, did not renew or are otherwise no longer operating.

GNP PREMIER PHARMACIES FOR FISCAL YEARS ~~2022~~2023 TO 2025~~2024~~

State	Year	Outlets at Start of Year	Outlets Opened	Terminations	Non-Renewal	Reacquired by Franchisor	Other	Outlets at End of Year
Alabama	2023~~2~~022	~~23~~25	4	~~2~~6	0	0	0	~~25~~23
	2024~~2~~023	~~25~~23	~~4~~2	~~6~~2	0	0	0	23
	~~2024~~2025	23	~~2~~8	~~2~~1	0	0	0	~~23~~30
Alaska	2023~~2~~022	~~7~~6	0	1	0	0	0	~~6~~5
	2024~~2~~023	~~6~~5	~~0~~1	1	0	0	0	5
	~~2024~~2025	5	~~1~~0	~~1~~0	0	0	0	5
Arizona	2023~~2~~022	4	~~0~~3	~~0~~1	0	0	0	~~4~~6
	2024~~2~~023	~~4~~6	~~3~~0	~~1~~0	0	0	0	6
	~~2024~~2025	6	0	0	0	0	0	6
Arkansas	2023~~2~~022	~~84~~86	~~4~~11	~~2~~6	0	0	0	~~86~~91
	2024~~2~~023	~~86~~91	~~11~~5	6	0	0	0	~~91~~90
	~~2024~~2025	~~91~~90	~~5~~4	~~6~~1	0	0	0	~~90~~93
California	2023~~2~~022	~~232~~252	~~35~~33	~~15~~18	0	0	0	~~252~~267
	2024~~2~~023	~~252~~267	~~33~~30	~~18~~28	0	0	0	~~267~~269
	~~2024~~2025	~~267~~269	~~30~~17	~~30~~46	0	0	0	~~267~~240
Colorado	2023~~2~~022	~~5~~9	~~4~~5	~~0~~1	0	0	0	~~9~~13
	2024~~2~~023	~~9~~13	~~5~~0	~~1~~0	0	0	0	13
	~~2024~~2025	13	~~0~~4	1	0	0	0	~~12~~16
Connecticut	2023~~2~~022	~~10~~12	~~2~~1	~~0~~2	0	0	0	~~12~~11
	2024~~2~~023	~~12~~11	1	~~2~~1	0	0	0	11
	~~2024~~2025	11	~~1~~5	~~1~~2	0	0	0	~~11~~14
Delaware	2023~~2~~022	~~3~~2	0	~~1~~0	0	0	0	2
	2024~~2~~023	2	0	0	0	0	0	2
	~~2024~~2025	2	0	0	0	0	0	2
District of Columbia	2023~~2~~022	~~0~~1	~~1~~0	0	0	0	0	1

	20242023	1	0	0	0	0	0	1
	20242025	1	0	0	0	0	0	1
Florida	20232022	124120	139	1714	0	0	0	120115
	20242023	120115	911	1421	0	0	0	115105
	20242025	115105	109	2018	0	0	0	10596
Georgia	20232022	147158	2312	128	0	0	0	158162
	20242023	158161	1210	97	0	0	0	161164
	20242025	161164	1014	712	0	0	0	164166
Guam	20232022	0	0	0	0	0	0	0
	20242023	0	0	0	0	0	0	0
	20242025	0	0	0	0	0	0	0
Hawaii	20232022	3336	32	05	0	0	0	3633
	20242023	3633	20	54	0	0	0	3329
	20242025	3329	02	4	0	0	0	2927
Idaho	20232022	2022	50	35	0	0	0	2217
	20242023	2217	01	51	0	0	0	17
	20242025	17	10	13	0	0	0	1714
Illinois	20232022	3740	45	1	0	0	0	4044
	20242023	4044	53	13	0	0	0	44
	20242025	44	26	36	0	0	0	4344
Indiana	20232022	3034	4	03	0	0	0	3435
	20242023	3435	40	3	0	0	0	3532
	20242025	3532	04	36	0	0	0	3230
Iowa	20232022	2933	42	04	0	0	0	3331
	20242023	3331	21	43	0	0	0	3129
	20242025	3129	10	3	0	0	0	2926
Kansas	20232022	3332	26	38	0	0	0	3230
	20242023	3230	63	82	0	0	0	3031

	20242025	3031	31	3	0	0	0	3029
Kentucky	20232022	111112	911	86	0	0	0	112117
	20242023	112117	114	610	0	0	0	117111
	20242025	117111	310	106	0	0	0	110115
Louisiana	20232022	1516	24	12	0	0	0	1618
	20242023	1618	43	23	0	0	0	18
	20242025	18	30	32	0	0	0	1816
Maine	20232022	11	1	10	0	0	0	1112
	20242023	1112	1	01	0	0	0	12
	20242025	12	10	14	0	0	0	128
Maryland	20232022	3234	21	010	0	0	0	3425
	20242023	3425	17	103	0	0	0	2529
	20242025	2529	70	35	0	0	0	2924
Massachusetts	20232022	2123	23	04	0	0	0	2322
	20242023	2322	31	43	0	0	0	2220
	20242025	2220	10	31	0	0	0	2019
Michigan	20232022	111108	712	109	0	0	0	108111
	20242023	108111	124	94	0	0	0	111
	20242025	111	47	420	0	0	0	11198
Minnesota	20232022	2621	0	51	0	0	0	2120
	20242023	2120	0	1	0	0	0	2019
	20242025	2019	01	12	0	0	0	1918
Mississippi	20232022	3230	05	24	0	0	0	3031
	20242023	3032	53	3	0	0	0	32
	20242025	32	34	2	0	0	0	3334
Missouri	20232022	4852	63	26	0	0	0	5249
	20242023	5249	34	65	0	0	0	4948
	20242025	4948	32	49	0	0	0	4841

Montana	20232022	3	0	0	0	0	0	3
	20242023	3	0	0	0	0	0	3
	20242025	3	0	0	0	0	0	3
Nebraska	20232022	1619	3	01	0	0	0	1921
	20242023	1921	30	10	0	0	0	21
	20242025	21	01	04	0	0	0	2118
Nevada	20232022	34	10	0	0	0	0	4
	20242023	4	0	04	0	0	0	40
	20242025	40	0	40	0	0	0	0
New Hampshire	20232022	0	0	0	0	0	0	0
	20242023	0	0	0	0	0	0	0
	20242025	0	02	01	0	0	0	01
New Jersey	20232022	103127	2611	212	0	0	0	127126
	20242023	127126	1115	1222	0	0	0	126119
	20242025	126119	158	2219	0	0	0	119108
New Mexico	20232022	1514	0	13	0	0	0	1411
	20242023	1411	01	30	0	0	0	1112
	20242025	1112	1	0	0	0	0	1213
New York	20232022	6066	913	38	0	0	0	6671
	20242023	6671	1325	8	0	0	0	7188
	20242025	7188	253	84	0	0	0	8887
North Carolina	20232022	98102	1219	810	0	0	0	102111
	20242023	102111	192	102	0	0	0	111
	20242025	111	23	210	0	0	0	111104
North Dakota	20232022	212	102	01	0	0	0	1213
	20242023	1213	21	10	0	0	0	1314
	20242025	1314	10	01	0	0	0	1413
	20232022	0	0	0	0	0	0	0

Northern Mariana Islands	20242023	0	0	0	0	0	0	0
	202420252025	0	0	0	0	0	0	0
Ohio	20232022	8589	73	38	0	0	0	8984
	20242023	8984	34	811	0	0	0	8477
	202420252025	8477	43	1112	0	0	0	7768
Oklahoma	20232022	14	1	1	0	0	0	14
	20242023	14	13	10	0	0	0	1417
	202420252025	1417	30	0	0	0	0	17
Oregon	20232022	10	01	01	0	0	0	10
	20242023	10	10	1	0	0	0	109
	202420252025	109	01	10	0	0	0	910
Pennsylvania	20232022	7577	94	7	0	0	0	7774
	20242023	7774	413	710	0	0	0	7477
	202420252025	7477	135	1011	0	0	0	7771
Puerto Rico	20232022	14	0	01	0	0	0	1413
	20242023	1413	05	10	0	0	0	1318
	202420252025	1318	40	02	0	0	0	1716
Rhode Island	20232022	0	0	0	0	0	0	0
	20242023	0	0	0	0	0	0	0
	202420252025	0	01	0	0	0	0	01
South Carolina	20232022	5259	78	0	0	0	0	5967
	20242023	5967	815	05	0	0	0	6777
	202420252025	6777	15	57	0	0	0	7785
South Dakota	20232022	32	02	10	0	0	0	24
	20242023	24	1	0	0	0	0	35
	202420252025	35	10	01	0	0	0	4
Tennessee	20232022	5764	118	43	0	0	0	6469
	20242023	6469	86	34	0	0	0	6971

	20242025	6971	57	48	0	0	0	70
Texas	20232022	187186	1017	1125	0	0	0	186178
	20242023	186178	178	2518	0	0	0	178168
	20242025	178168	815	1815	0	0	0	168
Utah	20232022	1716	1	20	0	0	0	1617
	20242023	1617	13	03	0	0	0	17
	20242025	17	30	30	0	0	0	17
Vermont	20232022	0	0	0	0	0	0	0
	20242023	0	0	0	0	0	0	0
	20242025	0	0	0	0	0	0	0
Virgin Islands	20232022	0	0	0	0	0	0	0
	20242023	0	0	0	0	0	0	0
	20242025	0	0	0	0	0	0	0
Virginia	20232022	4549	51	12	0	0	0	4948
	20242023	4948	13	25	0	0	0	4846
	20242025	4846	36	4	0	0	0	4748
Washington	20232022	2224	42	24	0	0	0	2422
	20242023	2422	21	42	0	0	0	2221
	20242025	2221	12	25	0	0	0	2118
West Virginia	20232022	22	13	12	0	0	0	2223
	20242023	2223	3	21	0	0	0	2325
	20242025	2325	32	13	0	0	0	2524
Wisconsin	20232022	1617	23	12	0	0	0	1718
	20242023	1718	3	20	0	0	0	1821
	20242025	1821	31	0	0	0	0	2122
Wyoming	20232022	6	10	10	0	0	0	6
	20242023	6	0	0	0	0	0	6
	20242025	6	0	0	0	0	0	6

Totals	2023~~2~~ ~~022~~	2275~~2153~~	~~257~~239	~~135~~216	0	0	0	~~2275~~229 8
	2024~~2~~ ~~023~~	~~2275~~2298	~~238~~207	~~216~~211	0	0	0	~~2297~~229 4
	~~2024~~2 025	~~2297~~2294	~~201~~174	~~211~~264	0	0	0	~~2287~~220 4

TABLE NO. 4
COMPANY-OWNED OUTLETS STATUS SUMMARY
FOR FISCAL YEARS ~~20222023~~ TO ~~20242025~~

State	Year	Outlets at Start of Year	Outlets Opened	Outlets Reacquired From Franchisee	Outlets Closed	Outlets Sold to Franchisee	Outlets At End of Year
	~~202220~~23	0	0	0	0	0	0
	~~202320~~24	0	0	0	0	0	0
Totals	~~202420~~25	0	0	0	0	0	0

TABLE NO. 5
PROJECTED FRANCHISEE OPENINGS AS OF SEPTEMBER 30, ~~20242025~~

State	GNP Premier Agreements Signed But Outlet Not Opened	Projected New Franchised Outlets in the Next Fiscal Year	Projected New Company Owned Outlets in the Next Fiscal Year
Alabama	0	~~4~~3	0
Alaska	0	~~0~~1	0
Arizona	0	~~1~~2	0
Arkansas	0	~~6~~8	0
California	0	~~28~~32	0
Colorado	0	3	0
Connecticut	0	~~2~~1	0
Delaware	0	0	0
District of Columbia	0	0	0
Florida	0	~~14~~10	0
Georgia	0	~~18~~11	0
Hawaii	0	~~2~~1	0
Idaho	0	~~2~~1	0
Illinois	0	4	0
Indiana	0	~~4~~2	0
Iowa	0	~~3~~2	0
Kansas	0	~~4~~5	0
Kentucky	0	~~10~~7	0
Louisiana	0	~~3~~4	0
Maine	0	~~0~~1	0
Maryland	0	~~3~~4	0
Massachusetts	0	2	0
Michigan	0	~~11~~8	0
Minnesota	0	0	0
Mississippi	0	~~3~~4	0

State	GNP Premier Agreements Signed But Outlet Not Opened	Projected New Franchised Outlets in the Next Fiscal Year	Projected New Company Owned Outlets in the Next Fiscal Year
Missouri	0	3	0
Montana	0	0	0
Nebraska	0	2	0
Nevada	0	0	0
New Hampshire	0	0	0
New Jersey	0	~~15~~13	0
New Mexico	0	~~0~~1	0
New York	0	~~8~~19	0
North Carolina	0	~~13~~11	0
North Dakota	0	~~4~~2	0
Ohio	0	4	0
Oklahoma	0	~~1~~2	0
Oregon	0	~~0~~1	0
Pennsylvania	0	~~7~~9	0
Rhode Island	0	0	0
South Carolina	0	~~9~~12	0
South Dakota	0	~~0~~1	0
Tennessee	0	~~10~~7	0
Texas	0	~~12~~13	0
Utah	0	~~1~~2	0
Vermont	0	0	0
Virginia	0	~~4~~2	0
Washington	0	2	0
West Virginia	0	~~2~~3	0
Wisconsin	0	~~2~~3	0
Wyoming	0	0	0
Puerto Rico	0	~~0~~2	0
Guam	0	0	0
Northern Mariana Islands	0	0	0
Virgin Island	0	0	0
Totals	0	~~226~~230	0

List of Current Franchisees

A list of current franchisees is provided in Exhibit D.

List of Former Franchisees and Licensees

We did not offer franchises for the operation of GNP Premier Pharmacies or otherwise until 2009 and have never refused to renew a franchise (other than as part of a total account closure for non-franchise

related reasons such as credit concerns); ~~159~~45 franchisees transferred ownership during ~~2024~~FY 2025, and no franchisee has failed to communicate with us during the 10 weeks preceding the date of this Disclosure Document. If you buy this franchise, your contact information may be disclosed to other buyers when you leave the franchise system. Former franchisees are listed in Exhibit D.

If you enter into a GNP Premier Agreement, information about your agreement may be disclosed to others who are interested in the GNP Premier Program if you leave the GNP Premier Program.

Purchase of Previously Owned Franchise

If you are purchasing a previously owned GNP Premier Pharmacy or Voluntary Pharmacy from us, we will provide you additional information on this previously owned pharmacy in an addendum to this Disclosure Document, but only to the extent we have such information.

Confidentiality Clauses

During the last three fiscal years, we have not signed any agreements with Voluntary Pharmacies or GNP Premier Pharmacies that contain confidentiality clauses that would restrict their ability to speak openly about their experience (or we will agree to waive any such restriction upon request).

Trademark-Specific Franchisee Organizations

We are not currently aware of any trademark-specific franchisee organizations associated with the franchise GNP Premier Program which we have created, sponsored or endorsed, or any independent franchisee organizations that have asked to be included in this Disclosure Document. As noted above, there are regional and national GNP Advisory Boards. *See* Item 11.

ITEM 21
FINANCIAL STATEMENTS

Attached to this Disclosure Document as Exhibit E are the financial statements for Cencora, our parent. Our financial information is consolidated within that of Cencora.

Audited Financial Statements

The Consolidated Financial Statements are the consolidated financial position of Cencora ~~at~~on September 30, ~~2024~~2025 and 2024~~2023~~, and the consolidated results of their operations and their cash flows for each of the three years in the period ending on September 30, ~~2024~~2025.

Our parent, Cencora, has agreed to absolutely and irrevocably guarantee all obligations of ABDC to any franchisee under the GNP Premier Agreement and related agreements in this Disclosure Document. The guarantee is included in Exhibit E following the financial statements.

ITEM 22
CONTRACTS

Depending on Available Programs in which you elect to participate, you will sign the GNP Premier Agreement and the Data Authorization Supplement and agree to terms in some or all of its exhibits, all of which are attached as exhibits to this Disclosure Document.

Exhibit B - GNP Premier Agreement (with Data Authorization Supplement):

Exhibit A -	Data Protection Provisions
Exhibit B -	HIPAA Business Associate Agreement
Exhibit C -	Provisions
Exhibit D -	State-Specific Amendments/Addenda
Exhibit E -	Master Program Agreement

Program Selection and Data Authorizations:

Term Sheet 1 -	Elevate Provider Network
Term Sheet 2 -	Elevate Advanced Features
Term Sheet 2A -	Pre & Post Edit Solutions (PPE)
Term Sheet 2B -	Claim Reconciliation Services
Term Sheet 2C -	Outcomes ~~PCS Solution~~Patient Care Services
Term Sheet 2D -	EnlivenHealth Patient Care Services
Term Sheet 3 -	InSite from ABDC
Term Sheet 4 -	Five-Star Rebate
Term Sheet 5 -	The Front-End Solution Programs
Term Sheet 6 -	Digital Marketing
Term Sheet 7 -	Business Coaching
Term Sheet 8 -	Pharmacy System Data Services
Term Sheet 9 -	Unsaleable Returns
Term Sheet 10 -	Statement of Work for Special Projects (Form)

ITEM 23
RECEIPTS

Please sign two copies of the Receipt attached as the last two pages to this Disclosure Document. After execution, you keep one copy and provide the other to us.

AmerisourceBergen

Good Neighbor Pharmacy

EXHIBIT A
STATE ADMINISTRATORS AND AGENTS FOR SERVICE OF PROCESS

STATE ADMINISTRATORS

CALIFORNIA
Department of Financial Protection and Innovation
320 West 4th Street, Suite 750
Los Angeles, California 90013
(866) 275-2677 or (213) 576-7500

HAWAII
Department of Commerce and Consumer Affairs
Business Registrations Division
335 Merchant Street, Room 203
Honolulu, Hawaii 96813
(808) 586 2722

ILLINOIS
Office of Attorney General
500 South Second Street
Springfield, Illinois 62706
(217) 782 4465

INDIANA
Franchise Section
Securities Division
302 W. Washington St., Room E 111
Indianapolis, Indiana 46204
(317) 232 6681

KENTUCKY
Office of the Attorney General
1024 Capital Center Drive
Frankfort, Kentucky 40602
(502) 696 5300

MARYLAND
Office of Attorney General
Securities Division
200 St. Paul Place
Baltimore, Maryland 21202
(410) 576 7042

MICHIGAN
Office of the Attorney General
~~Consumer Protection~~Corporate Oversight Division
~~Antitrust and~~ Franchise Section
G. Mennen Williams Building, ~~7th~~5th Floor
525 W. Ottawa Street
Lansing, Michigan 48909
(517) 373-7117

MINNESOTA
Department of Commerce
85 7th Place East, Suite 280
St. Paul, Minnesota 55101-2198
(651) 539-1600

NEBRASKA
Department of Banking and Finance
1200 N Street, Suite 311
P.O. Box 95006
Lincoln, Nebraska 68509
(402) 471 3445

NEW YORK
Office of the Attorney General
Investor Protection Bureau
28 Liberty Street, ~~15th~~21st Floor
New York, NY 10005
Tel: 212-416-8222

NORTH DAKOTA
North Dakota Securities Department
600 East Blvd., Fifth Floor
Bismarck, North Dakota 58505
(701) 328 4712

OREGON
Division of Consumer and Business Services
Finance and Corporate Securities
350 Winter Street N.E.
Labor and Industries Building, Room 21
Salem, Oregon 97310
(503) 378 4387

RHODE ISLAND
Securities Division
1511 Pontiac Avenue
John O. Pastore Complex – Building 69-1
Cranston, Rhode Island 02920
(401) 222 3048

SOUTH DAKOTA
Division of Insurance
Securities Regulation
124 Euclid, Suite 104
Pierre, South Dakota 57501
(605) 773 3563

TEXAS
Statutory Document Section
Secretary of State
P.O. Box 12887
Austin, Texas 78711
(512) 475 1769

UTAH
Division of Consumer Protection
Utah Department of Commerce
160 East Three Hundred South
P.O. Box 146704
Salt Lake City, Utah 84114 6704
(801) 530 6601

VIRGINIA
State Corporation Commission
Division of Securities and Retail Franchising
1300 East Main Street, 9th Floor
Richmond, Virginia 23219
(804) 371 9051

WASHINGTON
Department of Financial Institutions
Securities Division
150 Israel Road, S.W.
Tumwater, Washington 98501
(360) 902 8760

WISCONSIN
Division of Securities
Department of Financial Institutions
P.O. Box 1768
Madison, Wisconsin 53701 or
345 W. Washington, 4th Floor
Madison, Wisconsin 53703
(608) 266 8559

AmerisourceBergen

GOOD NEIGHBOR PHARMACY

AGENTS FOR SERVICE OF PROCESS

CALIFORNIA
Commissioner of ion
Department of Financial Protection and Innovation
320 West 4th Street, Suite 750
Los Angeles, California 90013-1105

HAWAII
Commissioner of Securities
Department of Commerce and Consumer Affairs
Business Registrations Division
335 Merchant Street, Room 203
Honolulu, Hawaii 96813

ILLINOIS
Illinois Attorney General
500 South Second Street
Springfield, Illinois 62706

INDIANA
Secretary of State
201 State House
200 W. Washington Street
Indianapolis, Indiana 46204

MARYLAND
Maryland Securities Commissioner
Office of the Attorney General
200 St. Paul Place
Baltimore, Maryland 21202-2020

MICHIGAN
Michigan Department of ~~Labor & Economic Growth~~Attorney General
~~Commercial Services & Corporations Bureau~~
~~611~~Corporate Oversight Division
G. Mennen Williams Bldg., 5th Floor
525 W. Ottawa Street
Lansing, Michigan ~~48909~~48913

MINNESOTA
Commissioner of Commerce
85 7th Place East, Suite 280
St. Paul, Minnesota 55101-2198

NEW YORK
New York Secretary of State
New York Department of State
One Commerce Plaza,
99 Washington Avenue, 6th Floor

NORTH DAKOTA
Securities Commissioner
North Dakota Securities Department
600 East Boulevard, Fifth Floor
Bismarck, North Dakota 58505

OREGON
Director
Department of Consumer and Business Services
Division of Finance and Corporate Securities
Labor and Industries Building
Salem, Oregon 97310

RHODE ISLAND
Director
Department of Business Regulation
1511 Pontiac Avenue
John O. Pastore Complex – Building 69-1
Cranston, Rhode Island 02920

SOUTH DAKOTA
Department of Labor and Regulation
Division of Securities
125 Euclid, Suite 104
Pierre, South Dakota 57501
(605) 773 3563

VIRGINIA
Clerk of the State Corporation Commission
1300 East Main Street, 1st Floor
Richmond, Virginia 23219

WASHINGTON
Director of Financial Institutions
Securities Division
150 Israel Rd. S.W.
Tumwater, Washington 98501

WISCONSIN
Commissioner of Securities
Fourth Floor
345 West Washington Avenue
Madison, Wisconsin 53703

AmerisourceBergen

Albany, NY 12231-0001
(518) 473-2492

AmerisourceBergen

EXHIBIT B

GNP PREMIER AGREEMENT

Good Neighbor Pharmacy®
Premier Participation Agreement
Summary & Signature Page

This Good Neighbor Pharmacy® Premier Participation Agreement ("**Agreement**") between AmerisourceBergen Drug Corporation, a Delaware corporation with offices at 1 West First Avenue, Conshohocken, PA 19428 ("**ABDC**") and Customer (identified below and also referred to herein as "**you**" or "**your**") is effective as of the effective date indicated below on this page ("**Effective Date**") if it is accepted by ABDC.

CUSTOMER

Legal Name: _____

D/B/A: _____

Address 1: _____

Address 2: _____

City, State, Zip: _____

Attach list as Exhibit F for multiple locations or if pharmacy address is different.

ENTITY

Check one:

☐ Corporation ☐ Partnership
☐ Limited Liability Company ☐ Individual
☐ Limited Partnership ☐ Other:

State of Formation: _____

ACCOUNT

NCPDP No: _____ *For Single Locations Only*

PROGRAM

Effective Date: _____

Term: 5 years (with 60-day "no cause" termination in Section 7)

Customer's Designated Manager: _____

Initial Fee: None

Monthly Fee: $599 per Pharmacy Location

Available Program Participation: See Sections 4(g) and 4(h), Exhibit E and Term Sheets 1 to 10

Disclosure Compliance Franchise Disclosure Document Delivery Date: _____

Each party's authorized officer, partner or principal signed this Good Neighbor Pharmacy® Premier Participation Agreement as of the date indicated and such Agreement shall be effective as of its Effective Date.

Customer	**ABDC**
By: _____	By: _____
Name: _____	Name: _____
Title: _____	Title: _____
Date Signed: _____	Date Signed: _____

Do Not Sign Before: _____

AmerisourceBergen

GOOD NEIGHBOR PHARMACY

TABLE OF CONTENTS

Table of Contents

1. Grant 1
2. Fees 2
3. Modifications of GNP Premier Program and Marks 2
4. Customer's Obligations 3
5. Required Signage 5
6. GNP Private Label Products 5
7. Term and Termination 6
8. Internet Operations 6
9. Trademarks and Intellectual Property 7
10. Transfers 9
11. GNP License Program Release 9
12. Post-Termination Obligations 9
13. Program Master Terms 10
14. Dispute Resolution 12
15. Miscellaneous 14

Exhibit A – Data Protection Provisions 15
Exhibit B – HIPAA Business Associate Agreement 18
Exhibit C – Provisions 21
Exhibit D – State-Specific Amendments 24
Exhibit E – Master Program Agreement 31
Available Program Enrollment Form & Data Authorization 37
Term Sheet 1 – Elevate Provider Network® 40
Term Sheet 2 – Elevate Advanced Features 47
Term Sheet 2A – Pre & Post Edit Solutions 49
Term Sheet 2B – Claim Reconciliation Services 52
Term Sheet 2C – Outcomes PCS Services 55
Term Sheet 2D – Enliven Health Patient Care Services 57
Term Sheet 3 – InSite from ABDC / InSite for POS System 60
Term Sheet 4 – Five-Star Rebate Program 62
Term Sheet 5 – First to Shelf / Planogram Services / Merchandising Services
Retail Product Zone Pricing / Front-End Support Kit 64
Term Sheet 6 – Digital Marketing 65
Term Sheet 7 – Business Coaching 67
Term Sheet 8 – Pharmacy Data Services 69
Term Sheet 9 – Unsaleable Returns 70
Term Sheet 10 – Statement of Work-Services (Form) for Special Projects 72

Current Term Sheets are posted on AB Central (https://abcorder.amerisourcebergen.com)

AmerisourceBergen

GOOD NEIGHBOR PHARMACY

Good Neighbor Pharmacy®
Premier Participation Agreement

A. ABDC, a nationwide wholesaler of pharmaceuticals and sundries, and its ~~corporate affiliates~~Corporate Affiliates (as defined below) have, with expenditure of time, skill, effort and money, developed an advertising and merchandising program, "Good Neighbor Pharmacy" for community pharmacies. As used in this Agreement, a "**Corporate Affiliate**" means a person or entity that controls, is controlled by or is under common control with another person or entity, either by virtue of equity ownership, by contract or by other means.

B. Customer owns and operates one or more community pharmacies (each a "**Pharmacy**") and desires to obtain the right to use the Good Neighbor Pharmacy® Premier program ("**GNP Premier Program**") in operating each Pharmacy pursuant to this Agreement, which such right ABDC is willing to grant subject to the terms and conditions provided herein.

C. Customer is joining the GNP Premier Program to promote and advertise its Pharmacy, to contribute to the collective goodwill of the GNP Premier Program and to actively participate in its programs.

D. This Agreement, including its Addenda, Exhibits, Term Sheets, as well as their respective enrollment forms and Data Authorizations, each as may be amended from time to time as permitted herein, is the entire agreement between the parties related to the GNP Premier Program (excluding only the disclosure document described in Recital G below) and~~, pursuant to Section 13(g),~~ is independent of any unrelated business relationships between the parties. This Agreement supersedes any Master Program Agreement ~~signed~~entered into by and between the parties for so long as the customer is party to ~~the Premier Participation~~this Agreement; provided, however, that any obligations outstanding as of the Effective Date originating from the Master Program Agreement, any Available Program (as defined in Section 4(g)) selections, any Data Authorization forms relating to Available Programs, and any other terms or agreements the context of which show the parties intended them to survive, shall carry over into this Agreement and shall survive, and such Master Program Agreement shall be reinstated upon termination of this Agreement. Nothing in this Agreement or in any related agreement will disclaim ABDC's representations in the Franchise Disclosure Document that was furnished to you.

E. Customer confirms that, as reflected on the Summary and Signature Page, it received (1) a complete copy of this Agreement, including its exhibits, with all blanks filled in, at least seven days before execution, and (2) the Franchise Disclosure Document, required by the Trade Regulation Rule of the Federal Trade Commission entitled "Disclosure Requirements and Prohibitions Concerning Franchising," at least fourteen (14) days before execution.

1. Grant.

(a) Use of Marks & GNP Premier Program. Subject to this Agreement, ABDC hereby grants and Customer accepts certain non-exclusive rights to use all or part of the GNP Premier Program. In turn, Customer will use the "Good Neighbor Pharmacy" and related trademarks, service marks and their successors (~~"~~(collectively, "**Marks**") to operate Pharmacy under the GNP Premier Program, and to advertise and promote Pharmacy using the Marks, all as required by this Agreement. Customer's use of the Marks is subject to the conditions set forth in Section 9 of this Agreement.

(b) Pharmacy Locations. Pursuant to this Agreement, Customer may operate each Pharmacy as a GNP Pharmacy at its existing Pharmacy location, where Customer was previously operating its pharmacy business, or new Pharmacy location, where Customer is a start-up pharmacy (each such location, a "**Pharmacy Location**"). In granting rights under this Agreement, ABDC makes no assurance, express or implied, about suitability of such location for a pharmacy, or any other purpose, and ABDC will not be responsible if Pharmacy does not meet Customer's expectations for revenue, operations or other criteria.

(c) Internet Operations. Customer may sell products and services using internet websites only as expressly permitted herein or as otherwise authorized by ABDC in writing.

(d) Unapproved Operations. Customer may not use any Mark or other distinctive or unique elements of the GNP Premier Program to operate any business other than Pharmacy at the Pharmacy Location, without

ABDC's express prior written approval. ~~Such~~Customer understands and acknowledges that such use constitutes willful infringement of the Marks and the GNP Premier Program.

(e) Non-Exclusivity. Customer's rights with respect to the GNP Premier Program are not exclusive. ABDC may among other things: (1) establish and operate GNP Pharmacies (defined in Section 4(a)) and allow others to do so, including ones in the GNP Premier Program~~,~~; (2) offer and sell the GNP Premier Program and related products and services to other customers~~,~~; and (3) establish, operate, offer and sell other businesses, goods and services, or allow others to do so, including those that are the same, similar or different and using some, all or none of the Marks, in each case regardless of proximity to or competitive impact on GNP Pharmacies.

(f) Administration. In certain instances, ABDC receives revenue from the sale of items (other than ABDC's core distribution items such as Rx, OTC, etc.) related to the GNP Premier Program that are purchased by GNP Pharmacies from third parties, such as volume discounts, rebates or other benefits based on GNP Pharmacies' aggregate purchases. Such benefits will be used to generally enhance and promote the GNP Premier Program or to benefit GNP Pharmacies generally. This provision is not meant to circumvent or eliminate opportunities for revenue sharing with GNP Pharmacies, and in such cases ABDC may allocate such benefits directly and proportionally to participating GNP Pharmacies and deduct expenses to administer and coordinate suppliers. In connection with programs for GNP Pharmacies and related products and services, Customer hereby assigns ABDC the right to collect related promotional and advertising allowances.

2. Fees.

(a) Initial Fee. In consideration of Customer's anticipated initial expenditures which may be required to meet GNP Premier Program requirements, ABDC does not charge an initial fee associated with its granting of rights as provided in this Agreement.

(b) Periodic Fees. In consideration for Customer's continuing use of the Marks and the GNP Premier Program and participating in Available Programs that are Required or Optional (each as defined in Section 4(g)-(h)), Customer agrees to pay ABDC for each Pharmacy Location the GNP Premier monthly fee provided on the Summary and Signature Page ("**Monthly Fee**") which such Monthly Fees may be prorated as applicable. ABDC will add to the billed amount applicable fees for Available Programs ~~(defined in Section 4(g))~~ and applicable sales, use or other tax or charges. Unless otherwise agreed, payment is due pursuant to payment terms under Customer's PVA (defined in Section 4(f)). ABDC may increase the Monthly Fee upon sixty (60) days' notice.

(c) GNP Manual. ABDC will provide to Customer the GNP Manual (defined in Section 4(a)), in electronic format, and additions and supplements to the GNP Manual as they become available. Notwithstanding the foregoing, Customer understands and agrees that the current version of the GNP Manual on file in ABDC's offices is the standard, official version for purposes of resolving any question or dispute concerning ~~its~~GNP Manual contents.

3. Modification of GNP Premier Program and Marks.

(a) Modifications. ABDC may modify the GNP Premier Program and Marks, including: (i) adding, changing or discontinuing them; (ii) changing decorative, non-functional components that provide Pharmacy a distinctive, memorable appearance ("**Trade Dress**"); and (iii) adding, changing or discontinuing "Good Neighbor Pharmacy" brand private label product ("**GNP Private Label Product**"). Customer will comply with and adopt, at its expense, any and all such changes, including changing Trade Dress, signage and Pharmacy operations items.

(b) Innovations. The GNP Premier Program is continually enhanced through feedback provided by GNP Pharmacies, including sharing of successful and innovative uses of the GNP Premier Program. If Customer suggests, enhances or develops an innovation or improvement related to any aspect of the GNP Premier Program and ABDC incorporates it into its programs for use in or by other GNP Pharmacies

(whether on a temporary or permanent basis and whether applicable to some or all GNP Pharmacies): (i) such innovation or improvement will become part of such programs without compensation to Customer or any other party; and (ii) Customer hereby irrevocably assigns ~~ownership of~~to ABDC all right, title, and interest in and to such enhancements, innovations, and improvements ~~to ABDC~~, including all intellectual property rights and proprietary rights attributable thereto, and agrees to take any additional steps ABDC may request in connection with ABDC's ownership of the same.

4. Customer's Obligations.

(a) Pharmacy Operation. Operation and appearance of each pharmacy that operates under the ~~GNP~~"Good Neighbor Pharmacy" trademark and other Marks, including those in the GNP Premier Program and pharmacies operating under a Good Neighbor Pharmacy Voluntary License (collectively, "**GNP Pharmacies**~~")~~"), reflect on other GNP Pharmacies and goodwill of the GNP Premier Program. Customer will use best efforts to operate its business at each Pharmacy with diligence and vigor, and maintain the highest possible ethics and maintain Pharmacy and personnel in a manner that are a credit to the community and reflect the high standards and quality of the GNP Premier Program, including~~, without limitation,~~ interacting with and treating all customers and ~~GNP~~ABDC personnel in a respectful and professional manner. GNP prescribes or recommends standards, practices, procedures, policies and advice relating to the appearance, operations, management and marketing of GNP Pharmacies~~, including Available Programs (~~" (collectively, "**Standards**"), as updated by ABDC from time to time and provided in the materials it provides or makes available to you ("**GNP Manual**"). Customer ~~is expected to make commercially reasonable efforts to be~~shall become active and compliant with all required Available Programs within one hundred twenty (120) days after the Effective Date ~~of the GNP Premier Agreement. It~~; provided, however, that Customer understands and acknowledges that it may take four (4) to six (6) weeks for a third-party Payor to recognize that ~~you are~~Customer is authorized to provide Covered Services to its Members~~.~~ (each as defined under Term Sheet 1). Customer will operate Pharmacy and perform its obligations ~~pursuant to~~hereunder in accordance with applicable law, this Agreement, the GNP Manual, and Standards and other agreements. ~~Customer will comply fully with all laws applicable to its business.~~

(b) Pharmacy Appearance and Integrity. Customer will maintain all interior and exterior areas at each Pharmacy Location in a safe and sanitary condition. Customer will keep equipment, decorations, fixtures, furnishings and improvements in good order and promptly repair or replace those that are damaged, worn or obsolete. Customer will provide appropriate training for Pharmacy personnel on proper use and display of Marks under this Agreement, the GNP Manual and Standards.

(c) Signage. Customer will purchase exterior and interior signage from suppliers meeting Standards to ABDC's reasonable satisfaction and display all required signage at each Pharmacy in accordance with the Standards.

(d) Placard. Customer will display in a reasonably visible manner in each Pharmacy Location a notice stating, "This business is independently owned and operated by [insert name of Customer]." Customer ~~may~~shall not make ~~no~~any statement or representation contrary to Paragraph 8.5 of the Provisions (Exhibit C).

(e) Designated Manager. Customer will designate one (1) owner, partner or other authorized person as ~~to be~~ Customer's primary contact ("**Customer's Designated Manager**") with ABDC and its staff to administer and coordinate the relationship under this Agreement.

(f) Prime Vendor Agreement. Customer will purchase brand and generic prescription (Rx), over-the-counter (OTC), health and beauty care (HBC), and GNP Private Label Products from ABDC pursuant to a prime vendor agreement or other applicable distribution agreement ("**PVA**"), which shall be executed separately. Separately, animal health products may be purchased from MWI Veterinary Supply Co., an affiliate of ABDC, pursuant to a GNP - Animal Health Purchase Agreement~~.~~ or other applicable distribution agreement. ABDC will provide access to electronic catalogs of such products, which are typically updated daily including new products as they are available. Customer will place orders using one of ABDC's available order systems, with purchases subject to the PVA or as otherwise agreed,

including terms for payment, credit, liability, risk of loss, shortages, delays and compliance with law. All such orders will be at ABDC's standard then-current wholesale prices under the PVA.

(g) Available Programs. ABDC offers a variety of programs and services ("**Available Programs**") in which pharmacies may participate to improve their operational and financial performance. General terms for Available Programs are provided in the Master Program Agreement (Exhibit E) and the Provisions (Exhibit C), with specific descriptions, terms, and conditions respecting each Available Program provided in Term Sheets 1 to 10 ("**Term Sheets**"). ABDC may unilaterally amend this Agreement, including, without limitation, developing new or modifying existing Exhibits hereto and/or Available Programs and their respective policies, procedures, and corresponding Term Sheets, which any such amendments are effective sixty (60) days after they are available or any shorter period specified in a Term Sheet, as applicable. As noted in the Master Program Agreement, Customer may incur additional expenses for Available Programs. Current Term Sheets are posted on AB Central (https://abcorder.amerisourcebergen.com). ABDC will provide notice via fax or email respecting any unilateral amendment to this Agreement as provided herein.

(h) Required & Optional Programs. Each GNP Premier Program participant must participate in certain Available Programs ("**Required**") and has the option to participate in others that are included with or without an additional cost ("**Optional**"). Customer enrollment and onboarding in Required Available Programs will begin as of the Effective Date~~.~~; provided, however, that Customer may be required to fulfill certain prerequisite conditions before the services offered in such Available Program are made available to Customer, and some Available Programs may not be immediately available to Customer. For an Available Program that is Optional, Customer may (i) enroll during the Term by submitting applicable information required to set-up Customer's participation and requesting that ABDC begin providing such Available Program and (ii) disenroll by requesting that ABDC discontinue providing such Available Program, pursuant to the terms of the respective Term Sheet. All Term Sheets incorporate the provisions of this Agreement, including all Exhibits attached hereto, by this reference. Currently, the following are Available Programs~~.~~:

	AVAILABLE PROGRAMS	
	Managed Care	
Required	☐ Elevate Provider Network	Term Sheet 1
Required	☐ Elevate Advanced Features	Term Sheet 2
Required	☐ Pre & Post Edit Solutions (PPE)	Term Sheet 2A
Optional	☐ Claim Reconciliation Services	Term Sheet 2B
Optional	☐ Outcomes ~~PCS~~Patient Care Services Solution	Term Sheet 2C
Optional	☐ EnlivenHealth Patient Care Services Solution	Term Sheet 2D
	Data Analytics and Pharmacy Performance	
Required	☐ InSite for Pharmacy Management System Data	Term Sheet 3
Optional	☐ InSite for Point-of-Sale System Data	
Optional	☐ Five-Star Rebate	Term Sheet 4
	Front-End Solution Programs	Term Sheet 5
Required	☐ First-to-Shelf – AutoShip New OTC & GNP Private Label Products	
Optional	☐ Planogram Services	
Optional	☐ Retail Product Zone Pricing Service	
Optional	☐ Front-End Support Kit	
Optional	☐ Merchandising Services	
	Digital Marketing	Term Sheet 6
Optional	☐ My GNP Website	
Optional	☐ My GNP Mobile App	
Optional	☐ Social Media Marketing	
Optional	☐ Local Listings Management	

	AVAILABLE PROGRAMS	
Optional	**Business Coaching** ☐ Business Coaching	Term Sheet 7
	Miscellaneous	
Optional	☐ Pharmacy Data Services	Term Sheet 8
Optional	☐ Unsaleable Returns	Term Sheet 9
Optional	☐ Statement of Work-Service (Form) for Special Projects	Term Sheet 10

(i) Elevate Provider Network℠. GNP Premier Program participants each participate in the Elevate Provider Network® ("**Elevate Provider Network**"), pursuant to which ABDC will assist Customer to participate in and obtain payment from certain Payors (as defined in Term Sheet 1). Customer must designate the Elevate Provider Network as its primary contracting entity and may not appoint any other pharmacy services administration organization ("**PSAO**") or other party to act as its primary agent/contracting entity for agreements with Payors without ABDC's prior written approval or ABDC may terminate this Agreement. Such termination will be effective at the earlier of the date on which Customer's designation of another PSAO is effective or thirty (30) days after Customer's receipt of ABDC's termination notice under this Section 4(i). Participation in Elevate Advanced Features is required notwithstanding Customer's designation of an alternative PSAO.

(j) Business Coaching. Within six (6) months of Customer completing all prerequisite conditions necessary to enroll in the Required Available Programs, Customer will be enrolled in the Business Coaching Available Program and assigned a Business ~~Coach~~Coaching Associate (as defined in Term Sheet 7), who will provide to Customer certain recommendations related to increasing Pharmacy's performance. Business Coaching is provided at no additional cost to Pharmacies enrolled in the GNP Premier Program.

(k) Confidential Information. Customer will maintain in strict confidence all ABDC Confidential Information (as defined in and in accordance with Paragraph 4 of the Provisions (Exhibit C) and Term Sheets) and take all necessary action to ensure that its employees and other representatives do not disclose any ABDC Confidential Information except as expressly permitted herein.

(l) Display of Material. Customer will display at each Pharmacy Location: (i) Good Neighbor Pharmacy product identification material; (ii) point-of-purchase promotional material; (iii) promotional memorabilia and merchandise; and (iv) other advertising and marketing material that ABDC requires Customer to use in operating Pharmacy, in each case in accordance with this Agreement and in such manner as ABDC may otherwise periodically ~~designates~~designate.

5. Required Signage.

(a) Initial Signage. Each Pharmacy Location must be prominently identified as a participating "Good Neighbor Pharmacy®" member as ABDC designates. At each ~~pharmacy location~~Pharmacy Location, within ninety (90) days after signing the GNP Premier Agreement, Customer must install GNP signage and Trade Dress that meets the Standards. ABDC's current signage Standards require: (i) at least one (1) "GOOD NEIGHBOR PHARMACY" identification window decal; (ii) at least one (1) "GOOD NEIGHBOR PHARMACY" logo, which is available in both standard and customized interior and exterior versions; (iii) "GOOD NEIGHBOR PHARMACY" member plaque; and (iv) any other signage required by ABDC, as set forth in the GNP Manual. All signage must meet applicable Standards~~(~~, including ~~for~~Standards relating to appearance, placement and visibility of signs~~)~~, as provided in the GNP Manual and be kept in good repair. Customer will use best efforts to maximize visibility of exterior "GOOD NEIGHBOR PHARMACY" signs subject to any legal limitations. For each Pharmacy Location, Customer will obtain all required approvals, including government permits, before installing or removing any signs, structures or other items associated with the Marks.

(b) Initial Signage Allowance. ABDC provides complimentary signage packages to all new franchisees that, when applied according to the Standards, meet applicable minimum requirements ~~(~~; provided, however, that for an existing Voluntary Pharmacy converting to a GNP Premier Pharmacy, ABDC may provide only a partial package as compliant signage may already be installed~~)~~.. To encourage you to enhance the appearance of your GNP Premier Pharmacy and further apply the Good Neighbor Pharmacy Trade Dress at your Pharmacy Location, ABDC offers new franchisees up to ~~$~~Two Thousand Five Hundred dollars ($2,500.00) in matching funds as a one-time allowance of up to ~~$~~Two Thousand Five Hundred dollars ($2,500.00) per Pharmacy Location to install additional or enhanced exterior signage and other Trade Dress that meets the Standards within one hundred eighty (180) days of ~~signing the Premier~~ executing this Agreement. If ~~the~~ Customer terminates this ~~Premier~~ Agreement for any reason, other than an uncured default by ABDC, within twelve (12) months of executing the ~~Premier~~ Agreement, Customer will reimburse ABDC, in addition to any other amounts or damages that may be owed to ABDC under this Agreement or any other agreement, the full amount ABDC paid to Customer in matching funds under this provision. Customer acknowledges and agrees that the foregoing reimbursement does not constitute liquidated damages, and is not exclusive of any other rights or remedies that may be available to the parties. ABDC associates are unable to assist with measuring or installation of any signage items.

(c) Compliance Exceptions. If Customer needs to vary signage from the applicable requirements under this Agreement or the GNP Manual, variations will be documented on a GNP Compliance Exception Request Form to be reviewed and approved by ABDC~~,~~ in its sole discretion. Such approval must be given by ABDC in writing prior to Customer's use of non-conforming signage.

6. GNP Private Label Products. Customer will periodically purchase and offer for sale~~,~~ a representative assortment of GNP Private Label Products in quantities reasonably anticipated to meet consumer demand, taking into account, among other things, Pharmacy's size and market, as determined by Customer in its reasonable discretion based on its general business experience. Customer will feature the GNP Private Label Products as its preferred alternative to national brands and will use best efforts to promote and sell GNP Private Label Products. Customer hereby authorizes ABDC to initiate commercially reasonable orders on its behalf for new GNP Private Label Products as they are introduced.

7. Term and Termination.

(a) Initial & Renewal Terms. The initial term of this Agreement begins on its Effective Date on the Summary and Signature Page and, subject to earlier termination, ends five (5) years after the Effective Date ("**Initial Term**"). Thereafter, the Term will renew automatically for additional, consecutive two-year periods (each, a "**Renewal Term**" and, together with the Initial Term, the "**Term**") unless either party gives the other party one hundred twenty (120) days' prior written notice of its intent to not renew the Term.

(b) Mutual Termination. Either party may terminate this Agreement with respect to one or more Pharmacy Locations with or without cause upon sixty (60) days' prior written notice to the other party. Termination for less than all Pharmacy Locations will not terminate this Agreement with respect to a Pharmacy Location that is not named in the termination notice. Termination of this Agreement will not, by itself, terminate any other agreement between the parties.

(c) Termination for Breaching GNP Obligations. ABDC may terminate this Agreement immediately upon notice to Customer and without providing Customer the opportunity to cure if (i) Customer or a Principal (as defined below) breaches its obligations to protect Confidential Information; (ii) breaches its obligations relating to use of the Marks or ABDC's online portal maintained in connection with the GNP Premier Program (the "**GNP Portal**"); or (iii) Customer or a Principal is convicted of or pleads guilty or no contest to a felony or any other offense that ABDC determines may adversely affect other GNP Pharmacies, Available Programs, related programs, or goodwill of the Marks or the GNP Premier Program, such as fraud, sexual harassment, battery, drug possession and crimes of moral turpitude. "**Principal**" means each officer, director or owner of Customer or any Corporate Affiliate.

(d) Default. Additionally, either party may terminate this Agreement for cause pursuant to Paragraph 5 of the Provisions (Exhibit C).

8. Internet Operations.

(a) General. Customer may promote Pharmacy and sell products using the Marks on the internet pursuant to the GNP Manual and Standards. Any such internet operation will clearly identify Customer's community pharmacy business and be incidental to and an extension of such business. Internet operations must comply fully with applicable federal and state laws, including laws in states in which patients reside. Notwithstanding the foregoing, ABDC may: (i) restrict use of an internet domain name, vanity URL, home page or other web address that includes a Mark (or require a separate license for such use); and/or (ii) limit or require use of hyperlinks ~~or other material~~ (such as required links to ABDC websites~~),~~) or other material, including material such as text, images, photographs, video, and/or sound that ABDC or a third party owns or has the right to use or limit the use of. Customer must promptly discontinue any such use if ABDC notifies Customer it is disapproved.

(b) Customer Responsible. Notwithstanding ABDC's right to disapprove content of Customer's website, Customer is solely responsible for accuracy of information it provides on the internet or otherwise.

(c) ABDC Websites. ABDC may advertise GNP Pharmacies on the internet and in other media in its discretion, including design and content, and discontinue some or all such advertising without liability. ABDC may create interior pages on websites with information about Pharmacy and link to any Customer website, including advertising or other opportunities.

(d) Publicity. Customer hereby authorizes ABDC to use, publish, and copyright photographs of the Pharmacy Locations and Customer's statements ~~created~~made during the Term for editorial, promotional, advertising or other purposes, with or without Customer's name or other identifying information, in any media, including on ABDC's websites and the GNP Portal. ABDC will, upon Customer's request, remove from ABDC's websites or the GNP Portal any such photographs or statements that identify Customer.

9. Trademarks and Intellectual Property.

(a) Right to Use Marks and Copyrighted Material. Customer may use the Marks only as necessary for operation and promotion of Pharmacy and only for a Pharmacy Location, including advertising. Customer may not use the Marks: (i) other than in compliance with Standards and such other quality controls as ABDC adopts to promote and defend the Mark's goodwill; or (ii) in connection with developing or operating any business other than Pharmacy ~~(~~, including any additional pharmacy owned or operated by Customer that is not a GNP Pharmacy ~~listed in this Agreement).~~. Customer will promptly discontinue any advertising or other use of Marks or Copyrighted Material (defined in Section 9(b)) if ABDC notifies Customer that such use is disapproved. Customer agrees that ABDC owns all right, title and interest in and to the Marks and Copyrighted Material. Customer acquires no right, title, or interest in the Marks or Copyrighted Material other than the right to use them pursuant to this Agreement and the GNP Manual and Standards. ABDC expressly reserves any and all rights not otherwise specified herein.

(b) Prohibitions Concerning the Marks and Copyrighted Material. Customer understands ABDC is authorized by law to prevent unauthorized use of the Marks, to control quality of associated goods and services, and to control the copying and distribution of the Copyrighted Material. "**Copyrighted Material**" means any material produced by or for ABDC, including works derived from other Copyrighted Material, including (1) program guides and manuals used in Pharmacy's operation and marketing activities, including the GNP Manual; (2) training material, including printed, audio, video, or electronic material; (3) signage plans and specifications; (4) product posters, photographs, and graphics; (5) advertising and marketing material; (6) labels, forms, and reports ~~provided by ABDC~~; (7) computer software developed or provided by ABDC; (8) all Trade Dress and Trade Dress elements; and (9) any other material protected by copyright law or marked or identified by ABDC as protected by copyright. Without limiting the foregoing, Customer agrees to the following:

(i) As between ABDC and Customer, ABDC is the lawful owner of each Mark and all Copyrighted Material, with the right to use them and license Customer to use them, with Customer's interest solely as a licensee, and with Customer's use inuring to ABDC's benefit. Customer hereby unconditionally disclaims any ownership interest in any Mark or Copyrighted Material.

(ii) Customer may not use any Marks, including "Good Neighbor Pharmacy", or any abbreviation, acronym or variation of them as part of its name or as part of the name of any business entity. However, Customer may file an assumed name or fictitious name certificate to the ~~effect~~extent that Customer is operating Pharmacy under a trade name that includes the "Good Neighbor Pharmacy" Mark in accordance with the GNP Manual.

(iii) Customer may only use Marks and Copyrighted Material in advertising, promotion, sale, and distribution of products and services offered by Pharmacy as ABDC has expressly permitted in writing.

(iv) Customer may use Marks or Copyrighted Material on the internet only as permitted by Section 8 and this Section 9.

(v) Customer will, if it adopts and uses any additional trade names, trademarks, brand names, Copyrighted Material, slogans, commercial symbols, and/or logos that ABDC develops related to the GNP Premier Program: (A) ~~Customer will~~ use all the Marks in the precise form ABDC prescribes; (B) observe ABDC directions regarding the use, copying and distribution of the Copyrighted Material, presentation and manner of the Marks' display and use; and (C) not copy or distribute any Copyrighted Material in violation of this Agreement.

(vi) Customer will not knowingly permit, and will promptly report to ABDC upon becoming aware of, any apparent unauthorized use of a Mark and any apparent unauthorized use or copying of any Copyrighted Material by any person, or use by any person of a trade name, trademark, service mark, or symbol that might be construed as an infringement of any Mark or as unfair competition or passing-off at common law, and will actively cooperate with ABDC in investigating and prosecuting any infringement claims. ABDC may make any determination on infringement or other unlawful use, including whether to pursue or settle such claims.

(vii) Customer may not challenge validity of any Mark or ABDC's rights in or to them, and Customer may not make any written or oral admission that a Mark or any Copyrighted Material is invalid or infringes rights of any person. Customer will promptly notify ABDC of any allegation of invalidity or infringement of which Customer becomes aware. ABDC does not warrant that its ownership of any Mark or Copyrighted Material is incontestable or that they do not infringe or conflict with rights of any other party but ABDC will indemnify Customer for any third party Claim as defined in and pursuant to Paragraph 6 of the Provisions (Exhibit C) relating to infringement by a Mark or any Copyrighted Material.

(c) GNP Premier Program, ABDC Confidential Information and GNP Manual. Customer acknowledges that the GNP Premier Program and all ABDC Confidential Information (as defined in Exhibit C, Section 4) belong exclusively to ABDC and that, as between ABDC and Customer, ideas and information in the GNP Manual are ABDC's exclusive property. ~~Further,~~Customer further understands and acknowledges that unauthorized use or disclosure of ABDC Confidential Information, including any part of the GNP Premier Program, an ABDC Trade Secret (as defined below) or other information in the GNP Manual, may adversely affect the business, competitive position and/or goodwill of ABDC, the GNP Premier Program, and other GNP Pharmacies. "**Trade Secret**" means information that derives actual or potential independent economic value from not being generally well known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use and that is subject to reasonable efforts to maintain its secrecy. For avoidance of doubt, in assessing whether information is "Confidential Information" or a "Trade Secret," the parties intend to exclude information that a licensed pharmacist, with background and experience comparable to Customer, would know without access to ABDC's material. Accordingly, Customer agrees to the following, each of which survive termination of this Agreement and perpetually bind Customer and its Principals:

(i) Customer must hold all ABDC Confidential Information, including elements of the GNP Premier Program and GNP Manual, in strict confidence and limit disclosing ABDC Trade Secrets and operating or management procedures as required by ABDC, including to Customer's Designated Manager or to Pharmacy bona fide employees or others to whom such disclosure is necessary for their duties. Customer will instruct and routinely remind such people that the GNP Premier Program, ABDC Confidential Information, and GNP Manual contents are confidential and may not be disclosed or appropriated.

(ii) Customer may not use any element of the GNP Premier Program or operating, management, or marketing procedures provided in the GNP Manual in connection with any business other than Pharmacy~~.~~ and only for a Pharmacy Location.

(iii) Customer may not, without ABDC's prior written consent, download, copy, or permit any person to download or copy any part of the GNP Manual or other printed, graphic, audio, or visual item that contains ABDC Confidential Information. Customer may not otherwise permit their use or inspection by any person other than Customer's Designated Manager and bona fide Pharmacy employees to whom such disclosure is necessary in relation to their duties, and authorized ABDC representatives.

(iv) All training material, including videos, audios, and computer programs related to the GNP Premier Program, contain ABDC Confidential Information, including procedures and business practices.

(d) Internet Domain Names. Customer acknowledges that ABDC is the sole owner of internet domain names related to the GNP Premier Program, including "GoodNeighborPharmacy.com" and "mygnp.com". Customer hereby unconditionally disclaims any ownership interest in or to: (i) any such phrase or colorably or confusingly similar internet domain name; (ii) any such domain name and any domain names that may be colorably or confusingly similar to them; and (iii) the words "Good Neighbor" and "Good Neighbor Pharmacy" and any abbreviation, acronym, or variation of such words, including "GNP". Customer may not register any internet domain name in any class or category that contains "Good Neighbor", "Good Neighbor Pharmacy", or "GNP", or any abbreviation, acronym, or variation of those words.

(e) Equitable Relief. In addition to other rights, ABDC may obtain injunctive relief, without bond, against Customer and any Principal restraining unauthorized or prohibited use of any Mark, Copyrighted Material, ABDC Confidential Information, or ABDC Trade Secret, with or without terminating this Agreement.

10. Transfers. Customer will notify ABDC of changes in ownership, name, business form (e.g., sole proprietorship, partnership ~~or~~, corporation~~)~~, etc.), state of incorporation or formation, or any intent to sell, close, move or modify its operations prior to such change, sale, closure or modification, and provide other information ABDC reasonably requests. ABDC may immediately terminate this Agreement upon or following any sale or transfer of Customer's business, in whole or in part, or sale of 25% or more of Customer's assets or equity to a: (i) pharmaceutical wholesale distributor; (ii) franchisor or licensor of a pharmacy advertising or merchandising program; (iii) chain of ten (10) or more pharmacies doing business under the same or a substantially similar name; or (iv) Corporate Affiliate. This Agreement inures to the benefit of and binds heirs, successors, and assigns of each party. Customer hereby consents to ABDC's: (a) assigning part or all of its obligations hereunder to any ABDC Corporate Affiliate; and (b) granting a security interest in this Agreement in connection with any financing or securitization by ABDC or any Corporate Affiliate thereof, in either case without prior written notice to Customer.

11. GNP License Program Release. If Customer participated with ABDC's prior voluntary program related to pharmacies operating under the name "Good Neighbor Pharmacy" ("**ABDC's Prior Program**") and its related programs and agreements, each party, their Principals and Corporate Affiliates hereby release each other and their Principals and Corporate Affiliates from claims or other obligations they may have against any others now or in the future, but only to the extent they relate to an offer or sale of ABDC's Prior Program or its related programs and agreements, including fraudulent inducement claims or sales law violations. This Section 11 does not affect any claim related, directly or indirectly, to: (i) the offer, sale or execution of this

Agreement; (ii) performance by anyone under ABDC's Prior Program or its related programs and agreements; or (iii) other agreements between the parties.

12. Post-Termination Obligations.

(a) Use of Marks. If this Agreement expires or is terminated for a Pharmacy Location: (i) Customer's right and privilege to use the GNP Premier Program, Marks, Copyrighted Material, ABDC Confidential Information, and all components of the GNP Manual will absolutely and unconditionally cease for such Pharmacy Location, effective as of the applicable expiration or termination effective date, provided, however, such termination or expiration will not, by itself, affect Customer's right to buy products under its PVA; and (ii) ABDC may remove information about such Pharmacy Location from websites, including the GNP Portal, and suspend or terminate Customer's access to the GNP Portal. During the sixty (60) days prior to expiration or cause-free termination of this Agreement, Customer will immediately begin to comply with the following for such Pharmacy Location so that such steps are completed by the end of the Term (and will do so promptly if this Agreement is terminated for cause), and Customer's failure to comply fully with the following requirements by such date shall constitute willful trademark and copyright infringement:

(i) Discontinue use of the GNP Premier Program, Marks, Copyrighted Material, ABDC Confidential Information, and all components of the GNP Manual;

(ii) Return to ABDC all parts of the GNP Manual or any other printed, graphic, audio, or visual item designated by ABDC as containing ABDC Confidential Information (Customer may elect to completely destroy all parts of the GNP Manual, whether in physical or electronic form, in lieu of returning same to ABDC);

(iii) Remove from each Pharmacy Location all interior and exterior GNP signage and other uses of the Marks;

(iv) Cancel all advertising arrangements relating to Customer's use of Marks or Copyrighted Material, including "yellow pages" or similar listings, as soon as reasonably possible, and promptly cancel any assumed or fictitious name filings related to the Marks; and

(v) Alter Pharmacy's interior to remove all Trade Dress items and otherwise eliminate the distinctive features of the GNP Premier Program.

(b) Goodwill for Marks. Upon expiration or termination of this Agreement, all goodwill associated with the Marks and Copyrighted Material will inure to ABDC.

(c) ABDC Rights. If Customer does not comply with Section 12(a), in addition to other rights, ABDC may, at Customer's expense, enter the applicable Pharmacy Location(s) on seven (7) days' notice to effect compliance with such obligations, including removal and storage of signs and alteration or removal of Trade Dress items.

(d) Payment. In addition to other rights, ABDC may recover all amounts owed to ABDC in connection with this Agreement, plus interest and late fees under Paragraph 2.2 of the Provisions (Exhibit C), with or without terminating this Agreement. For any obligation referred to an attorney for collection or collected through a judicial proceeding, Customer will pay ABDC attorneys' fees and costs and for ABDC's staff and administrative time.

(e) Equitable Relief. In addition to other rights, ABDC will be entitled to injunctive relief, without bond, to enforce compliance with requirements of this Section 12.

(f) Damages. In addition to other rights, ABDC may recover damages from Customer and any Principal for: (i) unauthorized or prohibited use of any Mark, Copyrighted Material, or ABDC Trade Secret; and/or (ii) any loss of customer or future goodwill associated with the Marks or GNP Premier Program.

(g) Survival. The parties' obligations, the context of which show the parties intended them to survive, will remain in effect after the Term, including indemnification, confidentiality and choice of law obligations. Without limiting the foregoing, the parties' other business relationships, including the PVA, are

independent of this Agreement and ~~its~~the Available Programs hereunder. Except as agreed: (i) performance under this Agreement or its expiration or termination will not affect such other agreements; and (ii) performance under such other agreements or their expiration or termination will not affect this Agreement.

13. Available Program Terms.

(a) Term. In addition to other applicable terms and conditions provided herein, Customer's enrollment and participation in Available Programs is subject to the following terms:

(i) Respecting any Available Programs that are Required and in which Customer is not previously enrolled, Customer will begin enrollment and onboarding steps beginning on the Effective Date of this Agreement, to the extent immediately available and subject to satisfaction of any prerequisite conditions, and such participation shall terminate upon the expiration or earlier termination of this Agreement; provided, however, Available Programs may continue thereafter subject to applicable provisions of this Agreement~~(~~, or, if adopted by the parties following termination of this Agreement, ABDC's Master Program Agreement~~)~~, until such Available Program is terminated pursuant to Paragraph 5 of Exhibit C (Provisions) or as ~~follows~~provided in this Section 13.

(ii) Either party may terminate one or more Available Programs at one or more Pharmacies, with or without cause, at any time upon sixty (60) days' written notice to the other party; provided, however (A) termination of specific Available Programs may be subject to restrictions or termination obligations; (B) Customer may not terminate any Available Program that is Required unless Customer also terminates this Agreement; and (C) ABDC will use commercially reasonable efforts to give Customer at least sixty (60) days' prior written notice before terminating any Available Program that is Required and the option for Customer to exercise its right to terminate this Agreement on the date such Available Program is to be terminated, notwithstanding Customer's other notice requirements. Termination of less than all Available Programs at all ~~Pharmacies~~Pharmacy Locations will not terminate Customer's rights or obligations pursuant to the Master Program Agreement (Exhibit E) nor any Term Sheets not explicitly terminated by Customer or ABDC, unless Customer executes a replacement Master Program Agreement to supersede the version attached hereto.

(iii) ~~Other Available Programs (that is, Optional) commence (to~~To the extent immediately available and subject to satisfaction of any prerequisite conditions~~)~~, Optional Available Programs commence and terminate as of the date on which Customer enrolls or disenrolls as provided in Section 4(h).

(iv) Notwithstanding the foregoing, ABDC may immediately and at any time terminate or modify, as applicable, any ~~Pharmacy's~~Pharmacy Location's participation in any Available Program that includes eligibility qualifications, requirements, and/or criteria, as provided in applicable Term Sheets and/or enrollment forms, that such Pharmacy Location does not satisfy.

(b) Fees. Each Term Sheet states applicable per-Pharmacy fees, which such fees may be prorated as applicable. Some Available Programs require Customer to incur other expenses, which are Customer's responsibility. "**Premier**" fees apply to GNP Pharmacies under the GNP Premier Program, including Customer. Fees for GNP and Others (each as defined below), which apply to non-Premier GNP Pharmacies ("**GNP**") and Pharmacies that are not Premier or GNP Pharmacies ("**Others**"), respectively, are not applicable to Customer. Applicable fees may be increased on sixty (60) days' prior written notice.

(c) ABDC Commitments.

(i) Programs and Services. ABDC will use commercially reasonable efforts to provide Available Programs in which Customer enrolls from time to time pursuant to terms in the applicable Term Sheet, industry standards, laws and the GNP Manual. In addition to written material, ABDC or others, including Payors (as defined under Term Sheet 1), may, to the extent permitted by applicable agreements between ABDC and Payors, publish the GNP Manual, Standards, policies, procedures, and updates to each of these on AB Central or other websites they maintain, or make them available

on request. A listing of current Available Programs and applicable Term Sheets are accessible on AB Central or from Customer's ABDC sales representative.

(ii) Statements of Work. From time-to-time, Customer may engage ABDC to provide other goods and services including custom work or a special project, terms of which will be as agreed pursuant to a Statement of Work (Term Sheet 10) and governed by this Agreement.

(iii) Privacy. ABDC will protect and only use Pharmacy Data (as defined in Exhibit A) provided by, or on behalf of, Customer, pursuant to the Data Protection Provisions (Exhibit A) in connection with any Available Program that involves access to Pharmacy Data and, in connection with any Available Program that involves access to protected health information (PHI as defined in Exhibit B), such as Elevate Provider Network, InSite, Pre & Post Edit Solutions, Claim Reconciliation Services, ~~Outcomes PCS Solutions, EnlivenHealth Patient Care Services Solutions,~~ Business Coaching, and the ABDC Order Monitoring Program, pursuant to the HIPAA Business Associate Agreement (Exhibit B or as otherwise agreed) under the Health Insurance Portability and Accountability Act of 1996 ("**HIPAA**"), the HITECH Act, and implementing regulations including the Privacy, Security, and Breach Notification Rules (each defined in Exhibit B).

(d) Customer Commitments.

(i) Compliance. Customer will comply with this Agreement, all laws, Term Sheets and the GNP Manual, including qualifications Customer must meet to be eligible for each Available Program in which Customer is enrolled, including, without limitation, all Required Available Programs. If Customer does not, it may not participate in such Available Program or, if it is participating, its right to do so may be revoked. Customer is responsible for acquiring and maintaining all equipment, software and other items specified as necessary in Program Guides, as updated from time to time. Such items must be purchased from suppliers meeting Standards to ABDC's reasonable satisfaction.

(ii) Use of Programs. Customer may only use an Available Program for its own Pharmacy business and only at a Pharmacy Location for which Customer has enrolled in such Available Program. Nothing supplied by ABDC pursuant to this Agreement, including performance measurements, business advice, cost or price data is a substitute for Customer's business and professional judgment or will dictate to Customer at what price to sell pharmaceuticals or other merchandise, except to the extent Customer agrees (e.g., under Elevate Provider Network). Customer is ~~fully~~solely responsible for use of data and advice obtained through Available Programs and must keep confidential and not disclose, redistribute, supply, license, or sell any data or information, including reports and methods, relating to Available Programs.

14. Dispute Resolution

(a) Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania, without reference to its conflict of laws principles.

(b) Dispute Resolution. Customer must first bring any claim or dispute between Customer and ABDC to ABDC's management, after providing notice as set forth in Section 14(f) of this Agreement, and make every effort to resolve the dispute internally. Customer must exhaust this internal dispute resolution procedure before Customer may bring Customer's dispute before a third party. This agreement to first attempt resolution of disputes internally shall survive termination or expiration of this Agreement. If the parties are unable to resolve any claim or dispute internally within ninety (90) days, Customer agrees that any controversy or claim arising out of or relating to this Agreement, or the breach thereof, shall be determined by final and binding arbitration administered by the American Arbitration Association ("AAA") under its Commercial Arbitration Rules and Mediation Procedures to take place in Philadelphia, Pennsylvania. Any arbitration award or decision may be filed in a court of competent jurisdiction for enforcement. Notwithstanding the foregoing, the~~This agreement to first attempt resolution of disputes internally shall survive termination or expiration of this Agreement. The~~ parties will not be required to first attempt to resolve a controversy, dispute, or claim

through mediation as set forth in this Section 14(b) if such controversy, dispute, or claim concerns an allegation that a party has violated (or threatens to violate, or poses an imminent risk of violating): (i) any federally protected intellectual property rights or other rights in or to the Marks, ABDC's franchise system, or ~~in~~ any Confidential Information or other ABDC information; (ii) any of the restrictive covenants contained in this Agreement; and (iii) any of Customer's payment obligations under this Agreement.

(c) Injunctive Relief. Customer acknowledges and agrees that irreparable harm could be caused to ABDC by Customer's violation of certain provisions of this Agreement and, as such, in addition to any other relief available at law or equity, ABDC shall be entitled to obtain in any court of competent jurisdiction, without bond, restraining orders or temporary or permanent injunctions in order to: (i) enforce, among other items, the provisions of this Agreement relating to: (A) Customer's use of the Marks and Confidential Information (including any proprietary software used in connection with the GNP Premier Program); (B) the in-term covenant not to compete, as well as any other violations of the restrictive covenants set forth in this Agreement; (C) Customer's obligations on termination or expiration of this Agreement; (D) disputes and controversies based on or arising under the Lanham Act, or otherwise involving the Marks, as now or hereafter amended; and/or (E) disputes and controversies involving enforcement of the ABDC's rights or Customer's obligations with respect to confidentiality under this Agreement; and (ii) prohibit any act or omission by Customer or its employees that constitutes a violation of applicable law, threatens ABDC's franchise system, or threatens other customers of ABDC. Customer's only remedy if such an injunction is entered will be the dissolution of the injunction, if appropriate, and Customer hereby waives any and all ~~damage~~ claims for damages if the injunction is wrongfully issued.

(d) Venue. Subject to Sections 14(b), 14(c), 14(f), and 14(h) of this Agreement, the parties agree that any actions arising out of or related to this Agreement must be initiated and litigated to conclusion exclusively in the state court of general jurisdiction closest to ABDC's then-current corporate headquarters or, if appropriate, the United States District Court for the Eastern District of Pennsylvania. Customer acknowledges that this Agreement has been entered into in the Commonwealth of Pennsylvania, and that Customer is to receive valuable and continuing services emanating from ABDC's headquarters in Pennsylvania, including but not limited to training, assistance, support and the development of ~~the Good Neighbor Pharmacy~~ABDC's franchise system. In recognition of such services and their origin, Customer hereby irrevocably consents to the personal jurisdiction of the state and federal courts of Pennsylvania as set forth in this Section.

(e) Third Party Beneficiaries. ABDC's officers, directors, shareholders, agents and/or employees are express third party beneficiaries of the provisions of this Agreement, including the dispute resolution provisions set forth in this Section 14, each having authority to specifically enforce the right to mediate/arbitrate claims asserted against such person(s) by Customer.

(f) Notice Requirement. As a condition precedent to commencing an action for damages or for violation or breach of this Agreement, Customer must notify ABDC within thirty (30) days after the occurrence of the violation or breach, and failure to timely give such notice shall preclude any claim for damages.

(g) No Withholding of Payments. Customer shall not withhold all or any part of any payment to ABDC or any of its affiliates on the grounds of ABDC's alleged nonperformance or as an offset against any amount ABDC or any of ABDC's affiliates allegedly may owe Customer under this Agreement or any related agreements.

(h) Limitation of Actions. Without in any way limiting the foregoing, Customer further agrees that no cause of action arising out of or under this Agreement may be maintained by Customer against ABDC unless Customer brings an action/suit against ABDC before the expiration of one (1) year after the act, transaction or occurrence upon which such action is based or the expiration of one (1) year after Customer becomes aware of facts or circumstances reasonably indicating that Customer may have a claim against ABDC hereunder, whichever occurs sooner. Any action or suit that Customer does not bring within this period shall be barred

as a claim, counterclaim, defense, or set-off. Customer hereby waives the right to obtain any remedy based on alleged fraud, misrepresentation, or deceit by ABDC, including, without limitation, rescission of this Agreement, in any mediation, judicial, or other adjudicatory proceeding arising hereunder, except upon a ground expressly provided in this Agreement.

(i) Waiver of Punitive Damages. ~~CUSTOMER HEREBY WAIVES~~ TO THE FULLEST EXTENT PERMITTED BY LAW, CUSTOMER HEREBY WAIVES ANY RIGHT TO OR CLAIM FOR ANY PUNITIVE, EXEMPLARY, INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT LIMITATION, LOST PROFITS) AGAINST ABDC ARISING OUT OF ANY CAUSE WHATSOEVER (WHETHER SUCH CAUSE BE BASED IN CONTRACT, NEGLIGENCE, STRICT LIABILITY, OTHER TORT OR OTHERWISE), EVEN IF ABDC WAS ADVISED AS TO THE POSSIBILITY OR LIKELIHOOD OF SUCH DAMAGES, AND AGREES THAT IN THE EVENT OF A DISPUTE, CUSTOMER'S RECOVERY SHALL BE LIMITED TO ACTUAL DIRECT DAMAGES. If any other term of this Agreement is found or determined to be unconscionable or unenforceable for any reason, the foregoing provisions shall continue in full force and effect, including, without limitation, the waiver of any right to claim any consequential damages. Nothing in this Section or any other provision of this Agreement shall be construed to prevent ABDC from claiming and obtaining expectation or consequential damages, including lost future royalties for the balance of the term of this Agreement if such termination is due to Customer's default, which the parties agree and acknowledge ABDC may claim under this Agreement.

(j) WAIVER OF JURY TRIAL. THE PARTIES HEREBY AGREE TO WAIVE TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM, WHETHER AT LAW OR EQUITY, REGARDLESS OF WHICH PARTY BRINGS SUIT. THIS WAIVER SHALL APPLY TO ANY MATTER WHATSOEVER BETWEEN THE PARTIES ~~HERETO~~ WHICH ARISES OUT OF OR IS RELATED IN ANY WAY TO THIS AGREEMENT, THE PERFORMANCE OF EITHER PARTY, AND/OR CUSTOMER'S PURCHASE FROM ABDC OF THE FRANCHISE AND/OR ANY GOODS OR SERVICES.

(k) WAIVER OF CLASS ACTIONS. THE PARTIES AGREE THAT ALL PROCEEDINGS ARISING OUT OF OR RELATED TO THIS AGREEMENT, OR THE SALE OF THE FRANCHISED BUSINESS, WILL BE CONDUCTED ON AN INDIVIDUAL, NOT A CLASS-WIDE BASIS, AND THAT ANY PROCEEDING BETWEEN CUSTOMER, CUSTOMER'S GUARANTORS OR PRINCIPALS, AND/OR ABDC OR ITS AFFILIATES, OFFICERS, OR EMPLOYEES MAY NOT BE CONSOLIDATED WITH ANY OTHER PROCEEDING BETWEEN ABDC AND ANY OTHER THIRD PARTY.

15. Miscellaneous

(a) Exhibit A (Data Protection Provisions), Exhibit B (HIPAA Business Associate Agreement), Exhibit C (Provisions to this Agreement), Exhibit D (State-Specific Amendments), Exhibit E (Master Program Agreement) and Term Sheets 1 to 10 (Term Sheets), each as may be amended from time to time, are incorporated herein by this reference.

(b) References to "**Master Program Agreement**" or Customer's "**Premier Agreement**" in this Agreement, Exhibits, and Term Sheets mean this Agreement, including the Exhibits, Term Sheets, and their respective enrollment forms and Data Authorizations, each as amended from time to time as permitted herein. Nothing in this Agreement, related agreements, exhibits, and/or Term Sheets is intended to disclaim the express representations made in the Franchise Disclosure Document.

(c) Customer consents to receiving notices, advertisements, and other marketing materials by fax or email from ABDC and its Corporate Affiliates.

(d) References in Term Sheets to "**Program Guides**" mean the GNP Manual and Standards and to "**GNP License**" mean GNP pharmacies that are not in the GNP Premier Program.

(e) Definition of certain capitalized terms may be found as follows:

ABDC	Opening paragraph
ABDC's Prior Program	Section 11
Agreement	Opening paragraph
Available Programs	Section 4(g)
Copyrighted Material	Section 9(b)
Corporate Affiliate	Recital A
Customer	Opening paragraph
Customer's Designated Manager	Section 4(e)
Effective Date	Opening paragraph
GNP Manual	Section 4(a)
GNP Pharmacy	Section 4(a)
GNP Premier Program	Recital B
GNP Private Label Products	Section 3(a)
GNP Portal	Section 7(c)
Marks	Section 1(a)
Monthly Fee	Section 2(b)
Optional (Available Programs)	Section 4(h)
Pharmacy	Recital B
Principal	Section 7(c)
PSAO (pharmacy services administration organization)	Section 4(i)
PVA	Section 4(f)
Required (Available Programs)	Section 4(h)
Standards	Section 4(a)
Term	Section 7(a)
Term Sheets	Section 4(g)
Trade Dress	Section 3(a)
Trade Secret	Section 9(c)

❖❖❖

DATA PROTECTION PROVISIONS

Overview

ABDC has developed these Data Protection Provisions to protect Pharmacy Data collected from each Pharmacy participating in Available Programs under the Agreement. In these provisions, "**Pharmacy Data**" means the financial, operational, performance, business, pharmacy, and patient data that ABDC receives directly or indirectly from Customer or from Customer's system vendor, switch vendor, Payors (as defined in Term Sheet 1), or other Program Partners. Pharmacy Data may include but is not limited to point-of-sale transaction data, prescription data, or claim reimbursement data. Pharmacy Data includes any information, regardless of the format it is in (for example, paper, electronic, or films).

1.0 Restrictions on Access to Pharmacy Data. ABDC will protect Pharmacy Data by maintaining logical access controls (such as unique user identification and dual factor authentication for remote access) and as set forth in Paragraph 4.0. Access to Pharmacy Data will be provided on a "business need-to-know" basis so users are granted the least amount of access required to successfully fulfill their job requirements. Access that is not explicitly defined is not allowed.

1.2 Limited or Specific Use and Disclosure. Use and disclosure of Pharmacy Data and Business Contact Information (as defined below) will be restricted to only the purposes: (i) set forth in this Agreement and/or applicable Term Sheets in connection with the Available Programs in which Customer participates; (ii) set forth in Customer's distribution agreement with ABDC to measure and help improve purchase performance~~,~~ and as well as compliance with, Customer's contractual requirements with ABDC; and (iii) as may be otherwise agreed upon in writing. ABDC also uses and/or discloses Pharmacy Data and Business Contact Information to: (1) identify, validate, and/or develop programs, solutions or actions that might benefit Customer's business ~~and to~~; (2) evaluate, manage, and improve Available Programs in which Customer participates; and (3) conduct outreach campaigns in connection with the foregoing, including sharing with: (a) ABDC's affiliates; (b) members of ABDC's sales team; (c) and Customer's buying group, aggregation group, or group purchasing organization (if any). In addition, other people Customer specifically authorizes may access Pharmacy Data and Business Contact Information, but only to the extent Customer so authorizes. Customer releases IQVIA and any other third-party data aggregators to share with ABDC, information that IQVIA or applicable third parties receive under data supply agreements with Customer, as well as information received from other data sources. Customer consents to IQVIA's and other third-party aggregator's use of Customer's information, including Business Contact Information, to produce reports and provide them to ABDC and acknowledges that the reports may include pharmacy and product names and purchasing dollars.

1.3 Business Contact Information. Customer and ABDC acknowledge that each party is an independent data controller with respect to Business Contact Information. "**Business Contact Information**" is personal data of each party's employees, independent contractors, and workforce personnel processed by the other party for the purpose of facilitating the Available Programs under this Agreement and maintaining the business relationship with the other party. ABDC further uses and discloses Business Contact Information as described in Section 1.2 of this Exhibit A and in accordance with its privacy policy, available at https://www.cencora.com/global-privacy-statementoverview as may be updated from time to time. Customer and ABDC agree to comply with the California Consumer Privacy Act, as amended ("**CCPA**"), as may be applicable to Business Contact Information. Each party grants the other party the right to take reasonable and appropriate steps to ensure each party's use of Business Contact Information is consistent with the party's obligations under the CCPA, as applicable. With respect to Business Contact Information, each party will notify the other party if it determines that it cannot fulfill its obligations under the CCPA, as applicable, in which case the other party will have the right to take reasonable and appropriate steps to stop and remediate unauthorized use of Business Contact Information.

2.0 No Restrictions on Derivative Works. Except as otherwise agreed-upon by the parties, ABDC may create, use, and/or disclose de-identified, aggregated Pharmacy Data and/or Business Contact Information, or other derivative works created by ABDC using Pharmacy Data and/or Business Contact Information, as long as Customer cannot be specifically identified, such as comparative financial analyses by business type or analyses of manufacturer market share, and any PHI that has been appropriately de-identified. This provision is not meant to circumvent or eliminate opportunities for revenue sharing through data sales or similar programs or offerings.

3.0 Required Disclosure of Pharmacy Data. There may be times when ABDC becomes obligated to disclose Pharmacy Data or other information to other parties not referenced in Paragraph 1.0. For instance, ABDC may be requested or may become legally compelled to answer oral questions, interrogatories, requests for information or documents, subpoenas, civil investigative demands or similar processes and to disclose Pharmacy Data. Nothing in these provisions prevents ABDC from responding to any such disclosure requests or obligations, taking reasonable steps to prevent fraud or other illegal activity, or disclosing information about activities it reasonably believes are illegal.

4.0 Security of Pharmacy Data. ABDC employs industry standard information security and physical security ("IT Security") safeguards, procedures and practices to protect the privacy and security of Pharmacy

Data ABDC receives, accesses, uses, creates, or discloses pursuant to this Agreement. These security safeguards are: (a) at least equal to industry standards; (b) in accordance with the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") and the Health Information Technology for Economic and Clinical Health Act ("HITECH"); and (c) reasonably appropriate to protect against accidental or unlawful destruction, loss, alteration or unauthorized third-party disclosure or access of Pharmacy Data.

5.0 Physical Safeguards. All Pharmacy Data is stored in a physically and logically secure environment that protects it from unauthorized access, modification, theft, misuse or destruction. ABDC maintains appropriate levels of physical security controls over ABDC facilities, including alarm systems, visitor access procedures, security guards, cameras, and video surveillance. ABDC ensures that the facilities have proper environmental controls including power, connectivity, temperature controls, fire suppression, uninterruptible power supply and backup generator to support availability of the Services. ABDC maintains an active and up-to-date anti-malware program to protect the ABDC system, software and Pharmacy Data and Services.

6.0 Data Encryption. ABDC uses encryption to the extent required by HIPAA regulations to receive, transmit, and store all PHI. Although there cannot be a guaranty of the security of Pharmacy Data, ABDC utilizes adequate security for Pharmacy Data transmitted across public networks – at a minimum, TLS 1.2 128 bit is used for web traffic and 256 bit or better for bulk data transfer, with the exception of electronic mail transmission. Transmission of data may include, but is not limited to, file transfer methods, file upload or file download, and file exports.

7.0 License and Retention of Data. Customer hereby grants to ABDC an irrevocable, non-exclusive, royalty-free license to use and/or disclose Pharmacy Data and Business Contact Information as permitted hereunder and as may be necessary for ABDC or the Program Partners to provide Customer with the Available Programs or as otherwise may be required by law. ABDC uniformly retains Pharmacy Data and Business Contact Information for all participating Pharmacies for as long as is reasonably necessary or appropriate for the fulfillment of Available Programs under the Agreement, including InSite from ABDC, or as necessary for legal and/or compliance purposes. ABDC maintains strict change control processes for both hardware and software changes and ensures that all ABDC personnel are familiar with and utilize this process. ABDC securely and completely disposes of Pharmacy Data and Business Contact Information residing on ABDC equipment that will be retired. When Pharmacy Data or Business Contact Information is no longer required to fulfill those purposes, ABDC will use reasonable efforts to have it destroyed, erased or made anonymous.

8.0 Disaster Recovery and Data Backup. ABDC shall maintain and implement disaster recovery procedures in accordance with ABDC's written Disaster Recovery Plan. ABDC's Disaster Recovery Plan shall contain procedures designed to safeguard Pharmacy Data and the availability of the services and solutions included in the Available Programs in which Customer participates hereunder.

8.1 Testing. ABDC periodically performs disaster recovery testing on its electronic systems associated with the services provided in connection with the Available Programs in which Customer participates hereunder.

8.2 Software Lifecycle. ABDC shall use commercially reasonable efforts to identify vulnerabilities, risks and threats as early as possible at any time during the software lifecycle. The software lifecycle shall mean from development, management, and updates through retirement of such application. ABDC shall maintain a strict change control process for ABDC software development lifecycle.

8.3 Data Management. ABDC deploys certain techniques on its electronic systems associated with the services being offered in connection with the Available Programs in which Customer participates hereunder that are intended to safeguard Pharmacy Data, including vulnerability scanning tools, data loss prevention monitoring, penetration testing, implementation of a security information and event management system, and maintenance of a formal risk management program. Confirmed vulnerabilities are prioritized based upon risk level.

8.4 Data Backups. ABDC performs daily backups of Pharmacy Data. ABDC agrees to store all backup Pharmacy Data as part of its designated backup and recovery processes using a commercially supported encryption solution. Data backups are retained for twelve (12) days should the need to restore from data backups arise. ABDC shall be responsible for periodically testing that backup processes are working to ensure that data can be recovered in a reasonable timeframe in the instance of an outage or disaster on the primary infrastructure.

9.0 Incident Response. ABDC shall maintain a program plan to detect and respond to data security incidents. The program shall include identification, containment, mitigation and remediation of an incident (security breach or attack) and communication to Customer of any data security incident resulting in a Breach (as defined by HIPAA) of Pharmacy Data. ABDC shall meet Federal and applicable regulatory requirements for breach notification. ABDC shall cooperate and coordinate with Customer and authorities should a confirmed security breach of Pharmacy Data occur. Without limiting the generality of the foregoing, ABDC will take all reasonable measures to secure and defend ABDC locations and equipment both physically and logically against "hackers" and others who may seek, without authorization, to

modify or access the ABDC systems or the information found therein.

10.0 Employee Screening and Security Awareness. Prior to employment, each ABDC employee undergoes a formal security clearance review that includes a criminal background check. Any past activity that would subject confidential information and critical systems to risk is cause to restrict an ABDC employee's access to Pharmacy Data. To ensure security awareness by its employees, ABDC: (a) maintains policies or codes of conduct documenting responsibilities regarding data security practices; (b) requires its employees to acknowledge and review these documents at least biennially; (c) provides security awareness and HIPAA training to its workforce as part of ABDC's overall awareness program; (d) requires confidentiality agreements to be completed as part of hiring process to ensure that ABDC's workforce understands their responsibilities regarding the protection of Pharmacy Data.

ABDC believes that its security policies and safeguards are reasonable and appropriate to adequately protect such information, regardless of the format in which such information is held. ABDC intends to review and update its security policies and safeguards on a regular basis. ABDC requires that its employees keep all Pharmacy Data and Business Contact Information confidential.

❖❖❖

HIPAA BUSINESS ASSOCIATE AGREEMENT

This HIPAA Business Associate Agreement ("**BA Agreement**") is effective as of the Effective Date of the agreement (GNP Premier Participation Agreement or Master Program Agreement, including all Exhibits, Amendments, Attachments, Term Sheets, Schedules, and Addenda thereto, as applicable) for Available Programs ("**Agreement**") between AmerisourceBergen Drug Corporation ("**Business Associate**") and Customer, as defined in the Agreement ("**Covered Entity**" and, collectively with Business Associate, the "**Parties**"). This BA Agreement amends the Agreement only to the extent the Parties use, disclose or create Protected Health Information as a Business Associate or Covered Entity, respectively.

WHEREAS, Business Associate provides Services to Covered Entity that may involve the use, disclosure and/or creation of Protected Health Information.

WHEREAS, Covered Entity and Business Associate desire to enter into this BA Agreement to address certain requirements that are now or will become applicable to Covered Entity (and, in certain instances, Business Associate) pursuant to the Health Insurance Portability and Accountability Act of 1996 ("**HIPAA**") (Pub. L. 104-191), as amended by, among other authorities, the Health Information Technology for Economic and Clinical Health Act ("**HITECH Act**") (42 U.S.C. §17921 et seq.) and implementing regulations, including, as defined below, the Privacy Rule, Security Rule and Breach Notification Rule.

NOW THEREFORE, in consideration of the mutual covenants and agreements contained in this BA Agreement and for other good and valuable consideration, the receipt and sufficiency of which are acknowledged by the Parties, the Parties hereby agree as follows:

1. DEFINITIONS.

Any citations in the definitions below shall reference the provision as currently drafted and as it is subsequently updated, amended or revised, as applicable. Capitalized terms or phrases used, but not otherwise defined, in this BA Agreement shall have the same meaning as those terms or phrases in the Privacy Rule, Security Rule or Breach Notification Rule, as applicable.

1.1 **Breach** is defined in 45 C.F.R. §164.402.

1.2 **Breach Notification Rule** means the final rule related to Breach notification for Unsecured Protected Health Information at 45 C.F.R. Parts 160 and 164.

1.3 **Business Associate** means AmerisourceBergen Drug Corporation in its capacity as a business associate as defined in 45 C.F.R. §160.103.

1.4 **Covered Entity** means Customer in its capacity as a covered entity as defined in 45 C.F.R. §160.103.

1.5 **Designated Record Set** is defined in 45 C.F.R. §164.501.

1.6 **Electronic Protected Health InfoRMATion** and **ePHI** are defined in 45 C.F.R. §160.103, limited to the information created or received by Business Associate from or on behalf of Covered Entity.

1.7 **Individual** is defined in 45 C.F.R. §160.103 and shall include a person who qualifies as a personal representative in accordance with 45 C.F.R. §164.502(g).

1.8 **Health Care Operations** is defined in 45 C.F.R. §164.501.

1.9 **Privacy Officer** is defined in 45 C.F.R. §164.530(a)(1).

1.10 **Privacy Rule** means the Standards for Privacy of Individually Identifiable Health Information, codified at 45 C.F.R. Parts 160 and 164, Subparts A and E.

1.11 **Protected Health Information** and **PHI** have the meaning they are given in 45 C.F.R. §160.103, limited to the information created or received by Business Associate from or on behalf of Covered Entity.

~~1.12 **Required by Law** is defined in 45 C.F.R. §164.103.~~

~~1.13~~ 1.12 **Reproductive Health Care** includes, but is not limited to, an individual's receipt of contraception, management of pregnancy and pregnancy-related conditions, miscarriage management, pregnancy termination, fertility or infertility diagnosis and treatment, assistive reproductive technology, and other diagnoses, treatment and care that affect the reproductive system, where the care or services are lawfully obtained.

1.13 **Required by Law** is defined in 45 C.F.R. §164.103.

1.14 **Security Rule** means the Security Standards for Protection of Electronic Protected Health Information, codified at 45 C.F.R. §164 Subparts A and C.

1.~~14~~15 **Secretary** means the Secretary of the Department of Health and Human Services or his or her designee.

1.~~15~~16 **Security Incident** is defined in 45 C.F.R. §164.304.

~~1.16~~ 1.17 **Substance Abuse Disorder (SUD)** means a treatable mental disorder that affects a person's brain and behavior, leading to their inability to control their use of substances like legal or illegal drugs, alcohol, or medications. Symptoms can be moderate to severe, with addiction being the most severe form of SUD.

1.18 **Tracking Technology** is defined as any tracking technology utilized by Business Associate including, but not limited to cookies, pixels, codes, fingerprinting scripts, web beacons, etc., whether collected via user authenticated web pages, unauthenticated pages, or mobile applications, as set forth in the December 1, 2022, Office for Civil Rights Bulletin on Requirements under HIPAA for Online Tracking Technologies to Protect the Privacy and Security of Health Information.

1.19 **Unsecured PHI** is defined in the Breach Notification Rule at 45 C.F.R. §164.402.

2. PERMITTED USES AND DISCLOSURES OF PROTECTED HEALTH INFORMATION BY BUSINESS ASSOCIATE.

2.1 **Services.** Pursuant to the Agreement, Business Associate provides services ("**Services**") for, or on behalf of, Covered Entity that involve the use, disclosure and/or creation of PHI. Except as otherwise specified herein, Business Associate may make any and all uses and disclosures of PHI necessary to perform its obligations under the Agreement. All other uses and disclosures not authorized by this BA Agreement are prohibited. Moreover, Business Associate may use and disclose PHI for the purposes authorized by this BA Agreement only: (i) to its employees, subcontractors and agents, in

accordance with Paragraph 3.5; (ii) as directed by Covered Entity; or (iii) as otherwise permitted by the terms of this BA Agreement including, but not limited to, Paragraphs 2.2 and 2.3.

2.2 **Uses and Disclosures by Business Associate.** Unless otherwise limited herein, Business Associate may:

2.2.1 Use, consistent with 45 C.F.R. §164.504(e)(4), the PHI in its possession if necessary (i) for its proper management and administration and/or (ii) to carry out any present or future legal responsibilities of Business Associate provided that such uses are permitted under state and federal confidentiality laws.

2.2.2 Disclose, consistent with 45 C.F.R. §164.504(e)(4), the PHI in its possession to third parties for the purpose of its proper management and administration and/or to carry out any present or future legal responsibilities of Business Associate, provided that Business Associate represents to Covered Entity, in writing, that (i) the disclosures are Required by Law, as provided for in 45 C.F.R. §164.103; or (ii) Business Associate has received from the third party written assurances regarding its confidential handling of such PHI as required under 45 C.F.R. §164.504(e)(4) and the third party notifies Business Associate of any breaches in the confidentiality of the PHI.

2.3 **Additional Activities of Business Associate.** In addition to using and disclosing the PHI to perform the Services and the purposes enumerated in Paragraph 2.2, Business Associate may:

2.3.1 If the Agreement is for data aggregation services, consistent with 45 C.F.R. §164.504(e)(2)(i)(B), aggregate the PHI in its possession with the PHI of other covered entities that Business Associate has in its possession through its capacity as a business associate to said other covered entities provided that the purpose of such aggregation is to provide Covered Entity with data analyses relating to the Health Care Operations of Covered Entity. Under no circumstances may Business Associate disclose PHI of Covered Entity to another entity, including a covered entity, absent the explicit authorization of Covered Entity.

2.3.2 De-identify any and all PHI provided that the de-identification substantially conforms to the requirements of 45 C.F.R. §164.514(b). Pursuant to 45 C.F.R. §164.502(d)(2), de-identified information does not constitute PHI and is not subject to the terms of this BA Agreement.

2.3.3 Use and/or disclose PHI to report violations of law to appropriate federal and State authorities, consistent with 45 C.F.R. §164.502(j)(1).

3. PRIVACY RULE AND HITECH ACT RESPONSIBILITIES OF THE BUSINESS ASSOCIATE. With regard to its use and/or disclosure of PHI, Business Associate hereby agrees to do the following:

3.1 Use and/or disclose the PHI only as permitted or required by this BA Agreement, including as permitted in Paragraph 2.2 and 2.3, or as otherwise permitted or Required by Law.

3.2 Report to Covered Entity's designated Privacy Officer, in writing, any use and/or disclosure of the PHI that is not permitted or required by this BA Agreement of which Business Associate becomes aware within fifteen (15) days of Business Associate becoming aware of such unauthorized use and/or disclosure.

3.3 Establish procedures for mitigating, to the extent practicable, any deleterious effects from any improper use and/or disclosure of PHI that Business Associate reports to Covered Entity.

3.4 To the extent that Business Associate is to carry out one or more of Covered Entity's obligations under Subpart E of 45 C.F.R. Part 164, comply with the requirements of Subpart E that apply to Covered Entity in the performance of such obligations, including the use of appropriate safeguards to prevent unauthorized use and/or disclosure of PHI.

3.5 Require all of its subcontractors and agents that create, receive, maintain, or transmit PHI on behalf of Business Associate to agree, in writing, to adhere to substantially similar restrictions and conditions (in all material respects) on the use and/or disclosure of PHI and other restrictions and requirements that relate to PHI that apply to Business Associate pursuant to Paragraphs 2.0 through 5.0.

3.6 Make available all records, books, agreements, policies and procedures relating to the use and/or disclosure of PHI to the Secretary for purposes of determining Covered Entity's compliance with the Privacy Rule, subject to attorney-client and other applicable legal privileges.

3.7 Within fifteen (15) days of receiving a written request from Covered Entity, provide to Covered Entity such information as is requested by Covered Entity to permit Covered Entity to respond to a request by an Individual to inspect and obtain a copy of PHI about the Individual that is maintained in a Designated Record Set by Business Associate, for as long as the PHI is maintained in the Designated Record Set by Business Associate, in accordance with 45 C.F.R. §164.524; to amend PHI or a record about the Individual maintained in a Designated Record Set by Business Associate, for as long as PHI is maintained in the Designated Record Set by Business Associate, in accordance with 45 C.F.R. §164.526; and for an accounting of the disclosures of the Individual's PHI in accordance with 45 C.F.R. §164.528. The Parties agree and acknowledge that it is Covered Entity's responsibility to respond to all such requests.

3.8 Disclose to its subcontractors, agents or other third parties, and request from Covered Entity, only the minimum PHI necessary to perform or fulfill a specific function required or permitted hereunder, unless the disclosure is not subject to the minimum necessary standard in 45 C.F.R. §164.502(b).

3.9 Comply with Confidentiality of Substance Use Disorder (SUD) Patient Records under 42 CFR Part 2 in alignment with HIPAA regulations as stated in the Federal Register, Vol. 89, No. 33, February 16, 2024.

3.10 Comply with the HIPAA Privacy Rule to Support Reproductive to provide protection for individuals who receive reproductive health care when the care is provided lawfully, without risk of an individual's identity or health information being disclosed for purposes of state criminal, civil or administrative investigations.

3.10.1 Business Associate is prohibited from the disclosure of PHI to conduct or assist with a criminal, civil, or administrative investigation into or impose criminal, civil, or administrative liability on any person for the mere act of seeking, obtaining, providing, or facilitating reproductive health care,

where such health care is lawful under the circumstances in which it is provided.

3.11 Update its applicable Notice of Privacy Practices (if any) to support reproductive health care privacy and Confidentiality of Substance Use Disorder (SUD) Patient Records.

4. SECURITY RULE AND HITECH ACT RESPONSIBILITIES OF THE BUSINESS ASSOCIATE. With regard to its use and/or disclosure of ePHI, Business Associate hereby agrees to do the following:

4.1 Comply with 45 C.F.R. §§164.308, 164.310, 164.312 and 164.316, with respect to ePHI, to prevent use or disclosure of ePHI other than as provided for by this BA Agreement.

4.2 Require all of its subcontractors and agents that create, receive, maintain, or transmit ePHI on behalf of the BA to agree, in writing, to adhere to substantially similar restrictions and conditions (in all material respects) concerning ePHI that apply to Business Associate pursuant to this Paragraph 4.0.

4.3 Report to Covered Entity any Security Incident of which it becomes aware that involves the Confidentiality, Integrity or Availability of the ePHI that it creates, receives, maintains or transmits for or on behalf of Covered Entity. This Paragraph satisfies any reporting required by Business Associate of attempted but Unsuccessful Security Incidents (as defined below) for which the parties agree no additional report shall be required. "**Unsuccessful Security Incidents**" include activity such as "pings" and other broadcast attacks on Business Associate's firewall, port scans, unsuccessful log-on attempts, denials of service and any other attempts to penetrate such computer networks or systems that do not result in unauthorized access, use or disclosure of ePHI. Separate from the requirements related to Security Incident reporting, Business Associate shall also make the reports to Covered Entity as set forth in Paragraph 5.0, related to a Breach of Unsecured PHI.

~~4.4~~ 4.4 In the event Business Associate utilizes Tracking Technology with respect to its Services, Business Associate is prohibited from using or disclosing any such data resulting from the Tracking Technology for purposes other than as delineated in this Agreement. For the avoidance of doubt, this BA Agreement prohibits Business Associate's Use of PHI or other data obtained from utilizing such Tracking Technology for its own use and/or benefit.

4.5 Authorize termination of this BA Agreement by Covered Entity if Covered Entity determines that Business Associate has violated a material term of this BA Agreement, in accordance with Paragraph 6.2.

5. BREACH NOTIFICATION RULE OBLIGATIONS.

5.1 Business Associate will notify Covered Entity within fifteen (15) business days of the discovery of a Breach of Unsecured PHI.

5.2 Any notice pursuant to Paragraph 5.1 will include, to the extent possible, the identification of each Individual whose Unsecured PHI has been, or is reasonably believed by Business Associate, to have been accessed, acquired or disclosed during such Breach. Business Associate will also provide Covered Entity other available information that Covered Entity is required to include in its notification to the Individual.

6. TERM AND TERMINATION.

6.1 **Term.** This BA Agreement is effective on the Effective Date of the Agreement and shall continue in effect until all obligations of the Parties have been met, unless terminated as provided in this Paragraph 6.0. In addition, certain provisions and requirements of this BA Agreement shall survive its expiration or other termination in accordance with Paragraph 7.1.

6.2 **Termination by Covered Entity.** As provided for under 45 C.F.R. §164.504(e)(2)(iii), Covered Entity may immediately terminate this BA Agreement, any other provision of the Agreement notwithstanding, if Covered Entity determines that Business Associate has breached a material term of this BA Agreement; provided that Covered Entity (i) provides Business Associate with written notice of the existence of an alleged breach; and (ii) affords Business Associate an opportunity to cure said alleged breach. Failure to cure in the manner set forth in this Paragraph 6.2 is grounds for the immediate termination of this BA Agreement and the Agreement by Covered Entity, any other provision of the Agreement notwithstanding, but termination of the Agreement may be allowed only to the extent that the use, disclosure and/or creation of PHI is required in order for Business Associate to carry out its responsibilities under the Agreement.

6.3 **Termination by Business Associate.** Business Associate shall have the same rights and options related to termination as set forth in Paragraph 6.2 with respect to Covered Entity.

6.4 **Effect of Termination.** Upon the event of termination pursuant to this Paragraph 6.0, Business Associate agrees to return or destroy all PHI pursuant to 45 C.F.R. §164.504(e)(2)(ii)(J), if it is feasible to do so. Prior to doing so, Business Associate further agrees to recover any PHI in the possession of its subcontractors or agents. If it is not feasible for Business Associate to return or destroy said PHI, Business Associate agrees to extend any and all protections, limitations and restrictions contained in this BA Agreement to Business Associate's use and/or disclosure of any PHI retained after the termination of this BA Agreement, and to limit any further uses and/or disclosures to the purposes that make the return or destruction of the PHI infeasible. If it is infeasible for Business Associate to obtain, from a subcontractor or agent any PHI in the possession of the subcontractor or agent, Business Associate shall require the subcontractors and agents to agree to extend any and all protections, limitations and restrictions contained in this BA Agreement to the subcontractors' and/or agents' use and/or disclosure of any PHI retained after the termination of this BA Agreement, and to limit any further uses and/or disclosures to the purposes that make the return or destruction of the PHI infeasible.

7. MISCELLANEOUS.

~~7.1~~ 7.1 **Part 2 Compliance**. If, and only to the extent applicable to Business Associate, Business Associate acknowledges that if its Services under the Agreement require it to access, use, disclose, maintain, or transmit information that is protected by Confidentiality of Substance Use Disorder Patient Records law and its implementing regulations set forth at 42 U.S.C. §290dd-2 and 42 C.F.R. Part 2 ("Part 2"), Business Associate is a Qualified Service Organization and is fully bound by the Part 2 regulations. If necessary, Business Associate will resist in judicial proceedings any efforts to obtain access to patient records protected by Part 2 except as expressly permitted by 42 C.F.R. §§2.1-2.68.

Business Associate further acknowledges that any records it receives from Covered Entity that are protected by Part 2 are subject to protections that may prohibit Business Associate from disclosing such information to subcontractors or agents without the specific written consent of the individual and that any unauthorized disclosure of information is a federal criminal offense.

7.2 **Survival.** The respective rights and obligations of Business Associate and Covered Entity under the provisions of Paragraphs 2, 3, 4, 5, 6.4 and 7.1, solely with respect to PHI Business Associate retains in accordance with Paragraph 6.4 because it is not feasible to return or destroy such PHI, shall survive termination of this BA Agreement indefinitely.

7.~~2~~3 **No Third Party Beneficiaries.** Nothing express or implied in this BA Agreement is intended to confer, nor shall anything herein confer, upon any person other than the Parties and the respective successors or assigns of the Parties, any rights, remedies, obligations, or liabilities whatsoever.

7.~~3~~4 **Notices.** Any notices to be given hereunder to a Party shall be made via U.S. Mail or express courier to such Party's address given below.

If to Business Associate, to:
Cencora, Inc., Attn: Privacy Officer
1 W. First Ave.
Conshohocken, PA, 19428

If to Covered Entity, to:
To address on Signature Page of agreement for Available Programs (GNP Premier or Master Program Agreement)
Attn: Privacy Officer

Each Party named above may change its address and that of its representative for notice by the giving of notice thereof in the manner hereinabove provided.

7.~~4~~5 **Counterparts; Facsimiles.** This BA Agreement may be executed in any number of counterparts, delivered by facsimile transmission or by electronic delivery in portable document format or other similar format, each of which shall be deemed an original.

7.~~5~~6 **Limitation of Liability.** Neither Party will be liable to the other Party for any incidental, indirect, exemplary, consequential, special or punitive damages with respect to the matters addressed in this BA Agreement.

7.~~6~~7 **Severability.** Should any provision of this BA Agreement be held illegal, invalid or unenforceable by any governmental body or court of competent jurisdiction, such holding shall not diminish the validity or enforceability of any other provision of this BA Agreement.

7.~~7~~8 **Governing Law.** This BA Agreement shall be governed by and construed in accordance with the internal laws of the Commonwealth of Pennsylvania without regard to its conflict of laws provisions.

7.9 **Notice of Privacy Practice Limitations.** Covered Entity shall promptly notify Business Associate, in writing, of any limitations in its notice of privacy practices under 45 C.F.R. §164.520, to the extent that such limitations may affect Business Associate's Use or Disclosure of PHI.

❖❖❖

PROVISIONS

Capitalized terms used but not otherwise defined in this Exhibit C will have the meaning ascribed to such terms in the GNP Premier Agreement.

The following Provisions apply to the GNP Premier Agreement and each of the Available Programs.

1. DUTIES OF ABDC. ABDC will use commercially reasonable efforts to provide requested Available Programs, which may be subject to restrictions or requirements. Available Programs in Hawaii, Alaska, U.S. territories and foreign countries may be unavailable or subject to higher prices.

2. DUTIES OF CUSTOMER

2.1 Disclosure. Customer will maintain all certificates licenses, permits, registrations and other required approvals and report and reflect discounts, rebates and other price reductions pursuant to 42 USC Sec. 1320a-7b(b)(3)(A) on cost reports or claims submitted to federal or state healthcare programs, retain invoices and related pricing documentation and make them available on request. ABDC may suspend Available Programs, payments and services immediately upon the loss, restriction or suspension of any certificate, license, permit, registration or other approval that Customer is required to maintain under this Agreement or any agreement with a Payor. ABDC may suspend Available Programs, payments and services immediately upon the exclusion of Customer or any of its pharmacists, pharmacy technicians or other employees from Medicare, Medicaid or any other federal or state healthcare program.

2.2 Distribution Agreement. Available Programs are intended for Customer's locations operating in good standing under a distribution agreement that designates ABDC as its prime vendor for sourcing prescription products.

2.2 Payments. Available Program payments must be received by ABDC on the date due. If payment is delinquent, ABDC may suspend Available Programs and services or withhold payments to Customer and assess a per-day late payment fee of the lower of 0.05% (18%/360) or the maximum legal rate on the outstanding balance until paid, beginning on the first business day after such due date.

3. NO WARRANTIES; LIMITATION OF LIABILITY. ABDC DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING THOSE OF MERCHANTABILITY, TITLE, NON-INFRINGEMENT AND FITNESS FOR A PARTICULAR PURPOSE, FOR PROGRAMS, PRODUCTS AND SERVICES. NO ORAL OR WRITTEN INFORMATION PROVIDED BY ABDC, ITS EMPLOYEES OR OTHER REPRESENTATIVES WILL CREATE ANY SUCH WARRANTY. IN NO EVENT WILL ABDC, ITS AFFILIATES (OR THEIR RESPECTIVE OWNERS, DIRECTORS, OFFICERS, EMPLOYEES, SUBCONTRACTORS OR REPRESENTATIVES) BE LIABLE FOR ANY SPECIAL, INCIDENTAL, INDIRECT, CONSEQUENTIAL, EXEMPLARY OR PUNITIVE DAMAGES, OR LOST PROFITS IN CONNECTION WITH OR RELATED TO THIS AGREEMENT, AVAILABLE PROGRAMS, OR ANY PRODUCTS OR SERVICES PROVIDED BY ABDC HEREUNDER, EVEN IF ABDC OR ANOTHER PERSON IS NOTIFIED OF THE LIKELIHOOD THAT DAMAGES MAY OCCUR. **Unless otherwise specified in a Term Sheet, liability of ABDC and its affiliates with respect to any and all direct and/or third party Claims related to this Master Program Agreement (including any and all Exhibits and Addendums) or any Available Program, whether in contract, in tort, under a warranty or otherwise, will not exceed the total fees paid by Customer during the twelve (12) month period immediately preceding the Claim accrual date for the Available Programs to which such Claim is related, less any credits or refunds by ABDC to Customer.** Unless ABDC's decisions and actions are inconsistent with Customer's express rights and obligations, ABDC may exercise its business judgment in assessing the best interest of Available Programs, including terms, commitments, and requirements for all of its customers generally and in the aggregate, without specifically considering Customer's individual interest. ABDC decisions and actions will be reasonable if any business justification is based on the best interests of Available Programs or customers generally. This disclaimer of warranties and limitation of liability shall survive the expiration of this Agreement.

4. CONFIDENTIALITY. Customer, its employees and representatives will protect and keep strictly confidential all proprietary and confidential information ("**Confidential Information**") disclosed by ABDC and not use or disclose it except in connection with Available Programs or as agreed. Subject to such exception, Confidential Information specifically includes this Agreement, Term Sheets, Program Guides, ABDC's methods of doing business, pricing, payment and other related financial terms, and other information related to any Available Program. Confidential Information does not include information that: (i) at the time of disclosure by ABDC, is generally available to the public; (ii) after disclosure by ABDC, becomes generally available to the public other than as a result of a breach of this Agreement by Customer; (iii) Customer can establish via written records: (1) was already in Customer's possession at the time the information was disclosed by ABDC; and (2) with respect to such information and the source thereof, was not otherwise subject to confidentiality obligations; (iv) Customer receives from a third party without obligation of confidentiality with respect to such information or otherwise applicable to such third party; or (v) Customer can establish via written records was developed independently by Customer without direct or indirect use or reference of any Confidential Information. In the event Customer becomes obligated to disclose this Agreement and/or any Confidential Information, including, without limitation, disclosures required by applicable law, upon becoming aware of any such disclosure obligation: (a) Customer will immediately notify ABDC in writing and reasonably cooperate with ABDC in connection therewith; (b) Customer will comply with Payor and other third party advance notice requirements prior to disclosure of Confidential Information; and (c) Customer will request the highest level of confidential treatment available under applicable law if it discloses this Agreement or Confidential Information.

5. TERMINATION OF MASTER PROGRAM AGREEMENT

5.1 Default. In addition to other available remedies for Available Programs, either party may immediately terminate this Master Program Agreement for cause upon written notice to the other party upon the other party's (a)(i) filing an application for or consenting to appointment of a trustee, receiver or custodian of its assets; (ii) having an order for relief entered in Bankruptcy Code proceedings; (iii) making a general assignment for the benefit of

creditors; (iv) having a trustee, receiver or custodian of its assets appointed unless proceedings and the person appointed are dismissed within 30 days; (v) insolvency within the meaning of Uniform Commercial Code Section 1-201 or failing generally to pay its debts as they become due within the meaning of Bankruptcy Section 303(h)(1) (11 U.S.C. §303(h)(1)), as amended; or (vi) certification in writing of its inability to pay its debts as they become due (and either party may periodically require the other to certify its ability to pay its debts as they become due) (collectively, "**Bankruptcy**"); (b) failure to pay any amount due and such failure continues five days after written notice; or (c) failure to perform any other material obligation of this Master Program Agreement or any other agreement between the parties or their affiliates and such failure continues for 30 days after it receives notice of such breach from the non-breaching party.

5.2 Survival Upon Termination. Within five days of expiration or earlier termination of this Master Program Agreement for any reason, amounts owed by either party to the other will be immediately due and paid to the other party. Customer will return all Available Program materials, including Term Sheets, Program Guides and Licensed Material, or pay to ABDC their replacement cost. Obligations in Paragraphs 4.0, 5.2, 6.0 and 8.0 and any provision the context of which shows the parties intended it to survive will remain in effect after the Term.

6. INDEMNIFICATION. Each party ("**Indemnifying Party**") will indemnify, defend, and hold harmless the other, its affiliates, its employees and representatives ("**Indemnified Party**") against all claims and damages (including expenses and attorneys' fees) ("**Claim**") to the extent arising out of Indemnifying Party's obligations hereunder, but only to the extent permitted by law (with any such limits applying equally to the parties). Failure to give prompt written notice of a Claim will not relieve Indemnifying Party of liability except to the extent caused by such failure. Indemnifying Party will defend Claims with counsel reasonably satisfactory to Indemnified Party and Indemnified Party will cooperate fully in such defense. Without limiting the foregoing, Customer's obligations include any Claim arising from its infringement or other violation of a patent, trademark, copyright or other proprietary right owned or controlled by ABDC or any third party except to the extent arising from use that complies with this Agreement.

7. COMPUTER APPLICATIONS, SOFTWARE & DATA

7.1 License. ABDC grants Customer a non-exclusive, limited, nontransferable, non-sublicenseable, and revocable license to use computer applications, including websites, software and data related to Available Programs and related documentation ("Licensed Material"). Customer may not make, or allow others to make, copies of the Licensed Material except one backup copy. Customer must include all proprietary notices in permitted copies~~.~~ of Licensed Material. Customer may not modify Licensed Material ~~or~~, create derivative works ~~and may not~~, or otherwise translate, reverse engineer, disassemble or decompile ~~software or other~~the Licensed Material.

7.2 Limited Warranty. ABDC warrants that ~~software and other~~the Licensed Material will perform substantially in accordance with its documentation if the Licensed Material is operated as directed, no modification of the Licensed Material is made by any person other than ABDC and only the most current release of the Licensed Material is used. ABDC DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING THOSE OF MERCHANTABILITY, TITLE, NON-INFRINGEMENT AND FITNESS FOR A PARTICULAR PURPOSE, FOR LICENSED MATERIAL, AND ACCURACY OF ANY DATA. ALL DATA IS PROVIDED "AS IS." DUE TO THE NATURE OF SOFTWARE AND DATA, ERRORS AND INTERRUPTIONS MAY OCCUR AND CUSTOMER HAS ALL RISKS FOR QUALITY AND PERFORMANCE. No oral or written information provided by ABDC, its employees or other representatives will create any warranty.

7.3 Remedy. If ABDC breaches a warranty in Paragraph 7.2, as Customer's sole remedy (other than the indemnity for third party Claims under Paragraph 6.0), ABDC will, at its option and expense (i) repair or replace Licensed Material so it performs substantially in accordance with its documentation; or (ii) advise Customer how to achieve substantially the same functionality using different procedures.

8. MISCELLANEOUS

8.1 Force Majeure. ABDC may reduce, delay, suspend or eliminate any Available Program, in whole or in part, without liability or obligation if ABDC's performance is prevented, delayed or otherwise affected by any cause beyond its control, including labor disputes, fire, terrorism, acts of God, unavailability of an Available Program, or material component thereof, loss of access to data, delays by suppliers, loss of facilities or internet, telecommunication or electrical systems, pandemic, voluntary foregoing a right in order to comply with or accommodate government orders or requests, or compliance with any law or otherwise.

8.2 Notices. Except as provided otherwise herein, notices must be in writing and personally delivered or sent by certified mail, prepaid, return receipt requested; by overnight delivery; or, by facsimile or email as provided in this Section 8.2. Notices will be deemed delivered (i) upon delivery when personally delivered or sent by certified mail or overnight delivery; (ii) upon delivery if sent by facsimile or email during normal business hours of the receiving party (or, otherwise, on the following business day) with a confirming copy sent by U.S. mail or overnight delivery; or (iii) upon delivery if sent by facsimile or email (with no confirming copy required) for notices by ABDC of updates to this Agreement, Term Sheets or ~~policies, including the Data Protection Provisions (Exhibit A).~~other Available Program documentation.

To Customer: Customer's address on the Agreement signature page.

To ABDC : AmerisourceBergen Drug Corporation
1 W. First Ave.
Conshohocken, PA 19428
Attn: Sr. Director - Strategic Program Operations

With copy to: Cencora, Inc.
1 W. First Ave.
Conshohocken, PA 19428
Attn: Legal Department

8.3 Assignment. Neither party may assign this Master Program Agreement without the other party's prior written consent, and attempted assignment in contravention of this Agreement shall be void and of no effect. Valid assignment of this Agreement will inure to the benefit of and be binding upon each party and its heirs, successors and assigns. Notwithstanding the foregoing, ABDC may, without notice, assign part or all of its obligations hereunder to any affiliate or may do so (or grant a security interest herein) in connection with any financing or

securitization by ABDC or any corporate affiliate. Customer will notify ABDC of changes in ownership, name, business form (e.g., sole proprietorship, partnership or corporation), state of incorporation or formation, or any intent to sell, close, move or modify its operations prior to such change, sale, closure or modification, and provide other information ABDC reasonably requests.

8.4 EEO Requirements. ABDC and Customer each warrant it does not and will not discriminate against any employee or applicant for employment because of race, creed, color, national origin, religion, gender, sexual preference, veteran status, handicap or as otherwise prohibited by law and will meet affirmative action obligations imposed by law.

8.5 Independent Parties. This Master Program Agreement will not create a partnership, joint venture, agency, employment, fiduciary or other special relationship between ABDC and Customer or its employees or representatives. No representation to the contrary will be binding.

8.6 Attorneys' Fees; Choice of Law. The successful party in any legal action may recover all costs it incurs, including reasonable attorneys' fees. Pennsylvania law governs this Agreement without reference to its conflict of laws provisions.

8.7 Dispute Resolution. Customer must first bring any claim or dispute under this Agreement to ABDC's management and make every effort to resolve the dispute internally before bringing a dispute before a third party. If the parties are unable to resolve any claim or dispute internally within 90 days, Customer agrees that any controversy or claim arising out of or relating to this Agreement, or the breach thereof, shall be determined by final and binding arbitration administered by the American Arbitration Association under its Commercial Arbitration Rules and Mediation Procedures. Any arbitration award or decision may be filed in a court of competent jurisdiction for enforcement.

8.8 Third Party Beneficiaries. Other than ABDC's officers, directors, and/or employees, there are no other third party beneficiaries.

8.9 WAIVER OF CLASS ACTIONS. Customer waives the right to litigate in court or arbitrate any claim or dispute as a class action, either as a member of a class, or as a representative.

8.10 Compliance with Law; Healthcare Exclusions. Each party will comply with all laws, and maintain its eligibility to participate in Medicare, Medicaid and other federal and state healthcare programs. Customer will promptly disclose if it (or any of its pharmacists or pharmacy technicians or other employees) becomes an excluded entity or individual on an HHS-OIG or comparable list for Medicare, Medicaid or other federal or state healthcare programs.

8.11 Setoff. Without limiting ABDC's other legal rights, ABDC and its affiliates may withhold, delay, or setoff any amounts owed to Customer pursuant to this Agreement or an Available Program, or take any other lawful actions, to: (i) recover any amount (including, but not limited to, principal, interest, costs, and reasonable attorneys' fees) owed by Customer to ABDC or its affiliates under this ~~or~~Agreement, any ~~other agreements between ABDC or its affiliates and Customer~~Available Program, or any other agreement, including but not limited ~~to Customer's~~a distribution agreement~~ or,~~ credit agreement~~ with ABDC or its affiliates,~~ and/or any other master program agreement between Customer and ~~ABDC's~~ABDC or its affiliates~~. Any forbearance or delay in~~; and/or (ii) satisfy, or remit payment towards the ~~exercise~~satisfaction of~~ any right or remedy hereunder or as~~, any amount (including, but not limited to, principal, interest, costs, and reasonable attorneys' fees) owed by Customer to a third party creditor (e.g., Internal Revenue Service, etc.) pursuant to which ABDC becomes legally obligated to remit such amounts otherwise ~~afforded by law will not be a waiver of or preclude the exercise of any such right or remedy.~~owed to Customer.

8.12 Ownership. Customer must disclose to ABDC, in writing, the identity of any and all Payors that, directly or indirectly, own an interest in Customer's business and/or otherwise exercise control over Customer's management.

8.13 Miscellaneous. Any forbearance or delay in the exercise of any right or remedy hereunder or as otherwise afforded by law will not be a waiver of or preclude the exercise of any such right or remedy. All provisions are severable. This Agreement supersedes prior oral or written agreements by the parties that relate to its subject matter. This Agreement only benefits the parties hereto and will not, except as expressly provided herein, create or convey a benefit to anyone who is not a party hereto. Captions are intended for convenience of reference only. "**Including**" means "including but not limited to." Except as provided otherwise herein, the parties may not modify this Agreement other than by a subsequent writing signed by each party. This Master Program Agreement will be interpreted as if written jointly by the parties. In the event of a conflict between the terms of this Master Program Agreement and any Term Sheet, the terms of this Master Program Agreement will control except to the extent expressly and specifically amended by or provided otherwise in such Term Sheet. Any such modification will be valid only for that particular Term Sheet and will not amend this Master Program Agreement generally.

❖❖❖

STATE-SPECIFIC AMENDMENTS

Each provision of these state-specific amendments ("Amendments") to this GNP Premier Participation Agreement ("Agreement") will be effective only to the extent that jurisdictional requirements of such respective states' laws applicable to the Agreement are met independently of these Amendments. These Amendments have no effect if jurisdictional requirements are not met.

CALIFORNIA

The California Department of Corporations requires that certain provisions in franchise documents be amended to be consistent with California law, including the California Franchise Investment Law, CAL. CORPORATIONS CODE Section 31000 et seq., and the California Franchise Relations Act, CAL. BUS. & PROF. CODE Section 20000 et seq. To the extent the Agreement has provisions that are inconsistent with the following, such provisions are hereby amended:

a. California Business and Professions Code Sections 20000 through 20043 provide rights to Customer concerning nonrenewal and termination of the Agreement. The Federal Bankruptcy Code also provides rights to Customer concerning termination of the Agreement upon certain bankruptcy-related events. To the extent the Agreement has a provision is inconsistent with these laws, these laws will control.

b. If Customer is required in the Agreement to execute a release of claims, such release will exclude claims arising under the California Franchise Investment Law and the California Franchise Relations Act with respect to the offer or sale of the Agreement and the Premier Candidate Agreement.

c. If the Agreement requires payment of liquidated damages that is inconsistent with California Civil Code Section 1671, the liquidated damage clause may be unenforceable.

d. If the Agreement has a covenant not to compete which extends beyond the expiration or termination of the Agreement, the covenant may be unenforceable under California law.

e. If the Agreement requires litigation, arbitration or mediation to be conducted in a forum other than the State of California, the requirement may be unenforceable under California law.

f. If the Agreement requires that it be governed by a state's law, other than the State of California, such requirement may be unenforceable.

g. Section 8.6 of Exhibit C of the Agreement is hereby amended to state that the representations made in the Franchise Disclosure Document are not excluded from that on which Customer may rely.

HAWAII

a. No release language set forth in the GNP Premier Agreement shall relieve the franchisor or any other party, directly or indirectly, from liability imposed by the laws concerning franchising in the State of Hawaii.

b. The GNP Premier Agreement is hereby supplemented with the following provision:

Hawaii Law. Pursuant to Section 482E-6(3) of the Hawaii Revised Statutes, for so long as such statute remains in effect and so provides, upon termination or refusal to renew the franchise, Franchisee shall be compensated for the fair market value, at the time of termination or expiration of the franchise, of Franchisee's inventory, supplies, materials and furnishings purchased from the Franchisor or a supplier designated by the Franchisor, exclusive of personalized materials which have no value to the Franchisor. If the Franchisor refuses to renew a franchise for the purpose of converting the franchised business to one owned by the Franchisor, the Franchisor, in addition to the remedies provided in this paragraph, shall compensate Franchisee for the loss of goodwill. The Franchisor may deduct from such compensation reasonable costs incurred in removing, transporting and disposing of Franchisee's inventory, supplies, materials and furnishings pursuant to this paragraph, and may offset from such compensation any moneys due to the Franchisor.

c. Notwithstanding anything contained in the Franchise Agreement or Area Development Agreement to the contrary, you do not have to pay us the Initial Franchise Fee until we perform our pre-opening obligations under the Franchise Agreement and your first Franchised Business is open. Once we complete this obligation and you are open, you must immediately pay us all initial fees we deferred.

ILLINOIS

ILLINOIS ADDENDUM TO THE PARTICIPATION (FRANCHISE) AGREEMENT

Illinois law governs the Participation (Franchise) Agreement.

In conformance with Section 4 of the Illinois Franchise Disclosure Act, any provision in a franchise agreement that designates jurisdiction and venue in a forum outside of the State of Illinois is void. However, a franchise agreement may provide for arbitration to take place outside of Illinois.

Franchisees' rights upon Termination and Non-Renewal are set forth in sections 19 and 20 of the Illinois Franchise Disclosure Act.

Any condition, stipulation or provision purporting to bind any person acquiring any franchise to waive compliance with the Illinois Franchise Disclosure Act or any other law of Illinois is void.

While the Franchisor's Parent company has guaranteed to assume the duties and obligations of the Participation (Franchise) Agreement if the Franchisor is unable to do so – the Parent company's financial condition calls into question its ability to fulfill such a guarantee. Notwithstanding anything contained in the Franchise Agreement to the contrary, you do not have to pay us the Initial Franchise Fee until we perform our pre-opening obligations under the Franchise Agreement and your Franchised Business has commenced business operations. The Illinois Attorney General's Office imposed this deferral requirement due to Franchisor's financial condition.

Nothing in the Premier Participation Agreement (Franchise Agreement), related agreements, exhibits and Term Sheets are intended to disclaim the express representations made in the Franchise Disclosure Document.

There is no training program for this franchise opportunity.

AmerisourceBergen Drug Corporation	Franchisee:_____
By: _____	By: _____
Title:_____	Title: _____

INDIANA

a. Any Franchise Agreement executed in and operative within the State of Indiana shall be governed by applicable Indiana franchise laws and the right of any franchisee to institute a civil action or initiate proceedings within the State of Indiana shall not be deemed to have been abridged in any form or manner by any provisions contained in the Franchise Agreement.

b. In compliance with Indiana Code section 23-2-2.7-1(9), any provisions in the Franchise Agreement relating to non-competition upon the termination or non-renewal of the Franchise Agreement shall be limited to a geographic area not greater than the territory granted in the Franchise Agreement and shall be construed in accordance with Indiana Code section 23-2-2.7-1(9).

c. Indiana Code section 23-2-2.7-1(10) prohibits the choice of an exclusive forum other than Indiana.

d. Indiana Code section 23-2.2.7-1(10) prohibits the limitation of litigation. The Indiana Secretary of State has interpreted this section to prohibit provisions in contracts regarding liquidated damages. Accordingly, any provisions in the Franchise Agreement regarding liquidated damages may not be enforceable. To the extent that any provision of the Franchise Agreement conflicts with Indiana Code section 23-2-2.7-1 (10), Indiana law will control.

e. Indiana Code sections 23-2-2.7-1 (1) and 23-2-2.5-30 impose different time limitations for litigation brought for breach of the Agreement or violation of Indiana law in connection with the Agreement. To the extent that any provision of the Agreement conflicts with Indiana law, Indiana law will control.

f. In compliance with Indiana Code section 23-2-2.7-1 (10), any inference contained in the Franchise Agreement to the effect that the Franchisor "is entitled" to injunctive relief shall, when applicable to a Franchise Agreement executed

in and operative within the State of Indiana, hereby be deleted, understood to mean and replaced with the words "may seek."

g. Indiana Code sections 23-2-2.5 and 23-2-2.7 supersede the choice of law clauses of the Franchise Agreement.

h. Indiana Code section 23-2.2.7-1 makes it unlawful for a franchisor to terminate a franchise without good cause or to refuse to renew a franchise on bad faith.

i. In compliance with Indiana Code section 23-2-2.7-1 (5), any requirement that the Franchisee must execute a release upon termination of the Franchise Agreement shall not be mandatory and is hereby made discretionary. However, Franchisee shall execute all other documents necessary to fully rescind all agreements between the parties.

MARYLAND

The Maryland Securities Division requires that certain provisions in franchise documents be amended to be consistent with Maryland law, including the Maryland Franchise Registration and Disclosure Law, Md. Code Ann., Bus. Reg. §§ 14-201 - 14-233 (2004 Repl. Vol. and Supp. 2008) (the "Maryland Franchise and Disclosure Law "). To the extent that the Agreement has provisions that are inconsistent with the following, such provisions are hereby amended:

a. If Customer is required in the Agreement to execute a release of claims and/or to acknowledge facts that would negate or remove from judicial review any statement, misrepresentation or action that would violate Maryland Franchise and Disclosure Law, or a rule or order under the Maryland Franchise and Disclosure Law, such release will exclude claims arising under the Maryland Franchise and Disclosure Law, and such acknowledgments will be void with respect to claims under the Maryland Franchise and Disclosure Law relating to the offer and sale of the Agreement and related agreements.

b. If the Agreement requires litigation to be conducted in a forum other than the State of Maryland, the requirement will not be interpreted to limit any rights Customer may have under the Maryland Franchise and Disclosure Law to bring suit in the state of Maryland.

c. Any general release required as a condition of renewal, sale, and/or assignment/transfer will not apply to any liability under the Maryland Franchise and Disclosure Law.

d. The Agreement is hereby amended to reflect that any claims arising under the Maryland Franchise and Disclosure Law must be brought within 3 years after the grant of the franchise.

e. Based upon the financial information submitted, the Commissioner has determined that all fees paid to the franchisor by the franchisee, including payment for goods and services received from the franchisor before the business opens, shall be deferred pending satisfaction of all of the franchisor's pre-opening obligations to the franchisee.

f. The Maryland Franchise and Disclosure Law prohibits a franchisor from requiring a prospective franchisee to assent to any release, estoppel or waiver of liability as a condition of purchasing a franchise. The Agreement requires prospective franchisees to disclaim the occurrence and/or acknowledge the non-occurrence of acts that would constitute a violation of the Maryland Franchise and Disclosure Law. Such representations are not intended to nor will they act as a release, estoppel or waiver of any liability incurred under the Maryland Franchise and Disclosure Law resulting from the offer or sale of the franchise.

g. No statement, questionnaire, or acknowledgment signed or agreed to by a franchisee in connection with the commencement of the franchise relationship shall have the effect of (i) waiving any claims under any applicable state franchise law, including fraud in the inducement, or (ii) disclaiming reliance on any statement made by any franchisor, franchise seller, or other person acting on behalf of the franchisor. This provision supersedes any other term of any document executed in connection with the franchise.

MINNESOTA

The Commissioner of Commerce for the State of Minnesota requires that certain provisions in franchise documents be amended to be consistent with Minnesota Franchise Act, Minn. Stat. Section 80.01 et seq., and of the Rules and Regulations promulgated under the Act (collectively the "Minnesota Act"). To the extent that the Agreement and Franchise Disclosure Document have provisions that are inconsistent with the following, such provisions are hereby amended:

a. The Minnesota Department of Commerce requires that ABDC indemnify Minnesota franchisees against liability to third parties resulting from claims by third parties that a franchisee's use of the Marks infringes trademark rights of the third party. ABDC does not indemnify against the consequences of Customer's use of the Marks except in accordance with the requirements of the Agreement, and, as a condition to indemnification, Customer must provide notice to ABDC of any such claim within ten (10) days after the earlier of (i) actual notice of the claim or (ii) receipt of written notice of the claim, and must therein tender the defense of the claim to ABDC. If ABDC accepts the tender of defense, ABDC has the right to manage the defense of the claim including the right to compromise, settle or otherwise resolve the claim, and to determine whether to appeal a final determination of the claim. If either the Agreement or the Franchise Disclosure Document has a provision that is inconsistent with the Minnesota Act, such provision will be superseded by the Minnesota Act's requirements and will have no force or effect.

b. Minnesota Act, Sec. 80C.14, Subd. 4., requires, except in certain specified cases, that Customer be given written notice of ABDC's intention not to renew 180 days prior to expiration of the franchise and that Customer be given sufficient opportunity to operate the franchise in order to enable Customer the opportunity to recover the fair market value of the franchise as a going concern. If either the Agreement or the Franchise Disclosure Document has a provision that is inconsistent with the Minnesota Act, such provision will be superseded by the Minnesota Act's requirements and will have no force or effect.

c. Minnesota Act, Sec. 80C.14, Subd. 3., requires, except in certain specified cases, that Customer be given 90 days notice of termination (with 60 days to cure). If either the Agreement or the Franchise Disclosure Document has a provision that is inconsistent with the Minnesota Act, such provision will be superseded by the Minnesota Act's requirements and will have no force or effect.

d. Minn. Rule 2860.4400(D) prohibits ABDC from requiring Customer to assent to a general release. If either the Agreement or the Franchise Disclosure Document requires Customer to execute a release of claims or to acknowledge facts that would negate or remove from judicial review any statement, misrepresentation or action that would violate the Franchise Act, such release will exclude claims arising under the Minnesota Act, and such acknowledgments will be void with respect to claims under the Minnesota Act.

e. Minnesota Statutes, Section 80C.21 and Minn. Rule 2860.4400(J) prohibit ABDC from requiring litigation to be conducted outside Minnesota, requiring waiver of a jury trial or requiring Customer to consent to liquidated damages, termination penalties or judgment notes. In addition, nothing in the Agreement or the Franchise Disclosure Document can abrogate or reduce Customer's rights under Minnesota Statutes, Chapter 80C or Customer's rights to any procedure, forum or remedies provided for by the laws of the jurisdiction.

f. Notwithstanding anything contained in the Franchise Agreement to the contrary, you do not have to pay us the Initial Franchise Fee until we perform our pre-opening obligations under the Franchise Agreement and your Franchised Business is open. Once we complete this obligation and you are open, you must immediately pay us all initial fees we deferred.

NEW YORK

The New York Department of Law requires that certain provisions in franchise documents be amended to be consistent with New York law, including the General Business Law, Article 33, Sections 680 through 695 (1989). To the extent that the Agreement has provisions that are inconsistent with the following, such provisions hereby amended:

a. If the Agreement requires Customer to execute a release of claims or to acknowledge facts that would negate or remove from judicial review any statement, misrepresentation or action that would violate the General Business Law, or any regulation, rule or order under the Law, such release will exclude claims arising under the New York General Business Law, Article 33, Section 680 through 695 and the regulations promulgated thereunder, and such acknowledgments will be void. It is the intent of this provision that non-waiver provisions of Sections 687.4 and 687.5 of the General Business Law be satisfied.

b. If the Agreement requires that it be governed by a state's law, other than the State of New York, the choice of law provision will not waive any rights conferred upon Customer under the New York General Business Law, Article 33, Sections 680 through 695.

NORTH DAKOTA

The North Dakota Securities Commissioner requires that certain provisions in franchise documents be amended to be consistent with North Dakota law, including the North Dakota Franchise Investment Law, North Dakota Century Code Annotated Chapter 51-19, Sections 51-19-01 through 51-19-17 (1993) (the "Law"). To the extent that the Agreement has provisions that are inconsistent with the following, such provisions are hereby amended:

a. If Customer is required in the Agreement to execute a release of claims or to acknowledge facts that would negate or remove from judicial review any statement, misrepresentation or action that would violate the Law, or a rule or order under the Law, such release will exclude claims arising under the North Dakota Franchise Investment Law, and such acknowledgments will be void with respect to claims under the Law, as to the offer and sale of the Agreement.

b. Covenants not to compete during the term of and upon termination or expiration of the Agreement are enforceable only under certain conditions according to North Dakota law. If the Agreement has a covenant not to compete that is inconsistent with North Dakota law, the covenant may be unenforceable.

c. The Commissioner has held that requiring franchisees to consent to the jurisdiction of courts outside of North Dakota is unfair, unjust or inequitable within the intent of Section 51-19-09 of the North Dakota Franchise Investment Law.

d. If the Agreement requires that law of a state other than North Dakota govern it, to the extent that such law conflicts with the North Dakota law, North Dakota law will control.

e. If the Agreement requires litigation, mediation or arbitration to be conducted in a forum other than North Dakota, the requirement may be unenforceable under the Law. Arbitration involving a franchise purchased in North Dakota must be held either in a location mutually agreed upon prior to the arbitration or if the parties cannot agree on a location, the location will be determined by the arbitrator.

f. If the Agreement requires payment of a termination penalty, the requirement may be unenforceable under the Law.

RHODE ISLAND

The Rhode Island Securities Division requires that certain provisions in franchise documents be amended to be consistent with Rhode Island law, including the Franchise Investment Act, R.I. Gen. Law. ch. 395 Sec. 19-28.1-1 -19-28.1-34 (the "Rhode Island Act"). To the extent that the Agreement has provisions that are inconsistent with the following, such provisions are hereby amended:

a. If the Agreement requires litigation to be conducted in a forum other than Rhode Island, the requirement is void under Rhode Island Act Sec. 19-28.1-14.

b. If the Agreement requires that it be governed by law of a state other than Rhode Island, to the extent that such law conflicts with the Rhode Island Act it is void under Sec. 19-28.1-14.

c. If Customer is required in the Agreement to execute a release of claims or to acknowledge facts that would negate or remove from judicial review any statement, misrepresentation or action that would violate the Rhode Island Act, or a rule or order under the Rhode Island Act, such release will exclude claims arising under the Rhode Island Act, and such acknowledgments will be void with respect to claims under the Rhode Island Act, as to the offer and sale of the Agreement.

SOUTH DAKOTA

a. Neither the franchisor nor any person identified in Item 2 has any material arbitration proceeding pending, or has during the 10-year period immediately preceding the date of this Disclosure Document been a party to concluded material arbitration proceedings.

b. Although the Franchise Agreement requires all arbitration proceedings to be held where the American Arbitration Association designates, the site of any arbitration started pursuant to the Franchise Agreement will be at a site mutually agreed upon by you and us.

c. We may not terminate the Franchise Agreement for a breach, for failure to meet performance and quality standards and/or for failure to make royalty payments unless you receive thirty (30) days prior written notice from us and you

are provided with an opportunity to cure the defaults. Covenants not to compete upon termination or expiration of the Franchise Agreement are generally unenforceable in the State of South Dakota.

d. The laws of the State of South Dakota will govern matters pertaining to franchise registration, employment, covenants not to compete, and other matters of local concern; but as to contractual and all other matters, the Franchise Agreement will be subject to the applications, construction, enforcement and interpretation under the governing law of Pennsylvania.

e. Any provision in the Franchise Agreement restricting jurisdiction or venue to a forum outside of the State of South Dakota or requiring the application of the laws of another state is void with respect to a claim otherwise enforceable under the South Dakota Franchise Act.

f. Any provision that provides that the parties waive their right to claim punitive, exemplary, incidental, indirect, special or consequential damages may not be enforceable under South Dakota law.

VIRGINIA

The Virginia State Corporation Commission's Division of Securities and Retail Franchising requires us to defer payment of the initial franchise fee and other initial payments owed by franchisees to the franchisor until the franchisor has completed its pre-opening obligations under the franchise agreement.

WASHINGTON

In the event of a conflict of laws, the provisions of the Washington Franchise Investment Protection Act, Chapter 19.100 RCW will prevail.

RCW 19.100.180 may supersede the franchise agreement in your relationship with the franchisor including the areas of termination and renewal of your franchise. There may also be court decisions which may supersede the franchise agreement in your relationship with the franchisor including the areas of termination and renewal of your franchise.

In any arbitration or mediation involving a franchise purchased in Washington, the arbitration or mediation site will be either in the state of Washington, or in a place mutually agreed upon at the time of the arbitration or mediation, or as determined by the arbitrator or mediator at the time of arbitration or mediation. In addition, if litigation is not precluded by the franchise agreement, a franchisee may bring an action or proceeding arising out of or in connection with the sale of franchises, or a violation of the Washington Franchise Investment Protection Act, in Washington.

A release or waiver of rights executed by a franchisee may not include rights under the Washington Franchise Investment Protection Act or any rule or order thereunder except when executed pursuant to a negotiated settlement after the agreement is in effect and where the parties are represented by independent counsel. Provisions such as those which unreasonably restrict or limit the statute of limitations period for claims under the Act, or rights or remedies under the Act such as a right to a jury trial, may not be enforceable.

Transfer fees are collectable to the extent that they reflect the franchisor's reasonable estimated or actual costs in effecting a transfer.

Pursuant to RCW 49.62.020, a noncompetition covenant is void and unenforceable against an employee, including an employee of a franchisee, unless the employee's earnings from the party seeking enforcement, when annualized, exceed $100,000 per year (an amount that will be adjusted annually for inflation). In addition, a noncompetition covenant is void and unenforceable against an independent contractor of a franchisee under RCW 49.62.030 unless the independent contractor's earnings from the party seeking enforcement, when annualized, exceed $250,000 per year (an amount that will be adjusted annually for inflation). As a result, any provisions contained in the franchise agreement or elsewhere that conflict with these limitations are void and unenforceable in Washington.

RCW 49.62.060 prohibits a franchisor from restricting, restraining, or prohibiting a franchisee from (i) soliciting or hiring any employee of a franchisee of the same franchisor or (ii) soliciting or hiring any employee of the franchisor. As a result, any such provisions contained in the franchise agreement or elsewhere are void and unenforceable in Washington. The undersigned does hereby acknowledge receipt of this addendum.

In lieu of an impound of franchise fees, the Franchisor will not require or accept the payment of any initial franchise fees until the franchisee has (a) received all initial training that it is entitled to under the franchise agreement or offering circular, and (b) is open for business.

WISCONSIN

The Wisconsin Department of Financial Institutions requires that certain provisions in franchise documents be amended to be consistent with Wisconsin Law, including The Wisconsin Fair Dealership Law, ch. 135, Wis. Stats. (the "Wisconsin Act"). To the extent that the Agreement has provisions that are inconsistent with the following, such provisions are hereby amended:

a. The Wisconsin Fair Dealership Law supersedes any provisions contained in the Agreement that are inconsistent with the Wisconsin Act.

MASTER PROGRAM AGREEMENT

1. TERM. The term of this Agreement ("**Term**") starts on its Effective Date and continues until all Available Programs have been terminated pursuant to Paragraph 5.0 of Exhibit C of the GNP Premier Agreement or as follows. Either party may terminate this Master Program Agreement or one or more Available Programs at one or more Pharmacies, with or without cause, at any time upon sixty (60) days' prior written notice, although termination of specific Available Programs may be subject to restrictions or termination obligations ~~as indicated~~provided on the applicable Term Sheet. Notwithstanding the preceding sentence, ABDC may immediately and at any time terminate or modify, as applicable, any Pharmacy's participation in any Available Program that includes eligibility qualifications, requirements, and/or criteria, as provided in applicable Term Sheets and/or enrollment forms, that such Pharmacy does not satisfy. Termination of less than all Available Programs at all Pharmacies will not terminate this Agreement with respect to any Available Program and/or Pharmacy that is not named in the termination notice.

2. FEES. Each Term Sheet states applicable per-Pharmacy fees, which such fees shall apply during the term of Customer's participation in each corresponding Available Program and may be prorated as applicable. Some Available Programs require Customer to incur other expenses, which are Customer's responsibility. "**Premier**" fees apply to Pharmacy locations under a Good Neighbor Pharmacy Premier Participation Agreement ("**Premier Agreement**"). "**GNP**" fees apply to Pharmacies under a Good Neighbor Pharmacy Voluntary License ("**GNP License**"). "**Other**" fees apply to Pharmacies that do not participate in the Good Neighbor Pharmacy program and may be higher. Applicable fees may be increased on sixty (60) days' prior written notice.

3. ABDC COMMITMENTS.

(a) **Programs and Services.** ABDC will promptly provide Available Programs (subject to roll-out schedules and sequential program activation) in which Customer enrolls from time to time pursuant to applicable industry standards ~~and~~, laws ~~and~~, Term Sheets, and program materials ABDC provides or makes available to Customer that prescribe or recommend standards, practices, procedures, policies and ~~advice~~guidance relating to the Available Program ("**Program Guides**"). In addition to written material, ABDC and others, including Payors (as defined under Term Sheet 1), may publish Term Sheets, Program Guides, policies, procedures, and updates to each of these on AB Central or other websites they maintain, or make them available on request. A listing of current Available Programs and applicable Term Sheets are accessible on AB Central or from Customer's ABDC sales representative.

(b) **Statements of Work.** From time-to-time, Customer may engage ABDC to provide other goods and services ~~including~~, such as custom work or a special project ~~with terms agreed~~, pursuant to a "statement of work" hereunder. Each statement of work will be subject to the terms and conditions of this Agreement, will be attached hereto, and is hereby incorporate into and made a part of this Agreement.

(c) **Data Protection.** ABDC will protect and only use Pharmacy Data and Business Contact Information provided by or on behalf of Customer pursuant to Exhibit A in connection with any Available Program that involves access to such information and, in connection with any Available Program that involves access to protected health information (PHI in Exhibit B), pursuant to the Business Associate Agreement (Exhibit B or as otherwise agreed~~) under HIPAA, the HITECH Act and implementing regulations including the Privacy, Security, and Breach Notification Rules (each defined in Exhibit B).~~).

4. CUSTOMER COMMITMENTS.

(a) **Program Agreement.** During the Term, Customer may request to enroll a Pharmacy in an Available Program by submitting the required ~~program~~Available Program enrollment form(s) to request that ABDC begin providing the Available Program. For Available Programs that involve access to Pharmacy Data, Customer will sign a Data Authorization as part of enrollment.

(b) **Compliance.** Customer will comply with this Agreement, Term Sheets and Program Guides, including qualifications or other actions Customer must meet to be eligible, each as amended by ABDC from time to time. If Customer does not comply, it may not participate in such Available Program or, if it is participating, its right to do so may be revoked. Customer is responsible for acquiring and maintaining all equipment, software and services, including ~~"Change Healthcare"~~ claims switch services~~,~~ provided by "Change Healthcare", or such services provided by another claims switch services provider approved by ABDC in writing, as may be required for ~~certain~~ Available ~~Programs, specified as necessary in~~ Program ~~Guides~~participation. Such items and services must be purchased from vendors meeting Available Program specifications to ABDC's reasonable satisfaction.

(c) **Payment**. Unless otherwise agreed, ABDC will bill fees monthly and add to the billed amount any applicable sales, use or other tax or charges, with payment due under terms of Customer's prime vendor agreement or ABDC's standard terms.

(d) **Use of Available Programs**. Customer may only use an Available Program for its own business and only at a Pharmacy that Customer has enrolled in such Available Program. Nothing supplied by ABDC under this Agreement, including performance measurements, business advice, or cost or price data, is a substitute for Customer's business and professional judgment or will dictate to Customer at what price to sell services, pharmaceuticals or other merchandise, except to the extent Customer and a third

party each agree (including as a part of the Elevate Provider Network). Customer is ~~fully~~solely responsible for use of data and advice obtained through Available Programs. Except as expressly permitted otherwise herein respecting disclosures required by law, Customer must keep confidential and not disclose, redistribute, reverse engineer, supply, license or sell any analyses, processes, advice or any other intellectual property of ABDC, including reports and methods, relating to Available Programs.

5. PROVISIONS AND POLICIES. ABDC may unilaterally amend this Agreement, including, without limitation, developing new or modifying existing Exhibits hereto and/or Available Programs and their respective policies, procedures, and corresponding Term Sheets, which any such amendments are effective sixty (60) days after they are made available or any shorter period specified in a Term Sheet, as applicable. Customer consents to receiving notices, advertisements and other marketing materials by fax or email from ABDC and its corporate affiliates. ABDC will provide notice via fax or email respecting any unilateral amendment to this Agreement as provided herein. Participation in an Available Program and all Term Sheets incorporate this Agreement, including all Exhibits attached hereto, by this reference.

STATE-SPECIFIC ADDENDA TO MASTER PROGRAM AGREEMENT

MARYLAND

The Maryland Insurance Administration requires that certain provisions in pharmacy services administrative contracts (as defined in Md. Code, Ins. § 15-2001(d)) between pharmacy services administrative organizations (as defined in Md. Code, Ins. § 15-2001(e)) and independent pharmacies (as defined in Md. Code, Ins. § 15-2001(b)) be amended to be consistent with applicable Maryland law. To the extent that Customer is a pharmacy or owns certain pharmacies that satisfy the definition of "independent pharmacy" as defined in Md. Code, Ins. § 15-2001(b), the following Maryland State Addendum to the Master Agreement applies and amends the terms of the Agreement, as follows:

MARYLAND STATE ADDENDUM TO MASTER PROGRAM AGREEMENT

This Maryland State Addendum to Master Program Agreement (this "**Addendum**") is incorporated in its entirety into, and made a part of, that certain Master Program Agreement, including all term sheets, exhibits, addenda, schedules and amendments thereto (collectively, the "**Agreement**") entered into by and between AmerisourceBergen Drug Corporation d/b/a Elevate Provider Network ("**ABDC**") and Customer (as defined in the Agreement), effective as of the Effective Date (as defined in the Agreement). ABDC and Customer are also referred to in this Addendum as a "**Party**" and, collectively, the "**Parties**".

RECITALS

A. WHEREAS, ABDC is a pharmacy services administrative organization and operates a network of pharmacies, including Customer, that have authorized ABDC to enter into and bind the pharmacies to certain Payor Contracts on their behalf.

B. WHEREAS, the Parties entered into the Agreement as of the Effective Date.

C. WHEREAS, Customer is a pharmacy or owns certain pharmacies that satisfy the definition of "**independent pharmacy**" as defined in Md. Code, Ins. § 15-2001(b).

D. WHEREAS, in order to comply with applicable provisions of the Insurance Article, Annotated Code of Maryland, including, without limitation, Title 15, Subtitles 15 and 20 of the Insurance Article, Annotated Code of Maryland, including, without limitation, Insurance Article §§ 15-1611, 15-1628, 15-1628.1, 15-1628.2, 15-1628.3, 15-1629, 15-1631, 15-1633, 15-1634, 15-1635, 15-1636, 15-1637, 15-1638, 15-1639, 15-2011, 15-2013(c), 15-2014(c), 15-2015, and 15-2016, Annotated Code of Maryland, and the corresponding regulations promulgated in connection therewith, including, without limitation, the Code of Maryland Regulations (collectively, the "**MD Laws**"), the Parties desire to mutually amend the Agreement as provided herein.

NOW THEREFORE, the Parties agree as follows:

1. **Incorporation**. The initial paragraph and Recitals to this Addendum are hereby incorporated herein and made a part hereof.

2. **Scope**. For independent pharmacies (as defined in Md. Code, Ins. § 15-2001(b)) receiving services in the State of Maryland, this Addendum modifies the Agreement with respect to the Parties' performance and activities in accordance with certain legislative and regulatory requirements applicable to the Parties in the State of Maryland. Notwithstanding anything to the contrary contained herein or in the Agreement, in the event of any conflict between the terms of this Addendum and the Agreement, the terms of this Addendum shall control.

3. **Definitions**.

    a. "**Brand Drug**" or "**Brand Name Drug**" shall be as defined in Health Occupations Article, §12-504, Annotated Code of Maryland.

    b. "**Generic Drug**" shall be as defined in Health Occupations Article, §12-504, Annotated Code of Maryland.

    c. "**Multisource Generic Drug**" means a generic drug as defined in Health-General Article, §21-2C-01(f), Annotated Code of Maryland, for which there is at least one other drug and does not include a Brand Name Drug.

    d. For the purposes of this Addendum, the term "**Pharmacy(ies)**" shall include Customer and/or Customer's pharmacies, as applicable, in the State of Maryland that satisfy the definition of "independent pharmacy" as defined in Md. Code, Ins. § 15-2001(b).

    e. All capitalized terms contained but not otherwise defined herein shall be defined as set forth in the Agreement.

4. **Compliance**. ABDC shall comply with, and may not engage in any activity that is prohibited pursuant to, the MD Laws. To the extent that the Agreement contains any provisions, or portions thereof, in violation of the MD Laws, such provisions, or portions thereof, are deleted in their entirety. Without in any way limiting the foregoing, ABDC's obligations pursuant to the MD Laws shall include the following:

    a. Pharmacies will not be directly or indirectly charged or held responsible for a fee or performance-based reimbursement related to adjudication of a Claim or an incentive program.

    b. ABDC may not make or allow any reduction in payment to the Pharmacies for pharmacy services or directly or indirectly reduce, or allow the reduction of, a payment to the Pharmacies for a pharmacy service under a reconciliation process to an effective rate of reimbursement, including generic effective rates, brand effective rates, direct and indirect remuneration fees, or any other reduction or aggregate reduction of payments.

    c. Except to the extent expressly provided otherwise under the MD Laws, if a Claim has been approved through adjudication, ABDC may not retroactively deny or modify, or allow the retroactive denial or modification of, reimbursement to a Pharmacy or Pharmacy's pharmacist(s), as applicable, for the approved Claim.

    d. Pharmacy and/or Pharmacy's pharmacist(s), as applicable, are not prohibited from providing or discussing retail prices or cost sharing with beneficiaries.

    e. ABDC may not reimburse, or allow the reimbursement of, a covered drug in an amount that differs, including zero, based on the identity of the wholesale distributor used by a Pharmacy for acquisition of the covered drug.

    f. Except for instances of error or fraud, ABDC may not, nor may ABDC allow a pharmacy benefits manager to, reclassify, recategorize, or recharacterize an adjudicated Claim.

    g. Pharmacy and/or Pharmacy's pharmacists are not in any way prohibited or restricted from filing a complaint with the Maryland Insurance Commissioner.

    h. ABDC's internal appeals procedures regarding the investigation and resolution of disputes filed against ABDC by a Pharmacy shall be as provided in the Agreement; provided, however, that such procedures shall only apply to the extent not otherwise prohibited by the MD Laws.

5. **Miscellaneous**.

    a. Changes in Law. This Addendum will, without the need for further action from the Parties, be deemed automatically amended to incorporate any and all changes to the MD Laws, including any additional provisions required to be included herein pursuant to the MD Laws, effectuated after the Effective Date.

    b. Governing Law. For independent pharmacies receiving services in the State of Maryland, each of the Agreement and this Addendum will be interpreted and governed by the laws of the State of Maryland without regard to its choice-of-law principles.

    c. Ownership Disclosure. Customer acknowledges that ABDC exists and functions as a fictitiously named subdivision operating under AmerisourceBergen Drug Corporation, a prescription drug, biologics, and medical device distribution company. ABDC will notify Customer within 5 days of any material change in its ownership or control as it relates to the foregoing.

    d. Disclosure to Customer. ABDC will provide copies of Payor Contracts, including any payment schedules or reimbursement rates applicable thereto, in addition to any amendments thereto, to Customer within five (5) business days following the execution thereof. For the avoidance of doubt, any and all Payor Contracts provided hereunder shall constitute Confidential Information and, without in any way limiting Customer's other confidentiality obligations in connection with the same, may not be disclosed to ABDC's competitors.

    e. No Purchase Required. Nothing in the Agreement shall in any way require Customer to purchase drugs, biologics, or medical devices from ABDC.

SOUTH CAROLINA

The South Carolina Department of Insurance requires that certain provisions in PSAO-pharmacy contracts (as defined in S.C. Code § 38-71-2310(6)) between pharmacy services administrative organizations (as defined in S.C. Code § 38-71-2310(5)) and pharmacies (as defined in S.C. Code § 38-71-2310(2)) be amended to be consistent with applicable South Carolina law. To the extent that Customer is a pharmacy or owns certain pharmacies that satisfy the definition of "pharmacy" as defined in S.C. Code § 38-71-2310(2), the following South Carolina State Addendum to the Master Agreement applies and amends the terms of the Agreement, as follows:

SOUTH CAROLINA STATE ADDENDUM TO MASTER PROGRAM AGREEMENT

This South Carolina State Addendum to Master Program Agreement (this "**Addendum**") is incorporated in its entirety into, and made a part of, that certain Master Program Agreement, including all Term Sheets, Exhibits, Addenda, Schedules and Amendments thereto, (collectively, the "**Agreement**") entered into by and between AmerisourceBergen Drug Corporation d/b/a Elevate Provider Network ("**ABDC**") and Customer (as defined in the Agreement), effective as of the Effective Date (as defined in the Agreement). ABDC and Customer are also referred to in this Addendum as a "**Party**" and, collectively, the "**Parties**".

RECITALS

A. ABDC is a pharmacy services administrative organization and operates a network of pharmacies, including Customer, that have authorized ABDC to enter into and bind the pharmacies to certain Payor Contracts on their behalf.

B. The Parties entered into the Agreement as of the Effective Date.

C. Customer is a pharmacy or owns certain pharmacies that satisfy the definition of "pharmacy" as defined in S.C. Code § 38-71-2310(2).

D. In order to comply with applicable provisions of the South Carolina Code of Laws, including, without limitation, Title 38, Chapter 71 of the South Carolina Code of Laws, including, without limitation, Insurance Article §§ 38-71-2310, 38-71-2320, 38-71-2330, 38-71-2340, and 38-71-2350, South Carolina Code of Laws, and the corresponding regulations promulgated in connection therewith, including, without limitation, the South Carolina Code of State Regulations (collectively, the "**SC Laws**"), the Parties desire to amend the Agreement as provided herein.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree to be legally bound as follows:

1. **Incorporation**. The initial paragraph and Recitals to this Addendum are hereby incorporated herein and made a part hereof.

2. **Scope**. For pharmacies (as defined in S.C. Code § 38-71-2310(2)) receiving services in the State of South Carolina, this Addendum modifies the Agreement with respect to the Parties' performance and activities in accordance with certain legislative and regulatory requirements applicable to the Parties in the State of South Carolina. Notwithstanding anything to the contrary contained herein or in the Agreement, in the event of any conflict between the terms of this Addendum and the Agreement, the terms of this Addendum shall control.

3. **Definitions**.

    a. For the purposes of this Addendum, the term "**Pharmacy(ies)**" shall include Customer and/or Customer's pharmacies, as applicable, in the State of South Carolina that satisfy the definition of "pharmacy" as defined in S.C. Code § 38-71-2310(2).

    b. All capitalized terms contained but not otherwise defined herein shall be defined as set forth in the Agreement.

4. **Compliance**. ABDC shall comply with, and may not engage in any activity that is prohibited pursuant to, the SC Laws.

5. **Miscellaneous**.

a. Changes in Law. The Parties agree to take any and all actions with respect to this Addendum as may be necessary to comply with any and all changes to the SC Laws, as may be amended from time to time, including, without limitation, amending this Addendum to incorporate any additional provisions required to be included herein or amending this Addendum to amend or remove any provisions included herein required to be amended or removed.

b. Governing Law. For pharmacies receiving services in the State of South Carolina, each of the Agreement and this Addendum will be interpreted and governed by the laws of the State of South Carolina without regard to its choice-of-law principles.

c. Ownership Disclosure. Customer acknowledges that ABDC exists and functions as a fictitiously named subdivision operating under AmerisourceBergen Drug Corporation, a prescription drug, biologics, and medical device distribution company. ABDC will notify Customer within five (5) days of any material change in its ownership or control as it relates to the foregoing.

d. Disclosure to Customer. ABDC will provide copies of Payor Contracts, including any payment schedules or reimbursement rates applicable thereto, in addition to any amendments thereto, to Customer within three (3) days following the execution thereof. For the avoidance of doubt, any and all Payor Contracts provided hereunder shall constitute Confidential Information and, without in any way limiting Customer's other confidentiality obligations in connection with the same, may not be disclosed to ABDC's competitors.

e. No Purchase Required. Nothing in the Agreement shall in any way require Customer to purchase drugs, biologics, or medical devices from ABDC.

AVAILABLE PROGRAM ENROLLMENT FORM & DATA AUTHORIZATION

Eligibility for Available Programs

This ~~form~~Available Program Enrollment Form & Data Authorization (this "Enrollment Form") is used to initiate the enrollment process respecting the Available Programs provided herein. Enrollment is not complete unless all requirements, including, without limitation, activation and onboarding steps, are met. Term Sheets outline applicable eligibility criteria, requirements, and prerequisites. AmerisourceBergen Drug Corporation ("ABDC") may immediately and at any time terminate or modify, as applicable, any of Customer's, or any of its Pharmacy's, participation in any Available Program that includes eligibility qualifications, requirements, and/or criteria, as provided in applicable Term Sheets and/or enrollment forms, that Customer, or any of its Pharmacies, does not satisfy. Available Programs are intended for Customer's locations operating in good standing under a distribution agreement that designates ABDC as its prime vendor.

☐ **Elevate Provider Network℠ (Term Sheet 1)**

By selecting Elevate Provider Network, Customer hereby grants its authority to ~~Elevate Provider Network~~ABDC to serve as its contracting agent to negotiate and execute Payor Contracts on behalf of Customer, pursuant to which Customer's pharmacy locations will be bound and comply with all such terms and conditions**.** Members not enrolled in the GNP Premier Program pay a monthly fee ~~of $189 per location~~ranging from $249 - $575 per location, dependent upon the nature of the member's Master Program Agreement with ABDC, as elected by the member in writing and/or otherwise confirmed by ABDC in writing, as follows: (1) *Standard*: $249/location/month; (2) *Enhanced*: $399/location/month; (3) *Enhanced Plus*: $575/location/month. *See Term Sheet 1 for additional terms and conditions*.

☐ **Elevate Advanced Features (Term Sheet 2 – 3)**

Elevate Advanced Features is a suite of services made available by ABDC and/or certain of the Program Partners (as defined below) and designed to assist Customer with its healthcare operations, including treatment, payment, and healthcare operations activities. Fee is included for Elevate Provider Network members. Members not enrolled in the GNP Premier Program pay monthly fee of $~~189.~~249. Additional fees may apply if Customer: (i) processes more than 10,000 claims in a month; (ii) uses an alternative, approved switch service provider for Elevate Advanced Features; and/or (iii) elects to receive optional and/or enhanced Elevate Advanced Features services (e.g., enhanced reporting, etc.). Excludes enrollment in patient care services solutions offerings via ABDC which require the execution of a separate enrollment form, direct agreement with the respective Program Partner, and payment of additional fees (which vary depending on the method of enrollment utilized). *See Term Sheet 2 for additional terms and conditions.*

- **Includes PPE Solutions (Term Sheet 2A)**

  Powered by Change Healthcare, participation in Pre and Post Edit Solutions requires Customer to have or execute an agreement with Change Healthcare for claims switching services. *See Term Sheet 2A for additional terms and conditions.*

- **Includes Claim Reconciliation Services (Term Sheet 2B)**

  Powered by EnlivenHealth, the self-service option is included; Customer may upgrade to Concierge Service directly with EnlivenHealth or use an outside reconciliation vendor at additional fees. *See Term Sheet 2B for additional terms and conditions.*

- **Optional: Outcomes Patient Care Services (Term Sheet 2C)**

  Outcomes makes available its Outcomes Premium Solution offering real-time analytics and ongoing management tools designed to assist subscribing pharmacies in improving, among other things, patient health outcomes, patient adherence, and clinical service; requires separate enrollment. *See Term Sheet 2C for additional terms and conditions.*

- **Optional: EnlivenHealth Patient Care Services (Term Sheet 2D)**

  EnlivenHealth makes available its Amplicare Treat Solution offering real-time analytics and ongoing management tools designed to assist subscribing pharmacies in improving, among other things, patient health outcomes, patient adherence, and clinical services; requires separate enrollment. *See Term Sheet 2D for additional terms and conditions.*

- **Includes in InSite from ABDC (Term Sheet 3)**

  A proprietary data analytics system used to measure and compare pharmacy performance by organizing and analyzing Pharmacy Data (as defined below). Fee is included with Elevate Advanced Features. *See Term Sheet 3 for additional terms and conditions.*

- **Optional: Enroll my Pharmacy (LTC NCPDP only) in InSite from ABDC (Term Sheet 3)**

A proprietary data analytics system used to measure and compare pharmacy performance by organizing and analyzing Pharmacy Data (as defined below). Fee is included with Elevate Advanced Features. *See Term Sheet 3 for additional terms and conditions.*

☐ **Five-Star Rebate (Term Sheet 4)**

A PRxO Generics rebate that recognizes and rewards performance in pharmacy quality measures. In exchange, Customer provides consent to extract dispense usage data from Pharmacy Data (as defined below) and, unless restricted by Customer's designated buying group agreement (if any), share it with ABDC sales and other associates to identify missed opportunities and to assist Customer in optimizing purchase performance. Five-Star rebate is only available to retail NCPDP accounts. *See Term Sheet 4 for additional terms and conditions.*

Front-End Solution programs (Term Sheet 5)

The following interrelated programs are designed to assist Customer in promoting traditional drugstore non-prescription product categories. *See Term Sheet 5 for additional terms and conditions.* Certain services are available only to Premier and GNP Pharmacies. Please identify your selections below:

☐ **Planogram services**

Premier: Included; no additional fee
GNP: No additional fee
Other: $55 per month ($89 combined with Zone Pricing)

☐ **Retail Product Zone Pricing Service**

Premier: Included; no additional fee
GNP: No additional fee
Other: $45 per month ($89 with Planograms)

☐ **First To Shelf™ (AutoShip New OTC)**

Premier: Required; no additional fee
GNP: No additional fee
Other: Not available

☐ **Front-End Support Kit**

Premier: Optional; no additional fee
GNP: No additional fee
Other: Not available

☐ **Merchandising Services**

Premier: Included; no additional fee
GNP: ~~$399/merchandiser/day~~Limited availability (pricing based on scope of work)
Other: Limited availability (pricing based on scope of work)

Digital Marketing programs (Term Sheet 6)

The following interrelated programs are part of an overall strategy to attract and engage patients and consumers online. *See Term Sheet 6 for additional terms and conditions.*

☐ **MyGNP Website**

Premier: Included; no additional fee
GNP: Included; no additional fee
Other: Not available

☐ **My GNP Mobile App**

Premier: Included; no additional fee
GNP: Included; no additional fee
Other: Not available

☐ **Digital and Social Media Marketing**

Premier: Included; ~~no~~ additional ~~fee~~fees apply to optional digital advertising services in which Customer enrolls
GNP: Not available
Other: Not available

☐ **Local Listings Management**

Premier: Included; no additional fee
GNP: Included; no additional fee
Other: Not available

Business Coaching (Term Sheet 7)

ABDC assigns a business coach to Customer who will assess the current performance and practices of Customer's pharmacy locations and recommend new practices and opportunities to improve profitability. *See Term Sheet 7 for additional terms and conditions.*

☐ **Business Coaching**

Premier: Included; no additional fee
GNP: Not available
Other: Not available

Pharmacy Data Services (Term Sheet 8)

ABDC will furnish the selected data services to Customer to assist with pharmacy computer applications, including pharmacy management and point-of sale systems. Multi-location computer systems, whether or not connected, will be charged per Pharmacy or other location. *See Term Sheet 8 for additional terms and conditions.*

☐ **Catalog & Price Update Service - OTC**

Premier: Included; no additional fee
GNP: $55 per month
Other: $55 per month

☐ **Catalog & Price Update Service - Rx**

Premier: Included; no additional fee
GNP: $55 per month
Other: $55 per month

Unsaleable Returns (Term Sheet 9)
ABDC will assist you in recovering the value of unsaleable products by providing a comprehensive solution for disposal including all processing, shipping, and destruction costs. *See Term Sheet 9 for additional terms and conditions.*

☐ **Unsaleable Returns**

Premier: Included; no additional fee
GNP: Included; no additional fee
Other: Not available

☐ **On-Site Assistance**

Premier: Included; no additional fee
GNP: Not available
Other: Not available

Additional Terms

Data Authorization Consent
These programs ("Available Programs") are designed to aid Customer's pharmacy locations in its treatment, payment, and healthcare operations activities ~~("Available Programs").~~. In order for ABDC and its Program Partners (as described below) to provide Customer with the Available Programs, Customer, by signing below: (i) authorizes ABDC to receive financial, operational, pharmacy, performance, business, operational, pharmacy, and patient data, including protected health information, on behalf of Customer ("Pharmacy Data") directly from Customer or indirectly from third parties supporting or participating in the Available Programs, including without limitation Customer's designated pharmacy system vendor, designated point-of-sale system vendor, designated reconciliation service provider, Payors (as defined under Term Sheet 1), IQVIA, InSite, IntrinsiQ Specialty Solutions, ~~LLC,~~Inc., Change Healthcare (a part of Optum®) or other claims switching service provider approved by ABDC in writing, EnlivenHealth (f/k/a FDS AMPLICARE), Retail Insights and Outcomes Operating, Inc. (f/k/a/ Prescribe Wellness) or other patient services provider approved by ABDC in writing (collectively, "Program Partners"); and (ii) authorizes and directs ABDC and the Program Partners to exchange Pharmacy Data on Customer's behalf to support Customer's participation in the Available Programs.

This data authorization is intended to constitute Customer's written consent under the applicable HIPAA Business Associate Agreement or similar document between Customer, ABDC and/or Program Partners for the exchange of Pharmacy Data on Customer's behalf. ABDC's receipt and use of Pharmacy Data is subject to the terms of the program documentation applicable to the specific Available Programs in which Customer enrolls ("Program Documentation"), such as the parties' MPA (as defined below) and accompanying Exhibits and Term Sheets. Customer acknowledges that in conformance with the Program Documentation, ABDC associates with a need to know may access and use Pharmacy Data including protected health information to assist Customer in its treatment, payment, and healthcare operations activities. This authorization will automatically terminate thirty (30) days after Customer ceases its participation in the Available Programs.

Business Coach Data Authorization Consent
Customer will furnish certain business, operational and financial data regarding its Pharmacy location, including protected health information, ("~~Business~~Coaching Data") to its Business ~~Coach.~~Coaching Associate. ABDC's receipt and use of ~~Business~~Coaching Data is subject to the terms of the applicable Program Documentation, such as the parties' MPA (as defined below) and accompanying Exhibits and related Term Sheets. This ~~Business~~Coaching Data authorization is intended to constitute Customer's written consent under the applicable HIPAA Business Associate Agreement or similar document between Customer and ABDC and/or Program Partners for the exchange of ~~Business~~Coaching Data on Customer's behalf. This ~~Business~~Coaching Data authorization is in addition to and supplements Customer's Data Authorization Consent for Pharmacy Data previously executed and provided to ABDC. Customer acknowledges that in conformance with the Program Documentation, ABDC associates with a need to know may access and use ~~Business~~Coaching Data, including protected health information, to assist Customer in its treatment, payment, and healthcare operations activities. This authorization will automatically terminate thirty (30) days after Customer ceases its participation in the Available Programs.

Acknowledgment of Terms
Customer represents and warrants that: (i) it has executed or will execute a Master Program Agreement or GNP Premier Agreement (~~collectively "**MPA**~~as applicable, the "Agreement") with ABDC~~.~~; (ii) it has the full power and authority to enter into

this Enrollment Form; (ii) the individual executing this Enrollment Form on Customer's behalf is fully authorized and empowered to legally bind Customer hereto; (iii) it has obtained any and all consents, approvals, and/or authorizations necessary to permit ABDC's and the Program Partners' receipt, use, disclosure, maintenance, and exchanging of Pharmacy Data as contemplated herein and the Agreement, including, without limitation, all necessary authorizations and/or consents from its customers and patients, which such activities are necessary to facilitate ABDC's provision of services to Customer pursuant to the Agreement; and (iv) Customer's entering into this Enrollment Form does not conflict with any contract or agreement to which Customer is a party. If Customer has not yet executed an ~~MPA~~Agreement, this ~~Available Program~~ Enrollment Form ~~& Data Authorization~~ and related Term Sheets will become effective on the effective date of the ~~MPA. Customer represents and warrants that it has the legal authority to enter into the MPA, all related Term Sheets, and this Available Program Enrollment Form & Data Authorization.~~Agreement. This ~~Available Program~~ Enrollment Form ~~& Data Authorization are~~is incorporated ~~by reference with~~into, and ~~into~~made a part of, the ~~MPA~~Agreement and ~~Term Sheets and are~~is binding upon the parties. Capitalized terms used but not separately defined herein shall have the same meaning as provided in the Agreement.

PHARMACY

NCPDP ID: _____

D/B/A: _____

Address: _____

_____

_____

Customer

By: _____

Name: _____

Title: _____

Date Signed: _____

❖❖❖

Fax completed form to 877-687-8699
or, email to
or, mail to AmerisourceBergen Drug Corporation · 1 West First Avenue, Conshohocken, PA 19428

Elevate Provider Network℠
Term Sheet

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Certain capitalized words applicable to the Elevate Network (as defined below) are defined at the end of this Term Sheet. Capitalized words not herein defined have the meaning set forth in the Master Program Agreement and Exhibits thereto.

1. Program Description

a) Negotiated Payor Contracts and Central Pay. On behalf of Network Providers that join the Elevate Provider Network ("Elevate Network"), ABDC negotiates and enters into written agreements with Payors ("Payor Contracts"). By entering into the Elevate Network as a Network Provider, Customer hereby authorizes ABDC to negotiate and enter into Payor Contracts with Payors on behalf of Network Provider ~~and to enter into such Payor Contracts~~, and Network Provider agrees to be bound by such Payor Contracts. Payor Contracts encompass a variety of areas, including, but not limited to, pharmaceutical-product and/or clinical service reimbursement rates that may be tied to an individual Network Provider, one (1) or more pharmacists affiliated with and/or performing on behalf of a Network Provider, or Elevate Network-wide aggregate performance metrics (such as STAR quality measures) or financial metrics (such as network-wide aggregate brand or generic effective rates~~)~~), for Network Providers to provide Covered Services to Members. Most Payors pay Network Providers for Covered Services through Central Pay.

b) Elevate Advanced Features. Network Providers will be concurrently enrolled in the Elevate Advanced Features (Term Sheet 2) which requires Network Providers to utilize Claims switch services provided by Change Healthcare (a part of Optum® and hereinafter, "Change Healthcare") or other Claims switch service provider approved by ABDC in writing. Network Providers may request to opt out of Elevate Advanced Features, which Elevate Network may, in its sole discretion, allow without reduction in the monthly fee. Please see the Term Sheets specific to the Elevate Advanced Features for program descriptions and terms and conditions.

2. Pricing and Availability

Participation fees respecting this Available Program vary dependent upon the nature of Customer's Master Program Agreement with ABDC, as elected by Customer and/or otherwise confirmed by ABDC in writing, as follows:

Standard

Premier: Required; no additional fee
GNP: $~~189~~249/month (incl. Elevate Advanced Features)
Other: $~~189~~249/month (incl. Elevate Advanced Features)

Enhanced

GNP: $399/month (incl. Elevate Advanced Features)
Other: $399/month (incl. Elevate Advanced Features)

Enhanced Plus

GNP: $575/month (incl. Elevate Advanced Features)
Other: $575/month (incl. Elevate Advanced Features)

**Additional fees may apply for ~~stores processing~~Network Providers that: (i) process more than 10,000 Claims in a month~~.~~ ~~Additional data fees may apply for stores that~~; (ii) use alternative, approved switch service providers for Elevate Advanced Features~~.~~; and/or (iii) elect to receive optional and/or enhanced Elevate Advanced Features services (e.g., enhanced reporting, etc.).*

3. ABDC Responsibilities

a) Payor Contracts. ABDC enters into Payor Contracts on behalf of ~~the Elevate~~participating Network Providers for Payor Contract participation and arranges for payment of Claims through Central Pay. Payor Contracts, take effect for each applicable Network Provider as Payors recognize its participation. ABDC makes no representation or warranty, including any implied warranty, about Payors, financial viability of individual rates or networks, or applicability of any particular Payor Contract to any particular Network Provider, and ABDC assumes no fiscal responsibility for any Claims. ABDC is not a surety or guarantor for Claim payment; nor is ABDC a fiduciary beyond what has been expressly granted in Section 4 (a). In no event shall ABDC be obligated to pay Customer for any services rendered by each Network Provider if ABDC has not received monies from Payor with respect to the Network Provider that is sufficient to pay for such services.

b) Help Desk and Other Services. ABDC provides help desk service during normal business hours, publishes newsletters, provides certain other Claims-related assistance, and provides or makes available other offerings, which may be subject to additional terms and conditions, in connection with Network Providers' participation in the Elevate Network, including an online portal through which Network Providers may access certain information relating to Elevate Network participation.

c) Disputes. Nominal fees paid by Network Providers are for simplified access to Payor Contracts through the Elevate Network. Fees are not sufficient, nor does this Available Program have resources, to resolve reimbursement, payment, audit and other disputes arising among Customer, its Network Providers, Payors and/or others, including current or Former Participants and other network providers. Customer will comply with each Payor's respective dispute resolution processes, including Network Provider rights and obligations in connection therewith, as provided in the applicable Elevate Documents. As a courtesy, ABDC may assist with initial investigations of such disputes to clarify their nature and attempt prompt resolution. Customer authorizes ABDC to provide information related to such disputes to Payors, including invoices from ABDC's records and supporting

material provided by Customer, and to receive information and documents related to disputes from Payors.

d) Promote Elevate Network. ABDC promotes the Elevate Network to Payors, including reporting to Payors specific capabilities, services and accreditations of individual Network Providers.

e) Central Pay. ABDC makes EFT deposits to Customer's account(s) after ABDC matches payment received from a Payor on Customer's Network Provider(s)' behalf with corresponding electronic EOBs, less fees and any other charges, withholds, or offsets imposed under the Agreement. For Network Providers in good standing with ABDC and Payors, ABDC makes commercially reasonable efforts to wire bank instructions within one (1) business day after receiving funds and matching EOBs. Notwithstanding the foregoing, ABDC may reduce the frequency of payments made to Former Participants and/or Network Providers that are not in good standing with ABDC and/or Payors, including without limitation, using commercially reasonable efforts to wire bank instructions within one (1) week after receiving funds and matching EOBs.

f) Central Pay System. ABDC makes available a web-based portal with defined security protocols, for Customer to access, print and download EOBs, including Claim, payment and deposit detail for up to the prior thirty-six (36) months by Network Provider. Network Providers may also receive Claim reimbursement information via email~~, fax~~ or ~~mobile applications~~fax. Former Participants will lose access to Central Pay twelve (12) months after the last payment is received by a Payor.

g) Outside Reconciliation Vendors. As an alternative to the reconciliation services included under Elevate Advanced Features, ABDC collaborates with other pharmacy system and reconciliation service providers that meet ABDC's specifications ("Outside Reconciliation Vendors") and provides automated EOBs to Network Provider's Outside Reconciliation Vendor or for direct import into Network Provider's pharmacy system (not widely available). ABDC charges each Network Provider or its Outside Reconciliation Vendor ~~a $55.00 per month~~an additional monthly fee, which such fee can be confirmed by ABDC upon written request, to provide automated EOBs.

4. Customer Responsibilities

a) Grant Authorization to ABDC. By enrolling in this Available Program, Customer represents and warrants that it has: (i) executed a Master Program Agreement with ABDC; and (ii) the legal authority to enter into the Master Program Agreement and all related Term Sheets for each Network Provider. Customer hereby grants its authority to ABDC: (1) to serve as its contracting agent to negotiate and execute Payor Contracts on behalf of Network Provider(s) pursuant to which Network Provider(s) will be bound and comply with all such terms and conditions; (2) to collect and receive on Network Provider's behalf, accounts receivable generated by billings and Claims for reimbursement; and (3) to deposit into ABDC's Central Pay account any remuneration provided under or in connection with Payor Contracts on behalf of Network Provider(s).

b) Acceptable Star Ratings. Certain Payors may use aggregate performance network-wide Star ratings as determinants in reimbursement formulas. Network Provider(s) must use reasonable efforts to achieve and retain an average star rating of 3.0 or higher.

c) Licensing, Training & Elevate Documents. Each Network Provider will comply with the Elevate Documents and with this Term Sheet. Elevate Documents and updates may be published on one or more web-based portals maintained by ABDC or Payors. Upon request, and upon Network Provider's execution of a non-disclosure form, ABDC will provide current copies of Elevate Documents applicable to Network Provider's participation hereunder, including applicable Payor Contracts, or direct Network Provider to online resources. As part of its applicable obligations required to remain in good standing: (i) each Network Provider, its pharmacists, and other employees will maintain and keep current all applicable licenses, authorizations, approvals, permits, ~~and~~ certifications, and training necessary to provide Covered Services, including, without limitation, unrestricted licensure, accreditation, and/or certification from the U.S. Drug Enforcement Agency, each applicable board of pharmacy, and as otherwise required under Payor Contracts; (ii) Customer will: (1) maintain and timely update any and all such information in Network Provider's NCPDP profile; and (2) timely provide evidence of any of the foregoing to ABDC or Payors upon request; and (iii) respecting specialized Covered Services, such as long-term care, compounding, home infusion, mail order, specialty drug or immunization, and/or other clinical services permitted by law, each Network Provider and its employees, including, without limitation, any pharmacist(s) affiliated with and/or performing on behalf of Network Provider, must: (1) meet applicable licensing, accreditation, certification, training and other requirements; and (2) otherwise comply with applicable laws and obligations under the Elevate Documents.

d) Enrollment. Where Payor Contract enrollment requires additional materials to be submitted, Customer will promptly and accurately complete enrollment materials, initiate access for each authorized user, prevent disclosure or misuse of passwords, and promptly validate receipt of test deposits to its account for each Network Provider. Customer will promptly update such information on request and upon changes in Network Provider's ownership, licensing, disciplinary history, banking, payment instructions, or other information provided in enrollment materials and updates and otherwise comply with Program Guides. Not all Payors use Central Pay, and some require separate enrollment materials.

e) Outside Reconciliation Services. By directing ABDC to provide EOBs to its Outside Reconciliation Vendor, Customer authorizes ABDC as its business associate to provide protected health information and other Pharmacy Data and warrants to ABDC that it has all required agreements in effect for each Network Provider, including business associate agreements. Customer will promptly notify ABDC if any such agreement terminates so ABDC discontinues disclosure. Except as otherwise agreed upon by and between Customer and ABDC in writing, Outside Reconciliation Vendors ~~each determine~~are solely responsible for determining applicable pricing and

features, which Customer must determine are compatible with its systems.

f) Dispute Liability. While ABDC may provide courtesy assistance with disputes under Paragraph 3(c), each Network Provider is solely responsible for its relationships with Payors, including responding to, defending and resolving any and all Payor disputes, whether relating to matters respecting payment or otherwise, including paying applicable legal expenses and any amounts owed as a result of a dispute. Customer must comply with applicable notice requirements in connection with Payor disputes as provided in Section 8 herein. Any such dispute notice shall include, without limitation, a description of the nature and extent of the dispute.

g) Central Payments and Offsets. As part of its applicable obligations required to remain in good standing, Customer agrees to not incur a negative balance in its Central Pay account with Elevate Network. Customer acknowledges and agrees that ABDC may withhold, delay, or offset Central Pay amounts owed to Network Provider(s) in the event of an audit, investigation, network and individual obligations related to Payor Contracts, or other disputed amount between the Payor and a Network Provider. Customer agrees to reimburse ABDC in full and to indemnify ABDC for any offset taken by a Payor against a Network Provider. In addition, ABDC may, in advance, reduce, delay, or offset any payments to a Network Provider, including without limitation payments from another Payor, if in ABDC's reasonable determination an anticipated offset by a Payor may result in a negative balance for such Network Provider. In such a case, Customer expressly authorizes ABDC, at its discretion and based on its best judgement and information, to withhold an amount of funds which may be at issue between Network Provider and Payor. If Customer incurs a negative balance under Central Pay, ABDC may, at its option: (i) withhold funds from future payments until such time as such Network Provider's balance under Central Pay is zero dollars or above, (ii) debit Network Provider's bank account for the negative amount, or (iii) invoice Network Provider for such negative amount, which sum will be due and payable with five (5) days following Network Provider's receipt of invoice. Finally, without limiting ABDC's other legal rights, ABDC and its affiliates may withhold, delay or setoff Central Pay amounts owed to Network Provider, or take any other lawful actions, to: (x) recover any amount (including, but not limited to, principal, interest, costs, and reasonable attorneys' fees) owed by Customer to ABDC or its affiliates under this or any other ~~agreements between ABDC or its affiliates and Customer~~agreement, including but not limited to a ~~Customer's~~ distribution agreement ~~or~~, credit agreement ~~with ABDC or its affiliates or its affiliates~~, and/or any other master program agreement between Customer and ABDC's affiliates; and/or (y) satisfy, or remit payment towards the satisfaction of, any amount (including, but not limited to, principal, interest, costs, and reasonable attorneys' fees) owed by Customer to a third party creditor (e.g., Internal Revenue Service, etc.) pursuant to which ABDC becomes legally obligated to remit such Central Pay amounts otherwise owed to Network Provider. Any forbearance or delay in the exercise of any right or remedy hereunder or as otherwise afforded by law will not be a waiver of or preclude the exercise of any such right or remedy.

h) Network-wide Aggregate Performance Payor Contracts. Customer acknowledges that reimbursement rates can be tied to individual and network-wide performance or financial metrics (such as brand and/or generic effective rates) that may result in periodic or post-year-end recoupments from Network Provider(s) to meet individual or aggregate network-wide financial obligations under certain Payor Contracts. Accordingly, if a Network Provider's performance under a network-wide Payor Contract has a materially adverse impact on the Elevate Network as a whole, Elevate may either initiate holds as outlined above to mitigate the adverse impact or seek to de-affiliate Network Provider from the Payor Contract or the Elevate Network as a whole. Network Providers that terminate prior to the end of the calendar year will be reconciled by ABDC pursuant to Section 10(c) below.

i) Elevate Network Goodwill. Because operation and appearance of each Network Provider reflects on other network providers and the Elevate Network, Customer will use its best efforts to operate each Network Provider with diligence and vigor, maintain the highest possible ethics, and maintain its facilities and personnel in a manner that is a credit to the community and reflects the high standards and quality of the Elevate Network, including, without limitation, interacting with and treating all customers and ABDC personnel in a respectful and professional manner.

j) Exclusivity; Payor Contracts. By enrolling as a Network Provider, Customer authorizes ABDC to be Network Provider(s)'s exclusive contracting entity for Payor Contracts and Central Pay for such Network Provider. A Network Provider may contract directly with certain Payors but ABDC may terminate this Term Sheet if an enrolled Network Provider designates another pharmacy services administration organization (PSAO) or other party as a contracting entity for Payor Contracts and Central Pay without ABDC's prior written approval, with termination effective at the earlier of the date such designation is effective or thirty (30) days after ABDC's termination notice under this Paragraph 4(j).

k) Covered Services. Network Provider must provide Covered Services to all Members in accordance with the Elevate Documents and applicable laws.

l) Accept Payor Reimbursements. Customer authorizes ABDC to receive payment and EOBs from Payors for each Network Provider and make deposits to Customer's account(s) and initiate adjustments for entries as determined by ABDC or a Payor through a Network Provider audit or for obligations related to Payor Contracts, as determined by ABDC or a Payor in accordance with a Payor Contract. Customer will accept negotiated compensation, inclusive of copayments and charges, as full payment for Network Provider providing Covered Services.

m) Protect Confidential Information. Customer must protect all Confidential Information of ABDC and Payors, including methods of doing business, any information related to performance under Elevate Documents, and any lists of customers, clients, Payors, claim processors or other network providers, as required pursuant to Paragraph 7 of this Term Sheet, Paragraph 4.0 of Exhibit C (Provisions) and the Elevate Documents, and Customer may only use and disclose such Confidential Information as expressly permitted by the Elevate

Documents. Except as expressly permitted by the Elevate Documents, Customer may not use or disclose any such Confidential Information for its own benefit, for the benefit of any other party, or for any other reason without ABDC's and/or Payors' prior written consent, as applicable.

n) Insurance Coverage. Customer will for each Network Provider maintain and provide evidence of commercial general liability insurance and professional liability insurance (including druggist's liability coverage) with limits of at least $1,000,000 per incident and $3,000,000 annual aggregate (or such higher limits as ABDC may reasonably require) for claims arising out of bodily injury, property damage, personal injury, advertising injury, and Covered Services, as well as such other insurance as required by Payors or applicable law. Such insurance will be underwritten on an "occurrence" basis covering activities, acts and omissions of Network Provider(s) and its personnel and will include ABDC and its corporate affiliates as additional insured. During the Term, such insurance will be evidenced by a certificate of insurance that provides ABDC with at least thirty (30) days' written notice of cancellation, non-renewal or material change. Customer will: (i) provide ABDC, or any Payor upon such Payor's request, with a copy(ies) of such policy(ies) and each renewal prior to expiration; and (ii) as part of its applicable obligations required to maintain in good standing, maintain and timely update such information in Network Provider's NCPDP profile. Any pharmacist or other healthcare professional providing Covered Services who is not separately insured by policies with similar coverage and limits must be covered on Network Provider's insurance. Lower limits in any Payor Contract or related material do not override coverage limits in this Paragraph 4(n).

o) EEO Requirements. Customer warrants that it's Network Provider(s) does not and will not discriminate against any employee or applicant for employment because of race, creed, color, national origin, religion, gender, sexual orientation or preference, veteran status, handicap or as otherwise prohibited by law and will meet affirmative action obligations imposed by law.

p) Compliance with Distribution Agreement. Participation as a Network Provider is intended for Customers operating under a distribution agreement with ABDC naming ABDC as Network Provider's primary vendor of pharmaceutical products. Customer must be in compliance with the terms of its distribution agreement or Network Provider(s)'s participation in Elevate Network may be revoked.

q) Maintenance of NCPDP Profile~~.~~; NPI Registry. As part of its applicable obligations required to remain in good standing, Customer will maintain and timely update: (i) each Network Provider's National Council for Prescription Drug Programs ("NCPDP") Service Provider Profile, Parts I and Parts II (as applicable per NCPDP~~),~~); and (ii) the national provider identifier ("NPI") and corresponding National Plan and Provider Enumeration System ("NPPES") registry information associated with each pharmacist that is affiliated with Network Provider and provides Covered Services comprising clinical services in connection with applicable Payor Contract participation, in each case as required by applicable law, ABDC, Payors, and the Elevate Documents.

5. Changes to Elevate Documents

a) Terms. Customer's Network Provider(s) will comply with Elevate Documents which ABDC or a Payor may, as applicable, amend as it determines is appropriate in its sole discretion. As applicable, ABDC or the Payor will give Customer notice of material changes and an opportunity to accept such new provisions or to withdraw from the affected Elevate Document (to the extent permitted) or the Elevate Network. Elevate Documents and this Term Sheet are the entire agreement related to Customer's and its Network Provider's participation in the Elevate Network.

b) Conflicts, Superiority. For any conflict between this Term Sheet and any Elevate Document, the order of precedence (with the first being controlling) is: (i) the Elevate Documents comprising Payor materials; (ii) all other Elevate Documents; and (iii) this Term Sheet, unless specifically stated otherwise that this Term Sheet supersedes such conflict.

6. Payor Contract Obligations. Customer's obligations respecting Payor Contracts include but are not limited to the following:

a) Maintain Records. Customer will maintain for each Network Provider all records and other information required by law and the Elevate Documents. Without limiting the preceding sentence, Customer will maintain for each Network Provider adequate records and other information related to Covered Services provided to Members for seven (7) years or any longer period required by law or Elevate Documents.

b) Confidentiality. Customer and ABDC will each: (i) safeguard confidentiality of Member health records as required by the Agreement, Payor Contracts, and applicable law; and (ii) ensure that any subcontractors do so as required. Customer will ensure that each Network Provider complies with all applicable confidentiality requirements. As required, ABDC and Customer entered into a HIPAA Business Associate Agreement (Exhibit B or as otherwise agreed).

c) Access to Records. To the extent permitted by the respective Payor Contract or other Elevate Document, Payors may examine and audit Network Provider's records and other information that relates to Network Provider's participation in the Elevate Network.

d) General Compliance. Without in any way limiting Customer's obligations as otherwise provided herein, Customer shall comply with any and all Payor Contract requirements, including, without limitation, requirements respecting insurance and credentialing as provided in this Term Sheet and the Elevate Documents.

7. Use of Information

a) Ownership of Confidential Information. As among Customer, ABDC and Payors, each party is the sole owner of its Confidential Information.

b) Use of Certain Data. Payors provide performance data for Covered Services, for both the Elevate Network in its entirety and individual Network Providers, to ABDC. Such information is Confidential Information that may be used and disclosed by ABDC if it safeguards confidentiality of Member health records.

c) Marketing and Benefit Information. ABDC and Payors may use, disclose, and reproduce each Network Provider's name, address, trademarks, logos, and other contact information in communications related to available benefits and information about Covered Services for Members. Customer may only refer to or list ABDC, Elevate Network, or Payors in advertising, media announcements or promotional or other material in compliance with this Term Sheet and Elevate Documents. Customer will promptly discontinue any such use if ABDC notifies Customer it is disapproved.

d) Pharmacy Data Authorization. Without in any way limiting, and in accordance with, Exhibit A of the Agreement: (i) Customer understands, acknowledges, and agrees that: (1) ABDC may receive and retain Pharmacy Data (including, without limitation, Claims and payment detail received from Payors) in the InSite pharmacy performance management system from ABDC for all Network Providers; and (2) de-identified data may be disclosed to third parties if Network Provider(s) is unidentifiable as its source; and (ii) Customer authorizes: (1) ABDC to receive Pharmacy Data from Payors and other Program Partners for each Network Provider, and to use, disclose, and exchange such Pharmacy Data to and among Payors and other Program Partners in connection with Payor Contract activities; (2) access to and use of Pharmacy Data by ABDC and its managed care specialists in order to assist Customer, file a MAC price appeal with a Payor, measure Payor and Network Provider compliance and performance, improve negotiations and assist and promote Network Providers with Payors; (3) ABDC, as its business associate, to combine Pharmacy Data with similar data received as a business associate of multiple covered entities, and to use such cumulative data to prepare reports, analyses and compilations relating to business performance and market trends to benchmark Customer and other covered entities against peer groups to improve all parties' overall efficiency and performance of healthcare operations.

e) EQUIPP® Data Authorization. Customer authorizes ABDC to receive EQUIPP performance data from Pharmacy Quality Solutions, Inc. and to share the findings with members of ABDC's sales force and Customer's buying group (if any).

8. General

a) Independent Parties. Pursuant to Paragraph 8.5 of Exhibit C (Provisions), Network Provider, ABDC and each Payor are independent contractors. Customer is solely responsible for operating and maintaining its Network Provider's facilities, equipment and software and for providing Covered Services to Members. All medical, clinical and related decisions with respect to Covered Services are made solely by Customer and its personnel and not by ABDC or others. The relationship between a Member and Network Provider is subject to all requirements and privileges of the pharmacist-patient relationship.

b) Adverse Actions. In addition to fraud, waste and abuse or other periodic compliance attestations and any reporting obligations under Elevate Documents, Customer must immediately notify ABDC, via email at Elevate_audits@amerisourcebergen.com, if: (i) Customer or Network Provider initiates, anticipates, or otherwise becomes subject to an appeal, dispute, or other legal process, including, without limitation, state or federal governmental investigation, arbitration, or other legal action, involving a Payor or otherwise relating to participation in an Available Program, or otherwise is or becomes obligated to produce documents, testimony, and/or information in connection therewith, whether pursuant to a subpoena, state or federal governmental demand (e.g., civil investigative demand, etc.), or otherwise; (ii) its Network Provider's pharmacy license is suspended, challenged, or otherwise threatened; (iii) any action or restriction, such as actions or restrictions implemented by governmental agencies, bodies or other instrumentalities (e.g., law enforcement seizure, etc.), may affect Network Provider(s)' ability to meet its obligations, such as those required by a Payor, licensing agency (board of pharmacy, DEA, etc.), or other regulatory body; (iv) it or any owner, Network Provider, or employee is or becomes an excluded entity or individual on an HHS-OIG or comparable federal or state list(s) for Medicare, Medicaid, General Services Administration (GSA) System for Award Management (SAM) and other healthcare services; or (v) any other occurrence may adversely impact Network Provider's participation under a Payor Contract or ability to perform its obligations and/or otherwise comply with the Elevate Documents (collectively, "**Adverse Actions**"). Without limiting the foregoing, Customer must also comply with any separate reporting obligations required of Network Providers by Payors with respect to Adverse Actions or other events as provided in the Elevate Documents.

9. Termination

a) Termination. In addition to termination without cause under the Agreement, the parties may terminate for cause pursuant to Paragraph 4(h) of this Term Sheet or Paragraph 5.0 of Exhibit C (Provisions). Additionally, ABDC may terminate for cause upon written notice to Customer if Customer or its Network Provider(s) fails to perform, in any material respect, its obligations under Elevate Documents and its failure is not cured within 30 days (or any shorter cure period in a Payor Contract or related material). Such notice will describe the nature of the failure and action required to cure the default, if a cure is possible. ABDC may immediately and in its sole discretion terminate a Payor Contract with respect to a Network Provider upon notice to Network Provider(s) ("De-Affiliation"). Upon Network Provider's De-Affiliation from a particular Payor Contract, such Network Provider will no longer receive Central Payments from that Payor and will need to contract directly with such Payor to remain in the Payor's network.

b) Immediate Termination. Notwithstanding anything to the contrary contained herein, ABDC or a Payor may terminate an Elevate Document immediately with respect to a Network Provider, and ABDC may terminate this Term Sheet immediately, without advanced notice, if Network Provider: (i) provides a product or service to any Member that is contaminated, adulterated or does not otherwise meet legal or professional standards; (ii) violates any federal, state or local law applicable to compounding, sale, dispensing, storage, packaging or use of products or services to Members; (iii) cannot provide Covered Services due to an Adverse Action or

otherwise; (iv) commits an act or omission that gives a Payor the right to immediately terminate Network Provider from a Payor Contract as determined by the Elevate Documents; or (v) incurs a negative balance in its Central Pay account with Elevate Network.

c) Effect. Termination of this Term Sheet in its entirety by ABDC will terminate Network Provider as to all Payor Contracts. Termination by ABDC or a Payor of one or more Network Providers will not cause termination of other Network Providers. Termination by one Payor of a Network Provider will not result in termination of other Payors as to that Network Provider. Termination of this Term Sheet or a Payor Contract with respect to either a Network Provider or a Former Participant for any reason shall not affect the rights and obligations of the Payor, Network Provider, and/or Former Participant arising out of any transactions occurring prior to the effective date of such termination. In the event a Network Provider and/or Former Participant(s) has incurred financial obligations to a Payor under a Payor Contract ~~from the Elevate,~~ such Network~~, such~~ Provider and/or Former Participant acknowledges and agrees that such applicable Payor is permitted to deduct such financial obligations from ~~Payors'~~its then current financial obligations to such Former Participant or Network Provider.

10. Termination Obligations

a) Withholding for Payor Obligations. Upon notice of termination to a Network Provider of this Term Sheet for any reason, ABDC will withhold: (i) a security deposit of $10,000 or 10% of such Network Provider's prior 12-month average deposits, whichever is greater ("Security Deposit"), to cover typical post-termination Payor adjustments and obligations; and (ii) any amounts necessary to satisfy Former Participant's reasonably anticipated or then outstanding liabilities to ABDC or a Payor under Paragraphs 4(g), (h) and (l) (e.g., audit, Claim reversals, BER, GER, and/or DIR, etc.) based on best available data.

b) Post-Termination Deposits and Security Deposits.

Notwithstanding Paragraph 5.2 of Exhibit C (Provisions), ABDC will make EFT deposits under Paragraph 3(e) to Former Participant to extent that the net balance exceeds its Security Deposit and any amounts withheld under Paragraphs 4(g), (h), (l), and 10(a)(2). ABDC may charge Former Participant a nominal processing fee for each deposit after termination.

Subject to reduction or delay under this Paragraph 10(b) or Paragraphs 4(g), (h), and (l), ABDC will pay Former Participant any remaining Security Deposit once there has been no account activity for ~~180~~120 days, and any outstanding obligations have been satisfied, or invoice Former Participant any negative amount, which Former Participant shall promptly pay. Any new Payor activity post termination will restart the ~~180~~120-day time period. By way of example, if there is Payor activity at day ~~179~~119 following Former Participant's termination from the Elevate Network, the ~~180~~120-day clock will begin again, and will continue to be reset each time there is new Payor activity. Notwithstanding anything herein to the contrary, in ABDC's discretion, at the end of the initial ~~180~~120 days, ABDC may evaluate the account's activity and reduce some or all of Former Participant's Security Deposit.

c) Reconciliation of Aggregate Network-Wide Performance Payor Contracts. The amount owed by Former Participant shall be determined by ABDC based on data provided to ABDC by the applicable Payor(s). ABDC's resulting calculation shall constitute the final allocation of financial liabilities owed by such Former Participant to a Payor under such Payor Contract for the applicable time period.

ABDC has the discretion to initiate a final allocation of all Former Participant's liabilities owed to a Payor under an aggregate network-wide performance Payor Contract.

The financial liabilities owed by a Former Participant to a Payor may be recouped by ABDC through: (i) withholding funds under Section 4(g) or Section 10; (ii) invoicing a Former Participant; and/or (iii) permitting the direct recoupment by a Payor from the Former Participant's then current payments.

Upon ABDC's final allocation to a Former Participant, in the event that any previously withheld funds under Section 10(a)(ii) exceed the amount of ABDC's final allocation of financial liabilities and all other liabilities owed, ABDC will release any excess funds to Former Participant.

Remainder of page left intentionally blank

11. Definitions

a) **Central Pay** is the ~~central~~centralized payment system implemented by Elevate Network to receive, on behalf of Network Providers, funds from or on behalf of Payors.

b) **Covered Service** is a Network Provider's (i) dispensing of a covered drug or device to a Member under a Payor Contract, pursuant to a prescription when required by law; and/or (ii) providing of such other covered services and/or benefits under a Payor Contract (e.g., clinical services, etc.) in accordance with applicable law, in each case pursuant to Elevate Documents and for which Customer accepts Payor's compensation and any ~~copayment~~cost share amount as full payment.

c) **Claim** is a Network Provider's claim to be paid for providing a Covered Service to a Member.

d) **Elevate Documents** means the Master Program Agreement and related Exhibits, and Program Guides, Payor Contracts and related material, including Payors' provider manuals and Provider Plan Specifications.

e) **EOBs** mean explanation of benefits/remittance advice, 835 file or other electronic remittance advice.

f) **Former Participant** is a former Network Provider of the Elevate Network.

g) **Member** is an eligible person covered by Provider Plan Specifications, including primary beneficiaries and, if permitted, their eligible and enrolled dependents.

h) **Network Provider** means, as applicable: (i) Customer's Pharmacy(ies) and other dispensing site(s), as identified by NCPDP number~~.~~; and/or (ii) those pharmacist(s), as identified by NPI number, affiliated with Customer's Pharmacy(ies) that provide(s) Covered Services comprising reimbursable clinical services in connection with participation in applicable Payor Contracts.

i) **Payor** is an entity that has entered or will enter into a Payor Contract with ABDC in connection with applicable Covered Services to be provided by participating Network Providers thereunder, including: (i) a pharmacy benefit manager, health plan, or other third party that sponsors or administers prescription drug programs ~~or~~, health benefit plans, clinical services plans or programs, and/or is primarily responsible for processing and paying Claims; (ii) a prescription drug discount company; and/or (iii) a workers' compensation processing company. From time to time under one or more Elevate Document, ABDC may also be a Payor that contracts with Network Providers as part of providing its pharmacy benefit plan administration services.

j) **Provider Plan Specifications** are written descriptions of a Payor's pharmacy benefit plan describing Covered Services, coverage exclusions, service limits and other requirements. ABDC or a Payor may add new Provider Plan Specifications or amend existing ones on 30 calendar days' notice to Customer or such other period specified in a Payor Contract.

❖❖❖

Elevate Advanced Features Term Sheet

1. Program Description

Elevate Advanced Features is a suite of services designed to assist Customer with its healthcare operations including treatment, payment, and healthcare operations activities.

In order for ABDC and its Program Partners (as defined below) to provide Customer with the services under this Term Sheet, Customer must authorize ABDC to receive Customer's Pharmacy Data directly from Customer or indirectly from third parties supporting or participating in the Available Programs, including, without limitation, Customer's designated pharmacy system vendor, Customer's designated point-of-sale system vendor, Customer's designated reconciliation service provider, Change Healthcare (a part of Optum®, "Change Healthcare"), or other claims switching services provider approved by ABDC in writing, Payors, IntrinsiQ Specialty Solutions, Inc., EnlivenHealth ~~(formerly known as FDS AMPLICARE),~~, IQVIA, InSite, Retail Insights and Outcomes Operating, Inc. (formerly known as Prescribe Wellness, "Outcomes") or other patient services provider approved by ABDC in writing (collectively, "**Program Partners**"). ABDC reserves the right to change Program Partners at any time.

2. Pricing

Premier: Included; no additional fee.
GNP: $~~189~~249/month or included under Elevate Provider Network.
Other: $~~189~~ 249/month or included under Elevate Provider Network.

Additional ~~data~~ fees may apply for ~~stores~~Network Providers that: (i) process more than 10,000 claims in a month; (ii) use alternative, approved switch service providers for Elevate Advanced Features~~.~~; and/or (iii) elect to receive optional and/or enhanced Elevate Advanced Features services (e.g., enhanced reporting, etc.).

3. Program Prerequisites

a) Claims Switching. ABDC's current Program Partner for claims switching services is Change Healthcare. ~~ABDC reserves the right to change Program Partners at any time.~~ Unless otherwise approved in advance and in writing by ABDC, Customer's Network Provider(s) must utilize Change Healthcare as its claims switching services provider and is responsible for claim switching service fees from Change Healthcare or other approved claim switching services provider (or indirectly through its participating system vendor). ~~Claim switching service fees are not included as a part of this Available Program; provided, however, that~~Notwithstanding anything to the ~~extent that~~contrary contained herein, if ABDC ~~changes its fee structure, ABDC will provide Customer 60 days' prior notice. For the avoidance of doubt,~~approves Customer's ~~Network Provider(s) may only utilize~~use of an alternative claims switching services provider ~~upon obtaining~~, such approved alternative vendor shall constitute ABDC's ~~prior approval~~respective Program Partner for the purposes of Customer's provision of Pharmacy Data and participation in ~~writing~~applicable Available Programs. Claim switching service fees are not included as a part of this Available Program.

b) System Vendor Collaboration. Customer's Network Provider(s) designated pharmacy system vendor and designated point-of-sale system vendor must be participating system vendors with ABDC and must collaborate with ABDC and ABDC's Program Partners.

c) Customer System Configuration. Customer must cooperate with its participating system vendor and ABDC's Program Partners to initiate and maintain the configuration changes necessary to meet applicable Available Program requirements.

d) HIPAA Compliance. As required, ABDC and Customer have entered into a HIPAA Business Associate Agreement (Exhibit B or as otherwise agreed).

4. Data Authorization

a) Authorization to Receive Pharmacy Data. Customer authorizes ABDC to receive Pharmacy Data provided by or on behalf of Customer either directly from Customer or indirectly from the Program Partners.

b) Authorization and Direction to Exchange Data. Customer authorizes and directs ABDC and the Program Partners to use and exchange Pharmacy Data on Customer's behalf to support Customer's participation in the Available Programs.

c) Written Consent. Enrolling in and activating the Available Program services constitutes Customer's written consent under the applicable HIPAA Business Associate Agreement or similar document between Customer, ABDC and/or Program Partners and participating system vendors for the use and exchange of Pharmacy Data on Customer's behalf.

d) Receipt and Use of Pharmacy Data. ABDC's receipt and use of Pharmacy Data is subject to the terms of the program documentation applicable to the specific Available Programs in which Customer enrolls (collectively, "**Program Documentation**"), such as the parties' Master Program Agreement and accompanying Data Protection Provisions, HIPAA Business Associate Agreement and Term Sheets. Customer acknowledges that in conformance with the Program Documentation, ABDC associates with a need to know may access and use Pharmacy Data including protected health information to assist Customer in its treatment, payment, and healthcare operations activities. This authorization will automatically terminate thirty (30) days after Customer's Network Provider(s) cease its participation in the Available Programs.

5. Advanced Features Description

a) PPE and Data Capture Services from Change Healthcare. ABDC works with Change Healthcare to enhance and extend its pre and post edit services with custom edits. Claim transactions are captured and furnished to ABDC. In addition, Change Healthcare makes portions of the solutions accessible through a web-based portal and offers optional services such as payer compliance re-billing and electronic medical claims billing for immunization services. See Term Sheet 2A.

b) Claim Reconciliation Services from EnlivenHealth. ABDC works with EnlivenHealth to provide claims reconciliation and related services through a web-based portal to track and resolve the accurate payment of third-party claims. See Term Sheet 2B.

c) ~~Outcomes One~~Outcomes Premium from Outcomes. ABDC works with Outcomes to provide an optional, web-based patient care services solution offering real-time analytics and ongoing management tools designed to assist subscribing pharmacies in improving, among other things, patient health outcomes, patient adherence, and clinical services. See Term Sheet 2C.

~~d)~~ EnlivenHealth Tools and ~~Amplicare Clinical~~Treat Solution

d) ~~from EnlivenHealth~~. ABDC works with EnlivenHealth to provide a web-based tool providing consolidated information relating to the practice of pharmacy and an optional, web-based patient care services solution designed to assist subscribing pharmacies in improving, among other things, patient health outcomes and offering new patient care services. See Term Sheet 2D.

e) InSite from ABDC. Pharmacy Data received by or on behalf of Customer is loaded to InSite from ABDC, a proprietary data analytics system used to measure and compare pharmacy performance. See Term Sheet 3.

All *other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Capitalized words not defined in this Term Sheet have the meaning defined in the Master Program Agreement or Elevate Provider Network Term Sheet, as applicable*.

❖❖❖

PPE Solutions
Term Sheet

1. Program Description

ABDC has been appointed as a reseller of pre and post-edit and other services of "**Change Healthcare**" and works with Change Healthcare (a part of Optum®), as a Program Partner, to enhance and extend these services through means such as the use of custom edits and data capture for participation in ABDC programs ("**PPE Solutions**"). ABDC and Change Healthcare provide the PPE Solutions to assist Customer with its healthcare operations including aiding in the accurate submission of claims for third party reimbursement. PPE Solutions consists of a series of edits providing financial, administrative and legal compliance reviews on prescription claims prior to being forwarded to, and another series of edits on responses received from, Payors. In addition to the integration of PPE Solutions with Customer's systems, Change Healthcare makes portions of the solutions accessible through web-based tools, including on-demand reports. Optional services of Change Healthcare offered through ABDC include payer compliance re-billing and electronic medical claims billing for immunization services, and are also subject to this Term Sheet.

2. Pricing

a) The fees for PPE Solutions are covered as part of the Advanced Features of the Elevate Provider Network (Term Sheet 2). Additional fees may apply for stores processing more than 10,000 claims in a month.

b) If Customer opts to participate in Change Healthcare's optional services respecting payer compliance re-billing, electronic medical claims billing for immunization services, or other services, additional fees will apply at the following negotiated pricing:

- Payer Compliance Claims: $1.00 per successful claim
- MedRx Immunization Claims: $1.00 per successful claim
- Other Services: Prevailing rate

3. Obligations of Customer

a) To participate in PPE Solutions, Customer must utilize Change Healthcare as its switch provider and participate in InSite from ABDC (Term Sheet 3).

b) Customer is responsible for claim switching service fees from Change Healthcare (or indirectly through its participating system vendor), which fees are not included as a part of this Program.

c) Customer must cooperate with its participating system vendor and Change Healthcare to initiate the configuration changes that participating system vendor has made to meet program requirements.

d) Customer appoints ABDC and Change Healthcare as its agents for providing and performing the PPE Solutions.

e) Customer will transmit all prescription claims and transactions in compliance with the procedures, data element standards, formats, codes, protocols, rules and edits set forth in the then relevant specifications agreed upon by Change Healthcare and ABDC for implementation of the PPE Solutions ("**PPE Specifications**").

f) Customer shall conform Customer's system to changes in the PPE Specifications resulting from any non-optional feature, enhancement, product or module furnished to Customer without charge by Change Healthcare, and Customer must comply with the applicable timeline designated by Change Healthcare (which cannot be less than ninety (90) days).

g) Customer will use the PPE Solutions in accordance with applicable laws and regulations, this Term Sheet, the PPE Specifications and other conditions established by ABDC and Change Healthcare from time to time as set forth in any manuals, materials, documents, or instructions furnished by ABDC or Change Healthcare to Customer ("**PPE Materials**").

h) Customer will ensure that all data supplied by Customer is correct, complete, and in the proper format as set forth in the PPE Specifications and PPE Materials. Customer is responsible for correcting any incorrect, incomplete or non-formatted data (or reimbursing Change Healthcare for its reasonable costs to do the same).

i) Customer will comply with ABDC's and Change Healthcare's procedures to secure any authorizations then required by applicable law or industry practice in connection with its transmission process, and to maintain prescription claims data transmitted through the PPE Solutions and afford access thereto in accordance with procedures then required by applicable law or industry practice.

j) Customer will permit ABDC and Change Healthcare to confirm Customer's compliance with Customer's obligations pursuant to this Term Sheet.

k) With regard to the use and/or disclosure of "Protected Health Information" (as defined in Title 45 parts 160 through 164 of the United States Code of Federal Regulations) by ABDC or Change Healthcare, Customer will: (i) obtain any consent, authorization or permission that may be required by the Privacy Regulation (as defined in Section 6 below) or any other applicable federal, state or local laws and/or regulations prior to furnishing ABDC or Change Healthcare the Protected Health Information pertaining to an individual; and (ii) not furnish to Change Healthcare any Protected Health Information that is subject to any arrangements permitted or required of Customer, including but not limited to, arrangements agreed to by Customer under 45 C.F.R. § 164.522 that may impact in any manner the use and/or disclosure of Protected Health Information by Change Healthcare under this Term Sheet.

l) Customer represents and warrants that its notice of privacy practices permits Customer to use and disclose Protected Health Information in the manner that ABDC and Change Healthcare are authorized to use and disclose Protected Health Information under this Term Sheet.

4. Obligations of Change Healthcare

a) Change Healthcare will provide the PPE Solutions as provided in the PPE Specifications and PPE Materials and in accordance with applicable laws and regulations.

b) Change Healthcare shall have no responsibility for determining the accuracy of any claim submitted, for settling disputed claims, for settling disputed payments, for settling disagreements or disputes between a third party payor or plan and Customer, for any liability for the acts of a third party payor or plan and/or Customer that violate the Social Security Act and related regulations and/or guidelines, or for any liability foreseeable or otherwise occurring beyond Change Healthcare's transmission of data.

c) Change Healthcare will:

(i) maintain and make available its internal practices, books and records relating to the use and/or disclosure of Protected Health Information to the Secretary of HHS for purposes of determining Customer's compliance with the Privacy Regulation;

(ii) document and, within thirty (30) days of receiving a written request from Customer, make available to Customer such information necessary for Customer to make an accounting of disclosures of an individual's Protected Health Information in accordance with 45 C.F.R. § 164.528 and, as of the date compliance is required by final regulations, 42 U.S.C. § 17935(c);

(iii) within fifteen (15) days of receiving a written request from Customer, make available Protected Health Information, in accordance with 45 C.F.R. § 164.524, as necessary for Customer to respond to individuals' requests for access to Protected Health Information about them, including, as of September 23, 2013, providing or sending a copy to a designated third party and providing or sending a copy in electronic format, to the extent that the Protected Health Information in Change Healthcare's possession constitutes a Designated Record Set; and

(vi) within thirty (30) days of receiving a written request from Customer, incorporate any amendments or corrections to the Protected Health Information in accordance with 45 C.F.R. § 164.526, to the extent that the Protected Health Information in Change Healthcare's possession constitutes a Designated Record Set.

d) Upon the termination of the PPE Solutions, Change Healthcare will return or destroy all Protected Health Information, including such information in the possession of Change Healthcare's subcontractors, if it is feasible to do so. If return or destruction of said Protected Health Information is not feasible, Change Healthcare will extend any and all protections, limitations and restrictions contained in this Term Sheet to Change Healthcare's use and/or disclosure of any Protected Health Information retained after the termination of the PPE Solutions, and limit any further uses and/or disclosures to the purposes that make the return or destruction of the Protected Health Information infeasible.

5. License

Subject to this Term Sheet, Change Healthcare hereby licenses to Customer a personal, nonexclusive, nontransferable end user license for so long as Customer utilizes the PPE Solutions in compliance with the PPE Specifications and PPE Materials.

6. Compliance

a) Change Healthcare, ABDC and Customer desire to meet their obligations, to the extent applicable, under the Standards for Privacy of Individually Identifiable Health Information (the "**Privacy Regulation**") and the Health Insurance Reform: Security Standards (the "**Security Regulation**") published by the U.S. Department of Health and Human Services ("**HHS**") at 45 C.F.R. parts 160 and 164 under the Health Insurance Portability and Accountability Act of 1996, as amended ("**HIPAA**").

b) Except as otherwise specified herein, Change Healthcare and ABDC may make any and all uses and disclosures of Protected Health Information created, maintained or transmitted from or on behalf of a Customer necessary to perform the PPE Solutions. Change Healthcare may perform Data Aggregation services for the Health Care Operations of Customer.

c) Unless otherwise limited herein, Change Healthcare and ABDC may: (i) consistent with 45 C.F.R. § 164.504(e)(4), use and disclose the Protected Health Information in its possession for its proper management and administration and to fulfill any present or future legal responsibilities of Change Healthcare or ABDC, provided that (a) the disclosures are required by law; or (b) any third party to which Change Healthcare or ABDC discloses Protected Health Information for those purposes provides reasonable assurances that the information will be held confidentially and used or further disclosed only as required by law or for the purpose for which it was disclosed to the third party, and the third party promptly will notify Change Healthcare and ABDC of any instances of which it becomes aware in which the confidentiality of the information has been breached; and (ii) de-identify any and all Protected Health Information in accordance with 45 C.F.R. § 164.514(b).

d) Customer acknowledges and agrees that de-identified information is not Protected Health Information and that each of Change Healthcare and ABDC on behalf of itself and/or its affiliates may use such de-identified information for any lawful purpose and consistent with this Term Sheet.

e) ABDC may amend this Term Sheet to give effect to any amendment to any provision of HIPAA, or its implementing regulations set forth at 45 C.F.R. parts 160 through 164, or other applicable law.

f) The parties' obligations under this Term Sheet will be construed in light of any interpretation and/or guidance on HIPAA, the Privacy Regulation and/or the Security Regulation issued by HHS from time to time. Regulatory citations are to the United States Code of Federal Regulations Title 45 parts 160 through 164, as interpreted and amended from time to time by HHS, for so long as such regulations are in effect. Unless otherwise specified, all capitalized terms not otherwise defined shall have the meaning established for purposes of Title 45

parts 160 through 164 of the United States Code of Federal Regulations, as amended from time to time.

7. Warranties and Limitations

a) ABDC, on behalf of Change Healthcare, warrants that the PPE Solutions will substantially conform in all material respects to its published specifications. Customer's sole remedy for breach of the foregoing warranty is for ABDC to use reasonable efforts to cause Change Healthcare to use commercially reasonable efforts to attempt to correct such flaw in a timely manner, to the extent that such flaw is due to the malfunction of Change Healthcare's computer, operating systems, programs, or to errors by Change Healthcare's employees. This warranty does not apply to any media or documentation which has been subjected to damage or abuse or to any claim which results, in whole or in part, from changes in the operating characteristics of computer hardware or computer operating systems made after the release of the applicable PPE Solutions, or which results from problems in the interaction of PPE Solutions with non-Change Healthcare software or equipment, or from a breach by Customer of any of its obligations hereunder.

b) EXCEPT FOR THE WARRANTIES CONTAINED IN THIS SECTION 7, THERE ARE NO OTHER WARRANTIES OF ANY KIND WITH RESPECT TO THE PPE SOLUTIONS, EXPRESSED OR IMPLIED OR STATUTORY, INCLUDING WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR A PARTICULAR PURPOSE, ALL OF WHICH ARE EXPRESSLY DISCLAIMED.

8. Exclusions of Consequential Damages and Limitations of Liability

a) NEITHER ABDC NOR CHANGE HEALTHCARE GUARANTEES THE PAYMENT OR THE TIMING OF PAYMENT OF ANY CLAIMS SUBMITTED THROUGH THE PPE SOLUTIONS. PAYMENT REMAINS THE RESPONSIBILITY OF THE PARTICULAR PAYOR OF HEALTH CARE SERVICES AND/OR SUPPLIER TO WHICH THE CUSTOMER IS SUBMITTING.

b) CUSTOMER ACKNOWLEDGES THAT THE PPE SOLUTIONS ARE PROVIDED SOLELY BY CHANGE HEALTHCARE.

c) NEITHER ABDC NOR CHANGE HEALTHCARE SHALL BE LIABLE FOR INCIDENTAL, CONSEQUENTIAL OR SPECIAL DAMAGES ARISING OUT OF THE PPE SOLUTIONS AND CUSTOMER'S USE OF THE PPE SOLUTIONS EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

d) ABDC'S AND CHANGE HEALTHCARE'S AGGREGATE LIABILITY TO CUSTOMER UNDER THIS TERM SHEET AND WITH RESPECT TO THE PPE SOLUTIONS (WHETHER UNDER CONTRACT, TORT, OR ANY OTHER THEORY OF LAW OR EQUITY) SHALL NOT EXCEED, UNDER ANY CIRCUMSTANCES, THE VALUE OF THE PPE SOLUTIONS GIVING RISE TO THE CLAIM. THE FOREGOING LIMITATION OF LIABILITY REPRESENTS THE ALLOCATION OF RISK OF FAILURE AMONG THE PARTIES AS REFLECTED IN THE PRICING HEREUNDER AND IS AN ESSENTIAL ELEMENT OF THE BASIS OF THE BARGAIN AMONG THE PARTIES.

e) NOTWITHSTANDING ANYTHING TO THE CONTRARY HEREIN, NOTHING IN THIS TERM SHEET OR THE MASTER PROGRAM AGREEMENT SHALL LIMIT CHANGE HEALTHCARE'S LIABILITY FOR (I) FRAUDULENT MISREPRESENTATION, (II) GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT, OR (III) ANY OTHER LIABILITY THAT CANNOT BE EXCLUDED OR LIMITED UNDER APPLICABLE LAW.

f) Any claim against ABDC or Change Healthcare by Customer must be asserted in writing within thirty (30) days after Change Healthcare should have transmitted information received from a Customer or the transmission of inaccurate information on which the claim is based, whichever is applicable. Customer hereby agrees to promptly supply to Change Healthcare documentation reasonably requested by Change Healthcare to support any claim of Customer.

g) No party will be responsible for delays or failures in performance resulting from acts or events beyond its control, including but not limited to, acts of nature, governmental actions, fire, labor difficulties or shortages, civil disturbances, transportation problems, interruptions of power, supply or communications or natural disasters, provided such party takes reasonable efforts to minimize the effect of such acts or events.

h) The provisions of this Section 8 shall control over any conflicting provision elsewhere in the Master Program Agreement.

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Capitalized words not defined in this Term Sheet have the meaning defined in the Master Program Agreement or Elevate Provider Network Term Sheet, as applicable.

❖❖❖

Claim Reconciliation Services
Term Sheet

1. Program Description

a) ABDC works with EnlivenHealth (formerly known as FDS AMPLICARE, Inc.) ("**EnlivenHealth**"), as a Program Partner, to provide claims reconciliation and related services through a web-based portal for review of claim reconciliation opportunities ("**Reconciliation Services**") for up to the prior 24 months by Network Provider. ABDC and EnlivenHealth provide this solution to aid Customer in its payment and healthcare operations activities including measuring the accuracy of third-party claim payments ("**Healthcare Operations**"). ABDC and EnlivenHealth make portions of the solutions accessible through web-based tools, including on-demand reports and training materials. Through the Elevate Help Desk, ABDC also provides email templates that enable a Pharmacy to dispute a claim that has not been paid or that has been underpaid and helpful hints based on the context of the activity of the user to help Customer identify possible reasons for disputed claims.

b) ABDC will furnish to EnlivenHealth the claims data Customer's Network Provider(s) submits through the Change Healthcare claims switch services, or other claims switching services provider approved by ABDC in writing, via Network Provider's system vendor ("**Claims Data**") to match Network Provider's claims to Network Provider's payment remittance data received by ABDC from various Payors ("**Remittance Data**").

c) An optional service offered by EnlivenHealth provides enhanced reconciliation services in which a EnlivenHealth analyst will conduct activities normally conducted by a Network Provider's staff including chasing certain underpaid claims on behalf of Customer ("**EnlivenHealth Concierge Solutions**"). EnlivenHealth Concierge Solutions are subject to the terms and conditions agreed upon directly between Customer and EnlivenHealth.

2. Pricing and Availability

Premier: Included; no additional fee
GNP: Included in Elevate Advanced Features
Elevate: Included in Elevate Advanced Features
Other: Not available

Additional fees may apply for ~~stores~~Network Providers processing more than 10,000 claims in a month.

a) Should Customer request reconciliation for previous Claims Data or Remittance Data dating prior to the beginning of the provision of Reconciliation Services to Customer, EnlivenHealth will attempt to retrieve such data and EnlivenHealth will invoice Customer directly for any costs associated with such retrieval.

b) If Customer opts to have its Network Provider(s) participate in EnlivenHealth Concierge Solutions, Customer will enter into an agreement directly with EnlivenHealth and be invoiced directly by EnlivenHealth for EnlivenHealth Concierge Solutions. The Fees for EnlivenHealth Concierge Solutions are in addition to the fees charged for Advanced Features, and ~~are available at the negotiated price of $199.00 per month per store~~can be confirmed by ABDC upon written request.

3. Customer Obligations

a) Unless specifically authorized otherwise, Network Provider(s) must participate in InSite from ABDC (Term Sheet 3) and PPE Solutions (Term Sheet 2A).

b) Customer authorizes and directs ABDC to furnish Claims Data and Remittance Data to EnlivenHealth for Network Provider(s) for the purpose of providing Reconciliation Services. Customer further authorizes ABDC to use its data, including Claims Data and Remittance Data and PHI, for program administration, including measuring Payor compliance across ABDC customers. Customer acknowledges and agrees that de-identified information is not PHI and that each of EnlivenHealth and ABDC on behalf of itself and/or its affiliates may use such de-identified information for any lawful purpose and consistent with the terms and conditions of this Term Sheet.

c) Customer represents and warrants that its notice of privacy practices permits Customer to use and disclose PHI in the manner that ABDC and EnlivenHealth are authorized to use and disclose PHI under this Term Sheet.

d) Customer will comply with ABDC's and EnlivenHealth's procedures to secure any authorizations then required by applicable law or industry practice in connection with its transmission process.

e) For claims submitted to Payors not contracted with Elevate, EnlivenHealth will obtain electronic remittance advices directly based on the Payor's ability and willingness to provide such remittance advices.

f) Customer acknowledges that EnlivenHealth will only be able to reconcile remittance advices received directly by the Customer if uploaded or keyed in manually by Customer to the EnlivenHealth system.

g) Customer will use the Reconciliation Services in accordance with applicable laws and regulations and the reasonable conditions, rules, and regulations established by ABDC and EnlivenHealth from time to time and as set forth in any manuals, materials, documents, or instructions furnished by ABDC or EnlivenHealth to Customer, provided the same are not in conflict with any provisions of the Master Program Agreement or this Term Sheet ("**Reconciliation Materials**").

h) Notwithstanding the provision of Reconciliation Services under this Term Sheet, Network Provider is ultimately responsible for submitting accurate claims to and receiving accurate reimbursement from Payors, and for responding to, defending and resolving such disputes (including legal expenses).

4. EnlivenHealth and ABDC Obligations

a) EnlivenHealth will provide the Reconciliation Services as provided in this Term Sheet and the Reconciliation Materials and in accordance with applicable laws and regulations.

b) EnlivenHealth will use due care in performing all Reconciliation Services and will use its best efforts to correct any errors to the extent that such errors are due to the malfunction of EnlivenHealth's systems or to errors by EnlivenHealth's

employees or agents. Corrections shall be limited to rerunning of jobs or recreation of data or program files.

c) EnlivenHealth will make webinars or similar training opportunities available to Customer on the use of Reconciliation Services.

d) If Network Provider participates in EnlivenHealth's commercial reconciliation offering prior to joining Elevate or signing up for Reconciliation Services, Customer authorizes ABDC and EnlivenHealth to terminate its then current agreement with EnlivenHealth and to enroll Network Provider in Reconciliation Services. EnlivenHealth will release Network Provider from any existing agreement.

e) ABDC will provide assistance with Reconciliation Services through its Elevate help desk, available during normal business hours.

5. License

Subject to this Term Sheet, EnlivenHealth hereby licenses to Customer a personal, nonexclusive, nontransferable end user license for each Network Provider for so long as such Network Provider utilizes the Reconciliation Services in compliance with the Reconciliation Materials.

6. Warranties and Limitations

a) ABDC, on behalf of EnlivenHealth, warrants that the Reconciliation Services will substantially conform in all material respects to its published specifications. Customer's sole remedy for breach of the foregoing warranty is for ABDC to use reasonable efforts to cause EnlivenHealth to use commercially reasonable efforts to attempt to correct such flaw in a timely manner, to the extent that such flaw is due to the malfunction of EnlivenHealth's computer, operating systems, programs, or to errors by EnlivenHealth's employees. This warranty does not apply to any media or documentation which has been subjected to damage or abuse or to any claim which results, in whole or in part, from changes in the operating characteristics of computer hardware or computer operating systems made after the release of the applicable Reconciliation Services, or which results from problems in the interaction of Reconciliation Services with non-EnlivenHealth software or equipment, or from a breach by Customer of any of its obligations hereunder.

b) EXCEPT FOR THE WARRANTIES CONTAINED IN THIS SECTION 6, THERE ARE NO OTHER WARRANTIES OF ANY KIND WITH RESPECT TO THE RECONCILIATION SERVICES, EXPRESSED OR IMPLIED OR STATUTORY, INCLUDING WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR A PARTICULAR PURPOSE, ALL OF WHICH ARE EXPRESSLY DISCLAIMED.

7. Exclusions of Consequential Damages and Limitations of Liability

a) ABDC and EnlivenHealth shall not be liable for any errors occurring as a result of failure by Customer to comply with this Term Sheet or the Reconciliation Materials.

b) EnlivenHealth and ABDC shall have no responsibility for determining the accuracy of any claim submitted, for settling disputed claims, for settling disputed payments, for settling disagreements or dispute between a Payor and Customer, for any liability for the acts of a Payor and/or Customer that violate the Social Security Act and related regulations and/or guidelines, or for any liability foreseeable or otherwise occurring beyond EnlivenHealth's transmission of data.

c) NEITHER ABDC NOR ENLIVENHEALTH GUARANTEES THE PAYMENT OR THE TIMING OF PAYMENT OF ANY CLAIMS SUBMITTED THROUGH THE RECONCILIATION SERVICES. PAYMENT REMAINS THE RESPONSIBILITY OF THE PARTICULAR PAYOR OF HEALTH CARE SERVICES AND/OR SUPPLIER TO WHICH THE CUSTOMER IS SUBMITTING.

d) CUSTOMER ACKNOWLEDGES THAT THE ENLIVENHEALTH CONCIERGE SOLUTIONS ARE PROVIDED SOLELY BY ENLIVENHEALTH.

e) NEITHER ABDC NOR ENLIVENHEALTH SHALL BE LIABLE FOR INCIDENTAL, CONSEQUENTIAL OR SPECIAL DAMAGES ARISING OUT OF THE RECONCILIATION SERVICES AND CUSTOMER'S USE OF THE RECONCILIATION SERVICES EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

ABDC'S AND ENLIVENHEALTH'S AGGREGATE LIABILITY TO CUSTOMER UNDER THIS TERM SHEET AND WITH RESPECT TO THE RECONCILIATION SERVICES (WHETHER UNDER CONTRACT, TORT, OR ANY OTHER THEORY OF LAW OR EQUITY) SHALL NOT EXCEED, UNDER ANY CIRCUMSTANCES, THE VALUE OF THE RECONCILIATION SERVICES GIVING RISE TO THE CLAIM. THE FOREGOING LIMITATION OF LIABILITY REPRESENTS THE ALLOCATION OF RISK OF FAILURE AMONG THE PARTIES AS REFLECTED IN THE PRICING HEREUNDER AND IS AN ESSENTIAL ELEMENT OF THE BASIS OF THE BARGAIN AMONG THE PARTIES.

f) NOTWITHSTANDING ANYTHING TO THE CONTRARY HEREIN, NOTHING IN THIS TERM SHEET OR THE MASTER PROGRAM AGREEMENT SHALL LIMIT ENLIVENHEALTH'S LIABILITY FOR (I) FRAUDULENT MISREPRESENTATION, (II) GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT, OR (III) ANY OTHER LIABILITY THAT CANNOT BE EXCLUDED OR LIMITED UNDER APPLICABLE LAW.

g) Any claim against ABDC or EnlivenHealth by Customer must be asserted in writing within thirty (30) days after EnlivenHealth should have processed information received from a Customer or the transmission of inaccurate information on which the claim is based, whichever is applicable. Customer hereby agrees to promptly supply to EnlivenHealth documentation reasonably requested by EnlivenHealth to support any claim. No party will be responsible for delays or failures in performance resulting from acts or events beyond its control, including but not limited to, acts of nature, governmental actions, fire, labor difficulties or shortages, civil disturbances, transportation problems, interruptions of power, supply or communications or natural disasters, provided such party takes reasonable efforts to minimize the effect of such acts or events.

h) No party will be responsible for delays or failures in performance resulting from acts or events beyond its control, including but not limited to, acts of nature, governmental actions,

fire, labor difficulties or shortages, civil disturbances, transportation problems, interruptions of power, supply or communications or natural disasters, provided such party takes reasonable efforts to minimize the effect of such acts or events.

i) The provisions of this Section 7 shall control over any conflicting provision elsewhere in the Master Program Agreement.

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Capitalized words not defined in this Term Sheet have the meaning defined in the Master Program Agreement or the Elevate Provider Network Term Sheet.

❖❖❖

Outcomes Patient Care Services

Term Sheet

1. Program Description

a) ABDC works with Outcomes, as a Program Partner, to provide an optional web-based patient care services solution (the "Outcomes ~~PCS~~Premium Solution") offering real-time analytics and ongoing management tools designed to assist subscribing pharmacies in improving, among other things, patient health outcomes, patient adherence, and clinical services. The Outcomes ~~PCS~~ Premium Solution is currently made available through Prescribe Wellness functionality but will be transitioned to ~~OutcomesOne~~Outcomes Premium.

b) Enrollment in the Outcomes ~~PCS~~ Premium Solution is optional, and Customer may enroll through ABDC or directly through Outcomes, as provided more fully in this Term Sheet; provided, however, that Customer may not enroll in the Outcomes ~~PCS~~ Premium Solution through ABDC to the extent that Customer is enrolled in the Amplicare Clinical Solution (as defined under Term Sheet 2D) through ABDC. Enrollment in the Outcomes ~~PCS~~Premium Solution requires, among other things, the execution of an agreement directly with Outcomes and completion of an applicable enrollment form with ABDC.

2. Pricing

a) Fees for the Outcomes ~~PCS~~Premium Solution are in addition to the fees charged for Elevate Advanced Features (see Term Sheet 2), will be invoiced directly by Outcomes, and may be increased by up to Five Percent (5%) annually. Applicable fees to be paid by Customer may vary and are dependent upon the manner in which Customer enrolls in the Outcomes ~~PCS~~Premium Solution and applicable Outcomes ~~PCS~~Premium Solution modules chosen by Customer. If Customer enrolls in the Outcomes ~~PCS~~Premium Solution directly through Outcomes, Customer will pay Outcomes' prevailing rates. Alternatively, to the extent that Customer enrolls in the Outcomes ~~PCS~~Premium Solution through ABDC, remains affiliated with ABDC, maintains on file with ABDC an active and valid Outcomes ~~PCS~~Premium Solution enrollment form, and otherwise satisfies all applicable requirements, including, without limitation, utilization requirements provided under Section 3(h) below, Customer will pay the following rates for the following Outcomes ~~PCS~~Premium Solution modules:

- ~~OutcomesOne~~Outcomes Premium ~~(formerly PEC):~~: $49/store/month
- ~~OutcomesOne~~Outcomes Premium + Vaccine: $129/store/month

~~• OutcomesOne Complete~~ • Outcomes Premium + Vaccine + Engagement: $249/store/month

b) For the avoidance of doubt, the fees to be paid by Customer for the Outcomes ~~PCS~~Premium Solution are subject to increase if Customer enrolls in the Outcomes ~~PCS~~Premium Solution through ABDC and fails to satisfy the conditions and requirements provided in Section 2(a) above.

3. Obligations of Customer

a) To access the Outcomes ~~PCS~~Premium Solution~~–~~, Customer must sign a HIPAA Business Associate Agreement directly with Outcomes and timely pay all applicable amounts due.

b) Customer must complete all applicable enrollment requirements, including, without limitation, completion of an applicable enrollment for with ABDC.

c) Unless specifically authorized otherwise by ABDC in writing, Customer must participate in Elevate Advanced Features (Term Sheet 2).

d) Customer authorizes ABDC and Outcomes to utilize Pharmacy Data to measure and improve the performance, or the future development of any Outcomes product, and to use and disclose to third parties de-identified Pharmacy Data aggregated across other ABDC and/or Outcomes customers, as applicable. Customer represents and warrants that its notice of privacy practices permits Customer to use and disclose Protected Health Information in the manner that ABDC and Outcomes are authorized to use and disclose Protected Health Information under this Term Sheet.

e) Customer will use the Outcomes ~~PCS~~Premium Solution in accordance with: (i) applicable laws and regulations; (ii) the reasonable conditions, rules, and requirements established by ABDC and/or Outcomes from time to time and as set forth in any manuals, materials, documents, or instructions furnished by ABDC or Outcomes to Customer (collectively the "Outcomes ~~PCS~~Premium **Materials**"); and (iii) any other agreement between Outcomes and Customer respecting the Outcomes ~~PCS~~Premium Solution.

f) Customer will take strict measures to protect the security of its assigned Outcomes ~~PCS~~Premium Solution account and corresponding username and password and agrees that all consequences resulting from the use of said account shall be the sole responsibility of Customer. Customer is solely responsible for all information submitted through the Outcomes ~~PCS~~Premium Solution via its assigned account.

g) Customer may not rent, disclose, publish, sell, assign, lease, sublicense, market or transfer any content of ABDC or Outcomes nor use it in any manner not expressly authorized by this Term Sheet or the Outcomes ~~PCS~~Premium Materials.

h) In order to remain eligible for the pricing terms provided under Section 2(a) above respecting Outcomes ~~PCS~~Premium Solution enrollment through ABDC, Customer must access and utilize the Outcomes ~~PCS~~Premium Solution, on average during each month, at least one (1) time. If Customer's use fails to meet such frequency requirement, the fees to be paid by Customer shall be subject to increase, as provided under Section 2 above, for the periods during which such failure occurs.

4. Grant of Rights and IP Rights

a) To the extent permitted by law, ABDC grants to Customer a limited, non-transferable, non-exclusive right to use the Outcomes ~~PCS~~Premium Solution subject to the Outcomes ~~PCS~~Premium Materials, this Term Sheet, and any other agreement between Outcomes and Customer respecting the Outcomes ~~PCS~~Premium Solution. Customer's use of the Outcomes ~~PCS~~Premium Solution is restricted to Customer's own internal business purposes. Customer shall have no right to resell, distribute or otherwise transfer or permit usage of the Outcomes ~~PCS~~Premium Solution by any other person. Title to the Outcomes ~~PCS~~Premium Solution and all rights of copyright, patent or other intellectual property therein are and shall at all times remain solely and exclusively with ABDC or Outcomes, as applicable. Customer shall keep its use of the Outcomes ~~PCS~~Premium Solution free and clear of all liens, claims and encumbrances. ABDC and Outcomes, respectively and as applicable, reserve any and all rights not expressly granted herein.

b) Customer acknowledges and agrees that all content, products, programs and/or technology on and accessible through the Outcomes ~~PCS~~Premium Solution (excluding Pharmacy Data provided by Customer) is the property of either Outcomes or ABDC, and Customer shall not claim any interest in such property.

c) Customer will not alter or remove any copyright or trademark notice or proprietary legend contained in or on any content of the Outcomes ~~PCS~~Premium Solution. Any trademark, logos and marks displayed on the Outcomes ~~PCS~~Premium Solution, whether registered or unregistered, are property of their respective owners.

5. Warranties and Limitations

a) THE OUTCOMES ~~PCS~~PREMIUM SOLUTION IS PROVIDED "AS-IS" AND WITHOUT ANY WARRANTY OR CONDITION WHATSOEVER. NEITHER ABDC NOR OUTCOMES MAKES ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR INFORMATION SECURITY, IN RELATION TO THE USE OF THE OUTCOMES ~~PCS~~PREMIUM SOLUTION. FURTHER, AND WITHOUT LIMITING THE FOREGOING, NEITHER ABDC NOR OUTCOMES MAKES ANY WARRANTY THAT ACCESS TO OR USE OF THE OUTCOMES ~~PCS~~PREMIUM SOLUTION WILL BE UNINTERRUPTED OR ERROR-FREE, OR AS TO ANY RESULTS THAT MAY BE OBTAINED BY USE OF THE OUTCOMES ~~PCS~~PREMIUM SOLUTION BY CUSTOMER AND/OR ANY PERSON, IRRESPECTIVE OF WHETHER ABDC OR OUTCOMES HAS BEEN INFORMED OF, KNEW OF OR SHOULD HAVE KNOWN OF THE LIKELIHOOD OF SUCH DAMAGES.

6. Exclusions of Consequential Damages and Limitations of Liability

a) ABDC and Outcomes shall not be liable for any errors occurring as a result of failure by Customer to comply with this Term Sheet, the Outcomes ~~PCS~~Premium Materials, or any other agreement between Outcomes and Customer respecting the Outcomes ~~PCS~~Premium Solution.

b) CUSTOMER UNDERSTANDS AND ACKNOWLEDGES THAT: (I) THE OUTCOMES SERVICES AND OFFERINGS ARE PROVIDED SOLELY BY OUTCOMES; (II) ABDC DOES NOT OWN, OPERATE OR MAINTAIN THE OUTCOMES ~~PCS~~PREMIUM SOLUTION; (III) USE OF THE OUTCOMES ~~PCS~~PREMIUM SOLUTION IS AT CUSTOMER'S SOLE RISK AND DISCRETION; AND (IV) EXCEPT AS EXPRESSLY PROVIDED IN THIS TERM SHEET, ALL TERMS AND CONDITIONS APPLICABLE TO THE OUTCOMES ~~PCS~~PREMIUM SOLUTION ARE DETERMINED SOLELY BY OUTCOMES.

c) NEITHER ABDC NOR OUTCOMES SHALL BE LIABLE FOR INCIDENTAL, CONSEQUENTIAL OR SPECIAL DAMAGES ARISING OUT OF THE OUTCOMES ~~PCS~~PREMIUM SOLUTION AND CUSTOMER'S USE OF THE OUTCOMES ~~PCS~~PREMIUM SOLUTION , EVEN IF SUCH PARTY HAS BEEN INFORMED OF, KNEW OF, OR SHOULD HAVE KNOWN OF THE LIKELIHOOD OF SUCH DAMAGES.

d) ABDC'S AND OUTCOMES' AGGREGATE LIABILITY TO CUSTOMER UNDER THIS TERM SHEET AND WITH RESPECT TO THE OUTCOMES ~~PCS~~PREMIUM SOLUTION (WHETHER UNDER CONTRACT, TORT, OR ANY OTHER THEORY OF LAW OR EQUITY) SHALL NOT EXCEED, UNDER ANY CIRCUMSTANCES, THE VALUE OF THE SERVICES RELATING TO THE OUTCOMES ~~PCS~~PREMIUM SOLUTION GIVING RISE TO THE CLAIM. THE FOREGOING LIMITATION OF LIABILITY REPRESENTS THE ALLOCATION OF RISK OF FAILURE AMONG THE PARTIES AS REFLECTED IN THE PRICING HEREUNDER AND IS AN ESSENTIAL ELEMENT OF THE BASIS OF THE BARGAIN AMONG THE PARTIES.

e) No party will be responsible for delays or failures in performance resulting from acts or events beyond its control, including but not limited to, acts of nature, governmental actions, fire, labor difficulties or shortages, civil disturbances, transportation problems, interruptions of power, supply or communications or natural disasters, provided such party takes reasonable efforts to minimize the effect of such acts or events.

f) The provisions of this Section 6 shall control over any conflicting provision elsewhere in the Master Program Agreement.

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby

incorporated by reference into this Term Sheet. Capitalized words not defined in this Term Sheet have the meaning defined in the Master Program Agreement, Elevate Provider Network Term Sheet, or Elevate Advanced Features Term Sheet, as applicable.

❖❖❖

EnlivenHealth Patient Care Services
Term Sheet

1. Program Description

a) ABDC works with EnlivenHealth, as a Program Partner, to make available for enrollment a web-based patient care services solution (the "~~**Amplicare Clinical**~~**Treat Solution**") offering real-time analytics and ongoing management tools designed to assist subscribing pharmacies in improving, among other things, patient health outcomes, patient adherence, and clinical services. Enrollment in the ~~Amplicare Clinical~~Treat Solution is optional, and Customer may enroll through ABDC or directly through EnlivenHealth, as provided more fully in this Term Sheet; provided, however, that Customer may not enroll in the ~~Amplicare Clinical~~Treat Solution through ABDC to the extent that Customer is enrolled in the Outcomes ~~PCS~~Premium Solution (as defined under Term Sheet 2C) through ABDC. Enrollment in the ~~Amplicare Clinical~~Treat Solution requires, among other things, the execution of an agreement directly with EnlivenHealth and completion of an applicable enrollment form with ABDC.

b) ABDC also works with EnlivenHealth to provide access to its ~~Scope of~~Pharmacy Clinical Practice ~~and Reimbursement Snapshot~~by State tools (collectively, the "**EnlivenHealth Tools**") for all Good Neighbor Pharmacy and Elevate Provider Network pharmacy members.

2. Pricing

a) Access to the EnlivenHealth Tools is provided at no additional cost.

b) Fees for the ~~Amplicare Clinical~~Treat Solution are in addition to the fees charged for Elevate Advanced Features (see Term Sheet 2) and will be invoiced directly by EnlivenHealth. Applicable fees to be paid by Customer may vary and are dependent upon the manner in which Customer enrolls in the ~~Amplicare Clinical~~Treat Solution and applicable ~~Amplicare Clinical~~Treat Solution bundles chosen by Customer. If Customer enrolls in the ~~Amplicare Clinical~~Treat Solution directly through EnlivenHealth, Customer will pay EnlivenHealth's prevailing rates. Alternatively, to the extent that Customer enrolls in the ~~Amplicare Clinical~~Treat Solution through ABDC, remains affiliated with ABDC, maintains on file with ABDC an active and valid ~~Amplicare Clinical~~Treat Solution enrollment form, and otherwise satisfies all applicable requirements, Customer will pay the following rates for the following ~~Amplicare Clinical~~Treat Solution bundles:

- ~~Clinical (includes care opportunities and medication therapy management):~~
- Essentials: $100/store/month
- ~~Clinical Plus: $249~~• Workflow: $100/store/month
- ~~Premium: $349/store/month~~
- ~~Platinum: $409~~• All-in: $185/store/month

**Additional transaction fees may apply based on the bundle chosen, as provided under Customer's direct agreement with EnlivenHealth respecting the ~~Amplicare Clinical~~Treat Solution.*

c) For the avoidance of doubt, the fees to be paid by Customer for the ~~Amplicare Clinical~~Treat Solution are subject to

increase if Customer enrolls in the ~~Amplicare Clinical~~Treat Solution through ABDC and fails to satisfy the conditions and requirements provided in Section 2(b) above.

3. Obligations of Customer

a) To access the ~~Amplicare Clinical~~Treat Solution, Customer must sign a HIPAA Business Associate Agreement directly with EnlivenHealth.

b) To access the EnlivenHealth Tools, Customer must acknowledge and agree to applicable terms and conditions provided by ABDC and/or EnlivenHealth and timely pay all amounts due.

c) Customer must complete all applicable enrollment requirements, including, without limitation, completion of an applicable enrollment form with ABDC.

d) Unless specifically authorized otherwise by ABDC in writing, Customer must participate in Elevate Advanced Features (Term Sheet2) and InSite from ABDC (Term Sheet 3).

e) Customer will use the EnlivenHealth Tools and ~~Amplicare Clinical~~Treat Solution in accordance with: (i) applicable laws and regulations and the reasonable conditions, rules, and regulations established by ABDC and EnlivenHealth from time to time and as set forth in any manuals, materials, documents, or instructions furnished by ABDC or EnlivenHealth to Customer (collectively, the "EnlivenHealth PCS Materials"); and (ii) any other agreement between EnlivenHealth and Customer respecting the ~~Amplicare Clinical~~Treat Solution and/or EnlivenHealth Tools.

f) Customer will take strict measures to protect the security of its assigned ~~Amplicare Clinical~~Treat Solution and EnlivenHealth Tools accounts and corresponding usernames and passwords and agrees that all consequences resulting from the use of said accounts shall be the sole responsibility of Customer. Customer is solely responsible for all access, use, and/or information submitted through the EnlivenHealth Tools and ~~Amplicare Clinical~~Treat Solution via its assigned accounts. Customer understands and acknowledges that its accounts may be disabled, suspended, or terminated in the event of unauthorized use of any such account.

g) Customer may not rent, disclose, publish, sell, assign, lease, sublicense, market or transfer any content of ABDC or EnlivenHealth nor use it in any manner not expressly authorized by this Term Sheet or the EnlivenHealth PCS Materials.

4. Grant of Rights and IP Rights

a) To the extent permitted by law, ABDC grants to Customer a limited, non-transferable, non-exclusive right to use the EnlivenHealth Tools, subject to the EnlivenHealth PCS

Materials, this Term Sheet, and any other agreement between EnlivenHealth and Customer respecting the EnlivenHealth Tools, including, without limitation, terms and conditions of use determined by EnlivenHealth. Customer's use of EnlivenHealth Tools and ~~Amplicare Clinical~~Treat Solution is restricted to Customer's own internal business purposes. Customer shall have no right to resell, distribute or otherwise transfer or permit usage of the EnlivenHealth Tools and/or ~~Amplicare Clinical~~Treat Solution by any other person. Title to the EnlivenHealth Tools and ~~Amplicare Clinical~~Treat Solution and all rights of copyright, patent or other intellectual property therein are and shall at all times remain solely and exclusively with ABDC or Enliven Health, as applicable. Customer shall keep its use of the EnlivenHealth Tools and ~~Amplicare Clinical~~Treat Solution free and clear of all liens, claims and encumbrances. ABDC and EnlivenHealth, respectively and as applicable, reserve any and all rights not expressly granted herein.

b) Customer acknowledges and agrees that all content, products, programs and/or technology on and accessible through the EnlivenHealth Tools and/or ~~Amplicare Clinical~~Treat Solution (excluding Pharmacy Data provided by Customer) is the property of EnlivenHealth and Customer shall not claim any interest in such property.

c) Customer will not alter or remove any copyright or trademark notice or proprietary legend contained in or on any content of the EnlivenHealth Tools and/or ~~Amplicare Clinical~~Treat Solution. Any trademark, logos and marks displayed on the EnlivenHealth Tools and/or ~~Amplicare Clinical~~Treat Solution, whether registered or unregistered, are property of their respective owners.

5. Warranties and Limitations

a) Customer understands and acknowledges that, with respect to the EnlivenHealth Tools: (i) the EnlivenHealth Tools do not include information concerning every circumstance available nor does ABDC or EnlivenHealth engage in the practice of medicine; (ii) neither ABDC nor the EnlivenHealth Tools provide any business, medical, pharmaceutical, or other professional advice in connection with the Agreement or as part of or because of the provision of the EnlivenHealth Tools; and (iii) neither ABDC nor the EnlivenHealth Tools have the ability to determine: (1) the legality of utilizing the EnlivenHealth Tools in the state in which the EnlivenHealth Tools are being utilized by Customer; (2) the appropriateness of the use of the EnlivenHealth Tools by or for Customer; or (3) whether Customer understands the information provided in the EnlivenHealth Tools.

b) THE ENLIVENHEALTH TOOLS AND ~~AMPLICARE CLINICAL~~TREAT SOLUTION ARE PROVIDED "AS-IS" AND WITHOUT ANY WARRANTY OR CONDITION WHATSOEVER. NEITHER ABDC NOR ENLIVENHEALTH MAKES ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR INFORMATION SECURITY, IN RELATION TO THE USE OF THE ~~AMPLICARE CLINICAL~~TREAT SOLUTION OR ENLIVENHEALTH TOOLS, AND ABDC AND ENLIVENHEALTH DISCLAIM ALL REPRESENTATIONS, WARRANTIES, AND CONDITIONS OF ANY KIND OR NATURE, EXPRESS OR IMPLIED, ARISING OUT OF OR RELATED TO THE ENLIVENHEALTH TOOLS OR ~~AMPLICARE CLINICAL~~TREAT SOLUTION, OR RESULTS DERIVED THEREFROM, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OR CONDITIONS REGARDING ACCURACY, QUALITY, CORRECTNESS, COMPLETENESS, COMPREHENSIVENESS, AND SUITABILITY AND/OR ANY WARRANTY THAT THE ENLIVENHEALTH TOOLS OR ~~AMPLICARE CLINICAL~~TREAT SOLUTION, OR THE CONTENTS THEREIN, WILL MEET ANY PARTICULAR REQUIREMENTS OF OR GUARANTEE REIMBURSEMENT FOR CUSTOMER OR THAT ACCESS TO OR USE OF THE ENLIVENHEALTH TOOLS OR ~~AMPLICARE CLINICAL~~TREAT SOLUTION WILL BE UNINTERRUPTED OR ERROR-FREE. FURTHER, AND WITHOUT LIMITING THE FOREGOING, NEITHER ABDC NOR ENLIVENHEALTH MAKES ANY WARRANTY AS TO ANY RESULTS THAT MAY BE OBTAINED BY USE OF THE ~~AMPLICARE CLINICAL~~TREAT SOLUTION OR ENLIVENHEALTH TOOLS BY CUSTOMER AND/OR ANY PERSON, IRRESPECTIVE OF WHETHER ABDC OR ENLIVENHEALTH HAS BEEN INFORMED OF, KNEW OF OR SHOULD HAVE KNOWN OF THE LIKELIHOOD OF SUCH DAMAGES.

6. Exclusions of Consequential Damages and Limitations of Liability

a) ABDC and Enliven Health shall not be liable for any errors occurring as a result of failure by Customer to comply with this Term Sheet, the EnlivenHealth PCS Materials, or any other agreement between EnlivenHealth and Customer respecting the EnlivenHealth Tools and/or ~~Amplicare Clinical~~Treat Solution.

b) CUSTOMER UNDERSTANDS AND ACKNOWLEDGES THAT: (I) THE ENLIVENHEALTH SERVICES AND OFFERINGS ARE PROVIDED SOLELY BY ENLIVENHEALTH; (II) ABDC DOES NOT OWN, OPERATE, OR MAINTAIN THE ENLIVENHEALTH TOOLS OR ~~AMPLICARE CLINICAL~~TREAT SOLUTION; (III) USE OF THE ENLIVENHEALTH TOOLS AND ~~AMPLICARE CLINICAL~~TREAT SOLUTION IS AT CUSTOMER'S SOLE RISK AND DISCRETION; AND (IV) EXCEPT AS EXPRESSLY PROVIDED IN THIS TERM SHEET, ALL TERMS AND CONDITIONS APPLICABLE TO THE ENLIVENHEALTH TOOLS AND ~~AMPLICARE CLINICAL~~TREAT SOLUTION ARE DETERMINED SOLELY BY ENLIVENHEALTH.

c) NEITHER ABDC NOR ENLIVEN HEALTH SHALL BE LIABLE FOR INCIDENTAL, CONSEQUENTIAL OR SPECIAL DAMAGES ARISING OUT OF THE ~~AMPLICARE CLINICAL~~TREAT SOLUTION, ENLIVEN HEALTH TOOLS, AND/OR CUSTOMER'S USE THEREOF, EVEN IF SUCH PARTY HAS BEEN INFORMED OF, KNEW OF, OR SHOULD HAVE KNOWN

OF THE LIKELIHOOD OF SUCH DAMAGES.

d) ABDC'S AND ENLIVENHEALTH'S AGGREGATE LIABILITY TO CUSTOMER UNDER THIS TERM SHEET AND WITH RESPECT TO THE ~~AMPLICARE CLINICAL~~TREAT SOLUTION AND ENLIVENHEALTH TOOLS (WHETHER UNDER CONTRACT, TORT, OR ANY OTHER THEORY OF LAW OR EQUITY) SHALL NOT EXCEED, UNDER ANY CIRCUMSTANCES, THE VALUE OF THE SERVICES RELATING TO THE ~~AMPLICARE CLINICAL~~TREAT SOLUTION OR ENLIVENHEALTH TOOLS GIVING RISE TO THE CLAIM. THE FOREGOING LIMITATION OF LIABILITY REPRESENTS THE ALLOCATION OF RISK OF FAILURE AMONG THE PARTIES AS REFLECTED IN THE PRICING HEREUNDER AND IS AN ESSENTIAL ELEMENT OF THE BASIS OF THE BARGAIN AMONG THE PARTIES.

e) No party will be responsible for delays or failures in performance resulting from acts or events beyond its control,

including but not limited to, acts of nature, governmental actions, fire, labor difficulties or shortages, civil disturbances, transportation problems, interruptions of power, supply or communications or natural disasters, provided such party takes reasonable efforts to minimize the effect of such acts or events.

f) The provisions of this Section 6 shall control over any conflicting provision elsewhere in the Master Program Agreement.

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Capitalized words not defined in this Term Sheet have the meaning defined in the Master Program Agreement, Elevate Provider Network Term Sheet, or Elevate Advanced Features Term Sheet, as applicable.

❖❖❖

InSite from ABDC
Term Sheet

1. Program Description

a) InSite from ABDC is a proprietary data analytics system used to measure and compare pharmacy performance by organizing and analyzing detailed prescription and other business transaction data, including Pharmacy Data.

b) InSitePOS from ABDC is a proprietary data analytics system used to measure and compare the performance of pharmacy front ends by organizing and analyzing detailed business transaction data collected from point-of-sale systems, including Pharmacy Data. ABDC collaborates with its Program Partner, Retail Insights, on the collection and cleansing of the data.

c) TruVuPOS is an ABDC service offered to consumer goods manufacturers, in collaboration with ABDC's Program Partner, Retail Insights, to gain access for participating pharmacies to manufacturer offerings, and to provide funding to help support the programs.

These programs are designed to aid Customer in its treatment, payment, and healthcare operations activities, and are collectively referred to as "**InSite from ABDC**".

2. Pricing

Premier: Included; no additional fee
GNP: Included in Elevate Advanced Features
Other: Included in Elevate Advanced Features

Additional fees may apply for Network Providers that: (i) process more than 10,000 Claims in a month; (ii) use alternative, approved switch service providers for Elevate Advanced Features; and/or (iii) elect to receive optional and/or enhanced Elevate Advanced Features services (e.g., enhanced reporting, etc.).

3. Data Authorization & Program Partners

a) Customer authorizes ABDC to receive Pharmacy Data provided by or on behalf of Customer directly or indirectly from Customer or ABDC's Program Partners in connection with the Permitted Uses (as defined below).

b) Without in any way limiting the scope of such definition as provided under ~~Exhibit A of~~ the Agreement~~,~~ and/or Term Sheet 2 (Elevate Advanced Features), ABDC's ~~"~~Program Partners~~"~~ respecting this Available Program include but are not limited to:

(i) Change Healthcare (a part of Optum®). Provides pre and post edit and data capture services.

(ii) EnlivenHealth. Provides central payment services, claim reconciliation services, and the EnlivenHealth Tools (as defined under Term Sheet 2D) and hosts and makes available for enrollment through ABDC the ~~Amplicare Clinical~~Treat Solution (as defined under Term Sheet 2D).

(iii) Outcomes. Hosts and makes available for enrollment through ABDC the Outcomes PCS Solution (as defined under Term Sheet 2C).

(iv) Retail Insights. Collects, organizes, and analyzes transaction data from point-of-sale systems and operates the TruVuPOS program with ABDC and consumer goods manufacturers to assist pharmacies in gaining access to promotional monies and other retail programs.

c) Customer represents and warrants that its notice of privacy practices permits Customer to use and disclose protected health information in the manner that ABDC is authorized to use and disclose protected health information under the Agreement and this Term Sheet.

4. Advanced Features

InSite from ABDC is included in, and required for participation in each of, the Advanced Features (Term Sheet 2) of the Elevate Provider Network (Term Sheet 1), which include Pre and Post Edit Services and data capture from Change Healthcare (Term Sheet 2A), Claim Reconciliation Services from EnlivenHealth (Term Sheet 2B), Outcomes ~~PCS~~Premium Solution from Outcomes (Term Sheet 2C), and Patient Care Services from EnlivenHealth (Term Sheet 2D). To participate in ~~an~~one (1) or more Advanced ~~Feature~~Features, Customer must enroll and comply with the terms and conditions in the applicable Term Sheet~~.~~(s).

5. Customer Responsibilities

a) Procure Systems. To participate, Customer must acquire systems from one or more participating system vendors and is responsible for the costs to acquire, maintain and update its systems, which vary based on Customer's choices.

b) Data Flow. Customer will comply with instructions of ABDC, ABDC's Program Partners and system vendors to ensure the quality and timely receipt of all Pharmacy Data, including cash or private pay claims as required, by InSite and will use reasonable efforts to resolve any process failures or missing data. Customer will obtain all necessary authorizations from its customers/patients to transmit Pharmacy Data to ABDC and its Program Partners. Claims data capture and corresponding switching services through Change Healthcare are required unless otherwise approved by ABDC in writing, in which case such approved alternative vendor shall constitute ABDC's respective Program Partner for the purposes of Customer's provision of Pharmacy Data and participation in applicable Available Programs.

c) HIPAA Compliance. As required, ABDC and Customer entered into a HIPAA Business Associate Agreement (Exhibit B or as otherwise agreed).

6. ABDC Responsibilities

a) System Vendors. ABDC will collaborate with certain system vendors that Customer may designate to facilitate the delivery of Pharmacy Data provided by or on behalf of Customer and the implementation of various business initiatives, including Available Programs.

b) InSite. Using InSite, ABDC will provide Customer with reports, analyses and other compilations about business performance, including various benchmark comparisons against peer groups of similar pharmacies

using de-identified Pharmacy Data and other data to assess and improve overall efficiency and performance of healthcare operations.

c) Report Availability. Certain reports and performance measurements are provided to all participating Pharmacies. Some reports or features have additional fees or are only available as part of another Available Program.

d) Protection of Customer Data. ABDC will protect Pharmacy Data provided by or on behalf of Customer pursuant to the Data Protection Provisions (Exhibit A), which describes steps ABDC takes to safeguard Pharmacy Data. ABDC may only use Pharmacy Data provided by or on behalf of Customer as set forth in the Master Program Agreement (including this Term Sheet and Term Sheets applicable to other Available Programs in which Customer enrolls) and as authorized by Customer in writing.

7. Use of Pharmacy Data

a) Pharmacy Data License. Customer hereby grants to ABDC an irrevocable, non-exclusive license to use, reproduce, create derivative works from, and market and distribute those derivative works from any and all Pharmacy Data captured directly or indirectly from Customer, Program Partners, or Payors for the Permitted Uses specified in Section 7(b) below.

b) Permitted Uses. Consistent with applicable laws and regulations, Customer authorizes ABDC to use, reproduce, and create derivative works from Pharmacy Data, and market and distribute those derivative works for the following purposes (collectively, "**Permitted Uses**"):

(i) providing Customer with reports, studies, analyses and other compilations relating to Customer's business performance to assist Customer in its treatment, payment, and healthcare operations activities;

(ii) in such a manner that Customer is unidentifiable as the source of the data and any protected health information is appropriately de-identified, combining Pharmacy Data with similar data received by ABDC as a business associate of multiple covered entities and using such cumulative data to prepare reports, analyses and compilations relating to business performance and market trends to benchmark Customer and other covered entities against peer groups to improve all parties' overall efficiency and performance of treatment, payment, and healthcare operations activities;

(iii) supporting Customer's participation in Advanced Features and other Available Programs by furnishing Pharmacy Data (including PHI), to Program Partners in connection with Advanced Features and other Available Programs to assist Customer in its treatment, payment, and healthcare operations activities;

(iv) supporting Customer's participation in InSite POS and TruVuPOS and other business offerings under The Front-End Solution (Term Sheet 5~~) where~~), whereby ABDC and Retail Insights furnish point-of-sale Pharmacy Data to manufacturers to support Customer's participation in manufacturer-sponsored promotions and related offerings;

(v) identifying validating, and/or developing programs, solutions or actions that might benefit Customer's business ~~and conduct~~, evaluating, managing, and/or improving the Available Programs in which Customer participates, and conducting outreach campaigns in connection with the foregoing, including sharing with ABDC's affiliates, members of ABDC's sales team, and Customer's Business Coaching Associate (as defined in Term Sheet 7), buying group, aggregation group, or group purchasing organization (if any); and

(vi) any other lawful use for which ABDC obtains the express written consent of Customer.

ABDC may not market or otherwise provide Pharmacy Data derivative works that include protected health information or, unless otherwise agreed by ABDC and Customer, that identify Customer as the source of specific data.

8. No Representations

Participating system vendors and Program Partners were chosen in part because of their established record in successfully developing, marketing, installing and supporting systems used by community pharmacies. However, ABDC has not performed any financial or other due diligence and makes no warranty, including any implied warranty, about any system vendor or Program Partner or its financial viability or responsibility. ABDC is not acting as a guarantor for any system vendor or Program Partner. Notwithstanding anything to the contrary contained herein or in the Agreement, ABDC reserves the right to change Program Partners at any time.

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Capitalized words not defined in this Term Sheet have the meaning defined in the Master Program Agreement, Elevate Provider Network Term Sheet, or Elevate Advanced Features Term Sheet, as applicable.

❖❖❖

Five-Star Rebate Program
Term Sheet

1. Program Description

This program is offered to recognize high performance in adherence and other pharmacy performance measures and to aid Customer in its healthcare operations activities, including meeting its purchasing obligations under its agreements with ABDC.

2. Data Consent

By enrolling in this Available Program, Customer hereby authorizes ABDC to derive dispense usage data from Pharmacy Data and to use and share such data, including pharmacy performance and benchmarking data, with ABDC's Sales and other associates, as well as Customer's designated buying group, for the purposes of aiding Customer in its healthcare operations activities, including meeting its purchasing obligations under its agreements with ABDC, as well as improving the overall effectiveness of the PRxO Generics program. In all cases, ABDC's use of Pharmacy Data will be in accordance with ABDC's Data Protection Provisions and applicable laws and regulations including HIPAA. The foregoing consent applies to Pharmacy Data captured through any Available Program in which Customer is enrolled as of or enrolls in subsequent to the Effective Date, notwithstanding any limitations of use in any such authorization. Customer may withdraw such consent at any point by providing written notice to ABDC, at which time Customer will no longer be eligible for the Five-Star Rebate.

3. Performance Measurements and Rebate Table

Currently, Star Measure Ratings used for the rebate calculation are based upon, and determined at such time as, the most recent ratings data provided to AmerisourceBergen by EQUIPP® and where necessary directly from MTM providers and others. ABDC calculates the average score used for the Five-Star Rebate calculation. Where rating thresholds vary between MAPD and PDP plans, the higher of the two is used. Where ratings are not available from EQUIPP a rating of 3.0 is used. In the future, ABDC may adopt alternative sources of STAR measures, directly calculate the measures using Pharmacy Data, as well as use alternative techniques to stratify pharmacy performance such as percentiles.

4. Eligibility

The Five-Star Rebate is available to retail, independent pharmacies not affiliated with a buying group, or whose buying group participates in this Available Program, that meet all applicable eligibility criteria. Eligibility requirements vary by participating buying group affiliation (if any~~)~~), and Customer may consult with its buying group for additional eligibility requirements. Customer must be a franchisee under the Premier program (including participation in Elevate Provider Network) or separately enrolled and active in Elevate Provider Network (Term Sheet 1~~),~~) to be eligible to participate in this Available Program. Customer must also be in compliance with all other required terms to be eligible and otherwise submit all required data for each quarter being measured in full, as applicable respecting each measurement period of participation.

5. Data Requirements

a) Elevate Advanced Features (Term Sheet 2)

b) Pre and Post Edits and data capture ~~(Term Sheet 2A)~~ with Change Healthcare (Term Sheet 2A) or data capture via other claims switching services provider approved by ABDC in writing

c) InSite from ABDC (Term Sheet 3).

To be eligible for the Five-Star Rebate, Customer must submit its third-party claims through the PPE program, or other claims switching services provider approved by ABDC in writing.

6. Helping Improve Purchase Performance

In coordination with Customer's buying group (if any), ABDC equips its teams and Customer's buying group with the results of matching dispensed quantities to wholesale purchase quantities so ABDC can collectively work with Customer to identify missed opportunities and assist Customer in optimizing its purchase performance and rebate opportunities.

7. ABDC Generics Rebate Table

Only one level of Five-Star Rebate is paid per pharmacy. Rebate performance will be measured at the end of each calendar quarter and, unless agreed-upon otherwise as between ABDC and Customer's buying group (if any), credits issued directly to Customer within six weeks of quarter end. Rebates are based and credited on net purchases of rebatable ABDC ~~Generics~~generics products during the quarter under Customer's applicable generics program.

Standard Calculation	
Average Star Rating 0.00 to 2.99	0.25%
Average Star Rating 3.00 to 3.99	0.50%
Average Star Rating 4.00 to 4.49	0.75%
Average Star Rating 4.50 to 5.00	1.00%

8. Other

a) Distribution Agreement. Customer must be in compliance with the terms of its distribution agreement with ABDC when credits are issued.

b) Other PRxO Generics Rebates. This Five-Star Rebate is in addition to all other discounts, rebates or other incentives related to PRxO Generics purchases.

c) Discount Reporting and Safe Harbor. Customer agrees to comply with all laws, including reporting on reflecting discounts, rebates and other price reductions, including this rebate, pursuant to 42 U.S.C. § 1320a-7b(b)(3)(A) and 42 CFR 1001.952(h) on cost reports or claims submitted to federal or state healthcare programs, retaining invoices and related pricing documentation and making them available on request to healthcare program representatives.

d) ABDC may modify or terminate this Five-Star Rebate Program at any time on 30 days' notice prior to the start of the next calendar quarter. In the event of termination of the Five-Star Rebate Program, ABDC's provision of rebates under this Available Program will cease concurrently upon the effective date of such termination, unless otherwise agreed to in writing by ABDC.

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Capitalized words not defined in this Term Sheet have the meaning defined in the Master Program Agreement, Elevate Provider Network Term Sheet, or Elevate Advanced Features Term Sheet, as applicable.

❖❖❖

Front-End Solution Programs
Term Sheet

1. Program Description
The following interrelated front-of-store services and programs (collectively, the "**Front-End Solution Programs**") are designed to assist Customer in promoting traditional drugstore non-prescription product categories. Certain services are available only to Premier and GNP Pharmacies. Separate enrollment is required for each Front-End Solution Program.

2. Planogram Services
ABDC regularly publishes and updates schematic diagrams ("**Planograms**") that specify optimal layouts of traditional drug store non-prescription product categories, designed to maximize consumer interest and increase Customer's sales. Customer must substantially comply with Planogram layouts and stock substantially all Planogram products.

Premier: Included; no additional fee
GNP: No additional fee
Other: $55 per month ($89 combined with Zone Pricing)

3. Retail Product Zone Pricing Service
ABDC regularly publishes and updates suggested retail price files for traditional drug store non-prescription products. Zone prices are based on factors, such as product, product category and targeted competitiveness. Customer is solely responsible for determining the extent to which it uses and/or implements any such suggested retail prices.

Premier: Included; no additional fee
GNP: No additional fee
Other: $45 per month ($89 combined with Planograms)

4. First To Shelf™ (AutoShip New OTC)
With First To Shelf™, ABDC delivers to Customer, without a corresponding order ("**AutoShip**"), commercially reasonable quantities of certain OTC products to facilitate prompt stocking of such products by Customer in anticipation of new or increased consumer demand. Such products may include new market break items, GNP Private Label Products and Rx-to-OTC switch items. Customer will accept and pay for such products and promptly display them for sale consistent with the Planogram.

Premier: Required; no additional fee
GNP: No additional fee
Other: Not available

5. Front-End Support Kit
As an integral component of the Good Neighbor Pharmacy program, ABDC provides in-store promotional materials in reasonable quantities in a monthly kit. Customer will promptly display in-store promotional materials consistent with directions from ABDC in Program Guides.

Premier: Option to opt-in during customer onboarding; no additional fee
GNP: Option to opt-in during customer onboarding; no additional fee
Other: Not available

6. Merchandising Services
ABDC will make reasonable efforts to assign a Retail Merchandising Specialist within six (6) months of Customer completing all Premier requirements. ABDC may reasonably limit time and resources devoted to Merchandising services. To continue receiving merchandising services Customer must allow the representative to execute the Planogram and requires Customer to maintain the Planogram sections in between visits by ABDC's representative.

Premier: Included; no additional fee
~~GNP: $399 /merchandiser/day~~GNP: Limited availability (pricing based on scope of work)
Other: Limited availability (pricing based on scope of work)

7. InSite POS from ABDC
Customer, if using InSite from ABDC, authorizes limited use and exchange of Pharmacy Data by and among (a): (i) ABDC, including merchandisers and sales associates; (ii) Customer's buying group, aggregation group, or group purchasing organization (if any); and (iii) ABDC's Program Partners, to assist Customer and to enhance the Front-End Solutions Program and related Available Programs through means such as measuring the effectiveness of promotions and other promotional material; and (b) manufacturers who partner with ABDC, or ABDC's Program Partners, to enable access to promotional offerings and to provide funding to help support the Front-End Solutions Program and related Available Programs.

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Capitalized words not defined in this Term Sheet have the meaning defined in the Master Program Agreement, Elevate Provider Network Term Sheet, or Elevate Advanced Features Term Sheet, as Applicable.

❖❖❖

Digital Marketing Programs
Term Sheet

1. Program Description

The following interrelated programs ("**Digital Marketing Programs**") are part of an overall strategy to attract and engage patients and consumers online. Separate enrollment is required for each Digital Marketing Program.

2. MyGNP Website

ABDC hosts a consumer website designed to attract patients and other consumers ("**Visitors**") and build their loyalty for Premier and GNP Pharmacies ("**Website**"), currently www.MyGNP.com. This Available Program includes an individual subdomain ("Local Page") and Local Page subdomain name, maintenance, user data, licensed content, and prescription refill requests.

Premier: Included; no additional fee
GNP: Included; no additional fee
Other: Not available

3. MyGNP Mobile App

ABDC publishes a Good Neighbor Pharmacy branded application available for consumers to download and use on mobile phones. The application includes prescription refill requests.

Premier: Included; no additional fee
GNP: Included; no additional fee
Other: Not available

4. Social Media and Online Reviews

ABDC provides, through its respective Program Partner, a platform designed for online review and multi-network social media management, including a robust content library, performance statistics, and reputation management. Content may be posted by Customer or on behalf of Customer. Customer is solely responsible for any and all content posted by Customer, including, without limitation, content generated or altered by Customer through the use of artificial intelligence or related technology.

Premier: Included; no additional fee.
GNP: Not available
Other: Not available

5. Local Listings Management

ABDC assists Customer to claim and manage online business listings so that local consumers using search engines are presented full and accurate pharmacy information such as location, hours and contact information.

Premier: Included; no additional fee
GNP: Included; no additional fee
Other: Not available

6. Digital Marketing

ABDC runs or makes available certain pay-per-click advertising campaigns, such as pay-per-click advertising campaigns through internet search engine advertising platforms.
Premier: Included; no additional fee
GNP: Not available
Other: Not available

Additional optional digital advertising services, such as ad hoc digital marketing campaign opportunities, may be made available via separate enrollment form(s~~),~~) and subject to additional terms, conditions, and fees (which may vary based on options selected~~. To~~). Except as otherwise specified, to participate in additional advertising, a minimum advertising contribution of $100 is required in addition to agency and administrative fees.
~~Premier: Included; no additional fee~~
~~GNP: Not available~~
~~Other: Not available~~

7. Program Prerequisites

a) Good Neighbor Pharmacy. Customer must be a Premier or GNP Pharmacy in good standing.

b) Platform Permissions. Customer must enable and configure its social media accounts to allow ABDC to provide the services.

c) Interactive App Refill Service. ABDC, through its Program Partner Outcomes, offers an interactive mobile-application-based refill service for consumers ordering prescription refills through the "MyGNP" mobile application. Customer's eligibility to use the interactive prescription refill service is subject to Customer's enrollment in the Outcomes PCS Solution (Term Sheet 2C), the participation of its designated pharmacy system vendor, and other eligibility requirements provided in the Program Guides. Fax service is used for prescription refill requests that cannot be delivered through the interactive service.

d) HIPAA Compliance. As required, ABDC and Customer have entered into a HIPAA Business Associate Agreement (Exhibit B or as otherwise agreed).

8. ABDC Responsibilities

a) Hosting. ABDC through its service providers and Program Partners hosts or makes available the Website and Local Pages and publishes the mobile application.

b) ABDC Content. All materials provided by ABDC to Customer for the Digital Marketing Programs, including templates, content, data, graphics, design, information, computer software, logos, trademarks, processes, methodologies, know-how, or any other proprietary materials provided by ABDC or its licensors, (collectively, the "ABDC Content") are the sole and exclusive property of ABDC or its licensors. ABDC grants Customer a non-exclusive, limited license to use and display ABDC Content on the applicable application while Customer participates in this Available Program. ABDC controls and owns all rights to registered domain and subdomain names.

c) Templates. ABDC provides templates that allow Customer to provide limited content, in a format specified by ABDC, for the applicable program pursuant to this Term Sheet.

d) Visitor Data. ABDC collects certain click stream and similar data on Visitor usage, which it may choose to make available to Customer periodically. As between ABDC and Customer, information collected from the Digital Marketing Programs are the sole and exclusive property of ABDC, including email addresses provided by Visitors.

9. Customer Responsibilities

a) Customer Authorization and Content. Customer is responsible for all content and materials provided by Customer for use in any of the Digital Marketing Programs ("**Customer Content**"). Customer Content must be related to Customer's GNP business and comply with Program Guides. Customer must update and modify Customer Content so it is fresh and current. ABDC may remove, or demand that Customer remove, content that is not consistent with Program Guides.

b) Customer hereby authorizes and consents to ~~ABDC~~ABDC's use and access to Customer's social media accounts, website, and any other digital resources of Customer such as may be necessary for ABDC to carry out its responsibilities pursuant to this Term Sheet. Customer hereby consents to ABDC and Program Partners' use, access to, and exchange of business, operational, and financial data regarding Customer's Pharmacy (collectively, "**Business Data**") during the performance of its obligations. This Business Data authorization is in addition to and supplements Customer's data authorization and consent for Pharmacy Data previously executed and provided to ABDC for all other Terms Sheets associated with the MPA between the parties.

~~e~~c) Notwithstanding anything to the contrary contained in the Agreement, Customer hereby authorizes ABDC to receive, use, create, use and disclose derivative works of, and disclose to Customer's Business Coach (as defined in Term Sheet 7) and ABDC's and its affiliates' employees, affiliates, and Program Partners supporting the Digital Marketing Programs, as applicable, any and all Pharmacy Data (excluding PHI) and/or other data (if any) resulting from Customer's participation in the Digital Marketing Programs, including receipt, use, creation of derivative works, and/or disclosure in formats that may identify Customer as the source of such data, for the purposes of analysis, benchmarking, reporting, and as Customer may otherwise agree in writing.

d) Legal Compliance. Customer represents and warrants that: (i) it owns the Customer Content or is authorized to include it in emails and/or in its use of the Digital Marketing Programs; and (ii) no Customer Content will be inaccurate, deceptive, fraudulent; infringe on any third-party intellectual property rights; or otherwise violate any law.

~~d~~c) License. Customer hereby grants to ABDC a non-exclusive, royalty-free license to publish, transmit, modify, display, distribute, translate, and adapt Customer Content in connection with its performance under this Available Program.

~~e~~f) Privacy. Customer must comply with privacy laws for information collected from its use of the Digital Marketing Programs, including notices required by HIPAA for protected health information. Personal and non-personal information collected, used, or disclosed is subject to ABDC's privacy policy posted on the Website. The Website privacy policy does not apply, and ABDC is not responsible, when a Visitor is redirected to any other internet site.

10. Disclaimers

The Digital Marketing Programs may be unavailable due to scheduled maintenance and required repairs or due to causes beyond the control of ABDC or its hosting Program Partner. Pursuant to Paragraphs 3 and 7.2 of Exhibit C (Provisions) of the Premier Agreement, ABDC DOES NOT GUARANTEE AVAILABILITY OF THE DIGITAL MARKETING PROGRAMS AND DISCLAIMS ANY AND ALL LIABILITY FOR DIRECT, INDIRECT OR CONSEQUENTIAL DAMAGES ARISING FROM OR RELATED TO CUSTOMER'S OR VISITOR'S USE OF THE WEBSITE OR LOCAL PAGES, INCLUDING ANY INTERRUPTION OR UNAVAILABILITY.

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Capitalized words not defined in this Term Sheet have the meaning defined in the Master Program Agreement, Elevate Provider Network Term Sheet, or Elevate Advanced Features Term Sheet, as applicable.

❖❖❖

Business Coaching
Term Sheet

1. Program Description

a) ABDC will provide to Customer certain recommendations of industry best practices related to increasing Pharmacy's performance ("**Business Coaching**") through its representative ("**Business ~~Coach~~Coaching Associate**").

b) Business Coaching value depends on Customer providing complete and accurate information to the Business ~~Coach~~Coaching Associate and implementing recommended industry best practices as Customer determines are appropriate to its operations. Business Coaching focuses primarily on assessing Pharmacy's current performance and practices and identifying opportunities to improve performance with high impact changes that can be implemented in reasonable timeframes, based upon complexity of applicable changes, without significant capital investment.

c) This Available Program is not comprehensive business consulting, nor is it designed to build long-term business plans or investigate every potential opportunity for improvement; it is based on a specific set of performance indicators that ABDC found increased performance at other community pharmacies.

2. Pricing

Premier: Included; no additional fee
GNP: Not available
Other: Not available

3. Program Prerequisites

a) Pharmacy Data. Customer must be a Premier Pharmacy and must participate in Elevate Advanced Features (Term Sheet 2) and InSite from ABDC (Term Sheet 3).

b) HIPAA Compliance. As required, ABDC and Customer entered into a HIPAA Business Associate Agreement (Exhibit B or as otherwise agreed).

4. Duration of Program

ABDC will make reasonable efforts to assign a Business ~~Coach~~Coaching Associate within six (6) months of Customer completing all Premier requirements and to provide ongoing Business Coaching support as long as Customer is active in this Available Program, including, without limitation, remaining actively engaged with the assigned Business ~~Coach.~~Coaching Associate. ABDC may reasonably limit time and resources devoted to Business Coaching.

5. ABDC Responsibilities

a) Startup. Business ~~Coach~~Coaching Associate will work with Customer, or with other authorized Pharmacy personnel identified by customer (collectively, "**Authorized Pharmacy Personnel**"), to gather a defined set of business data, including financial and operational data, and data available through InSite from ABDC to enable the Business ~~Coach~~Coaching Associate and business analysts to analyze Pharmacy performance ("Coaching Data").

b) Recommendations. Based on the information provided by Customer and/or Authorized Pharmacy Personnel, data available through InSite from ABDC, comparisons with similar pharmacies, and information from other resources, such as local demographics, Business ~~Coach~~Coaching Associate and supporting business analysts will develop a report detailing their findings and include a set of recommended industry best practices related to increasing Pharmacy's performance.

c) Presentation of Findings and Recommendations. Business ~~Coach~~Coaching Associate will present and review the findings and recommendations in a series of discussions conducted face-to-face, using interactive internet presentations, or by telephone, the objective of which is to increase Customer's understanding of its business performance and enable Customer to select from all recommendations those that Customer determines are most appropriate for its business. Detailed findings may include benchmarking and comparisons of analytics with similar pharmacies, analysis of patient loyalty, assessment of product offerings and pricing strategies, or specific observations regarding inventory management, financial management, operational systems, labor and productivity, managed care reimbursements, hours of operation, patient care services, prescriber and patient marketing strategies, and front-end effectiveness. Presentation and review will be conducted directly with Customer or with applicable Authorized Pharmacy Personnel as agreed.

d) Implementation. Customer may implement the priority recommendations selected by Customer or Authorized Pharmacy Personnel, as applicable. Business ~~Coach~~Coaching Associate may also offer additional recommendations to mitigate issues Customer may experience in implementing the recommendations.

e) On-Going Coaching. As recommendations are implemented, Business ~~Coach~~Coaching Associate may encourage Customer or Authorized Pharmacy Personnel, as applicable, to pursue additional performance improvements based on previous findings.

f) Goal Setting. Business ~~Coach~~Coaching Associate will assist Customer or Authorized Pharmacy Personnel, as applicable, in establishing strategic, operational and growth goals for its coming year.

g) Authorization; Privacy of Customer Data. Customer authorizes limited use, disclosure, and exchange of Pharmacy Data by and among ABDC and Program Partners, including its associates and subcontractors who provide Business Coaching and analysis, pursuant to the Data Protection Provisions (Exhibit A) to assist Customer and improve the overall effectiveness of this Available Program. For greater clarity, except as set forth above, as may be applicable to Authorized Pharmacy Personnel, or as otherwise authorized by Customer, no other person will have access to Customer's Coaching Data, including members of ABDC's pharmacy distribution sales force engaged in selling products to Customer's Pharmacy. This enhanced privacy for Coaching Data supersedes any

otherwise authorized uses under the Master Program Agreement.

6. Customer Responsibilities

a) Gather Data. Prior to the initial meeting, Customer will gather a pre-defined list of business reports, to be supplemented as reasonably requested by Business ~~Coach~~Coaching Associate, including: (i) Financial statements: 12-month profit and loss statements, balance sheets, and payroll information; (ii) Operational data: inventory, labor and other information not available in InSite; and (iii) Other information: as deemed necessary. Full-scope business coaching services may not be able to commence until customer data is provided.

b) Customer Action. Customer will implement recommendations that Customer determines are appropriate to its operations, and monitor the operational and financial impact of such recommendations.

c) Customer Responsibility. Customer acknowledges and agrees that it is solely responsible for: (i) the decision to implement and the implementation of the industry best practices recommended by the Business ~~Coach~~Coaching Associate; and (ii) all actions, inactions, and/or other activity by its Authorized Pharmacy Personnel. ALL RISKS ASSOCIATED WITH BUSINESS COACHING, THE RESULTS THEREOF, OR OTHERWISE IN CONNECTION WITH THIS AVAILABLE PROGRAM, ARE EXPRESSLY ASSUMED BY CUSTOMER, AND ALL BUSINESS COACHING IS PROVIDED "AS-IS", WITHOUT REPRESENTATION OR WARRANTY OF ANY KIND, AND IS NOT INTENDED TO CONSTITUTE OR REFLECT LEGAL, MEDICAL, OR OTHER PROFESSIONAL~~, OR OTHER~~ ADVICE.

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Capitalized words not defined in this Term Sheet have the meaning defined in the Master Program Agreement, Elevate Provider Network Term Sheet, or Elevate Advanced Features Term Sheet, as applicable.

❖❖❖

.

Pharmacy Data Services
Term Sheet

1. Program Description

ABDC will furnish to Customer the following data services ("**Data Services**") to assist with pharmacy computer applications, including pharmacy management and point-of-sale systems. Data Services are only available to ABDC customers. Multi-location computer systems, whether or not connected, will be charged per Pharmacy or other location.

2. Electronic Order Entry and Confirmation

ABDC accepts electronic purchase orders directly from Customer's computer system and provides electronic confirmation that an order has been received and that stock is allocated to fill the order. Confirmation is sent directly to Customer's systems when enabled by Customer's system vendors. There are no fees for electronic order entry and confirmation.

3. Catalog and Price Updates–Rx Products

ABDC provides electronic product descriptions and pricing data that Customer may download to its pharmacy management and point of sale systems, including basic drug description fields, Customer's invoice cost, contract price, and standard reference benchmarks such as average wholesale price ("**AWP**") or Suggested Wholesale Price ("**SWP**") for prescription pharmaceuticals. ABDC currently obtains Data Services information from First Databank ("**FDB**") and, where FDB does not provide standard benchmarks available from other publishers, ABDC may supplement it by using an industry standard calculation (for example, 1.2 times FDB's WAC for brand Rx). Initial file loads may include all eligible products or be based on Customer's purchase history.

Premier:	Included; no additional fee
GNP:	$55 per month
Other:	$55 per month

4. Catalog and Price Updates–OTC Products

ABDC provides electronic pricing data for point-of-sale systems relating to Customer's invoice acquisition cost, contract prices, and retail selling prices for over-the-counter and other non-prescription products. Initial file loads can include all eligible products or be based on Customer's purchase history.

Premier:	Included; no additional fee
GNP:	$55 per month
Other:	$55 per month

5. Delivery Options

a) EDI File Download. Subject to capabilities of Customer's systems, allows unattended exchange of EDI documents to support all three Data Services.

b) Secure Web Site. A secure directory for downloading catalog and price update files (Rx and OTC).

6. Compendia Sources and Benchmark Prices

a) First Databank. ABDC obtains certain industry and benchmark price data for use in Data Services from FDB. Where FDB does not provide standard reference benchmarks (such as AWP) available from other publishers, ABDC may supplement it by using an industry standard calculation (for example, 1.2 times FDB's WAC for brand Rx).

b) Medi-Span. ABDC obtains certain industry and standard reference benchmarks ~~such as AWP~~ from Medi-Span.

7. Disclaimers

ABDC uses reasonable care in collecting and transmitting Data Services information. ABDC obtains some Data Services information from other parties it believes are reliable, such as SWP from FDB. However, pursuant to Paragraph 7.2 of Exhibit C (Provisions), ABDC does not warrant accuracy of codes, prices or other Data Services information. Data Services information is intended as a supplement to, and not a substitute for, knowledge, expertise, skill and judgment of Customer and Customer's pharmacists and other professionals. ABDC strongly encourages Customer to regularly review its systems to identify and address incorrect application of Data Services information, such as different assumptions about package size, case quantities, units of measure or units of use.

8. 340B Program

Notwithstanding any contrary provisions herein, if Customer is eligible to participate in the 340B drug purchase program established pursuant to the Veterans Health Care Act of 1992 as part of Public Law 102-585 ("**340B Program**") and uses the services of a third party ("**340B Service Provider**") to assist with its participation in the 340B Program, in the event that Customer requests ABDC to provide Data Services to its 340B Service Provider, Customer will: (i) enter into an agreement with its 340B Service Provider containing confidentiality and other provisions that are similar in form and substance to those set forth herein with respect to the Data Services; and (ii) indemnify ABDC with respect to any Data Services ABDC provides to a 340B Service Provider at Customer's request.

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Capitalized words not defined in this Term Sheet have the meaning defined in the Master Program Agreement, Elevate Provider Network Term Sheet, or Elevate Advanced Features Term Sheet, as applicable.

❖❖❖

Unsaleable Returns
Term Sheet

1. Program Description
ABDC's unsaleable returns program provides pharmacies with a comprehensive solution for the proper disposal of unsaleable pharmaceutical products and includes all processing, shipping, and ~~destruction~~disposal costs, while allowing pharmacies to optimize the recoverable value of returned products. This Available Program is available to retail, independent community pharmacies and long-term care pharmacies.

2. Contract Returns Processor
ABDC utilizes a third party as its designated "**Contract Returns Processor**" (currently Inmar Inc., hereinafter referred to as "**Inmar**"). Customer must be authorized by ABDC to participate in this Available Program. Customer must use the portal to administer and process returns which are shipped directly to Inmar and processed once per month for potential manufacturer credit ~~once each month~~. Returns received after the published cutoff dates are processed the following month. Unsaleable products should be returned during the month the product expires as printed on the container as certain manufacturers do not issue credit for products returned ~~earlier than three months~~ before the expiration date. Customer is solely responsible for tracking and monitoring returns activity on the portal including details of products deemed eligible for manufacturer credit and reasons for products deemed not eligible for credit. Reports are on the portal.

3. Credit Valuation

a) **Base Program.** Credit issued to Customer is based on the actual credit received from the manufacturer less Available Program fees to cover all shipping charges, processing and disposal costs, and financial reconciliation costs incurred by ABDC. Customer will receive a check for 80% of the manufacturer credit for eligible prescription products and 70% of the manufacturer credit for eligible non-prescription healthcare products.

b) **GNP Premier Program.** If Customer is a GNP Premier member, Customer may be issued a credit in advance of ABDC receiving credits from the manufacturer based on the Estimated Recovery Value ("ERV"). The ERV is calculated by ABDC based on the applicable manufacturer's return goods policies (which vary) and the manufacturer's credit issuance practices. Customer will receive a credit in the form of a check for the equivalent of 80% of the ERV for eligible prescription products and 70% of the ERV for eligible non-prescription healthcare products. The reduction of the ERV amount reflects a fee retained by ABDC for its services and costs incurred to manage this Available Program including shipping charges, processing and disposal costs, and financial reconciliation costs.

c) ABDC may adjust the ERV and credit amount at its discretion to reflect changes in manufacturer credit ~~calculations and~~ valuations, credit issuance policies, and distribution terms respective the products being returned. The amount credited to the Customer is not contingent on manufacturer issuing credit to ABDC, excluding the following conditions ("**Exclusions**"): unusually large quantities of products that are returned through this Available Program; MRNA and flu vaccine products subject to manufacturer return restrictions; returned products not purchased from ABDC; manufacturer making payments directly to Customer; and manufacturer selling products to distributors on a non-returnable basis. Adjustments to reported ERV subsequent to product return receipt and processing by Contract Returns Processor may alter check issuance dates and amounts paid to Customer for such Exclusions.

d) Contract Returns Processor's on-line portal may not always reflect most current ERV but provides the final credit amount issued to Customer in the form of a check. The products not eligible for ERV credit may be accepted by the Contract Returns Processor for disposal (but will not be returned to Customer). ABDC may adjust the fees retained or implement ancillary fees for certain services as necessary.

4. Payments

a) **Base Program**. Customer receives a monthly check that includes all manufacturer credits issued, on Customer's behalf, to ABDC during the previous month.
b) **GNP Premier Program**. If Customer is a GNP Premier member, Customer receives a single check for the eligible products returned to the Contract Return Processor during the monthly return period. The check will be issued within 45 days of the close of the return period when processed returns are eligible for credit, reported by the Contract Returns Processor, and not subject to Exclusions.

5. Premier Franchisee Benefits

a) On-Site Assistance. On-site assistance is available to *Good Neighbor Pharmacy* Premier Members that are in good standing. On-site services include processing of returns, packing and shipping of returned products, printing inventory manifests, and requesting Form 222 for CII Products. Such services are provided by Retail Merchandising Specialists and are optional. Eligible products may be returned directly to the Contract Returns Processor between on-site visits.
b) Prefunded Value. Customer's check amount is based on the credit valuation described in Section 3 and is issued within 45 days of the end of the Contract Returns Processor's reporting period. Customer is not required to reconcile the return claims to the manufacturers and the payment issued by manufacturers, which can take several months, enhancing cash flow and reducing expense.

6. Products Included
a) Prescription products, including controlled substances.
b) Full and partial containers.

c) Over-the-counter healthcare products in full containers.

7. Products Not Eligible for Credit

a) Products not purchased from ABDC and ineligible per manufacturer return goods policy or credit issuance practices.
b) Products not in manufacturer's original container.
c) Products returned outside manufacturer allowable dates.
d) Products that are private labeled (e.g., *Good Neighbor Pharmacy*~~).~~ private label products, etc.).
e) Products that are non-pharmaceuticals such as medical equipment and home healthcare aids.

8. Recalled Products

a) Recalled products may be returned by Customer directly to manufacturers or the manufacturer's returns processor according to the manufacturer's recall instructions issued at the time of the recall.
b) Recalled products may also be returned through this Available Program, and credit received according to the credit valuation terms in Section 3.

9. Other Terms

a) Other terms and conditions provided or required by the Contract Returns Processor (e.g., no acceptance of products that are leaking, broken, tampered with, contaminated, or otherwise soiled, etc.) may apply.
b) This Available Program does not cover unsaleable products returned to Customer's servicing distribution center.
c) This Available Program does not cover saleable products, flu vaccines, or Good Neighbor Pharmacy private label products, each of which should be returned directly to Customer's servicing distribution center in accordance with ABDC's standard returns policy.
d) Customer must comply with shipping, product handling and disposal, and return authorization requirements, including but not limited to DOT, DEA, FDA, HIPAA, and EPA requirements and applicable federal, state, and local laws.

10. Long-Term Care Pharmacies

Non-prescription products and excessive returns not in original manufacturer's packaging are not eligible for return.

11. Customers located in the State of Georgia

To comply with Georgia regulations, the following terms apply: (i) invoice credits are issued within 60 days after processing; (ii) prescription healthcare products must be purchased from ABDC to be eligible for credit; (iii) non-prescription healthcare products may be returned for disposal, but no credit is issued, (iv) products must be returned after the product expiration date and must be processed by Contracts Returns Processor within six months after the expiration date; and (v) the credit amount is based on Customer's purchase price from ABDC less a 7% fee.

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Capitalized words not defined in this Term Sheet have the meaning defined in the Master Program Agreement, Elevate Provider Network Term Sheet, or Elevate Advanced Features Term Sheet, as applicable.

❖❖❖

Statement of Work-Services (Form)

For Special Projects

AmerisourceBergen Drug Corporation ("**ABDC**") will furnish the following special services ("**Services**") to Customer pursuant to this Statement of Work ("**SOW**"). This SOW is effective as of _____ ("**SOW Effective Date**").

1. **Description of Work.** ABDC will perform the following Services:

A. Description: _____

_____

B. Schedule: _____

_____

C. ABDC Training: _____

_____

D. Performance of all Services will be concluded by: _____

2. **Compensation.** Customer will compensate ABDC as follows for Services.

A. Option 1–Time and materials. ABDC will issue invoices at the end of each [day/week/month] for Services performed in the previous [day/week/month]. Invoices will itemize charges with reasonable detail. Payment is due within 15 days from the applicable invoice date.

Customer will pay ABDC $_____ per_____ [day/week/month] per person.

B. Option 2–Fixed price. ABDC will invoice Customer for fixed amounts below. Invoices will itemize charges in reasonable detail. Payment is due within 15 days from the applicable invoice date.

Customer will pay ABDC $_____ as follows: _____ % upon execution of this SOW;

_____ % upon completion of:

_____

_____ % upon completion of:

_____

_____ % upon full completion of Services.

3. **Expenses.** Customer will reimburse ABDC for reasonable documented expenses incurred consistent with ABDC's travel and expense policy.

4. **Incorporation of Terms**. All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this SOW. Capitalized words not defined in this SOW have the meaning defined in the Master Program Agreement, Elevate Provider Network Term Sheet, or Elevate Advanced Features Term Sheet, as applicable.

IN WITNESS WHEREOF, each party's authorized officer, partner or principal has signed this Statement of Work as of the SOW Effective Date.

Customer	**ABDC**
By: _____	By: _____
Name: _____	Name: _____

Title: _____ Title: _____

Date Signed: _____ Date Signed: _____

NOTE: This form applies to special projects and other work that is outside the scope of any other Available Program and agreed upon by ABDC and Customer. Using this SOW Form allows the parties to quickly and easily agree on work to be done for ~~an ABDC customer~~Customer, as well as price and other terms. Special projects must be priced at full fair market value.

AmerisourceBergen

GOOD NEIGHBOR PHARMACY

EXHIBIT C
TABLE OF CONTENTS OF GNP MANUAL(S)

Table of Contents

Good Neighbor Pharmacy Overview	3	Elevate Provider Network	62
Good Neighbor Pharmacy Brand Guidelines	7	Business performance	69
Good Neighbor Pharmacy Central	27	Business coaching	71
In-Store Experience	28	Pet health	73
The Front-End solution, retail pricing, planograms and merchandising	30	Marketplace Overview	74
Good Neighbor Pharmacy private label products	31	Blood pressure management	75
Good Neighbor Pharmacy private label autoshipments	32	Expo RX Card	76
Free Vitamin Program	33	Credit card processing	78
Pharmacy and point of sale systems	34	*Good Neighbor Pharmacy* prescription bags	79
PRxO Generics	38	On-hold messaging services	80
Unsaleable returns program	42	Photo service	81
Good Neighbor Pharmacy University	43	Retailer gift cards and other popular prepaid cards	82
Marketing	56	Travel and trial size items	83
Marketing offerings and resources	58	Vials and caps	84
Protect your independence	60	*Good Neighbor Pharmacy* programs and resources	94

Table of Contents

Good Neighbor Pharmacy Overview	3
Good Neighbor Pharmacy Brand Guidelines	7
Good Neighbor Pharmacy Central	27
In-Store Experience	28
The Front-End solution, retail pricing, planograms and merchandising	30
Good Neighbor Pharmacy private label products	31
Good Neighbor Pharmacy private label autoshipments	32
Free Vitamin Program	33
Pharmacy and point of sale systems	34
PRxO Generics	37
Unsaleable returns program	41
Good Neighbor Pharmacy University	42
Marketing	55
Marketing offerings and resources	57
Protect your independence	59
Elevate Provider Network	61
Business performance	68
Pet health	70
Marketplace Overview	71
Blood pressure management	72
Expo RX Card	73
Credit card processing	75
Good Neighbor Pharmacy prescription bags	76
On-hold messaging services	77
Photo service	78
Retailer gift cards and other popular prepaid cards	79
Travel and trial size items	80
Vials and caps	81
Good Neighbor Pharmacy programs and resources	91

EXHIBIT D

LIST OF CURRENT AND FORMER FRANCHISEES AS OF SEPTEMBER 30, ~~2024~~2025

CURRENT FRANCHISEES

ACTIVE PREMIER FRANCHISEES

~~Pharmacy~~Account Name	Business Street Address	Business Address City	Business Address State	~~ZIP~~Zip Code	Business Phone
~~5 Minute Pharmacy~~Barnett's Drug	~~94-216 Farrington Highway, Suite B1-102~~1661 East Lee Street	~~Waipahu~~Rogersville	~~Hawaii~~Alabama	~~96797~~35652	(256) 247-5451
Beauregard Drugs, Inc	7667 Alabama Hwy 51 Suite A	Opelika	Alabama	36804	(334) 364-9993
~~5 Minute~~Boone's Pharmacy~~-Ala Moana~~	~~725 Kapiolani Boulevard Suite C111~~203 Lafayette Street	~~Honolulu~~Livingston	~~Hawaii~~Alabama	~~96813-6016~~35470	(205) 652-7022
~~5 MINUTE PHARMACY DOWNTOWN~~Borden Family Pharmacy	~~928 NUUANU AVE # 1-B~~3190 Alabama Highway 157	~~HONOLULU~~Cullman	~~Hawaii~~Alabama	~~96817-5190~~35058	(256) 734-7535
~~5 MINUTE PHARMACY LONG TERM CARE~~	~~94-449 Akoki St #102~~	~~WAIPAHU~~	~~Hawaii~~	~~96797-1922~~	
~~86th Street Community~~Chads Payless Pharmacy ~~Corp~~Inc	~~2789 86th~~501 West College Street	~~Brooklyn~~Florence	~~New York~~Alabama	~~112233~~5630	(256) 766-3298
Chandler Drugs	914 7th St South	Clanton	Alabama	35045-3718	(205) 755-8009
~~90th Street~~Ed Holcombe Discount Pharmacy	~~1262 Madison~~1062nd Avenue Southwest	~~New York~~Cullman	~~New York~~Alabama	~~101283~~55055	(256) 734-1083
Fort Payne Pharmacy	1614 Glenn Blvd SW	Fort Payne	Alabama	35968-3522	(256) 845-3402
Fred's Pharmacy	797 Military Street South	Hamilton	Alabama	35570	(205) 921-3193
Gadsden City Pharmacy	911 RAINBOW DR	GADSDEN	Alabama	35901	(256) 547-4479
~~A&B Sunset~~Hackleburg Pharmacy	~~4201 Sunset Boulevard~~34863 Highway 43	~~Steubenville~~Hackleburg	~~Ohio~~Alabama	~~439523~~55564	(205) 935-3392
~~A.~~J&~~ O Peninsula~~M Pharmacy and Compounding Center LLC	~~1860 El Camino Real Suite 108~~301 2nd Ave W.	~~Burlingame~~Oneonta	~~California~~Alabama	~~940103~~35121	(205) 274-2740

Jackson Apothecary	12755 Hwy 22E	New Site	Alabama	36256	(256) 392-3448
Jackson Drugs	1974 Cherokee Road	Alexander City	Alabama	35010-3437	(256) 234-2538
Killen Corner Drug	1621 Highway 72	Killen	Alabama	35645	(256) 757-2166
A+ Care FusionMill Street Pharmacy	204 North Greenville Avenue Suite 12410639 Alabama Highway 168	AllenBoaz	TexasAlabama	75002-9130359 57	(256) 593-5279
Payless Drugs	2512 31st Avenue North	Birmingham	Alabama	35207	(205) 252-4179
Payless Drugs	460 Walker Rd	Springville	Alabama	35146-0252	(205) 467-7988
Payless Drugs	4901 Gary Avenue	Fairfield	Alabama	35064-5064	(205) 785-4343
Payless Drugs	585 Morris Majestic Rd	Morris	Alabama	35116	(205) 647-0515
Payless Drugs	1310 Eastern Valley Rd	Bessemer	Alabama	35020	(205) 425-5258
A1CareRiverside Pharmacy	2001 E 4TH ST STE 112405 S 1st St	SANTA ANAGadsden	CaliforniaAlabama	92705-3916359 01-5358	(256) 546-3784
A-1Shoals Pharmacy	815-3 South Moody Road859 E Hobson St	PalatkaTuscumbia	FloridaAlabama	321773 5674-1773	(256) 389-9800
AalphaSouthside Pharmacy	174 South Alvarado Street11964 Escue Drive Suite A	Los AngelesTanner	CaliforniaAlabama	90057-2211356 71	(256) 232-6588
The Drug Store	464 N DEAN RD	AUBURN	Alabama	36830	(334) 821-4493
The Drug Store At Stevenson	205 Kentucky Avenue	Stevenson	Alabama	35772	(256) 437-6500
AbalaThe Pill Box Pharmacy	550 West Eaton Avenue,2422 Danville Rd SW Suite BJ	TracyDecatur	CaliforniaAlabama	95376-3445356 03	(256) 353-1121
Absolute WellnessThe Pill Box Pharmacy	19720 Ventura Boulevard Unit 100474 Highway 67 South	Woodland HillsDecatur	CaliforniaAlabama	913643 5603	(256) 353-0100
Young's Drug and General Store	24460 HIGHWAY 48	WOODLAND	Alabama	36280-5204	(256) 449-2372
Young Drug Store	88960 Hwy 9	Lineville	Alabama	36266	(256) 396-5632
Abundant LifeAlaska Family Pharmacy	117 North Main Street167 South Santa Claus Lane	BaxleyNorth Pole	GeorgiaAlaska	3151399 9705	(907) 488-8555
Alaska Family Pharmacy	1001 Noble Street	Fairbanks	Alaska	99701	(907) 452-2556
Access MedicalHarry Race Pharmacy	1271 Westwood Boulevard106 Lincoln Street	Los AngelesSitka	CaliforniaAlaska	900249 9835	(907) 313-6883
AccokeekPetersburg Rexall Drug and	15789 Livingston Road Suite 108215	AccokeekPetersburg	MarylandAlaska	206079 9833	(907) 772-3265

~~Health Care Inc~~	N Nordic Drive				
White's Pharmacy	705 Halibut Point Road	Sitka	Alaska	99835	(907) 313-6881
~~ACE Medical~~Desert Sky Pharmacy	~~9171 Wilshire Boulevard~~6750 W Thunderbird Rd Suite ~~B~~103	~~Beverly Hills~~Peoria	~~California~~Arizona	~~902108~~ 5381	(623) 209-0870
Potter's House Apothecary	21585 North 77th Avenue Suite 1500	Peoria	Arizona	85382	(623) 362-9322
Walton Drug	1520 West Thatcher Boulevard	Safford	Arizona	85546	(928) 428-6366
Walton Drug of Morenci	408 Burro Alley	Morenci	Arizona	85540	(928) 865-9946
White Mountain Pharmacy	4461 South White Mountain Road Suite E1	Show Low	Arizona	85901-7783	(928) 537-8555
White Mountain Pharmacy 2	2841 Highway 260 Box 2217	Overgaard	Arizona	85933	(928) 535-4300
~~Ace Pharmacy & Discount~~American Drug	~~1572 West 37th~~1 East Main Street	~~Hialeah~~Greenbrier	~~Florida~~Arkansas	~~33012~~72058	(501) 679-2211
~~ACME~~American Home Pharmacy	~~1548 East Fowler Avenue~~454 Ingram Street	~~Tampa~~Clinton	~~Florida~~Arkansas	~~33612~~72031-6609	(501) 745-4266
~~Acquaviva's~~Amity Road Pharmacy	~~1555 Port Malabar Northeast,~~810 Amity Road Suite 101	~~Palm Bay~~Conway	~~Florida~~Arkansas	~~32905~~72032	(501) 358-3863
~~Acts Pharmacy and Healthcare Services~~Beebe Drug Inc	~~1901 South Union Avenue Building B Suite 2011~~703 Dewitt Henry Drive	~~Tacoma~~Beebe	~~Washington~~Arkansas	~~98405~~72012	(501) 882-5402
Berry Drug of Dardanelle	417 Union Street	Dardanelle	Arkansas	72834	(479) 229-4811
Bono Family Pharmacy	10040 North Highway 63 Suite 4	Bono	Arkansas	72416	(870) 277-1543
C & D Drug Store	121 North Commerce Avenue	Russellville	Arkansas	72801	(479) 968-2456
~~Adair Drug~~Caldwell Pharmacy 1	~~510 Burkesville Street Suite 1~~804 S Falls Blvd	~~Columbia~~Wynne	~~Kentucky~~Arkansas	~~42728~~72396	(870) 238-7085
Cave City Pharmacy	301 South Main Street Suite C	Cave City	Arkansas	72521	(870) 283-5589
City Drug	1512 Linwood Dr	Paragould	Arkansas	72450-5814	(870) 236-8501
~~Adams-Cumberland~~City Pharmacy	~~3463 Biglerville Road~~606 South Park Street	~~Biglerville~~Pocahontas	~~Pennsylvania~~ Arkansas	~~17307~~72455	(870) 892-5517
Clarks Family Pharmacy	621 Commerce Street	Earle	Arkansas	72331	(870) 792-7177
Clarksville Family Pharmacy	510 South Rogers Street Suite 3	Clarksville	Arkansas	72830	(479) 647-3138
Clinic Drug Store,	1700 Harrison	Batesville	Arkansas	72501	(870) 793-5170

Inc.	Street, Suite D				
Collier Drug-Dickson	100 West Dickson Street	Fayetteville	Arkansas	72701	(479) 442-6262
Collier Drug-Prairie Grove	801 East Douglas Street	Prairie Grove	Arkansas	72753	(479) 846-2195
Conway MedCare Pharmacy	2521 College Avenue	Conway	Arkansas	72034	(501) 358-3498
AdamsCorner Drug Store	408 B 16th Avenue E830 East Main Street	CordeleMelbourne	GeorgiaArkansas	310157 2556	(870) 368-7171
Adams FamilyCrawford Pharmacy	6381 Hamilton107 Crawford Street	PrestonHot Springs	GeorgiaArkansas	318247 1913	(501) 624-4636
Deans Pharmacy #1	1640 South Whitehead Drive	Dewitt	Arkansas	72042	(870) 946-2381
AdamsDebbie's Family Pharmacy	98 Peachtree Street5403 W Pinnacle Point Dr	CuthbertRogers	GeorgiaArkansas	39840-5807727 58-8118	(479) 271-6300
East End Express Pharmacy	21019 Highway 167, Suite 100	Hensley	Arkansas	72065	(501) 486-4100
East End Pharmacy	20381 Arch Street Pike	Little Rock	Arkansas	72206	(501) 888-2830
ADD DrugFamily Clinic Pharmacy	1695 South Lumpkin1208 West Main Street	AthensWalnut Ridge	GeorgiaArkansas	306067 2476	(870) 886-8100
AdlerFamily Medical Center Pharmacy	3806 A North Church Street3016 S. University Ste 120	GreensboroLittle Rock	North CarolinaArkansas	274057 2204	(501) 562-3314
Food Giant Discount Pharmacy	605 North Illinois Street	Harrisburg	Arkansas	72432	(870) 578-5200
AdrienForrest City Family Pharmacy	7023 Miami Avenue1111 N Washington St	CincinnatiForrest City	OhioArkansas	452437 2335-1800	(870) 581-9029
Advanced CareGammel's Clinic Pharmacy Services	2136 Robinson909 Unity Road, Suite 2	JacksonCrossett	MichiganArkansas	492037 1635	(870) 364-5100
Garner Family Pharmacy LLC	765 East Matthew Avenue	Jonesboro	Arkansas	72401-3103	(870) 558-5488
Advanced HealthGreenbrier Pharmacy	7916 Oakland Drive61A South Broadview Street	PortageGreenbrier	MichiganArkansas	490247 2058-9161	(501) 402-4906
Hawkins Lakeside Pharmacy	902 Central Boulevard	Bull Shoals	Arkansas	72619	(870) 445-7188
Health-Care Pharmacy	10 Hospital Drive	Morrilton	Arkansas	72110	(501) 354-1460
AdvancedHickory Hill Pharmacy	288 Smith Street109 Hickory Hill Drive	Perth AmboyHelena	New JerseyArkansas	088617 2342	(870) 338-8351
Advanced RxHilltop Family Pharmacy-060	1400 Donelson Pike Ste A151706 Visions Avenue	NashvilleJonesboro	TennesseeArkansas	372177 2401	(870) 336-8310

Horseshoe Health & Medicine	600 Market Street	Horseshoe Bend	Arkansas	72512	(870) 670-4580
Hudson Pharmacy	1609 Main St	Van Buren	Arkansas	72956-4735	(479) 474-1193
Hyde Pharmacy Inc	1001 W Kings Hwy	Paragould	Arkansas	72450-4638	(870) 239-4036
iCareRx Pharmacy - Newport	1117 McLain Street Suite 400	Newport	Arkansas	72112	(870) 523-5555
~~Advance~~Imboden Medical Pharmacy	110 ~~South Oak~~North Walnut Street	~~Advance~~Imboden	~~Missouri~~Arkansas	~~63730~~72434	(870) 869-2046
~~A Family~~Joe's Pharmacy ~~Apple Valley~~Express	~~15863 Kasota Road~~2412 E Race Ave Suite ~~C~~F	~~Apple Valley~~Searcy	~~California~~Arkansas	~~92307~~72143-4730	(501) 268-9400
~~AGH Rediscripts~~Kavanaugh Pharmacy	~~9733 Healthway Drive~~5200 KAVANAUGH BLVD	~~Berlin~~LITTLE ROCK	~~Maryland~~Arkansas	~~21811~~72207	(501) 664-3844
Landmark Pharmacy	3401 Atwood Road, Suite E	Little Rock	Arkansas	72206	(501) 888-2223
~~AHCS Specialty Care Sacramento~~Marion Family Pharmacy	~~1820 Tribute Road Suite G~~134 Block Street	~~Sacramento~~Marion	~~California~~Arkansas	~~95815~~72364	(870) 739-1111
Mark's Pharmacy	205 E Main	Melbourne	Arkansas	72556	(870) 368-5355
Mayflower Family Pharmacy	616B Highway 365	Mayflower	Arkansas	72106-9630	(501) 470-9898
McCoy Tygart Drug Store Inc	821 North Rock	Sheridan	Arkansas	72150	(870) 942-5121
McHaney Drug PA	1400 W Hunt St	Paragould	Arkansas	72450-3574	(870) 236-3180
Medic Pharmacy	306 North Reynolds Road	Bryant	Arkansas	72022	(501) 847-3596
~~Akers United Drug~~Medi Quik Pharmacy	~~406 North Park~~810 West Commercial Street	~~Chewelah~~Ozark	~~Washington~~Arkansas	~~99109~~72949	(479) 667-4145
Medi-Quik Pharmacy	1531 East Main Street	Booneville	Arkansas	72927	(479) 675-3900
Medi-Sav Pharmacy #1	621 E Main St	Charleston	Arkansas	72933	(479) 965-2244
Medisav Pharmacy #2	8820 Rogers Avenue	Fort Smith	Arkansas	72903	(479) 452-0278
Medisav Pharmacy #3	1910 S Zero St., Suite A	Fort Smith	Arkansas	72901	(479) 646-2971
MedRelief Pharmacy	2895 State Highway 77 South Suite 3	Marion	Arkansas	72364	(870) 739-1700
Miller's Drug Store	231 S Main St	Malvern	Arkansas	72104-3736	(501) 332-2351
~~Alameda Thrifty~~Mitchell's Main Street Pharmacy	~~4900 ALAMEDA AVE~~214 EAST MAIN STREET	~~EL PASO~~Mountain View	~~Texas~~Arkansas	~~79905~~72560	(870) 269-3253
Mitchell's Medi	1523 South Main	Hope	Arkansas	71801	(870) 777-5555

Mart	Street				
Mitchell's Park Street Pharmacy	526 Park St. PO Box 569	Calico Rock	Arkansas	72519	(870) 297-8107
~~Alaska~~Nashville Family Pharmacy	~~1001 Noble Street~~330 S Main St	~~Fairbanks~~Nashville	~~Alaska~~Arkansas	~~99701~~71852-2410	(870) 912-0858
~~Alaska~~National Family Pharmacy	~~167 South Santa Claus Lane~~1615 Dodson Avenue	~~North Pole~~Fort Smith	~~Alaska~~Arkansas	~~99705~~72901	(479) 783-6135
Newton's Pharmacy	715 West Main Street	Russellville	Arkansas	72801	(479) 968-1157
Palace Drug	270 Main Street	Mammoth Spring	Arkansas	72554	(870) 625-3222
Palace Drug of Salem, LLC	106 West Highway 62	Salem	Arkansas	72576	(870) 895-3811
~~Alberts~~Piggott Pharmacy	~~201 South~~648 E Main ~~Street Suite 2~~St	~~Pittston~~Piggott	~~Pennsylvania~~Arkansas	~~18640~~72454	(870) 598-3183
Prescriptions Corner Drug	320 W Kingshighway	Paragould	Arkansas	72450-4229	(870) 239-9535
Prince Pharmacy	211 E Stadium Dr	Magnolia	Arkansas	71753	(870) 234-7292
Randolph County Drug	567 Highway 67 South Suite A	Pocahontas	Arkansas	72455	(870) 202-2536
Rector Downtown Drug	316 East 9th Street	Rector	Arkansas	72461	(870) 595-3523
ReedHutchins Pharmacy	408 West Main Street	Heber Springs	Arkansas	72543-3017	(501) 270-8888
Remedy Drug	8511 West Markham Street	Little Rock	Arkansas	72205	(501) 313-4480
Rison Pharmacy	301 Main St	Rison	Arkansas	71665-8835	(870) 325-6262
Rose Drug	211 E Main St	Clarksville	Arkansas	72830-3723	(479) 754-2180
Rose Drug Dover	8880 Market Street	Dover	Arkansas	72837	(479) 331-2133
Rose Drug of Dardanelle	1176 State Hwy 22 West Suite A	Dardanelle	Arkansas	72834	(479) 229-4040
Sheridan Family Pharmacy	677 Heritage Drive	Sheridan	Arkansas	72150	(870) 484-4488
Smith Drug / The Corner Gifts	695 E Third St	Gentry	Arkansas	72734-0629	(479) 736-2241
~~Albuquerque City~~Smith Drug and Compounding, Inc	~~205 Silver Avenue SW~~1629 Airport Road Suite D	~~Albuquerque~~Hot Springs	~~New Mexico~~Arkansas	~~87102~~71913	(501) 767-2220
Smith Drug and Compounding, Inc. #3	1500 Albert Pike Rd	Hot Springs	Arkansas	71913-4023	(501) 767-2230
Smith Drug and Compounding Inc	117 Piper Street Suite A	Hot Springs	Arkansas	71901	(501) 760-0808
Smith Drug And Compounding Inc.	1 Mercy Lane Street Suite 103	Hot Springs	Arkansas	71913-6408	(501) 624-2900
Sullivan Pharmacy	731 N MAIN ST STE B	HARRISON	Arkansas	72601	(870) 741-2119
~~Alexander's~~Tanglewood Drug Store	~~211 East Main Street~~6815 Cantrell Road	~~Fennville~~Little Rock	~~Michigan~~Arkansas	~~49408~~72207	(501) 664-4444

THE PHARMACY AT FLIPPIN STATION	109 N 1ST ST	FLIPPIN	Arkansas	72634	(870) 493-7367
The Prescription Pad Pharmacy	539 Highway 425 South	Monticello	Arkansas	71655	(870) 367-4227
Village Pharmacy	500 West Commercial Street	Ozark	Arkansas	72949	(479) 667-2101
Vilonia Family Pharmacy Inc	1122 Main Street Suite 14	Vilonia	Arkansas	72173	(501) 796-2204
Walden Drug	3104 W Kingshighway	Paragould	Arkansas	72450	(870) 236-6118
~~Alexa~~Watson Pharmacy	~~919 Tyson Avenue~~802 W 4th Street	~~Philadelphia~~Fordyce	~~Pennsylvania~~ Arkansas	~~19111~~71742	(870) 352-2161
Wilson Wil-Sav Pharmacy	5 Allen Chapel Road	Batesville	Arkansas	72501	(870) 251-2432
Winningham Pharmacy	232 W Main St #112	Bradford	Arkansas	72020	(501) 344-2763
Woodsprings Pharmacy	1807 Woodsprings Road	Jonesboro	Arkansas	72401	(870) 972-8310
Wynne Apothecary Inc	500 Falls Blvd N	Wynne	Arkansas	72396	(870) 238-8511
Dean's Pharmacy # 3	311 West Chestnut Street	Marianna	Arkansas	72360	(870) 295-4100
A1Care Pharmacy	2001 E 4th St Suite 112	Santa Ana	California	92705-3916	(714) 541-3900
Absolute Wellness Pharmacy	19720 Ventura Boulevard Unit 100	Woodland Hills	California	91364	(818) 912-6800
Access Medical Pharmacy	1271 Westwood Boulevard	Los Angeles	California	90024	(310) 873-6565
ACE Medical Pharmacy	9171 Wilshire Boulevard Suite B	Beverly Hills	California	90210	(310) 385-9128
A Family Pharmacy Apple Valley	15863 Kasota Rd Suite C	Apple Valley	California	92307	(760) 242-5452
Alhambra Professional Pharmacy	330 South Garfield Avenue, Suite 104	Alhambra	California	91801	(626) 458-8909
~~Aliton's Pharmacy Home Healthcare Centers~~	~~12 Sussex Street~~	~~Port Jervis~~	~~New York~~	~~12771-2253~~	
AllCare Pharmacy	12998 Hesperia Road Suite 102	Victorville	California	92395-8317	(760) 241-0508
AllCare Pharmacy	331 Main Street	Salinas	California	93901	(831) 424-8053
~~All Care Pharmacy~~	~~7125 Allen Road~~	~~Allen Park~~	~~Michigan~~	~~48101~~	
~~Allcare Pharmacy & Healthcare Services~~	~~112 South Oxley Drive~~	~~Lyons~~	~~Georgia~~	~~30436~~	
~~Allentown Pharmacy~~	~~2 South Main Street~~	~~Allentown~~	~~New Jersey~~	~~08501~~	
~~Alliance Specialty Pharmacy~~	~~25301 Van Dyke Avenue~~	~~Center Line~~	~~Michigan~~	~~48015~~	
~~Allstar Pharmacy~~	~~105 Terhune Avenue~~	~~Lodi~~	~~New Jersey~~	~~07644~~	
Alpha-1 Pharmacy	341 East Main Street	San Jacinto	California	92583-4206	(951) 225-4244

	Suite #104				
~~Alphacare Specialty Pharmacy~~	~~1510 Gunbarrel Road Suite 500~~	~~Chattanooga~~	~~Tennessee~~	~~37421-7175~~	
Alta Care Pharmacy	1004 W FOOTHILL BLVD SUITE 101	UPLAND	California	91786	(909) 360-8352
~~Altama Discount Pharmacy~~	~~5711 Altama Avenue suite G~~	~~Brunswick~~	~~Georgia~~	~~31525~~	
Altamed Pharmacy West Covina	1300 South Sunset Avenue Room 100	West Covina	California	91790-3342	(888) 499-9303
~~Alwan Pharmacy and Compounding Center~~	~~311 North Western Avenue~~	~~Peoria~~	~~Illinois~~	~~61604~~	
~~Alwood Pharmacy~~	~~211 South 1st Street~~	~~Alpha~~	~~Illinois~~	~~61413~~	
~~AMCARE PHARMACY~~Amcare Pharmacy	760 S WASHBURN AVENUE SUITE 01/02	CORONA	California	92882	(951) 268-6486
~~American Drug~~	~~1 East Main Street~~	~~Greenbrier~~	~~Arkansas~~	~~72058~~	
~~American Home Pharmacy~~	~~454 Ingram Street~~	~~Clinton~~	~~Arkansas~~	~~72031-6609~~	
~~American Surgical Pharmacy~~	~~103 East Highland Avenue~~	~~San Bernardino~~	~~California~~	~~92404~~	
~~Amity Road Pharmacy~~	~~810 Amity Road Suite 101~~	~~Conway~~	~~Arkansas~~	~~72032~~	
~~AM Pharmacy~~	~~10401 Anderson Mill Road Suite112B~~	~~Austin~~	~~Texas~~	~~78750~~	
~~ANDERSON'S PHARMACY~~	~~112 East Main Street~~	~~North Carrollton~~	~~Mississippi~~	~~38947~~	
~~Anderson Crossing Pharmacy~~	~~3318 Andersonville Highway~~	~~Andersonville~~	~~Tennessee~~	~~37705~~	
~~Anderson Family Pharmacy~~	~~1142 Jackson Street~~	~~Anderson~~	~~South Carolina~~	~~29625-2760~~	
~~Anderson Pharmacy~~	~~1108 Marquette Avenue~~	~~Bay City~~	~~Michigan~~	~~48706~~	
AndersonRx, Inc	2940 East Street	Anderson	California	96007	(530) 378-5566
~~Andres Pharmacy and Discount~~	~~7167 Southwest 8th Street~~	~~Miami~~	~~Florida~~	~~33144~~	
~~Andrew Browns Drug Store Inc~~	~~1502 Pittston Avenue~~	~~Scranton~~	~~Pennsylvania~~	~~18505~~	
~~Angelo Pharmacy~~	~~492 Ferry Street~~	~~Newark~~	~~New Jersey~~	~~07105~~	
~~Angier Family Pharmacy, LLC~~	~~50 East Depot Street~~	~~Angier~~	~~North Carolina~~	~~27501-6017~~	
~~Ann Arbor Pharmacy LLC~~	~~2418 East Stadium Boulevard~~	~~Ann Arbor~~	~~Michigan~~	~~48104~~	
~~A Plus Pharmacy~~	~~4750 East Moody Boulevard Suite 107~~	~~Bunnell~~	~~Florida~~	~~32110~~	
~~Apollo Pharmacy~~	~~418 West~~	~~SAVANNAH~~	~~Georgia~~	~~31401-3218~~	

	~~Broughton Street~~				
Apollo Pharmacy	29645 Rancho California Road Suite 129	Temecula	California	92591-5285	(951) 506-4006
~~Apollo Pharmacy #2~~	~~111 Canal Street Suite 101~~	~~Pooler~~	~~Georgia~~	~~31322-4054~~	
~~Apollo Pharmacy of Wyandotte~~	~~2000 Eureka Road~~	~~Wyandotte~~	~~Michigan~~	~~48192-6004~~	
~~Apothecare Pharmacy~~	~~1006 Main St~~	~~Wartburg~~	~~Tennessee~~	~~37887~~	
~~Apothecary Shoppe~~	~~82 South 1100 East, Suite 104~~	~~Salt Lake City~~	~~Utah~~	~~84102~~	
~~Appleby Drug Store~~	~~133 E Shirley St~~	~~Mount Union~~	~~Pennsylvania~~	~~17066~~	
~~Apple Discount Drug~~	~~520 Clinch Avenue~~	~~Clinton~~	~~Tennessee~~	~~37716-4228~~	
~~Arapaho Pharmacy~~	~~57 Arapaho Village~~	~~Richardson~~	~~Texas~~	~~75080~~	
~~Arbor Lakes Pharmacy~~	~~1549 Holmes Road~~	~~Ypsilanti~~	~~Michigan~~	~~48198~~	
~~Archdale Drug~~	~~11220 North Main Street~~	~~Archdale~~	~~North Carolina~~	~~27263~~	
Arden Medical Pharmacy	435 West Arden Avenue Suite 110	Glendale	California	91203	(818) 247-1842
~~AR-EX Drug Store~~	~~801 Broadway~~	~~Marysville~~	~~Kansas~~	~~66508~~	
~~AR-EX Pharmacy~~	~~370 New Brunswick Avenue~~	~~Fords~~	~~New Jersey~~	~~08863~~	
Arianna Medical Pharmacy	3600 North Verdugo Road Suite 103	Glendale	California	91208	(818) 957-9200
~~Aries Pharmacy~~	~~8200 State Route 366~~	~~Russells Point~~	~~Ohio~~	~~43348-9670~~	
Arka Pharmacy	621 East Glenoaks Boulevard Suite C	Glendale	California	91207	(818) 937-9394
~~Arlington Pharmacy~~	~~106 North Main Street~~	~~Arlington~~	~~Ohio~~	~~45814~~	
Armen Pharmacy	1025 East Broadway	Glendale	California	91205	(818) 551-0082
~~Armitage Pharmacy, Inc.~~	~~3650 West Armitage Avenue Suite 100~~	~~Chicago~~	~~Illinois~~	~~60647~~	
~~ARON'S PHARMACY~~	~~1209 NORTH 18TH ST~~	~~MONROE~~	~~Louisiana~~	~~71201~~	
~~Arrow Pharmacy~~	~~317 Bankhead Highway Suite A~~	~~Carrollton~~	~~Georgia~~	~~30117-2497~~	
~~ASG Rx Corp~~	~~10216 Liberty Avenue~~	~~Ozone Park~~	~~New York~~	~~11417~~	
~~Asheville Discount Pharmacy~~	~~76 Patton Avenue~~	~~Asheville~~	~~North Carolina~~	~~28801~~	
~~Ashland Drug~~	~~53 North Second Street~~	~~Ashland~~	~~Oregon~~	~~97520~~	
~~Asti's South Hills Pharmacy~~	~~250 Mt Lebanon Boulevard~~	~~Pittsburgh~~	~~Pennsylvania~~	~~15234~~	
Audrey Pharmacy	9741 Bolsa	Westminster	California	92683	(714) 531-1983

	Avenue, Suite 116				
Audrey Pharmacy #2	9822 Bolsa ~~Avenue~~Ave Suite G	Westminster	California	~~926839~~ 2683-6870	(714) 531-1244
Avalon Pharmacy	58471 29 Palms Highway, Suite 301	Yucca Valley	California	92284	(760) 365-7621
~~Avery Pharmacy & Health Care~~	~~436 Hospital Drive~~	~~Linville~~	~~North Carolina~~	~~28646~~	
~~Ayer Family Pharmacy~~	~~13 Park Street~~	~~Ayer~~	~~Massachusetts~~	~~01432-1120~~	
~~Aynor Family Pharmacy~~	~~240 8th Avenue~~	~~Aynor~~	~~South Carolina~~	~~29511~~	
~~Azaal Discount Pharmacy~~	~~9834 Conant Street~~	~~Hamtramck~~	~~Michigan~~	~~48212~~	
~~Azaal Pharmacy II LLC~~	~~15120 Michigan Avenue~~	~~Dearbon~~	~~Michigan~~	~~48126~~	
B&B ~~PHARMACY~~Pharmacy	10244 Rosecrans Avenue	Bellflower	California	90706	(562) 866-8363
~~B & B Pharmacy~~	~~300 North Ballard~~	~~Pampa~~	~~Texas~~	~~79065~~	
~~B & B Pharmacy~~	~~462 Haywood Road~~	~~Asheville~~	~~North Carolina~~	~~28806~~	
~~B & C Drug Company~~	~~702 12TH Street~~	~~Belleville~~	~~Kansas~~	~~66935~~	
~~Bachman Drug~~	~~129 South Fowler~~	~~Meade~~	~~Kansas~~	~~67864~~	
~~Baggett Pharmacy Inc~~	~~133 East Race Street~~	~~Kingston~~	~~Tennessee~~	~~37763~~	
~~Bainbridge Pharmacy~~	~~1420 East Evans Street~~	~~Bainbridge~~	~~Georgia~~	~~39819~~	
~~Bakers Family Pharmacy~~	~~200 West Main street~~	~~Jackson~~	~~Tennessee~~	~~38301~~	
Balboa Pharmacy	6465 Balboa Avenue Suite 101	San Diego	California	92111	(858) 278-0111
~~Baldwin Pharmacy LLC~~	~~1927 Grand Avenue~~	~~North Baldwin~~	~~New York~~	~~11510-2818~~	
~~Bangor Drug Company~~	~~711 Broadway Suite 1~~	~~Bangor~~	~~Maine~~	~~04401-3225~~	
~~Banner Drug Co~~	~~308A Mocksville Highway~~	~~Statesville~~	~~North Carolina~~	~~28625~~	
~~Banner Drug Downtown Statesville~~	~~307 North Center Street~~	~~Statesville~~	~~North Carolina~~	~~28677~~	
~~Banner Drug of Harmony~~	~~111 West Memorial Highway~~	~~Harmony~~	~~North Carolina~~	~~28634-0436~~	
~~Banner Elk Pharmacy~~	~~110 Park Avenue~~	~~Banner Elk~~	~~North Carolina~~	~~28604~~	
~~Barber's Pharmacy~~	~~731 Cameron Drive~~	~~Blackshear~~	~~Georgia~~	~~31516~~	
~~Barnes Drug Store~~	~~200 South Patterson Street~~	~~Valdosta~~	~~Georgia~~	~~31601~~	
~~Barnett's Drug~~	~~1661 East Lee Street~~	~~Rogersville~~	~~Alabama~~	~~35652~~	

~~Barr's Pharmacy~~	~~28 West Main~~	~~Xenia~~	~~Ohio~~	~~45385-2938~~	
~~Barr's Pharmacy of Blanchester~~	~~601 West Main Street~~	~~Blanchester~~	~~Ohio~~	~~45107-1141~~	
~~BARR'S PHARMACY OF HILLSBORO~~	~~119 South High Street~~	~~Hillsboro~~	~~Ohio~~	~~45133~~	
~~BARR'S PHARMACY OF SABINA~~	~~12459 East US Route 22 3~~	~~Sabina~~	~~Ohio~~	~~45169~~	
~~Barrachina Pharmacy~~	~~2004 East Expressway 83 Suite 2~~	~~Weslaco~~	~~Texas~~	~~78596~~	
Barrington Wilshire Pharmacy	11701 Wilshire Boulevard, Suite 3	Los Angeles	California	90025	(310) 473-3323
~~Barrys Drug Center~~	~~414 Poyntz Avenue~~	~~Manhattan~~	~~Kansas~~	~~66502-6086~~	
~~Basalt Clinic Pharmacy~~	~~110 Midland Avenue~~	~~Basalt~~	~~Colorado~~	~~81621~~	
Bascom Pharmacy	105 North Bascom Avenue, Suite 101	San Jose	California	95128	(408) 995-6020
~~Bastrop Medicine Shop~~	~~1110 Main Street, Suite A~~	~~Bastrop~~	~~Texas~~	~~78602~~	
~~Batts Drug Company Inc~~	~~115 Commerce Street~~	~~Hawkinsville~~	~~Georgia~~	~~31036~~	
~~Batts Drug Company Mansfield, LLC~~	~~4424 Highway 213~~	~~Mansfield~~	~~Georgia~~	~~30055~~	
~~Baxley Wellness Pharmacy Inc~~	~~160 Azalia Road~~	~~Baxley~~	~~Georgia~~	~~31513~~	
~~Bayboro Pharmacy~~	~~702 MAIN ST~~	~~BAYBORO~~	~~North Carolina~~	~~28515~~	
~~Bayfield Pharmacy~~	~~871 County Road 501~~	~~Bayfield~~	~~Colorado~~	~~81122~~	
~~Bay Pharmacy~~	~~112 South State Street~~	~~St Ignace~~	~~Michigan~~	~~49781~~	
~~Bay Pharmacy~~	~~7407 W FM 2147~~	~~Horseshoe Bay~~	~~Texas~~	~~78657~~	
~~Bayshore Pharmacy~~	~~2 Bayshore Plaza~~	~~Atlantic Highlands~~	~~New Jersey~~	~~07716~~	
~~Bay Shore Pharmacy~~	~~93 A 4th Street~~	~~Suttons Bay~~	~~Michigan~~	~~49682~~	
~~Bay Street Pharmacy~~	~~7746 Bay St~~	~~Sebastian~~	~~Florida~~	~~32958~~	
~~BBRx Pharmacy~~	~~6013 7th Avenue Unit B~~	~~Brooklyn~~	~~New York~~	~~11220~~	
~~Beach Pharmacy of Avon~~	~~41934 Highway 12~~	~~Avon~~	~~North Carolina~~	~~27915~~	
~~Beach Pharmacy of Hatteras~~	~~57353 Highway 12~~	~~Hatteras~~	~~North Carolina~~	~~27943~~	
~~Beach Street Pharmacy~~	~~7630 North Beach Street Suite 170~~	~~Fort Worth~~	~~Texas~~	~~76137~~	
Beach Terrace Pharmacy	12282 Beach ~~Boulevard~~Blvd	Stanton	California	90680-3970	(714) 786-8222
~~Beacon Prescriptions~~	~~25 Collins Road~~	~~Bristol~~	~~Connecticut~~	~~06010~~	
~~Beacon~~	~~875 Foxon Road~~	~~East Haven~~	~~Connecticut~~	~~06513~~	

~~Prescriptions~~					
~~Beacon Prescriptions~~	~~543 West Main Street~~	~~New Britain~~	~~Connecticut~~	~~06053~~	
~~Beacon Prescriptions~~	~~609 North Main Street~~	~~Southington~~	~~Connecticut~~	~~06489~~	
~~Beacon Prescriptions South St.~~	~~57 South Street~~	~~Bristol~~	~~Connecticut~~	~~06010~~	
Bear Creek Pharmacy	24046 Clinton Keith ~~Road~~Rd Suite 107	Wildomar	California	92595	(951) 677-4880
~~Beasley Drug Company~~	~~933 Center Street~~	~~Conyers~~	~~Georgia~~	~~30012~~	
~~Beauton Drug~~	~~124 North Washington~~	~~East Praire~~	~~Missouri~~	~~63845~~	
~~Bechtels Pharmacy~~	~~302 Main Street~~	~~Slatington~~	~~Pennsylvania~~	~~18080~~	
~~Beebe Drug Inc~~	~~703 Dewitt Henry Drive~~	~~Beebe~~	~~Arkansas~~	~~72012~~	
Beeman's Rx Pharmacy	355 East 21st Street	San Bernardino	California	92404	(909) 882-3719
Beemans Highland Pharmacy	399 East Highland Avenue	San Bernardino	California	92404	(909) 886-6851
~~Belew Drug Choto~~	~~1616 Choto Markets Way~~	~~Knoxville~~	~~Tennessee~~	~~37922~~	
~~Belew Drugs~~	~~2021 North Broadway St~~	~~Knoxville~~	~~Tennessee~~	~~37917~~	
~~Belew Drugs Asheville Highway~~	~~8622 Asheville Highway~~	~~Knoxville~~	~~Tennessee~~	~~37924-4107~~	
~~Belew Drugs Washington Pike~~	~~5908 Washington Pike Suite 102~~	~~Knoxville~~	~~Tennessee~~	~~37918~~	
~~Belleville Pharmacy, LLC.~~	~~338 Washington Avenue~~	~~Belleville~~	~~New Jersey~~	~~07109~~	
~~Bell Pharmacy~~	~~1907 Route 27~~	~~Edison~~	~~New Jersey~~	~~08817~~	
~~Ben Hill Pharmacy~~	~~3740 CAMPBELLTON RD SW~~	~~ATLANTA~~	~~Georgia~~	~~30331-5222~~	
~~Benivex Pharmacy~~	~~370 West Indian Trail~~	~~Aurora~~	~~Illinois~~	~~60506~~	
~~Bennett's Hometown Pharmacy~~	~~13202 Cleveland Street West, Suite 100~~	~~Nahunta~~	~~Georgia~~	~~31553~~	
~~Bennett's Hometown Pharmacy~~	~~26826 Highway 82~~	~~Waynesville~~	~~Georgia~~	~~31566~~	
~~Bennett's Hometown Pharmacy~~	~~4402 North Second Street Suite C~~	~~Folkston~~	~~Georgia~~	~~31537~~	
~~Benton Pharmacy~~	~~2606 Main Street~~	~~Benton~~	~~Kentucky~~	~~42025~~	
~~Berea Drug~~	~~402 Richmond Road Suite A~~	~~Berea~~	~~Kentucky~~	~~40403~~	
~~Berry & Sweeney~~	~~1377 North Fair~~	~~Pasadena~~	~~California~~	~~91103--2101~~	

~~Pharmacy~~	~~Oaks Avenue~~				
~~Berry Drug of Dardanelle~~	~~417 Union Street~~	~~Dardanelle~~	~~Arkansas~~	~~72834~~	
Best Care Pharmacy	1306 Main Street Suite 102	Ramona	California	92065	(760) 440-0550
~~Best Care Pharmacy~~	~~1040 South Pendleton Street~~	~~Easley~~	~~South Carolina~~	~~29642~~	
~~Best Care Pharmacy Plus~~	~~31500 Dequindre Road Suite 300~~	~~Warren~~	~~Michigan~~	~~48092~~	
~~BestRx~~	~~1103 North Main Street Suite E~~	~~Fountain Inn~~	~~South Carolina~~	~~29644-1336~~	
~~Betsy Layne Pharmacy Inc~~	~~11105 US Highway 23 South~~	~~Betsy Layne~~	~~Kentucky~~	~~41605~~	
~~BETTER HEALTH PHARMACY & WELLNESS~~	~~518 Burke Bypass~~	~~Olyphant~~	~~Pennsylvania~~	~~18447~~	
~~BETTER HEALTH RX CORP~~	~~503 W 125TH ST~~	~~NEW YORK~~	~~New York~~	~~10027-3402~~	
~~Better Life Pharmacy~~	~~1530 North McMullen Booth Road Suite D8~~	~~Clearwater~~	~~Florida~~	~~33759~~	
~~Better Life Pharmacy~~	~~5621 Atlantic Avenue Suite 103~~	~~Raleigh~~	~~North Carolina~~	~~27615~~	
Beverly Glen Pharmacy	2946 North Beverly Glen Circle	Los Angeles	California	90077	(310) 475-0568
~~Big Brothers Pharmacy~~	~~4801 Fenton Road~~	~~Flint~~	~~Michigan~~	~~48507~~	
~~Big Spring Pharmacy~~	~~91 South High Street~~	~~Newville~~	~~Pennsylvania~~	~~17241~~	
~~Biocare Pharmacy~~	~~10603 Bellaire Boulevard Suite B114~~	~~Houston~~	~~Texas~~	~~77072~~	
~~Bison Rx Inc~~	~~20442 Charleston Road~~	~~Buffalo~~	~~West Virginia~~	~~25033~~	
~~Bi-Wize Pharmacy~~	~~902 Main Street~~	~~Friona~~	~~Texas~~	~~79035~~	
BJRX Pharmacy	1801 East March Lane Suite B280	Stockton	California	95210-6653	(209) 474-2888
~~Black & White Pharmacy~~	~~8381 Bird Road~~	~~Miami~~	~~Florida~~	~~33155~~	
~~Black River Pharmacy~~	~~32A North Williamsburg County Highway~~	~~Kingstree~~	~~South Carolina~~	~~29556~~	
~~Blanks Pharmacy~~	~~272 Pike Street~~	~~Covington~~	~~Kentucky~~	~~41011~~	
~~Blood Pharmacy~~	~~410 Main Street~~	~~Neligh~~	~~Nebraska~~	~~68756~~	
~~Blood Pharmacy Tilden~~	~~103 East 2nd Street~~	~~Tilden~~	~~Nebraska~~	~~68781~~	
~~Blue Earth Drug~~	~~125 South Grove Street Suite 1~~	~~Blue Earth~~	~~Minnesota~~	~~56013~~	
~~Bluegrass Apothecary~~	~~3000 Alvey Park Drive West~~	~~Owensboro~~	~~Kentucky~~	~~42303~~	
~~Blythewood Pharmacy and~~	~~710-C University Village Drive~~	~~Blythewood~~	~~South Carolina~~	~~29016~~	

Home Medical Equipment				
Bobs Drugs	194 North Division Street	Hesperia	Michigan	49421
Bocage Pharmacy Centre	7150 Jefferson Highway Suite 680	Baton Rouge	Louisiana	70806
Boies Medical Center Pharmacy	828 Delbon Avenue	Turlock	California	95382
Bonaire Pharmacy	810 SR 96 Suite 1800	Warner Robins	Georgia	31088
Bond Pharmacy	703 West Buchanan	California	Missouri	65018
Bono Family Pharmacy	10040 North Highway 63 Suite 4	Bono	Arkansas	72416
Book's Pharmacy	1158 Logan Sewell Drive	Vidalia	Louisiana	71373-3342
Boomtown Drug	514 South Oklahoma Cutoff	Burkburnett	Texas	76354
Boone's Pharmacy	203 Lafayette Street	Livingston	Alabama	35470
Boone Drug and Health Care	345 Deerfield Road	Boone	North Carolina	28607
Boone Drug at Greenway	579 Greenway Road Suite 100	Boone	North Carolina	28607
Boone Drug at New Market	245 New Market Center	Boone	North Carolina	28607
Booneville Community Pharmacy	206 North Second Street	Booneville	Mississippi	38829
Borden Family Pharmacy	3190 Alabama Highway 157	Cullman	Alabama	35058
Boro Hall Pharmacy	565 Bound Brook Road	Middlesex	New Jersey	08846
BOTTINEAU CLINIC PHARMACY	314 OHMER ST	BOTTINEAU	North Dakota	58318
Bouvier Pharmacy Inc	515 Lincoln Street	Marlborough	Massachusetts	01752
Bowling Family Pharmacy	314 Treuhaft Boulevard	Barbourville	Kentucky	40906
Bowman's Hillsdale Pharmacy	6256 Southwest Capitol Highway	Portland	Oregon	97239-2674
Boyd's Pharmacy of Florence	306 Broad Street	Florence	New Jersey	08518
Boyd's Pharmacy of Mansfield	23202 Columbus Road Suite E	Columbus	New Jersey	08022
Boyd's Pharmacy of Medford	5-100 Wilkins Station Road	Medford	New Jersey	08055
Boyds Pharmacy of Bordentown	118 Farnsworth Avenue	Bordentown	New Jersey	08505
Boyds Pharmacy of Pemberton	17 Fort Dix Road	Pemberton	New Jersey	08068
Boyt Drugs	411 Main Street	Metuchen	New Jersey	08840

~~Brainerd Pharmacy~~	~~3602 Brainerd Road~~	~~Chattanooga~~	~~Tennessee~~	~~37411~~	
~~Brasstown Professional Pharmacy, Inc.~~	~~23B Murphy Highway~~	~~Blairsville~~	~~Georgia~~	~~30512~~	
~~BREHME DRUG~~	~~220 East Main Street~~	~~Manchester~~	~~Iowa~~	~~52057~~	
Brent Air Pharmacy	134 South Barrington Avenue	Los Angeles	California	90049	(310) 476-2211
Brentwood Pharmacy	2530B SAN VICENTE BLVD	Santa Monica	California	90402	(310) 393-0201
~~Brewster Family Pharmacy~~	~~360 North Wabash Avenue~~	~~Brewster~~	~~Ohio~~	~~44613~~	
~~Briarmill Pharmacy~~	~~1820 Lanes Mill Road~~	~~Brick~~	~~New Jersey~~	~~08724~~	
~~Brick City Drugs~~	~~159 Fountains Boulevard~~	~~Madison~~	~~Mississippi~~	~~39110~~	
Bright La Mirada Pharmacy	12675 La Mirada Boulevard Suite 100	La Mirada	California	90638	(562) 777-8175
~~BrightMed Pharmacy~~	~~9630 Clarewood Drive Suite A-3~~	~~Houston~~	~~Texas~~	~~77036~~	
Brimhall Pharmacy	8305 Brimhall ~~Road #~~Rd Suite 1603	Bakersfield	California	93312-2243	(661) 588-5555
~~Broadneck Pharmacy~~	~~269 Peninsula Farm Road~~	~~Arnold~~	~~Maryland~~	~~21012~~	
Broadway Pharmacy	~~7581 Broadway~~7600 Pacific Ave	Lemon Grove	California	91945-1605	(619) 717-8990
~~Broadway Pharmacy~~	~~2790 Broadway Avenue~~	~~North Bend~~	~~Oregon~~	~~97459~~	
~~Broken Arrow Family Drug~~	~~3359 South Elm Place~~	~~Broken Arrow~~	~~Oklahoma~~	~~74012~~	
~~Broken Arrow Family Drug North~~	~~1030 East Lansing Street~~	~~Broken Arrow~~	~~Oklahoma~~	~~74012-7010~~	
~~Brooke's Pharmacy~~	~~812 South Park Street Suite 5A~~	~~Carrollton~~	~~Georgia~~	~~30117~~	
~~Brooklet Drug~~	~~102 Parker Avenue South~~	~~Brooklet~~	~~Georgia~~	~~30415~~	
~~Brookshire Bros. Pharmacy of Kirbyville~~	~~1005 South Margaret~~	~~Kirbyville~~	~~Texas~~	~~75956~~	
~~Brothers Pharmacy~~	~~118 West Pierson Road~~	~~Flint~~	~~Michigan~~	~~48505~~	
~~Brown's Pharmacy~~	~~2021 North Macarthur, Suite 120~~	~~Irving~~	~~Texas~~	~~75061~~	
~~Brown's Pharmacy~~	~~63 Canton Street~~	~~Troy~~	~~Pennsylvania~~	~~16947~~	
~~Brownings Pharmacy~~	~~141 East Hibiscus Boulevard~~	~~Melbourne~~	~~Florida~~	~~32901~~	
~~Brownings~~	~~1919 Alice Street~~	~~Waycross~~	~~Georgia~~	~~31501~~	

~~Pharmacy~~					
~~Browns Pharmacy~~	~~121 Sullivan Street~~	~~Canton~~	~~Pennsylvania~~	~~17724~~	
~~Brownstone Rx~~	~~114 West Bayfield Street~~	~~Washburn~~	~~Wisconsin~~	~~54891~~	
~~Bruner Pharmacy~~	~~321 East Broadway Street~~	~~Monett~~	~~Missouri~~	~~65708~~	
~~Brunson's Pharmacy~~	~~12 North Brooks Street~~	~~Manning~~	~~South Carolina~~	~~29102~~	
BT ~~PHARMACY~~Pharmacy	14262 ~~BEACH BLVD~~Beach Blvd	~~WESTMINSTER~~Westminster	California	92683	(714) 622-5992
~~Buchanan Drugs~~	~~106 Courthouse Square~~	~~Buchanan~~	~~Georgia~~	~~30113~~	
~~Buckeye Pharmacy~~	~~15549 State Route 170 Suite 1~~	~~East Liverpool~~	~~Ohio~~	~~43920~~	
~~Buckleys Drug Store~~	~~35 East Palisade Avenue~~	~~Englewood~~	~~New Jersey~~	~~07631-2932~~	
~~Buford Street Drug Store~~	~~115 North Granard Street~~	~~Gaffney~~	~~South Carolina~~	~~29341~~	
~~Bunte's Pharmacy~~	~~115 East Main Avenue~~	~~Zeeland~~	~~Michigan~~	~~49464~~	
~~Bunting Family Pharmacy~~	~~1337 A New Road~~	~~Northfield~~	~~New Jersey~~	~~08225~~	
Burbank Compounding Pharmacy	201 S BUENA VISTA ST	Burbank	California	91505	(818) 563-2120
~~Burgess Drug Store Inc. #2~~	~~19 Medical Loop Suite 2~~	~~Whitley City~~	~~Kentucky~~	~~42653~~	
~~Burgess Drug Store Inc # 3~~	~~2157 South Highway 27~~	~~Stearns~~	~~Kentucky~~	~~42647~~	
Burt's Pharmacy	2900 Townsgate Road Suite 105	Westlake Village	California	91361	(805) 371-4000
Burt's Pharmacy	2333 Borchard Road	Newbury Park	California	91320	(805) 498-6675
Burt's Pharmacy Moorpark	865 Patriot Drive Suite 103	Moorpark	California	93021-3407	(805) 552-4500
~~Burwell Pharmacy~~	~~137 Grand Avenue~~	~~Burwell~~	~~Nebraska~~	~~68823-0520~~	
Bushards Pharmacy	244 Forest Avenue	Laguna Beach	California	92651	(949) 494-1059
~~Butler Drug Store~~	~~222 East Main Street~~	~~Portageville~~	~~Missouri~~	~~63873~~	
~~Butler Pharmacy~~	~~2301 Bridge Avenue~~	~~Point Pleasant~~	~~New Jersey~~	~~08742~~	
~~Byers Pharmacy~~	~~568 US HWY 36~~	~~Byers~~	~~Colorado~~	~~80103~~	
~~Byhalia Drug Company, LLC~~	~~7984 Hwy 178 W~~	~~Byhalia~~	~~Mississippi~~	~~38611~~	
~~C & C Pharmacy~~	~~621 West Memorial Drive~~	~~Dallas~~	~~Georgia~~	~~30132-4120~~	
~~C & D Drug Store~~	~~121 North Commerce Avenue~~	~~Russellville~~	~~Arkansas~~	~~72801~~	
~~C & R Pharmacy~~	~~204 North Detroit Street~~	~~West Liberty~~	~~Ohio~~	~~43357~~	
Cabrillo Pharmacy	146 North Brent	Ventura	California	93003	(805) 643-9939

	Street				
~~Cadillac Family Pharmacy~~	~~108 North Mitchell~~	~~Cadillac~~	~~Michigan~~	~~49601~~	
~~Caldwell Discount Drug Co~~	~~804 South Falls Blvd~~	~~Wynne~~	~~Arkansas~~	~~72396~~	
~~Caleb's Hometown Pharmacy~~	~~801 Main Street~~	~~Collins~~	~~Mississippi~~	~~39428~~	
~~Cali Pharmacy & Discount~~	~~1924-26 West 60th Street~~	~~Hialeah~~	~~Florida~~	~~33012~~	
~~Calvert City Pharmacy~~	~~906 E. 5th Ave.~~	~~Calvert City~~	~~Kentucky~~	~~42029~~	
~~Camacho Pharmacy~~	~~509 Elizabeth Avenue~~	~~Elizabeth~~	~~New Jersey~~	~~07206~~	
Camden Pharmacy and Gift Emporium	414 North Camden Drive	Beverly Hills	California	90210	(310) 273-3363
~~Campbell's Hometown Pharmacy~~	~~272 Highway 11 E~~	~~Bulls Gap~~	~~Tennessee~~	~~37711~~	
~~Campbell's Pharmacy~~	~~2175 Highway 35~~	~~Sea Girt~~	~~New Jersey~~	~~08750~~	
~~Campbell Drug~~	~~311 Main Street~~	~~Oshkosh~~	~~Nebraska~~	~~69154~~	
Campus Pharmacy	100 UCLA Medical Plaza Suite 150	Los Angeles	California	90024	(310) 208-2340
~~Cano Pharmacy~~	~~12600 Southwest 120th Street Suite 102~~	~~Miami~~	~~Florida~~	~~33186~~	
~~Cano Pharmacy~~	~~8300 West Flagler Street Suite 165~~	~~Miami~~	~~Florida~~	~~33144~~	
~~Cano Pharmacy 5~~	~~5190 North West 167th Street Suite 100~~	~~Miami Lakes~~	~~Florida~~	~~33014~~	
Capital City Pharmacy	339 Georgia ~~Street~~St	Vallejo	California	94590-5906	(707) 644-2272
~~Capitol Heights Pharmacy~~	~~1200 Madison Street~~	~~Denver~~	~~Colorado~~	~~80206~~	
Capsmart Pharmacy	2557 Mowry ~~Avenue~~Ave Suite 11	Fremont	California	~~945389~~ 4538-1614	(510) 896-8121
~~Cardenas Pharmacy~~	~~2741 Coral Way~~	~~Miami~~	~~Florida~~	~~33134~~	
~~Care More Pharmacy~~	~~151 Dorton Jenkins Highway~~	~~Dorton~~	~~Kentucky~~	~~41520~~	
Care Pharmacy	302 East Bullard Avenue	Fresno	California	93710	(559) 261-9888
~~Careplus Pharmacy~~	~~701 West Dr Martin Luther King Jr Boulevard Suite 1~~	~~Tampa~~	~~Florida~~	~~33603~~	
~~Care Rx Pharmacy~~	~~4501 Hale Avenue Suite 1~~	~~Harlingen~~	~~Texas~~	~~78550~~	
~~Care Rx Pharmacy~~	~~1167 East Tennessee Street~~	~~Tallahassee~~	~~Florida~~	~~32308-6913~~	

~~Carerx Specialty Pharmacy AP~~	~~13201 Stephens Road Suite G~~	~~Warren~~	~~Michigan~~	~~48089-4378~~	
~~Carlin Springs Pharmacy~~	~~611 South Carlin Springs Road Suite 105~~	~~Arlington~~	~~Virginia~~	~~22204~~	
~~Carlisle Pharmacy~~	~~771 Central Avenue~~	~~Carlisle~~	~~Ohio~~	~~45005~~	
~~Carrboro Family Pharmacy~~	~~104 Highway 54 West Bypass Unit J Carrboro Plaza~~	~~Carrboro~~	~~North Carolina~~	~~27510~~	
~~CARRINGTON DRUG INC~~	~~415 MAIN~~	~~CARRINGTON~~	~~North Dakota~~	~~58421~~	
~~Carroll Apothecary Inc~~	~~425 W US Highway 30 # 140~~	~~Carroll~~	~~Iowa~~	~~51401~~	
~~Carroll Drug Store~~	~~3 Village Green Way~~	~~Southwest Harbor~~	~~Maine~~	~~04679-1306~~	
~~Carroll Pharmacy~~	~~840 South Brightleaf Boulevard~~	~~Smithfield~~	~~North Carolina~~	~~27577-4377~~	
~~Cashiers Valley Pharmacy~~	~~52 Cashiers Shopping Center Highway 64 East~~	~~Cashiers~~	~~North Carolina~~	~~28717~~	
~~Castle Hill Drugs Inc~~	~~674 Castle Hills Avenue~~	~~Bronx~~	~~New York~~	~~10473~~	
~~Catching's Prescriptions LTD~~	~~1900 South Coulter Street Suite F~~	~~Amarillo~~	~~Texas~~	~~79106~~	
Catinat Pharmacy	9549 Bolsa Avenue Suite A	Westminster	California	92683	(714) 531-3560
~~Cave City Pharmacy~~	~~301 South Main Street Suite C~~	~~Cave City~~	~~Arkansas~~	~~72521~~	
~~Cayucos Pharmacy~~	~~72 South Ocean Avenue~~	~~Cayucos~~	~~California~~	~~93430~~	
~~CDS #10 Pharmacy~~	~~1308 Ashley Circle~~	~~Bowling Green~~	~~Kentucky~~	~~42104~~	
~~Cedar Springs Pharmacy~~	~~14111 White Creek Avenue Northeast Suite 12~~	~~Cedar Springs~~	~~Michigan~~	~~49319-8170~~	
~~Celina Drug~~	~~701 North Preston Road Suite 210~~	~~Celina~~	~~Texas~~	~~75009~~	
~~Center Drugs~~	~~133 Second Avenue Southeast~~	~~Cairo~~	~~Georgia~~	~~39828~~	
~~Center Pharmacy~~	~~1108 Liberty Avenue~~	~~Hillside~~	~~New Jersey~~	~~07205~~	
~~Center Pharmacy~~	~~105 North Smith Street~~	~~Pleasanton~~	~~Texas~~	~~78064~~	
Central Avenue Pharmacy	133 15th Street	Pacific Grove	California	93950	(831) 373-1225
~~Central Drugs~~	~~1955 Sunnycrest Drive Suite 100~~	~~Fullerton~~	~~California~~	~~92835~~	
Central Drugs	520 West La Habra Boulevard	La Habra	California	90631	(562) 691-6754
~~CENTRAL JERSEY PHARMACY~~	~~275 HOBART ST~~	~~PERTH AMBOY~~	~~New Jersey~~	~~08861-3396~~	

CENTRAL PHARMACY	4 8TH STREET NORTH	NEW ROCKFORD	North Dakota	58356	
CENTRAL PHARMACY INC	990 MAIN ST	CARRINGTON	North Dakota	58421	
Central Rx PharmacyDrugs #2	50 Eagle Rock Way1955 Sunnycrest Dr Suite C100	BrentwoodFullerton	California	94513-4941928 35-3627	(714) 515-1530
Central Valley Community Pharmacy	152 West 1500 North	Nephi	Utah	84648	
Central Valley Pharmacy	228 Route 32, Suite 103	Central Valley	New York	10917	
Centrastate Specialty Script	901 W Main Street (Main Lobby)	Freehold	New Jersey	07728-2537	
Century City Medical Plaza Pharmacy	2080 Century Park East, Suite 102	Los Angeles	California	90067	(310) 553-3434
Ceres Drug Store	2929 4th Street	Ceres	California	95307	(209) 537-0718
Chads PaylessChulaVista Pharmacy Inc	501 West College384 H Street Suite 100	FlorenceChula Vista	AlabamaCalifornia	356309 1910	(619) 781-8177
Coachella Valley Pharmacy	77-932 Country Club Dr Suite 2-2	Palm Desert	California	92211-3407	(760) 223-7188 Ext 0
Chaffee Drug StoreCollege Pharmacy	211 West Yoakum90 North Ashwood Avenue	ChaffeeVentura	MissouriCalifornia	637409 3003	(805) 642-4135
Chans Pharmacy Plus	2092 North University Drive	Pembroke Pines	Florida	33024	
ChapinCooley Health Pharmacy	138 A Amicks Ferry Road1091 S Mt Vernon Ave., # J	ChapinColton	South CarolinaCalifornia	290369 2324-3932	(909) 514-1730
Croal's Rexall Drugs	901 East Williams Street	Barstow	California	92311	(760) 256-8968
Chapman Drug Co IncDaniels Pharmacy	615 North Central943 Geneva Avenue	HapevilleSan Francisco	GeorgiaCalifornia	303549 4112	(415) 584-2210
CHAPMAN HEALTHCARE PHARMACYDelta Pharmacy	305 Maple Drive407 N Main St	VidaliaRio Vista	GeorgiaCalifornia	304749 4571-1616	(707) 374-5135
CharlesDesert Hospital Outpatient Pharmacy	5081 Okeechobee Boulevard1180 North Indian Canyon Drive Suite E140	West Palm BeachSprings	FloridaCalifornia	334179 2262	(760) 323-1001
Charlie'sDiablo Pharmacy of Mullens LLC	224 Howard Avenue12677 Alcosta Blvd Suite 145	MullensSan Ramon	West VirginiaCalifornia	258829 4583-4423	(925) 237-9939
Cherokee Main StreetDK Pharmacy	218 East Main Street10431 Lemon Avenue,	CherokeeRancho Cucamonga	IowaCalifornia	510129 1737	(909) 493-1500

	Suite G				
Dollar Drug	1055 West College Avenue, Suite C	Santa Rosa	California	95401	(707) 575-1313
Dorado Pharmacy	13003 Van Nuys Boulevard Suite E	Pacoima	California	91331-8324	(818) 485-5554
~~Chester Family~~Dorado Pharmacy 2	~~1645 J A Cochran Bypass Suite G~~13678 Van Nuys Boulevard	~~Chester~~Pacoima	~~South Carolina~~California	~~29706-3102~~91331-3616	(747) 274-1055
~~Choice~~Drug Co Pharmacy~~ Inc~~	~~5913~~307 North ~~Armenia Avenue~~Ash Street	~~Tampa~~Escondido	~~Florida~~California	~~336039~~92027	(760) 745-6672
~~ChulaVista~~Elevate Pharmacy	~~384 H~~8631 West 3rd Street Suite ~~100~~320 E	~~Chula Vista~~Los Angeles	California	~~919109~~90048	(310) 657-4090
~~Church Square~~El Monte Pharmacy	~~7905 Euclid Avenue~~3948 North Peck Road	~~Cleveland~~El Monte	~~Ohio~~California	~~441039~~91732	(626) 448-2507
~~Circle Drug~~Family First Pharmacy	~~3211 Robinson Drive~~4859 E. Cesar Chavez Blvd	~~Waco~~Fresno	~~Texas~~California	~~767069~~3727-3811	(559) 493-5566
Farmacia Anaheim	941 South Euclid Street	Anaheim	California	92802	(714) 215-4740
Farmacia Del Pueblo	653 Main Street	Brawley	California	92227	(760) 344-2000
Farmacia Del Pueblo	801 E Birch St Suite 4	Calexico	California	92231	(760) 768-6000
Farmacia Del Pueblo	1692 S 4th St Suite F	El Centro	California	92243	(760) 353-9000
~~Citizens Pharmacy~~Farmacia Estrella	~~5325 Atlanta Highway~~5020 South C Street	~~Flowery Branch~~Oxnard	~~Georgia~~California	~~305429~~3033	(805) 240-9962
Farmacia Familiar	1126 S Bristol St	Santa Ana	California	92704-3420	(714) 486-2277
Farmacia Santa Ana	307 East 1st Street Suite D	Santa Ana	California	92701-5302	(714) 542-5444
~~City~~Finley's Rexall Drug	~~630 RB Wilson Drive~~8554 Sierra Avenue	~~Huntingdon~~Fontana	~~Tennessee~~California	~~383449~~2335	(909) 822-2288
~~City Drug~~Foothill Remedy Drugs	~~1512 Linwood Drive~~6253 Foothill Boulevard	~~Paragould~~Tujunga	~~Arkansas~~California	~~724509~~1042	(818) 236-2500
~~City~~Fox Drug of Torrance	~~232 E JEFFERSON~~1327 El Prado	~~Van Alstyne~~Torrance	~~Texas~~California	~~754959~~0501	(310) 328-7244
~~City Drug~~Freeman Medical Pharmacy	~~1722 Carey~~301 North Prairie Avenue, Suite 110	~~Cheyenne~~Inglewood	~~Wyoming~~California	~~82001-4420~~90301	(310) 672-7000
~~City Drug~~Friendly #1 Pharmacy	~~1612 East Lamar Alexander Parkway~~485 Lewis Road, Suite D	~~Maryville~~San Jose	~~Tennessee~~California	~~378049~~5111	(408) 226-0200
~~City Drug~~Friendly	~~113 Bobo Drive~~639	~~Crystal Springs~~San	~~Mississippi~~Cal	~~390559~~	(408) 279-8188

#2 Pharmacy and Gifts	Tully Road, Suite A	Jose	ifornia	5111	
City Drug StoreFullerton Pharmacy	159 Academy Street1820 Fullerton Avenue Suite 105	Presque IsleCorona	MaineCalifornia	047699 2881	(951) 496-4222
City Drug StoreGalaxy Pharmacy	104 East Belknap1801 W Romneya Dr Suite 108	JacksboroAnaheim	TexasCalifornia	764589 2801-1824	(714) 833-5723
CITY HEALTHMART DRUG	128 E Cherokee Ave	Nowata	Oklahoma	74048	
CityGalaxy Pharmacy	606 South Park1295 East Anaheim Street	PocahontasLong Beach	ArkansasCalifornia	724559 0813	(562) 599-1301
GALAXY PHARMACY	1360 E ANAHEIM ST STE 106	LONG BEACH	California	90813-5516	(562) 336-1200
Gateway Pharmacy	1330 Gateway Boulevard Suite B-2	Fairfield	California	94533	(707) 422-0500
GKN Rx Inc	1471 B St Suite R	Livingston	California	95334-1432	(209) 398-2035
CityGolden Gate Pharmacy of Zebulon PC	460 Thomaston1836 Noriega Street	ZebulonSan Francisco	GeorgiaCalifornia	302959 4122	(415) 661-0790
ClabaughGonzales Rx Pharmacy	501 Court Street18 Fourth St	BeatriceGonzales	NebraskaCalifornia	683109 3926-0808	(831) 675-3643
Clark's FamilyGrove Pharmacy Inc	4501 MACCORKLE AVE SW STE 1018283 Grove Avenue Suite 108-109	South CharlestonRancho Cucamonga	West VirginiaCalifornia	253099 1730-3137	(909) 480-4401
Clark CountyHaig Pharmacy	716 Boone1112 South Glendale Avenue	WinchesterGlendale	KentuckyCalifornia	403919 1205	(818) 500-0800
Clark Drug CompanyHaller's Pharmacy and Medical Supply	206 West 6th Street37323 Fremont Boulevard	WaynesboroFremont	GeorgiaCalifornia	30830-1460945 36-5098	(510) 797-2772
Clark Drugs	500 Main Street	Munfordville	Kentucky	42765	
Clark Low CostHealthcare Pharmacy	3107 Clark14642 Newport Avenue	ClevelandTustin	OhioCalifornia	44109-1145927 80	(714) 669-4000
ClarkHendricks Pharmacy	104 South Main Street137 North Harvard Ave	CimarronClaremont	KansasCalifornia	678359 1711	(909) 624-1611
Clarks FamilyHepps Prescription Pharmacy	621 Commerce Street240 S La Cienega Blvd	EarleBeverly Hills	ArkansasCalifornia	723319 0211-3375	(310) 652-0550
High Street Pharmacy	4248 Macarthur Boulevard	Oakland	California	94619	(510) 530-1335
ClarksHinas Home	1946 42nd Street	Cedar	IowaCaliforni	524029	(661) 664-7979

Care Pharmacy	NE9508 Stockdale Highway Suite 130	RapidsBakersfield	a	3311	
Clarksville FamilyHinas Pharmacy	510 South Rogers Street 6300 White Lane Suite 3N	ClarksvilleBakersfield	ArkansasCalifornia	728309 3309	(661) 282-8805
Clay CommunityHoly Cross Specialty Pharmacy	118 Clay CO S/C11550 Indian Hills Rd Suite 130	ManchesterMission Hills	KentuckyCalifornia	409629 1345-1200	(818) 898-1628
Claypool HillHospital Dr Valley Pharmacy	12252 Governor George C Peery hwy7600 Hospital Dr Suite A	Pounding MillSacramento	VirginiaCalifornia	246379 5823-5406	(916) 423-2098
ClaysImperial Pharmacy	3513 Court Street1530 Palm Avenue	CatlettsburgSan Diego	KentuckyCalifornia	41129-1 011921 54	(619) 343-0095
Imperial Valley Pharmacy	1487 Ocotillo Dr	El Centro	California	92243-4212	(760) 970-5800
Clear Lake Professional BuildingIndio Medical Pharmacy	251 Medical Center81893 Doctor Carreon Boulevard, Suite 1007	WebsterIndio	TexasCalifornia	775989 2201	(760) 347-0659
ClearSpringInland Pharmacy	8031 Southpark Circle1001 E Latham Ave Suite BP	LittletonHemet	ColoradoCalifornia	801209 2543-4435	(951) 658-7111
Clear SpringIrvine Medical Center Pharmacy	34 Mulberry Street16300 Sand Canyon Avenue, Suite 101	Clear SpringIrvine	MarylandCalifornia	217229 2618	(949) 453-9789
CLEARSPRING PHARMACY, LTD	201 UNIVERSITY BLVD STE 105	DENVER	Colorado	80206	
Cleveland LowcostIvy Pharmacy	14529 Puritas16854 Ivy Avenue Suite C	ClevelandFontana	OhioCalifornia	441359 2335-1504	(909) 321-5588
Clinic Drug Store, Inc.	1700 Harrison Street, Suite D	Batesville	Arkansas	72501	
ClinicJeff Goodman Special Care Pharmacy	203 North 2nd Street1625 Schrader Boulevard, 1st Floor	Central CityLos Angeles	KentuckyCalifornia	423309 0028-6213	(323) 993-7513
ClinicJonathan's Pharmacy	58 Big A19341 Bear Valley Road Suite 101103	ToccoaApple Valley	GeorgiaCalifornia	305779 2308	(760) 983-2599
ClinicKanan Pharmacy and Medical Supplies	1115 South Marshall Street5847 Kanan Rd	BooneAgoura Hills	IowaCalifornia	500369 1301	(818) 889-3070
Clio CommunityKML	4180 West Vienna Road1655 S De	ClioCupertino	MichiganCalifornia	48420-9 497950	(408) 873-8123

Pharmacy Inc	Anza Blvd Suite 42			14	
Cloverdale Drugs	900 North Main Street	Cloverdale	Indiana	46120	
CLOVER PHARMACY	3100 Quakerbridge Road	Mercerville	New Jersey	08619	
Coachella ValleyKomoto Medical Pharmacy	77-932 Country Club Drive2110 Truxtun Avenue, Suite 2-2100	Palm DesertBakersfield	California	922119 3301	(661) 327-7524
COAL GROVE PHARMACYKomoto Pharmacy, Inc	600 MARION PIKE1017 Ellington St	IRONTONDelano	OhioCalifornia	456389 3215-2621	(661) 725-9489
Coastal Drug Company	204 Butler Avenue	Midway	Georgia	31320	
Coast HillsKovacs-Frey Pharmacy	2610 San Miguel2860 Artesia Boulevard	NewportRedondo Beach	California	926609 0278	(310) 371-7541
CoatsKramers Pharmacy-Inc	393 North McKinley29525 Canwood Street	CoatsAgoura Hills	North CarolinaCalifornia	275219 1301	(818) 706-8099
Cobb'sKyoto Pharmacy	510 Houston Street420 E 3rd St Suite 6	George WestLos Angeles	TexasCalifornia	780229 0013-1645	(213) 253-5999
La Buena Vida Pharmacy	51335 Cesar Chavez Street Suite 116	Coachella	California	92236	(760) 398-8866
Cocoa Beach DiscountLanvy Pharmacy	291 West Cocoa Beach Causeway14971 Brookhurst Street Suite A	Cocoa BeachWestminster	FloridaCalifornia	329319 2683	(714) 531-2828
Cole CampLark Drugs Pharmacy	512 West16251 Main Street	Cole CampGuerneville	MissouriCalifornia	653259 5446	(707) 869-9055
Coleman FamilyLarson's Pharmacy	211 East Railway142 West H Street	ColemanColton	MichiganCalifornia	486189 2324	(909) 825-1950
Coliseum Park ProfessionalLinda Rx Pharmacy	380 Hospital Drive1569 Lexann Avenue, Suite 175 A130	MaconSan Jose	GeorgiaCalifornia	312179 5121	(408) 270-2828
CollegeLinda Vista Pharmacy	90 North Ashwood Avenue4300 Rose Drive Suite D	VenturaYorba Linda	California	930039 2886	(714) 528-3610
Collier Drug DicksonLindhurst Pharmacy	100 West Dickson Street5991 Lindhurst Ave	FayettevilleMarysville	ArkansasCalifornia	727019 5901	(530) 741-9800
Collier Drug Prairie Grove	801 East Douglas Street	Prairie Grove	Arkansas	72753	
CollingsworthLos Alamitos Pharmacy	1016 16TH Street3801 Katella Avenue Suite 120	WellingtonLos Alamitos	TexasCalifornia	790959 0720	(562) 431-2505
ColonialLucerne	828 Clifton	CliftonLucerne	New	070139	(707) 274-6643

Pharmacy, Inc.	Avenue6244 East Highway 20		JerseyCalifornia	5458-1316	
ColonialMaggies Pharmacy	7510 Mechanicsville Pike2315 KUEHNER DR UNIT 107	MechanicsvilleSIMI VALLEY	VirginiaCalifornia	23111993063	(805) 770-1001
ColonialMagnolia Pharmacy	1915 North Cleveland-Massillon Road7130 Magnolia Ave Suite C	BathRiverside	OhioCalifornia	442109 2504-3864	(951) 327-7770
Colony Discount DrugsMaico Pharmacy	502 South Grant Street10161 Bolsa Avenue Suite 105B	FitzgeraldWestminster	GeorgiaCalifornia	31750-3398926 83	(714) 531-7000
Colquitt PharmacyManor Drug Medical & Mobility	215 West Main5795 North First Street	ColquittFresno	GeorgiaCalifornia	39837993710	(559) 431-4142
Colts NeckMarket Pharmacy	420 State Route 34 Suite 3099250 Reseda Blvd Unit 2C	Colts NeckNorthridge	New JerseyCalifornia	077229 1324	(818) 701-7777
Columbia PharmacyMcCarthy Drugs	803 Burkesville Street12025 San Vicente Blvd	ColumbiaLos Angeles	KentuckyCalifornia	427289 0049	(310) 452-1105
ComfortMedical Arts Pharmacy	4041320 Maricopa Highway 27Suite J	ComfortOjai	TexasCalifornia	780139 3023-3154	(805) 646-7211
CommonwealthMedical Pavilion Pharmacy	5425 North Mayo Trail,9460 No Name Uno Suite 102100	PikevilleGilroy	KentuckyCalifornia	415019 5020	(408) 842-2001
CommunityMed-Rx Pharmacy and Compounding	1089 Elizabeth Avenue Store 51031 East Vista Way	ElizabethVista	New JerseyCalifornia	072019 2084	(760) 724-7125
CommunityMeiji Pharmacy	897 N. Summit Street1630 W Redondo Bch Blvd Suite 14	Crescent CityGardena	FloridaCalifornia	321129 0247	(310) 538-2885
CommunityMendocino Coast Pharmacy	212 East 8TH350 Cypress Street	BeaverFort Bragg	OklahomaCalifornia	739329 5437-5408	(707) 962-0800
CommunityMexicare Pharmacy LLC	2904 Forsythe Ave9670 Magnolia Avenue Suite 107	MonroeRiverside	LouisianaCalifornia	712019 2503-3684	(951) 588-6727
CommunityMickey Fine Pharmacy of Chicago Ridge	9830 South Ridgeland433 North Roxbury Drive	Chicago RidgeBeverly Hills	IllinoisCalifornia	604639 0210-4280	(310) 271-6123
CommunityMickey Fine Pharmacy of	533 West Allegan Street2000	PlainwellLOS ANGELES	MichiganCalifornia	490809 0067-47	(310) 277-6123

Plainwell& Snack Shop	AVENUE OF THE STARS			00	
Ming & H Drugs	1717 MING AVE	BAKERSFIELD	California	93304-4595	(661) 444-8880
CommunityMing Plaza Pharmacy of Sterlington	200 Scott Drive2726 Ming Avenue Suite A	SterlingtonBakersfield	LouisianaCalifornia	712809 3304	(661) 545-6464
CommunityMontebello Professional Pharmacy of Winnsboro	3326 Front Street265 East Beverly Boulevard, Suite DB	WinnsboroMontebello	LouisianaCalifornia	712959 0640	(323) 722-1999
Condon East UnionMowry Medical Pharmacy	1403 East Union1999 Mowry Avenue Suite 2A	GreenvilleFremont	MississippiCalifornia	387039 4538	(510) 793-5011
ConfuciusMowry Plaza Pharmacy	7 Bowery Street, Store #A-104668 Mowry Avenue	New YorkFremont	New YorkCalifornia	100029 4536	(510) 745-9900
Conlin'sMyers Medical Pharmacy	30 Lawrence Street260 Hospital Drive, Suite 111	MethuenUkiah	MassachusettsCalifornia	018449 5482	(707) 468-1866
New Care	12384 Palmdale Road Suite 105	Victorville	California	92392	(909) 726-7890
Connect CareNewport Lido Pharmacy	2191 Highway 247 Connector351 Hospital Rd Suite 107	ByronNewport Beach	GeorgiaCalifornia	310089 2663	(949) 764-6580
ContinentalNhan Ai Pharmacy LLCInc	821 Southwest 6th Street14516 Brookhurst St	TopekaWestminster	KansasCalifornia	66603-3 130926 83-5750	(714) 852-3789
Continental RxNogales Pharmacy Inc	505 Southwest 8th Street18702 Colima Rd Suite 103	MiamiRowland Heights	FloridaCalifornia	331309 1748-29 91	(626) 810-2240
Conway MedCareNorth Chester Pharmacy	2521 College1822 North Chester Avenue	ConwayBakersfield	ArkansasCalifornia	720349 3308	(661) 399-3337
CONYERS PHARMACYNorth Lake Medical Pharmacy #1	1179 West Avenue5136 Hill Road 3	ConyersLakeport	GeorgiaCalifornia	300129 5453	(707) 263-6192
Cooley HealthNorth Lake Medical Pharmacy #2	1091 S Mt Vernon Ave., # J347 Lakeport Boulevard	ColtonLakeport	California	92324-3 932954 53	(707) 263-1328
COOPERSTOWN DRUGNuevo Pharmacy	901 BURREL AVE SE75 West Nuevo Road Suite H	COOPERSTOWNPerris	North DakotaCalifornia	584259 2571	(951) 322-4700
Co-Op Pharmacy	121 Center way	Greenbelt	Maryland	20770	
Corner Drug	204 VALLEY GREEN SQUARE	LE SUEUR	Minnesota	56058	
CORNER DRUGSOakdale	154 River Street5400 Balboa	Elk RapidsEncino	MichiganCalifornia	496299 1315	818-788-0770

Pharmacy	Boulevard Suite 100				
~~Corner~~Olivehurst Drug Store	~~205 West Cedar Rock Street~~4897 Olivehurst Avenue	~~Pickens~~Olivehurst	~~South Carolina~~California	~~29671~~95961	(530) 743-5451
~~Corner Drug Store~~	~~830 East Main Street~~	~~Melbourne~~	~~Arkansas~~	~~72556~~	
Orange Plaza Pharmacy - New	1010 W La Veta Ave Suite 130	Orange	California	92868-4301	(714) 550-9798
~~Corner Pharmacy~~Oxnard Drug	~~102~~105 West ~~Main~~5th Street	~~Barnesville~~Oxnard	~~Ohio~~California	~~43713~~93030	(805) 483-2115
~~Corner~~Panama Pharmacy	~~504 Rocksylvania~~6348 Ashe Rd STE 300-400	~~Iowa Falls~~Bakersfield	~~Iowa~~California	~~50126~~93313-9490	(661) 527-0000
~~Cornersburg Family Discount Drug~~Parke Vista Pharmacy	~~3307 Canfield Road~~3838 Sherman Dr Suite 1	~~Youngstown~~Riverside	~~Ohio~~California	~~44511~~92503-4088	(951) 687-4203
~~Cornerstone~~Parkside Pharmacy	~~205 Kilbourne Avenue~~4404 Del Rio Rd	~~Appalachia~~Sacramento	~~Virginia~~California	~~24216~~95822	(916) 452-2200
~~CornerstoneRx~~Parkview Medical Plaza Pharmacy	~~1720 South McCall Road~~3975 Jackson Street Suite ~~1~~109	~~Englewood~~Riverside	~~Florida~~California	~~34223-4867~~92503	(951) 637-0180
Pearsons Medical Group Pharmacy	1700 N Waterman Ave	San Bernardino	California	92404-5115	(909) 883-3088
~~Corona~~Plaza Pharmacy~~-Inc~~	~~10409A Corona Avenue~~430 E Avenida de los Arboles Suite 103	~~Corona~~Thousand Oaks	~~New York~~California	~~11368-2923~~91360-2934	(805) 492-2451
~~Country Market~~Primera Care Pharmacy~~-#11~~	~~1535 West Maumee Street~~17500 Foothill Boulevard Suite A-7A	~~Adrian~~Fontana	~~Michigan~~California	~~49221~~92335-3736	(909) 222-6944
Prime RX Rowland Heights	18399 COLIMA RD. STE. A	ROWLAND HEIGHTS	California	91748-2797	(626) 295-2515
~~Country Market~~Puente Hills Pharmacy~~-# 12~~	~~1255 South Main Street~~1850 S Azusa Ave Suite 101	~~Chelsea~~Hacienda Heights	~~Michigan~~California	~~48118~~91745-6854	(626) 912-3311
~~Country Market~~Queens Pharmacy~~-#66~~	~~11301 Brooklyn~~12677 Hesperia Road Suite 180	~~Brooklyn~~Victorville	~~Michigan~~California	~~49230~~92395	(760) 962-1200
~~Countryside~~Queens Pharmacy	~~402 East Price Avenue~~18522 Highway 18 Suite 103	~~Savannah~~Apple Valley	~~Missouri~~California	~~64485~~92307	(760) 946-4700
Raincross Pharmacy	4646 Brockton Avenue	Riverside	California	92506	(951) 788-4646
Ramsay Rexall	2246 Newport	Costa Mesa	California	92627	(949) 646-7744

Drug	Boulevard				
CowanRancho Drugs	112 North Lebanon Street17798 Wika Road	LebanonApple Valley	IndianaCalifornia	460529 2307	(760) 242-4900
Red Cross Pharmacy	525 5th Street Suite A	Eureka	California	95501-1032	(707) 440-0460
Cox Blythe Drug CoReliance Pharmacy	122 West College Street11333 N.SEPULVEDA BLVD.STE1200	BoonevilleMission Hills	MississippiCalifornia	38829 3498913 45	(818) 365-3986
Cox FamilyRight Care Pharmacy	2012 Garfield Avenue39872 Los Alamos Road Suite CA10	ParkersburgMurrieta	West VirginiaCalifornia	261019 2562	(951) 677-1114
Cox FamilyRMC Pharmacy Brockton	1212 Garfield7117 Brockton Avenue Suite 102	ParkersburgRiverside	West VirginiaCalifornia	261019 2506-2658	951-899-8199
CoxRMC Pharmacy IncTemescal Valley	300 2nd Avenue Southeast21634 Retreat Parkway Suite 100	CairoTemescal Valley	GeorgiaCalifornia	398289 2883-6100	(951) 963-3330
CRAWFORD BREAZEALE DRUG CORogers Drug Store	125 North Washington402 H Street	LincolntonModesto	GeorgiaCalifornia	30817 1784953 51	(209) 522-5229
CrawfordRoyalty Pharmacy	107 Crawford Street1902 Royalty Drive Suite 110	Hot SpringsPomona	ArkansasCalifornia	719139 1767	(909) 620-8008
Crescent Center DrugsRS Pharmacy	228 North Fairmont Avenue24990 Alessandro Blvd Suite J	MorristownMoreno Valley	TennesseeCalifornia	378149 2553-3915	(951) 414-3100
CrescentRubio Pharmacy	7261 West 87th Street16550 Ventura Blvd Suite 100	BridgeviewENCINO	IllinoisCalifornia	60455-1821914 36-2004	(818) 990-5100
CrivitzSafesave Pharmacy	710 Main737 Colusa Avenue	CrivitzYuba City	WisconsinCalifornia	541149 5991	(530) 674-3550
Croal's Rexall DrugsSaint Johns Plaza Pharmacy	901 East Williams1301 20th Street Suite 120	BarstowSanta Monica	California	923119 0404-2094	(310) 453-6553
CrossKeysSanborn Pharmacy	468 Hurffville Cross Keys323 North Sanborn Road Unit 2	SewellSalinas	New JerseyCalifornia	080809 3905-2247	(831) 287-6833
CrossroadsSanta Monica Medical Plaza Pharmacy	7605 B NC Highway 68 North1260 15th Street Suite 100	Oak RidgeSanta Monica	North CarolinaCalifornia	273109 0404	(310) 393-6767
CrownSavco Pharmacy	26795 US Highway 380 East455 O'Conner Drive, Suite 800190	AubreySan Jose	TexasCalifornia	76227-7852951 28	(408) 298-6190

Crystal Run Pharmacy	731 Route 211 E Ste 108	Middletown	New York	10941	
Cub Drug IncSave More Pharmacy	116349 East Main Street Suite 101	OlneyAlhambra	TexasCalifornia	76374-1922918 01-7909	(626) 282-8633
Cucamonga CommunitySea View Pharmacy	8237 Rochester Avenue665 Camino de Los Mares Suite 140101	Rancho CucamongaSan Clemente	California	91730-0717926 73	(949) 496-0123
CullSebastopol Family Pharmacy, Inc.	965 Highway 127 North652 Petaluma Avenue Suite I1	OwentonSebastopol	KentuckyCalifornia	403599 5472-4266	(707) 824-1876
Cure Aid Pharmacy	101 Amesbury Street Suite 207	Lawrence	Massachusetts	01840-1510	
CurexSelam Pharmacy LLC	900 Kern2447 Telegraph Ave Ste. A	TaftOakland	California	932689 4612-2404	(510) 984-1429
Curry's FamilySherman's Apothecary Pharmacy	1275 North 7th1212 South Main Street, Suite 101	RivertonSalinas	IllinoisCalifornia	625619 3901	(831) 422-5988
Custom Care Pharmacy	57 South Front Street	Milton	Pennsylvania	17847-1110	
Cynthiana HometownSierra Pharmacy	1134 US Highway 27210 South Grand Avenue Suite 116	CynthianaGlendora	KentuckyCalifornia	410319 1741	(626) 335-2300
CypressSilverado Pharmacy	17330 Spring Cypress Road,1473 Lincoln Ave Suite 160D	CypressCalistoga	TexasCalifornia	774299 4515-1702	(707) 942-5115
CypressSkinners Pharmacy	9451 Cypress Lake905 Deep Valley Drive	Fort MyersRolling Hills Estates	FloridaCalifornia	339199 0274	(310) 377-4871
D&DSmith's St Helena Pharmacy	2903 Central Avenue Suite A1390 Railroad Ave	CharlotteSaint Helena	North CarolinaCalifornia	28205-6073945 74-1194	(707) 963-2794
DakotamartSoledad Pharmacy and Wellness Center	120 West Sioux Avenue537 Front Street	PierreSoledad	South DakotaCalifornia	57501-1158939 60	(831) 677-6100
Dalcoma Specialty Pharmacy	43337 Schoenherr Road	Sterling Heights	Michigan	48313	
Damiano PharmacySORTPAK PHARMACY	270 Parker655 North Central Avenue 22nd Floor	CliftonGlendale	New JerseyCalifornia	070119 1203	(877) 570-7787
Dan'sSouth Gate Pharmacy - SF	110 Pleasant Street8200 LONG BEACH BLVD UNIT D-2	NantucketSOUTH GATE	MassachusettsCalifornia	025549 0280	(323) 537-2837
DANIELSON PHARMACY	77 Westcott Road	Danielson	Connecticut	06239-2929	
DanielsSouthwood	943 Geneva	San	California	941129	(424) 350-7995

Pharmacy	Avenue22220 Palos Verdes Boulevard	FranciscoTorrance		0505-2017	
DanielsSpectrum Pharmacy of Barnwell	178 Wren Street9430 Warner Ave Suite G	BarnwellFountain Valley	South CarolinaCalifornia	298129 2708-2826	(657) 616-0976
Dannys DrugsStans Drug	20029 Alberta Avenue3001 S Saviers Rd	OneidaOxnard	TennesseeCalifornia	37841-4129930 33-5395	(805) 486-2678
Dans WellnessSun Pharmacy	418 Garrisonville Road2559 S King Rd Suite 100B10	StaffordSan Jose	VirginiaCalifornia	225549 5122-1894	(408) 440-2077
DarleySunshine Center Pharmacy	111 Darley1166 Old Mission Road	ClaymontSouth San Francisco	DelawareCalifornia	197039 4080-1303	(650) 589-4133
DarlingtonSuper Care Pharmacy	1115 Main Street24825 Alessandro Blvd Suite 2	DarlingtonMoreno Valley	MarylandCalifornia	210349 2553	(951) 243-2530
Davenport Good NeighborSutter Pharmacy	525 Morgan Street501 Plumas St Suite 104	DavenportYuba City	WashingtonCalifornia	991229 5991	(530) 821-5110
DaviesTeplow Drugs	6046 Whipple Avenue Northeast404 E MAIN ST	North CantonBARSTOW	OhioCalifornia	447209 2311-2326	(760) 256-2726
Davies Pharmacy #1The Prescription Center	2915 West Tuscarawas Street9730 Wilshire Boulevard Suite 103 and 114	CantonBeverly Hills	OhioCalifornia	447089 0212	(310) 274-7113
The Prescription Shop	1215 West Whittier Boulevard	Montebello	California	90640	(323) 728-8127
DavilaThu Van Pharmacy	1423 Guadalupe Street 10362 Bolsa Avenue, Suite 108	San AntonioWestminster	TexasCalifornia	782079 2683	(714) 775-0772
Davis DrugsTormed Pharmacy	250 Lone Oak Road3440 Lomita Boulevard Suite 149	PaducahTorrance	KentuckyCalifornia	420019 0505	(310) 326-7706
Davis IslandsTotal Care Pharmacy	2321657 E DAVIS BLVD6th St	TampaBeaumont	FloridaCalifornia	336069 2223-5765	(951) 769-3105
DavisonTown Square Pharmacy, Inc	1509 South State Road81 709 Doctor Carreon Boulevard Suite FE3	DavisonIndio	MichiganCalifornia	48423-1966922 01-5526	(760) 342-4933
Davis Pharmacy	4523 Baltimore Avenue	Philadelphia	Pennsylvania	19143	
Davy Crockett DrugTri City RX Pharmacy Inc	107 South Fourth Street15940 QUANTICO RD SUITE 100	CrockettAPPLE VALLEY	TexasCalifornia	758359 2307	(760) 946-1414

DAYTON DRUG AND WELLNESS	6985 RHEA COUNTY HWY	Dayton	Tennessee	37321	
DealeTruxtun Pharmacy	5809 Deale Churchton Road5925 Truxtun Ave Suite B	DealeBakersfield	MarylandCalifornia	207519 3309-0434	(661) 324-7979
Dean'sTruxtun Pharmacy Delano	1640 South Whitehead Drive1228 Jefferson Street	DewittDelano	ArkansasCalifornia	720429 3215-9225	(661) 778-0111
Dean'sUSC Medical Plaza Pharmacy # 3	311 West Chestnut1510 San Pablo Street, Suite 144	MariannaLos Angeles	ArkansasCalifornia	723609 0033	(323) 442-5770
Debbie's FamilyUSC Pharmacy	5403 West Pinnacle Point Drive1025 W 34th St (KOH) Suite 105	RogersLos Angeles	ArkansasCalifornia	727589 0089-0028	(213) 821-6100
DedhamUSC Verdugo Hills Professional Pharmacy & Medical Supply	596 Providence Highway1808 Verdugo Boulevard Suite 111	DedhamGlendale	MassachusettsCalifornia	02026-6804912 08	(818) 952-2223
Deep River Drug	2401 B Hickswood Drive	High Point	North Carolina	27265	
Delray ShoresValley Care Pharmacy	124 Northeast 5th Avenue11441 HEACOCK ST STE D	Delray BeachMORENO VALLEY	FloridaCalifornia	334839 2557	(951) 200-4592
Delta of CharlestonValley Medical Pharmacy	346 East Bay630 Main Street	CharlestonBrawley	South CarolinaCalifornia	294019 2227	(760) 344-6303
Delta of Daniel IslandValley Pharmacy	901 Island Park Dr. Ste 103560 W Putnam Ave Suites 6 & 7	Daniel IslandPorterville	South CarolinaCalifornia	294929 3257-3269	(559) 854-7500
Delta of ElloreeValley Pharmacy	2611 Cleveland Street10400 Main St. Suite D	ElloreeLamont	South CarolinaCalifornia	290479 3241	(661) 735-7077
Delta of Eutawville	226 Porcher Avenue	Eutawville	South Carolina	29048	
Delta of Moncks Corner	402 East Main Street	Moncks Corner	South Carolina	29461	
DeltaVentura County Pharmacy	407 North Main Street3350 Loma Vista Road	Rio VistaVentura	California	945719 3003-3024	(805) 765-6046
DeltaVersailles Pharmacy & Medical Supply	6251 Highway 1622801 Encinal Avenue	HollywoodAlameda	South CarolinaCalifornia	29449-5 782945 01	(510) 523-4907
Via Lido Drugs	3445 Via Lido	Newport Beach	California	92663-3996	(949) 723-8921
DeltaVilla Park Pharmacy &	1400 Palm17821 Santiago Boulevard	Isle of PalmsVilla Park	South CarolinaCalif	29451-2 280928	(714) 998-3030

~~Medical Supply~~			ornia	61	
~~Delton Family~~Vine Discount Pharmacy and Medical Supply	~~338~~1253 North ~~Grove~~Vine Street	~~Delton~~Los Angeles	~~Michigan~~California	~~490469~~0038	(323) 957-9446
~~Dempsey's Drugs Jackson Heights~~Vineyard Pharmacy & Gifts	~~2717 NC Highway 11/55~~1900 McHenry Avenue	~~Kinston~~Escalon	~~North Carolina~~California	~~285049~~5320	(209) 838-0511
~~Dempsey's Drugs La Grange~~Vo Pharmacy	~~603~~12464 East Washington ~~Street~~Boulevard	~~La Grange~~Whittier	~~North Carolina~~California	~~285519~~0602-1005	(562) 646-3339
~~Denbigh~~Wagner Pharmacy	~~13349 Warwick Boulevard~~1224 East McFadden Avenue	~~Newport News~~Santa Ana	~~Virginia~~California	~~236029~~2705	(714) 547-3590
Wards Pharmacy	653 Long Beach Boulevard	Long Beach	California	90802	(562) 437-0678
Western Ave Pharmacy	501 Western Avenue	Glendale	California	91201	(818) 242-5887
~~Dennard Drugs~~Westside Drug	~~794 2nd~~1101 O Street	~~Soperton~~Firebaugh	~~Georgia~~California	~~304579~~3622	(559) 659-2159
~~Desert Hospital Outpatient~~West Care Pharmacy	~~1180 North Indian Canyon Drive Suite E140~~5353 Balboa Blvd.	~~Palm Springs~~Encino	California	~~922629~~1316	(818) 788-2411
~~Desert Sky~~White Memorial Medical Plaza Pharmacy	~~6750 West Thunderbird Road~~1701 East Cesar E Chavez Avenue Suite ~~103~~109	~~Peoria~~Los Angeles	~~Arizona~~California	~~853819~~0033	(323) 221-6000
~~Devine's~~Woodbridge Pharmacy	~~1949 Oak Tree Road~~4950 Barranca Parkway Suite 102	~~Edison~~Irvine	~~New Jersey~~California	~~088209~~2604	(949) 857-2141
~~Diablo Pharmacy~~Your Drug Store	~~2301 Camino Ramon Ste 190~~2303 Niles Point	~~San Ramon~~Bakersfield	California	~~94583-2060~~93306-4021	(661) 325-2487
Zweber Apothecary	11411 Brookshire Avenue, Suite 107	Downey	California	90241	(562) 923-1256
~~Diamond~~Basalt Clinic Pharmacy	~~503 Cadiz Road~~110 Midland Avenue	~~Wintersville~~Basalt	~~Ohio~~Colorado	~~439538~~1621	(970) 927-3833
Bayfield Pharmacy	871 County Road 501	Bayfield	Colorado	81122	(970) 884-9133
~~Dick's~~Byers Pharmacy	~~122 S. Walnut St~~568 US HWY 36	~~Arthur~~Byers	~~Illinois~~Colorado	~~619118~~0103	(303) 822-9371
~~Dillon Community~~Capitol Heights Pharmacy	~~200 West Harrison~~1200 Madison Street ~~Suite A~~	~~Dillon~~Denver	~~South Carolina~~Colorado	~~295368~~0206	(303) 388-3679
ClearSpring	8031 Southpark Cir	Littleton	Colorado	80120-5	(303) 707-1500

Pharmacy	Suite B			724	
ClearSpring Pharmacy, Ltd	201 University Blvd Suite 105	Denver	Colorado	80206	(303) 333-2010
~~Dillon Family Pharmacy~~Downtown Drug	~~603 North 6th~~825 Grand Avenue	~~Dillon~~Glenwood Springs	~~South Carolina~~Colorado	~~29536~~81601	(970) 945-7987
Gem Pharmacy	191 East Orchard Road, Suite 100	Littleton	Colorado	80121	(303) 795-3154
La Jara Pharmaceutical Center	412 Main Street	La Jara	Colorado	81140	(719) 274-5109
Lorenzo Apothecary	306 Main Street	Sterling	Colorado	80751-4345	(970) 522-0828
Mesa Pharmacy	25140 East Highway 50	Pueblo	Colorado	81006	(719) 544-1371
~~Dilworth~~Palace Drug	~~1300-B East Boulevard~~601 Main Street	~~Charlotte~~Canon City	~~North Carolina~~Colorado	~~28203~~81212	(719) 275-3375
~~DIMMITT PHARMACY~~Palace Drug Silver Cliff	~~201 NW 2ND ST~~94 Main St	~~DIMMITT~~Silver Cliff	~~Texas~~Colorado	~~79027~~81252	(719) 371-9402
~~DK~~Platte Valley Pharmacy	~~10431 Lemon Avenue, Suite G~~1610 PRAIRIE CENTER PKWY STE 2110	~~Rancho Cucamonga~~BRIGHTON	~~California~~Colorado	~~91737~~80601	(303) 483-7455
~~Dollar Drug~~The Pharmacy at St Michaels	~~1055 West College~~2914 67th Avenue~~,~~ Suite ~~C~~101	~~Santa Rosa~~Greeley	~~California~~Colorado	~~95401~~80634	(970) 978-4557
TKS Pharmacy	4809 Argonne St Suite 155	Denver	Colorado	80249-6801	(720) 583-2110
~~Don's~~Bailey's Pharmacy	~~1151 Water~~1137 MAIN Street Suite 100	~~Port Townsend~~East Hartford	~~Washington~~Connecticut	~~98368~~06108-2236	(860) 206-5737
~~Don Quijote Drugs~~Beacon Prescriptions	~~94-144 Farrington Highway~~543 W Main St	~~Waipahu~~New Britain	~~Hawaii~~Connecticut	~~96797~~06053-3915	(860) 225-6487
Beacon Prescriptions	25 Collins Road	Bristol	Connecticut	06010	(860) 589-5587
~~Don Quijote Drugs~~Beacon Prescriptions	~~801 KAHEKA ST~~609 North Main Street	~~HONOLULU~~Southington	~~Hawaii~~Connecticut	~~96814~~06489	(860) 628-3972
Beacon Prescriptions	875 Foxon Road	East Haven	Connecticut	06513	(203) 467-2600
Beacon Prescriptions South St.	57 South Street	Bristol	Connecticut	06010	(860) 583-1006
~~Dorado~~Danielson Pharmacy	~~4060 Faudree~~77 Westcott Road ~~Suite 101~~	~~Odessa~~Danielson	~~Texas~~Connecticut	~~79765~~06239	(860) 774-0050
~~Dorado~~Hancock Pharmacy &	~~13003 Van Nuys Boulevard Suite~~840	~~Pacoima~~MERIDEN	~~California~~Connecticut	~~91331-8324~~064	(203) 235-6323

Surgical	E MAIN ST			50	
~~Dorado~~Kent Station Pharmacy~~ 2~~	~~13678 Van Nuys Boulevard~~38 North Main Street	~~Pacoima~~Kent	~~California~~Connecticut	~~91331-3616~~06757	(860) 927-3725
~~Dottie's~~Medical Arts Pharmacy	~~325 Folly Road Suite 101~~461 Monroe Tpke	~~Charleston~~Monroe	~~South Carolina~~Connecticut	~~294120~~6468-2338	(203) 590-3737
~~Doug's~~Medical Pharmacy	~~430~~1213 Main Street	~~Rossville~~Willimantic	~~Kansas~~Connecticut	~~665330~~6226	(860) 423-1661
MSP	2117 Boston Ave	Bridgeport	Connecticut	06610-3030	(203) 212-3800
Rotary Drug	1030 Barnum Avenue	Stratford	Connecticut	06614	(203) 378-9394
Visels Pharmacy - New Haven, CT	714 Dixwell Ave	New Haven	Connecticut	06511-1097	(203) 562-6878
~~Dougs Family~~Darley Pharmacy	~~101 Darby Square~~111 Darley Road	~~Elverson~~Claymont	~~Pennsylvania~~Delaware	~~19520~~19703	(302) 798-0202
Dover Community Pharmacy	1035 South Governors Avenue	Dover	Delaware	19904	(302) 724-9323
~~Dover Family~~Mt Pleasant Care Pharmacy	~~1307 Donelson Parkway~~3169 Mount Pleasant Street Northwest	~~Dover~~Washington	~~Tennessee~~District of Columbia	~~370582~~0010-2798	(202) 387-3100
A-1 Pharmacy	815-3 South Moody Road	Palatka	Florida	32177	(386) 385-3987
~~DOWN HOME PHARMACY LLC AP~~Ace Pharmacy & Discount	~~1034 Main~~1572 West 37th Street	~~Bean Station~~Hialeah	~~Tennessee~~Florida	~~377083~~3012	(305) 558-1499
~~Downtown Drug~~ACME Pharmacy	~~8 2nd Street Northeast~~1548 E Fowler Ave Suite ~~201B~~102	~~Watertown~~Tampa	~~South Dakota~~Florida	~~57201-3622~~33612-5416	(813) 971-6565
~~DOWNTOWN DRUGS~~Acquaviva's Pharmacy	~~121 E BROADWAY~~1555 Port Malabar Northeast, Suite 101	~~MT PLEASANT~~Palm Bay	~~Michigan~~Florida	~~488583~~2905	(321) 725-7188
Andres Pharmacy and Discount	7167 Southwest 8th Street	Miami	Florida	33144	(305) 261-2822
~~Draffenville~~A Plus Pharmacy	~~153 US Highway 68~~4750 East Moody Boulevard Suite 107	~~Benton~~Bunnell	~~Kentucky~~Florida	~~420253~~2110	(386) 313-6959
~~Dr Aziz~~Bailey's Pharmacy	~~7320 East 82nd Street~~3850 W. Commercial Blvd. Suite 6	~~Indianapolis~~Tamarac	~~Indiana~~Florida	~~462563~~3309-3316	(954) 766-4090
~~DREXEL DISCOUNT DRUG, LLC~~Bailey's Pharmacy	~~2728 Highway 70 East~~3065 34TH Street N Suite B	~~Morganton~~Saint Petersburg	~~North Carolina~~Florida	~~286553~~3713-2401	(727) 256-1410
Bailey's Pharmacy	780 Us Highway 1	Vero Beach	Florida	32962-1	(772) 492-8559

	Suite 101			661	
Dripping SpringsBailey's Pharmacy	100 Commons Road5156 South Orange Avenue Suite 1B	Dripping SpringsPine Castle	TexasFlorida	786203 2809	(407) 930-3102
Baya Pharmacy East	780 SE Baya Dr	Lake City	Florida	32025	(386) 755-6677
Baya Pharmacy West	1465 West US Highway 90 Suite 110	Lake City	Florida	32055	(386) 755-2233
DrugCareBay Street Pharmacy	132 Whitfield Street7746 Bay St	EnfieldSebastian	North CarolinaFlorida	278233 2958	(772) 589-2043
Better Life Pharmacy #1	180 Patricia Ave	Dunedin	Florida	34698-8103	(727) 900-6404
Drug CityBlack & White Pharmacy	2805 North Point8381 Bird Road	BaltimoreMiami	MarylandFlorida	212223 3155	(305) 545-2108
Drug CoBrownings Pharmacy	307 North Ash Street141 East Hibiscus Boulevard	EscondidoMelbourne	CaliforniaFlorida	920273 2901	(321) 723-6520
Cali Pharmacy & Discount	1924-26 West 60th Street	Hialeah	Florida	33012	(305) 558-5055
Drug LoftCardenas Pharmacy	1408 Madison Avenue2741 Coral Way	New YorkMiami	New YorkFlorida	100293 3134	(305) 529-0003
Careplus Pharmacy	701 West Dr Martin Luther King Jr Boulevard Suite 1	Tampa	Florida	33603	(813) 849-0991
Drugs AmericaCare Rx Pharmacy	103 East 24Th1167 E Tennessee St	LumbertonTallahassee	North CarolinaFlorida	283583 2308-6913	(850) 577-1890
Drug Shoppe LlcCharles Pharmacy	2074 8th Ave5081 Okeechobee Boulevard	New YorkWest Palm Beach	New YorkFlorida	100263 3417	(561) 507-5300
Choice Pharmacy Inc	5913 North Armenia Avenue	Tampa	Florida	33603	(813) 870-6426
Cocoa Beach Discount Pharmacy	291 West Cocoa Beach Causeway	Cocoa Beach	Florida	32931	(321) 799-2030
Drug WorldCommunity Pharmacy	55 Chestnut897 N. Summit Street	Cold SpringCrescent City	New YorkFlorida	105163 2112	(386) 698-2666
DUFFEY DRUGContinental Rx	311 North Center505 Southwest 8th Street	FranklinMiami	TexasFlorida	778563 3130	(305) 856-2211
DundeeCypress Wellness Pharmacy	2750 Dundee Road, Suite 99451 Cypress Lake Dr	NorthbrookFort Myers	IllinoisFlorida	600623 3919	(239) 481-7322
DunewoodDavis Islands Pharmacy	1445 Sheldon Road Suite 104232 E Davis Blvd	Grand HavenTampa	MichiganFlorida	494173 3606-3795	(813) 254-1888

DunnesDelray Shores Pharmacy	2429 Claflin Road124 Northeast 5th Avenue	ManhattanDelray Beach	KansasFlorida	665023 3483	(561) 272-2124
Duval Pharmacy	2386 Dunn Avenue Suite 117	Jacksonville	Florida	32218	(904) 696-8882
Duval Pharmacy 201	7077 Normandy Boulevard Blvd Suite 5	Jacksonville	Florida	322053 2205-62 94	(904) 900-7700
Dyer Drug Store	133 McKinney Street	Farmersville	Texas	75442	
DykesElite Pharmacy	134 N Second St11216 West Hillsborough Avenue	CochranTampa	GeorgiaFlorid a	31014-1 619336 35	(813) 444-4493
Dynamic CareEmpath Health Pharmacy #1	4121 West 13 Mile Road3050 1st Ave S Pharmacy Dept	Royal OakSt Petersburg	MichiganFlori da	480733 3712-10 10	(727) 209-3500
E & SEmpath Health Pharmacy #3	1105 Walnut Street4703 N Florida Ave	DoniphanTampa	MissouriFlori da	639353 3603-37 34	(727) 523-2550
Eagle GroveEmpath Health Pharmacy #6	311 W. Broadway St5771 Roosevelt Blvd Building 410-466	Eagle GroveClearwater	IowaFlorida	505333 3760	(727) 523-2575
EagleE P Medical Equipment Pharmacy	109 West Main Street6440 SW 117TH AVE	FarwellMIAMI	MichiganFlori da	486223 3183	(305) 630-9307
EannelliFamilyCare Discount Pharmacy	405 Water Street514 E Colonial Dr	Prairie Du SacOrlando	WisconsinFlo rida	535783 2803-45 04	(407) 216-3474
East Austin Medicine ShopFarmacia Julia Discount	1909 E 38th 1/23000 NW 7th St Ste C2	AustinMiami	TexasFlorida	787233 3125	(305) 642-6211
Farmacia Julia Discount #2	3197 SW 18th St	Miami	Florida	33145-1 803	(305) 448-6523
East BurkeFive Points Pharmacy, Inc. and Wellness	300 Main Avenue West1108 Lake Drive	HildebranCocoa	North CarolinaFlori da	286373 2922	(321) 806-3951
East End ExpressFlagler Pharmacy	21019 Highway 167, Suite 100200 Moody Boulevard	HensleyFlagler Beach	ArkansasFlori da	720653 2136	(386) 777-0777
Fort Myers Prescription Shop	13195 Metro Parkway Suite 3	Fort Myers	Florida	33966	(239) 939-0249
East EndGLS Pharmacy LLC	20381 Arch15680 Southwest 72nd Street Pike	Little RockMiami	ArkansasFlori da	722063 3193-19 23	(786) 391-3618
Gulf Breeze Apothecary	1177 Gulf Breeze Pkwy	Gulf Breeze	Florida	32561-4 835	(850) 677-9340
East Jefferson MedicalGulf Gate Pharmacy	1623 Williams Boulevard2134 Gulf Gate Drive	KennerSarasota	LouisianaFlori da	70062-6 303342 31	(941) 493-6500
Eastman	1221 Plaza Avenue,	EastmanGulfport	GeorgiaFlorid	310233	(727) 223-1075

DrugsGulfport Pharmacy	Suite B5004 Gulfport Boulevard S		a	3707	
Eastover DrugHeartland Discount Pharmacy	3591 Dunn Road407 South Parrott Avenue	EastoverOkeechobee	North CarolinaFlorida	283123 4974	(863) 763-7633
Infinity Pharmacy	7551 West Hillsborough Avenue	Tampa	Florida	33615	(813) 462-2777
Eastridge PhelpsIsland Family Pharmacy Campbellsville	500 N BYPASS RD600 PLANTATION ISLAND DR S UNIT 3	CampbellsvilleST AUGUSTINE	KentuckyFlorida	427183 2080	(904) 461-1081
Eastridge Phelps Pharmacy Greensburg	460 Commerce Dr	Greensburg	Kentucky	42743-7758	
East Tennessee Discount Drug	524 Andrew Johnson Highway	Strawberry Plains	Tennessee	37871	
Economy DiscountJ's Pharmacy	9881 Commerce Street Suite A6416 Ridge Road	SummervillePort Richey	GeorgiaFlorida	307473 4668	(727) 847-2211
Economy DrugKabs Pharmacy #01	511 East Garland Street2812 E Bearss Ave	Grand SalineTampa	TexasFlorida	751403 3613	(813) 988-4000
Economy DrugKey Pharmacy	1006 West Trimble Avenue614 Crandon Boulevard	BerryvilleKey Biscayne	ArkansasFlorida	726163 3149	(305) 361-5445
Economy Drug Company IncKing Pharmacy & Compounding LLC	180 Town Mountain Road31201 US Highway 19 North Suite 1151	PikevillePalm Harbor	KentuckyFlorida	415013 4684-4422	(727) 772-6868
Eddie'sLa Cubana Pharmacy Discount	8408 Beverly Boulevard5965 SW 8th St Suite A	Los AngelesMiami	CaliforniaFlorida	900483 3144	(305) 267-6767
EdgewoodLittle Road Pharmacy	62 B Mountain Boulevard4211 Little Road Unit #4	WarrenNew Port Richey	New JerseyFlorida	070593 4655	(727) 372-5222
EdgewoodLogos Pharmacy	186 S Friendswood Dr7543 W Waters ave	FriendswoodTampa	TexasFlorida	775463 3615	(813) 886-2800
Ed HolcombeManatee Discount Pharmacy	106 2nd Avenue Southwest1802 59th Street West	CullmanBradenton	AlabamaFlorida	350553 4209	(941) 209-1234
EdmondsMarquez Pharmacy	7631 212th Street Southwest Suite D1005901 West 16th Avenue	EdmondsHialeah	WashingtonFlorida	98026-7565330 12	(305) 558-8002
Med-Care Infusion Services	3085 West 80th Street	Hialeah	Florida	33018	(305) 863-4277 Ext 2903
EhrhardtMedical Arts Pharmacy	12930 Broxton Bridge4417 Bee	EhrhardtSarasota	South CarolinaFlorida	290813 4233	(941) 706-1777

	Ridge Road		da		
Medicine Maxx	646 South Dillard Street	Winter Garden	Florida	34787	(407) 656-0081
ElevateMedplus Pharmacy	8631 West 3rd Street Suite 320 E1690 Jeremiah St Unit 107	Los AngelesMiddleburg	CaliforniaFlorida	900483 2068-8428	(904) 214-3105
Elgin Medicine ShopMedzDirect Inc #1	199 Highway 290 East1065 NE 125th St Suite A207	ElginNorth Miami	TexasFlorida	786213 3161-5821	(786) 347-0365
ElginMerit Pharmacy	1107 Ross Street2464 N State Rd 7	ElginLauderdale Lakes	South CarolinaFlorida	290453 3313	(954) 739-4666
Moultrie Pharmacy	3690 US 1 South	St. Augustine	Florida	32086	(904) 794-1399
New Life Pharmacy	22149 S Dixie Highway	Miami	Florida	33170	(305) 960-7176 Ext 22162
EliteNext Dose Pharmacy	112166802 West Hillsborough Avenue Suite 12	Tampa	Florida	336353 3634	(813) 930-9300
Oaks Pharmacy	1905 West State Road 434	Longwood	Florida	32750	(407) 350-5925
Elix RxOrlando Pharmacy	1090 Keolu Drive2909 North Orange Avenue Suite 112/113	KailuaOrlando	HawaiiFlorida	967343 2804	(407) 898-1331
Elizabeth'sOrtux Pharmacy on MainLLC	52 Main Avenue North9134 NW 25th St	BrittDoral	IowaFlorida	504233 3172	(786) 542-5007
Elkhorn DrugPathway Pharmacy	105 East Elkhorn202 Southwest 17th Street Suite A	Elkhorn CityOcala	KentuckyFlorida	415223 4471	(352) 624-2779
ElkhornPDL Pharmacy	603 E GENEVA ST3255 NW 7 St	ELKHORNMiami	WisconsinFlorida	531213 3125	(305) 266-3705
Perkins Indian River Pharmacy	3721 10th Court	Vero Beach	Florida	32960	(772) 567-2555
PharmacyGo	20041 S Tamiami Trail Suite 13	Estero	Florida	33928-2228	(239) 908-3187
Elkton FamilyPrime Rx Pharmacy	111 South Stuart Avenue10010 Cross Creek Blvd.	ElktonTampa	VirginiaFlorida	228273 3647-2595	(813) 955-7777
QuickRx@Bartow	1140 E Van Fleet Dr	Bartow	Florida	33830-7626	(863) 537-6910
Rx Express Pharmacy	8986 Ortega Park Dr	Navarre	Florida	32566	(850) 936-6446
Savers Drug Mart	200 Ocean Avenue	Melbourne Beach	Florida	32951-2350	(321) 725-5492
Ellis PrescriptionSave Rx Pharmacy	2441 West Brown Street231 Del Prado Boulevard South Suite 11	PhiladelphiaCape Coral	PennsylvaniaFlorida	191303 3990-5707	(239) 288-2244
Scripts Direct Pharmacy	8313 West Hillsborough	Tampa	Florida	33615	(813) 868-1999

	Avenue Suite 260				
St. Mary Pharmacy	1290 West Bay Drive	Largo	Florida	33770	(727) 585-1333
El MonteStarcare Pharmacy	3948 North Peck Road7200 RIDGE RD STE 106	El MontePort Richey	CaliforniaFlorida	917323 4668	(727) 312-4888
ELTON PHARMACYSt Mary Pharmacy II	2992 FULTON ST30606 US Highway 19 North	BrooklynPalm Harbor	New YorkFlorida	112083 4684	(727) 773-9000
ElwynSun Discount Pharmacy	5075 Edgmont3600 S Tuttle Ave	BrookhavenSarasota	Pennsylvania Florida	19015-1202342 39-7116	(941) 556-9622 Ext 0
Ely Drug of Bowling Green	4863 Scottsville Road	Bowling Green	Kentucky	42104	
Ely DrugsSun Pharmacy of Bradenton	415 Happy Valley Road53rd Ave W	GlasgowBradenton	KentuckyFlorida	421413 4207-34 16	(941) 444-9656 Ext 0
Elyria Lowcost Pharmacy	401 Cleveland Street	Elyria	Ohio	44035-6143	
Empath HealthSun Pharmacy of Venice	3050 1st Avenue South1214 E Venice Ave Suite C	St. PetersburgVenice	Florida	337733 4285-71 65	(941) 584-2080
Empath HealthSunshine Pharmacy	5771 Roosevelt Blvd5040 West SR 46 Suite 1126	ClearwaterSanford	Florida	337603 2771	(407) 878-4272
Empath HealthSuper Discount Pharmacy	4703 N Florida Avenue1423 S Collins St	TampaPlant City	Florida	33603-3734335 63	(813) 752-1133
EnglishUnion Pharmacy and Medical Supplies	2600 10th6456 West Flagler Street	Wichita FallsMiami	TexasFlorida	763093 3144	(305) 262-4646
E P Medical EquipmentUnion Pharmacy and Medical Supplies	64402501 SW 117TH AVE67th Ave	MIAMIMiami	Florida	331833 3155-29 68	(305) 661-8800
Erie DrugUniversity Pain Management Center Pharmacy	4502 Lewis Avenue3220 Cove Bend Drive	ToledoTampa	OhioFlorida	436123 3613	(813) 615-0742
Ernie'sVida Pharmacy	547250 West High Street24th Avenue, Suite A19/20	LondonHialeah	OhioFlorida	431403 3016	(305) 822-8234
Ernie'sVillage Pharmacy and Wellness Center Inc	410 South 32nd Street9408 SW 87th Ave Suite 105	MuskogeeMiami	OklahomaFlorida	744013 3176	(305) 274-8955
EssentialRxWellness Rx LLC	123 Summer7640 Northwest 25th Street Suite 365105	WorcesterMiami	Massachusetts Florida	01608-1216331 22	(305) 384-7600
EstherWinships Pharmacy	715643 South BroadwayEast Crooked Oak Avenue Seabranch	YonkersHobe Sound	New YorkFlorida	10701-4004334 55	(772) 324-8381

	Square				
EvansWinships Prescription PharmacyCenter	310 North Dotsy Avenue721 Northlake Boulevard	OdessaNorth Palm Beach	TexasFlorida	797633 3408	(561) 842-2444
EverCare Scripts Pharmacy	1903 East 9th Street2352 Bruce B Downs Blvd Suite 103	TrentonWesley Chapel	MissouriFlorida	64683-2645335 44-9203	(813) 751-3377 Ext 0
Evergreen ParkAbundant Life Pharmacy	2850 West 95th117 North Main Street, Suite 100	Evergreen ParkBaxley	IllinoisGeorgia	608053 1513	(912) 367-8404
EW ThomsonAdams Drug CoStore	213 Depot Street408 B 16th Ave E	DelhiCordele	LouisianaGeorgia	712323 1015	(229) 273-3433
Express CareAdams Family Pharmacy	3648 Old Denton Road Suite 10498 Peachtree Street	CarrolltonCuthbert	TexasGeorgia	750073 9840-5807	(229) 732-2077
Express CareAdams Family Pharmacy	1727 West Liberty6381 Hamilton Street Unit 2	AllentownPreston	Pennsylvania Georgia	181043 1824	(229) 828-2273
Exton Pharmacy at MarchwoodADD Drug	1 Marchwood Road1695 South Lumpkin Street	ExtonAthens	Pennsylvania Georgia	193413 0606	(706) 548-2239
FAIRHAVEN PHARMACY	72 MAIN ST	FAIRHAVEN	Massachusetts	02719-3014	
FAIRMONT PHARMACY	50 Bellefontaine St Ste 103	Pasadena	California	91105	
FairviewAllcare Pharmacy and Compounding	734 North Riverside112 South Oxley Drive	EspanolaLyons	New MexicoGeorgia	875323 0436	(912) 526-3200
FairviewAltama Pharmacy & Compounding	500 Katie Avenue5711 Altama Ave Suite G	HattiesburgBrunswick	MississippiGeorgia	394013 1525	(912) 264-2622
Fairway DrugApollo Pharmacy	1758 Front418 West Broughton Street Suite 106	LyndenSAVANNAH	WashingtonGeorgia	982643 1401-3218	(912) 999-6101
FaithApollo Pharmacy #2	140 Adams Lane,111 Canal Street Suite 500101	PikevillePooler	KentuckyGeorgia	415013 1322-4054	(912) 988-7185
FalakAugusta Pharmacy	2730 E Tremont Ave1944 Walton Way Suite C	BronxAugusta	New YorkGeorgia	10461-2877309 04-6711	(706) 287-2700
Fallston Pharmacy	2112 Belair Road Suite 11	Fallston	Maryland	21047	
FamcareBainbridge Pharmacy	1429 Burgettstown Plaza1420 East Evans Street	BurgettstownBainbridge	Pennsylvania Georgia	150213 9819	(229) 246-7200
Family Care Discount Pharmacy	514 East Colonial Drive	Orlando	Florida	32803	

~~Family Clinic~~Ball Ground Pharmacy	~~1208 West Main~~470 Valley Street	~~Walnut Ridge~~Ball Ground	~~Arkansas~~Georgia	~~724763~~ 0107	(770) 735-6161
~~Family Drug~~Barber's Pharmacy	~~1755 Lovers Gap Road~~731 Cameron Drive	~~Vansant~~Blackshear	~~Virginia~~Georgia	~~246563~~ 1516	(912) 449-4444
~~Family~~Barnes Drug ~~Center~~Store	~~517 West Front~~200 South Patterson Street	~~Coeburn~~Valdosta	~~Virginia~~Georgia	~~242303~~ 1601	(229) 242-1925
~~Family~~Batts Drug ~~Center~~Company Inc	~~110 West Main~~115 Commerce Street ~~Suite 1~~	~~Lebanon~~Hawkinsville	~~Virginia~~Georgia	~~242663~~ 1036	(478) 892-9021
~~Family First~~Baxley Wellness Pharmacy Inc	~~4859 East Kings Canyon~~160 Azalia Road	~~Fresno~~Baxley	~~California~~Georgia	~~93727-3811~~31513	(912) 705-3784
~~Family Medical Center Pharmacy~~Beasley Drug Company	~~3016 S. University Ste 120~~933 Center Street	~~Little Rock~~Conyers	~~Arkansas~~Georgia	~~722043~~ 0012	(770) 483-7211
~~Family Meds Inc~~	~~12114 Old Line Center R-7A~~	~~Waldorf~~	~~Maryland~~	~~20602~~	
~~Family~~Ben Hill Pharmacy	~~412 Central Avenue~~3740 Campbellton Rd SW	~~South Williamson~~Atlanta	~~Kentucky~~Georgia	~~415033~~ 0331-5222	(404) 565-0252
~~Family~~Bennett's Hometown Pharmacy	~~2124 Fayetteville Road Suite E~~26826 Highway 82	~~Rockingham~~Waynesville	~~North Carolina~~Georgia	~~283793~~ 1566	(912) 778-3784
~~Family Pharmacy~~	~~6 Hospital Drive~~	~~Lexington~~	~~Tennessee~~	~~38351~~	
~~Family~~Bennett's Hometown Pharmacy	~~7315 212th~~13202 Cleveland Street ~~Southwest~~West, Suite 100	~~Edmonds~~Nahunta	~~Washington~~Georgia	~~980263~~ 1553	(912) 462-3784
~~Family~~Bennett's Hometown Pharmacy	~~806~~4402 North ~~Sturgeon~~Second Street Suite C	~~Montgomery City~~Folkston	~~Missouri~~Georgia	~~633613~~ 1537	(912) 496-3784
~~Family Pharmacy~~	~~333 Newberry Street Northwest~~	~~Aiken~~	~~South Carolina~~	~~29801-3929~~	
~~Family~~Bonaire Pharmacy ~~Milan~~	~~6078 South 1st Street~~810 SR 96 Suite 1800	~~Milan~~Warner Robins	~~Tennessee~~Georgia	~~38358-3131~~31088	(478) 287-2169
~~Family Pharmacy of Jackson~~	~~265 KY Hwy 15 South, Suite 2~~	~~Jackson~~	~~Kentucky~~	~~41339~~	
~~Family~~Brasstown Professional Pharmacy ~~of Pottsboro~~, Inc.	~~563 W FM 120~~23B Murphy Highway	~~Pottsboro~~Blairsville	~~Texas~~Georgia	~~750763~~ 0512	(706) 745-2303
~~Family Pharmacy Scotts Hill~~	~~10091 Highway 100~~	~~Scotts Hill~~	~~Tennessee~~	~~38374~~	
~~Family~~Brooke's Pharmacy ~~South Aiken~~	~~110 Price Avenue~~812 South Park Street Suite	~~Aiken~~Carrollton	~~South Carolina~~Georgia	~~298033~~ 0117	(770) 834-9050

	5A				
~~FAMILY PLAZA PHARMACY~~Brooklet Drug	~~3570 W 9000 S STE 150~~102 Parker Avenue South	~~WEST JORDAN~~Brooklet	~~Utah~~Georgia	~~84088 8872~~30415	(912) 842-9886
~~Family Prescription Counter~~Brownings Pharmacy	~~335 Main~~1919 Alice Street	~~Duryea~~Waycross	~~Pennsylvania~~Georgia	~~18642~~31501	(912) 283-5504
Buchanan Drugs	106 Courthouse Square	Buchanan	Georgia	30113	(770) 646-3570
~~Family Wellness~~C & C Pharmacy	~~330 North Oak Avenue~~621 West Memorial Drive	~~Cookville~~Dallas	~~Tennessee~~Georgia	~~38501 2440~~30132-4120	(770) 445-2600
~~FARMACIA ABIMAR~~Center Drugs	~~CARR 780 KM 6.5 BO ANONES~~133 2nd Ave SE	~~NARANJITO~~Cairo	~~Puerto Rico~~Georgia	~~00719~~39828	(229) 377-2777
~~FARMACIA AMERICA~~Chapman Drug Co Inc	~~CALLE SALAS TORRES 3, ,ESQUINA MUNOZ RIVERA~~615 North Central Avenue	~~AGUAS BUENAS~~Hapeville	~~Puerto Rico~~Georgia	~~00703~~30354	(404) 761-1136
Chapman Healthcare Pharmacy	305 Maple Drive	Vidalia	Georgia	30474	(912) 538-0053
Citizens Pharmacy	5325 Atlanta Highway	Flowery Branch	Georgia	30542	(770) 967-3324
~~Farmacia Anaheim~~City Pharmacy of Zebulon PC	~~941 South Euclid~~460 Thomaston Street	~~Anaheim~~Zebulon	~~California~~Georgia	~~92802~~30295	(770) 567-8844
~~FARMACIA CARIBE~~Clark Drug Company	~~CARRETERA #3 KM 26.3~~206 West 6th Street	~~RIO GRANDE~~Waynesboro	~~Puerto Rico~~Georgia	~~00745~~30830-1460	(706) 558-3400
~~Farmacia Caribe~~Clinic Pharmacy	~~Centro Comercial Villas De Rio Grande~~58 Big A Road Suite 101	~~Rio Grande~~Toccoa	~~Puerto Rico~~Georgia	~~00745~~30577	(706) 886-2151
~~Farmacia Caribe II~~Coastal Drug Company	~~Calle K #HH17Y18, URB Alturas De Rio Grande~~90 Butler St Suite A	~~Rio Grande~~Midway	~~Puerto Rico~~Georgia	~~00745~~31320	(912) 884-9255
~~Farmacia Carraizo~~Coliseum Park Professional Pharmacy	~~Carretera 844 KM 5.6~~380 Hospital Drive, Suite 175 A	~~Trujillo Alto~~Macon	~~Puerto Rico~~Georgia	~~00928~~31217	(478) 745-5431
~~Farmacia Del Pueblo~~	~~801 East Birch Street Suite 4~~	~~Calexico~~	~~California~~	~~92231~~	
~~Farmacia Del Pueblo~~Colony Discount Drugs	~~1692~~502 South ~~4th~~Grant Street	~~El Centro~~Fitzgerald	~~California~~Georgia	~~92243~~31750-3398	(229) 423-9801
~~Farmacia Del Pueblo~~Colquitt Pharmacy	~~653~~215 West Main Street	~~Brawley~~Colquitt	~~California~~Georgia	~~92227~~39837	(229) 600-0524
~~Farmacia~~	~~5020 South C~~	~~Oxnard~~Byron	~~California~~Geo	~~93033~~3	(478) 654-5222

EstrellaConnect Care Pharmacy	Street2191 Highway 247 Connector		rgia	1008	
Farmacia FamiliarCONYERS PHARMACY	1126 South Bristol Street1179 West Avenue	Santa AnaConyers	CaliforniaGeorgia	927043 0012	(770) 929-1414
Farmacia FarmahorrosCox Pharmacy Inc	Local 101 Centro Comercial Villa Del Carmen300 2nd Avenue Southeast	CidraCairo	Puerto RicoGeorgia	007393 9828	(229) 377-9017
Farmacia Guayabal #2	Carr. #1 KM 113.60 Bo Cintrona	Juana Diaz	Puerto Rico	00795	
Farmacia Julia DiscountCRAWFORD-BREAZEALE DRUG CO	3000 Northwest 7th125 North Washington Street	MiamiLincolnton	FloridaGeorgia	331253 0817-1784	(706) 359-3343
Farmacia Julia Discount #2Dennard Drugs	3197 Southwest 18th794 2nd Street	MiamiSoperton	FloridaGeorgia	331453 0457	(912) 529-4545
Farmacia Los MaestrosDykes Pharmacy	Calle Muniz Souffront #459, Urb. Los Maestros134 N Second St	San JuanCochran	Puerto RicoGeorgia	009233 1014-1619	(478) 934-6344
Farmacia MagdaEastman Drugs	UU48 CALLE 37 Santa Juanita1221 Plaza Avenue, Suite B	BayamonEastman	Puerto RicoGeorgia	009563 1023	(478) 374-6670
Farmacia Martin	Calle Ruiz Belvis # 22	San German	Puerto Rico	00683	
Farmacia Nueva	Calle Munoz Rivera #16	Camuy	Puerto Rico	00627	
Farmacia Reyes 3	1320 San Alfonso Avenue	San Juan	Puerto Rico	00921-3621	
FARMACIA SAN ANTONIO	2319 Federal Street	Camden	New Jersey	08105	
Farmacia Santa AnaEconomy Discount Pharmacy	307 East 1st9881 Commerce Street Suite DA	Santa AnaSummerville	CaliforniaGeorgia	92701-5302307 47	(706) 808-1100
Farmacia Villas De Castro	Calle 2 A18 Villas De Castro	Caguas	Puerto Rico	00725	
Farmer's Prescription Shop	279 North Broad Street Ste B	Winder	Georgia	30680	(770) 867-9072
Ferguson Rexall Drugs	713 5th Street	Clay Center	Kansas	67432	
Fiesta MLK Pharmacy	3230 Martin Luther King	Dallas	Texas	75210	
Fievet Pharmacy	115 East Robert Toombs Avenue	Washington	Georgia	30673	(706) 678-2260
Fikes Pharmacy	101 East Second	Grandfield	Oklahoma	73546	
Finley's Rexall Drug	8554 Sierra Avenue	Fontana	California	92335	
First Choice	400 Poplar Street	MACON	Georgia	31201	(478) 309-1744

Primary Care					
First National Pharmacy	143 North First Street	Lehighton	Pennsylvania	18235	
Five Points Pharmacy	217 N. Camellia Blvd	Fort Valley	Georgia	31030	(478) 822-0555
Five PointsFolkston Pharmacy and Wellness	1108 Lake Drive3885 Main Street	CocoaFolkston	FloridaGeorgia	329223 1537	(912) 496-2044
FlaglerForest Heights Pharmacy	200 Moody Boulevard4439 Country Club Road	Flagler BeachStatesboro	FloridaGeorgia	321363 0458	(912) 489-7979
Flint FamilyFriendly City Pharmacy	G4444 Fenton Road1202 US Highway 41 North	FlintTifton	MichiganGeorgia	485073 1794	(229) 586-8193
Fulghum Drugs	73 Southwest Park Avenue	Baxley	Georgia	31513	(912) 367-2488
Georgetown Drug Company	1080 King George Blvd	Savannah	Georgia	31419	(912) 920-1500
Florida FamilyGlenn's Corner Pharmacy	14889 Tamiami Trl631 East Franklin Street	North PortSylvester	FloridaGeorgia	34287-2 732317 91	(229) 776-3600
Florida Medical ClinicGolden Isles Pharmacy of Wiregrass	2352 Bruce B Downs Boulevard Suite 1033010 Altama Avenue	Wesley ChapelBrunswick	FloridaGeorgia	335433 1520	(912) 266-8140
Flow's Health MartGolden Isles Pharmacy	1506 E BROADWAY615 South Palisade Drive	COLUMBIABrunswick	MissouriGeorgia	652013 1523-82 11	(912) 400-2929
Graves Pharmacy	770 Pine Street, Suite 100	Macon	Georgia	31201	(478) 745-0476
Hall Drug Co	90 Court Square	Blakely	Georgia	39823	(229) 723-3441
Haney's Drug Corner	623 Dixie Street	Carrollton	Georgia	30117	(770) 834-3393
Hawkinsville Drug Company	153 Commerce Street	Hawkinsville	Georgia	31036-8 420	(478) 783-0555
Health Delivery Pharmacy	1326 Eisenhower Drive Building 1	Savannah	Georgia	31406	(912) 200-9250
Flow'sHinesville Pharmacy	303 North Keene Street481 Elma G Miles Parkway	ColumbiaHinesville	MissouriGeorgia	652013 1313	(912) 876-8125
Hogan's Pharmacy	2704 North Oak Street Suite B-1	Valdosta	Georgia	31602	(229) 244-5353
FlynnsHometown Pharmacy	173 Elm236 West Clinton Street	PittsfieldGray	MassachusettsGeorgia	012013 1032	(478) 986-4827
FolkstonIHS Pharmacy & Gifts	3885 Main150 South Leroy Street	FolkstonMetter	Georgia	315373 0439	(912) 685-2803
IHS Pharmacy #3	13762 Highway 80	Jeffersonville	Georgia	31044	(478) 945-3500
Food Giant DiscountJackson Pharmacy	605 North Illinois Street170 JOHN RANDOLPH DR	HarrisburgHOSCHTON	ArkansasGeorgia	724323 0548-15 02	(706) 658-0064
Foothill Remedy DrugsJennings Mill	6253 Foothill Boulevard1360	TujungaWatkinsville	CaliforniaGeorgia	910423 0677-73	(706) 621-5996

Drug Company	Caduceus Wy Bldg 400 Suite 105			00	
~~Forest Heights Pharmacy~~Jones Prescription Shop	~~4439 Country Club Road~~101 Peachtree Street	~~Statesboro~~Jesup	Georgia	~~30458~~31545	(912) 427-8825
King's Hometown Pharmacy	33 SCHOOL CIRCLE SUITE A	BLAIRSVILLE	Georgia	30512-2984	(706) 400-5043
~~Fork Union~~Knight's Pharmacy	~~4316B James Madison Highway~~2 E William Wainwright St	~~Fork Union~~Reynolds	~~Virginia~~Georgia	~~23055~~31076	(478) 847-3666
Lacey Drug Company	4797 South Main Street	Acworth	Georgia	30101	(770) 974-3131
~~Forrest City Family~~Laceys Marietta Pharmacy	~~1111 N Washington~~790 Church St Suite 210	~~Forrest City~~Marietta	~~Arkansas~~Georgia	~~72335~~30060-7289	(770) 424-3131
Lane Drug Co.	19427 Hartford Street	Edison	Georgia	39846	(229) 835-2212
~~Four Seasons~~Lee-Goodrum Pharmacy	~~300 Morrison Drive~~40 Hospital Road	~~Princeton~~Newnan	~~West Virginia~~Georgia	~~24740-2765~~30263-1200	(770) 253-1121
~~Fowler's~~Lily's Pharmacy	~~1908 Laurens~~11670 Jones Bridge Road Suite E	~~Greenville~~Johns Creek	~~South Carolina~~Georgia	~~29607~~30005	(678) 964-5459
~~Fox Drug of Torrance~~	~~1327 El Prado~~	~~Torrance~~	~~California~~	~~90501~~	
~~Franklin~~Live Oak Pharmacy	~~94-31 59th~~98 Oakland Avenue East	~~Elmhurst~~Camilla	~~New York~~Georgia	~~11373~~31730	(229) 336-2255
~~Franklyn~~Lo Cost Pharmacy	~~204 WARREN AVE~~612 East 69th Street	~~Hohokus~~Savannah	~~New Jersey~~Georgia	~~07423~~31405	(912) 352-0375
Ludowici Drugs	11 West Cypress Street	Ludowici	Georgia	31316	(912) 545-2125
Lula Pharmacy and Foothills Gift Shop	6102 Banks Street	Lula	Georgia	30554	(770) 869-3616
Madden's Pharmacy, Inc.	101 College Avenue	Elberton	Georgia	30635-1705	(706) 283-1701
Maddox Drugs	1330 Big A Road	Toccoa	Georgia	30577	(706) 886-3119
Madison Drug Company	213 NORTH MAIN STREET	MADISON	Georgia	30650	(706) 342-1722
~~Frazier's Prater~~Magnolia Drug Co Inc	~~49 S.~~112 North Church Street	~~Salyersville~~Homerville	~~Kentucky~~Georgia	~~41465~~31634	(912) 470-7277
~~Fred's~~Max Brown Pharmacy	~~797 Military~~809 North Jefferson Street~~ South~~	~~Hamilton~~Dublin	~~Alabama~~Georgia	~~35570~~31021	(478) 272-8086
McCaysville Drug Center Inc	131 Blue Ridge Drive	McCaysville	Georgia	30555	(706) 492-4126
~~Fred's~~Medical Arts Pharmacy Inc	~~121 West Prairie~~650 North Cobb Street	~~Vicksburg~~Milledgeville	~~Michigan~~Georgia	~~49097~~31061	(478) 452-1222

~~Frederick Community~~Medical Park Pharmacy	~~2450 Frederick Douglas Boulevard~~2406 Bellevue Rd	~~New York~~Dublin	~~New York~~Georgia	~~10029~~31021	(478) 272-8065
Medicine Stop	1544 Watson Boulevard	Warner Robins	Georgia	31093	(478) 922-2067
Medi-Save Pharmacy	800 South Slappey Boulevard	Albany	Georgia	31701	(229) 435-1306
~~Freds Granville~~MediThrift Pharmacy	~~75 Quaker~~324 West Patton Street	~~Granville~~Lafayette	~~New York~~Georgia	~~12832~~30728	(706) 638-3114
~~Freds~~Mid-City Pharmacy	~~808 West Michigan Avenue~~196 E Main St	~~Three Rivers~~Canton	~~Michigan~~Georgia	~~49093~~30114-2799	(770) 479-5533
Midtown Pharmacy	2660 Buena Vista Road Suite A	Columbus	Georgia	31906	(706) 596-8871
~~Freedom~~Misty's Pharmacy	~~3902 Hardy~~149 NW Broad St	~~Hattiesburg~~Jesup	~~Mississippi~~Georgia	~~39402-1541~~31545	(912) 427-3726
Mitch's Pharmacy	5 E Coffee St	Hazlehurst	Georgia	31539	(912) 699-3784
Morris Drug Co	646 Main Street North	Pearson	Georgia	31642	(912) 422-3631
Mount Vernon Drug Company	115 West Spring Street	Mount Vernon	Georgia	30445	(912) 616-9922
Moyes Drug Store	162 East Railroad Street South East	Pelham	Georgia	31779	(229) 294-4058
Murrayville Pharmacy	5304 Thompson Bridge Rd	Murrayville	Georgia	30564	(770) 534-2245
~~Freeman Medical~~North Columbus Pharmacy	~~301 North Prairie Avenue,~~6490 Veterans Parkway Suite ~~110~~B	~~Inglewood~~Columbus	~~California~~Georgia	~~90301~~31909	(706) 327-5125
Northside Drugs	1109 HWY 19 NORTH	THOMASTON	Georgia	30286	(706) 648-2181
OCILLA PHARMACY	515 North Irwin Avenue	OCILLA	Georgia	31774-1542	(229) 468-5929
~~Friendly #1~~PeachRx Pharmacy	~~485 Lewis Road, Suite D~~610 Shurling Drive	~~San Jose~~Macon	~~California~~Georgia	~~95111~~31211	(478) 314-7993
Pembroke Pharmacy	137 East Bacon Street	Pembroke	Georgia	31321	(912) 653-2772
Phillips Pharmacy	306 West First Street	Vidalia	Georgia	30474	(912) 537-3049
Pillar Drug Company	1 Hidden Creek Drive	Guyton	Georgia	31312	(912) 772-9100
~~Friendly #2~~Pooler Pharmacy	~~639 Tully Road, Suite A~~1557 POOLER PARKWAY SUITE 400	~~San Jose~~POOLER	~~California~~Georgia	~~95111~~31322	(912) 348-4420
Powells Northside Pharmacy	440 Charter Boulevard Suite 1107	Macon	Georgia	31210	(478) 474-6767
~~Friendly~~	~~1202 US Highway~~	~~Tifton~~Macon	Georgia	~~31794~~3	(478) 781-1213

~~City~~Powells Pharmacy	~~41 North~~4839 Bloomfield Road			1206-4399	
Premier Drugstore	8446 Campbellton Street	Douglasville	Georgia	30134	(770) 635-8509
Prescription Shop	710 Medical Center Dr	Eastman	Georgia	31023	(478) 374-5514
Quick Rx Drugs #6	504 N LAUREL ST	SPRINGFIELD	Georgia	31329	(912) 754-6444
~~Friendly~~Richmond Hill Pharmacy	~~2176 East Garrison Street Suite D~~2409 US Highway 17	~~Eagle Pass~~Richmond Hill	~~Texas~~Georgia	~~78852~~31324	(912) 756-3331
Riggins Pharmacy	12240 Augusta Road	Lavonia	Georgia	30553	(706) 356-8863
Riverside Pharmacy Inc	935 Green St NE	Gainesville	Georgia	30501	(770) 532-6253
Robins Pharmacy	150 South Houston Lake Road Suite 300	Warner Robins	Georgia	31088-9056	(478) 333-6767
~~Friendly~~Rome Community Pharmacy	~~3712-G Lawndale Drive~~501 East 2nd Avenue	~~Greensboro~~Rome	~~North Carolina~~Georgia	~~27455~~30161-3249	(706) 622-2063
Rose City Pharmacy	616 South Broad Street	Thomasville	Georgia	31792-5551	(229) 233-7733
Ross Drug	127 North Main Street	Sylvania	Georgia	30467	(912) 564-7002
Sanders Drugs	61 Falls Road	Toccoa	Georgia	30577	(706) 297-0111
Sandersville Drug Co.	528 Sparta Road	Sandersville	Georgia	31082	(478) 552-7333
Satilla Wellness Pharmacy	515 South City Boulevard Suite D & E	Waycross	Georgia	31501	(912) 514-4111
Sawnee Drug Co	2515 Business Drive	Cumming	Georgia	30028	(770) 889-8900
Silver Creek Pharmacy	4450 Rockmart Highway	Silver Creek	Georgia	30173	(706) 292-0106
~~Friendship~~Smith's Pharmacy	~~5532 Highway 15 Suite 1~~141 Eighth St.	~~Ecru~~McRae Helena	~~Mississippi~~Georgia	~~38841~~31037	(229) 868-2580
SOUTHERN DRUG CO-DARIEN	1001 North Way	Darien	Georgia	31305	(912) 437-6353
Southern Drug Co - Jesup	918 S 1st St.	Jesup	Georgia	31545	(912) 559-2961
Southern Drug Company	4075 East First Street	Blue Ridge	Georgia	30513	(706) 632-4448
St Simons Drug Company	209 Longview Plaza	St Simons Is	Georgia	31522	(912) 638-8676
Swan Pharmacy Inc	48 N Main St	Wadley	Georgia	30477	(478) 252-5252
Tallapoosa Drug	2066 US Hwy 78	Tallapoosa	Georgia	30176-1464	(770) 574-2339
~~Frisco~~Temple Pharmacy	~~14550 State Highway 121 Suite 150~~285 Sage St	~~Frisco~~Temple	~~Texas~~Georgia	~~75035~~30179-0608	(770) 562-3268

THE MEDICINE CABINET	102 S PIERCE ST	ALMA	Georgia	31510	(912) 383-0634
THE MEDICINE CABINET	2607 PLANT AVENUE	WAYCROSS	Georgia	31501	(912) 490-6337
The Medicine Cabinet	300 MOOTY BRIDGE RD STE 112	LAGRANGE	Georgia	30240-1881	(706) 298-4930
The Medicine Cabinet	1704 ROANOKE RD	LAGRANGE	Georgia	30240-3803	(706) 298-6460
The Medicine Cabinet	1194 WARM SPRINGS HWY	MANCHESTER	Georgia	31816	(706) 846-2002
The Medicine Cabinet	205 VERNON STREET	LAGRANGE	Georgia	30240	(706) 298-4928
The Medicine Cabinet of Brunswick LLC	2500 Starling St Suite 102	Brunswick	Georgia	31520	(912) 265-7000
The Medicine Cabinet of Douglas	722 Shirley Avenue	Douglas	Georgia	31533	(912) 383-8510
The Medicine Cabinet of Dubline LLC	1819 RICE AVE	DUBLIN	Georgia	31021-0537	(478) 272-1822
The Medicine Cabinet of Waycross - Downtown, LLC	620 Tebeau St	Waycross	Georgia	31501	(912) 283-2772
The Medicine Cabinet - Ward Street, LLC	223 W ASHLEY ST	DOUGLAS	Georgia	31533-3124	(912) 383-6337
The Pharmacy Place	2035 Commerce Dr N	Peachtree City	Georgia	30269-3538	(678) 271-3970
Thomson Drug Company	501 Mount Pleasant Road	Thomson	Georgia	30824	(706) 595-6126
Thrifty Mac Pharmacy	218 S Main St	Madison	Georgia	30650	(706) 342-4141
Tomlinson Pharmacy	108 Rowe St	Dublin	Georgia	31021	(478) 272-7722
~~Fulghum Drugs~~Towne Pharmacy	~~73 Southwest Park Avenue~~6014 Highway 21 South Suite P	~~Baxley~~Rincon	Georgia	~~31513~~31326	(912) 826-0250
Trenton Pharmacy	11969 S Main St	Trenton	Georgia	30752-2855	(706) 500-1301
Trumarx Drugs	501 Gordon Avenue	Thomasville	Georgia	31792	(229) 226-8700
Twin City Drug Co	507 South Railroad Avenue	Twin City	Georgia	30471-0040	(478) 763-2151
Unadilla Drug Company	413 2nd Street	Unadilla	Georgia	31091	(478) 627-3041
~~Fullerton~~Valurite Discount Pharmacy	~~1820 Fullerton Avenue Suite 105~~1006 Professional Boulevard	~~Corona~~Dalton	~~California~~Georgia	~~92881~~30720	(706) 217-2700
Village Drug Shop	740 Prince Avenue	Athens	Georgia	30606-2	(706) 548-4444

of Athens				296	
Villa Rica Drugs	222 W Wilson St	Villa Rica	Georgia	30180-1807	(770) 456-4663
Walker Pharmacy & Gifts Inc	2425 Northside Drive West	Statesboro	Georgia	30458	(912) 764-6175
Walker Pharmacy Market District	1198 Merchants Way	Statesboro	Georgia	30458	(912) 681-3784
Wauka Mountain Pharmacy	5233 Cleveland Highway	Clermont	Georgia	30527	(770) 983-9556
Wayne Drug Co	192 North First Street	Jesup	Georgia	31545	(912) 427-4288
West End Pharmacy	824 West Avenue	Cartersville	Georgia	30120	(770) 606-0697
WOODBINE PHARMACY	908 GEORGIA AVE	WOODBINE	Georgia	31569	(912) 576-6998
WYATT'S PHARMACY	10671 Veterans Memorial Hwy.	Lithia Springs	Georgia	30122	(770) 948-8825
Young Life Pharmacy	1769 Candler Road	Decatur	Georgia	30032-3276	(404) 549-9671
5 Minute Pharmacy	94-216 Farrington Highway, Suite B1-102	Waipahu	Hawaii	96797	(808) 677-5550
5 MINUTE PHARMACY DOWNTOWN	928 NUUANU AVE # 1-B	HONOLULU	Hawaii	96817-5190	(808) 809-6661
5 MINUTE PHARMACY LONG TERM CARE	94-449 Akoki St #102	WAIPAHU	Hawaii	96797-1922	(808) 671-5511
~~Fulton~~Don Quijote Drugs	~~1657 25th Street Northwest~~801 Kaheka St	~~Canton~~Honolulu	~~Ohio~~Hawaii	~~44709~~96814	(808) 973-6661
Family Pharmacy INC	1451 South King Street Suite 203 A	Honolulu	Hawaii	96814	(808) 379-2347
~~Future~~KTA Kamuela Pharmacy	~~979 Route 9 North~~65-1158 Mamalahoa Highway	~~Howell~~Kamuela	~~New Jersey~~Hawaii	~~07731~~96743	(808) 885-0033
KTA Keauhou Pharmacy	78-6831 Alii Drive	Kailua-Kona	Hawaii	96740	(808) 322-2511
KTA Ponahawai Pharmacy	670 Ponahawai Street Suite 211	Hilo	Hawaii	96720	808-865-0505
~~Future~~KTA Puainako Pharmacy ~~3~~	~~680 Route 33~~50 E ~~Unit 8~~Puainako St	~~East Windsor~~Hilo	~~New Jersey~~Hawaii	~~08520~~96720-5243	(808) 959-8700
KTA Waikoloa Village Pharmacy	68-3916 Paniolo Avenue	Waikoloa	Hawaii	96738	(808) 883-8434
Maui Clinic Pharmacy	22 Hana Hwy, Suite B	Kahului	Hawaii	96732	(808) 877-6222
Medipharm Pharmacy	891 Ululani Street Suite 113	Hilo	Hawaii	96720	(808) 969-9163
Medipharm Pharmacy	197 Sand Island Access Road, Suite 208	Honolulu	Hawaii	96819-4901	(808) 744-9080

FuturePharmacyPharmacare No. 4	700 Tennent Road99 128 Aiea Heights Drive Suite 9103	ManalapanAiea	New JerseyHawaii	077269 6701	(808) 840-5681
FutureRainbow Pharmacy II	72 Route 3431 Seventh Street	Old BridgeLanai City	New JerseyHawaii	088579 6763	(808) 565-9332
Times Pharmacy #1	1772 S King St	Honolulu	Hawaii	96826	(808) 973-5851
Times Pharmacy #10	47 388 Hui Iwa St	Kaneohe	Hawaii	96744	(808) 239-3204
Times Pharmacy #11	1425 Liliha St	Honolulu	Hawaii	96817	(808) 522-5082
Gadsden CityTimes Pharmacy #12	911 RAINBOW DR98 1264 Kaahumanu Street	GADSDENPearl City	AlabamaHawaii	359019 6782	(808) 483-3078
Gail'sTimes Pharmacy #18	810 Woodrow Wilson Ray Circle94 615 Kupuohi St	BridgeportWaipahu	TexasHawaii	764269 6797	(808) 677-5999
Times Pharmacy #2	1173 21st Avenue	Honolulu	Hawaii	96816	(808) 733-2031
Times Pharmacy #24	3350 Lower Honoapiilani Rd	Lahaina	Hawaii	96761-8402	(808) 661-8008
Times Pharmacy #25	1620 North School Street	Honolulu	Hawaii	96817	(808) 853-2268
Times Pharmacy #4	45 934 Kamehameha Hwy	Kaneohe	Hawaii	96744	(808) 233-4601
Times Pharmacy #6	94 766 Farrington Highway	Waipahu	Hawaii	96797	(808) 677-1513
GalaxyTimes Pharmacy #9	1801 West Romneya99 115 Aiea Heights Drive Suite 108	AnaheimAiea	CaliforniaHawaii	928019 6701	(808) 483-3071
GALAXY PHARMACYKaleo's Pharmacy LLC	1360 E ANAHEIM ST STE 1064475 Papalina Rd Suite C1	LONG BEACHKalaheo	CaliforniaHawaii	90813-5516967 41-8503	(808) 431-4455
Jacks Pharmacy Inc	103 East College Avenue	St Maries	Idaho	83861	(208) 245-4578
London Drug	6 S Main	Grace	Idaho	83241	(208) 425-3766
Galaxy PharmacyMaag Prescription and Medical Supply	1295 East Anaheim333 West Center Street	Long BeachPocatello	CaliforniaIdaho	908138 3204	(208) 233-2063
Medicine Man Athol Pharmacy	30585 North Roberts Road	Athol	Idaho	83801	(208) 683-1309
Galloway SandsMedicine Man Bonners Ferry Pharmacy	58 Physicians Dr, Ste 56452 Main Street	SupplyBonners Ferry	North CarolinaIdaho	284628 3805	(208) 267-4021
Medicine Man Hayden Pharmacy	240 West Hayden Avenue	Hayden	Idaho	83835	(208) 772-3311
Medicine Man North Pharmacy	305 West Kathleen Avenue	Coeur D' Alene	Idaho	83815	(208) 765-2268
Medicine Man Prairie Pharmacy	8093 Cornerstone Drive	Hayden	Idaho	83835	(208) 762-9355

Mike's Pharmacy & Compounding	180 S Holmes Ave	Idaho Falls	Idaho	83401	(208) 525-8700
SavMor Drug	139 Main Ave W	Twin Falls	Idaho	83301-6194	(208) 733-8323
The Prescription Pad	1620 N Whitley Dr	Fruitland	Idaho	83619-2271	(208) 452-7075
Valley Apothecary	201 North Washington Avenue	Ketchum	Idaho	83340	(208) 726-2679
Vic's Family Pharmacy	118 South Midland Boulevard	Nampa	Idaho	83686	(208) 442-1000
~~Galloway Sands~~Vic's Family Pharmacy ~~#2~~	1513 ~~N. Howe Street, Suite 8~~12th Avenue Road	~~Southport~~Nampa	~~North Carolina~~Idaho	~~284618~~3686	(208) 465-7000
~~Gammel's Clinic~~Alwood Pharmacy	~~909 Unity Road~~211 South 1st Street	~~Crossett~~Alpha	~~Arkansas~~Illinois	~~716356~~1413	(309) 629-4506
Armitage Pharmacy, Inc.	3650 West Armitage Avenue Suite 100	Chicago	Illinois	60647	(773) 486-8800
Benivex Pharmacy	370 West Indian Trail	Aurora	Illinois	60506	(630) 800-1636
Bond County Pharmacy	224A E Harris Ave	Greenville	Illinois	62246-2150	(618) 690-5000
Byrd-Watson Drug #2	1071 West Broadway	Centralia	Illinois	62801-5309	(618) 532-2200
Cains Drug Store	1401 North 8th Street	Vandalia	Illinois	62471	(618) 283-0196
Community Pharmacy of Chicago Ridge	9830 South Ridgeland	Chicago Ridge	Illinois	60463	(708) 229-2100
~~Garfield Lowcost~~Crescent Pharmacy	~~5050 Turney Road~~7261 West 87th Street	~~Garfield Heights~~Bridgeview	~~Ohio~~Illinois	~~441256~~0455-1821	(708) 598-0505
~~Gaston~~Curry's Family Pharmacy	~~1118 Mack~~1275 North 7th Street	~~Gaston~~Riverton	~~South Carolina~~Illinois	~~290536~~2561	(217) 629-7001
~~Gateway~~Dick's Pharmacy	~~165 Nutt Road~~122 S. Walnut St	~~Phoenixville~~Arthur	~~Pennsylvania~~Illinois	~~194606~~1911	(217) 543-2913
~~Gateway~~Dundee Pharmacy	~~1330 Gateway Boulevard~~ 2750 Dundee Road, Suite ~~B-2~~9	~~Fairfield~~Northbrook	~~California~~Illinois	~~945336~~0062	(847) 480-1000
Harrys Pharmacy Inc	620 East Jackson	Auburn	Illinois	62615	(217) 438-6141
HUDSON DRUG SHOP	108 N MARKET	Paxton	Illinois	60957	(217) 379-4858
~~Gateway~~Illini Clinic Pharmacy	~~1048 North McEwan Street~~855 Illini Drive, Suite 200	~~Clare~~Silvis	~~Michigan~~Illinois	~~486176~~1282	(309) 792-7002
Katsaros Pharmacy	1521 East 53rd Street	Chicago	Illinois	60615	(773) 288-8700
Kremer Pharmacy	206A North Pearl	Teutopolis	Illinois	62467-1	(217) 857-3000

	Street			134	
KREMER PHARMACY ALTAMONT	12 N 3RD ST	ALTAMONT	Illinois	62411-1271	(618) 483-5100
Kwikrx Pharmacy	13015 West 143rd Street	Homer Glen	Illinois	60491	(708) 292-0043
~~Gatlin Medical Arts~~Mexicare Pharmacy	~~420 Country Club Road~~3200 West 26th Street	~~Pratt~~Chicago	~~Kansas~~Illinois	~~671246~~ 0623	(773) 890-1800
Moreland & Devitt Inc	124 North Congress Street	Rushville	Illinois	62681	(217) 322-3335
~~Gaughns Drug Store~~Moreland & Devitt Pharmacy	~~348 Pennsylvania Avenue West~~201 South State Street	~~Warren~~Beardstown	~~Pennsylvania~~Illinois	~~163656~~ 2618-1219	(217) 909-4333
Morton Alwan Pharmacy	419 Maxine Drive	Morton	Illinois	61550	(309) 291-0180
Oakwood Apothecary	17 N HAMILTON ST	SULLIVAN	Illinois	61951	(217) 728-2760
OGDEN PHARMACY	2040 Ogden Avenue Suite 117	Aurora	Illinois	60504-7205	(630) 320-8600
~~Gem Drugs~~Orion Family Pharmacy LLC	~~139 Central~~201 11th Avenue	~~Reserve~~Orion	~~Louisiana~~Illinois	~~700846~~ 1273	(309) 526-8008
Pearman Pharmacy	116 West Court Street	Paris	Illinois	61944	(217) 465-8455
Plum Street Pharmacy	311 Plum Street	Carmi	Illinois	62821	(618) 382-8400
Prime Plus Pharmacy	2955 W 95th St	Evergreen Park	Illinois	60805-2409	(708) 741-7501
Princeville Pharmacy	206 East Main	Princeville	Illinois	61559	(309) 385-4955
Rigg FamilyCare Pharmacy	37 W MAIN ST	ALBION	Illinois	62806-1006	(618) 445-2581
Scotts Family Pharmacy	220 N Sangamon Ave	Gibson City	Illinois	60936-1397	(217) 784-8241
~~Gem Drugs Gramercy~~Sears Pharmacy	~~1635 Highway 3125~~1003 Madison St	~~Gramercy~~Oak Park	~~Louisiana~~Illinois	~~700526~~ 0302-4499	(708) 386-6304
Sherman's Pharmacy	91 Knoxville Avenue	Brimfield	Illinois	61517	(309) 446-3292
Silver Pharmacy	1890 Silver Cross Boulevard Suite 120	New Lenox	Illinois	60451-9528	(815) 800-3100
Southwest Express Pharmacy	11164 Southwest Highway	Palos Hills	Illinois	60465-2709	(708) 541-1000
~~GeneRx Discount~~St. Jude Pharmacy	~~1235 South Josey Lane~~ 301 Madison Street Suite ~~533~~114	~~Carrollton~~Joliet	~~Texas~~Illinois	~~750066~~ 0435	(815) 900-9000
Staywell Pharmacy	912 East Northwest Highway	Palatine	Illinois	60074-6506	(847) 496-5559
Tablets Pharmacy Inc	9603 S Pulaski Rd	Evergreen Park	Illinois	60805	(708) 272-1212
Vorac Pharmacy	114 S State St	Geneseo	Illinois	61254-1	(309) 944-2166

LLC				348	
Wear Drug	408 Walnut Street	Carthage	Illinois	62321	(217) 357-9327
Wellcreek Pharmacy - Bethalto	333 West Bethalto Drive Suite B	Bethalto	Illinois	62010	(618) 377-5356
WellCreek Pharmacy-Charleston	1 West Lincoln Avenue	Charleston	Illinois	61920	(217) 512-2816
Xpress Pharmacy Inc	6700 W 95th St Suite 150	Oak Lawn	Illinois	60453-2106	(708) 598-5000
Alwan Pharmacy and Compounding Center	311 North Western Avenue	Peoria	Illinois	61604	(309) 676-6333
~~George's Family Pharmacy~~Cloverdale Drugs	~~480~~900 North Main Street	~~Brookville~~Cloverdale	Indiana	~~47012~~46120	(765) 795-4100
Cowan Drugs	112 North Lebanon Street	Lebanon	Indiana	46052	(765) 482-0180
Dr Aziz Pharmacy	7320 East 82nd Street	Indianapolis	Indiana	46256	(317) 842-5771
George's Family Pharmacy	~~24128 State Line Road~~326 South Washington Street Suite 22	~~Lawrenceburg~~Versailles	Indiana	~~47025~~47042	(812) 689-0200
George's Family Pharmacy	124 West Indian Trail Suite C	Milan	Indiana	47031	(812) 654-6251
George's Family Pharmacy	~~326 South Washington~~480 Main Street ~~Suite 22~~	~~Versailles~~Brookville	Indiana	~~47042~~47012	(765) 647-6251
George's Family Pharmacy	24128 State Line Road	Lawrenceburg	Indiana	47025	(812) 637-6251
George's Family Pharmacy, Inc.	1198 State Road 46 East	Batesville	Indiana	47006	(812) 932-6251
George's Family Pharmacy, Inc.	330 East 5th Street	Connersville	Indiana	47331-2604	(765) 825-6251
George's Pharmacy East Side	5543 E Washington St	Indianapolis	Indiana	46219-6448	(317) 359-8278
~~Georgetown Drug Company~~Herbst Apothecary Inc	~~1080 King George Boulevard~~201 N Dixon Rd	~~Savannah~~Kokomo	~~Georgia~~Indiana	~~31419~~46901-4097	(765) 457-1191
~~Georgies Outpatient~~Herbst Pharmacy	~~6 Earlin Avenue~~ 300 E Southway Blvd Suite ~~130~~E	~~Browns Mills~~Kokomo	~~New Jersey~~Indiana	~~08015~~46902-6411	(765) 455-5418
~~Gerdes~~Herbst Pharmacy	~~245~~710 W Main ~~Street~~St	~~Conneaut~~Greentown	~~Ohio~~Indiana	~~44030~~46936	(765) 628-3446
JR Pharmacy LLC 2	15 Southland Shopping Cntr	Terre Haute	Indiana	47802	(812) 232-6655
JR Pharmacy Poplar LLC	1101 Poplar St	Terre Haute	Indiana	47807-4565	(812) 235-7373
JR Pharmacy Rockville LLC 4	1330 N Lincoln Rd	Rockville	Indiana	47872-1215	(765) 569-6900
JR Scripts Pharmacy No 1	2902 Poplar St	Terre Haute	Indiana	47803-2661	(812) 478-1006

LLC					
~~Get Rx Help~~Mathes Pharmacy	~~688 Westwood Ave Ste 3~~1621 Charlestown Road	~~River Vale~~New Albany	~~New Jersey~~Indiana	~~07675-6375~~47150	(812) 944-3612
Medicine Plus	2412 West 16th Street	Bedford	Indiana	47421	(812) 275-3383
~~Giant Discount~~MedWorks Pharmacy	~~6611 Savannah Highway~~2123 Intelliplex Drive	~~Neeses~~Shelbyville	~~South Carolina~~Indiana	~~291074~~6176-8538	(317) 421-2020
~~Giara Pharmacy, Inc.~~	~~5400 Balboa Boulevard~~	~~Encino~~	~~California~~	~~91315~~	
Millers Pharmacy	420 South Detroit Street	Lagrange	Indiana	46761	(260) 463-7464
~~Gibbs Drug Store~~Parkside Pharmacy	~~216 Clay~~1639 North Lebanon Street	~~Nocona~~Lebanon	~~Texas~~Indiana	~~762554~~6052	(765) 482-1600
~~Gibson's~~Paul's Pharmacy	~~2401 Central Avenue~~2345 W Franklin St	~~Dodge City~~Evansville	~~Kansas~~Indiana	~~678014~~7712-5172	(812) 425-4364
~~Gibson's~~Paul's Pharmacy East	~~1206 Paris~~1150 South Green River Road	~~Mayfield~~Evansville	~~Kentucky~~Indiana	~~420664~~7715	(812) 962-3500
PAULS PHARMACY	3408 N 1ST AVE	EVANSVILLE	Indiana	47710-3302	(812) 422-8255
Pharmacy 1 Express	730 West 2nd Street	Bloomington	Indiana	47403	(812) 331-7979
Seifert Drug #2	100 N Elkhart St	Wakarusa	Indiana	46573	(574) 862-1454
~~Gibson Prescription Pharmacy~~Seifert Drug #3	~~600 South Palestine~~2102 North Main Street Suite 100	~~Athens~~Nappanee	~~Texas~~Indiana	~~757514~~6550	(574) 773-8280
~~Gibsonville Pharmacy~~Seifert Healthcare LLC #1	~~220 Burlington Avenue~~222 Harrison St	~~Gibsonville~~Elkhart	~~North Carolina~~Indiana	~~272494~~6516-3120	(574) 295-4333
~~Gilberts Drug Store~~Webb's Family Pharmacy	~~212 South State~~724 Main Street	~~Oscoda~~Rochester	~~Michigan~~Indiana	~~487504~~6975	(574) 223-2216
~~GKN RX INC~~Brehme Drug	~~1471 B ST STE R~~220 E Main St	~~LIVINGSTON~~Manchester	~~California~~Iowa	~~95334-1426~~52057	(563) 927-3509
~~Glenn's~~Carroll Apothecary	~~520 West Gum Street~~425 W US Hwy 30 Suite 140	~~Marion~~Carroll	~~Kentucky~~Iowa	~~420645~~1401	(712) 792-2671
Cherokee Main Street Pharmacy	218 E Main St	Cherokee	Iowa	51012	(712) 225-2320
~~Glenn's Corner~~Clarks Pharmacy	~~631 East Franklin~~1946 42nd Street NE	~~Sylvester~~Cedar Rapids	~~Georgia~~Iowa	~~317915~~2402	(319) 393-3210
~~Glenn's Prescription Center~~Clinic Pharmacy	~~119 East Main~~1115 South Marshall Street	~~Salem~~Boone	~~Kentucky~~Iowa	~~420785~~0036	(515) 432-7123
~~Global~~Eagle Grove	~~926 B Montreal~~	~~Clarkston~~Eagle	~~Georgia~~Iowa	~~300215~~	(515) 448-3814

Pharmacy	~~Road Suite 2~~311 W Broadway St	Grove		0533	
~~GLOBAL REXALL DRUG~~	~~424 E ST~~	~~FAIRBURY~~	~~Nebraska~~	~~68352-2535~~	
~~GLS~~Holstein Community Pharmacy~~ LLC~~	~~15680 Southwest 72nd~~108 North Main Street	~~Miami~~Holstein	~~Florida~~Iowa	~~33193-1923~~510 25-7754	(712) 368-0010
Koerner-Whipple Pharmacy	104 First Street Northwest	Hampton	Iowa	50441	(641) 456-2510
~~GNO~~Larry's Pharmacy 1	~~1151 Barataria Blvd Suite 1200~~1310 10th Ave N	~~Marrero~~Humboldt	~~Louisiana~~Iowa	~~70072-3082~~505 48-1112	(515) 332-1627
Mahaska Drug, Inc	205 North E Street	Oskaloosa	Iowa	52577	(641) 673-3439
Main Street Drug	204 N Main St	Charles City	Iowa	50616-2017	(641) 228-3519
~~Godwin~~Medical Associates Pharmacy	~~3061 Godwin Boulevard Suite 109~~120 South Story Street	~~Suffolk~~Boone	~~Virginia~~Iowa	~~23434-6662~~500 36	(515) 432-3460
Mercy Family Pharmacy-Clear Lake	1410 6th Avenue South Suite 200	Clear Lake	Iowa	50428	(641) 231-8900
~~Golden Gate~~Mercy Family Pharmacy - Greene	~~1836 Noriega~~104 East Traer Street	~~San Francisco~~Greene	~~California~~Iowa	~~941225~~0636	(641) 816-3013
MercyOne FOREST PARK PHARMACY	1010 4th Street Southwest Suite 110	Mason City	Iowa	50401	(641) 428-6100
~~Golden Isles~~MercyOne Northwood Pharmacy	~~3010 Altama Avenue~~98 North 10th Street	~~Brunswick~~Northwood	~~Georgia~~Iowa	~~315205~~0459-1438	(641) 324-2116
~~Gold Hill~~MercyOne Regency Pharmacy	~~808 Second~~621 South Illinois Avenue Suite 101	~~Gold Hill~~Mason City	~~Oregon~~Iowa	~~975255~~0401	(641) 428-6940
~~Gonzales Rx~~MercyOne Sheffield Pharmacy	~~18 Fourth Street~~115 Gilman	~~Gonzales~~Sheffield	~~California~~Iowa	~~93926-0808~~504 75	(641) 892-4640
~~Goodale~~MercyOne Westside Pharmacy	~~16~~910 North ~~Sussex Street~~Eisenhower Avenue	~~Dover~~Mason City	~~New Jersey~~Iowa	~~078015~~0401	(641) 428-5630
~~Good Health~~Meyer Pharmacy	~~530 Joralemon~~110 10th St~~.~~ SW	~~Belleville~~Waverly	~~New Jersey~~Iowa	~~071095~~0677	(319) 352-3120
~~Good Neighbor~~North Scott Pharmacy	~~60 Cassady Avenue Suite 3~~225 East LeClaire Road	~~Danville~~Eldridge	~~Kentucky~~Iowa	~~404225~~2748	(563) 285-2001
Sergeant Bluff Pharmacy	105 Gaul Drive Suite A	Sergeant Bluff	Iowa	51054	(712) 943-1494
~~GOOD RX~~Smart Pharmacy #22	~~5221 33rd~~616 North 8th Street ~~East~~	~~Bradenton~~Osage	~~Florida~~Iowa	~~34203-4330~~504 61	(641) 732-5806

GoodykoontzSouth Side Drug Store Inc	2924 East Cumberland Road337 Church Street	BluefieldOttumwa	West VirginiaIowa	2470152501	(641) 682-3467
Spring City Pharmacy LLC	101 N WALNUT ST	COLFAX	Iowa	50054	(515) 674-3784
Summit Pharmacy	300 West Burlington Avenue	Fairfield	Iowa	52556-3241	(641) 472-7987
Gordon's Pharmacy and GiftsB & C Drug Company	314 S. Main702 12TH Street	CanyonvilleBellevill e	OregonKansa s	9741766935	(785) 527-2146
Bachman Drug	129 South Fowler	Meade	Kansas	67864	(620) 873-2641
Barrys Drug Center	414 Poyntz Avenue	Manhattan	Kansas	66502-6086	(785) 776-8833
GosneyClark Pharmacy	911 Highway 24/36 East104 S Main St	Monroe CityCimarron	MissouriKans as	6345667835-9998	(620) 855-2242
GothamContinental Pharmacy IncLLC	2258 3rd Avenue821 Southwest 6th Street	New YorkTopeka	New YorkKansas	10035666603-3130	(785) 232-6975
Grand BlancDoug's Pharmacy	2227 East Hill Road430 Main Street	Grand BlancRossville	MichiganKan sas	48439-5000665 33	(785) 584-6722
Grand CareDunne's Pharmacy Inc	6656 Grand Avenue2429 Claflin Rd	MaspethManhattan	New YorkKansas	11378-0009665 02-2785	(785) 539-2345
Ferguson Rexall Drugs	713 5th Street	Clay Center	Kansas	67432	(785) 632-3121
GrandGatlin Medical Arts Pharmacy	733 Grand Avenue420 Country Club Road	HannibalPratt	MissouriKans as	6340167124	(620) 672-7447
Grand ValueGibson's Pharmacy	10920 Grand River2401 Central Avenue	DetroitDodge City	MichiganKan sas	4820467801	(620) 227-8193
Grant County Drug	219 NorthN Main StreetSt	Ulysses	Kansas	6788067880-2130	(620) 356-1446
Graves Pharmacy	770 Pine Street, Suite 100	Macon	Georgia	31201	
Greater Care Pharmacy	24800 HOOVER RD STE B	WARREN	Michigan	48089-1965	
Greeley County Drug	422 Broadway Avenue	Tribune	Kansas	67879-7701	(620) 376-4224
Hamilton County Drug	302 East Avenue A	Syracuse	Kansas	67878	(620) 384-7424
GreenbriarHumboldt Pharmacy	250 East FM 2449204 South Ninth Street	PonderHumboldt	TexasKansas	7625966748-1908	(620) 473-2520
Iola Pharmacy	109 East Madison	Iola	Kansas	66749	(620) 365-3176
Green CrossKellstrom Pharmacy	1305 Airport Freeway Ste 1101860 Claflin Rd	BedfordManhattan	TexasKansas	7602166502-3492	(785) 776-1200

Ken's Sunflower Pharmacy	7222 West 80th Street	Overland Park	Kansas	66204	(913) 341-7244
Moffet Drug	102 South State	Norton	Kansas	67654	(785) 877-2721
Newman Community Rx 1430	1400 W 12th Ave	Emporia	Kansas	66801	(620) 342-1242
S and S Drugs	110 South Mill Street	Beloit	Kansas	67420	(785) 738-2285
Silver Creek Pharmacy & Gifts	945 Market St	La Cygne	Kansas	66040	(913) 757-4744
St Marys Pharmacy	520 W Bertrand Ave	Saint Marys	Kansas	66536-1698	(785) 437-2967
~~Greene~~Stockton Pharmacy	~~331~~402 Main Street	~~Stanardsville~~Stockton	~~Virginia~~Kansas	~~229736~~7669	(785) 425-7172
Taylor Drug	201 South Summit Street	Arkansas City	Kansas	67005-2895	(620) 442-3500
The Downtown Drug Store	516 East 4th Street	Tonganoxie	Kansas	66086	(913) 369-3800
The Medicine Store	760 Northstar Court	Tonganoxie	Kansas	66086-0580	(913) 369-2100
The Medicine Store	15415 Pinehurst Drive	Basehor	Kansas	66007	(913) 724-3666
Wamego Drug Store	501 Lincoln St	Wamego	Kansas	66547-1633	(785) 456-9292
Ward Drug	142 South Penn Avenue	Oberlin	Kansas	67749	(785) 475-2285
~~Greenfield Pharmacy~~Adair Drug	~~105 N GRAND STE~~510 Burkesville Street Suite 1	~~GREENFIELD~~Columbia	~~Missouri~~Kentucky	~~656614~~2728	(270) 384-9999
~~Green River~~Benton Pharmacy	~~50 DILLON ST~~2606 Main St	~~Liberty~~Benton	Kentucky	~~425394~~2025	(270) 527-1409
~~Greensboro Pharmacy~~Berea Drug	~~102 South Main Street~~402 Richmond Road Suite A	~~Greensboro~~Berea	~~Maryland~~Kentucky	~~216394~~0403	(859) 986-4521
Betsy Layne Pharmacy Inc	11105 US Highway 23 South	Betsy Layne	Kentucky	41605	(606) 478-9474
~~Greenville~~Blanks Pharmacy	~~117 North Main~~272 Pike Street	~~Greenville~~Covington	Kentucky	~~423454~~1011	(859) 261-1313
~~Greenwood Drugs~~Bluegrass Apothecary	~~400 West~~3000 Alvey Park ~~Avenue~~Drive West	~~Greenwood~~Owensboro	~~Mississippi~~Kentucky	~~389304~~2303	(270) 926-4080
~~Griffith and Feil Drug~~	~~1405 Chestnut Street~~	~~Kenova~~	~~West Virginia~~	~~25530~~	
~~Grove Harbor Medical Center~~Bowling Family Pharmacy	~~12555 Garden Grove~~314 Treuhaft Boulevard ~~Suite 102~~	~~Garden Grove~~Barbourville	~~California~~Kentucky	~~928434~~0906	(606) 546-2210
Burgess Drug Store Inc. #2	19 Medical Loop Suite 2	Whitley City	Kentucky	42653	(606) 376-5043
Burgess Drug Store Inc # 3	2157 South Highway 27	Stearns	Kentucky	42647	(606) 376-9662
~~Grove~~Calvert City	~~8283 Grove Avenue~~	~~Rancho~~	~~California~~Ken	~~91730-3~~	(270) 395-4350

Pharmacy	Suite 108 109906 E 5th Ave	CucamongaCalvert City	tucky	137420 29-0365	
GroveCare More Pharmacy	123 Grove Street151 Dorton Jenkins Hwy	MontclairDorton	New JerseyKentucky	070424 1520	(606) 639-2273
Guardian AngelCDS #10 Pharmacy	1537 North Zaragoza Road Suite 1A1308 Ashley Cir	El PasoBowling Green	TexasKentucky	799364 2104-3339	(270) 781-5661
Clark Drugs	500 Main St	Munfordville	Kentucky	42765-0127	(270) 524-3669
Clay Community Pharmacy	118 Clay CO S/C	Manchester	Kentucky	40962	(606) 599-0209
Clays Pharmacy	3513 Court Street	Catlettsburg	Kentucky	41129-1011	(606) 865-2025
Clinic Pharmacy	203 North 2nd Street	Central City	Kentucky	42330	(270) 754-4300
Gulf Breeze ApothecaryColumbia Pharmacy	1177 Gulf Breeze Parkway803 Burkesville Street	Gulf BreezeColumbia	FloridaKentucky	325614 2728	(270) 384-2118
Gulf GateCommonwealth Pharmacy	2134 Gulf Gate Drive5425 North Mayo Trail, Suite 102	SarasotaPikeville	FloridaKentucky	342314 1501	(606) 437-0701
Cull Family Pharmacy	965 Highway 127 North	Owenton	Kentucky	40359	(502) 484-3046
Cynthiana Hometown Pharmacy	1134 US Highway 27 South	Cynthiana	Kentucky	41031	(859) 234-5600
Davis Drugs	250 Lone Oak Road	Paducah	Kentucky	42001	(270) 443-1442
GulfportDraffenville Pharmacy	5004 Gulfport Boulevard S153 US Hwy 68 E	GulfportBenton	FloridaKentucky	337074 2025	(270) 527-1404
Gun LakeDuncan Clinic Pharmacy	71 124th Avenue1111 Medical Center Circle	ShelbyvilleMayfield	MichiganKentucky	493444 2066	(270) 247-7000
Guy's Pharmacy of Crystal SpringsDuncan Prescription Center	512 West Marion Avenue1520 Cuba Road	Crystal SpringsMayfield	MississippiKentucky	390594 2066	(270) 247-3345
Eastridge-Phelps Pharmacy Campbellsville	500 N BYPASS RD	Campbellsville	Kentucky	42718	(270) 789-0577
Guy'sEastridge-Phelps Pharmacy of SummitGreensburg	1121 Highway 98 and 51460 Commerce Dr	SummitGreensburg	MississippiKentucky	396664 2743-7758	(270) 299-2333
Guy's Pharmacy of TylertownEconomy Drug Company Inc	3000 Plaza Drive180 Town Mountain Road Suite B115	TylertownPikeville	MississippiKentucky	396674 1501	(606) 437-7333
Elkhorn Drug	105 East Elkhorn	Elkhorn City	Kentucky	41522	(606) 754-0221

	Street				
Ely Drug of Bowling Green	4863 Scottsville Road	Bowling Green	Kentucky	42104	(270) 467-5225
Ely Drugs #2	415 Happy Vlly Rd	Glasgow	Kentucky	42141	(270) 651-8359
Faith Pharmacy	140 Adams Lane, Suite 500	Pikeville	Kentucky	41501	(606) 509-6337
~~Guys~~ Family Pharmacy~~ Inc~~	~~817 Randolph Street~~412 Central Avenue	~~Thomasville~~South Williamson	~~North Carolina~~Kentucky	~~273604~~ 1503	(606) 237-7430
~~Guys~~Family Pharmacy of ~~Brookhaven~~Jackson	~~1005 West Congress Street~~265 KY Hwy 15 South, Suite 2	~~Brookhaven~~Jackson	~~Mississippi~~Kentucky	~~396014~~ 1339	(606) 666-5519
~~Guys~~Gibson's Pharmacy~~ of Hazlehurst~~	~~212 Caldwell Drive~~1206 Paris Road	~~Hazlehurst~~Mayfield	~~Mississippi~~Kentucky	~~390834~~ 2066	(270) 247-1055
Glenn's Apothecary	520 West Gum Street	Marion	Kentucky	42064	(270) 965-4101
Glenn's Prescription Center	119 East Main Street	Salem	Kentucky	42078	(270) 988-3226
~~Gwidt~~Good Neighbor Pharmacy	~~203 East Westgor~~60 Cassady Avenue Suite 3	~~Wittenberg~~Danville	~~Wisconsin~~Kentucky	~~54499-0253~~40422	(859) 936-1222
Green River Pharmacy	50 DILLON ST	Liberty	Kentucky	42539	(606) 787-2100
Greenville Pharmacy	117 North Main Street	Greenville	Kentucky	42345	(270) 338-3800
H & N Drug Inc	515 Memorial Drive Suite 2	Manchester	Kentucky	40962	(606) 598-5025
~~Haag~~Health First Pharmacy	~~1400 West 12th Avenue~~111 S Main St	~~Emporia~~Greensburg	~~Kansas~~Kentucky	~~668014~~ 2743	(270) 299-2467
~~Habersham Drug~~Heritage Pharmacy	~~638 Historic Highway 441 Suite A~~870 Parkway Drive	~~Demorest~~Salyersville	~~Georgia~~Kentucky	~~305354~~ 1465	(606) 349-7733
~~Hackleburg~~Highland Pharmacy	~~34863 Highway 43~~301 Rogers Road	~~Hackleburg~~Glasgow	~~Alabama~~Kentucky	~~355644~~ 2141	(270) 629-4300
~~Haig~~Hometown Pharmacy of Jackson	~~1112 South Glendale Avenue~~95 Jackson Heights	~~Glendale~~Jackson	~~California~~Kentucky	~~912054~~ 1339	(606) 666-5500
~~Haire Drug Center~~Horton Brothers and Brown Pharmacy LLC	~~805 1st Street~~201 East Main St	~~Cleveland~~Grayson	~~Mississippi~~Kentucky	~~38732-2309~~41143	(606) 474-5655
~~Haisch~~Irvine Health Care Pharmacy	~~303 East 5th Street~~1325 Richmond Road	~~Canton~~Irvine	~~South Dakota~~Kentucky	~~570134~~ 0336	(606) 723-5446
J&R PHARMACY	34 US Hwy 68 E Unit A	Benton	Kentucky	42025	(270) 527-3135
J & R Pharmacy	817 Main St	Benton	Kentucky	42025	(270) 527-9374

~~Hale Center Clinical~~Jamestown Pharmacy	~~601 Avenue G~~1417 North Main Street, Suite A	~~Hale Center~~Jamestown	~~Texas~~Kentucky	~~79041~~42629	(270) 343-4443
Jay's Pharmacy Inc	400 South Highway 27	Somerset	Kentucky	42501	(606) 678-2784
Jeff's Prescription Shop	2415 Ring Rd	Elizabethtown	Kentucky	42701	(270) 765-2157
Kimper Pharmacy	9711 State Highway 194 East	Kimper	Kentucky	41539	(606) 631-3327
King Drug and Home Care	1156 Carter Road	Owensboro	Kentucky	42301	(270) 683-7010
Knight's Pharmacy	191 Glades Road	Berea	Kentucky	40403	(859) 986-0500
Lewis County Primary Care Center	211 Kentucky 59	Vanceburg	Kentucky	41179	(606) 796-2686
~~Hall~~Liberty Drug ~~Co~~	~~90 Court Square~~256 N Wallace Wilkinson Blvd	~~Blakely~~Liberty	~~Georgia~~Kentucky	~~398234~~2539-3014	(606) 448-2469
~~Haller's~~Lincoln Parkway Pharmacy ~~and Medical Supply~~	~~37323 Fremont Boulevard~~117 Lincoln Drive	~~Fremont~~Hodgenville	~~California~~Kentucky	~~945364~~2748	(270) 358-2117
~~Halsey Drug Company~~Lone Oak Pharmacy	~~55 South Main Street~~3535 Lone Oak Road	~~Sparta~~Paducah	~~North Carolina~~Kentucky	~~286754~~2001	(270) 554-7944
Louisa Drug Store	408 North Lock Avenue	Louisa	Kentucky	41230	(606) 638-4155
~~Hamilton County~~Madison Drug	~~302 East~~110 Big Hill Avenue~~A~~	~~Syracuse~~Richmond	~~Kansas~~Kentucky	~~678784~~0475	(859) 624-1565
~~Hamilton Discount~~Maysville OB/GYN Family Health Center Pharmacy	~~6851 Shallowford Road~~927 Kenton Station Drive	~~Chattanooga~~Maysville	~~Tennessee~~Kentucky	~~374214~~1056	(606) 759-1189
~~HANCOCK PHARMACY & SURGICAL~~Mccays Total Pharmacy	~~840 E MAIN ST~~260 Boggs Lane	~~MERIDEN~~Richmond	~~Connecticut~~Kentucky	~~064504~~0475-2591	(859) 623-4216
~~Haney's Drug Corner~~MED EXPRESS PHARMACY	~~623 Dixie Street~~212 South Mayo Trail	~~Carrollton~~Paintsville	~~Georgia~~Kentucky	~~301174~~1240	(606) 789-1444
Medical Arts Pharmacy	300 S 8th St	Murray	Kentucky	42071-2883	(270) 753-2011
Medical Center Pharmacy	1010 Medical Center Drive	Powderly	Kentucky	42367	(270) 338-9993
MEDICINE CABINET PHARMACY	230 STATE HIGHWAY 2	OLIVE HILL	Kentucky	41164	(606) 286-2035
~~Hanger~~Metcalfe Drugs	~~207 Sparks Avenue Suite 1~~115 East	~~Jeffersonville~~Edmonton	~~Indiana~~Kentucky	~~471304~~2129	(270) 432-3051

	Stockton Street				
Hankinson Drug	323 Main Avenue S	Hankinson	North Dakota	58041	
Hansford HospitalMidtown Pharmacy Express	710 South Roland500 North Main Street	SpearmanBeaver Dam	TexasKentucky	790814 2320	(270) 274-9224
Harbor DrugOptimum Wellness Center	114 South Huron Avenue716 Broadway Street	Harbor BeachPaintsville	MichiganKentucky	484414 1240	(606) 220-2553
Parkland Drugs	209 N Dixie Hwy	Cave City	Kentucky	42127	(270) 773-3152
Parkview Pharmacy, Inc	8274 Kentucky Rte 122	Minnie	Kentucky	41651	(606) 377-2117
Harbor Drug #2Parkway Pharmacy	2046 Black River Street186 Breanna Blvd, Suite 2400	DeckervilleSalyersville	MichiganKentucky	484274 1465	(606) 349-4400
Harleyville DrugPharmacy Arts	108 West Main Street31 Burnley Road	HarleyvilleScottsville	South CarolinaKentucky	294484 2164	(270) 618-4444
Pharmacy Express	415 South L. Rogers Wells Boulevard	Glasgow	Kentucky	42141	(270) 651-7948
HarrisburgPikeville Medical Center Outpatient Pharmacy	230 North 3rd Street Suite 106911 Bypass Rd Bldg E, Ste 1	HarrisburgPikeville	OregonKentucky	974464 1501	(606) 218-3576
Plaza Drug of London	731 North Laurel Road	London	Kentucky	40741	(606) 657-5245
Harrison DiscountProfessional Pharmacy	1442 North Harrison419 Town Mountain Road Suite 101	ShawneePikeville	OklahomaKentucky	748014 1501	(606) 432-0196
Harrison FamilyProfessional Pharmacy of Somerset	182 North Second342 Bogle Street	HarrisonSomerset	MichiganKentucky	486254 2503	(606) 679-1169
HarrisReidland Pharmacy	1224 First Street5433 Reidland Rd	KennettPaducah	MissouriKentucky	638574 2003-0368	(270) 898-7313
Rite Value Pharmacy	2673 Highway 644	Louisa	Kentucky	41230	(606) 638-9627
HarroldsRite-Value Pharmacy Inc	250 Old River Road94 Board Walk Suite 2	Wilkes BarreInez	Pennsylvania Kentucky	18702-1614412 24	(606) 298-2080
Harry RaceRiverview Pharmacy	106 Lincoln201 South Water Street	SitkaLouisa	AlaskaKentucky	998354 1230	(606) 638-9218
Hart and DilatushRussell Springs Pharmacy	601 West Riverside92 Joe T. Petty Drive, Suite 140100	SpokaneRussell Springs	WashingtonKentucky	992014 2642	(270) 866-2778
Save Discount Drugs	716 Madison Avenue	Covington	Kentucky	41011	(859) 431-2857
Hawkins Lakeside PharmacySave	902 Central2208 Fort Campbell	Bull ShoalsHopkinsville	ArkansasKentucky	726194 2240	(270) 885-5515

More Drugs	Boulevard				
Shelbyville Pharmacy	182 Frankfort Road	Shelbyville	Kentucky	40065	(502) 437-3008
~~Hawkinsville Drug Company~~Smithland Drugs	~~153 Commerce~~203 East Adair Street	~~Hawkinsville~~Smithland	~~Georgia~~Kentucky	~~31036 8420~~42081	(270) 928-2161
~~HAWK PHARMACY~~	~~120 West Park~~	~~Iowa Park~~	~~Texas~~	~~76367~~	
~~Haworth Apothecary~~Stovalls Prescription Shop	~~169 Terrace~~202 South Court Street	~~Haworth~~Scottsville	~~New Jersey~~Kentucky	~~076414~~2164	(270) 237-5402
~~Hayden~~Strawberry Hills Pharmacy	~~1200 Ward Avenue~~2670 New Holt Road Suite D	~~Caruthersville~~Paducah	~~Missouri~~Kentucky	~~638304~~2001	(270) 444-7070
Stultz Pharmacy	1615 Ashland Road	Greenup	Kentucky	41144	(606) 473-7346
Sutton Pharmacy	330 W Maple St	Lancaster	Kentucky	40444-1058	(859) 792-4611
~~Haysi Drug Center~~Taylor Pharmacy	~~23906 Dickenson Highway~~109 Fairgrounds Road	~~Haysi~~Hardinsburg	~~Virginia~~Kentucky	~~242564~~0143	(270) 756-5222
The Prescription Pad	465 Keene Centre Drive	Nicholasville	Kentucky	40356	(859) 887-2841
~~Hazard's~~Thompson's Pharmacy	~~290 Main~~1064 North College Street	~~Cornwall~~Harrodsburg	~~New York~~Kentucky	~~12518 1579~~40330	(859) 734-3004
~~Hazel's Compounding Rx~~Thrifty Pharmacy	~~2404 Smith Ranch Rd STE 100~~127 East Main Street	~~PEARLAND~~Providence	~~Texas~~Kentucky	~~775844~~2450	(270) 667-2049
Tompkinsville Drug Company	1513 Edmonton RD	Tompkinsville	Kentucky	42167	(270) 487-6155
~~Hazlet~~Total Care Pharmacy #1	~~2874 Highway 35~~209 South Main Cross Street	~~Hazlet~~Flemingsburg	~~New Jersey~~Kentucky	~~077304~~1041	(606) 845-2101
~~HB~~Total Care Pharmacy #2	~~98 Ridge Road~~118 Clark Street	~~North Arlington~~Flemingsburg	~~New Jersey~~Kentucky	~~070314~~1041	(606) 845-3421
~~HCA~~Total Care Pharmacy ~~& Medical Equipment~~#4	~~1113 West Lexington Avenue~~700 Violet Road	~~Winchester~~Crittenden	Kentucky	~~403914~~1030	(859) 428-0900
~~Healing Springs~~Total Care Pharmacy #5	~~2449 Ross Millville Road,~~45 Klee Way Suite ~~185~~A	~~Hamilton~~Falmouth	~~Ohio~~Kentucky	~~45013 8952~~41040	(859) 654-3232
~~Health~~Total Care ~~Connections~~Pharmacy #7	~~402 South~~206 West Main Street ~~Suite 100~~	~~Raeford~~Morehead	~~North Carolina~~Kentucky	~~283764~~0351	(606) 784-4491
~~Healthcare~~Total Pharmacy Care	~~14642 Newport Avenue~~533 Hambley Boulevard	~~Tustin~~Pikeville	~~California~~Kentucky	~~927804~~1501	(606) 433-0555
~~Healthcare~~Total Pharmacy Care #3	~~1825 Madison Avenue~~420 North	~~New York~~Prestonberg	~~New York~~Kentucky	~~100354~~1653	(606) 889-8570

	Lake Drive				
~~Health Care~~Total Pharmacy Care #4	~~10 Hospital Drive~~263 KY ROUTE 122	~~Morrilton~~Martin	~~Arkansas~~Kentucky	~~721104~~ 1649	(606) 949-1555
~~Health Delivery~~Total Pharmacy Care #5	~~1326 Eisenhower Drive Building ~~1~~~13380 Phelps 632 Road	~~Savannah~~Phelps	~~Georgia~~Kentucky	~~314064~~ 1553	(606) 456-3446
~~Health Fair~~Total Pharmacy Care #6	~~315 Willow Avenue~~6162 Zebulon Highway	~~Hoboken~~Pikeville	~~New Jersey~~Kentucky	~~07030-3807~~41501	(606) 631-9137
~~Health First~~Total Pharmacy Care of Belfry	~~111 South Main Street~~20 State Highway 319	~~Greensburg~~Belfry	Kentucky	~~427434~~ 1514	(606) 237-0555
Town and Country Pharmacy	736 East Main Street	Glasgow	Kentucky	42141	(270) 629-4633
~~Health Max~~Versailles Independent Pharmacy	~~80-07 Jamaica Avenue~~166 Frankfort Street	~~Woodhaven~~Versailles	~~New York~~Kentucky	~~114214~~ 0383	(859) 879-0199
~~Health Park~~Walter's Family Pharmacy	~~8300 Health Park Suite 227~~604 S 12th St	~~Raleigh~~Murray	~~North Carolina~~Kentucky	~~276154~~ 2071-2916	(270) 753-7688
~~Health Plus Pharmacy~~Weathers Drugs	~~3104 West Mile 5 Road Suite 2~~44 Public Square	~~Mission~~Elkton	~~Texas~~Kentucky	~~785744~~ 2220	(270) 265-2155
West Knox Pharmacy, LLC	14161 North US Highway 25 East	Corbin	Kentucky	40701-6183	(606) 258-1111
Yates Pharmacy LLC	432 Hopkinsville Road	Russellville	Kentucky	42276	(270) 726-8451
Your Hometown Pharmacy Taylorsville	913 Taylorsville Road	Taylorsville	Kentucky	40071	(502) 477-1973
Mountain Apothecary	834 South Mayo Terrace	Paintsville	Kentucky	41240	(606) 789-6150
ARON'S PHARMACY	1209 NORTH 18TH ST	MONROE	Louisiana	71201	(318) 323-2242
Book's Pharmacy	1158 Logan Sewell Drive	Vidalia	Louisiana	71373-3342	(318) 414-2616
Community Pharmacy LLC	2904 Forsythe Ave	Monroe	Louisiana	71201	(318) 398-2100
~~HealthPlus~~Community Pharmacy of ~~Brighton~~Sterlington	~~2305 Genoa Business Park, Suite 140~~200 Scott Drive	~~Brighton~~Sterlington	~~Michigan~~Louisiana	~~481147~~ 1280	(318) 667-0197
~~HealthPlus~~Community Pharmacy of ~~Howell~~Winnsboro	~~1225 South Latson Road~~3326 Front Street Suite ~~100~~D	~~Howell~~Winnsboro	~~Michigan~~Louisiana	~~488437~~ 1295	(318) 435-9681
~~Healthridge Pharmacy~~E.W. Thomson Drug Co	~~3130 US 70 Highway~~213 Depot St	~~Black Mountain~~Delhi	~~North Carolina~~Louisiana	~~287117~~ 1232	(318) 878-2261
East Jefferson Medical Pharmacy	1301 Williams Blvd	Kenner	Louisiana	70062-6303	(504) 468-2361

#1					
~~Health Source Plus Pharmacy, LLC~~Gem Drugs	~~118-07 Metropolitan~~139 Central Avenue	~~Kew Gardens~~Reserve	~~New York~~Louisiana	~~11415~~70084	(985) 536-3957
Gem Drugs Gramercy	1635 Highway 3125	Gramercy	Louisiana	70052	(225) 869-3651
J & K Drug	7190 Highway 165 South	Columbia	Louisiana	71418	(318) 649-0825
Minsky Drug Store	405 Lake Street	Lake Providence	Louisiana	71254	(318) 559-2400
Morgans Pharmacy	1806 FOURTH STREET	JONESVILLE	Louisiana	71343	(318) 339-8532
Russo's Pharmacy	7902 Highway 23	Belle Chasse	Louisiana	70037	(504) 394-4444
~~Healthville~~Scott's Pharmacy	~~7215 Mcpherson Rd~~114 Serio Boulevard	~~Laredo~~Ferriday	~~Texas~~Louisiana	~~78041~~71334	(318) 757-3035
~~Healthy Harlem Rx Corp~~Village Pharmacy #3	~~1875 Lexington Avenue~~7659 Gilbert St Suite A	~~New York~~Gilbert	~~New York~~Louisiana	~~10035-4733~~713 36-3410	(318) 907-2077
~~Heartland Discount~~Williams Family Pharmacy, LLC	~~407 South Parrott Avenue~~1058 Tanglewood Drive	~~Okeechobee~~Franklinton	~~Florida~~Louisiana	~~34974~~70438-5673	(985) 839-7200
Bangor Drug Company	711 Broadway Suite 1	Bangor	Maine	04401-3225	(207) 922-3849
Carroll Drug Store	3 Village Green Way	Southwest Harbor	Maine	04679-1306	(207) 244-5588
City Drug Store	159 Academy Street	Presque Isle	Maine	04769	(207) 764-4424
Hebert Rexall Pharmacy	31 MAIN ST	Van Buren	Maine	04785	(207) 868-2242
~~Heights Specialty Pharmacy~~	~~450 Boulevard~~	~~Hasbrouck Heights~~	~~New Jersey~~	~~07604~~	
~~Heights Terrace~~Mars Hill Pharmacy Inc	~~475 South Poplar~~106 Main Street	~~Hazleton~~Mars Hill	~~Pennsylvania~~Maine	~~18201~~04758	(207) 425-4431
~~Heike~~Milbridge Pharmacy	~~213 West~~11 Main Street	~~Durand~~Milbridge	~~Wisconsin~~Maine	~~54736~~04658-0458	(207) 546-2304
~~Heller's~~Presque Isle Pharmacy	~~664 Mount Prospect Avenue~~797 Main St	~~Newark~~Presque Isle	~~New Jersey~~Maine	~~07104~~04769	(207) 760-9100
~~Hemmingsen Drug Store~~	~~132 West Michigan Avenue~~	~~Marshall~~	~~Michigan~~	~~49068~~	
~~Henderson~~Spruce Mountain Pharmacy ~~Services~~Inc.	~~186 West~~148 Main Street	~~Chillicothe~~Jay	~~Ohio~~Maine	~~45601-3106~~04239	(207) 897-9080
~~Hendricks~~AGH RediScripts Pharmacy	~~137 North Harvard Avenue~~9733 Healthway Dr	~~Claremont~~Berlin	~~California~~Maryland	~~91711-4717~~21811	(410) 641-9241
~~Henrietta~~Broadneck Pharmacy	~~124 North Bridge~~269 Peninsula Farm	~~Henrietta~~Arnold	~~Texas~~Maryland	~~76365~~21012	(410) 544-3733

	Road				
HephzibahClear Spring Pharmacy	4819 Windsor Spring Road34 Mulberry Street	HephzibahClear Spring	GeorgiaMaryland	308152 1722	(301) 842-2774
Hepps PrescriptionCo-Op Pharmacy	240 South La Cienega Boulevard Suite 100121 Center way	Beverly HillsGreenbelt	CaliforniaMaryland	902112 0770	(301) 474-4400
Deale Pharmacy	5809 Deale Churchton Road	Deale	Maryland	20751	(410) 867-2455
Herbst Apothecary IncDrug City Pharmacy	2012805 North DixonPoint Road	KokomoBaltimore	IndianaMaryland	469012 1222	(410) 284-2424
HerbstFallston Pharmacy	300 East Southway Boulevard2112 Belair Road Suite E11	KokomoFallston	IndianaMaryland	46902-6411210 47	(410) 879-9000
HerbstGreensboro Pharmacy	710 West102 South Main Street	GreentownGreensboro	IndianaMaryland	469362 1639	(410) 482-6256
Herche Bloor Pharmacy	104 East 5th Street	East Liverpool	Ohio	43920	
Hereford Pharmacy	809 South 25 Mile Avenue	Hereford	Texas	79045	
Hereford Pharmacy and Gift Shop	216 Mount Carmel Road	Parkton	Maryland	21120	(410) 329-6209
HeritageHigh Street Discount Pharmacy	870 Parkway Drive30 High Street	SalyersvilleWaldorf	KentuckyMaryland	414652 0602-1846	(240) 448-3301
HeritageJarrettsville Pharmacy	3529 Heritage Trace Parkway Suite 1413714 Norrisville Rd	KellerJarrettsville	TexasMaryland	762442 1084	(410) 557-7717
Karemore Pharmacy	12085 North Somerset Avenue Suite 5	Princess Anne	Maryland	21853	(410) 651-3980
HerndonLaplata Pharmacy	175 West Main Street6501 Crain Highway	CamdenLa Plata	TennesseeMaryland	38320-1621206 46-4268	(301) 934-4050
Herold'sMedsurg Pharmacy	2057 Charlie3037 Marshall Hall Boulevard Suite CRoad	CharlestonBryans Road	South CarolinaMaryland	294142 0616-3240	(240) 903-3949
Hibbitts Drug Company LLCMeritus Medical Center	735 North Main Street11116 Medical Campus Rd Ste 2460	New EltonHagerstown	South CarolinaMaryland	298092 1742-6700	3017909281
Hickory HillMt Carmel Pharmacy	109 Hickory Hill Drive111 Mount Carmel Road	HelenaParkton	ArkansasMaryland	723422 1120	(410) 343-0110
Hicksville Pharmacy	495 South Broadway Unit 16	Hicksville	New York	11801	
HicksvilleNorthern Pharmacy and	116 East High Street6701 Harford	HicksvilleBaltimore	OhioMaryland	435262 1234-77	(410) 254-2055

Home MedicalMed Equipment	Road			07	
Hidenwood Pharmacy, Inc	35 Hidenwood Shopping Center	Newport News	Virginia	23606	
Highland DrugPittsville Pharmacy	504 East Avenue34205 Old Ocean City Road Unit E	AlpinePittsville	TexasMaryland	798302 1850-2083	(410) 835-8585
HighlandSteves Pharmacy	301 Rogers Road16117 Mcmullen Highway Southwest	GlasgowCumberland	KentuckyMaryland	421412 1502	(301) 729-2600
HighlandUltra Care Pharmacy	4000 Highland Road12619 Wisteria Drive Suite 113A	WaterfordGermantown	MichiganMaryland	483282 0874-5259	(301) 569-6464
High Street DiscountUltra Care Pharmacy	30 High Street4419 Falls Road Suite B	WaldorfBaltimore	Maryland	20602-1846212 11-1295	(410) 878-1031
Ultra Care Pharmacy-Columbia	10798 Hickory Ridge Road Suite A	Columbia	Maryland	21044-3646	(410) 997-0005
Whiteford Pharmacy	2338 Whiteford Road	Whiteford	Maryland	21160	(410) 452-5221
High StreetWilliamsport Pharmacy	4248 Macarthur Boulevard100 E Potomac St	OaklandWilliamsport	CaliforniaMaryland	946192 1795	(301) 223-4101
High TouchAyer Family Pharmacy	344 West Grand13 Park Street	ElizabethAyer	New JerseyMassachusetts	07202-1202014 32-1120	(978) 391-4061
HillcrestBouvier Pharmacy Inc	1015 Hillcrest Drive, Suite B515 Lincoln Street	VernonMarlborough	TexasMassachusetts	763840 1752	(508) 485-0432
HILLSBORO DRUG	13 N MAIN ST	HILLSBORO	North Dakota	58045-4202	
Hilltop MarketConlin's Pharmacy	1706 Visions Avenue30 Lawrence Street	JonesboroMethuen	ArkansasMassachusetts	724010 1844	(978) 552-1700
HilsCure-Aid Pharmacy	800 North Morley101 Amesbury Street Suite 207	MoberlyLawrence	MissouriMassachusetts	65270-2617018 40-1510	(978) 984-5285
Hinas Home CareDans Pharmacy	9508 Stockdale Highway Suite 130110 Pleasant St	BakersfieldNantucket	CaliforniaMassachusetts	933110 2554	(508) 825-9100
HinasDedham Pharmacy & Medical Supply	6300 White Lane Suite N596 Providence Highway	BakersfieldDedham	CaliforniaMassachusetts	933090 2026-6804	(781) 326-7007
EssentialRx	123 Summer St Suite 365	Worcester	Massachusetts	01608-1216	(508) 363-6602
FAIRHAVEN PHARMACY	72 MAIN ST	FAIRHAVEN	Massachusetts	02719-3014	(508) 525-4455
HinesvilleFlynns	481 Elma G Miles	HinesvillePittsfield	GeorgiaMassa	313130	(413) 445-5567

Pharmacy	~~Parkway~~173 Elm St		chusetts	1201-6589	
Hingham Centre Pharmacy	294 Main ~~Street~~St	Hingham	Massachusetts	02043	(781) 749-1277
~~Hixson~~Margolis Pharmacy	~~5508 Hixson Pharmacy Suite 1~~447 Broadway	~~Hixson~~Chelsea	~~Tennessee~~Massachusetts	~~373430~~2150	(617) 884-3524
~~Hodges & Sargent~~Nantasket Pharmacy Inc	~~206 South Key~~480 Nantasket Avenue	~~Lampasas~~Hull	~~Texas~~Massachusetts	~~765500~~2045	(781) 925-1270
~~Hoffmans~~Norwood Pharmacy	~~2323 Lake Avenue~~54 Broadway	~~Ashtabula~~Norwood	~~Ohio~~Massachusetts	~~44004-3109~~02062	(781) 349-8895
~~Hogan's~~Pepperell Family Pharmacy	~~815 West Front~~74 Main Street	~~Lillington~~Pepperell	~~North Carolina~~Massachusetts	~~275460~~1463	(978) 433-6130
~~Hogan's~~Scituate Pharmacy	~~2704 North Oak Street Suite B-1~~384 Gannett Road	~~Valdosta~~Scituate	~~Georgia~~Massachusetts	~~316020~~2066	(781) 545-1020
~~Holbrook~~Standard Pharmacy ~~& Surgical~~@ Healthfirst	~~233 Union Avenue~~387 Quarry St	~~Holbrook~~Fall River	~~New York~~Massachusetts	~~117410~~2723-1007	(774) 322-1335
Walpole Pharmacy	699 Main Street	Walpole	Massachusetts	02081	(508) 645-8866
Walsh Pharmacy	202 Rock Street	Fall River	Massachusetts	02720	(508) 679-1300
Whittier Health Pharmacy Inc	1012 Tremont Street	Roxbury	Massachusetts	02120-3432	(617) 541-6846
Advanced Care Pharmacy Services	2136 Robinson Road, Suite 2	Jackson	Michigan	49203	(517) 750-2180
~~Holder Drug~~Advanced Health Pharmacy	~~513 Barnes~~7916 Oakland Drive	~~Alva~~Portage	~~Oklahoma~~Michigan	~~73717-2288~~49024	(269) 324-1100
~~Holihans~~Alexander's Drug Store	~~128 North~~211 East Main Street	~~Evart~~Fennville	Michigan	~~496314~~9408	(269) 561-4411
~~Holland Center~~All Care Pharmacy	~~621 Milford Warren Glen Road~~7125 Allen Rd	~~Milford~~Allen Park	~~New Jersey~~Michigan	~~088484~~8101	(313) 386-2273
~~Holly~~Alliance Specialty Pharmacy	~~31 North Baltimore~~25301 Van Dyke Avenue	~~Mt. Holly Springs~~Center Line	~~Pennsylvania~~Michigan	~~17065-1302~~48015	(248) 230-8044
Anderson Pharmacy	1108 Marquette Ave	Bay City	Michigan	48706-4000	(989) 684-8905
~~Holly~~Apollo Pharmacy of Wyandotte	~~4048 Grange Hall Road Suite D~~2000 Eureka Rd	~~Holly~~Wyandotte	Michigan	~~48442-1193~~48192-6004	(734) 550-0850
Azaal Discount Pharmacy	9834 Conant Street	Hamtramck	Michigan	48212	(313) 872-0021
Azaal Pharmacy ll LLC	15120 Michigan Avenue	Dearbon	Michigan	48126	(313) 733-8034
~~Holly Springs~~Bay Pharmacy	~~648 Holly Springs Road~~112 South State Street	~~Holly Springs~~St Ignace	~~North Carolina~~Michigan	~~275404~~9781	(906) 643-7725
Best Care	31500 Dequindre	Warren	Michigan	48092	(586) 999-5544

Pharmacy Plus	Rd Suite 300				
Big Brothers Pharmacy	4801 Fenton Road	Flint	Michigan	48507	(810) 820-8685
Bobs Drugs	194 North Division Street	Hesperia	Michigan	49421	(231) 854-6605
Bosticks Drug Store	117 West Main Street	Manton	Michigan	49663	(231) 824-6465
Brothers Pharmacy	118 West Pierson Road	Flint	Michigan	48505	(810) 785-7770
Bunte's Pharmacy	115 East Main Avenue	Zeeland	Michigan	49464	(616) 772-4685
~~Holstein Community~~Cadillac Family Pharmacy	108 North ~~Main Street~~Mitchell	~~Holstein~~Cadillac	~~Iowa~~Michigan	~~51025 7754~~49601	(231) 775-8200
~~Holy Cross~~Carerx Specialty Pharmacy AP	~~11550 Indian Hills~~13201 Stephens Road Suite ~~130~~G	~~Mission Hills~~Warren	~~California~~Michigan	~~913454~~8089-4378	(734) 656-4082
~~Holzer Family~~Cedar Springs Pharmacy	~~90 Jackson Pike~~14111 White Creek Avenue Northeast Suite 12	~~Gallipolis~~Cedar Springs	~~Ohio~~Michigan	~~456314~~9319-8170	(616) 439-2779
Central Drug Store Inc	301 Bridge Street	Charlevoix	Michigan	49720-1414	(231) 547-2424
~~Holzer Family~~Clio Community Pharmacy	~~280 Pattonsville~~4180 West Vienna Road Suite 4	~~Jackson~~Clio	~~Ohio~~Michigan	~~456404~~8420-9497	(810) 547-7201
~~Holzer~~Coleman Family Pharmacy ~~Athens~~	~~2131~~211 East ~~State~~Railway Street	~~Athens~~Coleman	~~Ohio~~Michigan	~~457014~~8618	(989) 465-6661
~~Hometown Old Country Pharmacy, Inc.~~CORNER DRUGS	~~8534 Ridge Road~~154 River Street	~~New Port Richey~~Elk Rapids	~~Florida~~Michigan	~~346544~~9629	(231) 264-8033
~~Hometown~~Davison Pharmacy	~~101 Medical Drive~~1509 South State Road Suite F	~~Palestine~~Davison	~~Texas~~Michigan	~~758014~~8423-1966	(810) 412-4666
Delton Family Pharmacy	338 N Grove St	Delton	Michigan	49046	(269) 623-5250
Downtown Drugs	121 E Broadway	Mt Pleasant	Michigan	48858-2368	(989) 773-5544
Dynamic Care Pharmacy	4121 West 13 Mile Road	Royal Oak	Michigan	48073	(248) 850-1802 Ext 1
~~Hometown~~Eagle Pharmacy	~~236~~109 West ~~Clinton~~Main Street	~~Gray~~Farwell	~~Georgia~~Michigan	~~310324~~8622	(989) 588-2900
~~Hometown~~Fenkell Rx Pharmacy	~~199 Old Courthouse Road~~18360 Fenkell Ave	~~Appomattox~~Detroit	~~Virginia~~Michigan	~~245224~~8223-2314	(313) 519-5700
~~Hometown~~Flint Family Pharmacy	~~196 Amelon Square~~G4444 Fenton Road	~~Madison Heights~~Flint	~~Virginia~~Michigan	~~24572 5990~~48507	(810) 235-7995

HometownFred's Pharmacy	310 Charlie Drive121 West Prairie Street	WhitesboroVicksburg	TexasMichigan	762734 9097	(269) 649-0660
HometownFreds Pharmacy	201 East Commerce808 West Michigan Avenue	FairfieldThree Rivers	TexasMichigan	758404 9093	(269) 278-2355
HometownGateway Pharmacy	1201 Olive1048 North McEwan Street	GainesvilleClare	TexasMichigan	762404 8617	(989) 386-2900
Hometown PharmacyGilberts Drug Store	2800 Highway 22 West212 S State St	CorsicanaOscoda	TexasMichigan	751104 8750	(989) 739-7585
Home TownGrand Blanc Pharmacy	3899 Indian Ripple2227 East Hill Road Suite A	BeavercreekGrand Blanc	OhioMichigan	454404 8439-5000	(810) 498-4334
HometownGrand Value Pharmacy of Jackson	95 Jackson Heights10920 Grand River Avenue	JacksonDetroit	KentuckyMichigan	413394 8204	(313) 931-0010
Honea PathGrayling Pharmacy	309 East Greer Street500 N James St	Honea PathGrayling	South CarolinaMichigan	29654-1 818497 38	(989) 348-2000
HonestGreat Lakes Pharmacy of Midland	7740 Garvey1120 Eastman Avenue Unit A	RosemeadMidland	CaliforniaMichigan	91770-3 061486 40	(989) 835-7911
HonestGun Lake Pharmacy	210 North Garfield Avenue Suite 10171 124th Ave	Monterey ParkShelbyville	CaliforniaMichigan	917544 9344	(269) 672-7774
HOPEWELL PHARMACYHarbor Drug	1 West Broad Street114 South Huron Avenue	HopewellHarbor Beach	New JerseyMichigan	085254 8441	(989) 315-8605
Horseshoe Health & MedicineHarrison Family Pharmacy	600 Market182 North Second Street	Horseshoe BendHarrison	ArkansasMichigan	725124 8625	(989) 539-2900
Horsham SquareHealthPlus Pharmacy of Brighton	575 Horsham Road Unit C202305 Genoa Business Park, Suite 140	HorshamBrighton	Pennsylvania Michigan	190444 8114	(810) 229-4420
Horton Brothers and BrownHealthPlus Pharmacy LLCof Howell	201 East Main Street1225 South Latson Road Suite 100	GraysonHowell	KentuckyMichigan	411434 8843	(517) 579-2797
HoskinsHemmingsen Drug Store #2	111 North Main Street132 West Michigan Avenue	ClintonMarshall	TennesseeMichigan	377164 9068	(269) 781-3411
Hospital DriveHighland Pharmacy	409 Altapass4000 Highland Road Suite 113	Spruce PineWaterford	North CarolinaMichigan	287774 8328	(248) 977-1394
Hospital Dr Valley	7600 Hospital Dr	SacramentoEvart	CaliforniaMic	958234	(231) 734-2551

PharmacyHolihans Drug Store	Ste A128 N Main St		higan	9631	
HUDSON DRUG SHOP	108 N MARKET	Paxton	Illinois	60957	
HudsonHolly Pharmacy	40 Spring Street4048 Grange Hall Road Suite D	OssiningHolly	New YorkMichigan	105624 8442-1193	(248) 467-8003
Hudson Pharmacy	1609 East Main	Van Buren	Arkansas	72956	
HUDSON PHARMACY, INC.	325 Railroad Street Suite D	Hudson	Michigan	49247	(517) 448-3111
Humboldt Pharmacy	204 South Ninth Street	Humboldt	Kansas	66748-1908	
Hurley Drug Company Inc	210 Logan Street	Williamson	West Virginia	25661	
Huron Market Pharmacy	1116 West Huron Street	Waterford	Michigan	48328-3734	(248) 977-4848
Hursh DrugsJill's Genuine Care Pharmacy	90 North Diamond Street23603 Farmington Rd	MansfieldFarmington	OhioMichigan	449024 8336-3102	(248) 987-5940
Hyde Pharmacy Inc	1001 West Kings Highway	Paragould	Arkansas	72450	
HylandsKingsley Pharmacy LLCand Compounding Center	108 West Oklahoma114 South Brownson Avenue	WheelerKingsley	TexasMichigan	790964 9649	(231) 263-7701
Hylan Medicine CabinetKronner Pharmacy	1988 Hylan Boulevard778 W Houghton Lake Dr	Staten IslandProdenville	New YorkMichigan	103064 8651-9451	(989) 366-7611
IaegerLapeer Pharmacy	4381 Coal Heritage944 Baldwin Road, US Route 52 Suite B	IaegerLapeer	West VirginiaMichigan	248444 8446	(810) 245-9600
iCareRxLC Family Pharmacy– Newport	1117 McLain Street Suite 40057 North Morey Road	NewportLake City	ArkansasMichigan	721124 9651	(231) 559-0005
Lefave Pharmacy & Compounding	1202 W Chisholm St	Alpena	Michigan	49707-1620	(989) 354-3189
IHSLeroy Pharmacy & Gifts	150 South1280 North Leroy Street	MetterFenton	GeorgiaMichigan	304394 8430-2760	(810) 373-5808
IHS Pharmacy #3	13762 Highway 80	Jeffersonville	Georgia	31044	
IHS Pharmacy Jamestown	4940 Cottonville Road	Jamestown	Ohio	45335-1522	
Illini ClinicMaple Pharmacy	855 Illini Drive,5829 West Maple Road Suite 200129	SilvisWest Bloomfield	IllinoisMichigan	612824 8322	(248) 757-2503
Iman'sMcBain Family Pharmacy INC	2360 East 12th119 North Roland Street	Kansas CityMc Bain	MissouriMichigan	64127-1237496 57	(231) 825-8175

~~Imboden Medical~~Medcenter Pharmacy	~~110~~7210 North ~~Walnut~~Main Street, Suite 102	~~Imboden~~Clarkston	~~Arkansas~~Michigan	~~724344~~ 8346	(248) 625-3885
~~Imperial~~Mesick Pharmacy	~~1530 Palm~~112 Mesick Avenue	~~San Diego~~Mesick	~~California~~Michigan	~~921544~~ 9668	(231) 885-1751
~~Indio Medical~~Miller Pharmacy	~~81893 Doctor Carreon Boulevard, Suite 7~~206 North Broadway Street	~~Indio~~Union City	~~California~~Michigan	~~922014~~ 9094	5177413604
~~Infinity~~Millington Pharmacy	~~7551 West Hillsborough Avenue~~4729 Main Street	~~Tampa~~Millington	~~Florida~~Michigan	~~336154~~ 8746	(989) 871-2820
~~Infinity Pharmacy~~	~~2700 South 60th Street~~	~~Milwaukee~~	~~Wisconsin~~	~~53219~~	
~~Inland~~Mills Pharmacy & Apothecary	~~1001 E Latham Avenue~~1744 West Maple Suite ~~P~~A	~~Hemet~~Birmingham	~~California~~Michigan	~~925434~~ 8009	(248) 644-5060
~~Innova~~Mission Pharmacy	~~5830 Jameson Ct~~926 South Mission Street	~~Carmichael~~Mount Pleasant	~~California~~Michigan	~~956084~~ 8858	(989) 773-8200
~~Iola~~Monroe Pharmacy	~~109 East Madison~~2507 Monroe Street	~~Iola~~Dearborn	~~Kansas~~Michigan	~~667494~~ 8124	(313) 274-9141
~~Irmo Drug~~Moore Family Pharmacy Allegan	~~1009 Lake Murray Blvd~~100 Monroe Street, Suite B	~~Irmo~~Allegan	~~South Carolina~~Michigan	~~290634~~ 9010	(269) 673-6749
~~Irvine Health Care~~Moore Family Pharmacy Hamilton	~~1325 Richmond Road~~3416 M40	~~Irvine~~Hamilton	~~Kentucky~~Michigan	~~403364~~ 9419-9512	(269) 751-8482
~~Irvine Medical Center~~Moore Family Pharmacy South Haven	~~16300 Sand Canyon Avenue, Suite 101~~08337 M 140 Unit 2	~~Irvine~~South Haven	~~California~~Michigan	~~926184~~ 9090	(269) 637-3222
~~Island Family~~Niles Wellcare Pharmacy	~~600 PLANTATION ISLAND DR S UNIT 3~~70 E Main St	~~ST AUGUSTINE~~Niles	~~Florida~~Michigan	~~320804~~ 9120-2200	(269) 262-4343
~~Island~~Noor Pharmacy	~~210 South Highway 64~~4092 East 14 Mile Road Suite 200	~~Manteo~~Warren	~~North Carolina~~Michigan	~~279544~~ 8092	(586) 268-3900
~~Island~~Park Pharmacy SCS	~~2181 A Old Mountain~~20225 East 9 Mile Road Suite 100	~~Statesville~~Saint Clair Shores	~~North Carolina~~Michigan	~~286254~~ 8080-1775	(586) 999-8200
~~Island View~~ Pharmacy Care	~~2038 West 1900 South~~4652 N M37 Hwy	~~Syracuse~~Middleville	~~Utah~~Michigan	~~840754~~ 9333-0159	(269) 795-7936
~~Islip~~Pontiac Pharmacy ~~and Surgical~~	~~437 Main~~1925 North Perry Street	~~Islip~~Pontiac	~~New York~~Michigan	~~117514~~ 8340-2237	(248) 499-6070
~~Ivan~~Professional	~~691 Columbus~~	~~New York~~Caledonia	~~New~~	~~100254~~	(616) 891-1116

Pharmacy	~~Avenue~~9175 Cherry Valley		~~York~~Michigan	9316	
~~Ivy~~Rexall Pharmacy	~~16854 Ivy Avenue~~8483 Holly Road Suite ~~C~~202	~~Fontana~~Grand Blanc	~~California~~Michigan	~~92335-1504~~48439	(810) 344-6422
~~J's~~Rogers Pharmacy	~~6416 Ridge Road~~316 West Nepessing Street	~~Port Richey~~Lapeer	~~Florida~~Michigan	~~346684~~8446	(810) 664-0600
~~J & B Drugstore~~	~~352 Main Street~~	~~Grantsville~~	~~West Virginia~~	~~26147~~	
~~J & K Drug~~Saginaw Valley Pharmacy	~~7190 Highway 165 South~~5618 State Street	~~Columbia~~Saginaw	~~Louisiana~~Michigan	~~714184~~8603	(989) 220-1718
~~J&M Pharmacy and Compounding Center LLC~~	~~301 2nd Avenue West~~	~~Oneonta~~	~~Alabama~~	~~35121~~	
~~JABOS PHARMACY, INC.~~Saugatuck Drug Store	~~602 East Broadway~~201 Butler St	~~Newport~~Saugatuck	~~Tennessee~~Michigan	~~378214~~9453	(269) 857-2300
~~Jackson Drugs~~	~~1974 Cherokee Road~~	~~Alexander City~~	~~Alabama~~	~~35010-3437~~	
~~Jacks~~Schmidt & Sons Pharmacy of Tecumseh Inc	~~103~~120 East ~~College Avenue~~Chicago Boulevard	~~St Maries~~Tecumseh	~~Idaho~~Michigan	~~838614~~9286	(517) 423-3250
~~Jamestown~~Sheba Discount Pharmacy	~~1417 North Main Street, Suite A~~10136 Vernor Highway	~~Jamestown~~Dearborn	~~Kentucky~~Michigan	~~426294~~8120	(313) 841-8820
~~Jarrettsville~~Shelby Family Pharmacy	~~3714 Norrisville~~48887 Hayes Road	~~Jarrettsville~~Shelby Township	~~Maryland~~Michigan	~~210844~~8315	(586) 461-2900
~~Jay's~~Shores Specialty Pharmacy ~~Inc~~	~~400 South Highway 27~~29306 Harper Avenue	~~Somerset~~Saint Clair Shores	~~Kentucky~~Michigan	~~425014~~8081	(586) 200-1824
~~J Drugs~~	~~1205 Avenue J~~	~~Brooklyn~~	~~New York~~	~~11230~~	
~~J Drugs II~~	~~3402 Avenue N~~	~~Brooklyn~~	~~New York~~	~~11234~~	
~~Jeff's Prescription Shop~~SRX Specialty Care Pharmacy	~~2415 Ring~~3412 West 13 Mile Road	~~Elizabethtown~~Royal Oak	~~Kentucky~~Michigan	~~427014~~8073-6708	(248) 607-3110
~~Jeff Co Drug Center~~	~~127 West Meeting Street~~	~~Dandridge~~	~~Tennessee~~	~~37725~~	
~~Jefferson Drug Store~~	~~418 East Main Street~~	~~Jefferson~~	~~North Carolina~~	~~28640~~	
~~Jefferson Good Neighbor~~St. Charles Pharmacy	~~194 B Turkeysag Trail~~1008 N Saginaw St	~~Palmyra~~Saint Charles	~~Virginia~~Michigan	~~229634~~8655-1401	(989) 865-9971
~~Jeff Goodman Special Care Pharmacy~~	~~1625 Schrader Boulevard, 1st Floor~~	~~Los Angeles~~	~~California~~	~~90028-6213~~	
~~Jersey Drugs~~	~~286 Central Avenue~~	~~Jersey City~~	~~New Jersey~~	~~07307~~	
~~Jersey Shore~~State Street Pharmacy &	~~580~~192 North	~~Barnegat~~Caro	~~New~~	~~080054~~8723	(989) 672-3500

Wellness Center Inc	~~Main~~State Street		~~Jersey~~Michigan		
~~Jill's Genuine Care~~Sterling Heights Pharmacy ~~LLC~~	~~23603 Farmington~~38924 Dequindre Road	~~Farmington~~Sterling Heights	Michigan	~~483364~~8310	(586) 983-9740
~~John Smith Professional~~Sunshine Pharmacy	~~100 Lantana~~43009 Hayes Road~~, Suite 201~~	~~Crossville~~Sterling Heights	~~Tennessee~~Michigan	~~385554~~8313	(586) 286-5005
~~Jonathan's~~Swartz Creek Pharmacy	~~19341 Bear Valley~~8021 Miller Road ~~Suite 103~~	~~Apple Valley~~Swartz Creek	~~California~~Michigan	~~923084~~8473-1342	(810) 635-3355
~~Jones & Counts Pharmacy~~Taylor Discount Drugs	~~251 Main Street~~9320 Telegraph Road	~~Hays~~Taylor	~~Virginia~~Michigan	~~242564~~8180	(313) 299-8810
~~Jones Drug Store~~Thompson Pharmacy and Medical	~~125 Court~~324 South Union Street	~~Jackson~~Traverse City	~~Missouri~~Michigan	~~637554~~9684	(231) 947-4212
~~Jones Prescription Shop~~	~~101 Peachtree Street~~	~~Jesup~~	~~Georgia~~	~~31545~~	
~~Jordan~~TLC Pharmacy	~~1332 Highway 16~~2959 South Telegraph Road	~~Graham~~Dearborn	~~Texas~~Michigan	~~764504~~8124	(313) 274-0800
~~JR Pharmacy LLC 2~~	~~15 Southland Shopping Center~~	~~Terre Haute~~	~~Indiana~~	~~47802~~	
~~JR Pharmacy Poplar LLC~~	~~1101 Poplar Street~~	~~Terre Haute~~	~~Indiana~~	~~47807~~	
~~JR Pharmacy Rockville LLC 4~~	~~1330 North Lincoln Road~~	~~Rockville~~	~~Indiana~~	~~47872~~	
~~JR Scripts~~Ubly Pharmacy	~~2902 Poplar~~2031 East Main Street	~~Terre Haute~~Ubly	~~Indiana~~Michigan	~~478034~~8475-9726	(989) 658-3324
~~J RX~~USA Pharmacy	~~6515 Fresh Pond Road~~47315 Van Dyke Ave	~~Ridgewood~~Shelby Township	~~New York~~Michigan	~~113854~~8317-3363	(586) 326-0006
~~K & K~~Wackerly Pharmacy	~~187 Mill Street~~957 West Midland Road	~~Liberty~~Auburn	~~New York~~Michigan	~~127544~~8611	(989) 662-7773
~~K & K Pharmacy~~WARE'S PHARMACY	~~1411 West American Blvd~~304 South Jefferson Street	~~Muleshoe~~Mason	~~Texas~~Michigan	~~793474~~8854	(517) 676-9199
~~Kabs~~Watkins Pharmacy & Surgical Supply	~~2812~~1391 East ~~Bearss Avenue~~Sherman Boulevard	~~Tampa~~Muskegon	~~Florida~~Michigan	~~336134~~9444	(231) 739-7158
~~Kahler~~We Care Pharmacy Plus	~~1941 Airport Highway~~1412 South Lapeer Road	~~Toledo~~Lake Orion	~~Ohio~~Michigan	~~436094~~8360	(248) 690-9686
~~Kaleo's Pharmacy LLC~~	~~4475 Papalina Road Suite C1~~	~~Kalaheo~~	~~Hawaii~~	~~96741~~	

KananYinger Pharmacy and Medical SuppliesShoppe	5847 Kanan1704 South Custer Road	Agoura HillsMonroe	CaliforniaMichigan	913014 8161	(734) 243-5451
KareBlue Earth Drug #4	100 North Church125 South Grove Street, Suite A1	BloomfieldBlue Earth	New MexicoMinnesota	874135 6013	(507) 526-2121
Corner Drug	101 Main St S Suite 115	Le Sueur	Minnesota	56058-1915	(507) 665-3301
KareKennedy Drug - Aztec	100 Llano Street223 South Lakeshore Drive	AztecLake City	New MexicoMinnesota	874105 5041	(651) 345-3411
KaremoreMackenthun Beck Pharmacy Inc	12085 North Somerset Avenue Suite 5851 Market Place Dr	Princess AnneWaconia	MarylandMinnesota	218535 5387	(952) 442-4407
Sterling	700 Division Street South	Northfield	Minnesota	55057	(507) 645-4455
Sterling Drug	410 Hoffman Drive	Owatonna	Minnesota	55060	(507) 451-0240
Sterling Drug #04	400 South State Street 50	Fairmont	Minnesota	56031	(507) 238-2797
Katsaros PharmacySterling Drug #08	1521 East 53rd511 10th Street	ChicagoWorthington	IllinoisMinnesota	606155 6187	(507) 372-7533
Katy Medical Complex PharmacySterling Drug #20	21700 Kingsland209 Maine Avenue, Suite 105	KatyAdrian	TexasMinnesota	774505 6110	(507) 483-2332
Katz PharmacySterling Drug #24	2 East Eagle Road115 West Jessie Street	HavertownRushford	Pennsylvania Minnesota	190835 5971	(507) 864-2153
Kavanaugh PharmacySterling Drug #26	5200 KAVANAUGH BLVD615 West Esch Drive	LITTLE ROCKCaledonia	ArkansasMinnesota	722075 5921	(507) 725-3328
Keller Apothecary	5346 Devonshire Avenue	Saint Louis	Missouri	63109	
Kelley-Ross Pharmacy at the PolyclinicSterling Drug #29	904 7th Avenue306 Main Street Suite 103	SeattleLa Crescent	Washington Minnesota	981045 5947	(507) 895-8784
KELLSTROM PHARMACYSterling Pharmacy	1860 Claflin Road1109 W Oakland Ave	ManhattanAustin	KansasMinnesota	665025 5912	(507) 433-7123
Ken's SunflowerTrumm Drug Clinic Pharmacy	7222610 30th Ave West 80th Street	Overland ParkAlexandria	KansasMinnesota	662045 6308-0397	(320) 763-3116
Kennebec Pharmacy & Home CareTrumm Drug Downtown	839 Commercial600 Fillmore Street	RockportAlexandria	MaineMinnesota	048565 6308	(320) 763-3111

KennedyTrumm Drug Elbow Lake	22311 Central Avenue South Lakeshore Drive	Elbow Lake City	Minnesota	550415 6531	(218) 685-4471
Kennedy PharmacyTrumm Drug Glenwood	42 East Laurel Road Suite 19007 Fourth Avenue SE	StratfordGlenwood	New JerseyMinnesota	080845 6334	(320) 634-4434
Trumm Drug Parkers Prairie	114 E Soo St	Parkers Prairie	Minnesota	56361	(218) 338-2661
Kent Station PharmacyANDERSON'S PHARMACY	38 North112 East Main Street	KentNorth Carrollton	ConnecticutMississippi	067573 8947	(662) 237-9294
KEX RX PHARMACY & HOME CAREBooneville Community Pharmacy	120 E 18TH ST206 North Second Street	FALLS CITYBooneville	NebraskaMississippi	683553 8829	(662) 728-1951
KeyBrick City Drugs	910 North Westwood159 Fountains Boulevard	Poplar BluffMadison	MissouriMississippi	639013 9110	(769) 231-1400
Key Drugs at DexterByhalia Drug Company, LLC	1007 West Business US Highway 607984 Hwy 178 W	DexterByhalia	MissouriMississippi	638413 8611	(662) 838-3784
KeyCaleb's Hometown Pharmacy	614 Crandon Boulevard801 Main Street	Key BiscayneCollins	FloridaMississippi	331493 9428	(601) 765-5055
Kilgore ExpressCity Drug Pharmacy #6and Gifts	1614 Glenn Boulevard Southwest113 Bobo Drive	Fort PayneCrystal Springs	AlabamaMississippi	359683 9059	(601) 892-4121
Killen CornerCity Drug Pharmacy and Gifts	162127190 Highway 7228 Suite 100	KillenHazlehurst	AlabamaMississippi	356453 9083-2224	(601) 892-4124
Kim'sCondon East Union Pharmacy	479 Dellwood Rd1403 East Union	WaynesvilleGreenville	North CarolinaMississippi	287863 8703	(662) 332-0941
Kimper PharmacyCox-Blythe Drug Co	9711 State Highway 194 East122 West College Street	KimperBooneville	KentuckyMississippi	415393 8829-3498	(662) 728-5732
King's HometownFairview Pharmacy & Compounding	33 SCHOOL CIRCLE SUITE A500 Katie Avenue	BLAIRSVILLEHattiesburg	GeorgiaMississippi	30512-2984394 01	(601) 544-4871
King'sFreedom Pharmacy	16 Wayne Brooks Lane3902 Hardy St	HayesvilleHattiesburg	North CarolinaMississippi	289043 9402-1541	(601) 450-6979
King's Pharmacy	30 Peachtree Street	Murphy	North Carolina	28906	
King Drug and Home Care	1156 Carter Road	Owensboro	Kentucky	42301	

KING DRUG CO LLC	142 SOUTH MAIN STREET	KING	North Carolina	27021-0426	
KingFriendship Pharmacy & Compounding LLC	31201 US5532 Highway 19 North15 Suite 1	Palm HarborEcru	FloridaMississippi	34684-4422388 41	(662) 488-0317
Kingsbay Chemists Inc.Greenwood Drugs	3610 Nostrand400 West Park Avenue	BrooklynGreenwood	New YorkMississippi	112293 8930	(662) 477-0700
KingsleyGuy's Pharmacy and Compounding Centerof Crystal Springs	114 South Brownson512 West Marion Avenue	KingsleyCrystal Springs	MichiganMississippi	496493 9059	(601) 647-0030
Guy's Pharmacy of Tylertown	3000 Plaza Drive Suite B	Tylertown	Mississippi	39667	(601) 377-1982
KinkeadGuys Pharmacy of Brookhaven	105 South Allen1005 West Congress Street	CentraliaBrookhaven	MissouriMississippi	652403 9601	(601) 833-6333
Kinston ClinicGuys Pharmacy Northof Hazlehurst	701 Doctors212 Caldwell Drive Suite P	KinstonHazlehurst	North CarolinaMississippi	285013 9083	(601) 524-4897
Haire Drug Center	805 1st Street	Cleveland	Mississippi	38732-2309	(662) 843-4211
LITTLE'S PHARMACY	122 Main Street	Raleigh	Mississippi	39153	(601) 782-4552
KitchMacon Primary Pharmacy	10501 Quaker Avenue Suite 30034 Hospital Road	LubbockMacon	TexasMississippi	79424-8312393 41	(662) 788-4398
McGuffee Drug	102 North Main Street	Mendenhall	Mississippi	39114	(601) 847-2511
Medical Center Pharmacy	312 Marion Avenue	Mc Comb	Mississippi	39648	(601) 684-9602
KK'sNorth Sunflower Medical Center Pharmacy #251	980860 North Walnut Creek Drive #118Oak Avenue	MansfieldRuleville	TexasMississippi	760633 8771	(662) 756-4381
KK'sOkolona Pharmacy #51	2480210 W Illinois AvenueMain St	DallasOkolona	TexasMississippi	752333 8860-1608	(662) 447-0300
KMLPark Place Pharmacy	1655 South de Anza Boulevard, Suite 246 Parkway Lane	CupertinoPetal	CaliforniaMississippi	950143 9465	(601) 450-3673
Pearsons Discount Drugs LLC	101 E Washington St	Houston	Mississippi	38851-2225	(662) 456-2551
Sav- Mor Drugs and Gifts	1967 Commerce Street	Grenada	Mississippi	38901	(662) 226-6741
Knight'sStepp-Saver Pharmacy	191 Glades Road203 North Newberger Avenue	BereaBruce	KentuckyMississippi	404033 8915-0656	(662) 983-4011
KnollsStricklands Cash And Save	16630 Marquez Avenue703 Front	Pacific PalisadesRichton	CaliforniaMississippi	902723 9476	(601) 788-6332

Discount Pharmacy	St N				
Sunflower Greenwood Pharmacy	201 West Park Avenue	Greenwood	Mississippi	38930-3008	(662) 219-2733
~~Koblin's~~The Pharmacy of Quitman	~~96~~125 Main Street	~~Nyack~~Quitman	~~New York~~Mississippi	~~109603~~ 9355	(601) 776-6282
Wards Pharmacy	122 South Front Street	Ellisville	Mississippi	39437-3118	(601) 477-8587
Williams Tylertown Pharmacy LLC	201 Hospital Drive	Tylertown	Mississippi	39667-2019	(601) 222-1770
Winona Drugs	500 North Applegate Street Suite A	Winona	Mississippi	38967	(662) 535-0800
~~Koerner Whipple~~Advance Pharmacy	~~104 First Street Northwest~~110 South Oak	~~Hampton~~Advance	~~Iowa~~Missouri	~~504416~~ 3730	(573) 722-3562
~~Komoto~~Albers Medical Pharmacy	~~2110 Truxtun Avenue,~~4400 Broadway Suite ~~100~~106	~~Bakersfield~~Kansas City	~~California~~Missouri	~~933016~~ 4111	(816) 931-0100
Beauton Drug	124 North Washington	East Praire	Missouri	63845	(573) 649-3923
~~Komoto~~Bond Pharmacy	~~1017 Ellington Street~~703 West Buchanan	~~Delano~~California	~~California~~Missouri	~~932156~~ 5018	(573) 796-3145
~~Kovacs Frey~~Bruner Pharmacy	~~2860 Artesia Boulevard~~321 East Broadway Street	~~Redondo Beach~~Monett	~~California~~Missouri	~~902786~~ 5708	(417) 235-3139
~~Kraege~~Butler Drug Store	~~113~~222 East Main Street	~~Yorktown~~Portageville	~~Texas~~Missouri	~~78164-2030~~63873	(573) 379-5469
Chaffee Drug Store	211 West Yoakum Avenue	Chaffee	Missouri	63740	(573) 887-3622
~~Kramers~~Cole Camp Pharmacy	~~29525 Canwood~~512 West Main Street	~~Agoura Hills~~Cole Camp	~~California~~Missouri	~~913016~~ 5325	(660) 668-4646
~~Kratzer's Hometown~~Country side Pharmacy~~ Mt Orab~~	~~155 North Point Drive~~402 E Price Ave	~~Mount Orab~~Savannah	~~Ohio~~Missouri	~~451546~~ 4485	(816) 324-5111
~~Kremer~~E & S Pharmacy	~~206A North Pearl~~1105 Walnut Street	~~Teutopolis~~Doniphan	~~Illinois~~Missouri	~~62467-1134~~63935	(573) 996-7157
~~KREMER~~EAST SIDE DISCOUNT PHARMACY ~~ALTAMONT~~	~~12 N 3RD ST~~400 EAST PINE STREET	~~ALTAMONT~~POPLAR BLUFF	~~Illinois~~Missouri	~~62411-1271~~63901	(573) 686-7238
~~Kressaty's~~Family Pharmacy	~~1068 Ringwood Avenue~~806 North Sturgeon	~~Haskell~~Montgomery City	~~New Jersey~~Missouri	~~074206~~ 3361	(573) 564-2273
~~Kronner~~Flow's	~~778 West~~	~~Prudenville~~Columbi	~~Michigan~~Miss	~~486516~~	(573) 447-8093

Pharmacy	~~Houghton Lake Drive~~303 North Keene Street	a	ouri	5201	
~~Krutieks~~Flow's Pharmacy	~~589 Crescent Street~~1506 E BROADWAY	~~Brooklyn~~COLUMBIA	~~New York~~Missouri	~~112086~~ 5201	(573) 449-5366
~~KTA Kamuela~~Gosney Pharmacy	~~65-1158 Mamalahoa~~911 Highway 24/36 East	~~Kamuela~~Monroe City	~~Hawaii~~Missouri	~~967436~~ 3456	(573) 735-1130
~~KTA Keauhou~~Grand Pharmacy	~~78-6831 Alii Drive~~733 Grand Avenue	~~Kailua-Kona~~Hannibal	~~Hawaii~~Missouri	~~967406~~ 3401	(573) 221-2792
~~KTA Puainako~~Greenfield Pharmacy	~~50 East Puainako Street~~105 N GRAND STE 1	~~Hilo~~GREENFIELD	~~Hawaii~~Missouri	~~967206~~ 5661	(417) 637-2909
~~KTA Waikoloa Village~~Harris Pharmacy	~~68-3916 Paniolo Avenue~~1224 First St	~~Waikoloa~~Kennett	~~Hawaii~~Missouri	~~967386~~ 3857	(573) 888-6006
Hayden Pharmacy	1200 Ward Avenue	Caruthersville	Missouri	63830	(573) 333-4606
~~Kwikrx~~Iman's Pharmacy INC	~~13015 West 143rd~~2360 East 12th Street	~~Homer Glen~~Kansas City	~~Illinois~~Missouri	~~604916~~ 4127-1237	(816) 569-6310
~~Kyoto Pharmacy~~Jones Drug Store	~~420 East 3rd~~125 Court Street	~~Los Angeles~~Jackson	~~California~~Missouri	~~900136~~ 3755	(573) 243-3524
Key Drugs	910 North Westwood Boulevard	Poplar Bluff	Missouri	63901	(573) 785-8218
Kinkead Pharmacy	105 South Allen Street	Centralia	Missouri	65240	(573) 682-2155
L & S Pharmacy	406 South Main Street	Charleston	Missouri	63834	(573) 683-3307
~~La Buena Vida Pharmacy~~	~~51335 Cesar Chavez Street Suite 116~~	~~Coachella~~	~~California~~	~~92236~~	
~~Lacey Drug Company~~	~~4797 South Main Street~~	~~Acworth~~	~~Georgia~~	~~30101~~	
~~Laceys Marietta Pharmacy~~	~~790 Church Street, Suite 170~~	~~Marietta~~	~~Georgia~~	~~30060~~	
~~La Cubana Pharmacy Discount~~	~~5965 Southwest 8th Street Suite A~~	~~Miami~~	~~Florida~~	~~33144~~	
~~LAFAYETTE PHARMACY~~	~~526 Highway 52 Bypass West~~	~~Lafayette~~	~~Tennessee~~	~~37083~~	
Lakeland Pharmacy #1	18565 Business 13	Branson West	Missouri	65737	(417) 272-8064
Lakeland Pharmacy #2	1232 Branson Hills ~~Parkway~~Pkwy Suite 205	Branson	Missouri	65616	(417) 336-4701
Lakeland Pharmacy #3	104 Cortney Lane	Crane	Missouri	65633	(417) 723-5241
Lakeland Pharmacy	16269 US	Forsyth	Missouri	65653-7	(417) 546-5151

#4	~~Highway~~Hwy 160			122	
Lakeland Pharmacy #7	110 Bear Dr~~.~~ Suite 4	Willow Springs	Missouri	~~657936~~ 5793-1512	(417) 469-9009
~~Lake Murray~~Lindenwood Drug ~~Company~~	~~105 Snapdragon Court Suite A~~6903 Lansdowne	~~Chapin~~St. Louis	~~South Carolina~~Missouri	~~29036-8343~~63109	(314) 781-2445
~~Lake Murray Drug Company of Irmo~~	~~2 Palmetto Wood Parkway Suite 100~~	~~Irmo~~	~~South Carolina~~	~~29063~~	
~~Lakeside~~New Madrid Pharmacy	~~605 North~~457 Main Street	~~Eufaula~~New Madrid	~~Oklahoma~~Missouri	~~744326~~3869	(573) 748-3080
~~LAKESIDE PHARMACY~~Pill Box Pharmacy	~~9615 SHERRILL ESTATES ROAD SUITE B~~304 East Jackson Street 2D	~~HUNTERSVILLE~~Willard	~~North Carolina~~Missouri	~~280786~~5781	(417) 742-3508
~~LAKESIDE PHARMACY-ANTIGO~~	~~536 5TH AVE~~	~~ANTIGO~~	~~Wisconsin~~	~~54409~~	
~~Lakeside Specialty~~Rogersville Pharmacy	~~480 River Highway, Suite A~~317 South Main Street	~~Mooresville~~Rogersville	~~North Carolina~~Missouri	~~28117-6958~~65742	(417) 753-7774
~~LAKETOWN PHARMACY~~Saults Drug Store Inc	~~1550 S PIONEER WAY STE 105~~505 Court Street	~~MOSES LAKE~~Fulton	~~Washington~~ Missouri	~~988376~~5251	(573) 642-4186
~~Lake Worth~~Scotland County Pharmacy	~~4701 BOAT CLUB RD SUITE 115~~445 East Grand Avenue	~~Fort Worth~~Memphis	~~Texas~~Missouri	~~761356~~3555	(660) 465-2400
~~Lake Wylie~~Scott Family Pharmacy	~~221 Latitude Lane Suite 109~~414 West Grand Avenue	~~Lake Wylie~~Campbell	~~South Carolina~~Missouri	~~297106~~3933	(573) 246-2514
~~LAKOTA DRUG~~Sterling Pharmacy	~~117 MAIN ST~~808 Hunter Avenue Suite 1A	~~LAKOTA~~Sikeston	~~North Dakota~~Missouri	~~583446~~3801	(573) 475-1900
~~Lamar Plaza Drug Store~~	~~1509 South Lamar Boulevard Suite 550~~	~~Austin~~	~~Texas~~	~~78704~~	
~~Landmark Pharmacy~~Sterling Retail KC	~~3401 Atwood~~3338 Northeast Ralph Powell Road, Suite E	~~Little Rock~~Lees Summit	~~Arkansas~~Missouri	~~722066~~4064	(816) 788-7928
~~Landy's~~Summit Pharmacy	~~835 Sparkleberry Lane~~140 Northstar Drive	~~Columbia~~Holts Summit	~~South Carolina~~Missouri	~~29229-6544~~65043-1123	(573) 826-4151
~~Lane Drug Co.~~Twin City Pharmacy	~~19427 Hartford~~106 North First Street	~~Edison~~Marble Hill	~~Georgia~~Missouri	~~398466~~3764	(573) 238-4177
~~LANGDON COMMUNITY DRUG~~	~~805 3RD ST~~	~~LANGDON~~	~~North Dakota~~	~~58249~~	
~~Lanvy~~Hils Pharmacy	~~14971 Brookhurst~~800 North Morley Street ~~Suite A~~	~~Westminster~~Moberly	~~California~~Missouri	~~926836~~5270-2617	(660) 263-4457

Missoula Pharmacy, Inc.	1211 South Reserve Street, Suite 102	Missoula	Montana	59801	(406) 728-5650
~~Lapeer~~Sykes Pharmacy	~~944 Baldwin Road Suite B~~202 2nd Ave West	~~Lapeer~~Kalispell	~~Michigan~~Montana	~~484465~~ 59901-4463	(406) 257-4806
Sykes Pharmacy Columbia Falls	500 12th Ave W Suite 1A	Columbia Falls	Montana	59912-3818	(406) 206-7277
~~Laplata~~Burwell Pharmacy	~~6501 Crain Highway~~137 Grand Avenue	~~La Plata~~Burwell	~~Maryland~~Nebraska	~~20646-4268~~68823-0520	(308) 346-4747
~~LARIMORE DRUG AND GIFT INC~~Clabaugh Pharmacy	~~203 TOWNER AVE~~501 Court Street	~~LARIMORE~~Beatrice	~~North Dakota~~Nebraska	~~58251-0438~~68310	(402) 223-3591
GLOBAL REXALL DRUG	424 E ST	FAIRBURY	Nebraska	68352-2535	(402) 729-2620
~~Lark Drugs Pharmacy~~Manion's Drug Store	~~16251~~719 Main Street	~~Guernerville~~Creighton	~~California~~Nebraska	~~954466~~8729	(402) 358-3535
~~Larry's~~Medicine Man Pharmacy	~~1310 10th Ave~~748 North Main Street	~~Humboldt~~North Bend	~~Iowa~~Nebraska	~~505486~~8649	(402) 652-3217
~~Larson's~~Medicine Man Pharmacy	~~142 West H~~15615 Pacific Street Suite 8	~~Colton~~Omaha	~~California~~Nebraska	~~923246~~8118	(402) 496-9757
~~Las Villas~~Medicine Man Pharmacy ~~Discount and Medical Supplies~~	~~716 West 29th Street~~122 WEST 16TH STREET	~~Hialeah~~SCHUYLER	~~Florida~~Nebraska	~~330126~~8661	(402) 352-3020
MEDICINE MAN PHARMACY	526 NORTH LINDEN STREET	WAHOO	Nebraska	68066	(402) 443-4167
~~La Tienda~~Nein Pharmacy	~~1301 South Canal~~1012 Main Street	~~Carlsbad~~Bridgeport	~~New Mexico~~Nebraska	~~882206~~9336	(308) 262-1070
~~Laurelton~~O'Neill Family Pharmacy	~~22412 Merrick Boulevard~~317 E Douglas St	~~Laurelton~~Oneill	~~New York~~Nebraska	~~114136~~8763-1829	(402) 336-2660
~~Lawrence Pharmacy~~ONEWORLD PHARMACY	~~1156 North George Washington Highway~~4920 S 30TH ST STE 105	~~Chesapeake~~OMAHA	~~Virginia~~Nebraska	~~233236~~8107	(402) 502-5832
~~LC~~Plainview Family Pharmacy	~~57 North Morey Road~~103 S Main St	~~Lake City~~Plainview	~~Michigan~~Nebraska	~~496516~~8769-0217	(402) 582-4202
~~Lee's Inlet Apothecary and Gifts~~Steffen Drug	~~3579 Highway 17 Business~~214 North Broadway	~~Murrells Inlet~~Hartington	~~South Carolina~~Nebraska	~~295766~~8739-0248	(402) 254-3549
~~Lee Davis~~Sutton Pharmacy	~~7016 Lee Park Rd Suite 400~~210 N Saunders Ave	~~Mechanicsville~~Sutton	~~Virginia~~Nebraska	~~231116~~8979	(402) 773-4300
~~Lee Goodrum Pharmacy~~ViaRx	~~40 Hospital Road~~825 North 90th Street	~~Newnan~~Omaha	~~Georgia~~Nebraska	~~30263-1200~~68114	(402) 614-6363

Le FaveWeaver Pharmacy and Home Medical Equipment	1202 West Chisholm1014 G Street	AlpenaGeneva	MichiganNebraska	4970768361	(402) 759-4433
Lenox PharmacyWells Drug	27 Lenox Avenue113 S 4th St	New YorkAlbion	New YorkNebraska	10026686620-1215	(402) 395-2184
Western Drug	806 Illinois	Sidney	Nebraska	69162	(308) 254-2032
Lenox Terrace DrugFisherville Pharmacy	20 West 135th Street219 Fisherville Rd Suite C	New YorkPenacook	New YorkHampshire	10037033303-2074	(603) 565-0210
LeonardAdvanced Pharmacy	122 West Collins288 Smith Street	LeonardPerth Amboy	TexasNew Jersey	754520 8861	(732) 324-4490
LeroyAllentown Pharmacy	1280 North Leroy Street2 S Main St	FentonAllentown	MichiganNew Jersey	48430-2760085 01-9501	(609) 259-6121
Levy'sAllstar Pharmacy & Surgical	299 Stuyvesant Avenue105 Terhune Ave	LyndhurstLodi	New Jersey	07071007644-2805	(973) 473-2243
Lewis County Primary Care Center	211 Kentucky 59	Vanceburg	Kentucky	41179	
Liberty Drug and SurgicalAngelo Pharmacy	195 Main492 Ferry Street	ChathamNewark	New Jersey	07928007105	(973) 589-6530
Liberty FamilyAR-EX Pharmacy	115 West Main Street370 New Brunswick Avenue	LibertyFords	South CarolinaNew Jersey	29657-0063088 63	(732) 738-1085
Lifeline Rx LLCBayshore Pharmacy	9252 KENNEDY BLVD UNIT 32 Bayshore Plaza	NORTH BERGENAtlantic Highlands	New Jersey	07047007716	(732) 291-2900
Lifestream Pharmacy	847 EASTON ROAD SUITE 2775	WARRINGTON	Pennsylvania	18976	
Lily'sBell Pharmacy	11670 Jones Bridge Road Suite E1907 Route 27	Johns CreekEdison	GeorgiaNew Jersey	300050 8817	(732) 985-1211
Lincoln ParkwayBoro Hall Pharmacy	117 Lincoln Drive565 Bound Brook Road	HodgenvilleMiddlesex	KentuckyNew Jersey	427480 8846	(732) 968-0414
LincolnBoyd's Pharmacy of Florence	821 South 38th306 Broad Street	TacomaFlorence	WashingtonNew Jersey	984180 8518	(609) 499-0100
Linda RxBoyd's Pharmacy of Mansfield	1569 Lexann Avenue,23202 Columbus Road Suite 130E	San JoseColumbus	CaliforniaNew Jersey	951210 8022	(609) 298-7474
Linda Vista Pharmacy	4300 Rose Drive Suite D	Yorba Linda	California	92886	
LindbergBoyd's Pharmacy of	5203 South McColl5-100	EdinburgMedford	TexasNew Jersey	785390 8055	(609) 975-8197

Medford	Wilkins Station Road				
~~Lindenwood Drug~~Boyds Pharmacy of Bordentown	~~6903 Lansdowne~~118 Farnsworth Avenue	~~St. Louis~~Bordentown	~~Missouri~~New Jersey	~~631090~~ 8505	(609) 298-1811
~~Lindhurst Pharmacy~~	~~5991 Lindhurst Ave~~	~~Marysville~~	~~California~~	~~95901~~	
~~Liss~~Boyds Pharmacy of Pemberton	~~794 Mount Prospect Avenue~~17 Fort Dix Road	~~Newark~~Pemberton	New Jersey	~~071040~~ 8068	(609) 894-8288
~~LITTLE'S PHARMACY~~Boyt Drugs	~~122~~411 Main Street	~~Raleigh~~Metuchen	~~Mississippi~~New Jersey	~~391530~~ 8840	(732) 548-2125
~~Little Road~~Briarmill Pharmacy	~~4211 Little~~1820 Lanes Mill Road ~~Unit #4~~	~~New Port Richey~~Brick	~~Florida~~New Jersey	~~346550~~ 8724	(732) 840-1800
~~Little Silver Family Pharmacy~~Buckleys Drug Store	~~10 Church Street~~35 East Palisade Avenue	~~Little Silver~~Englewood	New Jersey	~~077390~~ 7631-2932	(201) 569-1345
~~Live Oak~~Bunting Family Pharmacy	~~98 Oakland Avenue East~~1337-A New Road	~~Camilla~~Northfield	~~Georgia~~New Jersey	~~317300~~ 8225	(609) 484-0026
Burgess Chemist	559 FRANKLIN AVENUE	NUTLEY	New Jersey	07110	(973) 235-0909
~~Livewell~~Butler Pharmacy	~~477 State Route 10 Unit 13~~2301 Bridge Avenue	~~Randolph~~Point Pleasant	New Jersey	~~07869-2 142~~08742	(732) 892-4488
Camacho Pharmacy	509 Elizabeth Avenue	Elizabeth	New Jersey	07206	(908) 355-1784
~~Lo Cost~~Campbell's Pharmacy	~~612 East 69th Street~~2175 Highway 35	~~Savannah~~Sea Girt	~~Georgia~~New Jersey	~~314050~~ 8750	(732) 974-2929
~~Logos~~Center Pharmacy	~~7543 W Waters ave~~1108 Liberty Avenue	~~Tampa~~Hillside	~~Florida~~New Jersey	~~336150~~ 7205	(908) 354-3169
~~London Drug~~CENTRAL JERSEY PHARMACY	~~6 S Main~~275 HOBART ST	~~Grace~~PERTH AMBOY	~~Idaho~~New Jersey	~~832410~~ 8861-3396	(732) 979-2410
Centrastate Specialty Script	901 W Main Street (Main Lobby)	Freehold	New Jersey	07728-2537	(732) 414-1977
~~Lone Oak Pharmacy~~CLOVER PHARMACY	~~3535 Lone Oak~~3100 Quakerbridge Road	~~Paducah~~Mercerville	~~Kentucky~~New Jersey	~~420010~~ 8619	(609) 588-5445
~~Lone Star~~Colonial Pharmacy	~~13230 Fm 1764 Rd STE B~~828 Clifton Avenue	~~Santa Fe~~Clifton	~~Texas~~New Jersey	~~775100~~ 7013	(973) 473-4000
~~Lone Star~~Colts Neck Pharmacy	~~1395 Sattler Road~~420 State Route 34 Suite ~~8~~309	~~Canyon Lake~~Colts Neck	~~Texas~~New Jersey	~~781320~~ 7722	(732) 780-5480
~~Lorain~~	~~12940 Lorain~~	~~Cleveland~~Sewell	~~Ohio~~New	~~44111-2~~	(856) 716-6149

LowcostCrossKeys Pharmacy	Avenue468 Hurffville Cross Keys Road Unit 2		Jersey	61208080	
Lorenzo Apothecary	306 Main Street	Sterling	Colorado	80751-4345	
Loretto Drugs LLC	106 Church Street	Loretto	Tennessee	38469	
Los AlamitosDamiano Pharmacy	3801 Katella270 Parker Avenue Suite 120	Los AlamitosClifton	CaliforniaNew Jersey	90720070011	(973) 546-6700
Loudoun Community Pharmacy	19415 Deerfield Avenue Suite 116	Lansdowne	Virginia	20176-8470	
Loving CareDevine's Pharmacy	1653 Lincoln Highway1949 Oak Tree Road	Edison	New Jersey	08817088820	(732) 549-7117
Lowe'sEdgewood Pharmacy	1536 East Broadway62 B Mountain Blvd	MaryvilleWarren	TennesseeNew Jersey	37804070059	(908) 754-4400
Lucerne Pharmacy, Inc.	6244 East Highway 20	Lucerne	California	95458-1316	
Ludowici DrugsFARMACIA SAN ANTONIO	11 West Cypress2319 Federal Street	LudowiciCamden	GeorgiaNew Jersey	31316081105	(856) 964-4600
LulaFranklyn Pharmacy and Foothills Gift Shop	6102 Banks Street204 WARREN AVE	LulaHohokus	GeorgiaNew Jersey	30554074423	(201) 444-5550
Lynn's DakotamartFuture Pharmacy - Belle Fourche	600 National Street979 Route 9 N	Belle FourcheHowell	South DakotaNew Jersey	57717077731-3365	(732) 431-8170
Lynn's La VegaFuture Pharmacy 3	2401680 Route 33 E Waco DriveUnit 8	WacoEast Windsor	TexasNew Jersey	76705085 20	(609) 632-2170
Lynn'sFuture Pharmacy Hewitt4	511 North Hewitt Drive700 Tennent Rd Suite 19	HewitManalapan	TexasNew Jersey	76643077726-3148	(732) 851-7100
Lynns Dakotamart Pharmacy Hot SpringsFuture Pharmacy II	501 South 6th Street72 Route 34	Hot SpringsOld Bridge	South DakotaNew Jersey	57747088857	(732) 952-5550
Maag Prescription and Medical Supply	333 West Center Street	Pocatello	Idaho	83204	
Mabrys Drug Store	41 West Main Street	Hamlet	North Carolina	28345	
Mac's Edgemoor Pharmacy	643 Edgemoor Road	Powell	Tennessee	37849	
Mac'sGarden Pharmacy	2419 Washington Pike2467 State Hwy 33	KnoxvilleNeptune	TennesseeNew Jersey	37917077753-3762	(732) 922-4121
Mac'sGeorgies Family Pharmacy	125 S PETERS RD332 W St	KNOXVILLELinden	TennesseeNew Jersey	37923-5202070	(908) 925-4567

at South Peters	Georges Ave			36	
Mac's Pharmacy Oak Ridge	45 New York Avenue	Oak Ridge	Tennessee	37830-6410	
MAC'S PHARMACY TOWNSENDGeorgies Outpatient Pharmacy	7959 E LAMAR ALEXANDER PKWY6 Earlin Avenue Suite 130	TOWNSENDBrowns Mills	TennesseeNew Jersey	37882-4033080 15	(609) 726-5800
Mackenthun Beck Pharmacy Inc	851 Market Place Drive	Waconia	Minnesota	55387	
Macon PrimaryGeorgies Parlin Pharmacy	34 Hospital Road499 Ernston Rd	MaconParlin	MississippiNew Jersey	3934108859-1406	(732) 952-3022
Madden'sGet Rx Help Pharmacy, Inc.	101 College Avenue688 Westwood Ave Ste 3	ElbertonRiver Vale	GeorgiaNew Jersey	30635-1705076 75-6375	(201) 666-6100
Maddox Drugs	1330 Big A Road	Toccoa	Georgia	30577	
Madison Drug	110 Big Hill Avenue	Richmond	Kentucky	40475	
Madison Drug Company Inc	114 North Main Street	Madison	Virginia	22727	
MadisonGoodale Pharmacy	66 Main16 North Sussex Street	MadisonDover	New Jersey	0794007801	(973) 366-0976
MadisonGood Health Pharmacy & Gifts Inc	4401 US HWY 25 70530 Joralemon St.	MARSHALLBellevill e	North CarolinaNew Jersey	28753007109	(973) 759-2761
Madison Pharmacy and HomecareHaworth Apothecary	125 West Murphy169 Terrace Street	MadisonHaworth	North CarolinaNew Jersey	27025007641	(201) 384-7171
MaduraHazlet Pharmacy	115 North Broadway2874 Highway 35 South	South AmboyHazlet	New Jersey	08879007730	(732) 264-3310
MAGGIES PHARMACY	2315 KUEHNER DR UNIT 107	SIMI VALLEY	California	93063	
Magnolia Drug Co Inc	112 North Church Street	Homerville	Georgia	31634	
MagnoliaHB Pharmacy	18230 FM 1488, Suite 10098 Ridge Road	MagnoliaNorth Arlington	TexasNew Jersey	7735407031	(201) 997-2010
Mahaska Drug, Inc	205 North E Street	Oskaloosa	Iowa	52577	
MaicoHealth Fair Pharmacy	10161 Bolsa315 Willow Avenue Suite 105B	WestminsterHoboken	CaliforniaNew Jersey	9268307030-3807	(201) 222-6968
Main Street DrugHeights Specialty Pharmacy	225 West Main450 Boulevard	WilburtonHasbrouck Heights	OklahomaNew Jersey	7457807604	(201) 288-0404
Main Street Drug Inc.	204 North Main Street	Charles City	Iowa	50616	
Main StreetHeller's Pharmacy	2117 Boston664 Mount Prospect Avenue	BridgeportNewark	ConnecticutNew Jersey	0661007104	(973) 482-5353
Main StreetHigh	435344 West	Oak HillElizabeth	West	259010	(908) 353-2000

Touch Pharmacy	MainGrand Street Suite 1		VirginiaNew Jersey	7202-1202	
Malakoff Pharmacy	409 West Royall Boulevard	Malakoff	Texas	75148	
Malheur Drug	198 A Street West	Vale	Oregon	97918	
Maloney Prescription PharmacyHOPEWELL PHARMACY	1405 Hailey1 West Broad Street	SweetwaterHopewell	TexasNew Jersey	7955608525	(609) 466-1960
Manatee Discount Pharmacy	1802 59th Street West	Bradenton	Florida	34209	
Jersey Drugs	286 Central Avenue	Jersey City	New Jersey	07307	(201) 656-4392
Manion's Drug StoreJersey Shore Pharmacy	719580 North Main Street	CreightonBarnegat	NebraskaNew Jersey	68729080005	(609) 660-1111
Manitowoc PharmaciesKennedy Pharmacy	919 South 8th Street42 E Laurel Rd Suite 1900	ManitowocStratford	WisconsinNew Jersey	542200 8084-1350	(856) 346-3535
Mannings 8th AveLevys Pharmacy	6402 8th Avenue Suite G103299 Stuyvesant Ave	BrooklynLyndhurst	New YorkJersey	112200 7071-1838	(201) 438-1026
ManorLiberty Drug Medical & Mobilityand Surgical	5795 North First195 Main Street	FresnoChatham	CaliforniaNew Jersey	937100 7928	(973) 635-6200
Lifeline Rx LLC	9252 KENNEDY BLVD UNIT 3	NORTH BERGEN	New Jersey	07047	(201) 624-8015
MapleLiss Pharmacy	5829 West Maple Road Suite 129794 Mt Prospect Ave	West BloomfieldNewark	MichiganNew Jersey	483220 7104-3295	(973) 483-4749
Marcus HookLittle Silver Family Pharmacy	46 E 10TH ST10 Church Street	Marcus HookLittle Silver	Pennsylvania New Jersey	190610 7739	(732) 741-1121
MargolisLiveWell Pharmacy	447 Broadway477 State Route 10 Unit 13	ChelseaRandolph	MassachusettsNew Jersey	021500 7869-2142	(973) 775-9818
Marion FamilyLoving Care Pharmacy	134 Block Street1653 Lincoln Highway	MarionEdison	ArkansasNew Jersey	723640 8817	(732) 832-2862
Mark'sMadison Pharmacy	205 East66 Main Street	MelbourneMadison	ArkansasNew Jersey	725560 7940	(973) 377-0075
MarketMadura Pharmacy	9250 Reseda Boulevard Suite 2C115 North Broadway	NorthridgeSouth Amboy	CaliforniaNew Jersey	913240 8879	(732) 721-1732
Market Street Pharmacy	10 Market Street	Belvidere	New Jersey	07823-1444	(908) 475-1421
Market StreetMedical Mall Pharmacy	1612 Market Street9 Hospital Dr Suite B3	WilmingtonToms River	North CarolinaNew Jersey	284010 8755	(732) 244-4747
MARKS FAMILY PHARMACYMiddlet	205 East 3rd Ave877 Main St	OneidaBelford	TennesseeNew Jersey	37841-5885077	(732) 471-9100

own Family Pharmacy				18	
~~Marple~~Middle Village Pharmacy	~~2070 Sproul Road~~393 Piaget Avenue	~~Broomall~~Clifton	~~Pennsylvania~~ New Jersey	~~19008~~07011	(973) 478-0600
~~Marquez~~Midtown Pharmacy	~~5901 West 16th~~581 Kearny Avenue	~~Hialeah~~Kearny	~~Florida~~New Jersey	~~33012~~07032	(201) 991-3454
~~Marshall's Drug Store~~Miguel's Pharmacy	~~50 Cross Street~~1787 River Road	~~Urbanna~~Camden	~~Virginia~~New Jersey	~~23175~~08105	(856) 757-0200
~~Mars Hill~~Montclair Pharmacy~~ Inc~~	~~106 Main Street~~732 Valley Road	~~Mars Hill~~Upper Montclair	~~Maine~~New Jersey	~~04758~~07043	(973) 744-2113
~~Martin Tipton~~Morris Plains Pharmacy ~~Hillside~~	~~5901 Bell Street Unit 30~~712 Speedwell Avenue	~~Amarillo~~Morris Plains	~~Texas~~New Jersey	~~79109-6263~~07950-2231	(973) 539-3635
~~Martin Tipton~~Newport Pharmacy~~ LLC~~	~~1501 South Tyler~~165 Erie Street	~~Amarillo~~Jersey City	~~Texas~~New Jersey	~~79101~~07302	(201) 963-1903
~~Mast Family Drug~~North Warren Pharmacy and Gift	~~418 Dabney Drive~~155 Route 94	~~Henderson~~Blairstown	~~North Carolina~~New Jersey	~~27536~~07825	(908) 362-5156 Ext 4
~~Mast~~Novecks Pharmacy	~~307 West Boulevard~~7823 Bergenline Avenue	~~Williamston~~North Bergen	~~North Carolina~~New Jersey	~~27892~~07047-4996	(201) 869-1235
~~Mathes~~Olssons Pharmacy	~~1621 Charlestown Road~~576 Lafayette Ave	~~New Albany~~Hawthorne	~~Indiana~~New Jersey	~~47150~~07506-2400	(973) 427-1700
~~Matthews Pharmacy~~Paramount Drug	~~101 Canal St~~54 East Scott Street	~~Ellenville~~Riverside	New ~~York~~Jersey	~~12428-1400~~08075	(856) 461-0953
Parkview Pharmacy	1430 Queen Anne Rd	Teaneck	New Jersey	07666-3518	(201) 837-6368
PERFECT CARE PHARMACY	1727 JOHN F KENNEDY BLVD	Jersey City	New Jersey	07305	(201) 984-2585
~~Mauch Chunk~~Peter Pan Pharmacy	~~1204 North Street~~2125 Park Avenue	~~Jim Thorpe~~South Plainfield	~~Pennsylvania~~ New Jersey	~~18229~~07080	(908) 754-7607
~~Maui Clinic~~ Pharmacy Town	~~22 Hana Hwy, Suite B~~1590 State Highway 35	~~Kahului~~Ocean	~~Hawaii~~New Jersey	~~96732~~07712	(732) 493-5100
~~Max Brown~~Plumsted Pharmacy	~~809 North Jefferson Street~~28 Brindletown Road	~~Dublin~~New Egypt	~~Georgia~~New Jersey	~~31021~~08533	(609) 758-8829
Plymouth Park Pharmacy Inc	11 12 Saddle River Road	Fair Lawn	New Jersey	07410	(201) 797-0006
Preston Drugs & Surgicals	127 Hawkins Place	Boonton	New Jersey	07005	(973) 334-3460
Princeton Pike Rx LLC	3100 Princeton Pike Suite 4B	Lawrenceville	New Jersey	08648-2376	(609) 450-3740
~~Max Discount~~Quick	~~4531 Highway 58 Suite 105~~100	~~Chattanooga~~Millstown	~~Tennessee~~New Jersey	~~37416~~08850	(732) 745-7222

Mart Pharmacy	Ryders Lane				
MaxwellRaritan Valley Pharmacy	626 North Highway 1551055 Route 202 N	FrankstonBranchburg	TexasNew Jersey	757630 8876	(908) 429-5544
Max WellReading Ridge Pharmacy Services	375 West Street8 Reading Road, Suite 206	WarminsterFlemington	PennsylvaniaNew Jersey	189740 8822	(908) 782-7576
MayflowerReef Family Pharmacy	616B Highway 3651037 S Route 9	MayflowerCape May Court House	ArkansasNew Jersey	721060 8210	(609) 465-0004
Mayson'sRichards Pharmacy	4199 F1 Winchester Road207 Broad Avenue	MarshallPalisades Park	VirginiaNew Jersey	20115-3 26907650	(201) 944-0863
Maysville OB/GYN Family Health CenterRiverview Pharmacy	927 Kenton Station Drive2405 Hamburg Turnpike Suite C	MaysvilleWayne	KentuckyNew Jersey	410560 7470	(973) 831-4080
McBain FamilyRobinson Wellness Pharmacy	119 North Roland Street27 E Main St	Mc BainMendham	MichiganNew Jersey	496570 7945-1505	(973) 543-2525
S.RESES PHARMACY	269 West White Horse Pike	Pomona	New Jersey	08240	(609) 965-3600
McCarthyScott Drugs	12025 San Vincete Blvd.701 Park Avenue	Los AngelesPlainfield	CaliforniaNew Jersey	900490 7060	(908) 754-1600
Mccays TotalSiegels Pharmacy	260 Boggs Lane1201 S Broad St	RichmondTrenton	KentuckyNew Jersey	40475-2 591086 10-6231	(609) 394-8111
McCaysville Drug Center IncSILVERTON PHARMACY	131 Blue Ridge Drive1824 Hooper Avenue	McCaysvilleToms River	GeorgiaNew Jersey	305550 8753	(732) 255-3121
McCoy Tygart Drug Store IncSkaff's Corner Pharmacy	821 North Rock1112 Saint Georges Avenue	SheridanRahway	ArkansasNew Jersey	721500 7065	(732) 381-4144
McDowellsSomerset Park Pharmacy	1004 Main Street900 Easton Avenue Suite 26	Scotland NeckSomerset	North CarolinaNew Jersey	278740 8873	(732) 846-6666
McFaddenSpringview Pharmacy	115 East Main Street4 Elmwood Avenue	BainbridgeIrvington	OhioNew Jersey	456120 7111	(973) 372-1300
McGuffee DrugTHE ROBBINS PHARMACY	102 North Main Street2108 PENNINGTON RD	MendenhallTRENTON	MississippiNew Jersey	391140 8638-1498	(609) 882-2404
McGuire ParkTiffany Natural Pharmacy	2106 East Main Street1115 South Avenue West	RichmondWestfield	VirginiaNew Jersey	232230 7090	(908) 233-2200
McHaney Drug P.A.Twin City Pharmacy	1400 West Hunt Street1708 Park Avenue	ParagouldSouth Plainfield	ArkansasNew Jersey	72450-3 57407080	(908) 755-7696
McKinneyUnion Avenue Legend	1601433 West	McKinneyBound Brook	TexasNew Jersey	750690 8805	(732) 356-3113

Pharmacy	~~University Drive~~Union Avenue				
~~McMinnville Drug Center~~Valley Pharmacy	~~1500 Sparta~~75 Washington Valley Road	~~McMinnville~~Bedminster	~~Tennessee~~New Jersey	~~371100~~7921	(908) 658-4900
~~Meadowbrook~~Value Mart Pharmacy	~~6624 Meadowbrook Drive~~314 Main Street	~~Fort Worth~~Orange	~~Texas~~New Jersey	~~761120~~7050	(973) 676-0866
~~Mears~~Village Pharmacy	~~1050 Shepard Lane~~1278 Yardville Allentown Rd Suite ~~1~~5	~~Farmington~~Allentown	~~Utah~~New Jersey	~~84025-2716~~08501	(609) 259-2202
~~Med-Care Infusion Services~~	~~3085 West 80th Street~~	~~Hialeah~~	~~Florida~~	~~33018~~	
~~Medcenter~~West Milford Pharmacy	~~1419 East Bustamante Street~~1495 Union Valley Road	~~Laredo~~West Milford	~~Texas~~New Jersey	~~780410~~7480	(973) 728-1400
~~Medcenter~~Westminster Pharmacy	~~7210~~577 North ~~Main~~Broad Street~~, Suite 102~~	~~Clarkston~~Elizabeth	~~Michigan~~New Jersey	~~483460~~7208	(908) 352-7111
~~MED EXPRESS PHARMACY~~	~~212 South Mayo Trail~~	~~Paintsville~~	~~Kentucky~~	~~41240~~	
~~Medical Arts~~CHRISTUS St. Vincent Outpatient Pharmacy	~~4417 Bee Ridge Road~~465 Saint Michaels Drive Suite 112	~~Sarasota~~Santa Fe	~~Florida~~New Mexico	~~342338~~7505-7621	(505) 913-5000
~~Medical Arts~~Fairview Pharmacy	~~1320 Maricopa Highway~~734 N Riverside Dr	~~Ojai~~Espanola	~~California~~New Mexico	~~930238~~7532	(505) 753-2209
FarmaKeio NM	2100 Louisiana Blvd NE Suite 460	Albuquerque	New Mexico	87110-5419	(505) 705-3540
Kare Drug #4	100 North Church Street, Suite A	Bloomfield	New Mexico	87413	(505) 632-3324
~~Medical Arts Pharmacy~~Kare Drug - Aztec	~~2102 Pecos~~100 Llano Street	~~San Angelo~~Aztec	~~Texas~~New Mexico	~~769018~~7410	(505) 334-6411
~~Medical Arts~~La Tienda Pharmacy	~~300~~1301 South ~~8th~~Canal Street	~~Murray~~Carlsbad	~~Kentucky~~New Mexico	~~420718~~8220	(575) 628-0637
~~Medical Arts~~Mesilla Valley Pharmacy ~~Inc~~& Consulting	~~650 North Cobb Street~~4119 White Sage Arc Suite F	~~Milledgeville~~Las Cruces	~~Georgia~~New Mexico	~~310618~~8011	(575) 323-2093
~~Medical Associates~~Mt Cristo Pharmacy LLC	~~120 South Story Street~~1155 Mcnutt Rd Suite 110	~~Boone~~Sunland Park	~~Iowa~~New Mexico	~~500368~~8063-9175	(575) 332-9393
Nowell Pharmacy LLC	122 W Adams	Lovington	New Mexico	88260	(575) 396-4242
~~Medical Center~~Pinon	~~1050~~2300 East ~~South Temple~~30th	~~Salt Lake City~~Farmington	~~Utah~~New Mexico	~~841028~~7401	(505) 327-4826

Family Pharmacy	Street, Suite B-101				
Medical CenterRoden-Smith Pharmacy	312 Marion Avenue305 E Llano Estacado Boulevard	Mc CombClovis	MississippiNew Mexico	396488101	(575) 762-3848
Medical CenterRoute 66 Pharmacy	805 LONG DR117 Camino de Vida Suite 200	ROCKINGHAMSanta Rosa	North CarolinaNew Mexico	283798435	(575) 472-5666
Medical CenterSierra Blanca Pharmacy	1010 Medical Center1206 Mechem Drive	PowderlyRuidoso	KentuckyNew Mexico	423678345	(575) 258-2456
Medical Center Prescription Shop	710 Medical Center Drive	Eastman	Georgia	31023	
Medical Mall86th Street Community Pharmacy Corp	9 Hosptial Drive Suite B32789 86th Street	Toms RiverBrooklyn	New JerseyYork	0875511223	(718) 266-2137
Medical Park90th Street Pharmacy	1503 Slate Creek Road1262 Madison Ave	GrundyNew York	VirginiaNew York	24614101280590	(212) 289-9168
Medical ParkAliton's Pharmacy Home Healthcare Centers	2406 Bellevue Road12 Sussex St	DublinPort Jervis	GeorgiaNew York	31021127712253	(845) 856-8314
ASG Rx Corp	10216 Liberty Avenue	Ozone Park	New York	11417	(347) 960-8788
Medical ParkBaldwin Pharmacy LLC	921 LONG DRIVE1927 Grand Avenue	ROCKINGHAMNorth Baldwin	North CarolinaNew York	283791151028 18	(516) 544-4454
Medical PavilionBBRx Pharmacy	9460 No Name Uno Suite 1006013 7th Avenue Unit B	GilroyBrooklyn	CaliforniaNew York	95020111220	7184390502
Better Health Rx Corp	503 W 125th St	New York	New York	10027-3402	(212) 222-8600
Big Apple Rx Inc	220 Saint Nicholas Avenue	New York	New York	10027-6237	(646) 609-6300
Castle Hill Drugs Inc	674 Castle Hills Avenue	Bronx	New York	10473	(718) 239-5400
MedicalCentral Valley Pharmacy	1213 Main Street228 Route 32, Suite 103	WillimanticCentral Valley	ConnecticutNew York	06226109917	(845) 928-1117
Medical PlazaConfucius Pharmacy	615 North Third7 Bowery Street, Suite 1Store #A-104	LongviewNew York	TexasNew York	75601110002	(212) 966-4420
Medical VillageCorona Pharmacy Inc	517 Lauchwood Road10409A Corona Avenue	LaurinburgCorona	North CarolinaNew York	28352113682923	(718) 685-2388
Medi CenterCrystal Run Pharmacy	1262 Boston Road731 Route 211 E Ste 108	BronxMiddletown	New York	10456110941	(845) 692-7628
Medicine And MoreDrug Loft Pharmacy	100 Fort Jefferson1408 Madison Avenue	GreenvilleNew York	OhioNew York	45331110029	(212) 996-9499

Drug Shoppe Llc	2074 8th Ave	New York	New York	10026	(212) 222-3652
Drug World #28	55 Chestnut St	Cold Spring	New York	10516	(845) 265-6352
MEDICINE CABINETELTON PHARMACY	230 STATE HIGHWAY 22992 FULTON ST	OLIVE HILLBrooklyn	KentuckyNew York	41164112 08	(718) 827-8943
Medicine Center of Canton	2526 West Tuscarawas Street	Canton	Ohio	44708	
Medicine CenterEsther Pharmacy	251 East Street71 South Broadway	MinervaYonkers	OhioNew York	44657107 01-4004	(914) 965-2661
Medicine CenterFalak Pharmacy	551 West High Avenue2730 E Tremont Ave	New PhiladelphiaBronx	OhioNew York	44663104 61-2877	(718) 597-5230
Medicine CenterFranklin Pharmacy	700 West Main Street94-31 59th Ave	LouisvilleElmhurst	OhioNew York	44641113 73-5168	(718) 592-7200
Medicine ChestFrederick Community Pharmacy	814 Montgomery Road2450 Frederick Douglas Boulevard	GrahamNew York	TexasNew York	76450100 29	(212) 690-5202
Medicine Man AtholFreds Granville Pharmacy	30585 North Roberts Road75 Quaker Street	AtholGranville	IdahoNew York	83801128 32	(518) 642-3733
Medicine Man Bonners Ferry Pharmacy	6452 Main Street	Bonners Ferry	Idaho	83805	
Medicine Man HaydenGotham Pharmacy Inc	240 West Hayden2258 3rd Avenue	HaydenNew York	IdahoNew York	83835100 35	(212) 289-7800
Medicine Man North Pharmacy	305 West Kathleen Avenue	Coeur D' Alene	Idaho	83815	
Medicine ManHazard's Pharmacy	748 North290 Main Street	North BendCornwall	NebraskaNew York	68649125 18-1579	(845) 534-4345
MEDICINE MAN PHARMACY	526 NORTH LINDEN STREET	WAHOO	Nebraska	68066	
Medicine ManHealthcare Pharmacy	122 WEST 16TH STREET1825 Madison Avenue	SCHUYLERNew York	NebraskaNew York	68661100 35	(212) 369-5555
Medicine ManHealth Max Pharmacy	15615 Pacific Street Suite 880-07 Jamaica Avenue	OmahaWoodhaven	NebraskaNew York	68118114 21	(718) 296-0400
Medicine Man PrairieHealth Source Plus Pharmacy, LLC	8093 Cornerstone Drive118-07 Metropolitan Avenue	HaydenKew Gardens	IdahoNew York	83835114 15	(718) 849-6700
Medicine Man RathdrumHicksville Pharmacy	15837 North Westwood Drive495 South Broadway Unit 16	RathdrumHicksville	IdahoNew York	83858118 01	(516) 396-0608
Medicine Man	805 East	Post FallsHolbrook	IdahoNew	838541	(631) 585-7092

SouthwestHolbrook Pharmacy & Surgical	Polston233 Union Avenue		York	1741	
Medicine Man WestHudson Pharmacy	802 East Medical Court40 Spring Street	Post FallsOssining	IdahoNew York	838541 0562	(914) 941-4476 Ext 121
Hylan Medicine Mart of West ColumbiaCabinet	1300 Sunset1988 Hylan Boulevard	West ColumbiaStaten Island	South CarolinaNew York	291691 0306	(718) 667-4300
Medicine MartIslip Pharmacy and Surgical	1401437 Main Street	ConwayIslip	South CarolinaNew York	295261 1751	(631) 581-8077
Medicine MaxxJ Drugs	646 South Dillard Street1205 Avenue J	Winter GardenBrooklyn	FloridaNew York	347871 1230	(718) 258-6686
Medicine PlusJ Drugs II	2412 West 16th Street3402 Avenue N	BedfordBrooklyn	IndianaNew York	474211 1234	(718) 258-5858
Medicine Stop	1544 Watson Boulevard	Warner Robins	Georgia	31093	
MedicJ RX Pharmacy	306 North Reynolds6515 Fresh Pond Road	BryantRidgewood	ArkansasNew York	720221 1385	(718) 366-0626
MedipharmK & K Pharmacy	197 Sand Island Access Road, Suite 208187 Mill Street	HonoluluLiberty	HawaiiNew York	96819-4901127 54	(845) 292-3430
Medipharm Pharmacy	891 Ululani Street Suite 113	Hilo	Hawaii	96720	
Medi Quik PharmacyKingsbay Chemists Inc.	810 West Commercial Street3610 Nostrand Avenue	OzarkBrooklyn	ArkansasNew York	729491 1229	(718) 891-3447
Medi QuikKoblin's Pharmacy	1531 East96 Main Street	BoonevilleNyack	ArkansasNew York	729271 0960	(845) 358-0688
MediSaveKruticks Pharmacy	1023A West Dekalb589 Crescent Street	CamdenBrooklyn	South CarolinaNew York	290201 1208	(718) 277-0573
Medi-SaveLaurelton Pharmacy	800 South Slappey22412 Merrick Boulevard	AlbanyLaurelton	GeorgiaNew York	317011 1413	(718) 977-0700
Medisav HomecareLenox Pharmacy	621 East Main Street27 Lenox Avenue	CharlestonNew York	ArkansasNew York	729331 0026	(212) 678-9722
Lenox Terrace Drug	20 West 135th Street	New York	New York	10037	(212) 234-2050
Medisav Mannings 8th Ave Pharmacy #2	8820 Rogers6402 8th Avenue Suite G103	Fort SmithBrooklyn	ArkansasNew York	729031 1220	(718) 238-3850
Medisav Pharmacy #3	1910 S Zero St., Suite A	Fort Smith	Arkansas	72901	
MediThriftMatthews Pharmacy	324 West Patton Street101 Canal St	LafayetteEllenville	GeorgiaNew York	307281 2428-1400	(845) 647-6222

MedmartMedi Center Pharmacy	2618-A Memorial Boulevard1262 Boston Road	ConnellsvilleBronx	Pennsylvania New York	154251 0456	(347) 699-6006
MedRelief Pharmacy	2895 State Highway 77 South Suite 3	Marion	Arkansas	72364	
Medrite Pharmacy	7316 Roosevelt Ave	JACKSON HEIGHTS	New York	11372-6 336	(917) 832-6035
Med Rx	620 National Rd Suite 400	Wheeling	West Virginia	26003	
Med-Rx Pharmacy and Compounding	1031 East Vista Way	Vista	California	92084	
MEDS	1104 2ND AVENUE	NEW YORK	New York	10022-2 007	(212) 371-6000
Medsurg PharmacyMiddlepo rt Family Health Center	3037 Marshall Hall81 Rochester Road	Bryans RoadMiddleport	MarylandNew York	20616-3 240141 05	(716) 735-3261
MedWorksMiddlet own Pharmacy	2123 Intelliplex Drive149 Wickham Avenue	ShelbyvilleMiddleto wn	IndianaNew York	46176-8 538109 40	(845) 342-5566
Medz DirectNaples Apothecary Inc	1065 Northeast 125th129 South Main Street Suite 207	MiamiNaples	FloridaNew York	331611 4512-95 74	(585) 374-5040
NEVINS DRUGS	739 Fulton St	Brooklyn	New York	11217	(718) 422-0100
MeijiNew Age Pharmacy	1630 West Redondo Beach Boulevard, Suite 142918 Avenue J	GardenaBrooklyn	CaliforniaNew York	902471 1210	(718) 253-1700
Memorial Medical CenterNew York Ave Pharmacy	9806 Venice Boulevard3424 Church Avenue	Culver CityBrooklyn	CaliforniaNew York	902321 1203	(718) 856-8048
Ocean Breeze Pharmacy	1817 Hylan Boulevard	Staten Island	New York	10305-1 918	(718) 987-2525
Mendocino CoastPalmer Pharmacy	350 Cypress2 East Main Street	Fort BraggJohnstown	CaliforniaNew York	95437-5 408120 95	(518) 762-8319
Mercy Family Pharmacy Clear Lake	1410 6th Avenue South Suite 200	Clear Lake	Iowa	50428	
Mercy Family Pharmacy - Greene	104 East Traer Street	Greene	Iowa	50636	
MercyOne FOREST PARK PHARMACY	1010 4th Street Southwest Suite 110	Mason City	Iowa	50401	
MercyOne NorthwoodParkdal e Pharmacy	98 North 10th Street945 Rosedale Road	NorthwoodValley Stream	IowaNew York	50459-1 438115 81	(516) 791-6500
Pine Plains Pharmacy, Inc.	2965 Church St	Pine Plains	New York	12567-5 547	(518) 398-5588
MercyOne RegencyPlus	621 South Illinois5223 7th	Mason CityBrooklyn	IowaNew York	504011 1220	(718) 851-0817

Pharmacy	Avenue Suite 101				
MercyOne Sheffield PharmacyPrescription Center	115 Gilman296 Route 59	SheffieldTallman	IowaNew York	504751 0982	(845) 368-9700
MercyOne Westside PharmacyPrescription Center of Ossining	910 North Eisenhower162 Croton Avenue	Mason CityOssining	IowaNew York	504011 0562	(914) 941-1661
Prescription Centre & Surgicals	35H Middle Country Road	Coram	New York	11727	(631) 698-2868
Queens Drugs & Surgical	146-14 Jamaica Avenue	Jamaica	New York	11435	(718) 297-0099
Queens Drugs & Surgical	80-04 Baxter Avenue	Elmhurst	New York	11373	(718) 457-0099
MeridianRidgewood Pharmacy	1110 E Pleasant Run Rd STE A389 Onderdonk Avenue	DesotoRidgewood	TexasNew York	751151 1385	(718) 381-3622
MeritRosebank Pharmacy	2464 North State Road 7500 Tompkins Ave	Lauderdale LakesStaten Island	FloridaNew York	333131 0305-1798	(718) 727-0426
Meritus Medical Center	11116 Medical Campus Rd Ste 2460	Hagerstown	Maryland	21742-6700	
MesaRossi Pharmacy	25140 East Highway 501891 Eastern Parkway	PuebloBrooklyn	ColoradoNew York	810061 1233	(718) 346-2506
MesickRx Box Pharmacy	112 Mesick3265 Richmond Avenue	MesickStaten Island	MichiganNew York	496681 0312-2123	(718) 500-3269
Mesilla ValleyRye Beach Pharmacy & Consulting	4119 White Sage Arc Suite F464 Forest Ave	Las CrucesRye	New MexicoYork	880111 0580-3645	(914) 967-0856
MetcalfeSaldo Drugs	115 East Stockton Street384 Graham Avenue	EdmontonBrooklyn	KentuckyNew York	421291 1211	(718) 389-8015
MexicareSchultz Pharmacy	9670 Magnolia150 West Railroad Avenue Suite 107	RiversideGarnerville	CaliforniaNew York	92503-3684109 23	(845) 429-5075
MexicareSouth Fulton Pharmacy Inc.	3200 West 26th Street301 S Fulton Ave	ChicagoMount Vernon	IllinoisNew York	606231 0553-1715	(914) 667-7772
MeyerSt. George Pharmacy	110 10th Street Southwest99 Stuyvesant Place	WaverlyStaten Island	IowaNew York	506771 0301	(718) 447-0333
Mickey FineStony Point Pharmacy	433 North Roxbury69 South Liberty Drive	Beverly HillsStony Point	CaliforniaNew York	90210-4280109 80	(845) 942-1373
Mickey FineSuper Health Pharmacy & Snack Shop	2000 AVENUE OF THE STARS6390 Amboy Road	LOS ANGELESStaten Island	CaliforniaNew York	90067-4700103 09	(718) 967-4600

Mid-CityThe Medicine Cabinet Pharmacy	196 East273 New Main Street	CantonYonkers	GeorgiaNew York	30114107701-1318	(914) 377-2334
Middleport Family Health CenterTower Drugs	81 Rochester Road272-68 Grand Central Parkway	MiddleportFloral Park	New York	14105110005	(718) 631-9300
Middletown FamilyTriangle Pharmacy	877 Main Street119-01 Jamaica Avenue	BelfordRichmond Hill	New JerseyYork	07718-2001114 18	(718) 847-9850
MiddletownTruCare Pharmacy	149 Wickham Avenue358 Route 202 North	MiddletownPomona	New York	10940109 70	(845) 364-5300
Upper Eastside Chemists INC	855 Lexington Avenue #1	New York	New York	10065	(212) 734-5678
Middle VillageV-Care Pharmacy Inc	393 Piaget Avenue59 East Eckerson Rd	CliftonSpring Valley	New JerseyYork	07011109 77	(845) 371-2018
Village Drug	126 Main St	Penn Yan	New York	14527	(315) 536-0100
Washingtonville Pharmacy	32 West Main Street Unit 2	Washingtonville	New York	10992	(845) 496-8001
MidtownWater Street Pharmacy	2660 Buena Vista Road Suite A14 Water St	ColumbusDundee	GeorgiaNew York	31906148 37-10 86	(607) 243-8114
MidtownWellness Pharmacy	581 Kearny Avenue144 West 72nd Street	KearnyNew York	New JerseyYork	07032100 23-33 44	(212) 439-4718
West Hempstead Pharmacy	449 Hempstead Avenue	West Hempstead	New York	11552	(516) 292-6161
West Islip Pharmacy	432 Montauk Highway	West Islip	New York	11788	(631) 482-9209
Wurlitzer Family Pharmacy Inc	521 DIVISION ST	NORTH TONAWANDA	New York	14120-4403	(716) 260-1131
MidtownAdler Pharmacy-Express	5003806 A North MainChurch Street	Beaver DamGreensboro	KentuckyNorth Carolina	42320274 05	(336) 897-3810
Archdale Drug Co Inc	11220 North Main St	Archdale	North Carolina	27263	(336) 434-2776
Mid ValleyAsheville Discount Pharmacy	400 E EXPRESSWAY 8376 Patton Ave	MercedesAsheville	TexasNorth Carolina	78570288 01	(828) 258-8511
Avery Pharmacy & Health Care	436 Hospital Drive	Linville	North Carolina	28646	(828) 737-7476
Mike'sB & B Pharmacy	180 South Holmes Avenue462 Haywood Rd	Idaho FallsAsheville	IdahoNorth Carolina	83401288 06	(828) 252-2718
Banner Drug Co	308A Mocksville Highway	Statesville	North Carolina	28625	(704) 878-6681
Banner Drug of Harmony	111 West Memorial Highway	Harmony	North Carolina	28634-0436	(704) 546-5885
Banner Elk Pharmacy	110 Park Avenue	Banner Elk	North Carolina	28604	(828) 898-4271
MilbridgeBayboro Pharmacy	11702 Main StreetSt	MilbridgeBayboro	MaineNorth Carolina	04658-0458285	(252)745-5539

				15	
~~Miller's Drug~~Beach Pharmacy of Avon	~~231 South Main~~41934 Highway 12	~~Malvern~~Avon	~~Arkansas~~North Carolina	~~72104~~27915	(252) 995-3811
Beach Pharmacy of Hatteras	57353 Highway 12	Hatteras	North Carolina	27943	(252) 986-2400
Boone Drug and Health Care	345 Deerfield Road	Boone	North Carolina	28607	(828) 264-3055
Boone Drug at Greenway	579 Greenway Road Suite 100	Boone	North Carolina	28607	(828) 355-3350
Boone Drug at King Street	202 W King St	Boone	North Carolina	28607-3516	(828) 264-8929
Boone Drug at New Market	245 New Market Center	Boone	North Carolina	28607	(828) 264-9144
~~Miller~~Carrboro Family Pharmacy	~~206 North Broadway Street~~104 Hwy 54 W Bypass Unit J Carrboro Plz	~~Union City~~Carrboro	~~Michigan~~North Carolina	~~49094~~27510	(919) 933-7629
~~Millers~~Carroll Pharmacy	~~420 South Detroit Street~~840 S Brightleaf Blvd	~~Lagrange~~Smithfield	~~Indiana~~North Carolina	~~46761~~27577-4377	(919) 934-7164
~~Millington~~Cashiers Valley Pharmacy	~~4729 Main Street~~52 Cashiers Shopping Center Highway 64 East	~~Millington~~Cashiers	~~Michigan~~North Carolina	~~48746~~28717	(828) 743-3114
~~Mills Pharmacy & Apothecary~~	~~1744 West Maple Suite A~~	~~Birmingham~~	~~Michigan~~	~~48009~~	
~~Mill Street~~Crossroads Pharmacy	~~10639 Alabama~~7605-B NC Highway ~~168~~68 North	~~Boaz~~Oak Ridge	~~Alabama~~North Carolina	~~35957~~27310	(336) 441-4041 Ext 1
~~Ming & H Drugs~~Deep River Drug	~~1717 MING AVE~~2401 B Hickswood Dr	~~BAKERSFIELD~~High Point	~~California~~North Carolina	~~93304-4595~~27265	(336) 454-3784
Dempsey's Drugs Jackson Heights	2717 NC Highway 11/55	Kinston	North Carolina	28504	(252) 686-5295
Dempsey's Drugs La Grange	603 East Washington Street	La Grange	North Carolina	28551	(252) 582-3600
~~Ming Plaza Pharmacy~~DREXEL DISCOUNT DRUG, LLC	~~2726 Ming Avenue Suite A~~2728 Highway 70 East	~~Bakersfield~~Morganton	~~California~~North Carolina	~~93304~~28655	(828) 433-6777
~~Minsky Drug Store~~DrugCare Pharmacy	~~405 Lake~~132 Whitfield Street	~~Lake Providence~~Enfield	~~Louisiana~~North Carolina	~~71254~~27823	(252) 445-3414
East Burke Pharmacy, Inc.	300 Main Avenue West	Hildebran	North Carolina	28637	(828) 397-3420
Eastover Drug	3591 Dunn Road	Eastover	North Carolina	28312	(910) 483-4555
~~Mission Medical~~Family Pharmacy	~~27800 Medical Center~~2124 Fayetteville Road	~~Mission Viejo~~Rockingham	~~California~~North Carolina	~~92691-6410~~28379	(910) 895-7775

	Suite 99E				
MissionFriendly Pharmacy	926 South Mission Street3712-G Lawndale Drive	Mount PleasantGreensboro	MichiganNorth Carolina	488582 7455	(336) 790-7343
MissoulaGalloway-Sands Pharmacy, Inc. #2	1211 South Reserve1513 North Howe Street, Suite 1028	MissoulaSouthport	MontanaNorth Carolina	598012 8461	(910) 454-9090
Misty'sGibsonville Pharmacy	149 Northwest Broad Street220 Burlington Avenue	JesupGibsonville	GeorgiaNorth Carolina	315452 7249	(336) 449-5501
Mitch'sGuys Family Pharmacy Inc	5 East Coffee817 Randolph Street	HazlehurstThomasville	GeorgiaNorth Carolina	315392 7360	(336) 476-5632
Mitchell's Main Street PharmacyHalsey Drug Company	214 EAST MAIN STREET55 South Main Street	Mountain ViewSparta	ArkansasNorth Carolina	725602 8675	(336) 372-5599
Mitchell's Medi MartHealth Care Connections	1523402 South Main Street Suite 100	HopeRaeford	ArkansasNorth Carolina	718012 8376	(910) 848-0630
Health Park Pharmacy	8300 Health Park Suite 227	Raleigh	North Carolina	27615	(919) 847-7645
Mitchell's Park StreetHealthridge Pharmacy	526 Park St. PO Box 5693130 US 70 Highway	Calico RockBlack Mountain	ArkansasNorth Carolina	725192 8711	(828) 669-9970
Hermitage Pharmacy	1509 South Cannon Boulevard	Kannapolis	North Carolina	28083	(704) 298-0435
Hogan's Pharmacy	815 West Front Street	Lillington	North Carolina	27546	(910) 893-4544
Moffet DrugHospital Drive Pharmacy	102 South State409 Altapass Road	NortonSpruce Pine	KansasNorth Carolina	676542 8777	(828) 765-2025
Island Pharmacy	210 South Highway 64	Manteo	North Carolina	27954	(252) 473-5801
MonahansIsland Pharmacy	801 East 4th Street2181-A Old Mountain Rd	MonahansStatesville	TexasNorth Carolina	797562 8625	(704) 873-0000
Jefferson Drug Store	418 East Main Street	Jefferson	North Carolina	28640	(336) 246-9492
MonroeKim's Pharmacy	2507 Monroe Street479 Dellwood Rd	DearbornWaynesville	MichiganNorth Carolina	481242 8786	(828) 452-2313
MonroeKing's Pharmacy	4122 Monroe Street16 Wayne Brooks Lane	ToledoHayesville	OhioNorth Carolina	436062 8904	(828) 516-9950
King's Pharmacy	30 Peachtree Street	Murphy	North Carolina	28906	(828) 837-7474
Montclair PharmacyKING DRUG CO LLC	732 Valley Road142 SOUTH MAIN STREET	Upper MontclairKING	New JerseyNorth Carolina	070432 7021-0426	(336) 983-3147
Kinston Clinic Pharmacy North	701 Doctors Drive Suite P	Kinston	North Carolina	28501	(252) 523-3187

~~Montebello Professional Pharmacy~~LAKESIDE PHARMACY	~~265 East Beverly Boulevard, Suite~~9615 SHERRILL ESTATES ROAD SUITE B	~~Montebello~~HUNTERSVILLE	~~California~~North Carolina	~~90640~~28078	(980) 441-8600
Lakeside Specialty Pharmacy	480 River Highway, Suite A	Mooresville	North Carolina	28117-6958	(704) 360-2029
~~Montpelier Pharmacy~~Mabrys Drug Store	~~17128 Mountain Road~~41 West Main Street	~~Montpelier~~Hamlet	~~Virginia~~North Carolina	~~23192~~28345	(910) 582-1776
~~MOONS PHARMACY INC~~Madison Pharmacy & Gifts Inc	~~717 2ND ST W~~4401 US HWY 25 70	~~TIFTON~~MARSHALL	~~Georgia~~North Carolina	~~31794-4201~~28753	(828) 380-6527
~~Moore Family~~Madison Pharmacy ~~Allegan~~and Homecare	~~100 Monroe~~125 West Murphy Street~~, Suite B~~	~~Allegan~~Madison	~~Michigan~~North Carolina	~~49010~~27025	(336) 548-0049
~~Moore Family~~Market Street Pharmacy ~~Hamilton~~	~~3416 Michigan Route 40~~1612 Market Street	~~Hamilton~~Wilmington	~~Michigan~~North Carolina	~~49419~~28401	(910) 763-0845
~~Moore~~Mast Family ~~Pharmacy South Haven~~Drug	~~08337 M 140 Unit 2~~418 Dabney Drive	~~South Haven~~Henderson	~~Michigan~~North Carolina	~~49090~~27536	(252) 438-4158
Mast Pharmacy	307 West Boulevard	Williamston	North Carolina	27892	(252) 792-1015
~~Moores~~McDowells Pharmacy	~~200 South Rachal~~1004 Main Street	~~Sinton~~Scotland Neck	~~Texas~~North Carolina	~~78387~~27874	(252) 826-4137
~~Moore Than Medicine~~Medical Arts Pharmacy of Lenoir	~~105 Southwest 2nd Street~~202 Harper Ave NW Suite A	~~Tulia~~Lenoir	~~Texas~~North Carolina	~~79088~~28645-5196	(828) 758-2356
Medical Center Pharmacy	805 S Long Dr	Rockingham	North Carolina	28379	(910) 997-4471
Medical Park Pharmacy	921 S Long Dr Suite 105	Rockingham	North Carolina	28379	(910) 417-3490
Medical Village Pharmacy	517 Lauchwood Rd	Laurinburg	North Carolina	28352-5595	(910) 276-1154
Moose Drug Company	8374 West Franklin Street	Mount Pleasant	North Carolina	28124	(704) 436-9613
Moose Pharmacy of Kannapolis	1113 North Main Street	Kannapolis	North Carolina	28081	(704) 932-9111
Moose Pharmacy of Locust	1750 West Main Street	Locust	North Carolina	28097	(704) 888-2114
Moose Pharmacy of Monroe	215 East Jefferson Street	Monroe	North Carolina	28112	(704) 283-8131
Moose Pharmacy of Mt. Holly	125 West Central Avenue	Mount Holly	North Carolina	28120	(704) 827-2211

Moose Pharmacy of Salisbury	1408 West Innes Street	Salisbury	North Carolina	28144	(704) 636-6340
Moose Professional Pharmacy	270 Copperfield Boulevard Suite 101740 Church Street N	Concord	North Carolina	28025	(704) 784-9613
Moreland & Devitt IncNorth Main Pharmacy	124901 North CongressMain Street	RushvilleMount Airy	IllinoisNorth Carolina	626812 7030	(336) 756-7855
Moreland & DevittNorth Village Pharmacy	201 South State Street1493 Main St	BeardstownYancey ville	IllinoisNorth Carolina	62618-1 219273 79	(336) 694-4104
MorgansOld Main Pharmacy	1806 FOURTH STREET407 West 3rd Street	JONESVILLEPembro ke	LouisianaNort h Carolina	713432 8372	(910) 521-5600
MorrisPharmville Drug Co	6463754 South Main Street North	PearsonFarmville	GeorgiaNorth Carolina	316422 7828-85 46	(252) 787-5990
Morrison'sPike's Pharmacy Inc	6113 Ridge Avenue2133 Shamrock Drive	PhiladelphiaCharlot te	Pennsylvania North Carolina	191282 8205	(704) 563-2286
Morris PlainsPineville Pharmacy	712 Speedwell Avenue311 South Polk Street Suite 80	Morris PlainsPineville	New JerseyNorth Carolina	07950-2 231281 34-8631	(704) 275-8791
MorristownPort City Pharmacy	925 West 4th North Street6756 Gordon Rd., Suite 130	MorristownWilmin gton	TennesseeNo rth Carolina	378142 8411-84 40	(910) 444-3300
Prescriptions Plus	703-1 East King Street	Kings Mountain	North Carolina	28086	(704) 739-4519
Prescriptions Plus	1614 West Franklin Boulevard	Gastonia	North Carolina	28052	(704) 867-3518
Price Pharmacy	110 East Bank Street	Granite Quarry	North Carolina	28072	(704) 279-2579
Morton AlwanPrice Pharmacy	419 Maxine Drive422 North Highway 29	MortonChina Grove	IllinoisNorth Carolina	615502 8023	(704) 856-2579
MoultrieProfession al Pharmacy	3690 US 1 South140 Roxboro Rd	St. AugustineOxford	FloridaNorth Carolina	320862 7565	(919) 693-8555
PSA Clinic Pharmacy	2294 US Highway 70	Swannanoa	North Carolina	28778-2 907	(828) 686-3804
MoundsvilleQwik Med Pharmacy	118 North Lafayette Avenue204 Westwood Shopping Cntr	MoundsvilleFayette ville	West VirginiaNorth Carolina	260412 8314-15 28	(910) 676-7570
Mountain ApothecaryRed Springs Old Main	834300 South Mayo TerraceMain Street	PaintsvilleRed Springs	KentuckyNort h Carolina	412402 8377-16 24	(910) 227-2425
Roan Mountain Pharmacy of Bakersville	604 South 226 Highway	Bakersville	North Carolina	28705-8 809	(828) 820-8058

Rocky Mount Medical Park Pharm	901 North Winstead Avenue Suite 100	Rocky Mount	North Carolina	27804-8760	(252) 443-7979
~~Mountain City~~Rocky Point Pavilion Pharmacy	~~1641 South Shady Street~~7910 US Highway 117 Suite 110	~~Mountain City~~Rocky Point	~~Tennessee~~North Carolina	~~37683-1641~~28457	(910) 210-2030
Roosevelt Pharmacy	1606 E Roosevelt Blvd Suite 103	Monroe	North Carolina	28112-4049	(704) 774-1313
Rowland Old Main Pharmacy	101 South Bond Street	Rowland	North Carolina	28383	(910) 422-3774
~~Mount Vernon~~Scotland Drug Company	~~115 West Spring~~140 South Main Street	~~Mount Vernon~~Laurinburg	~~Georgia~~North Carolina	~~30445~~28352	(910) 276-3001
~~Mowry Medical Pharmacy~~Seashore Drugs	~~1999 Mowry Avenue Suite 2A~~10227 Beach Drive Southwest	~~Fremont~~Calabash	~~California~~North Carolina	~~94538~~28467	(910) 579-3200
Seven Lakes Prescription Shoppe Inc	120 Mac Dougall Dr	West End	North Carolina	27376	(910) 673-7467
Spindale Drug	109 W Main Street	Spindale	North Carolina	28160	(828)286-3746
Stedman Drug Center	7445 Clinton Road	Stedman	North Carolina	28391-8901	(910) 323-4555
~~Mowry Plaza~~Sunshine Family Pharmacy	~~668 Mowry Avenue~~1187 Duck Road	~~Fremont~~Duck	~~California~~North Carolina	~~94536~~27949	(252) 715-0170
TAR HEEL DRUG	316 South Main Street	Graham	North Carolina	27253	(336) 227-2093
The Apothecary at St James	2571 ST JAMES DR UNIT 102-C	SOUTHPORT	North Carolina	28461-8201	(910) 946-7999
~~Moye's~~The Drug Store	~~162 East Railroad~~104 North Henry Street~~ South East~~	~~Pelham~~Stoneville	~~Georgia~~North Carolina	~~31779~~27408-0258	(336) 573-2200
~~MS Pharmacy~~Thomas Drugs	~~27721 Tomball Parkway Suite 400~~7917 E Oak Island Dr	~~Tomball~~Oak Island	~~Texas~~North Carolina	~~77375~~28465	(910) 278-6050
Thomas Drugs	4750 Main St	Shallotte	North Carolina	28470	(910) 754-4720
Thomas Drug Store	609 East Cumberland Street	Dunn	North Carolina	28334	(910) 892-2114
Thorne Discount Drug	2900 North Main Street	Tarboro	North Carolina	27886-1921	(252) 823-5655 Ext 124
~~Mt Carmel~~Village Pharmacy	~~111 Mount Carmel Road~~14057 Highway 17 Suite 100	~~Parkton~~Hampstead	~~Maryland~~North Carolina	~~21120~~28443	(910) 319-6050
~~Mt Cristo Pharmacy~~Warren's Drug Store, Inc	~~1155 Mcnutt Rd Suite 110~~943 South Fifth Street	~~Sunland Park~~Mebane	~~New Mexico~~North Carolina	~~88063-9175~~27302	(919) 563-3102

Warrensville Drug Store	5121 North Carolina Highway 88 West	Warrensville	North Carolina	28693	(336) 384-3900
~~Mt Pleasant Care Pharmacy~~Whispering Pines Prescription Shoppe	~~3169 Mount Pleasant Street Northwest~~7305 NC Highway 22	~~Washington~~Carthage	~~District of Columbia~~North Carolina	~~20010-2798~~28327-8512	(910) 949-3700
~~Munsey~~Your Pharmacy of Lexington	~~106 Administration Road~~100 West Third Street	~~Oak Ridge~~Lexington	~~Tennessee~~North Carolina	~~378302~~7292	(336) 249-0322
~~Munson Community Health Center Pharmacy~~BOTTINEAU CLINIC PHARMACY	~~550 Munson Avenue Suite G-100~~314 OHMER ST	~~Traverse City~~BOTTINEAU	~~Michigan~~North Dakota	~~496865~~8318	(701) 228-2220
CARRINGTON DRUG INC	415 MAIN	CARRINGTON	North Dakota	58421	(701) 652-2521
CENTRAL PHARMACY	4 8TH STREET NORTH	NEW ROCKFORD	North Dakota	58356	(701) 947-5313
CENTRAL PHARMACY INC	990 MAIN ST	CARRINGTON	North Dakota	58421	(701) 652-2651
COOPERSTOWN DRUG	901 BURREL AVE SE	COOPERSTOWN	North Dakota	58425	(701) 797-2414
Hankinson Drug	323 Main Avenue S	Hankinson	North Dakota	58041	(701) 242-7414
HILLSBORO DRUG	13 N MAIN ST	HILLSBORO	North Dakota	58045-4202	(701) 636-5231
LAKOTA DRUG	117 MAIN ST	LAKOTA	North Dakota	58344	(701) 247-2781
LANGDON COMMUNITY DRUG	805 3RD ST	LANGDON	North Dakota	58249	(701) 256-3330
LARIMORE DRUG AND GIFT INC	203 TOWNER AVE	LARIMORE	North Dakota	58251-0438	(701) 343-2461
Northport Drug	2522 Broadway N	Fargo	North Dakota	58102	(701) 235-5543
Northwood Drug	10 NORTH MAIN STREET	NORTHWOOD	North Dakota	58267	(701) 587-5271
Skips Budget Drug	2015 Library Circle #102	Grand Forks	North Dakota	58201	(701) 772-4805
~~Murrayville~~A&B Sunset Pharmacy	~~5304 Thompson Bridge Road~~4201 Sunset Boulevard	~~Murrayville~~Steubenville	~~Georgia~~Ohio	~~305644~~3952	(740) 264-1669
~~Myers Medical~~Adrien Pharmacy	~~260 Hospital Drive, Suite 111~~7023 Miami Ave	~~Ukiah~~Cincinnati	~~California~~Ohio	~~954824~~5243-2636	(513) 561-7700
~~Nantasket~~Aries Pharmacy~~ Inc~~	~~480 Nantasket Avenue~~8200 State Route 366	~~Hull~~Russells Point	~~Massachusetts~~Ohio	~~020454~~3348-9670	(937) 843-3700
~~Naples Apothecary Inc~~Arlington Pharmacy	~~129 South~~106 North Main Street	~~Naples~~Arlington	~~New York~~Ohio	~~14512-9574~~45814	(419) 365-5202
~~Naples~~Barr's	~~49 8th St N~~	~~Naples~~Xenia	~~Florida~~Ohio	~~341024~~	(937) 347-1200

Pharmacy~~ LLC~~	~~Suite A~~28 West Main			5385-2938	
~~Nashville Family~~Barr's Pharmacy of Blanchester	~~330 South~~601 West Main Street	~~Nashville~~Blanchester	~~Arkansas~~Ohio	~~718524~~ 5107-1141	(937) 625-1238
BARR'S PHARMACY OF HILLSBORO	119 South High Street	Hillsboro	Ohio	45133	(937) 840-0136
BARR'S PHARMACY OF SABINA	12459 East US Route 22 3	Sabina	Ohio	45169	(937) 584-2424
~~National~~Brewster Family Pharmacy	~~1615 Dodson~~360 North Wabash Avenue	~~Fort Smith~~Brewster	~~Arkansas~~Ohio	~~729014~~ 4613	(330) 767-3436
~~Neighborhood~~Buckeye Pharmacy	~~5701 Chestnut Street~~15549 State Route 170 Suite 1	~~Philadelphia~~East Liverpool	~~Pennsylvania~~ Ohio	~~191394~~ 3920	(330) 382-7726
~~Neil's~~C & R Pharmacy	~~512 West Franklin~~204 North Detroit Street	~~Shelton~~West Liberty	~~Washington~~Ohio	~~985844~~ 3357	(937) 650-3333
~~Nein~~Church Square Pharmacy	~~1012 Main Street~~1956 E 79th St	~~Bridgeport~~Cleveland	~~Nebraska~~Ohio	~~693364~~ 4103	(216) 721-1772
~~NEVINS DRUGS~~	~~739 Fulton St~~	~~Brooklyn~~	~~New York~~	~~11217~~	
~~New Age~~Clark LowCost Pharmacy	~~2918~~3107 Clark Avenue~~J~~	~~Brooklyn~~Cleveland	~~New York~~Ohio	~~112104~~ 4109-1145	(216) 651-8685
~~Newark~~Cleveland Lowcost Pharmacy	~~635 Market Street Unit 1C~~14529 Puritas Avenue	~~Newark~~Cleveland	~~New Jersey~~Ohio	~~07105-3618~~ 44135	(216) 476-1400
~~New Care~~COAL GROVE PHARMACY	~~12384 Palmdale Road Suite 105~~600 MARION PIKE	~~Victorville~~IRONTON	~~California~~Ohio	~~923924~~ 5638	(740) 533-2479
~~New Falls Pharmacy~~Davies Drug Inc	~~2235 Veterans Highway~~6046 Whipple Ave NW	~~Levittown~~North Canton	~~Pennsylvania~~ Ohio	~~19056-3001~~ 44720	(330) 305-9075
~~Newhard~~Davies Pharmacy #1	~~1001 Main~~2915 West Tuscarawas Street	~~Northampton~~Canton	~~Pennsylvania~~ Ohio	~~180674~~ 4708	(330) 454-5151
~~New Life~~Diamond Pharmacy	~~22149 S Dixie Highway~~503 Cadiz Road	~~Miami~~Wintersville	~~Florida~~Ohio	~~331704~~ 3953	(740) 264-6500
~~New Madrid~~Elyria Lowcost Pharmacy	~~457 Main~~401 Cleveland Street	~~New Madrid~~Elyria	~~Missouri~~Ohio	~~638694~~ 4035-6143	(440) 309-4036
Erie Drug	4502 Lewis Avenue	Toledo	Ohio	43612	(419) 476-4322
~~New Martinsville~~Ernie's Pharmacy	~~193 N STATE ROUTE 2~~54 West High Street Suite A	~~New Martinville~~London	~~West Virginia~~Ohio	~~261554~~ 3140	(740) 852-5131
~~Newport Coast~~Essentra	~~400 Newport Center~~73	~~Newport Beach~~Marengo	~~California~~Ohio	~~926604~~ 3334	(419) 253-0632

Pharmacy	Sportmans Drive Suite B				
~~Newport Lido Pharmacy LTC~~Fulton Drugs	~~351 Hospital Road, Suite 107~~1657 25th St NW	~~Newport Beach~~Canton	~~California~~Ohio	~~926634~~4709	(330) 456-2476
Garfield Lowcost Pharmacy	5050 Turney Road	Garfield Heights	Ohio	44125	(216) 510-5649
~~Newport~~Gerdes Pharmacy	~~165 Erie~~245 Main Street	~~Jersey City~~Conneaut	~~New Jersey~~Ohio	~~073024~~4030	(440) 593-2578
HealingSprings Pharmacy	2449 Ross Millville Road, Suite 185	Hamilton	Ohio	45013-8952	(513) 863-8000
~~Newton's~~Henderson Pharmacy Services	~~715~~186 West Main Street	~~Russellville~~Chillicothe	~~Arkansas~~Ohio	~~728014~~5601-3106	(740) 702-1181
Herche Bloor Pharmacy	104 East 5th Street	East Liverpool	Ohio	43920	(330) 385-0825
~~New York Ave~~Hicksville Pharmacy and Home Medical	~~3424 Church Avenue~~116 East High Street	~~Brooklyn~~Hicksville	~~New York~~Ohio	~~112034~~3526	(419) 542-6218
~~Next Dose~~Hoffmans Pharmacy	~~6802 West Hillsborough~~2323 Lake Avenue ~~Suite 12~~	~~Tampa~~Ashtabula	~~Florida~~Ohio	~~336344~~4004-3109	(440) 992-3000
~~Nicolet~~Holzer Family Pharmacy	~~15481 Commercial Road~~90 Jackson Pike	~~Lakewood~~Gallipolis	~~Wisconsin~~Ohio	~~541384~~5631	(740) 446-5236
~~Nightingale Drug~~	~~1020 12th Avenue South East~~	~~Dyersville~~	~~Iowa~~	~~52040~~	
~~Niles Wellcare~~Holzer Family Pharmacy	~~70 East Main~~280 Pattonsville Road	~~Niles~~Jackson	~~Michigan~~Ohio	~~491204~~5640	(740) 395-8870
~~Nogales~~Holzer Family Pharmacy Athens	~~18702 Colima Road Suite 103~~2131 East State Street	~~Rowland Heights~~Athens	~~California~~Ohio	~~917484~~5701	(740) 589-3181
~~Noor~~Home Town Pharmacy	~~4092 East 14 Mile~~3899 Indian Ripple Road Suite ~~200~~A	~~Warren~~Beavercreek	~~Michigan~~Ohio	~~480924~~5440	(937) 320-1500
~~Norman's Pharmacy~~Hursh Drugs	~~2105 South Day~~90 North Diamond Street	~~Brenham~~Mansfield	~~Texas~~Ohio	~~77833-5512~~44902	(419) 524-0521
IHS Pharmacy-Jamestown	4940 Cottonville Road	Jamestown	Ohio	45335-1522	(937) 675-6500
~~North Chester~~Kahler Pharmacy	~~1822 North Chester Avenue~~1941 Airport Highway	~~Bakersfield~~Toledo	~~California~~Ohio	~~933084~~3609	(419) 382-2911
~~North Columbus~~Kratzer's Hometown Pharmacy Mount Orab	~~6490 Veterans Parkway Suite B~~155 North Point Drive	~~Columbus~~Mount Orab	~~Georgia~~Ohio	~~319094~~5154	(937) 444-0135

Northern Maine Medical CenterLorain Lowcost Pharmacy	104 Main Street12940 Lorain Avenue	MadawaskaCleveland	MaineOhio	047564 4111-2612	(216) 999-7120
Northern Maine Medical CenterMcFadden Pharmacy	194115 East Main Street	Fort KentBainbridge	MaineOhio	04743-1428456 12	(740) 634-3231
Northern Pharmacy and Med EquipmentMedicine And More	6701 Harford Road100 Fort Jefferson Avenue	BaltimoreGreenville	MarylandOhio	21234-7707453 31	(937) 547-1642
Medicine Center of Canton	2526 W Tuscarawas St	Canton	Ohio	44708	(330) 455-5422
North Lake MedicalMedicine Center Pharmacy #1	5136 Hill Road 3251 East St	LakeportMinerva	CaliforniaOhio	954534 4657	(330) 868-6200
North Lake Medical Pharmacy #2	347 Lakeport Boulevard	Lakeport	California	95453	
North MainMedicine Center Pharmacy	901 North700 West Main Street	Mount AiryLouisville	North CarolinaOhio	270304 4641	(330) 875-5525
Monroe Pharmacy	4122 Monroe Street	Toledo	Ohio	43606	(419) 473-1531
North Olmsted Lowcost Pharmacy	26901 BROOKPARK ROAD EXT	NORTH OLMSTED	Ohio	44070-3176	(440) 741-7044
Northport DrugOkuley's Pharmacy Inc	2522 North Broadway102 S Main St	FargoContinental	North DakotaOhio	581024 5831-9194	(419) 596-3898
North Rialto Drug	531 East Foothill Boulevard	Rialto	California	92376	
North ScottProspect Pharmacy	225 East LeClaire Road171 South Main Street	EldridgeProspect	IowaOhio	527484 3342	(740) 494-2663
NorthsideQuays Drugs	1109 HWY 19 NORTH2 PUBLIC SQ	THOMASTONGALION	GeorgiaOhio	302864 4833	(419) 468-3044
North Sunflower Medical CenterRichwood Pharmacy	860 North Oak Avenue24 West Ottawa Street	RulevilleRichwood	MississippiOhio	387714 3344	(740) 943-2233
North ViewRoselawn Pharmacy	2121 North Robbins Drive7601 Reading Road	LaytonCincinnati	UtahOhio	840414 5237	(513) 761-1212
North VillageSaint Paris Pharmacy	1493 North Main Street122 SOUTH SPRINGFIELD STREET	YanceyvilleSAINT PARIS	North CarolinaOhio	273794 3072-0563	(937) 663-6001
North Warren Pharmacy and Gift	155 Route 94	Blairstown	New Jersey	07825	
Northwood Drug	10 NORTH MAIN	NORTHWOOD	North Dakota	58267	

	STREET				
NorwoodSand Run Pharmacy	54 Broadway40 Sand Run Rd	NorwoodAkron	MassachusettsOhio	020624 4313-6288	(330) 864-2138
Noubar's El AdobeSave Rite Pharmacy	2010 Wilshire Boulevard, Suite F-20103235 Belmont Street	Los AngelesBellaire	CaliforniaOhio	900574 3906	(740) 676-3433
Noubar's El Adobe Pharmacy Inc	5207 Hollywood Boulevard	Los Angeles	California	90027	
NovecksPharmacySheliga Drug	7823 Bergenline6025 St. Clair Avenue	North BergenCleveland	New JerseyOhio	07047-4996441 03	(216) 431-1035
NowellSt. Elizabeth's Pharmacy, LLC	122 West Adams1 Elizabeth Place Suite 1015	LovingtonDayton	New MexicoOhio	882604 5417	(937) 424-4599
NPSSt. Luke's Lowcost Pharmacy	275 Cumberland Bend11201 Shaker Boulevard Suite 126	NashvilleCleveland	TennesseeOhio	372284 4104-3833	(216) 795-4000
NuCare Pharmacy	6050 Lake Worth Boulevard	Lake Worth	Texas	76135	
NucareStewart's Pharmacy	7960 Verree Road1013 Jefferson Street	PhiladelphiaGreenfield	Pennsylvania Ohio	191114 5123	(937) 981-3245
NUEVA FARMACIA SANTA ANA	CALLE 1 B3 URBANIZACION SANTA ANA	VEGA ALTA	Puerto Rico	00692	
Nuevo Pharmacy	75 West Nuevo Road Suite H	Perris	California	92571	
Nunally Drug StoreSwisher & Lohse Pharmacy	226636 East Main Street	BaxterPomeroy	TennesseeOhio	385444 5769	(740) 992-2955
Nyes Pharmacy	1600 10th Avenue	Conway	South Carolina	29526	
O'Neill Family Pharmacy	317 East Douglas Street	Oneill	Nebraska	68763	
OakdalePharmacyThe Drug Store of Perrysburg	5400 Balboa Boulevard Suite 100580 Craig Dr Unit 12	EncinoPerrysburg	CaliforniaOhio	913164 3551	(419) 873-9100
Oaks PharmacyThe DrugStore on East State	1905 West934 E State Road 434St	LongwoodAthens	FloridaOhio	327504 5701	(740) 566-4690
Oakwood ApothecaryTOWNE PHARMACY	17 N HAMILTON ST283 Cline Ave	SULLIVANMansfield	IllinoisOhio	619514 4907	(419) 756-6032
Ocean BreezeTowne Pharmacy	1817 Hylan Boulevard849 Smith Road	Staten IslandAshland	New YorkOhio	10305-1918448 05	(419) 281-4040
Ochoa'sUptown Pharmacy Central	1002 South 10TH Avenue Suite A23	EdinburgWesterville	TexasOhio	785394 3081	(614) 882-2392

	North State Street				
OCILLA PHARMACY	515 North Irwin Avenue	OCILLA	Georgia	31774-1542	
Oconto FallsValley View Pharmacy	323 East Highland Drive11141 State Route 800 Northeast	Oconto FallsMagnolia	WisconsinOhio	5415444643	(330) 866-3380
OcontoWexler's Lake Milton Pharmacy	1008 Main Street17674 Mahoning Avenue	OcontoLake Milton	WisconsinOhio	54153-0073444 29	(330) 654-3792
OGDEN PHARMACY	2040 Ogden Avenue Suite 117	Aurora	Illinois	60504-7205	
OkolonaXtra Care Pharmacy	210 W Main St7920 South Mason Montgomery Road	OkolonaMason	MississippiOhio	38860-1608450 40-8249	(513) 770-0084
Okuley's PharmacyZEIGLER PHARMACY	102 South159 West Main Street	ContinentalWilmington	Ohio	45831-0388451 77	(937) 382-0921
Oldens PharmacyBroken Arrow Family Drug	101 Pleasant Street3359 South Elm Place	South WeymouthBroken Arrow	MassachusettsOklahoma	0219074012	(918) 451-3784
Olde Towne PharmacyBroken Arrow Family Drug North	102 West Jackson Boulevard1030 East Lansing Street	JonesboroughBroken Arrow	TennesseeOklahoma	376597 4012-7010	(918) 251-3784
Olde Virginia PharmacyCITY HEALTHMART DRUG	1592 Fincastle Street TPKE128 E Cherokee Ave	TazewellNowata	VirginiaOklahoma	246517 4048	(918) 273-3825
Old MainCommunity Pharmacy	407 West 3rd212 East 8TH Street	PembrokeBeaver	North CarolinaOklahoma	283727 3932	(580) 625-3646
Olivehurst Drug Store	4897 Olivehurst Avenue	Olivehurst	California	95961	
Olssons Pharmacy	576 Lafayette Avenue	Hawthorne	New Jersey	07506-2400	
ONEWORLD PHARMACY	4920 S 30TH ST STE 105	OMAHA	Nebraska	68107	
OptimumErnie's Pharmacy and Wellness Center Inc	716 Broadway410 South 32nd Street	PaintsvilleMuskogee	KentuckyOklahoma	4124077 4401	(918) 683-0611
OrangeFikes Pharmacy	130 West Main Street101 East Second	OrangeGrandfield	VirginiaOklahoma	2296073546	(580) 479-5696
Orange Plaza Pharmacy	1010 West La Veta Avenue, Suite 130	Orange	California	92868	
Orion Family Pharmacy LLC	201 11th Avenue	Orion	Illinois	61273	
OrlandoHarrison Discount Pharmacy	29091442 North Orange Avenue Suite 112Harrison St	OrlandoShawnee	FloridaOklahoma	328047 4801-5208	(405) 273-9906

Holder Drug	513 Barnes	Alva	Oklahoma	73717-2288	(580) 327-3332
~~Ortux~~Lakeside Pharmacy	~~9134~~605 North ~~West 25th~~Main Street	~~Doral~~Eufaula	~~Florida~~Oklahoma	~~331727~~ 4432	(918) 689-9940
Main Street Drug	225 West Main	Wilburton	Oklahoma	74578	(918) 465-9300
Owl Drug and The Gift House	418 West Cherokee St	WAGONER	Oklahoma	74467-5220	(918) 485-2722
~~Oxnard~~Rogers Drug Company	~~105 West 5th~~326 East Cherokee Street	~~Oxnard~~Wagoner	~~California~~Oklahoma	~~930307~~ 4467	(918) 485-2317
~~Pacific~~Rose Rock Pharmacy	~~11525 Brookshire Avenue,~~12100 S. Yukon Ave Suite ~~100~~A	~~Downey~~Glenpool	~~California~~Oklahoma	~~902417~~ 4033-6621	(918) 552-1040
~~Palace Drug~~Sooner Pharmacy of Oklahoma LLC	~~270 Main~~815 West Broadway Street	~~Mammoth Spring~~Sulphur	~~Arkansas~~Oklahoma	~~725547~~ 3086	(580) 622-2200
~~Palace~~Stroud Drug ~~of Salem, LLC~~	~~106~~406 West ~~Highway 62~~Main	~~Salem~~Stroud	~~Arkansas~~Oklahoma	~~725767~~ 4079	(918) 968-2323
~~PALACE DRUG - Retail~~Thrifty Pharmacy	~~601 Main Street~~10904 - L.N. May Avenue	~~Canon~~Oklahoma City	~~Colorado~~Oklahoma	~~812127~~ 3120	(405) 751-2852
~~PALACE DRUG SILVER CLIFF~~Westminster Family Drug	~~94 MAIN ST~~10911 Northeast 23rd Street	~~SILVER CLIFF~~Nicoma Park	~~Colorado~~Oklahoma	~~812527~~ 3066	(405) 769-8585
Ashland Drug	53 North Second Street	Ashland	Oregon	97520	(541) 482-3366
~~Palace~~Bowmans Hillsdale Pharmacy	~~1255 Main St~~6256 SW Capitol Hwy	~~Lander~~Portland	~~Wyoming~~Oregon	~~825209~~ 7239	(503) 244-7582
Broadway Pharmacy	2790 Broadway Ave	North Bend	Oregon	97459-2216	(541) 449-9190
Gold Beach Pharmacy	94202 2nd St	Gold Beach	Oregon	97444-7767	(541) 727-3300
Gold Hill Pharmacy	808 Second Avenue	Gold Hill	Oregon	97525	(541) 855-1544
~~Palacios Prescription Shoppe~~Gordon's Pharmacy and Gifts	~~321~~314 S. Main Street	~~Palacios~~Canyonville	~~Texas~~Oregon	~~774659~~ 7417	(541) 839-4452
~~Palm Care~~Harrisburg Pharmacy	~~4651 Babcock~~230 North 3rd Street ~~North East~~ Suite ~~5A~~106	~~Palm Bay~~Harrisburg	~~Florida~~Oregon	~~329059~~ 7446	(541) 995-9711
~~Palmer Pharmacy Plus~~Malheur Drug	~~2731~~198 A Street West ~~Northwest Highway Suite 105~~	~~Dallas~~Vale	~~Texas~~Oregon	~~752209~~ 7918	(541) 473-3333
Sempert's Drug	735 Spruce Street	Myrtle Point	Oregon	97458	(541) 572-5010
~~PALMYRA PHARMACY~~Stayton Pharmacy	~~1 East Broad Street~~102 Martin Drive, Suite A	~~Palmyra~~Stayton	~~New Jersey~~Oregon	~~08065-1604~~97383	(503) 769-2616 Ext 4
~~PANAMA~~	~~6348 Ashe Rd STE~~	~~Bakersfield~~Biglervil	~~California~~Pen	~~93313-9~~	(717) 486-8606

PHARMACYAdams-Cumberland Pharmacy	300-4003463 Biglerville Road	le	nsylvania	490173 07	
PaoliAlberts Pharmacy Inc	1564 East Lancaster Avenue201 South Main Street Suite 2	PaoliPittston	Pennsylvania	19301 18640	(570) 299-5150
Alexa Pharmacy	919 Tyson Avenue	Philadelphia	Pennsylvania	19111	(215) 437-7573
Andrew Browns Drug Store Inc	1502 Pittston Avenue	Scranton	Pennsylvania	18505	(570) 346-7319
ParamountAppleby Drug Store	54 East Scott Street133 E Shirley St	RiversideMount Union	New JerseyPennsylvania	08075 17066	(814) 542-4412
Park AvenueAsti's South Hills Pharmacy Inc	220 PARK AVE250 Mt Lebanon Blvd	CHAMBERSBURGPittsburgh	Pennsylvania	17201-1230 15234	(412) 561-2347
ParkdaleBechtels Pharmacy	945 Rosedale Road302 Main Street	Valley StreamSlatington	New YorkPennsylvania	11581 18080	(610) 767-4121
PARKER'S CITYBETTER HEALTH PHARMACY & WELLNESS	1005 East Court Street518 Burke Bypass	SeguinOlyphant	TexasPennsylvania	78155 18447	(570) 383-6700
Parke VistaBrown's Pharmacy	3838 Sherman Drive Suite 163 Canton Street	RiversideTroy	CaliforniaPennsylvania	92503 16947	(570) 297-5400
Parkland DrugsBrowns Pharmacy	209 North Dixie Highway121 Sullivan Street	Cave CityCanton	KentuckyPennsylvania	42127 17724	(570) 673-4372
Park Pharmacy SCS	20225 East 9 Mile Road Suite 100	Saint Clair Shores	Michigan	48080-1775	
Park PlaceCentennial Pharmacy Services	46 Parkway Lane1020 North Delaware Avenue Suite 200	PetalPhiladelphia	MississippiPennsylvania	39465 19125-4334	(267) 534-5025
ParksideCustom Care Pharmacy	4404 Del Rio Road57 S Front St	SacramentoMilton	CaliforniaPennsylvania	95822 17847-1110	(570) 246-5700
Parkview Medical PlazaDavis Pharmacy	3975 Jackson Street Suite 1094523 Baltimore Avenue	RiversidePhiladelphia	CaliforniaPennsylvania	92503 19143	(215) 222-3349
ParkviewDougs Family Pharmacy	8274 Kentucky Route 122101 Darby Square	MinnieElverson	KentuckyPennsylvania	41651 19520	(610) 286-0496
ParkviewEllis Prescription Pharmacy	1430 Queen Anne Road2441 West Brown Street	TeaneckPhiladelphia	New JerseyPennsylvania	07666 19130	(215) 765-1903
Park ViewExpress Care Pharmacy	4251727 West 100 SouthLiberty Street Unit 2	LaytonAllentown	UtahPennsylvania	84041 18104	(610) 351-2273
ParkwayFamcare	186 Breanna Blvd,	SalyersvilleBurgettst	KentuckyPenn	41465 1	(724) 947-7000

Pharmacy	~~Suite 400~~1429 Burgettstown Plaza	own	sylvania	5021	
~~Parlin Pharmacy~~Family Prescription Counter	~~499 Ernston Road~~335 Main Street	~~Parlin~~Duryea	~~New Jersey~~Pennsylvania	~~08859~~18642	(570) 457-6789
~~Parvin's~~First National Pharmacy	~~30~~143 North ~~Bryn Mawr Avenue~~First Street	~~Bryn Mawr~~Lehighton	Pennsylvania	~~19010~~18235	(610) 377-0450
~~Pathway~~Gateway Pharmacy	~~202 Southwest 17th Street Suite A~~165 Nutt Rd	~~Ocala~~Phoenixville	~~Florida~~Pennsylvania	~~34471~~19460-3999	(610) 933-2609
~~Patterson's~~Gaughns Drug Store	~~134 South Queen Street~~348 Pennsylvania Avenue West	~~Martinsburg~~Warren	~~West Virginia~~Pennsylvania	~~25401~~16365	(814) 723-2840
~~Pattie Drugs~~	~~868 Michigan Avenue~~	~~Baldwin~~	~~Michigan~~	~~49304~~	
~~Paul's Pharmacy~~	~~2345 West Franklin Street~~	~~Evansville~~	~~Indiana~~	~~47712~~	
~~Paul's~~Harrolds Pharmacy ~~East~~Inc	~~1150 South Green~~250 Old River Road	~~Evansville~~Wilkes Barre	~~Indiana~~Pennsylvania	~~47715~~18702-1614	(570) 822-5794
~~PAULS PHARMACY~~Heights Terrace Pharmacy	~~3408 N 1ST AVE~~475 South Poplar Street	~~EVANSVILLE~~Hazleton	~~Indiana~~Pennsylvania	~~47710-3302~~18201	(570) 454-8748
~~Pawleys Island Pharmacy of Litchfield~~	~~115 Willbrook Boulevard Unit A~~	~~Pawleys Island~~	~~South Carolina~~	~~29585~~	
~~Payless Drugs~~	~~460 Walker Drive~~	~~Springville~~	~~Alabama~~	~~35146-0252~~	
~~Payless Drugs~~	~~585 Morris Majestic Road~~	~~Morris~~	~~Alabama~~	~~35116~~	
~~Payless Drugs~~	~~2512 31st Avenue North~~	~~Birmingham~~	~~Alabama~~	~~35207~~	
~~Payless Drugs~~Holly Pharmacy	~~4901 Gary~~31 North Baltimore Avenue	~~Fairfield~~Mt. Holly Springs	~~Alabama~~Pennsylvania	~~35064-5064~~17065-1302	(717) 486-5321
~~Payne Family~~Horsham Square Pharmacy	~~200 South Main Street~~575 Horsham Road Unit C20	~~Floydada~~Horsham	~~Texas~~Pennsylvania	~~79235~~19044	(215) 674-5050
~~PCF~~Katz Pharmacy	~~2615 Strawberry~~2 East Eagle Road	~~Pasadena~~Havertown	~~Texas~~Pennsylvania	~~77502~~19083	(610) 446-4040
~~PDL~~Langhorne Pharmacy	~~7167 W Flagler Street~~172 N Pine St	~~Miami~~Langhorne	~~Florida~~Pennsylvania	~~33144~~19047	(215) 752-1100
~~Peak~~Lifestream Pharmacy	~~22 River Street~~847 EASTON ROAD SUITE 2775	~~Peak~~WARRINGTON	~~South Carolina~~Pennsylvania	~~29122~~18976	(215) 491-0999
~~Pearman~~Marple Pharmacy	~~116 West Court Street~~2070 Sproul Road	~~Paris~~Broomall	~~Illinois~~Pennsylvania	~~61944~~19008	(610) 356-6491
~~Pearsons Discount~~	~~101 East~~	~~Houston~~Jim Thorpe	~~Mississippi~~Pe	~~38851~~1	(570) 325-5020

Drug LLCMauch Chunk Pharmacy	Washington1204 North Street		nnsylvania	8229	
Pearsons Medical Group Pharmacy	1700 North Waterman Avenue	San Bernardino	California	92404	
Pelzel's HometownMax-Well Pharmacy Services	1340 North Highway 377, Suite 100375 West Street Road	Pilot PointWarminster	TexasPennsylvania	76258189974	(215) 956-9280
Pembroke Pharmacy	137 East Bacon Street	Pembroke	Georgia	31321	
Pennington Apothecary	6 North Main Street	Pennington	New Jersey	08534	
PeoplesMedmart Pharmacy #1	4018 North Lamar2618-A Memorial Boulevard	AustinConnellsville	TexasPennsylvania	78756154425	(724) 628-7500
PeoplesMorrison's Pharmacy #2	3801 B South Lamar Boulevard6113 Ridge Avenue	AustinPhiladelphia	TexasPennsylvania	78704119128	(215) 482-2697
PeoplesNazareth Outpatient Pharmacy #3	4201 Westbank Drive2601 Holme Ave Suite 100	AustinPhiladelphia	TexasPennsylvania	78746119152-2007	(215) 335-7985
Peoples Pharmacy #4	13860 North Highway 183 Suite C	Austin	Texas	78750	
Pepperell FamilyNeighborhood Pharmacy	74 Main Street5701 Chestnut St	PepperellPhiladelphia	MassachusettsPennsylvania	01463119139	(215) 307-3609
PERFECT CARE PHARMACY	1727 JOHN F KENNEDY BLVD	Jersey City	New Jersey	07305	
Perkins Indian RiverNew Falls Pharmacy	3721 10th Court2235 Veterans Highway	Vero BeachLevittown	FloridaPennsylvania	32960119056-3001	(215) 269-7000
Perrone Legend Pharmacy	3921 Benbrook Highway	Fort Worth	Texas	76116	
PeshtigoNewhard Pharmacy	220 French1001 Main Street	PeshtigoNorthampton	WisconsinPennsylvania	54157118067	(610) 262-6721
Peter PanNucare Pharmacy	2125 Park Avenue7960 Verree Road	South PlainfieldPhiladelphia	New JerseyPennsylvania	07080119111	(215) 342-0100
Petersburg Rexall Drug	215 N Nordic Drive	Petersburg	Alaska	99833	
PetrossianPaoli Pharmacy Inc	2701 West Alameda Avenue Suite 1001564 Lancaster Ave	BurbankPaoli	CaliforniaPennsylvania	91505119301	(610) 644-3880
PETS AND PEOPLE PHARMACY	9215 BROADWAY ST STE 113 SUITE 113	PEARLAND	Texas	77584-8987	
Pharmacare No. 4	99-128 Aiea Heights Drive Suite	Aiea	Hawaii	96701	

	103				
Pharmacia Sana	102 East Danieldale Road Suite 100	Duncanville	Texas	75137	
Pharmacy 1 Express	730 West 2nd Street	Bloomington	Indiana	47403	
Park Avenue Pharmacy Arts Inc	31 Burnley Road220 PARK AVE	ScottsvilleCHAMBERSBURG	KentuckyPennsylvania	421641 7201-1230	(717) 264-7312
Parvin's Pharmacy Care	465230 North M37 HighwayBryn Mawr Avenue	MiddlevilleBryn Mawr	MichiganPennsylvania	49333-0159190 10	(610) 525-0443
Pharmacy Express	415 South L. Rogers Wells Boulevard	Glasgow	Kentucky	42141	
PharmacyGO	20041 South Tamiami Trail Suite 13	Estero	Florida	33928-2228	
Pharmacy of America	1500 East Erie Avenue	Philadelphia	Pennsylvania	19124	(215) 289-9500
Pharmacy of America II	5872 Oxford Avenue	Philadelphia	Pennsylvania	19149	(215) 613-7900
Pharmacy of America III	217 WestW Lehigh AvenueAve Store #2	Philadelphia	Pennsylvania	19133	(215) 279-7981
Pharmacy of America IV	1900 North 9th Street	Philadelphia	Pennsylvania	19122	(215) 787-9999
Pharmacy of America IX Inc	1000 Cottman AvenueAve	Philadelphia	Pennsylvania	19111-1420191 11-3644	(215) 770-7869
Pharmacy of America V	232 West Girard Avenue	Philadelphia	Pennsylvania	19123-1538	(267) 858-4279
Pharmacy of America VI	919 Levick Street	Philadelphia	Pennsylvania	19111-5421	(215) 535-0555
Pharmacy of America VII	4654 North 5th Street	Philadelphia	Pennsylvania	19140	(267) 900-5858
Pharmacy of America VIII Inc	7522 Frankford Ave	Philadelphia	Pennsylvania	19136-3533	(215) 914-6911
Quality Care Pharmacy Town	1590 State Highway 351 Sprint Drive	OceanCarlisle	New JerseyPennsylvania	07712 17015	(717) 249-5691
PharmaRxQuik-Stop Pharmacy	11382 Miramar Parkway3506 East Lincoln Highway	MiramarThorndale	FloridaPennsylvania	33025-5805193 72	(610) 384-6100
PharmaxRann Pharmacy #1117	1117377 Main Street	ImperialHarleysville	MissouriPennsylvania	630521 9438-2309	(215) 256-4146
RIOS PHARMACY	35 South Morton Avenue	Morton	Pennsylvania	19070	(610) 543-1858
PharmaxRiteChoice Pharmacy #1160at 11th Street	116 Walnut Street850 N 11th St Floor 1 Room 148	FestusPhiladelphia	MissouriPennsylvania	630281 9123-1957	(215) 769-2155
PharmaxShafer's	610408 East	PotosiTamaqua	MissouriPenn	636641	(570) 668-0290

Pharmacy #1302	High Broad Street		sylvania	8252	
Pharmax Sheehans Pharmacy #1343	113 79 E Carey St. Francois Plaza	Leadington Plains	Missouri Pennsylvania	63601 18705-2007	(570) 823-3151
Pharmax Pharmacy #1365	60 Nesbit Drive Ste A	Bonne Terre	Missouri	63628	
Pharmcare	1834 Broadway Street Suite 106	Pearland	Texas	77581	
Pharmville Drug	3754 South Main Street	Farmville	North Carolina	27828-8546	
Phillips Shop and Carry Pharmacy	306 West First Street 1301 Lindley Avenue	Vidalia Philadelphia	Georgia Pennsylvania	30474 19141-2747	(267) 297-5030
Phipps Springfield Pharmacy, Huntingdon	20190 Main Street, East 1154 Baltimore Pike	Huntingdon Springfield	Tennessee Pennsylvania	38344 19064	(610) 544-4645
Phipps Pharmacy #1	205 B Hospital Drive	Mckenzie	Tennessee	38201	
Phipps Pharmacy #4	19 Hughes Drive	Jackson	Tennessee	38305	
Pickwick St. Clare Pharmacy	3219 Augusta 1203 Langhorne Newtown Road	Greenville Langhorne	South Carolina Pennsylvania	29605 19047	(215) 710-7427
Piedmont Family Pharmacy Standard Drug Store	600 Anderson 322 South Hancock Street	Piedmont McAdoo	South Carolina Pennsylvania	29673-1418 18237	(570) 929-1130
Piggott Stephens Pharmacy	648 E 1101 Main St Street	Piggott Honesdale	Arkansas Pennsylvania	72454 18431	(570) 253-7770
Pike's Summit Health Pharmacy Inc LLC	2133 Shamrock Drive 3400 Edgmont Avenue	Charlotte Brookhaven	North Carolina Pennsylvania	28205 19015-2804	(610) 872-5418
Pikeville Medical The Prescription Center Outpatient Pharmacy	911 Bypass Rd Bldg E, Ste 1 310 Adams Avenue	Pikeville Scranton	Kentucky Pennsylvania	41501 18503	(570) 343-2448
Pillar Drug Company Village Pharmacy at Spring House	1 Hidden Creek Drive 1121 North Bethlehem Pike Suite 40	Guyton Spring House	Georgia Pennsylvania	31312 19477-1011	(215) 646-1691
Pill Box Waltmire Pharmacy	304 East Jackson Street 2D 1435 Spring Garden Avenue	Willard Pittsburgh	Missouri Pennsylvania	65781 15212	(412) 323-1801
Pine Grove West Perry Pharmacy	13030 Shortline Hwy 1102 Montour Road	Pine Grove Loysville	West Virginia Pennsylvania	26419 17047	(717) 789-3093
West Reading Drug Store	538 Penn Avenue	West Reading	Pennsylvania	19611	(610) 375-4366
Pine Plains Woodlyn Pharmacy	2965 Church Street 1301 Jefferson Avenue	Pine Plains Woodlyn	New York Pennsylvania	12567-0339 19094	(610) 833-5600

Pine RidgeYorke Pharmacy	634 A Pine Ridge Drive5524 New Falls Road	West ColumbiaLevittown	South CarolinaPennsylvania	291721 9056	(215) 945-5700
PinevilleProfessional Pharmacy of Pennsburg/Red Hill	311 South Polk931 Main Street Suite 80	PinevillePennsburg	North CarolinaPennsylvania	28134-8631180 73	(215) 679-9700
Pinon Family PharmacyFARMACIA ABIMAR	2300 East 30th Street, Suite B-101CARR 780 KM 6.5 BO ANONES	FarmingtonNARANJITO	New MexicoPuerto Rico	8740100719	(787) 869-2021
FARMACIA CARIBE	CARRETERA #3 KM 26.3	RIO GRANDE	Puerto Rico	00745	(787) 888-1888
Pipeline PharmacyFarmacia Caribe	328 East Pipeline RoadCentro Comercial Villas De Rio Grande	HurstRio Grande	TexasPuerto Rico	76053-5831007 45	(787) 887-3060
Pittsville PharmacyFarmacia Caribe II	34205 Old Ocean City Road Unit ECalle K #HH17Y18, URB Alturas De Rio Grande	PittsvilleRio Grande	MarylandPuerto Rico	21850-2083007 45	(787) 887-4444
PLATTE VALLEY PHARMACYFarmacia Carraizo	1610 PRAIRIE CENTER PKWY STE 2110Carretera 844 KM 5.6	BRIGHTONTrujillo Alto	ColoradoPuerto Rico	8060100928	(787) 760-2650
Playa PharmacyFarmacia Farmahorros	8131 West Manchester AvenueLocal 101 Centro Comercial Villa Del Carmen	Playa Del ReyCidra	CaliforniaPuerto Rico	9029300739	(787) 739-3522
Plaza Drug of LondonFarmacia Guayabal	731 North Laurel RoadCarr. #1 KM 113.60 Bo. Cintrona	LondonJuana Diaz	KentuckyPuerto Rico	4074100795	(787) 260-3804
Plaza PharmacyFarmacia Los Maestros	430 East Avenida de los ArbolesCalle Muniz Souffront #459, Urb. Los Maestros	Thousand OaksSan Juan	CaliforniaPuerto Rico	9136000923	(787) 765-8811
Pleasant Grove PharmacyFarmacia Magda	3302 Richmond RoadUU48 Calle 37	TexarkanaBayamon	TexasPuerto Rico	75503-2134009 56-4789	(787) 786-0755
Plumsted Pharmacy	28 Brindletown Road	New Egypt	New Jersey	08533	
Plum Street PharmacyFarmacia Martin	311 Plum StreetCalle Ruiz Belvis # 22	CarmiSan German	IllinoisPuerto Rico	6282100683	(787) 892-1122
Farmacia Nueva	Calle Munoz Rivera #16	Camuy	Puerto Rico	00627	(787) 820-6892
Plus	5223 7thth1320 San	BrooklynSan Juan	New	112200	(787) 782-6403

PharmacyFarmacia Reyes 3	Alfonso Avenue		YorkPuerto Rico	0921-3621	
Plymouth Park Pharmacy IncFarmacia Villas De Castro	11 12 Saddle River RoadCalle 2 A18 Villas De Castro	Fair LawnCaguas	New JerseyPuerto Rico	0741000725	(787) 390-0990
NUEVA FARMACIA SANTA ANA	CALLE 1 B3 URBANIZACION SANTA ANA	VEGA ALTA	Puerto Rico	00692	(787) 270-2503
Su Farmacia Amiga Inc.	Ave Las Americas BU-1 Residencial Bairoa	Caguas	Puerto Rico	00725	(787) 743-6434
Super Farmacia Lizette	Calle Guillermo Esteves #103	Jayuya	Puerto Rico	00664	(787) 828-0755
PontiacMatt's Local Pharmacy	1925 North Perry Street88 East Main Road	PontiacMiddletown	MichiganRho de Island	48340-2237028 42-4912	(401) 619-5020
PoolerAynor Family Pharmacy	1557 POOLER PARKWAY SUITE 400240 8th Avenue	POOLERAynor	GeorgiaSouth Carolina	313222 9511	(843) 358-3520
PopularBlack River Pharmacy	5326 East US32A North Williamsburg County Highway 83 Suite A # 5	Rio Grande CityKingstree	TexasSouth Carolina	78582-9409295 56	(843) 355-5656
Popular Pharmacy 3	2849 East Grant Street	Roma	Texas	78584-8914	
Port CityBlythewood Pharmacy and Home Medical Equipment	6756 Gordon Road Suite130710-C University Village Drive	WilmingtonBlythewood	NorthSouth Carolina	28411-8440290 16	(803) 786-8110
Porter's PrescriptionBrunson's Pharmacy	935 Beaver Grade Road12 North Brooks Street	CoraopolisManning	Pennsylvania South Carolina	1510829102	(803) 435-2511
Potter's House Apothecary	21585 North 77th Avenue Suite 1500	Peoria	Arizona	85382	
Powdersville Family PharmacyBuford Street Drug Store	11061 Anderson Road115 N Granard St	PiedmontGaffney	South Carolina	29673-8203293 41-2342	(864) 488-3036
Powell Drug	140 North Bent Street	Powell	Wyoming	82435	
Powells NorthsideChapin Pharmacy	440 Charter Boulevard Suite 1107138A Amicks Ferry Rd	MaconChapin	GeorgiaSouth Carolina	3121029036	(803) 345-1114
PowellsChester Family Pharmacy	4839 Bloomfield Road1645 J A Cochran Bypass Suite G	MaconChester	GeorgiaSouth Carolina	3120629706-3102	(803) 581-1095
Powers Pharmacy	702205 West	LindenPickens	TexasSouth	755632	(864) 878-6357

No 1 IncCorner Drug Store	HoustonCedar Rock Street		Carolina	9671	
Preferred Pharmacy Sevierville	1024 Middle Creek Road Suite 1	Sevierville	Tennessee	37862	
Premier DrugstoreDaniels Pharmacy of Barnwell	8446 Campbellton178 Wren Street	DouglasvilleBarnwell	GeorgiaSouth Carolina	301342 9812	(803) 259-1234
Prescription Center	296 Route 59	Tallman	New York	10982	
Prescription Center of Ossining	162 Croton Avenue	Ossining	New York	10562	
Prescription Centre & Surgicals	35H Middle Country Road	Coram	New York	11727	
Prescriptions Corner Drug	320 West Kingshighway	Paragould	Arkansas	72450	
Prescription Shop Inc	909 East Holland Avenue	Alpine	Texas	79830	
Prescription Shop of Stuart	622 Colorado Avenue	Stuart	Florida	34994	
Prescriptions PlusDelta of Charleston #3	1614 West Franklin Boulevard346 East Bay St	GastoniaCharleston	NorthSouth Carolina	280522 9401	(843) 937-0960
Prescriptions PlusDelta of Elloree	703-1 East King Street2611 Cleveland St	Kings MountainElloree	NorthSouth Carolina	280862 9047	(843) 761-5255
Prescriptions PlusDelta of Eutawville	311-C Chesnee Highway226 Porcher Ave	GaffneyEutawville	South Carolina	293412 9048	(803) 492-9201
Prescriptions Plus LTDDelta of Moncks Corner	753 True Value Drive402 East Main St	LebanonMoncks Corner	IllinoisSouth Carolina	622542 9461	(843) 761-5255
Presque Isle Pharmacy	797 Main Street	Presque Isle	Maine	04769	
Preston Drugs & Surgicals	127 Hawkins Place	Boonton	New Jersey	07005	
PriceDelta Pharmacy & Medical Supply #5	110 East Bank Street901 Island Park Dr Suite 103	Granite QuarryDaniel Island	NorthSouth Carolina	280722 9492-8034	(843) 471-2870
PriceDelta Pharmacy & Medical Supply #6	422 North Highway 291400 Palm Blvd	China GroveIsle of Palms	NorthSouth Carolina	280232 9451-2280	(843) 885-8008
PRIME CARE DRUG & SURGICALS CORPDelta Pharmacy & Medical Supply #7	2066 FLATBUSH AVE6251 Hwy 162	BROOKLYNHollywood	New YorkSouth Carolina	112342 9449-5782	(843) 564-5720
Primemed Pharmacy	1387 George Dieter Ste A-104	El Paso	Texas	79936	
Prime Plus Pharmacy	2955 West 95th Street	Evergreen Park	Illinois	60805-2409	
Primera Care	17500 Foothill	Fontana	California	92335-3736	

Pharmacy	Boulevard Suite A-7A				
Prime Rx Pharmacy	10010 Cross Creek Blvd.	Tampa	Florida	33647-2595	
PRIME RX ROWLAND HEIGHTSDelta Rx - Litchfield	18399 COLIMA RD. STE.115 Willowbrook Boulevard Unit A	ROWLAND HEIGHTSPawleys Island	CaliforniaSouth Carolina	91748-2797295 85-6542	(854) 600-1006
PrinceDillon Community Pharmacy	211 E Stadium Dr200 W Harrison St Suite A	MagnoliaDillon	ArkansasSouth Carolina	717532 9536-3331	(843) 774-4749
Princeton Pike Rx LLC	3100 Princeton Pike Suite 4B	Lawrenceville	New Jersey	08648-2376	
PrincevilleDillon Family Pharmacy	206 East Main603 North 6th Avenue	PrincevilleDillon	IllinoisSouth Carolina	615592 9536	(843) 774-1816
Professional Pharmacy	140 Roxboro Road	Oxford	North Carolina	27565	
ProfessionalDottie's Pharmacy	419 Town Mountain325 Folly Road Suite 101	PikevilleCharleston	KentuckySouth Carolina	415012 9412	(843) 501-9500
ProfessionalElgin Pharmacy	9175 Cherry Valley1107 Ross Street	CaledoniaElgin	MichiganSouth Carolina	493162 9045	(803) 438-5735
ProfessionalFamily Pharmacy of Pennsburg/Red HillSouth Aiken	931 Main Street110 Price Avenue	PennsburgAiken	Pennsylvania South Carolina	180732 9803	(803) 648-1776
ProfessionalFowler's Pharmacy of Somerset	342 Bogle Street1908 Laurens Road	SomersetGreenville	KentuckySouth Carolina	425032 9607	(864) 288-5920
ProfessionalGaston Family Pharmacy Services and Medical Equipment	10993 Southwest 186 Street1118 Mack St	MiamiGaston	FloridaSouth Carolina	331572 9053	(803) 939-8489
Professional PlazaGiant Discount Pharmacy Inc	2065 North Robins Drive6611 Savannah Highway	LaytonNeeses	UtahSouth Carolina	84041-1133291 07	(803) 247-2135 Ext 3
GILDER & WEEKS PHARMACY	200 N MAIN STREET	JOANNA	South Carolina	29351	(864) 697-6580
Great Falls Pharmacy	503 Chester Avenue Suite A	Great Falls	South Carolina	29055	(803) 482-2249
Prospect PharmacyHarleyville Drug	171 South108 West Main Street	ProspectHarleyville	OhioSouth Carolina	433422 9448	(843) 462-7646
Prosperity Drug CompanyHerold's Pharmacy	101 North Main Street2057 Charlie Hall Boulevard Suite C	ProsperityCharleston	South Carolina	291272 9414	(843) 637-3037
Hibbitts Drug	735 North Main	New Ellenton	South	29809	(803) 443-0077

Company LLC	Street		Carolina		
PSA ClinicHonea Path Pharmacy	2294 US Highway 70309 East Greer Street	SwannanoaHonea Path	NorthSouth Carolina	2877829654-1818	(864) 369-5337
Pucci's PharmacyIrmo Drug	3257 Folsom1009 Lake Murray Blvd, Suite B	SacramentoIrmo	CaliforniaSouth Carolina	9581629063	(803) 749-7485
PUENTE HILLS PHARMACYKash and Karry Pharmacy	1850 S AZUSA AVE STE 101 Pete Hollis Boulevard	HACIENDA HEIGHTSGreenville	CaliforniaSouth Carolina	91745-6854296 01	(864) 232-6711
PulaskiKershaw Family Pharmacy	121 North Saint Augustine401 South Hampton Street	PulaskiKershaw	WisconsinSouth Carolina	5416229067-1832	(803) 475-6979
Purcellville PharmacyLake Murray Drug Company	609 East Main Street105 Snapdragon Court Suite QA	PurcellvilleChapin	VirginiaSouth Carolina	2013229036-8343	(803) 345-9999
Lake Murray Drug Company of Irmo	2 Palmetto Wood Parkway Suite 100	Irmo	South Carolina	29063	(803) 212-9999
QUALITY CARE PHARMACYLake Wylie Pharmacy	2300 West FM 544221 Latitude Lane Suite 130109	Lake Wylie	TexasSouth Carolina	75098297 10	(803) 831-2044
Quality CareLandy's Pharmacy	1 Sprint Drive835 Sparkleberry Lane	CarlisleColumbia	Pennsylvania South Carolina	17015292 29-6544	(803) 567-3107
Quays DrugsLee's Inlet Apothecary	2 PUBLIC SQ3579 Hwy 17 B	GALIONMurrells Inlet	OhioSouth Carolina	44833295 76	(843) 651-7979
Queens Drugs & SurgicalLiberty Family Pharmacy	146-14 Jamaica Avenue115 West Main Street	JamaicaLiberty	New YorkSouth Carolina	11435296 57-0063	(864) 843-9207
QueensLorex Drugs & Surgical	80-04 Baxter Avenue1310 Wilson Road	ElmhurstNewberry	New YorkSouth Carolina	11373291 08	(803) 276-0990
QueensMcLeskey Todd Pharmacy of Greer Inc	12677 Hesperia Road Suite 180109 North Main Street	VictorvilleGreer	CaliforniaSouth Carolina	92395296 50	(864) 877-0753
QUEENS PHARMACY.Medicine Mart of West Columbia #1	18522 Highway 18 Suite 1031300 Sunset Blvd	Apple ValleyWest Columbia	CaliforniaSouth Carolina	92307291 69	(803) 791-7043
QuickMedicine Mart Pharmacy	100 Ryders Lane1401 Main Street	MilltownConway	New JerseySouth Carolina	08850295 26	(843) 248-4609
QuickRx@Bartow Medicine Mart Pharmacy of Lexington	1140 East Van Fleet Drive348 B Columbia Ave	BartowLexington	FloridaSouth Carolina	33830-7626290 72	(803) 957-5969
Quik Stop Pharmacy	3506 East Lincoln Highway	Thorndale	Pennsylvania	19372	
QwikMedMediSave Pharmacy	204 Westwood Shopping	FayettevilleCamden	NorthSouth Carolina	2831429020-41	(803) 424-0064

	Center1025 W Dekalb St			62	
R & JMobley Drugs Inc	4633 Savannah Highway1073 West Meeting Street	NorthLancaster	South Carolina	29112 29720-2321	(803) 285-2021
RainbowNyes Pharmacy	431 Seventh Street1600 10th Avenue	Lanai CityConway	HawaiiSouth Carolina	967632 9526	(843) 248-5015
Raincross Pharmacy	4646 Brockton Avenue	Riverside	California	92506	
Ramsay Rexall Drug	2246 Newport Boulevard	Costa Mesa	California	92627	
Ramsey Drug	401 COLLEGE DRIVE SOUTH	DEVILS LAKE	North Dakota	58301	
Rancho Drugs	17798 Wika Road	Apple Valley	California	92307	
Randolph County Drug	567 Highway 67 South Suite A	Pocahontas	Arkansas	72455	
RannPeak Pharmacy	377 Main22 River Street	HarleysvillePeak	Pennsylvania South Carolina	19438-2309291 22	(803) 345-1707
Raritan ValleyPickwick Pharmacy	1055 Route 202 North3219 Augusta Road	BranchburgGreenville	New JerseySouth Carolina	088762 9605	(864) 277-4180
Reading RidgePiedmont Family Pharmacy	8 Reading Road, Suite 206600 Anderson Street	FlemingtonPiedmont	New JerseySouth Carolina	088222 9673-1418	(864) 832-9520
Rector Downtown Drug	316 East 9th Street	Rector	Arkansas	72461	
Red'sPine Ridge Pharmacy, LLC	3102 Garrett634 A Pine Ridge Drive	PerrytonWest Columbia	TexasSouth Carolina	790702 9172	(803) 955-3404
Red CrossPowdersville Family Pharmacy	525 5th Street Suite A11061 Anderson Road	EurekaPiedmont	CaliforniaSouth Carolina	95501-1032296 73-8203	(864) 373-9229
Red Springs Old MainPrescriptions Plus	300 South Main Street311-C Chesnee Highway	Red SpringsGaffney	NorthSouth Carolina	28377-1624293 41	(864) 649-5371
Reed'sProf Pharmacy 5of Greer Inc	2830 Northwestern Pike320 Memorial Drive	Capon BridgeGreer	West VirginiaSouth Carolina	267112 9650	(864) 877-3386
ReedHutchins PharmacyProsperity Drug Company	408 West101 North Main Street	Heber SpringsProsperity	ArkansasSouth Carolina	72543-3017291 27	(803) 364-2310
Reef Family PharmacyProsperity Drug of Batesburg-Leesville	1037 S Route 9317 Village Square Drive	Cape May Court HouseBatesburg Leesville	New JerseySouth Carolina	082102 9070-7055	(803) 580-2400
Reeves Sain Drug StoreR & J Drugs	1801 Memorial Blvd.4633 Savannah Highway	MurfreesboroNorth	TennesseeSouth Carolina	371292 9112	(803) 247-2133 Ext 5
Regenesis Health Care Pharmacy	750 South Church Street	Spartanburg	South Carolina	29306	(864) 699-3283 Ext 8864

ReGenesis Health Care Pharmacy	460 Langdon St	Spartanburg	South Carolina	29302-1614	(864) 285-9867
Regenesis Health Care Pharmacy #3	1663 E MAIN ST	Duncan	South Carolina	29334	(864) 416-7933
~~Regenesis Health Care Pharmacy #4~~	~~460 Langdon Street~~	~~Spartanburg~~	~~South Carolina~~	~~29302-1614~~	
Regenesis Organization Community Health Center #2	1341 North Limestone Street	Gaffney	South Carolina	29340-4733	(864) 582-2411 Ext 1011
~~Regions Mission Viejo Pharmacy~~	~~26024 Acero Suite 110~~	~~Mission Viejo~~	~~California~~	~~92691~~	
~~Regions Pharmacy~~	~~999 North Tustin Avenue Suite 216~~	~~Santa Ana~~	~~California~~	~~92705~~	
~~Reidland Pharmacy~~	~~5433 Reidland Road~~	~~Paducah~~	~~Kentucky~~	~~42003~~	
Reidville Road Pharmacy	2660 Reidville Road Suite 8	Spartanburg	South Carolina	29301-3512	(864) 435-9400
~~Reliance Pharmacy~~	~~11333 N.SEPULVEDA BLVD.STE1200~~	~~Mission Hills~~	~~California~~	~~91345~~	
~~Remedy Drug~~	~~8511 West Markham Street~~	~~Little Rock~~	~~Arkansas~~	~~72205~~	
~~REMINGTON DRUG CO~~	~~207 East Main Street~~	~~Remington~~	~~Virginia~~	~~22734~~	
~~Renegade Pharmacy Inc~~	~~18 Logan Street~~	~~Oceana~~	~~West Virginia~~	~~24870~~	
~~Rexall Pharmacy~~	~~8483 Holly Road Suite 202~~	~~Grand Blanc~~	~~Michigan~~	~~48439~~	
Reynolds Drug Store Inc	7 South Morgan Avenue	Andrews	South Carolina	29510	(843) 264-5454
~~Rhine Drug Company~~	~~119 First Street~~	~~Rhine~~	~~Georgia~~	~~31077~~	
~~Riccio Family Pharmacy~~	~~2217 Bristol Pike, Suite 2~~	~~Bensalem~~	~~Pennsylvania~~	~~19020~~	
~~Richard's Pharmacy~~	~~1112 East Griffin Parkway Suite B~~	~~Mission~~	~~Texas~~	~~78572~~	
~~Richard's Pharmacy~~	~~4630 South Closner Boulevard~~	~~Edinburg~~	~~Texas~~	~~78539~~	
~~Richard's Pharmacy~~	~~605 N Main Street Suite E~~	~~Donna~~	~~Texas~~	~~78537~~	
~~Richards Pharmacy~~	~~207 Broad Avenue~~	~~Palisades Park~~	~~New Jersey~~	~~07650~~	
Richburg Discount Pharmacy	3191 Lancaster Highway Suite H	Richburg	South Carolina	29729	(803) 500-2998
Rileys Drugs Inc	1207 West Main Street	Lexington	South Carolina	29072	(803) 359-2587
Sadler Hughes Apothecary	102 Jacobs Hwy	Clinton	South Carolina	29325-2599	(864) 833-4000
Santee Drug Center	3931-D Byrnes Dr	Saint Stephen	South Carolina	29479-0910	(843) 567-3291
~~Richmond Hill~~South End Pharmacy	~~2409 US Highway 17~~1401 Albright Rd	~~Richmond~~Rock Hill	~~Georgia~~South Carolina	~~313242~~9730	(803) 366-3784

RichwoodStuckey Pharmacy	24 West Ottawa207 South Main Street	RichwoodHemingway	OhioSouth Carolina	433442 9554	(843) 558-1010
RickerSweetgrass Pharmacy	1801 Big Horn Avenue1477 Long Grove Dr Suite 101	WorlandMt Pleasant	WyomingSouth Carolina	824012 9464	(843) 654-4013
Sweetgrass Pharmacy Carolina Park	3485 Park Avenue Blvd	Mt Pleasant	South Carolina	29466	(843) 800-7007
Ridge ViewTega Cay Pharmacy	3443 W 5600 South1741 Gold Hill Road Suite 106	RoyFort Mill	UtahSouth Carolina	840672 9708	(803) 547-6100
RidgewoodThe Pharmacy	389 Onderdonk Avenue2500 Hoffmeyer Road	RidgewoodFlorence	New YorkSouth Carolina	113852 9501-7407	(843) 773-2821
Triangle Pharmacy	1239 D Avenue	West Columbia	South Carolina	29169	(803) 794-4840
RidgmarTrue Pharmacy	2524 Mall Circle623 Beltline Blvd	Fort WorthColumbia	TexasSouth Carolina	761162 9205-1847	(803) 849-1500
Rigg FamilyCareTrue Pharmacy of Easley	37 W MAIN ST5809 Calhoun Memorial Highway Suite A	ALBIONEasley	IllinoisSouth Carolina	62806-1006296 40	(864) 810-5161
RigginsUnion Family Pharmacy LLC	12240 Augusta Road528 A Rice Ave	LavoniaUnion	GeorgiaSouth Carolina	305532 9379	(864) 427-3700
Riggs Drug	502 West Central Avenue	La Follette	Tennessee	37766	
Riggs Drug Jacksboro	2636 Jacksboro Pike	Jackboro	Tennessee	37757	
RileysWall Drugs of Pamplico Inc	1207 West Main616 South Walnut Street	LexingtonPamplico	South Carolina	290722 9583	(843) 905-0200
RIOS PHARMACYWannamaker Drug	35 South Morton Avenue107 West Blvd	MortonChesterfield	Pennsylvania South Carolina	190702 9709-1528	(843) 623-2999
Rison PharmacyWannamaker Drug	301 Main Street700 Chesterfield Hwy	RisonCheraw	ArkansasSouth Carolina	716652 9520	(843) 537-3221
RiteChoice Pharmacy at 11th Street	850 North 11th Street Floor 1 Room 148	Philadelphia	Pennsylvania	19123	
Rite ValueWaterway Pharmacy	26733373 Highway 6449 East	LouisaLittle River	KentuckySouth Carolina	412302 9566	(843) 734-0612
Rite-ValueWestbury Pharmacy	94 Board Walk Suite 2701 North Parler Ave	InezSaint George	KentuckySouth Carolina	412242 9477	(843) 563-9384
River City Pharmacy	5564 Little Debbie Parkway Suite 102	Ooltewah	Tennessee	37363-4356	
River OakWoodruff Health Mart Pharmacy	1080 West F Street,10195 Highway 221 Suite	OakdaleWoodruff	CaliforniaSouth Carolina	953612 9388-9358	(864) 670-8150

	D5				
RiverYorkville Pharmacy	124 Ames822 B East Liberty Street	Elk RapidsYork	MichiganSouth Carolina	496292 9745	(803) 628-7934
Riverside PharmacyDakotamart	22 Larry Joe Harless Drive120 West Sioux Avenue	GilbertPierre	West VirginiaSouth Dakota	256215 7501-1158	(605) 224-7396
RiversideHaisch Pharmacy	405 SOUTH 1ST ST303 E 5th St	GADSDENCanton	AlabamaSouth Dakota	359015 7013-1735	(605) 987-2661
RiversideLynn's Dakotamart Pharmacy Inc- Belle Fourche	935 Green600 National Street	GainesvilleBelle Fourche	GeorgiaSouth Dakota	305015 7717	(605) 892-2666
RiverviewLynns Dakotamart Pharmacy - Hot Springs	2405 Hamburg Turnpike Suite C509 Jensen Hwy	WayneHot Springs	New JerseySouth Dakota	074705 7747	(605) 745-3110
RMCAlphacare Specialty Pharmacy Brockton	7117 Brockton Avenue1510 Gunbarrel Road Suite 500	RiversideChattanooga	CaliforniaTennessee	92506-2658374 21-7175	(423) 888-9568
RMC Pharmacy Temescal Valley	21634 Retreat Parkway Suite 100	Temescal Valley	California	92883-6100	
Roan MountainAnderson Crossing Pharmacy	825133318 Andersonville Highway 19E	Roan MountainAndersonville	Tennessee	376873 7705	(865) 494-8444
Roan MountainApothecare Pharmacy of Bakersville	604 South 226 Highway1006 Main St	BakersvilleWartburg	North CarolinaTennessee	28705-8809378 87	4233467800
Roark's PharmacyApple Discount Drug	19118 Alberta Street520 Clinch Avenue	OneidaClinton	Tennessee	378413 7716-4228	(865) 457-0300
Baggett Pharmacy Inc	133 East Race Street	Kingston	Tennessee	37763	(865) 376-6452
RobinsonBakers Family Pharmacy	213 North Pinecrest Drive200 West Main street	AtlantaJackson	TexasTennessee	755513 8301	(731) 265-6555
Robinson Wellness Pharmacy	27 East Main Street	Mendham	New Jersey	07945	
Robins PharmacyBelew Drug Choto	150 South Houston Lake Road Suite 3001616 Choto Markets Way	Warner RobinsKnoxville	GeorgiaTennessee	31088-9056379 22-5760	(865) 766-4424
Rocky Mount Medical Park PharmBelew Drugs	901 North Winstead Avenue Suite 1002021 N Broadway St	Rocky MountKnoxville	North CarolinaTennessee	27804-8760379 17	(865) 525-4189
Rocky Point Pavilion PharmacyBelew Drugs Asheville Highway	7910 US8622 Asheville Highway 117 Suite 110	Rocky PointKnoxville	North CarolinaTennessee	284573 7924-4107	(865) 933-3441

Rocky Top PharmacyBelew Drugs Washington Pike	702 Grove Street5908 Washington Pike Suite 102	LoudonKnoxville	Tennessee	377743 7918-7012	(865) 525-4967
Brainerd Pharmacy	3602 Brainerd Road	Chattanooga	Tennessee	37411	(423) 305-1858
Roden-SmithCampbell's Hometown Pharmacy	305272 Highway 11 E Llano Estacado Boulevard	ClovisBulls Gap	New MexicoTennessee	881013 7711	(423) 235-6263
Rodger's PharmacyCity Drug	1909 Grand Avenue1612 East Lamar Alexander Parkway	LibertyMaryville	TexasTennessee	775753 7804	(865) 982-7162
Rogers Drug Company	326 East Cherokee Street	Wagoner	Oklahoma	74467	
RogersCity Drug Store	402 H Street630 RB Wilson Drive	ModestoHuntingdon	CaliforniaTennessee	953513 8344	(731) 986-2228
Crescent Center Drugs	228 North Fairmont Avenue	Morristown	Tennessee	37814	(423) 586-6263
Dannys Drugs	20029 Alberta Ave	Oneida	Tennessee	37841-4129	(423) 569-8652
DAYTON DRUG AND WELLNESS	6985 RHEA COUNTY HWY	Dayton	Tennessee	37321	(423) 775-5511
RogersDover Family Pharmacy	316 West Nepessing Street1307 Donelson Parkway	LapeerDover	MichiganTennessee	484463 7058	(931) 232-0123
Rogersville PharmacyDOWN HOME PHARMACY LLC AP	317 South1034 Main Street	RogersvilleBean Station	MissouriTennessee	657423 7708	(865) 993-4074
Rome Community PharmacyDUNLOP PHARMACY	501 East 2nd Avenue620 DUNLOP LN STE 110	RomeCLARKSVILLE	GeorgiaTennessee	30161-3 249370 40-6440	(931) 278-6422
Roosevelt PharmacyEAGLEDEN DISCOUNT DRUG	1606 East Roosevelt Boulevard Suite 10311510 CHAPMAN HWY	MonroeSEYMOUR	North CarolinaTennessee	281123 7865	(865) 299-4044
East Tennessee Discount Drug	524 Andrew Johnson Highway	Strawberry Plains	Tennessee	37871	(865) 933-4149
RosebankFamily Pharmacy	500 Tompkins Avenue6 Hospital Drive	Staten IslandLexington	New YorkTennessee	103053 8351	(731) 968-6979
Rose CityFamily Pharmacy Milan	6166078 South Broad1st Street	ThomasvilleMilan	GeorgiaTennessee	31792-5 551383 58-3131	(731) 238-3800
Rose DrugFamily Pharmacy Scotts Hill	211 East Main Street10091 Highway 100	ClarksvilleScotts Hill	ArkansasTennessee	728303 8374	(731) 549-2887
Rose Drug Dover	8880 Market Street	Dover	Arkansas	72837	

Rose Drug of Dardanelle	1176 State Highway 22, Suite A	Dardanelle	Arkansas	72834	
Roselawn Pharmacy	7601 Reading Road	Cincinnati	Ohio	45237	
Rose RockFamily Wellness Pharmacy	12100 South Yukon330 North Oak Avenue Suite A	GlenpoolCookville	OklahomaTennessee	740333 8501-2440	(931) 559-6337
Ross Drug	127 North Main Street	Sylvania	Georgia	30467	
RossiHamilton Discount Pharmacy	1891 Eastern Parkway6851 Shallowford Road	BrooklynChattanooga	New YorkTennessee	112333 7421	(423) 892-5955
Route 66Hermitage Pharmacy	117 Camino de Vida,3786 Central Pike Suite 200120	Santa RosaHermitage	New MexicoTennessee	884353 7076	(615) 454-3300
Rowland Old MainHerndon Pharmacy	101 South Bond175 West Main Street	RowlandCamden	North CarolinaTennessee	283833 8320-1621	(731) 584-4711
RoyalsHixson Pharmacy	20727 Wyoming Street5508 Hixson Pike Suite 1	FerndaleHixson	MichiganTennessee	482203 7343	(423) 498-5900
Royalty Pharmacy	1902 Royalty Drive Suite 110	Pomona	California	91767	
RUBIO PHARMACYHoskins Drug Store #2	16550 VENTURA BLD STE 100111 N Main St	ENCINOClinton	CaliforniaTennessee	91436-2004377 16	(865) 457-4340
JABOS PHARMACY, INC.	602 East Broadway	Newport	Tennessee	37821	(423) 623-3088
Rushville PharmacyJeff Co Drug Center	302 North Main127 West Meeting Street	RushvilleDandridge	IndianaTennessee	461733 7725	(865) 397-2868
Russell SpringsJohn Smith Professional Pharmacy	92 Joe T. Petty Drive100 Lantana Road, Suite 100201	Russell SpringsCrossville	KentuckyTennessee	426423 8555	(931) 484-1434
Russo's PharmacyLAFAYETTE PHARMACY	7902526 Highway 2352 Bypass West	Belle ChasseLafayette	LouisianaTennessee	700373 7083	(615) 666-4444
Loretto Drugs LLC	106 Church Street	Loretto	Tennessee	38469	(931) 853-5910
Rx BoxMac's Pharmacy	3265 Richmond Avenue2419 Washington Pike	Staten IslandKnoxville	New YorkTennessee	10312-2123379 17	(865) 524-3453
Rx ExpressMac's Pharmacy at South Peters	8986 Ortega Park Drive125 S Peters Rd	NavarreKnoxville	FloridaTennessee	325663 7923-5202	(865) 381-2500
RxMac's Pharmacy Oak Ridge	800 Swift Boulevard Suite 14045 New York Avenue	RichlandOak Ridge	WashingtonTennessee	99352-3559378 30-6410	(865) 298-8657
RYALS DRUG	12 S 2ND AVE7959	MCRAETOWNSEN	GeorgiaTenne	310553	(865) 421-6227

STOREMAC'S PHARMACY TOWNSEND	E LAMAR ALEXANDER PKWY	D	ssee	7882-4033	
S.RESESMARKS FAMILY PHARMACY	269 West White Horse Pike205 East 3rd Ave	PomonaOneida	New JerseyTennessee	082403 7841-5885	(423) 569-7800
S & J ArgyleMax Discount Pharmacy	101 Old Town Boulevard4531 Highway 58 Suite 102105	ArgyleChattanooga	TexasTennessee	762263 7416	(423) 803-5990
McMinnville Drug Center	1500 Sparta St	McMinnville	Tennessee	37110-1343	(931) 473-4471
S&JMorristown Pharmacy	801925 West Chapman Drive Suite 1004th North Street	SangerMorristown	TexasTennessee	762663 7814	(423) 587-4949
SafesaveMountain City Pharmacy	737 Colusa Avenue1641 South Shady St	YubaMountain City	CaliforniaTennessee	959913 7683-2015	(423) 727-0038
Saginaw ValleyMunsey Pharmacy	5618 State Street106 Administration Road	SaginawOak Ridge	MichiganTennessee	486033 7830	(865) 483-8429
Saint Johns Plaza PharmacyNewbern Drug #439	1301 20th Street625 W Main St Suite 120A	Santa MonicaNewbern	CaliforniaTennessee	90404-2094380 59	(731) 627-9573
Saint ParisNPS Pharmacy	122 SOUTH SPRINGFIELD STREET275 Cumberland Bend	SAINT PARISNashville	OhioTennessee	43072-0563372 28	(615) 743-1617
Saldo Drugs	384 Graham Avenue	Brooklyn	New York	11211	
Salem Hills PharmacyNunally Drug Store	118 North226 Main Street	SalemBaxter	UtahTennessee	846533 8544	(931) 858-3714
SALEM PHARMACY	3273 SALEM ROAD	COVINGTON	Georgia	30016	
SalineOlde Towne Pharmacy	75 East Bennett Street102 West Jackson Boulevard	SalineJonesborough	MichiganTennessee	481763 7659	(423) 753-4446
Phipps Pharmacy, Huntingdon	20190 Main Street, East	Huntingdon	Tennessee	38344	(731) 535-3522
SalmonPhipps Pharmacy #1	865 N 980 W15385 Highland Dr	OremMckenzie	UtahTennessee	840573 8201	(731) 352-0820
San Augustine Drug Co.Phipps Pharmacy #4	104 East Columbia19 Hughes Drive	San AugustineJackson	TexasTennessee	759723 8305	(731) 668-9072
SanbornPreferred Pharmacy Sevierville	323 North Sanborn1024 Middle Creek Road Suite 1	SalinasSevierville	CaliforniaTennessee	93905-2247378 62	(865) 366-1770
Sanders DrugsRiggs Drug	61 Falls Road2636 Jacksboro Pike	ToccoaJackboro	GeorgiaTennessee	305773 7757	(423) 566-1967

Jacksboro					
~~Sandersville Drug Co.~~	~~528 Sparta Road~~	~~Sandersville~~	~~Georgia~~	~~31082~~	
~~Sand Run~~River City Pharmacy	~~40 Sand Run Road~~5564 Little Debbie Parkway Suite 102	~~Akron~~Ooltewah	~~Ohio~~Tennessee	~~443133~~ 7363-4356	(423) 521-7279
~~S and S Drugs~~Roan Mountain Pharmacy	~~110 South Mill Street~~8251 Highway 19E	~~Beloit~~Roan Mountain	~~Kansas~~Tennessee	~~674203~~ 7687	(423) 772-3591
~~Santa Monica Medical Plaza~~Roark's Pharmacy	~~1260 15th~~19118 Alberta Street~~ Suite 100~~	~~Santa Monica~~Oneida	~~California~~Tennessee	~~904043~~ 7841	(423) 569-9000
~~Santee Drug Center~~Southland Pharmacy	~~3931 Byrnes~~482 Interstate Drive Suite ~~D~~K	~~Saint Stephen~~Manchester	~~South Carolina~~Tennessee	~~294793~~ 7355-3486	(931) 563-0008
~~Sarasota~~Stop-N-Go Discount Pharmacy	~~110 North Lime Avenue~~3984 Ringgold Road	~~Sarasota~~East Ridge	~~Florida~~Tennessee	~~342373~~ 7412	(423) 468-7161
Terry's Pharmacy Inc	310 East Central Avenue	La Follette	Tennessee	37766	(423) 562-4928
Terry's Pharmacy Jacksboro	2715 Jacksboro Pike	Jacksboro	Tennessee	37757	(423) 563-7455
~~Saugatuck~~The Drug Store at South Pittsburg	~~201 Butler Street~~335 South Cedar Avenue	~~Saugatuck~~South Pittsburg	~~Michigan~~Tennessee	~~494533~~ 7380	(423) 837-6855
~~Saults~~Tinsley Bible Drug ~~Store~~Co Inc #316	~~505 Court Street~~1224 Gay St	~~Fulton~~Dandridge	~~Missouri~~Tennessee	~~652513~~ 7725-0280	(865) 397-3444
~~Savco~~Town and Country Pharmacy	~~455 O'Conner Drive, Suite 190~~651 BROWN ST	~~San Jose~~CELINA	~~California~~Tennessee	~~951283~~ 8551-4019	(931) 243-6850
~~Save Discount Drugs~~US Pharmacy 001	~~716 Madison Avenue~~440 Saint Andrews Drive	~~Covington~~Murfreesboro	~~Kentucky~~Tennessee	~~410113~~ 7128	(615) 295-2301
~~Save More Drugs~~	~~2208 Fort Campbell Boulevard~~	~~Hopkinsville~~	~~Kentucky~~	~~42240~~	
~~Save More Pharmacy~~Val-U-Pharmacy	~~349 East Main~~2811 West Market Street ~~Suite 101~~	~~Alhambra~~Johnson City	~~California~~Tennessee	~~91801-7909~~37604	(423) 928-8004
~~Save Rite~~Village Pharmacy	~~3235 Belmont Street~~841 E 10th St	~~Bellaire~~Cookeville	~~Ohio~~Tennessee	~~439063~~ 8501-1903	(931) 400-0841
~~Save Rx~~WellCare Pharmacy	~~231 Del Prado Boulevard South~~2130 West Poplar Avenue Suite ~~11~~104	~~Cape Coral~~Collierville	~~Florida~~Tennessee	~~33990-5707~~38017	(901) 542-8001
~~SAVMOR DRUG~~	~~139 MAIN AVE W~~	~~TWIN FALLS~~	~~Idaho~~	~~83301-6194~~	
~~Sav- Mor~~Wilsons Sav-Mor Drugs	~~1967 Commerce~~265 East	~~Grenada~~Newport	~~Mississippi~~Tennessee	~~389013~~ 7821	(423) 623-3456

and Gifts	Main Street				
Savon DrugsAbernathy Drug & Mercantile	123 Leveridge318 Main St Unit A	East BernardAbernathy	Texas	774357 9311	(806) 298-2222
Sawnee Drug CoAlameda Thrifty Pharmacy	2515 Business Drive4900 Alameda Ave	CummingEl Paso	GeorgiaTexas	300287 9905-28 02	(915) 772-5331
Schmidt & SonsAM Pharmacy of Blissfield LLC	616 W. Adrian Street10401 Anderson Mill Road Suite112B	BlissfieldAustin	MichiganTexa s	492287 8750	(512) 270-4899
Schmidt & SonsAnderson's Gibson Pharmacy of Tecumseh Inc	120 East Chicago Boulevard600 S Palestine St Suite 100	TecumsehAthens	MichiganTexa s	492867 5751-22 60	(903) 675-7069
Schroeder Drugs #1201	540 East Fifth Street	Washington	Missouri	63090-0227	
SchultzArapaho Pharmacy	150 West Railroad Avenue57 Arapaho Village	GarnervilleRichards on	New YorkTexas	109237 5080	(972) 235-7133
Schulz and WrotenB & B Pharmacy	122300 North Washington StBallard	BeevillePampa	Texas	781027 9065	(806) 665-5788
SchwiettermanBaile y's Pharmacy	324 North Main Street6700 W Vickery Blvd Suite B	MinsterFort Worth	OhioTexas	458657 6116-91 56	(817) 862-7412
Bastrop Medicine Shop	1110 Main Street, Suite A	Bastrop	Texas	78602	(512) 350-4836
SchwiettermanBay Pharmacy	2 North Washington Street7407 W FM 2147	New BremenHorseshoe Bay	OhioTexas	458697 8657	(830) 598-1900
SchwiettermanBeac h Street Pharmacy	1302 Defiance7630 North Beach Street Suite 170	WapakonetaFort Worth	OhioTexas	458957 6137	(817) 427-8774
Schwieterman Pharmacy	404 West North Street	Coldwater	Ohio	45828	
ScituateBiocare Pharmacy	384 Gannett Road10603 Bellaire Boulevard Suite B114	ScituateHouston	Massachusett sTexas	020667 7072	(281) 530-5800
Scotland County Pharmacy	445 East Grand Avenue	Memphis	Missouri	63555	
Scotland Drug CompanyBi-Wize Pharmacy	140 South902 Main Street	LaurinburgFriona	North CarolinaTexas	283527 9035	(806) 250-2270
Boomtown Drug	514 South Oklahoma Cutoff	Burkburnett	Texas	76354	(940) 569-5600
Scott'sBrightMed Pharmacy	114 Serio Boulevard9630 Clarewood Drive Suite A-3	FerridayHouston	LouisianaTex as	713347 7036	(713) 772-7700

Scott DrugsBrookshire Bros. Pharmacy of Kirbyville	701 Park Avenue1005 South Margaret	PlainfieldKirbyville	New JerseyTexas	070607 5956	(409) 423-2248
Scott Family Pharmacy	414 West Grand Avenue	Campbell	Missouri	63933	
ScottieBrown's Pharmacy	1951 Second Street2021 N Macarthur Blvd Suite 120	RichlandsIrving	VirginiaTexas	246417 5061-21 70	(972) 254-8156
Scotts FamilyCareFusion Pharmacy	220 North Sangamon Avenue10 Medical Pkwy Suite 107	Gibson CityFarmers Branch	IllinoisTexas	609367 5234-78 69	(469) 502-3881
Script ChoiceCare Rx Pharmacy #1	9740 North 56th Street4501 Hale Ave Suite 1	Temple TerraceHarlingen	FloridaTexas	336177 8550-92 96	(956) 365-4677
Scripts Direct PharmacyCatching's Prescriptions LTD	8313 West Hillsborough Avenue1900 South Coulter Street Suite 260F	TampaAmarillo	FloridaTexas	336157 9106	(806) 355-2924
Celina Drug	701 North Preston Road Suite 210	Celina	Texas	75009	(972) 382-2832
SearsCenter Pharmacy	1003 Madison105 North Smith Street	Oak ParkPleasanton	IllinoisTexas	60302-4 499780 64	(830) 569-2512
Seashore DrugsCircle Drug	10227 Beach3211 Robinson Drive Southwest	CalabashWaco	North CarolinaTexas	284677 6706	(254) 662-0774
Seashore DrugsCity Drug	1304 Highway 17 North232 E JEFFERSON	Little RiverVan Alstyne	South CarolinaTexas	295667 5495	(903) 482-5279
City Drug Store	104 East Belknap	Jacksboro	Texas	76458	(940) 567-5576
Sea ViewClear Lake Professional Building Pharmacy	665 Camino de Los Mares251 Medical Center Boulevard, Suite 101100	San ClementeWebster	CaliforniaTexas	926737 7598	(281) 332-2496
SeawayCollingsworth Pharmacy	1707 Cherry1016 16TH Street	ToledoWellington	OhioTexas	436087 9095	(806) 447-1184
Sebastopol FamilyComfort Pharmacy, Inc.	652 Petaluma Avenue Suite I1404 Highway 27	SebastopolComfort	CaliforniaTexas	95472-4 266780 13	(830) 995-3300
SeifertCub Drug Inc	230 South116 East Main Street	ElkhartOlney	IndianaTexas	465167 6374-19 22	(940) 564-5551
Cypress Pharmacy	17330 Spring Cypress Road, Suite 160	Cypress	Texas	77429	(281) 213-3490
SeifertDaniel Drug #2Inc	100 N Elkhart3409 W 7th St	WakarusaFort Worth	IndianaTexas	465737 6107-27 18	(817) 332-6386
Seifert Drug #3	2102 N MAIN ST	NAPPANEE	Indiana	46550	

	SUITE A				
SelamDavila Pharmacy	2447 Telegraph Ave1423 Guadalupe Street Suite 108	OaklandSan Antonio	CaliforniaTexas	946127 8207	(210) 226-5293
Sempert'sDavy Crockett Drug Inc	735 Spruce107 South Fourth Street	Myrtle PointCrockett	OregonTexas	974587 5835	(936) 544-2275
DEVINE'S CRAWFORD RX	200 S. Teel Drive	Devine	Texas	78016	(830) 455-5071
DIMMITT PHARMACY	201 NW 2ND ST	DIMMITT	Texas	79027	(806) 647-3151
Sergeant BluffDorado Pharmacy	105 Gaul Drive4060 Faudree Road Suite A101	Sergeant BluffOdessa	IowaTexas	510547 9765	(432) 614-6828
Seven Lakes Prescription Shoppe IncDripping Springs Pharmacy	120 Mac Dougall Dr100 Commons Road Suite 1	West EndDripping Springs	North CarolinaTexas	273767 8620	(512) 858-7935
Shafer's PharmacyDUFFEY DRUG	408 East Broad311 North Center Street	TamaquaFranklin	Pennsylvania Texas	182527 7856	(979) 828-3536
Dyer Drug Store	133 McKinney Street	Farmersville	Texas	75442	(972) 782-6262
East Austin Medicine Shop	1909 E 38th 1/2 St Suite C2	Austin	Texas	78723-5749	(512) 643-0999
Shatto's FrontierEconomy Drug	1202511 East RichardsGarland Street	DouglasGrand Saline	WyomingTexas	826337 5140	(903) 962-3900
Shavano OaksEdgewood Pharmacy	12602 TOEPPERWEIN RD STE 118186 S Friendswood Dr	San AntonioFriendswood	Texas	782337 7546	(281) 993-4779
Shavano Oaks Pharmacy @ Westover HillsElgin Medicine Shop	3903 Wiseman Boulevard199 Highway 290 East Suite 313A	San AntonioElgin	Texas	782517 8621	(512) 285-6308
Sheba DiscountEnglish Pharmacy	10136 Vernor Highway2600 10th Street	DearbornWichita Falls	MichiganTexas	481207 6309	(940) 723-6060
Sheehans Pharmacy	79 East Carey Street	Plains	Pennsylvania	18705-2007	
Shelby FamilyExpress Care Pharmacy	48887 Hayes3648 Old Denton Road Suite 104	Shelby TownshipCarrollton	MichiganTexas	483157 5007	(214) 800-5526
ShelbyvilleFamily Pharmacy of Pottsboro	182 Frankfort Road563 W FM 120	ShelbyvillePottsboro	KentuckyTexas	400657 5076	(903) 786-2006
Sheliga Drug	6025 St. Clair Avenue	Cleveland	Ohio	44103	
ShepherdstownFiesta MLK Pharmacy	7670 Martinsburg Pike Suite 23230	ShepherdstownDallas	West VirginiaTexas	254437 5210	(214) 421-1067

	Martin Luther King				
Sheridan FamilyFriendly Pharmacy	677 Heritage Drive2176 East Garrison Street Suite D	SheridanEagle Pass	ArkansasTexas	721507 8852	(830) 752-6088
Sherman's Apothecary Pharmacy	1212 South Main Street, Suite 101	Salinas	California	93901	
Shop and CarryFrisco Pharmacy	1301 Lindley Avenue14550 State Highway 121 Suite 150	PhiladelphiaFrisco	Pennsylvania Texas	19141-2 747750 35	(469) 305-7058
Shores SpecialtyGail's Pharmacy	29306 Harper Avenue810 Woodrow Wilson Ray Circle	Saint Clair ShoresBridgeport	MichiganTexas	480817 6426	(940) 683-4011
Siegel'sGeneRx Discount Pharmacy	12011235 South Broad StreetJosey Lane Suite 533	TrentonCarrollton	New JerseyTexas	086107 5006	(972) 417-8895
Glen Rose Discount Drug	906 North East Big Bend Trail	Glen Rose	Texas	76043	(254) 897-2711
Sierra BlancaGreenbriar Pharmacy	1206 Mechem Drive250 East FM 2449	RuidosoPonder	New MexicoTexas	883457 6259	(940) 479-0111
SierraGreen Cross Pharmacy	210 South Grand Avenue Suite 1161305 Airport Freeway Ste 110	GlendoraBedford	CaliforniaTexas	917417 6021	(817) 354-7771
SilveradoGuardian Angel Pharmacy	1473 Lincoln Avenue1537 North Zaragoza Road Suite D1A	CalistogaEl Paso	CaliforniaTexas	945157 9936	(915) 850-0713
Silver CreekHale Center Clinical Pharmacy & Gifts	945 Market Street601 Avenue G	La CygneHale Center	KansasTexas	660407 9041	(806) 839-2466
SilverHansford Pharmacy	1890 Silver Cross Boulevard Suite 120710 S Roland St	New LenoxSpearman	IllinoisTexas	60451-9 528790 81-3499	(806) 659-2226
SILVERTONHAWK PHARMACY	1824 Hooper Avenue120 West Park	Toms RiverIowa Park	New JerseyTexas	087537 6367	(940) 592-4191
SistersvilleHealthville Pharmacy	312 Diamond Street7215 Mcpherson Rd	SistersvilleLaredo	West VirginiaTexas	261757 8041	(956) 701-3349
Sixth Street DrugsHenrietta Pharmacy	1020 Sixth Street124 North Bridge	Traverse CityHenrietta	MichiganTexas	496847 6365	(940) 538-4361
Skaff's CornerHereford Pharmacy	1112 Saint Georges809 South 25 Mile Avenue	RahwayHereford	New JerseyTexas	070657 9045	(806) 364-3400
SkinnersHeritage	905 Deep Valley	Rolling Hills	CaliforniaTex	902747	(817) 741-7100

Pharmacy	~~Drive~~3529 Heritage Trace Parkway Suite 141	~~Estates~~Keller	as	6244	
~~Skips Budget~~Highland Drug	~~2015 Library Circle #102~~504 East Avenue Unit E	~~Grand Forks~~Alpine	~~North Dakota~~Texas	~~582017~~ 79830	(432) 837-3931
~~Sky View Pharmacy~~	~~1750 East 3100 North~~	~~Layton~~	~~Utah~~	~~84040~~	
~~Smart Pharmacy #22~~	~~616 North 8th Street~~	~~Osage~~	~~Iowa~~	~~50461~~	
~~Smith's~~Hillcrest Pharmacy	~~133 West Hunting Park Avenue~~1015 Hillcrest Drive, Suite ~~200~~B	~~Philadelphia~~Vernon	~~Pennsylvania~~ Texas	~~191407~~ 6384	(940) 552-5414
~~Smith's~~Hodges & Sargent Pharmacy	~~111~~ 206 South ~~Broad Street~~Key Avenue	~~Kenbridge~~Lampasas	~~Virginia~~Texas	~~239447~~ 6550	(512) 556-3392
~~Smith's~~Hometown Pharmacy	~~141 Eighth St.~~201 East Commerce	~~McRae Helena~~Fairfield	~~Georgia~~Texas	~~310377~~ 5840	(903) 389-2541
~~Smith's~~Hometown Pharmacy	~~841 E Hunting Park Ave~~2800 Highway 22 West	~~Philadelphia~~Corsicana	~~Pennsylvania~~ Texas	~~19124-4800~~75110	(903) 872-3784
~~SMITH BROTHERS DRUG~~	~~25 West Main Street~~	~~Maple Shade~~	~~New Jersey~~	~~08052~~	
~~Smith Drug~~	~~695 East Third Street~~	~~Gentry~~	~~Arkansas~~	~~72734-0629~~	
~~Smith Drug and Compounding, Inc~~	~~1629 Airport Road Suite D~~	~~Hot Springs~~	~~Arkansas~~	~~71913~~	
~~Smith Drug and Compounding Inc~~	~~1500 Albert Pike Road~~	~~Hot Springs~~	~~Arkansas~~	~~71913-4023~~	
~~Smith Drug And Compounding Inc.~~	~~1 Mercy Lane Street Suite 103~~	~~Hot Springs~~	~~Arkansas~~	~~71913-6408~~	
~~Smithland Drugs~~	~~203 East Adair Street~~	~~Smithland~~	~~Kentucky~~	~~42081~~	
~~Smith~~Hometown Pharmacy	~~1800 Freedom Road Unit D~~310 Charlie Dr	~~Little Chute~~Whitesboro	~~Wisconsin~~Texas	~~541407~~ 6273	(903) 564-1234
~~Smiths St Helena~~Hometown Pharmacy	~~1390 Railroad Avenue~~101 Medical Drive	~~Saint Helena~~Palestine	~~California~~Texas	~~945747~~ 5801	(903) 729-3100
~~Sniteman Pharmacy~~	~~N3708 River Ave STE A~~	~~Neillsville~~	~~Wisconsin~~	~~54456-7218~~	
~~Soledad~~Hometown Pharmacy ~~and Wellness Center~~Gainesville	~~537 Front Street~~1201 Olive St	~~Soledad~~Gainesville	~~California~~Texas	~~939607~~ 6240	(940) 668-7384
~~Somerset Park Pharmacy~~	~~900 Easton Avenue Suite 26~~	~~Somerset~~	~~New Jersey~~	~~08873~~	
~~Sooner~~Hylands Pharmacy ~~of Oklahoma~~ LLC	~~815~~108 West ~~Broadway Street~~Oklahoma Avenue	~~Sulphur~~Wheeler	~~Oklahoma~~Texas	~~730867~~ 9096	(806) 826-5561

SORTPAK PHARMACY	655 North Central Avenue 22nd Floor	Glendale	California	91203	
SoutheastJordan Pharmacy	400 PARKER AVE N STE 500A1332 Hwy 16 S	BROOKLETGraham	GeorgiaTexas	30415-9506764 50	(940) 549-1011 Ext 0
South EndJoshua Pharmacy	1401 Albright Road504 North Broadway	Rock HillJoshua	South CarolinaTexas	2973076058	(817) 295-8531
Southern Chester CountyK & K Pharmacy	10111411 West Baltimore Pike Suite 109American Blvd	West GroveMuleshoe	Pennsylvania Texas	193907 9347	(806) 272-7511
SOUTHERN DRUG CO-DARIEN	1001 North Way	Darien	Georgia	31305	
Southern Drug Co - Jesup	918 S 1st St.	Jesup	Georgia	31545	
Southern Drug Company	4075 East First Street	Blue Ridge	Georgia	30513	
Southern StarKitch Pharmacy	6101 WINDHAVEN PARKWAY STE 12510501 Quaker Avenue Suite 300	PLANOLubbock	Texas	750937 9424-83 12	(806) 370-7311
South ForkKK's Pharmacy #251	732980 North Main StWalnut Creek Drive #118	MoorefieldMansfield	West VirginiaTexas	2683676063	(817) 453-5700
South FultonKK's Pharmacy Inc.#51	301 South Fulton2480 W Illinois Avenue	Mount VernonDallas	New YorkTexas	105537 5233	(214) 337-7770
SOUTH KITSAP PHARMACY	1397 OLNEY AVE SE STE 109	PORT ORCHARD	Washington	98366	
Southland Pharmacy	482 Interstate Drive Suite K	Manchester	Tennessee	37355-3486	
South SideKraege Drug Store	337 Church113 East Main Street	OttumwaYorktown	IowaTexas	525017 8164-20 30	(361) 564-2216
SouthsideLake Worth Pharmacy	11964 Escue Drive Suite A4701 BOAT CLUB RD SUITE 115	TannerFort Worth	AlabamaTexas	356717 6135	(817) 237-7877
South Street PharmacyLamar Plaza Drug Store	14561509 South StreetLamar Boulevard Suite 550	WheatlandAustin	WyomingTexas	822017 8704	(512) 442-6777
Southwood Pharmacy	22220 Palos Verdes Boulevard	Torrance	California	90505-2017	
SpearsLeonard Pharmacy	405 Becker Drive122 West Collins Street	Roanoke RapidsLeonard	North CarolinaTexas	278707 5452	(903) 587-3363
SpectrumLifetime Pharmacy	18 Endeavor26795 US Hwy 380 E Suite 100800	IrvineAubrey	CaliforniaTexas	926187 6227-78 52	(972) 999-1772

Spencers Drug Store Inc	100 North Main Street	Blackstone	Virginia	23824-1424	
Spindale Drug	109 W Main Street	Spindale	North Carolina	28160	
Spring City Pharmacy LLC	101 N WALNUT ST	COLFAX	Iowa	50054	
Springfield Pharmacy	1154 Baltimore Pike	Springfield	Pennsylvania	19064	
Spring GreenLindberg Pharmacy	1443 FM 1463 Road Suite 6505203 S McColl Rd	KatyEdinburg	Texas	77494-5479785 39	(956) 687-6204
Spring MillsLone Star Pharmacy	5759 Williamsport Pike 1395 Sattler Rd Suite 1058	MatinsburgNew Braunfels	West VirginiaTexas	254047 8132	(830) 964-3615
SpringviewLone Star Pharmacy	4 Elmwood Avenue13230 Fm 1764 Rd STE B	IrvingtonSanta Fe	New JerseyTexas	071117 7510	(409) 925-9995
Spruce Mountain Pharmacy Inc.	148 Main Street	Jay	Maine	04239	
SRX Specialty Care Pharmacy	3412 West 13 Mile Road	Royal Oak	Michigan	48073-6708	
ST.CHARLES PHARMACY	1008 North Saginaw Street	St Charles	Michigan	48655	
St. ClareLynn's La Vega Pharmacy	1203 Langhorne Newtown Road2401 E Waco Drive	LanghorneWaco	Pennsylvania Texas	190477 6705	(254) 799-4949
St. Elizabeth'sLynn's Pharmacy Hewitt	1 Elizabeth Place511 N Hewitt Dr Suite 10151	DaytonHewitt	OhioTexas	454177 6643-30 93	(254) 666-5000
St. GeorgeMagnolia Pharmacy	99 Stuyvesant Place18230 FM 1488, Suite 100	Staten IslandMagnolia	New YorkTexas	103017 7354	(281) 356-9089
St. Georges FamilyMalakoff Pharmacy	332409 W. St Georges Avenue Royall Blvd	LindenMalakoff	New JerseyTexas	070367 5148	(903) 489-1909
St. John ValleyMaloney Prescription Pharmacy	182 Market1405 Hailey Street Suite 2	Fort KentSweetwater	MaineTexas	047437 9556	(325) 236-6394
St. JudeMartin Tipton Pharmacy Hillside	301 Madison Street Suite 1145901 Bell St Unit 30	JolietAmarillo	IllinoisTexas	604357 9109-62 63	(806) 310-6255
St. Luke's Lowcost Pharmacy	11201 Shaker Boulevard Suite 126	Cleveland	Ohio	44104-3833	
ST. MARY'S PHARMACY	350 BOULEVARD	PASSAIC	New Jersey	7055	
St. Mary Pharmacy	1290 West Bay	Largo	Florida	33770	

	Drive				
Stan's Drug	3001 South Saviers Road	Oxnard	California	93033	
Standard Drug StoreMartin Tipton Pharmacy LLC	3221501 South HancockTyler Street	McAdooAmarillo	Pennsylvania Texas	18237 79101	(806) 373-2812
Standard Pharmacy @ Healthfirst	387 Quarry Street	Fall River	Massachusetts	02723	
StarcareMaxwell Pharmacy	7200 RIDGE RD STE 106626 North Highway 155	Port RicheyFrankston	FloridaTexas	346687 5763	(903) 876-2323
StaytonMeadowbrook Pharmacy	102 Martin6624 Meadowbrook Drive, Suite A	StaytonFort Worth	OregonTexas	973837 6112	(817) 451-6900
STAYWELL PHARMACY	912 E NORTHWEST HWY	PALATINE	Illinois	60074-6506	
Stedman Drug Center	7445 Clinton Road	Stedman	North Carolina	28391-8901	
Steffen Drug	214 North Broadway	Hartington	Nebraska	68739-0248	
StephensMedcenter Pharmacy	1101 Main1419 East Bustamante Street	HonesdaleLaredo	Pennsylvania Texas	184317 8041	(956) 791-1991
Stepp SaverMedical Plaza Pharmacy	203615 North Newberger AvenueThird Street, Suite 1	BruceLongview	MississippiTexas	38915-0656756 01	(903) 757-3477
Sterling	700 Division Street South	Northfield	Minnesota	55057	
Sterling Drug	1305 1st Avenue South West	Austin	Minnesota	55912	
Sterling Drug	410 Hoffman Drive	Owatonna	Minnesota	55060	
Sterling Drug #04	400 South State Street 50	Fairmont	Minnesota	56031	
Sterling Drug #08	511 10th Street	Worthington	Minnesota	56187	
Sterling Drug #19	430 2nd Avenue NW	Faribault	Minnesota	55021	
Sterling Drug #20	209 Maine Avenue, Suite 105	Adrian	Minnesota	56110	
Sterling Drug #24	115 West Jessie Street	Rushford	Minnesota	55971	
Sterling Drug #26	615 West Esch Drive	Caledonia	Minnesota	55921	
Sterling Drug #29	306 Main Street Suite 103	La Crescent	Minnesota	55947	
Sterling HeightsMedicine Chest Pharmacy	38924 Dequindre Road814 Montgomery Rd	Sterling HeightsGraham	MichiganTexas	483107 6450	(940) 549-8360
SterlingMeridian Pharmacy Group	808 Hunter Avenue1110 E Pleasant Run Rd	SikestonDesoto	MissouriTexas	638017 5115-4202	(214) 333-1600

	Suite 1AA				
Sterling Retail KC	3338 Northeast Ralph Powell Road, Suite E	Lees Summit	Missouri	64064	
StevesMid Valley Pharmacy	16117 Mcmullen Highway Southwest400 E Expressway 83	CumberlandMercedes	MarylandTexas	21502785570	(956) 565-4111
Stewart'sMonahans Pharmacy	1013 Jefferson801 East 4th Street	GreenfieldMonahans	OhioTexas	45123779756	(432) 943-4212
St Mary Pharmacy II	30606 US Highway 19 North	Palm Harbor	Florida	34684	
St MarysMoores Pharmacy	520 West Bertrand Avenue200 S Rachal St	Saint MarysSinton	KansasTexas	665367 8387-2552	(361) 364-1416
Stockton PharmacyMoore Than Medicine	616 W Dickinson Boulevard105 Southwest 2nd Street	Fort StocktonTulia	Texas	79735-2531790 88	(806) 995-3551
MS Pharmacy	27721 Tomball Parkway Suite 400	Tomball	Texas	77375	(832) 698-4522
StocktonNorman's Pharmacy	402 Main2105 South Day Street	StocktonBrenham	KansasTexas	676697 7833-5512	(979) 836-5264
Stone RidgeNuCare Pharmacy	24560 Southpoint Drive Unit 1906050 Lake Worth Boulevard	AldieLake Worth	VirginiaTexas	201057 6135	(817) 238-7773
Stony PointOchoa's Pharmacy Central	691002 South Liberty Drive10TH Avenue Suite A	Stony PointEdinburg	New YorkTexas	109807 8539	(956) 381-0967
Stop-N-Go Discount Pharmacy	3984 Ringgold Road	East Ridge	Tennessee	37412	
StovallsPalacios Prescription ShopShoppe	202 South Court321 Main Street	ScottsvillePalacios	KentuckyTexas	421647 7465-5461	(361) 972-3608
StrasburgPalmer Pharmacy Plus	33820 Old Valley Pike2731 West Northwest Highway Suite 7105	StrasburgDallas	VirginiaTexas	22657-3793752 20	(214) 765-9238
Strawberry HillsParkers City Pharmacy	2670 New Holt Road Suite D1005 E Court St	PaducahSeguin	KentuckyTexas	420017 8155	(830) 379-1450
Stroud Drug	406 West Main	Stroud	Oklahoma	74079	
St Simons Drug Company	209 Longview Plaza	St Simons Is	Georgia	31522	
Stuarts Draft Family Pharmacy	2929 Stuarts Draft Highway Suite 101	Stuarts Draft	Virginia	24477	
StuckeyPayne Family Pharmacy	207200 South Main Street	HemingwayFloydada	South CarolinaTexas	295547 9235	(806) 983-5111
Stucki FamilyPCF Pharmacy	568 West Telegraph Street	WashingtonPasadena	UtahTexas	84780-1596775	(713) 947-6767

	#32615 Strawberry Road			02	
Stultz Pharmacy	1615 Ashland Road	Greenup	Kentucky	41144	
Su Farmacia AmigaPecan Discount Drug	Avenida Las Americas BU 1 Residencial Bairoa9203 Plantation Drive Suite 1	CaguasGranbury	Puerto RicoTexas	007257 6049	(817) 573-9344
SullivanPelzel's Hometown Pharmacy	1140 Grand Avenue1340 North Highway 377, Suite 100	BacliffPilot Point	Texas	775187 6258	(940) 686-0123
SULLIVAN PHARMACY_NewPeoples Pharmacy #1	731 N MAIN ST STE B4018 North Lamar Boulevard	HARRISONAustin	ArkansasTexas	726017 8756	(512) 459-9090
Sumas DrugPeoples Pharmacy #2	1143 Cherry Street3801 B South Lamar Boulevard	SumasAustin	WashingtonTexas	982957 8704	(512) 444-8866
Summit Health Pharmacy LLC	3400 Edgmont Avenue	Brookhaven	Pennsylvania	19015-2804	
SummitPeoples Pharmacy #3	140 Northstar4201 Westbank Drive	Holts SummitAustin	MissouriTexas	65043-1123787 46	(512) 327-8877
SummitPeoples Pharmacy #4	300 West Burlington Avenue13860 US Hwy 183 N Suite C	FairfieldAustin	IowaTexas	52556-3241787 50	(512) 219-9499
Sun DiscountPerrone Legend Pharmacy	3600 S Tuttle AVE3921 Benbrook Highway	SarasotaFort Worth	FloridaTexas	342397 6116	(817) 738-2135
PETS AND PEOPLE PHARMACY	9215 BROADWAY ST STE 113 SUITE 113	PEARLAND	Texas	77584-8987	(281) 741-5825
Pharmacia Sana	102 East Danieldale Road Suite 100	Duncanville	Texas	75137	(469) 513-2499
Pharmcare	1834 Broadway Street Suite 106	Pearland	Texas	77581	(281) 996-7500
Sunflower GreenwoodPipeline Pharmacy	201 West Park Avenue328 East Pipeline Road	GreenwoodHurst	MississippiTexas	38930-3008760 53-5831	(817) 494-3606
SunPleasant Grove Pharmacy	2559 South King3302 Richmond Road	San JoseTexarkana	CaliforniaTexas	951227 5503-21 34	(903) 832-4545
SunPopular Pharmacy of Venice	12145326 East Venice AvenueUS Highway 83 Suite CA # 5	VeniceRio Grande City	FloridaTexas	342857 8582-94 09	(956) 317-1112
SunScriptPopular Pharmacy 3	7869 Pines Boulevard2849	Pembroke PinesRoma	FloridaTexas	330247 8584-89	(956) 847-9000

	East Grant Street			14	
~~Sunshine Center~~Powers Pharmacy No 1 Inc	~~1166 Old Mission Road~~702 West Houston Street	~~South San Francisco~~Linden	~~California~~Texas	~~94080-1303~~75563	(903) 756-7923
~~Sunshine Family Pharmacy~~Prescription Shop Inc	~~1187 Duck Road~~909 E Holland Ave	~~Duck~~Alpine	~~North Carolina~~Texas	~~27949~~79830	(432) 837-3498
Preston Road Apothecary Inc	9301 North Central Parkway Suite 110	Dallas	Texas	75231	(214) 361-6172
~~Sunshine~~Preston Road Pharmacy	~~43009 Hayes~~6901 Preston Road	~~Sterling Heights~~Dallas	~~Michigan~~Texas	~~48313~~75205	(214) 521-9991
~~Sunshine~~Primemed Pharmacy	~~5040 West SR 46~~10500 Vista Del Sol Dr Suite ~~1126~~A	~~Sanford~~El Paso	~~Florida~~Texas	~~32771~~79925-7925	(915) 595-1300
QUALITY CARE PHARMACY	2300 West FM 544 Suite 130	Wylie	Texas	75098	(972) 442-5333
~~Super Care~~Red's Pharmacy, LLC	~~24825 Alessandro Blvd Suite 2~~3102 Garrett Drive	~~Moreno Valley~~Perryton	~~California~~Texas	~~92553~~79070	(806) 435-3759
~~Super Discount~~Richard's Pharmacy	~~1423 South Collins Street~~1112 East Griffin Parkway Suite B	~~Plant City~~Mission	~~Florida~~Texas	~~33563~~78572	(956) 581-4200
~~Super Farmacia Lizette~~	~~Calle Guillermo Esteves #103~~	~~Jayuya~~	~~Puerto Rico~~	~~00664~~	
~~Super Health~~Richard's Pharmacy	~~6390 Amboy Road~~605 N Main Street Suite E	~~Staten Island~~Donna	~~New York~~Texas	~~10309~~78537	(956) 464-4131
~~Super Value~~Richard's Pharmacy	~~720 North Industrial Boulevard~~4630 S Closner Blvd	~~Euless~~Edinburg	Texas	~~76039~~78539	(956) 289-1880
~~Sutter~~Ridgmar Pharmacy	~~470 PLUMAS BLVD STE 103~~2524 Mall Circle	~~Yuba City~~Fort Worth	~~California~~Texas	~~95991~~76116	(817) 737-7377
~~SUTTON PHARMACY~~	~~210 North Saunders Avenue~~	~~Sutton~~	~~Nebraska~~	~~68979~~	
~~Sutton~~Robinson Family Pharmacy	~~330 West Maple Street~~213 North Pinecrest Drive	~~Lancaster~~Atlanta	~~Kentucky~~Texas	~~40444~~75551	(903) 796-1730
~~SWAN PHARMACY INC~~	~~48 North Main Street~~	~~Wadley~~	~~Georgia~~	~~30477~~	
~~Swartz Creek~~Rodger's Pharmacy	~~8021 Miller Road~~1909 Grand Avenue	~~Swartz Creek~~Liberty	~~Michigan~~Texas	~~48473-1342~~77575	(936) 776-5228
~~Sweetgrass~~S & J Argyle Pharmacy ~~and Compounding~~	~~1477 Long Grove Dr.~~101 Old Town Boulevard Suite ~~101~~102	~~Mt Pleasant~~Argyle	~~South Carolina~~Texas	~~29464~~76226	(940) 464-4500
~~Sweetgrass Pharmacy Carolina~~	~~3485 Park Avenue Boulevard~~	~~Mt Pleasant~~	~~South Carolina~~	~~29466-7242~~	

Park					
Swisher & LohseS&J Pharmacy	636 East Main Street801 West Chapman Drive Suite 100	PomeroySanger	OhioTexas	457697 6266	(940) 458-4448
Sykes Pharmacy	202 2nd Street Avenue West	Kalispell	Montana	59901	
Sykes Pharmacy Columbia FallsSan Augustine Drug Co.	500 12TH AVE W STE 1A104 East Columbia	Columbia FallsSan Augustine	MontanaTexas	599127 5972	(936) 275-3401
Tablets Pharmacy IncSavon Drugs	9603 S Pulaski Rd123 Leveridge	Evergreen ParkEast Bernard	IllinoisTexas	608057 7435	(979) 335-4810
Tallapoosa Drug	2066 US HIGHWAY 78	Tallapoosa	Georgia	30176-1464	
TallmansSchulz and Wroten Pharmacy	4 West Main Street122 N Washington St	Walla WallaBeeville	WashingtonTexas	993627 8102	(361) 358-1150
Tanglewood Drug Store	6815 Cantrell Road	Little Rock	Arkansas	72207	
TAR HEEL DRUG	316 South Main Street	Graham	North Carolina	27253	
Taylor Discount Drugs	9320 Telegraph Road	Taylor	Michigan	48180	
Taylor Drug	201 South Summit Street	Arkansas City	Kansas	67005-2895	
TaylorShavano Oaks Pharmacy	109 Fairgrounds Road12602 TOEPPERWEIN RD STE 118	HardinsburgSan Antonio	KentuckyTexas	401437 8233	(210) 448-9080
Tega CayShavano Oaks Pharmacy @ Westover Hills	1741 Gold Hill Road3903 Wiseman Blvd Suite 106101	Fort MillSan Antonio	South CarolinaTexas	297087 8251-4401	(210) 441-4501
TekoaSouthern Star Pharmacy	124 North Crosby Street6101 WINDHAVEN PARKWAY STE 125	TekoaPLANO	WashingtonTexas	990337 5093	(844) 290-7034
Temple AvenueSpring Green Pharmacy 1	2000 Snead Avenue6144 Sienna Ranch Road Suite 200	Colonial HeightsMissouri City	VirginiaTexas	23834-2428774 59-7120	(346) 341-7148
TempleStockton Pharmacy	285 Sage Street616 W Dickinson Blvd	TempleFort Stockton	GeorgiaTexas	301797 9735	(432) 336-2200
Teplow Drugs	404 E MAIN ST	BARSTOW	California	92311-2326	
Terry'sSullivan Pharmacy Inc	310 East Central1140 Grand Avenue	La FolletteBacliff	TennesseeTexas	377667 7518	(281) 339-4577
Terry'sSuper Value Pharmacy Jacksboro	2715 Jacksboro Pike720 North Industrial	JacksboroEuless	TennesseeTexas	377577 6039	(817) 283-5308

	Boulevard				
Texas Professional Pharmacy-Magnolia	18602 FM 1488 STE 700	Magnolia	Texas	77355	(281) 356-2216
~~The Apothecary~~	~~1470 Webb Street~~	~~Cumberland~~	~~Wisconsin~~	~~54829~~	
~~The Apothecary at St James~~	~~2571 ST JAMES DR UNIT 102-C~~	~~SOUTHPORT~~	~~North Carolina~~	~~28461-8201~~	
~~The Brown Drug Company~~	~~1121 Maine Street~~	~~Quincy~~	~~Illinois~~	~~62301~~	
~~The Downtown Drug Store~~	~~516 East 4th Street~~	~~Tonganoxie~~	~~Kansas~~	~~66086~~	
~~The Drug Store~~	~~104 North Henry Street~~	~~Stoneville~~	~~North Carolina~~	~~27408-0258~~	
The Drug Store	19 County Road 4114 Suite 1	Pittsburg	Texas	75686	(903) 708-7500
~~The Drug Store~~	~~464 N DEAN RD~~	~~AUBURN~~	~~Alabama~~	~~36830~~	
~~The Drug Store at South Pittsburg~~	~~335 South Cedar Avenue~~	~~South Pittsburg~~	~~Tennessee~~	~~37380~~	
~~The Drug Store At Stevenson~~	~~205 Kentucky Avenue~~	~~Stevenson~~	~~Alabama~~	~~35772~~	
~~The Drug Store of Perrysburg~~	~~580 Craig Drive Unit 12~~	~~Perrysburg~~	~~Ohio~~	~~43551~~	
~~The DrugStore on East State~~	~~934 E State St~~	~~Athens~~	~~Ohio~~	~~45701~~	
~~THE MEDICINE CABINET~~	~~102 S PIERCE ST~~	~~ALMA~~	~~Georgia~~	~~31510~~	
~~The Medicine Cabinet~~	~~300 MOOTY BRIDGE RD STE 112~~	~~LAGRANGE~~	~~Georgia~~	~~30240-1881~~	
~~The Medicine Cabinet~~	~~1704 ROANOKE RD~~	~~LAGRANGE~~	~~Georgia~~	~~30240-3803~~	
~~THE MEDICINE CABINET~~	~~2607 PLANT AVENUE~~	~~WAYCROSS~~	~~Georgia~~	~~31501~~	
~~The Medicine Cabinet~~	~~205 VERNON STREET~~	~~LAGRANGE~~	~~Georgia~~	~~30240~~	
~~The Medicine Cabinet~~	~~1194 WARM SPRINGS HWY~~	~~MANCHESTER~~	~~Georgia~~	~~31816~~	
~~The Medicine Cabinet of Brunswick LLC~~	~~2500 STARLING ST STE 102~~	~~BRUNSWICK~~	~~Georgia~~	~~31520~~	
~~The Medicine Cabinet of Douglas~~	~~722 Shirley Avenue~~	~~Douglas~~	~~Georgia~~	~~31533~~	
~~THE MEDICINE CABINET OF DUBLIN LLC~~	~~1819 RICE AVE~~	~~DUBLIN~~	~~Georgia~~	~~31021-0537~~	
~~The Medicine Cabinet of Waycross - Downtown, LLC~~	~~620 TEBEAU ST~~	~~WAYCROSS~~	~~Georgia~~	~~31501~~	
~~The Medicine Cabinet Pharmacy~~	~~273 New Main Street~~	~~Yonkers~~	~~New York~~	~~10701-1318~~	
~~THE MEDICINE CABINET - WARD~~	~~223 W ASHLEY ST~~	~~DOUGLAS~~	~~Georgia~~	~~31533-3124~~	

~~STREET, LLC~~					
~~The Medicine Store~~	~~15415 Pinehurst Drive~~	~~Basehor~~	~~Kansas~~	~~66007~~	
~~The Medicine Store~~	~~760 Northstar Court~~	~~Tonganoxie~~	~~Kansas~~	~~66086-0580~~	
The Med-Shop Pharmacy	111 East 2nd Street	Hughes Springs	Texas	75656	(903) 639-3508
~~THE PHARMACY AT FLIPPIN STATION~~	~~109 N 1ST ST~~	~~FLIPPIN~~	~~Arkansas~~	~~72634~~	
~~The Pharmacy at St Michaels~~	~~2914 67th Avenue Suite 101~~	~~Greeley~~	~~Colorado~~	~~80634~~	
~~The Pharmacy of Quitman~~	~~125 Main Street~~	~~Quitman~~	~~Mississippi~~	~~39355~~	
~~The Pharmacy Place~~	~~2005 Commerce Drive North~~	~~Peachtree City~~	~~Georgia~~	~~30269~~	
~~The Pill Box Pharmacy~~	~~474 Highway 67 South~~	~~Decatur~~	~~Alabama~~	~~35603~~	
~~The Pill Box Pharmacy~~	~~2422 Danville Road South West Suite J~~	~~Decatur~~	~~Alabama~~	~~35603~~	
~~The Prescription Center~~	~~9730 Wilshire Boulevard Suite 103 and 114~~	~~Beverly Hills~~	~~California~~	~~90212~~	
~~The Prescription Pad~~	~~1620 N Whitley Dr~~	~~Fruitland~~	~~Idaho~~	~~83619~~	
~~The Prescription Pad~~	~~465 Keene Centre Drive~~	~~Nicholasville~~	~~Kentucky~~	~~40356~~	
~~The Prescription Pad Pharmacy~~	~~539 Highway 425 South~~	~~Monticello~~	~~Arkansas~~	~~71655~~	
~~The Prescription Shop~~	~~1215 West Whittier Boulevard~~	~~Montebello~~	~~California~~	~~90640~~	
~~Thomas Drugs~~	~~7917 Oak Island Drive~~	~~Oak Island~~	~~North Carolina~~	~~28465~~	
~~Thomas Drugs~~	~~4750 Main Street~~	~~Shallotte~~	~~North Carolina~~	~~28470~~	
~~Thomas Drug Store~~	~~609 East Cumberland Street~~	~~Dunn~~	~~North Carolina~~	~~28334~~	
~~Thompson's Pharmacy~~	~~1064 North College Street~~	~~Harrodsburg~~	~~Kentucky~~	~~40330~~	
~~Thomson Drug Company~~	~~501 Mount Pleasant Road~~	~~Thomson~~	~~Georgia~~	~~30824~~	
~~Thorne Discount Drug~~	~~2900 North Main Street~~	~~Tarboro~~	~~North Carolina~~	~~27886-1921~~	
~~Thornhill's Pharmacy~~	~~600 8th Street~~	~~Shallowater~~	~~Texas~~	~~79363~~	
Thornhill's Pharmacy	6823 82nd Street Suite 600	Lubbock	Texas	79424	(806) 368-8400
~~Thrifty Mac Discount Drug Inc~~Thornhill's Pharmacy	~~218 South Main~~600 8th Street	~~Madison~~Shallowater	~~Georgia~~Texas	~~30650~~7 9363-5726	(806) 832-0300
~~Thrifty Pharmacy~~	~~127 East Main Street~~	~~Providence~~	~~Kentucky~~	~~42450~~	

~~Thrifty Pharmacy~~	~~10904 - L.N. May Avenue~~	~~Oklahoma City~~	~~Oklahoma~~	~~73120~~	
Thurman's Pro-Med Pharmacy	402 North Madison Avenue	Mount Pleasant	Texas	75455	(903) 572-6337
Thurman's Pro-Med Pharmacy Morris County	201 Main Street	Naples	Texas	75568-9765	(903) 897-0011
Total Pharmacy Ennis	329 N SHILOH RD	Garland	Texas	75042	(972) 276-7071
Town and Country Drug	2616 N Grandview	Odessa	Texas	79761-1608	(432) 366-2868
Trinity Pharmacy	1925 East Rosemeade Parkway	Carrolton	Texas	75007-2499	(972) 492-4411
~~Thu Van~~Tru Med Pharmacy	~~10362 Bolsa~~720 Avenue~~,~~ F N Suite ~~108~~1	~~Westminster~~Bay City	~~California~~Texas	~~92683~~77414	(979) 429-4044
Tyler Rx Pharmacy	2415 East 5th Street	Tyler	Texas	75701	(903) 593-1400
Valu-Rite Pharmacy	709 Woodrow Wilson Ray Circle	Bridgeport	Texas	76426	(940) 683-2950
Vina Pharmacy	11207 N Lamar Blvd Suite A	Austin	Texas	78753-3056	(512) 977-8844
VIP Pharmacy	10970 BEN CREWSHAW DR STE 107	El Paso	Texas	79935	(915) 629-2020
WeCare Pharmacy	4732 Sugar Grove Blvd Suite 203	Stafford	Texas	77477	(281) 783-8300
Whitewright Pharmacy	2065 Beasley Blvd, Suite 200	Whitewright	Texas	75491	(903) 364-5537
Yoakum Discount Pharmacy	1200 Carl Ramert Drive Suite A	Yoakum	Texas	77995	(361) 293-6881
~~Tibbitts Family~~Yoakum Discount Pharmacy	~~2940 North Church~~210 Nelson Street, Suite ~~201~~E	~~Layton~~Yoakum	~~Utah~~Texas	~~84040~~77995	(361) 741-7455
~~Tidewater Drug and Health Care~~Central Valley Community Pharmacy	~~30170 Three Notch Road Unit B~~152 West 1500 North	~~Charlotte Hall~~Nephi	~~Maryland~~Utah	~~20622-4119~~84648	(435) 623-3700
~~Tieton Village Drug~~FAMILY PLAZA PHARMACY	~~3708 Tieton Drive~~3570 W 9000 S STE 150	~~Yakima~~WEST JORDAN	~~Washington~~Utah	~~98902~~84088-8872	(801) 569-0175
~~Tiffany Natural~~Island View Pharmacy	~~1115 South Avenue~~2038 West 1900 South	~~Westfield~~Syracuse	~~New Jersey~~Utah	~~07090~~84075	(801) 773-7899
~~Times~~Mears Pharmacy~~ #1~~	~~1772 South King Street~~1050 Shepard Lane Suite 1	~~Honolulu~~Farmington	~~Hawaii~~Utah	~~96826~~84025-2716	(801) 447-9484
Medical Center Pharmacy	1050 East South Temple	Salt Lake City	Utah	84102	(801) 350-8140
~~Times~~North View	~~47 388 Hui Iwa~~	~~Kaneohe~~Layton	~~Hawaii~~Utah	~~96744~~84041	(801) 773-5666

Pharmacy #10	Street2121 North Robbins Drive				
TimesPark View Pharmacy #11	1425 Liliha Street425 West 100 South	HonoluluLayton	HawaiiUtah	968178 4041	(801) 682-8708
TimesProfessional Plaza Pharmacy #12, Inc	98 1264 Kaahumanu Street2065 North Robins Drive	Pearl CityLayton	HawaiiUtah	967828 4041-11 33	(801) 773-3863
TimesRidge View Pharmacy #18	94 615 Kupuohi Street3443 W 5600 South	WaipahuRoy	HawaiiUtah	967978 4067	(801) 825-6400
TimesSalem Hills Pharmacy #2	1173 21st Avenue118 N Main	HonoluluSalem	HawaiiUtah	968168 4653	(801) 723-0570
TimesSalmon Pharmacy #24	3350 Lower Honoapilani Road865 N 980 W	LahainaOrem	HawaiiUtah	96761 8 402840 57	(801) 225-2150
TimesSky View Pharmacy #25	16201750 East 3100 North School Street	HonoluluLayton	HawaiiUtah	968178 4040	(385) 405-2252
TimesStucki Family Pharmacy #4	45 934 Kamehameha Highway568 West Telegraph Street #3	KaneoheWashington	HawaiiUtah	967448 4780-15 96	(435) 627-8848
Times Pharmacy #6The Apothecary Shoppe #1	94 766 Farrington Highway82 S 1100 E Suite 104	WaipahuSalt Lake City	HawaiiUtah	967978 4102-15 25	(801) 521-6353
TimesTibbitts Family Pharmacy #8	1290 South Beretania2940 North Church Street, Suite 201	HonoluluLayton	HawaiiUtah	968148 4040	(801) 771-0363
TimesUniversity Pharmacy #9	99 115 Aiea Heights Drive1320 E 200 South	AieaSalt Lake City	HawaiiUtah	967018 4102	(801) 582-7624
Tinsley BibleWalker Drug Co Inc	1224 Gay290 South Main Street	DandridgeMoab	TennesseeUtah	377258 4532	(435) 259-5959
TLCCarlin Springs Pharmacy	2959611 South TelegraphCarlin Springs Road Suite 105	DearbornArlington	MichiganVirginia	481242 2204	(703) 379-4000
TomlinsonClaypool Hill Pharmacy	108 Rowe Street12252 Governor George C Peery hwy	DublinPounding Mill	GeorgiaVirginia	310212 4637	(276) 963-3502
Tompkinsville Drug Company	1513 Edmonton RD	Tompkinsville	Kentucky	42167	
TopekaColonial Pharmacy	101 North Main Street7510 Mechanicsville Pike	TopekaMechanicsville	IndianaVirginia	465712 3111	(804) 746-7997
Top Notch	943 Preston205	CharlottesvilleAppa	Virginia	229032	(276) 565-3434

~~Family~~Cornerstone Pharmacy	Kilbourne Avenue	lachia		4216	
Dans Wellness Pharmacy	418 Garrisonville Road Suite 100	Stafford	Virginia	22554	(540) 657-0006
~~Tormed~~Denbigh Pharmacy	~~3440 Lomita~~13349 Warwick Boulevard ~~Suite 149~~	~~Torrance~~Newport News	~~California~~Virginia	~~90505~~23602	(757) 877-0253
~~Total Care~~Dillwyn Pharmacy ~~#1~~	~~209 South~~1054 Main ~~Cross~~ Street	~~Flemingsburg~~Dillwyn	~~Kentucky~~Virginia	~~41041~~23936	(434) 983-2013
Elkton Family Pharmacy	111 S Stuart Ave	Elkton	Virginia	22827-1525	(540) 298-9090
~~Total Care Pharmacy #2~~Family Drug Center	~~118 Clark~~517 West Front Street	~~Flemingsburg~~Coeburn	~~Kentucky~~Virginia	~~41041~~24230	(276) 395-2257
~~Total Care Pharmacy #4~~Family Drug Center	~~700 Violet Road~~110 West Main Street Suite 1	~~Crittenden~~Lebanon	~~Kentucky~~Virginia	~~41030~~24266	(276) 889-1919
Fork Union Pharmacy	4316B James Madison Highway	Fork Union	Virginia	23055	(434) 842-3208
~~Total Care~~Godwin Pharmacy ~~#5~~	~~1100 West Shelby Street~~3061 Godwin Blvd Suite 109	~~Falmouth~~Suffolk	~~Kentucky~~Virginia	~~41040~~23434-6662	(757) 861-0080
~~Total Care~~Greene Pharmacy ~~#7~~	~~206 West~~331 Main Street	~~Morehead~~Stanardsville	~~Kentucky~~Virginia	~~40351~~22973	(434) 985-3424
~~Total Pharmacy Care~~Haysi Drug Center	~~533 Hambley Boulevard~~23906 Dickenson Highway	~~Pikeville~~Haysi	~~Kentucky~~Virginia	~~41501~~24256	(276) 865-5135
Hidenwood Pharmacy, Inc	35 Hidenwood Shopping Center	Newport News	Virginia	23606	(757) 595-1151
Hometown Pharmacy	196 Amelon Square	Madison Heights	Virginia	24572-5990	(434) 929-1000
~~Total~~Hometown Pharmacy ~~Care #3~~	~~420 NORTH LAKE DRIVE~~199 Old Courthouse Rd	~~PRESTONSBURG~~Appomattox	~~Kentucky~~Virginia	~~41653~~24522	(434) 352-3784
~~Total~~Jefferson Good Neighbor Pharmacy ~~Care #4~~	~~263 KY ROUTE 122~~194 B Turkeysag Trail	~~Martin~~Palmyra	~~Kentucky~~Virginia	~~41649~~22963	(434) 589-7902
~~Total~~Jones & Counts Pharmacy ~~Care #5~~	~~13380 Phelps 632 Road~~251 Main Street	~~Phelps~~Haysi	~~Kentucky~~Virginia	~~41553~~24256	(276) 865-5560
~~Total~~Lawrence Pharmacy ~~Care #6~~	~~6162 Zebulon~~1156 North George Washington Highway	~~Pikeville~~Chesapeake	~~Kentucky~~Virginia	~~41501~~23323	(757) 487-3458
~~Total~~Lee Davis Pharmacy ~~Care of Belfry~~	~~20 State Highway 319~~7016 Lee Park Rd Suite 400	~~Belfry~~Mechanicsville	~~Kentucky~~Virginia	~~41514~~23111	(804) 730-9200
~~Total~~Loudoun Community	~~329 N SHILOH RD~~19415 Deerfield	~~Garland~~Lansdowne	~~Texas~~Virginia	~~75042~~20176-84	(571) 499-4303

Pharmacy Ennis	Avenue Suite 116			70	
Tower DrugsLovettsville Pharmacy	272-68 Grand Central Parkway11 Town Center Dr Suite 195	Floral ParkLovettsville	New YorkVirginia	110052 0180-8569	(540) 306-5839
Town and CountryMadison Drug Company Inc	2745114 North GrandviewMain Street	OdessaMadison	TexasVirginia	797622 2727	(540) 948-4400
Marshall's Drug Store	50 Cross Street	Urbanna	Virginia	23175	(804) 758-5344
Town and CountryMcGuire Park Pharmacy	7362106 East Main Street	GlasgowRichmond	KentuckyVirginia	421412 3223	(804) 344-4444
Town and CountryMedical Park Pharmacy	651 BROWN ST1503 Slate Creek Road	CELINAGrundy	TennesseeVirginia	38551-4019246 14	(276) 935-6455
TowneMontpelier Pharmacy	849 Smith17128 Mountain Road	AshlandMontpelier	OhioVirginia	448052 3192	(804) 883-6363
Towne Pharmacy	6014 Highway 21 South Suite P	Rincon	Georgia	31326	
TOWNE PHARMACY	283 Cline Ave	Mansfield	Ohio	44907	
Town SquareOlde Virginia Pharmacy, Inc	81 709 Doctor Carreon Boulevard Suite E31592 Fincastle St Tpke	IndioTazewell	CaliforniaVirginia	92201-5526246 51	(276) 988-7977
Orange Pharmacy #2	130 W Main St	Orange	Virginia	22960	(540) 661-5006
TRENTON AVENUE PHARMACYPurcellville Pharmacy	3803 Ventnor Avenue609 East Main Street Suite Q	Atlantic CityPurcellville	New JerseyVirginia	084012 0132	(540) 751-9750
REMINGTON DRUG CO	207 East Main Street	Remington	Virginia	22734	(540) 439-3247
TrentonScottie Pharmacy	11969 S MAIN ST1951 Second Street	TRENTONRichlands	GeorgiaVirginia	30752-2855246 41	(276) 963-0284
TriangleSmith's Pharmacy	119-01 Jamaica Avenue111 South Broad Street	Richmond HillKenbridge	New YorkVirginia	114182 3944	(434) 676-2266
Spencers Drug Store Inc	100 North Main Street	Blackstone	Virginia	23824-1424	(434) 292-3132
TriangleStone Ridge Pharmacy	1239 D Avenue24560 Southpoint Dr Unit 190	West ColumbiaAldie	South CarolinaVirginia	291692 0105-3505	(703) 345-1046
Tri-AreaStrasburg Pharmacy	93 Oak Bay Road33820 Old Valley Pike Suite 7	Port HadlockStrasburg	WashingtonVirginia	983392 2657-3793	(540) 465-5001
Tri City RXStuarts Draft Family Pharmacy Inc	15940 QUANTICO RD SUITE 1002929 Stuarts Draft Highway Suite 101	APPLE VALLEYStuarts Draft	CaliforniaVirginia	923072 4477	(540) 337-3776

TruCareTemple Avenue Pharmacy	358 Route 202 North2000 Snead Avenue	PomonaColonial Heights	New YorkVirginia	109702 3834-2428	(804) 526-1000
Top Notch Family Pharmacy	943 Preston Avenue	Charlottesville	Virginia	22903	(434) 995-5595
True Blue Pharmacy Inc	12235 Grapefield Road Suite 1	Bastian	Virginia	24314	(276) 688-2424
TrueValley Pharmacy	3217 Devine Street351 Valley Health Way Suite 210	ColumbiaFront Royal	South CarolinaVirginia	292052 2630	(540) 635-0736
Trumarx DrugsValley Pharmacy	501 Gordon Avenue190 Campus Blvd Suite 110	ThomasvilleWinchester	GeorgiaVirginia	317922 2601	(540) 536-8899
TrumedWalnut Hill Pharmacy	2521 7th1950 South Sycamore Street	Bay CityPetersburg	TexasVirginia	774142 3805	(804) 733-7711
Trumm Drug (Clinic Pharmacy)Westbury Apothecary	610 30TH Avenue West8903 Three Chopt Road	AlexandriaHenrico	MinnesotaVirginia	563082 3229	(804) 285-3428
Westwood Pharmacy	5823 Patterson Avenue	Richmond	Virginia	23226	(804) 288-1933
Your Gordonsville Pharmacy	400 Gordon Avenue Ste D	Gordonsville	Virginia	22942	(540) 832-0000
TrummFamily Drug-Downtown	600 Fillmore Street1755 Lovers Gap Rd	AlexandriaVansant	MinnesotaVirginia	563082 4656	(276) 597-2419
Trumm Drug Elbow LakeDavenport Pharmacy	11 Central Avenue South525 Morgan St	Elbow LakeDavenport	MinnesotaWashington	565319 9122	(509) 725-1151
Trumm Drug Glenwood	7 Fourth Avenue SE	Glenwood	Minnesota	56334	
Trumm Drug Parkers PrairieDon's Pharmacy	114 East Soo1151 Water Street	Parkers PrairiePort Townsend	MinnesotaWashington	563619 8368	(360) 385-0969
Fairway Drug	1758 Front Street Suite 106	Lynden	Washington	98264	(360) 354-1226
TruxtunFamily Pharmacy	5925 Truxtun Avenue7315 212th St W Suite B100	BakersfieldEdmonds	CaliforniaWashington	933099 8026-7610	(425) 778-7778
TruxtunHart and Dilatush Pharmacy Delano	1228 Jefferson Street601 West Riverside Suite 140	DelanoSpokane	CaliforniaWashington	93215-9225992 01	(509) 624-2111
TustinKelley-Ross Pharmacy at the Polyclinic	13400 Newport9047th Avenue Suite 103	TustinSeattle	CaliforniaWashington	927809 8104	(206) 324-6990
Twin City Drug CoLAKETOWN PHARMACY	507 South Railroad Avenue1550 S PIONEER WAY STE 105	Twin CityMOSES LAKE	GeorgiaWashington	30471-0040988 37	(509) 765-8891
Twin CityLincoln	1708 Park	South	New	070809	(253) 473-1155

Pharmacy	Avenue821 South 38th Street	PlainfieldTacoma	JerseyWashington	8418	
Twin CityNeil's Pharmacy	106 North First Street512 West Franklin	Marble HillShelton	MissouriWashington	6376498584	(360) 426-3327
Tyler Rx Pharmacy	2415 East 5th Street800 Swift Boulevard Suite 140	TylerRichland	TexasWashington	757019 9352-3559	(509) 713-7444
TYLERTOWNSOUTH KITSAP PHARMACY LLC	201 HOSPITAL DR1397 OLNEY AVE SE STE 109	TYLERTOWNPORT ORCHARD	MississippiWashington	39667-2019983 66	(360) 876-5594
Ubly PharmacySumas Drug	2031 East Main1143 Cherry Street	UblySumas	MichiganWashington	48475-9726982 95	(360) 988-2681
Ultra CareTekoa Pharmacy	4419 Falls Road Suite B124 North Crosby Street	BaltimoreTekoa	MarylandWashington	21211-1295990 33	(509) 284-4205
Ultra Care PharmacyTieton Village Drug	12619 Wisteria3708 Tieton Drive Suite A	GermantownYakima	MarylandWashington	20874-5259989 02	(509) 966-6850
Ultra Care Pharmacy ColumbiaTri-Area Pharmacy	10798 Hickory Ridge93 Oak Bay Road Suite A	ColumbiaPort Hadlock	MarylandWashington	21044-3646983 39	(360) 379-9800
UnadillaValley Drug Company	413 2nd208 East Main Street	UnadillaEverson	GeorgiaWashington	3109199247	(360) 966-3481
Union Avenue LegendWhole Health Pharmacy	433 West Union Avenue800 South Pearl Street Suite 1	Bound BrookEllensburg	New JerseyWashington	088059 8926-3646	(509) 925-6800
UnionTallmans Pharmacy and Medical Supplies	64564 West FlaglerMain Street	MiamiWalla Walla	FloridaWashington	3314499362	(509) 525-1010
Bison Rx Inc	20442 Charleston Road	Buffalo	West Virginia	25033	(304) 937-3000
UnionCharlie's Pharmacy and Medical Supplies IIof Mullens LLC	2501 Southwest 67224 Howard Avenue	MiamiMullens	FloridaWest Virginia	331552 5882	(304) 294-5447
University Pain Management CenterClark's Family Pharmacy Inc	3220 Cove Bend Drive4501 Maccorkle Ave SW Suite 101	TampaSouth Charleston	FloridaWest Virginia	336132 5309-1444	(304) 766-8484
UniversityCox Family Pharmacy	1320 East 200 South2012 Garfield Avenue Suite C	Salt Lake CityParkersburg	UtahWest Virginia	8410226101	(304) 893-9100
Upper DarbyCrab Orchard Pharmacy	119 Long Lane1299 Robert C Byrd Dr	Upper DarbyCrab Orchard	PennsylvaniaWest Virginia	1908225827	(304) 253-7474
Upper Eastside Chemists INCFour	855 Lexington Avenue #1300	New YorkPrinceton	New YorkWest	100652 4740-27	(304) 487-0015

Seasons Pharmacy	Morrison Drive		Virginia	65	
Goodykoontz Drug Store	2924 E Cumberland Rd	Bluefield	West Virginia	24701	(304) 325-7121
~~Uptown Pharmacy~~Griffith and Feil Drug	~~23 North State~~1405 Chestnut Street	~~Westerville~~Kenova	~~Ohio~~West Virginia	~~430812~~5530	(304) 453-2381
~~UPTOWN PHARMACY & WELLNESS~~Hurley Drug Company Inc	~~3512 N OAKLAND AVE~~210 Logan Street	~~SHOREWOOD~~Williamson	~~Wisconsin~~West Virginia	~~53211-2701~~25661	(304) 235-3535
~~USA~~Iaeger Pharmacy	~~47315 Van Dyke Avenue~~4381 Coal Heritage Rd, US Rte 52	~~Shelby Township~~Iaeger	~~Michigan~~West Virginia	~~48317-3363~~24844	(304) 938-2819
~~USC Health Center Pharmacy~~J & B Drugstore	~~1025 West 34th~~352 Main Street	~~Los Angeles~~Grantsville	~~California~~West Virginia	~~90089-0028~~26147	(304) 354-7737
~~USC Medical Plaza~~Main Street Pharmacy	~~1510 San Pablo~~435 West Main Street~~,~~ Suite ~~144~~1	~~Los Angeles~~Oak Hill	~~California~~West Virginia	~~900332~~5901	(304) 465-7200
~~USC Verdugo Hills Professional Pharmacy~~Med Rx	~~1808 Verdugo Boulevard~~620 National Rd Suite ~~111~~400	~~Glendale~~Wheeling	~~California~~West Virginia	~~912082~~6003	(304) 232-4984
~~US Pharmacy 001~~	~~440 Saint Andrews Drive~~	~~Murfreesboro~~	~~Tennessee~~	~~37128~~	
~~Valley Apothecary~~Moundsville Pharmacy	~~201~~118 North ~~Washington~~Lafayette Avenue	~~Ketchum~~Moundsville	~~Idaho~~West Virginia	~~833402~~6041	(304) 845-0390
~~VALLEY CARE PHCY~~New Martinsville Pharmacy	~~11441 HEACOCK ST STE D~~193 N STATE ROUTE 2	~~MORENO VALLEY~~New Martinville	~~California~~West Virginia	~~925572~~6155	(304) 455-2171
~~Valley~~Pattersons Drug Store	~~208 East Main Street~~311 Medical Ct Unit A	~~Everson~~Martinsburg	~~Washington~~ West Virginia	~~982472~~5401	(304) 267-8903
~~Valley Medical~~Pine Grove Pharmacy	~~630 Main Street~~13030 Shortline Hwy	~~Brawley~~Pine Grove	~~California~~West Virginia	~~922272~~6419	(304) 889-3131
Reed's Pharmacy 5	2830 Northwestern Pike	Capon Bridge	West Virginia	26711	(304) 856-2901
Renegade Pharmacy Inc	18 Logan Street	Oceana	West Virginia	24870	(304) 682-0444
~~Valley~~Riverside Pharmacy	~~791 Hamburg Turnpike~~22 Larry Joe Harless Drive	~~Wayne~~Gilbert	~~New Jersey~~West Virginia	~~07470-8416~~25661	(304) 664-3343
~~Valley~~Shepherdstown Pharmacy	~~560 West Putnam Avenue~~7670 Martinsburg Pike Suite 2	~~Porterville~~Shepherdstown	~~California~~West Virginia	~~93257-3269~~25443	(304) 876-9966
~~Valley~~Sistersville Pharmacy	~~75 Washington Valley Road~~312 Diamond St	~~Bedminster~~Sistersville	~~New Jersey~~West Virginia	~~079212~~6175	(304) 652-3711

ValleySpring Mills Pharmacy	190 Campus Boulevard5759 Williamsport Pike Suite 110105	WinchesterMatinsburg	West Virginia	2260125404	(681) 242-3997
ValleyWaterfront Family Pharmacy	351 Valley Health Way215 Don Knotts Boulevard Suite 210120	Front RoyalMorgantown	West Virginia	2263026501	(304) 225-7979
Brownstone Rx	114 West Bayfield Street	Washburn	Wisconsin	54891	(715) 373-5588
Valley ViewCrivitz Pharmacy	11141 State Route 800 Northeast710 Main Avenue	MagnoliaCrivitz	OhioWisconsin	44643554114	(715) 854-7425
Valucare CenterEannelli Pharmacy	1378 Main405 Water Street	MarinettePrairie Du Sac	Wisconsin	54143553578	(608) 643-3396
Elkhorn Pharmacy	603 E GENEVA ST	ELKHORN	Wisconsin	53121	(262) 723-8444
Value MartGwidt Pharmacy	314 Main Street203 East Westgor Avenue	OrangeWittenberg	New JerseyWisconsin	07050554499-0253	(715) 253-2164
Val-U-PharmacyHeike Pharmacy	2811213 West MarketMain Street	Johnson CityDurand	TennesseeWisconsin	37604554736	(715) 672-5202
Valurite DiscountInfinity Pharmacy	1006 Professional Boulevard2700 South 60th Street	DaltonMilwaukee	GeorgiaWisconsin	30720553219	(414) 988-0008
Valu-RiteLakeside Pharmacy	709 Woodrow Wilson Ray Circle536 5th Ave	BridgeportAntigo	TexasWisconsin	76426554409	(715) 623-2631
Manitowoc Pharmacies	919 South 8th Street	Manitowoc	Wisconsin	54220	(920) 684-6789
Van HoutenNicolet Pharmacy	669 Van Houten Avenue15481 Commercial Rd	CliftonLakewood	New JerseyWisconsin	07013554138	(715) 276-3646
V-CareOconto Falls Pharmacy	59323 East Eckerson RoadHighland Drive	Spring ValleyOconto Falls	New YorkWisconsin	10977754154	(920) 848-3721
Ventura CountyOconto Pharmacy	3350 Loma Vista Road1008 Main Street	VenturaOconto	CaliforniaWisconsin	93003-3024541 53-0073	(920) 834-4455
Versailles IndependentPeshtigo Pharmacy	166 Frankfort220 French Street	VersaillesPeshtigo	KentuckyWisconsin	40383554157	(715) 582-4237
VersaillesPulaski Pharmacy	2801 Encinal Avenue121 North Saint Augustine Street	AlamedaPulaski	CaliforniaWisconsin	94501554162	(920) 822-3011
Via Lido Drugs	3445 Via Lido	Newport Beach	California	92663	
ViaRx	825 North 90th Street	Omaha	Nebraska	68114	
Vic's FamilySmith	1513 12th	NampaLittle Chute	IdahoWiscons	836865	(920) 788-8888

Pharmacy	~~Avenue~~1800 Freedom Road Unit D		in	4140	
~~Vic's Family~~Sniteman Pharmacy	~~118 South Midland Boulevard~~N3708 River Ave STE A	~~Nampa~~Neillsville	~~Idaho~~Wisconsin	~~836865~~ 4456-7218	(715) 743-3500
~~Victory Pharmacy~~	~~1837 River Oaks Drive~~	~~Calumet City~~	~~Illinois~~	~~60409-5071~~	
~~Vida Pharmacy~~The Apothecary	~~7250 West 24th Avenue, Suite 19/20~~1470 Webb Street	~~Hialeah~~Cumberland	~~Florida~~Wisconsin	~~330165~~ 4829	(715) 822-2424
~~Village Discount Pharmacy~~UPTOWN PHARMACY & WELLNESS	~~3990 East State Road 44 Suite 207~~3512 N OAKLAND AVE	~~Wildwood~~SHOREWOOD	~~Florida~~Wisconsin	~~34785-7480~~53211-2701	(414) 372-0700
~~Village Drug~~Valucare Center	~~126~~1378 Main ~~St~~Street	~~Penn Yan~~Marinette	~~New York~~Wisconsin	~~145275~~ 4143	(715) 732-0717
~~Village~~WellCreek Pharmacy Middleton	~~1278 Yardville Allentown Rd~~2532 Allen Blvd	~~Allentown~~Middleton	~~New Jersey~~Wisconsin	~~085015~~ 3562-2212	(608) 203-8090
~~Village~~Welltopia Pharmacy	~~9408 SW 87TH STREET SUITE 105~~136 North Main Street	~~MIAMI~~Thiensville	~~Florida~~Wisconsin	~~331765~~ 3092-1606	(262) 429-9429
~~Village~~Yellow River Pharmacy	~~500 West Commercial~~7438 Main Street West	~~Ozark~~Webster	~~Arkansas~~Wisconsin	~~729495~~ 4893	(715) 866-8644
~~Village~~City Drug Pharmacy	~~14057 Highway 17 Suite 100~~1722 Carey Ave	~~Hampstead~~Cheyenne	~~North Carolina~~Wyoming	~~284438~~ 2001-4420	(307) 514-0200
~~Village~~Palace Pharmacy	~~7659 Gilbert Street Suite A~~1255 Main St	~~Gilbert~~Lander	~~Louisiana~~Wyoming	~~71336-3410~~825 20	(307) 332-2270
Powell Drug	140 North Bent Street	Powell	Wyoming	82435	(307) 754-2031
~~Village~~Ricker Pharmacy ~~at Spring House~~	~~1121 North Bethlehem Pike Suite 40~~1801 Big Horn Avenue	~~Spring House~~Worland	~~Pennsylvania~~ Wyoming	~~19477-1011~~824 01	(307) 347-2281
Shatto's Frontier Drug	1202 East Richards Street	Douglas	Wyoming	82633	(307) 358-5077
~~Villa Park~~South Street Pharmacy	~~17821 Santiago Boulevard~~1456 South Street	~~Villa Park~~Wheatland	~~California~~Wyoming	~~928618~~ 2201	(307) 322-2486
~~VILLA RICA DRUGS~~	~~222 West Wilson Street~~	~~Villa Rica~~	~~Georgia~~	~~30180~~	
~~Vilonia Family Pharmacy Inc~~	~~1122 Main Street Suite 14~~	~~Vilonia~~	~~Arkansas~~	~~72173~~	
~~Vina Pharmacy~~	~~11207 North Lamar Boulevard Suite A~~	~~Austin~~	~~Texas~~	~~78753~~	
~~Vine Discount~~	~~1253 North Vine~~	~~Los Angeles~~	~~California~~	~~90038~~	

Pharmacy and Medical Supply	Street			
Vineyard Pharmacy & Gifts	1900 McHenry Avenue	Escalon	California	95320
VIP Pharmacy	1891 Lee Trevino Suite 200	El Paso	Texas	79936
Visels Pharmacy - New Haven, CT	714 Dixwell Avenue	New Haven	Connecticut	06511
Vo Pharmacy	12464 East Washington Boulevard	Whittier	California	90602-1005
Vorac Pharmacy	114 S State Street	Geneseo	Illinois	61254
Wackerly Pharmacy	957 West Midland Road	Auburn	Michigan	48611
Wagner Pharmacy	1224 East McFadden Avenue	Santa Ana	California	92705
Walden Drug	3104 W Kingshighway	Paragould	Arkansas	72450
Walker Drug	290 South Main Street	Moab	Utah	84532
Walker Pharmacy & Gifts Inc	2425 Northside Drive West	Statesboro	Georgia	30458
Walker Pharmacy Market District	1198 Merchants Way	Statesboro	Georgia	30458
Wall Drugs of Pamplico Inc	616 South Walnut Street	Pamplico	South Carolina	29583
Walnut Hill Pharmacy	1950 South Sycamore Street	Petersburg	Virginia	23805
Walpole Pharmacy	699 Main Street	Walpole	Massachusetts	02081
Walsh Pharmacy	202 Rock Street	Fall River	Massachusetts	02720
Walter's Family Pharmacy	604 South 12th Street	Murray	Kentucky	42071
Waltmire Pharmacy	1435 Spring Garden Avenue	Pittsburgh	Pennsylvania	15212
Walton Drug	1520 West Thatcher Boulevard	Safford	Arizona	85546
Walton Drug of Morenci	408 Burro Alley	Morenci	Arizona	85540
Wamego Drug Store	501 Lincoln Avenue	Wamego	Kansas	66547
Wannamaker Drug	700 CHESTERFIELD HWY	Cheraw	South Carolina	29520
Wannamaker Drug	107 West Boulevard	Chesterfield	South Carolina	29709-1528
Ward Drug	142 South Penn Avenue	Oberlin	Kansas	67749
Wards Pharmacy	122 South Front Street	Ellisville	Mississippi	39437-3118
Wards Pharmacy	653 Long Beach Boulevard	Long Beach	California	90802

WARE'S PHARMACY	304 South Jefferson Street	Mason	Michigan	48854
Warren's Drug Store, Inc	943 South Fifth Street	Mebane	North Carolina	27302
Warrensville Drug Store	5121 North Carolina Highway 88 West	Warrensville	North Carolina	28693
Washingtonville Pharmacy	32 West Main Street Unit 2	Washingtonville	New York	10992
Waterfront Family Pharmacy	215 Don Knotts Boulevard Suite 120	Morgantown	West Virginia	26501
Water Street Pharmacy	14 WATER ST	DUNDEE	New York	14837
Waterway Pharmacy	3373 Highway 9 East	Little River	South Carolina	29566
Watkins Pharmacy & Surgical Supply	1391 East Sherman Boulevard	Muskegon	Michigan	49444
Watson Pharmacy	802 W 4th Street	Fordyce	Arkansas	71742
Wauka Mountain Pharmacy	5233 Cleveland Highway	Clermont	Georgia	30527
Wayne Drug Co	192 North First Street	Jesup	Georgia	31545
Wear Drug	408 Walnut Street	Carthage	Illinois	62321
Weathers Drugs	44 Public Square	Elkton	Kentucky	42220
Weaver Pharmacy	1014 G Street	Geneva	Nebraska	68361
Webb's Family Pharmacy	724 Main Street	Rochester	Indiana	46975
WEBBS FT MYERS PRESC SHOP INC	13195 Metro Pkwy. Suite 3	Fort Myers	Florida	33966
Wecare Pharmacy	14823 Southwest Freeway Suite B	Sugar Land	Texas	77478-5007
We Care Pharmacy Plus	1412 South Lapeer Road	Lake Orion	Michigan	48360
Wellcreek Pharmacy - Bethalto	333 West Bethalto Drive Suite B	Bethalto	Illinois	62010
WellCreek Pharmacy-Charleston	1 West Lincoln Avenue	Charleston	Illinois	61920
WELLCREEK PHARMACY MIDDLETON	2532 ALLEN BLVD	MIDDLETON	Wisconsin	53562-2212
Wellness Pharmacy	144 West 72nd Street	New York	New York	10023-3344
Wellness Rx LLC	7640 Northwest 25th Street Suite 105	Miami	Florida	33122
WellnessRx	5971 University	San Diego	California	92115

Pharmacy	Avenue Suite 304			
Wells Drug	113 South 4th Street	Albion	Nebraska	68620
Westbury Apothecary	8903 Three Chopt Road	Henrico	Virginia	23229
Westbury Pharmacy	701 North Parler Avenue	Saint George	South Carolina	29477
West End Pharmacy	824 West Avenue	Cartersville	Georgia	30120
Western Ave Pharmacy	501 Western Avenue	Glendale	California	91201
Western Drug	806 Illinois	Sidney	Nebraska	69162
West Hempstead Pharmacy	449 Hempstead Avenue	West Hempstead	New York	11552
West Islip Pharmacy	432 Montauk Highway	West Islip	New York	11788
West Knox Pharmacy, LLC	14161 North US Highway 25 East	Corbin	Kentucky	40701-6183
West Milford Pharmacy	1495 Union Valley Road	West Milford	New Jersey	07480
Westminster Family Drug	10911 Northeast 23rd Street	Nicoma Park	Oklahoma	73066
Westminster Pharmacy	577 North Broad Street	Elizabeth	New Jersey	07208
West Perry Pharmacy	1102 Montour Road	Loysville	Pennsylvania	17047
West Reading Drug Store	538 Penn Avenue	West Reading	Pennsylvania	19611
Westside Drug	1101 O Street	Firebaugh	California	93622
WestSide Pharmacy	215 North Hermitage Avenue Suite 9	Trenton	New Jersey	08618
WEST VAL CARE PHCY	5353 BALBOA BLVD	ENCINO	California	91316
Westwood Pharmacy	5823 Patterson Avenue	Richmond	Virginia	23226
Wexler's Lake Milton Pharmacy	17674 Mahoning Avenue	Lake Milton	Ohio	44429
Whispering Pines Prescription Shoppe	7305 NC Highway 22	Carthage	North Carolina	28327-8512
White's Pharmacy	705 Halibut Point Road	Sitka	Alaska	99835
Whiteford Pharmacy	2338 Whiteford Road	Whiteford	Maryland	21160
White Memorial Medical Plaza Pharmacy	1701 East Cesar E Chavez Avenue Suite 109	Los Angeles	California	90033
White Mountain Pharmacy	4461 South White Mountain Road Suite E1	Show Low	Arizona	85901-7783
White Mountain	2841 Highway 260	Overgaard	Arizona	85933

Pharmacy 2	Box 2217			
Whitesell Pharmacy	236 North Market Street	Frederick	Maryland	21701
Whitewright Pharmacy	2065 Beasley Blvd, Suite 200	Whitewright	Texas	75491
Whittier Health Pharmacy Inc	1012 Tremont Street	Roxbury	Massachusetts	02120-3432
Whole Health Pharmacy	800 South Pearl Street Suite 1	Ellensburg	Washington	98926-3646
Williams Family Pharmacy, LLC	1058 Tanglewood Drive	Franklinton	Louisiana	70438-5673
Williamsport Pharmacy	100 E Potomac St	Williamsport	Maryland	21795
Wilsons Sav-Mor Drugs	265 East Main Street	Newport	Tennessee	37821
Wilson Wil-Sav Pharmacy	5 Allen Chapel Road	Batesville	Arkansas	72501
Winningham Pharmacy	232 West Main Street	Bradford	Arkansas	72020
Winona Drugs	500 North Applegate Street Suite A	Winona	Mississippi	38967
Winships Pharmacy	5643 South East Crooked Oak Avenue Seabranch Square	Hobe Sound	Florida	33455
Winships Prescription Center	721 Northlake Boulevard	North Palm Beach	Florida	33408
WOODBINE PHARMACY	908 GEORGIA AVE	WOODBINE	Georgia	31569
Woodbridge Pharmacy	4950 Barranca Parkway Suite 102	Irvine	California	92604
Woodbury Family Pharmacy	160 North Broad Street	Woodbury	New Jersey	08096
Woodlyn Pharmacy	1301 Jefferson Avenue	Woodlyn	Pennsylvania	19094
Woodruff Health Mart Pharmacy	10195 Highway 221 Suite 5	Woodruff	South Carolina	29388-9358
Woodsprings Pharmacy	1807 Woodsprings Road	Jonesboro	Arkansas	72401
Wurlitzer Family Pharmacy Inc	521 DIVISION ST	NORTH TONAWANDA	New York	14120-4403
Wyandotte Pharmacy	375 Eureka Road Suite A	Wyandotte	Michigan	48192-5839
Wyatt's Pharmacy	10671 Veterans Memorial Highway	Lithia Springs	Georgia	30122
Wynne Apothecary Inc	500 Falls Boulevard North	Wynne	Arkansas	72396
Xpress Meds	4201 West 95th Street Suite G	Oak Lawn	Illinois	60453-2615
Xpress Pharmacy	6700 West 95th Street Suite 150	Oak Lawn	Illinois	60453

~~Xtra Care Pharmacy~~	~~7920 South Mason Montgomery Road~~	~~Mason~~	~~Ohio~~	~~45040-8249~~
~~Yates Pharmacy LLC~~	~~432 Hopkinsville Road~~	~~Russellville~~	~~Kentucky~~	~~42276~~
~~Yellow River Pharmacy~~	~~7438 Main Street West~~	~~Webster~~	~~Wisconsin~~	~~54893~~
~~Yinger Pharmacy Shoppe~~	~~1036 North Monroe Street~~	~~Monroe~~	~~Michigan~~	~~48162~~
~~Yinger Pharmacy Shoppe~~	~~1704 South Custer Road~~	~~Monroe~~	~~Michigan~~	~~48161~~
~~Yoakum Discount Pharmacy~~	~~1200 Carl Ramert Drive Suite A~~	~~Yoakum~~	~~Texas~~	~~77995~~
~~Yoakum Discount Pharmacy~~	~~210 Nelson Street, Suite E~~	~~Yoakum~~	~~Texas~~	~~77995~~
~~Yorke Pharmacy~~	~~5524 New Falls Road~~	~~Levittown~~	~~Pennsylvania~~	~~19056~~
~~Yorkville Pharmacy~~	~~822 B East Liberty Street~~	~~York~~	~~South Carolina~~	~~29745~~
~~Young Life Pharmacy~~	~~1769 Candler Road~~	~~Decatur~~	~~Georgia~~	~~30032-3276~~
~~Your Drug Store~~	~~2303 Niles Point~~	~~Bakersfield~~	~~California~~	~~93306~~
~~Your Gordonsville Pharmacy~~	~~400 Gordon Avenue Ste D~~	~~Gordonsville~~	~~Virginia~~	~~22942~~
~~Your Pharmacy of Lexington~~	~~100 West Third Street~~	~~Lexington~~	~~North Carolina~~	~~27292~~
~~Zeigler Pharmacy~~	~~159 West Main Street~~	~~Wilmington~~	~~Ohio~~	~~45177~~
~~Zweber Apothecary~~	~~11411 Brookshire Avenue, Suite 107~~	~~Downey~~	~~California~~	~~90241~~

FRANCHISEES THAT LEFT THE SYSTEM
(~~2024~~2025)

Transfers

Account Name	Business Address	Business Address City	Business Address State	Zip Code	Business Phone
Kilgore Express Pharmacy #6	1614 Glenn Blvd SW	Fort Payne	Alabama	35968-3522	(256) 845-3402
Medi-Quik Pharmacy	1531 East Main Street	Booneville	Arkansas	72927	(479) 675-3900
Oakdale Pharmacy	5400 Balboa Boulevard Suite 100	Encino	California	91316	(818) 788-0770
Newport Lido Pharmacy LTC	351 Hospital Road	Newport Beach	California	92663	(949) 764-6580
Orange Plaza Pharmacy	1010 West La Veta Avenue Suite 130	Orange	California	92868-4301	(714) 550-9798

Meiji Pharmacy	1630 W Redondo Bch Blvd Suite 14	Gardena	California	90247	(310) 538-2885
Hendricks Pharmacy	137 North Harvard Avenue	Claremont	California	91711-4717	(909) 624-1611
Jonathan's Pharmacy	19341 Bear Valley Road Suite 103	Apple Valley	California	92308	(760) 983-2599
Fullerton Pharmacy	1820 Fullerton Avenue Suite 105	Corona	California	92881-3160	(951) 496-4222
Danielson Pharmacy	77 Westcott Rd	Danielson	Connecticut	06239-2929	(860) 774-0050
ROTARY DRUG	1030 BARNUM AVE	STRATFORD	Connecticut	06614	(203) 378-9394
Danielson Pharmacy	77 Westcott Rd	Danielson	Connecticut	06239-2929	(860) 774-0050
Cypress Wellness Pharmacy	9451 Cypress Lake Dr	Fort Myers	Florida	33919	(239) 481-7322
Allcare Pharmacy & Healthcare Services	112 South Oxley Drive	Lyons	Georgia	30436	(912) 526-3200
Wyatt's Pharmacy	10671 Veterans Memorial Highway	Lithia Springs	Georgia	30122	(770) 948-8825
Curry's Family Pharmacy	1275 North 7th Street	Riverton	Illinois	62561	(217) 629-7001
Seifert Drug	230 South Main Street	Elkhart	Indiana	46516	(574) 295-4333
Seifert Drug #2	100 N Elkhart St	Wakarusa	Indiana	46573	(574) 862-1454
Seifert Drug #3	2102 N Main St Suite 100	Nappanee	Indiana	46550	(574) 773-8280
Summit Pharmacy	300 West Burlington Avenue	Fairfield	Iowa	52556-3241	(641) 472-7987
Newman Community Rx 1430	1400 W 12th Ave	Emporia	Kansas	66801	(620) 342-1242
Walter's Family Pharmacy	604 South 12th Street	Murray	Kentucky	42071	(270) 753-7688
Care More Pharmacy	151 Dorton-Jenkins Highway	Dorton	Kentucky	41520	(606) 639-2273
TYLERTOWN PHARMACY LLC	201 HOSPITAL DR	TYLERTOWN	Mississippi	39667-2019	(601) 222-1770
Olssons Pharmacy	576 Lafayette Avenue	Hawthorne	New Jersey	07506-2400	(973) 427-1700
Galloway-Sands Pharmacy #2	1513 North Howe Street Suite 8	Southport	North Carolina	28461	(910) 454-9090
Kratzer?s Hometown Pharmacy Mt Orab	155 North Point Drive	Mount Orab	Ohio	45154	(937) 444-0135
Zeigler Pharmacy	159 W Main St	Wilmington	Ohio	45177	(937) 382-0921
Delta of Elloree	2611 Cleveland St	Elloree	South Carolina	29047	(843) 761-5255
Delta of Moncks Corner	402 East Main St	Moncks Corner	South Carolina	29461	(843) 761-5255
Delta of Charleston #3	346 East Bay St	Charleston	South Carolina	29401	(843) 937-0960
Dottie's Pharmacy	325 Folly Road Suite 101	Charleston	South Carolina	29412	(843) 501-9500
Belew Drugs Asheville Highway	8622 Asheville Highway	Knoxville	Tennessee	37924-4107	(865) 933-3441
Belew Drug Choto	1616 Choto Markets Way	Knoxville	Tennessee	37922-5760	(865) 766-4424

Belew Drugs	2021 N Broadway St	Knoxville	Tennessee	37917	(865) 525-4189
Thornhill's Pharmacy	6823 82nd Street Suite 600	Lubbock	Texas	79424	(806) 368-8400
Thornhill's Pharmacy	600 8th Street	Shallowater	Texas	79363	(806) 832-0300
English Pharmacy	2600 10th Street	Wichita Falls	Texas	76309	(940) 723-6060
Denbigh Pharmacy	13349 Warwick Boulevard	Newport News	Virginia	23602	(757) 877-0253
*Elkton Family Pharmacy	111 South Stuart Avenue	Elkton	Virginia	22827	(540) 298-9090
Orange Pharmacy	130 West Main Street	Orange	Virginia	22960	(540) 661-5006
Davenport Good Neighbor Pharmacy	525 Morgan Street	Davenport	Washington	99122	(509) 725-1151
FAMILY PHARMACY	7315 212th Street Southwest Suite 100	Edmonds	Washington	98026	(425) 778-7778
Riverside Pharmacy	22 Larry Joe Harless Drive	Gilbert	West Virginia	25621	(304) 664-3343
Riverside Pharmacy	22 Larry Joe Harless Drive	Gilbert	West Virginia	25621	(304) 664-3343

Terminations

Account Name	**Business Street Address**	**Business Address City**	**Business Address State**	**Zip Code**	**Business Phone**
Blood Pharmacy	410 Main Street	Neligh	Nebraska	68756	(402) 887-5426
Blood Pharmacy Tilden	103 East 2nd Street	Tilden	Nebraska	68781	(402) 368-5385
Hazel's Compounding Rx Pharmacy	2404 Smith Ranch Rd Suite 100	Pearland	Texas	77584-5120	(713) 340-0202
Petrossian Pharmacy	2701 West Alameda Avenue Suite 100	Burbank	California	91505	(818) 433-7166
Memorial Medical Center Pharmacy	9806 Venice Boulevard	Culver City	California	90232	(310) 837-6158
PharmaRx	11382 Miramar Parkway	Miramar	Florida	33025-5805	(786) 418-5383
Clark County Pharmacy	716 Boone Avenue	Winchester	Kentucky	40391	(859) 744-3350
BestRx	1103 North Main Street Suite E	Fountain Inn	South Carolina	29644-1336	(864) 210-1811
Eddie's Pharmacy	8408 Beverly Boulevard	Los Angeles	California	90048	(310) 358-2400
COLUMBINE DRUG	3515 Mountain Lion Drive	Loveland	Colorado	80537	(970) 663-4600
Health Plus Pharmacy	3104 West Mile 5 Road Suite 2	Mission	Texas	78574	(956) 424-3535
KwikRx Pharmacy	10322 South Harlem Avenue	Palos Hills	Illinois	60455	(708) 598-0808
Medical Arts Pharmacy	1320 Maricopa Highway	Ojai	California	93023	(805) 646-7211
Edmonds Pharmacy	7631 212th Street Southwest Suite	Edmonds	Washington	98026-7565	(425) 977-4880

	D100				
Reeves Sain Drug Store	1801 Memorial Blvd.	Murfreesboro	Tennessee	37129	(615) 896-5731
Kilgore Express Pharmacy #6	1614 Glenn Blvd SW	Fort Payne	Alabama	35968-3522	(256) 845-3402
Bay Shore Pharmacy	93 A 4th Street	Suttons Bay	Michigan	49682	(231) 271-6111
Dilworth Drug	1300-B East Boulevard	Charlotte	North Carolina	28203	(704) 910-4288
Barrachina Pharmacy	2004 E Expressway 83 Suite 2	Weslaco	Texas	78599	(956) 405-3089
SALEM PHARMACY	3273 SALEM ROAD	COVINGTON	Georgia	30016	(770) 274-6561
RMC Pharmacy Day Street	6405 Day Street	Riverside	California	92507	(951) 899-8188
Kressaty's Pharmacy	1068 Ringwood Ave	Haskell	New Jersey	07420-1441	(973) 835-1627
Hometown Old Country Pharmacy Inc	8534 Ridge Rd	New Port Richey	Florida	34654	(727) 816-9770
Arrow Pharmacy	317 Bankhead Highway Suite A	Carrollton	Georgia	30117-2497	(770) 858-5767
Curex Pharmacy	900 Kern Ave Ste. A	Taft	California	93268	(661) 745-4115
A & O Peninsula Pharmacy	1860 El Camino Real Suite 108	Burlingame	California	94010	(650) 692-6569
Naples Pharmacy LLC	49 8th St N Suite A	Naples	Florida	34102	(239) 231-3026
Keller Apothecary	5346 Devonshire Avenue	Saint Louis	Missouri	63109	(314) 352-5201
Holly Springs Pharmacy	648 Holly Springs Road	Holly Springs	North Carolina	27540	(919) 346-6689
Akers United Drug	406 North Park Street	Chewelah	Washington	99109	(509) 935-8441
Royals Pharmacy	20727 Wyoming Street	Ferndale	Michigan	48220	(248) 566-0116
Sarasota Discount Pharmacy	110 North Lime Avenue	Sarasota	Florida	34237	(941) 444-6888
Cayucos Pharmacy	72 South Ocean Avenue	Cayucos	California	93430	(805) 995-3538
Spring Green Pharmacy	1443 FM 1463 Rd Suite 650	Katy	Texas	77494-5479	281-769-1444
Prescription Shop of Stuart	622 Colorado Avenue	Stuart	Florida	34994-3087	(772) 287-3443
FAMILY PHARMACY	7315 212th Street Southwest Suite 100	Edmonds	Washington	98026	(425) 778-7778
Chans Pharmacy Plus	2092 North University Drive	Pembroke Pines	Florida	33024	(954) 367-3296
Tustin Pharmacy	13400 Newport Avenue	Tustin	California	92780	(714) 731-1344
KEX RX	807 MAIN ST.	ATCHISON	Kansas	66002	9133675252
Lowe's Pharmacy	1536 East Broadway	Maryville	Tennessee	37804	(865) 982-3020
ElixRx	1090 Keolu Drive Suite 112/113	Kailua	Hawaii	96734	(808) 260-9894

Pharmax Pharmacy #1117	1117 Main Street	Imperial	Missouri	63052	(636) 464-1100
Carlisle Pharmacy	771 Central Avenue	Carlisle	Ohio	45005	(937) 806-8470
Belleville Pharmacy	338 Washington Avenue	Belleville	New Jersey	07109	(973) 759-1956
Pawleys Island Pharmacy of Litchfield	115 Willbrook Boulevard Unit A	Pawleys Island	South Carolina	29585	(843) 314-0498
Danielson Pharmacy	77 Westcott Rd	Danielson	Connecticut	06239-2929	(860) 774-0050
Northern Maine Medical Center Pharmacy	104 Main Street	Madawaska	Maine	04756	(207) 728-7200
St. Matthews Community Pharmacy	200 N Hurstbourne Pkwy Suite 174	Louisville	Kentucky	40222-5138	(502) 690-4462
Advanced Rx Pharmacy 060	1400 Donelson Pike Ste A15	Nashville	Tennessee	37217	(615) 866-6292
HCA Pharmacy & Medical Equipment	1113 West Lexington Avenue	Winchester	Kentucky	40391	(859) 745-4445
Galloway Sands Pharmacy	58 Physicians Drive Suite 5	Supply	North Carolina	28462	(910) 754-7200
Pharmax Pharmacy #1160	116 Walnut Street	Festus	Missouri	63028	(636) 937-7997
Seashore Drugs	1304 Highway 17 North	Little River	South Carolina	29566	(843) 281-9797
Trenton Avenue Pharmacy	3803 Ventnor Ave	Atlantic City	New Jersey	08401	(609) 345-8901
Arbor Lakes Pharmacy	1549 Holmes Road	Ypsilanti	Michigan	48198	(734) 340-6050
5 Minute Pharmacy Ala Moana	725 Kapiolani Boulevard Suite C111	Honolulu	Hawaii	96813-6016	(808) 797-2905
Corner Pharmacy	102 West Main Street	Barnesville	Ohio	43713	(740) 425-2651
Schwieterman Pharmacy	1302 Defiance Street	Wapakoneta	Ohio	45895	(419) 738-5959
Central Rx Pharmacy	50 Eagle Rock Way Suite C	Brentwood	California	94513-4941	(925) 240-9777
Acts Pharmacy and Healthcare Services	1901 South Union Avenue Building B Suite 2011	Tacoma	Washington	98405	(253) 272-0324
Denbigh Pharmacy	13349 Warwick Boulevard	Newport News	Virginia	23602	(757) 877-0253
Cano Pharmacy 5	5190 North West 167th Street Suite 100	Miami Lakes	Florida	33014	(786) 870-1170
Pharmax Pharmacy #1365	60 Nesbit Drive Ste A	Bonne Terre	Missouri	63628	(573) 358-3301
Habersham Drug	638 Historic Highway 441 Suite A	Demorest	Georgia	30535	(706) 754-4128
Riggs Drug	502 West Central Avenue	La Follette	Tennessee	37766	(423) 562-5235 Ext 223
Yorke Pharmacy	5524 New Falls	Levittown	Pennsylvania	19056	(215) 945-5700

	Road				
Pharmax Pharmacy #1302	610 East High Street	Potosi	Missouri	63664	(573) 438-2189
Exton Pharmacy at Marchwood	1 Marchwood Road	Exton	Pennsylvania	19341	(610) 363-9444
Katy Medical Complex Pharmacy	21700 Kingsland, Suite 105	Katy	Texas	77450	(281) 829-6497
Coats Pharmacy Inc	393 N McKinley St	Coats	North Carolina	27521	(910) 897-8500
Cano Pharmacy	8300 West Flagler Street Suite 165	Miami	Florida	33144	(305) 456-3670
Hephzibah Pharmacy	4819 Windsor Spring Road	Hephzibah	Georgia	30815	(706) 592-4646
CornerstoneRx Pharmacy	1720 South McCall Road Suite J	Englewood	Florida	34223-4867	(941) 263-3331
Village Discount Pharmacy~~ NAME~~	~~STREET ADDRESS~~3990 East State Road 44 Suite 207	~~CITY~~Wildwood	~~STATE~~Florida	~~ZIP CODE~~34785-7480	(352) 492-9333
~~PRIME CARE DRUG & SURGICALS CORP~~	~~2066 FLATBUSH AVE~~	~~BROOKLYN~~	~~New York~~	~~11234~~	
~~Elmore~~Florida Family Pharmacy	~~401 Walnut Street~~14889 Tamiami Trl	~~Red Bluff~~North Port	~~California~~Florida	~~96080~~34287-2732	(941) 444-2215
~~Hometown~~Palm Care Pharmacy	~~110 Leroux~~4651 Babcock Street North East Suite 5A	~~Doniphan~~Palm Bay	~~Missouri~~Florida	~~63935~~32905	(321) 914-0484
~~Millers Of Wyckoff~~	~~678 Wyckoff Avenue~~	~~Wyckoff~~	~~New Jersey~~	~~07481~~	
~~Ultra Care~~D&D Pharmacy	~~3250 West Pleasant Run Road~~2903 Central Avenue Suite ~~165~~A	~~Lancaster~~Charlotte	~~Texas~~North Carolina	~~75146 1071~~28205-6073	(980) 272-6988
~~Overton~~Family Pharmacy	~~104 West Henderson~~333 Newberry Street Northwest	~~Overton~~Aiken	~~Texas~~South Carolina	~~75684~~29801-3929	(803) 649-1776
~~Trail Creek~~Clearfork Pharmacy	~~2700 Tibbets Drive~~1130 FM 1189 Suite ~~200~~109	~~Bedford~~Millsap	Texas	~~76022~~76066	(817) 609-4992
~~Westmoreland~~Guy's Pharmacy of Summit	~~1945 State Street~~1121 Highway 98 and 51	~~New Albany~~Summit	~~Indiana~~Mississippi	~~47150~~39666	(601) 465-0777
~~Deluxe~~Victory Pharmacy	~~8749 Frankford Avenue~~1837 River Oaks Drive	~~Philadelphia~~Calumet City	~~Pennsylvania~~Illinois	~~19136~~60409-5071	(708) 801-9626
~~Total Care~~Medical	~~40~~	~~Dry Ridge~~San Angelo	~~Kentucky~~Texas	~~41035~~76901	(325) 949-4636

Arts Pharmacy #3	Broadway2102 Pecos Street				
Maddox Drugs	1330 Big A Road	Toccoa	Georgia	30577	
Avenue CNewport Coast Pharmacy	178 Avenue C400 Newport Center Drive	New YorkNewport Beach	New YorkCalifornia	10009 92660	(949) 719-3707
GoodaleRiver Pharmacy	16 North Sussex124 Ames Street	DoverElk Rapids	New JerseyMichigan	07801 49629	(231) 264-8165
Teasley DrugWyatt's Pharmacy	205 Atlanta Street Southeast10671 Veterans Memorial Highway	GravetteLithia Springs	ArkansasGeorgia	72736 30122	(770) 948-8825
Ochoa's Pharmacy South	301 Conquest Boulevard	Edinburg	Texas	78539	
Gotham Pharmacy Inc	2258 3rd Avenue	New York	New York	10035	
Quess Rx	430 W Broadway	West Memphis	Arkansas	72301	
FullertonBig Spring Pharmacy	1820 Fullerton Avenue Suite 10591 South High Street	CoronaNewville	CaliforniaPennsylvania	92881-3160 17241	(717) 776-0288
EldonFrazier's Prater Drug Company	101 South Maple49 S. Church Street	EldonSalyersville	MissouriKentucky	65026 41465	(606) 349-3135
Hancock LambertSchwietzerman Pharmacy	342324 North Main Street	ClintwoodMinster	VirginiaOhio	24228 45865	(419) 628-2305
MiddletownAngier Family Pharmacy, LLC	877 Main50 East Depot Street	BelfordAngier	New JerseyNorth Carolina	07718 27501-6017	(919) 639-0155
ScottsAnn Arbor Pharmacy #1LLC	635 Pio Nono Avenue2418 East Stadium Boulevard	MaconAnn Arbor	GeorgiaMichigan	31204 48104	(734) 677-5555
Franklin Square Pharmacy Inc	925 Hempstead Turnpike	Franklin Square	New York	11010-3626	
TrinityRiverside Pharmacy	2797 South Maryland Parkway Suite 2822 Larry Joe Harless Drive	Las VegasGilbert	NevadaWest Virginia	89109 25621	(304) 664-3343
Pharm-A-Save MonroeSixth Street	17788 147th1020 Sixth Street	MonroeTraverse City	WashingtonMichigan	98272 49684	(231) 946-4570

Drugs	~~Southeast~~				
~~Charlie's~~Corner Pharmacy	~~2235 Veterans Highway~~504 Rocksylvania	~~Levittown~~Iowa Falls	~~Pennsylvania~~Iowa	~~19056~~50126	(641) 648-5550
Cornersburg Family Discount Drug	3307 Canfield Road	Youngstown	Ohio	44511	(330) 792-7654
~~Bright Plaza~~Abala Pharmacy	~~15725 East Whittier Boulevard~~550 West Eaton Avenue, Suite ~~A~~B	~~Whittier~~Tracy	California	~~90603~~95376-3445	(209) 832-7080
~~*Best Discount~~Newark Pharmacy	~~2316 34th~~635 Market Street Unit 1C	~~Lubbock~~Newark	~~Texas~~New Jersey	~~79411~~07105-3618	(973) 993-7510
~~Corner Drug Store~~	~~101 West Railroad Avenue~~	~~Magnolia~~	~~Mississippi~~	~~39652~~	
~~Marshall Medic~~Upper Darby Pharmacy	~~243 Highway 65 North~~119 Long Lane	~~Marshall~~Upper Darby	~~Arkansas~~Pennsylvania	~~72650~~19082-4103	(610) 352-3010
Schmidt & Sons Pharmacy of Blissfield LLC	616 W. Adrian Street	Blissfield	Michigan	49228	(517) 486-2145
~~Florida Medical Clinic~~Script Choice Pharmacy	~~38045 Market Square~~9740 North 56th Street	~~Zephyrhills~~Temple Terrace	Florida	~~33542~~33617	(813) 374-9944
~~Dripping Springs~~Knolls Pharmacy	~~100 Commons Road, Suite 1~~16630 Marquez Avenue	~~Dripping Springs~~Pacific Palisades	~~Texas~~California	~~78620~~90272	(310) 454-6000
~~West Milford Pharmacy~~SMITH BROTHERS DRUG	~~1495 Union Valley Road~~25 West Main Street	~~West Milford~~Maple Shade	New Jersey	~~07480~~08052	(856) 779-8300
~~Corner Drug LLC~~Dunewood Pharmacy	~~1041 Grass Valley~~1445 Sheldon Road Suite ~~A~~104	~~Winnemucca~~ Grand Haven	~~Nevada~~Michigan	~~89445~~49417	(616) 842-5193
~~Westmoreland Pharmacy Sellersburg~~	~~7600 Highway 60 Suite 400~~	~~Sellersburg~~	~~Indiana~~	~~47172~~	
~~Happy Druggist~~	~~26 South Main Street~~	~~Mechanicsburg~~	~~Ohio~~	~~43044~~	
~~Valencia~~Coast Hills Pharmacy~~-At Henry Mayo~~	~~23929 MCBEAN PKWY STE 100A~~2610 San Miguel Rd	~~SANTA CLARITA~~Newport Beach	California	~~91355-446~~7~~92660~~	(949) 720-7044
~~Royal Care~~Evans	~~378 SE Port~~	~~Port Saint~~	~~Florida~~Texa	~~34984~~79763	(432) 337-2361

Prescription Pharmacy	~~Saint Lucie Blvd~~310 North Dotsy Avenue	~~Lucie~~Odessa	s		
~~Perkins~~Medicine Man Southwest Pharmacy	~~4015 20th Street~~805 East Polston Avenue	~~Vero Beach~~Post Falls	~~Florida~~Idaho	~~32960~~83854	(208) 777-7732
Campbell Drug	311 Main Street	Oshkosh	Nebraska	69154	(308) 772-3333
~~Munsey~~Global Pharmacy	~~106 Administration~~926-B Montreal Road Suite 2	~~Oak Ridge~~Clarkston	~~Tennessee~~ Georgia	~~37830~~30021	(404) 299-8255
~~Red Cross~~Las Villas Pharmacy Discount and Medical Supplies	~~420 Main~~716 West 29th Street	~~Forest City~~Hialeah	~~Pennsylvania~~Florida	~~18421~~33012	(305) 883-7476
~~One to One~~Community Pharmacy of Plainwell	~~214 5th~~533 West Allegan Street	~~Kalona~~Plainwell	~~Iowa~~Michigan	~~52247~~49080	(269) 685-5847
~~City Drug Store~~	~~104 East Belknap~~	~~Jacksboro~~	~~Texas~~	~~76458~~	
~~Franks~~Evergreen Park Pharmacy	~~7548 Soquel Drive~~2850 West 95th Street, Suite 100	~~Aptos~~Evergreen Park	~~California~~Illinois	~~95003~~60805	(708) 423-4700
~~Medicine Mart Pharmacy~~Farmacia Monte Verde	~~1300 Sunset Boulevard~~Carr 174 KM 10.2 La Morenita, Guaraguao	~~West Columbia~~Bayamon	~~South Carolina~~Puerto Rico	~~29169~~00956	(787) 780-7383
~~Fontanelle~~Seifert Drug	~~401 Washington~~230 South Main Street	~~Fontanelle~~Elkhart	~~Iowa~~Indiana	~~50846~~46516	(574) 295-4333
~~Wildcat~~Marcus Hook Pharmacy	~~11231 Indian Creek Road~~46 E 10TH ST	~~Pound~~Marcus Hook	~~Virginia~~Pennsylvania	~~24279~~19061	(610) 485-7750
McKinney Pharmacy	1601 West University Drive	McKinney	Texas	75069	(972) 562-8700
Riccio Family Pharmacy	2217 Bristol Pike, Suite 2	Bensalem	Pennsylvania	19020	(215) 639-6680
~~Joliet Professional Pharmacy~~The Brown Drug Company	~~2401 West Jefferson~~1121 Maine Street ~~Suite 200~~	~~Joliet~~Quincy	Illinois	~~60435~~62301	(217) 228-6400
~~Carlin Springs~~Silverado Pharmacy	~~611 South Carlin Springs~~	~~Arlington~~Calistoga	~~Virginia~~California	~~22204~~94515	(707) 942-5115

	Road1473 Lincoln Avenue Suite 105D				
Lamar Plaza Drug Store	1509 South Lamar Boulevard	Austin	Texas	78704	
MassPack Ltc	6 Executive Park Drive	North Billerica	Massachusetts	01862	
St. PetersburgVan Houten Pharmacy	6399 38th669 Van Houten Avenue North Suite A-5	St. PetersburgClifton	FloridaNew Jersey	33710007013	(973) 779-1122
Happy DruggistSchwieterman Pharmacy – WJD	487404 West MainNorth Street	West JeffersonCold water	Ohio	4316245828	(419) 678-3435
TheSt. John Valley Pharmacy	333 South Plumosa Street182 Market St Suite 2	Merritt IslandFort Kent	FloridaMaine	3295204743	(207) 834-2880
Brundages Waymart PharmacyBatts Drug Company Mansfield, LLC	238 Belmont Street4424 Highway 213	WaymartMansfield	PennsylvaniaGeorgia	1847230055	(678) 712-7055
Plain City Druggist	480 South Jefferson Avenue	Plain City	Ohio	43064	
*E W Thomsons DrugNorthern Maine Medical Center Pharmacy	213 Depot194 East Main Street	DelhiFort Kent	LouisianaMaine	7123204743-1428	(207) 834-1690
Banner Drug Downtown Statesville	307 N Center St	Statesville	North Carolina	28677	(704) 872-0880
G & OMedicine Man West Pharmacy	2338 Broadway802 East Medical Court	PaducahPost Falls	KentuckyIdaho	4200183854	(208) 773-3566
ValenciaOakdale Pharmacy	25050 PEACHLAND AVE STE5400 Balboa Boulevard Suite 100	NEWHALLEncino	California	91321-2523 91316	(818) 788-0770
WestmorelandZeigler Pharmacy Jeffersonville	1495 East 10th Street159 W Main St	JeffersonvilleWilmington	IndianaOhio	4713045177	(937) 382-0921
NovecksSmith's St Helena Pharmacy	7823 BERGENLINE	North BergenSaint	New JerseyCalif	0704794574-1194	(707) 963-2794

	AVE1390 Railroad Ave	Helena	ornia		
ValleySmith's Pharmacy	647 State Route 93 Suite 6841 East Hunting Park Avenue	SugarloafPhiladelphia	Pennsylvania	18249-4800	(215) 537-3000
K&S Pharmacy	107 Avon Avenue S, Suite 1	Avon	Minnesota	55331	
Cambria Drug & GiftCountry Market Pharmacy # 12	22221255 South Main Street	CambriaChelsea	California Michigan	93428-48118	(734) 433-0129
Economy Drug	1006 West Trimble Avenue	Berryville	Arkansas	72616	(870) 423-2094
ChristiansRushville Pharmacy	1032302 North Main Street	Forest ParkRushville	GeorgiaIndiana	30297-46173	(765) 561-5467
ChoiceBocage Pharmacy Centre	401 South Parsons Avenue7150 Jefferson Highway Suite C680	BrandonBaton Rouge	FloridaLouisiana	33511-70806	(225) 364-2847
Times Pharmacy #3	590 Kailua Road	Kailua	Hawaii	96734	
Ganse Apothecary Retail	355 West King Street	Lancaster	Pennsylvania	17603-3751	
Munsey PharmacyHassler's Drug	106 Administration Road401 Front Street	Oak RidgeSpring City	Tennessee	37830-37381	(423) 365-9202
Westbrook ParkPharmax Pharmacy #1343	244 West Baltimore113 St. Francois Plaza	Clifton HeightsLeadington	PennsylvaniaMissouri	19018-63601	(573) 431-5040
Regency MedicalOrange Pharmacy	1000 Newbury Road Suite 100130 West Main Street	Newbury ParkOrange	CaliforniaVirginia	91320-22960	(540) 661-5006
Grapevine Drug RX	1115 West Northwest Highway Suite H	Grapevine	Texas	76051-5029	
T&T Drugs INC	1331 Clay Street	Henderson	Kentucky	42420	
Refill Pharmacy llc	8536 Del Webb Boulevard	Las Vegas	Nevada	89134-8676	
Jay'sSchwieterman Pharmacy	214 Highway 30862 North	JenkinsNew Bremen	KentuckyOhio	41537-45869	(419) 629-2336

	Washington Street				
~~Professional~~Dalcoma Specialty Pharmacy	~~1100 Burleyson~~43337 Schoenherr Road	~~Dalton~~Sterling Heights	~~Georgia~~Michigan	~~30720~~48313	(586) 697-3877
~~St. Georges Specialty~~GOOD RXS Pharmacy	~~521 North Wood Avenue~~5221 33rd Street East	~~Linden~~Bradenton	~~New Jersey~~Florida	~~07036~~34203-4330	(941) 900-4566
~~Parke Vista~~Hendricks Pharmacy	~~3838 Sherman Drive Suite 1~~137 North Harvard Avenue	~~Riverside~~Claremont	California	~~92503~~91711-4717	(909) 624-1611
Key Drugs at Dexter	1007 West Business US Highway 60	Dexter	Missouri	63841	(573) 614-5900
WellnessRx Pharmacy	5971 University Avenue Suite 304	San Diego	California	92115	(619) 582-1933
Better Life Pharmacy	5621 Atlantic Avenue Suite 103	Raleigh	North Carolina	27615	(919) 891-9555
~~Midtown~~Country Market Pharmacy ~~LLC~~#11	~~278 North 3rd~~1535 West Maumee Street	~~Gadsden~~Adrian	~~Alabama~~Michigan	~~35901~~49221	(517) 265-9162
Gibbs Drug Store	216 Clay Street	Nocona	Texas	76255	(940) 825-3226
~~Pepper~~Southern Chester County Pharmacy	~~195-197 East Plumstead Avenue~~1011 West Baltimore Pike Suite 109	~~Lansdowne~~West Grove	Pennsylvania	~~19050~~19390	(610) 869-3200
~~Karemore~~Medicine Man Rathdrum Pharmacy~~ #002~~	~~817 Snowhill Road Suite 2~~15837 North Westwood Drive	~~Salisbury~~Rathdrum	~~Maryland~~Idaho	~~21804~~83858	(208) 687-5717
~~MEDSURG PHARMACY~~	~~3037 Marshall Hall Road~~	~~Bryans Road~~	~~Maryland~~	~~20616-3240~~	
~~Arrow Prescription Center #12~~Olssons Pharmacy	~~500 Farmington~~576 Lafayette Avenue	~~Hartford~~Hawthorne	~~Connecticut~~New Jersey	~~06105~~07506-2400	(973) 427-1700
~~Cano~~Professional Pharmacy ~~13~~Services and Medical Equipment	~~4160 North Armenia Avenue Suite C~~10993 Southwest 186 Street	~~Tampa~~Miami	Florida	~~33607-645 3~~33157	(305) 253-6634
~~AHCS Specialty Care~~	~~12832 Valley View Drive Suite A & B~~	~~Garden Grove~~	~~California~~	~~92845~~	
~~Care~~Colonial Pharmacy	~~1400 West Kenneth~~1915 North	~~Glendale~~Bath	~~California~~Ohio	~~91201~~44210	(330) 666-3569

	Cleveland-Massillon Road				
M-C Drug StoreDavenport Good Neighbor Pharmacy	533 Porter525 Morgan Street	HelenaDavenport	ArkansasWashington	7234299122	(509) 725-1151
Don Quijote Drugs	94-144 Farrington Highway	Waipahu	Hawaii	96797	(808) 973-6661
RGV HometownIvan Pharmacy	608 East Harrison691 Columbus Avenue	HarlingenNew York	TexasNew York	78550-9160 10025	(212) 222-4400
AntwerpMunson Community Health Center Pharmacy	201 S. MAIN ST.550 Munson Avenue Suite G-100	ANTWERPTraverse City	OhioMichigan	45813-0246 49686	(231) 935-8730
Tinley Park Pharmacy	18210 South Lagrange Road Suite 101	Tinley Park	Illinois	60487	
South BayRiver Oak Pharmacy	520 North Prospect Avenue1080 West F Street, Suite 110D	Redondo BeachOakdale	California	90277-3026 95361	(209) 847-2226
Tidewater Drug and Health Care	30170 Three Notch Road Unit B	Charlotte Hall	Maryland	20622-4119	(301) 472-1720
SunScript LLC	7869 Pines Boulevard	Pembroke Pines	Florida	33024-6916	(954) 362-7645
Boulder CreekSmith's Pharmacy	13081 Central133 West Hunting Park Avenue Suite 200	Boulder CreekPhiladelphia	CaliforniaPennsylvania	9500619140	(215) 324-5100
AceOldens Pharmacy	186 Broadway101 Pleasant Street	Long BranchSouth Weymouth	New JerseyMassachusetts	0774002190	(781) 337-0187
986 Pharmacy #8028Prescriptions Plus LTD	3580 Santa Anita Ave #8753 True Value Drive	El MonteLebanon	CaliforniaIllinois	9173162254	(618) 537-6202
Fairley'sTopeka Pharmacy	7206 North East Sandy Boulevard101 N Main St	PortlandTopeka	OregonIndiana	97213-5795 46571	(260) 593-2252
Richard's Pharmacy	3509 East Main Avenue Suite 102	Alton	Texas	78573	
*Tega CaySpears Pharmacy	1741 Gold Hill Road, Suite 106405 Becker Drive	Fort MillRoanoke Rapids	SouthNorth Carolina	2970827870	(252) 676-8399

IFB Pharmacy LLC	2488 North University Drive	Pembroke Pines	Florida	33024	
Ron's ApothecaryYinger Pharmacy Shoppe	9101 Mendenhall Mall Road1036 North Monroe Street	JuneauMonroe	AlaskaMichigan	99801 48162	(734) 384-7044
Royal CareEnglish Pharmacy	595 21st2600 10th Street Unit 100	Vero BeachWichita Falls	FloridaTexas	32960-5449 76309	(940) 723-6060
XcellentCobb's Pharmacy	11880 Southwest 40TH Street Road510 Houston St	MiamiGeorge West	FloridaTexas	33177 78022-2340	(361) 449-2631
Country Market Pharmacy #66	11301 Brooklyn Road	Brooklyn	Michigan	49230	(517) 592-2475
Shields*Elkton Family Pharmacy	2196 Main Street Suite A111 South Stuart Avenue	DunedinElkton	FloridaVirginia	34698-5650 22827	(540) 298-9090
AtholAmerican Surgical Pharmacy	290 Main Street103 E Highland Ave	AtholSan Bernardino	MassachusettsCalifornia	01331 92404	(909) 882-3353
Finley Pharmacy	1016 West South Street	Benton	Arkansas	72015	
Crown DrugBerry & Sweeney Pharmacy	657 East University Drive1377 N Fair Oaks Ave	CarsonPasadena	California	90746 91103-2199	(626) 794-1124
BurgessSeifert Drug Store Inc #42	1 South Creek Drive Suite 122100 N Elkhart St	MonticelloWakarusa	KentuckyIndiana	42633 46573	(574) 862-1454
KNOX PROFESSIONAL PHARMACY	511 KNOX STREET	BARBOURVILLE	Kentucky	40906	
West WichitaCox Family Pharmacy LLC	8200 W CENTRAL AVE1212 Garfield Avenue Suite 102	WICHITAParkersburg	KansasWest Virginia	67212-9503 26101	(304) 865-7600
Sterling Drug	1305 1st Avenue South West	Austin	Minnesota	55912	(507) 433-4586
BAKER PHARMACY INCEverCare Pharmacy	38-42 Main1903 East 9th Street	SussexTrenton	New JerseyMissouri	07461 64683-2645	(660) 359-5700

~~Heyden~~Care More Pharmacy	~~20201 West 7 Mile Road~~151 Dorton-Jenkins Highway	~~Detroit~~Dorton	~~Michigan~~Kentucky	~~48219~~41520	(606) 639-2273
~~HealthPlus~~Saline Pharmacy ~~of Ann Arbor~~	~~4350 Jackson Road Suite 250~~75 E Bennett St	~~Ann Arbor~~Saline	Michigan	~~48103~~48176-1204	(734) 316-2162
~~Pinnacle Peak~~GNO Pharmacy	~~317 East 100 North~~1151 Barataria Blvd Suite ~~4~~1200	~~Price~~Marrero	~~Utah~~Louisiana	~~84501~~70072-3082	(504) 252-9686
~~Watervliet~~Woodbury Family Pharmacy	~~317~~160 North ~~Main~~Broad Street	~~Watervliet~~Woodbury	~~Michigan~~New Jersey	~~49089~~08096	(856) 251-1900
~~DONLON~~PALMYRA PHARMACY	~~201 West Water~~1 East Broad Street	~~Decorah~~Palmyra	~~Iowa~~New Jersey	~~52101~~08065-1604	(856) 786-1615
~~Tidewater Pharmacy Mt Pleasant~~Sterling Drug #19	~~421 Johnnie Dodds Boulevard, Suite 100~~430 2nd Avenue NW	~~Mount Pleasant~~Faribault	~~South Carolina~~Minnesota	~~29464~~55021	(507) 333-5464
~~Familycare Discount~~Cano Pharmacy	~~3633 Cortez Road West~~12600 Southwest 120th Street Suite ~~B9~~102	~~Bradenton~~Miami	Florida	~~34210~~33186	(305) 506-1930
~~Edmonds Pharmacy~~KEX RX PHARMACY & HOME CARE	~~7631 212th Street Southwest Suite D100~~120 E 18TH ST	~~Edmonds~~FALLS CITY	~~Washington~~Nebraska	~~98026~~68355	(402) 245-2029
~~Iselin~~Valley Pharmacy	~~1186 Green Street~~791 Hamburg Turnpike	~~Iselin~~Wayne	New Jersey	~~08832~~07470-8416	(973) 832-7200
~~Power's Pharmacy~~Pennington Apothecary	~~558 Lakehurst Road Units J & K~~6 North Main Street	~~Browns Mills~~Pennington	New Jersey	~~08015~~08534	(609) 737-9297
~~Ultra Care~~South Fork Pharmacy	~~10798 Hickory Ridge Road Suite A~~732 North Main St	~~Columbia~~Moorefield	~~Maryland~~ West Virginia	~~21044 364 6~~26836	(304) 530-1044
Schroeder Drugs #1201	540 East Fifth Street	Washington	Missouri	63090-0227	(636) 239-4707
~~Mauliola~~Times Pharmacy #8	~~95 Mahalani~~1290 South Beretania Street~~, Room~~	~~Wailuku~~Honolulu	Hawaii	~~96793~~96814	(808) 522-5071

	28 5				
Rocky Top Pharmacy Value	7012 Park Avenue702 Grove Street	GuttenbergLoudon	New JerseyTennessee	07093 4707737774	(865) 657-3500
Getwell Pharmacy and Drugs	2579 Lawrenceville Highway Suite A1	Decatur	Georgia	30033	
Texas StarThornhill's Pharmacy	3033 W Parker Road Suite 100600 8th Street	PlanoShallowater	Texas	7502379363	(806) 832-0300
Pucci's Pharmacy	3257 Folsom Blvd	Sacramento	California	95816	(916) 442-5891
Day's Miami HeightsAllcare Pharmacy & Healthcare Services	7567 Bridgetown Road112 South Oxley Drive	CincinnatiLyons	OhioGeorgia	45248-2014430436	(912) 526-3200
CourtyardMission Medical Pharmacy	23693 B Calabasas Road27800 Medical Center Rd Suite 99	CalabasasMission Viejo	California	9130292691-6410	(949) 364-0122
Hopewell DrugFamily Meds Inc	2508 Gray Street12114 Old Line Center R-7A	HopewellWaldorf	VirginiaMaryland	2386020602	(301) 396-9277
WatsonvilleRancho Park Pharmacy	1433 Freedom10587 (A) and (B) West Pico Boulevard	WatsonvilleLos Angeles	California	9507690064	(310) 475-3040
Fishersville FamilyHolland Center Pharmacy	16 Gosnell Xing Ste 101621 Milford Warren Glen Road	StauntonMilford	VirginiaNew Jersey	2440108848	(908) 995-0015
Barr PharmacyAccokeek Drug and Health Care Inc	1825 Academy Avenue15789 Livingston Road Suite 108	SangerAccokeek	California Maryland	9365720607	(301) 203-7205
KOONCE DRUG COMPANY INC	112 E 7TH AVE	CHADBOURN	North Carolina	28431	
KlingerWhitesell Pharmacy	102 West Jackson236 North Market Street	West UnityFrederick	OhioMaryland	4357021701	(301) 662-4848
Mission PlazaHoly Cross Pharmacy 2	4631 Teller Avenue11550 Indian Hills Road Suite 110130	Newport BeachMission Hills	California	9266091345	(818) 898-1628
La RxKEX RX	3744 Broadway	HoustonHIAW	TexasKansa	77017-304	7857422125

	Street Suite C101 SO. 6TH ST.	ATHA	s	666434	
AHCS SPECIALTY CARE	1820 Tribute Road Suite G	Sacramento	California	95815	
MorristownPorter's Pharmacy & Compounding Lab	66840 Belmont-Morristown935 Beaver Grade Rd	BelmontCoraopolis	OhioPennsylvania	4371815108-2790	(412) 264-2230
Mike'sMedicine Center Pharmacy	180 South Holmes Avenue551 W High Ave	Idaho FallsNew Philadelphia	IdahoOhio	8340144663	(330) 339-4466
OC CommunityWestSide Pharmacy	809 South Main Street Unit C215 N Hermitage Ave Suite 9	Santa AnaTrenton	CaliforniaNew Jersey	92701-6605 08618	(609) 394-0600
Rhine Drug Company	119 First Street	Rhine	Georgia	31077	(229) 385-5351
Spanish Fork Community Pharmacy	375 West Center Street1089 Elizabeth Avenue Store 5	Spanish ForkElizabeth	UtahNew Jersey	84660-2024 07201	(908) 469-6363
BaywoodEhrhardt Pharmacy	336 Drum Point12930 Broxton Bridge Road	BrickEhrhardt	New JerseySouth Carolina	0872329081	(803) 267-2121
Belmar TownElizabeth's Pharmacy on Main	91152 Main StreetAvenue North	BelmarBritt	New JerseyIowa	0771950423	(641) 843-3885
Care MedMac's Edgemoor Pharmacy LLC	4201 Palm Avenue Suite AA643 Edgemoor Road	HialeahPowell	FloridaTennessee	33012-4424 37849	(865) 945-3333
WilsonHarbor Drug #2	118 West 4th2046 Black River Street, Suite 2	HearneDeckerville	TexasMichigan	77859-2506 48427	(810) 376-8070
ArrowBeemans Lake Arrowhead Pharmacy	317 Bankhead Highway Unit A29099 Hospital Road	CarrolltonLake Arrowhead	GeorgiaCalifornia	3011792352	(909) 337-0747
Harry'sInnova Pharmacy	930 Sheriden Drive Suite C5830 Jameson Ct	CareyCarmichael	OhioCalifornia	43316-1502 95608	(916) 481-6900
AB Pharmacy	1510 GUNBARREL RD STE 500	CHATTANOOGA	Tennessee	37421-7175	

~~*Meliora~~Grove Harbor Medical Center Pharmacy	~~9430 WARNER AVE., STE G~~12555 Garden Grove Blvd Suite 102	~~Fountain Valley~~Garden Grove	California	~~92708~~92843	(714) 636-0593
~~Chair City~~Southeast Pharmacy	~~34 Connors Street~~400 Parker Ave N Suite 500A	~~Gardner~~Brooklet	~~Massachusetts~~Georgia	~~01440-2605~~30415-9506	(912) 842-2040
~~Wellness Lab~~Orange Plaza Pharmacy	~~140 North San Fernando Boulevard~~1010 West La Veta Avenue Suite 130	~~Burbank~~Orange	California	~~91502~~92868-4301	(714) 550-9798
~~Rubio~~Newport Lido Pharmacy LTC	~~16550 Ventura Boulevard~~351 Hospital Road, Suite ~~100~~107	~~Encino~~Newport Beach	California	~~91436~~92663	(949) 764-6580
~~Namaste Neighborhood~~Pacific Pharmacy	~~200 South Progress~~11525 Brookshire Avenue, Suite 100	~~Harrisburg~~Downey	~~Pennsylvania~~California	~~17109~~90241	(562) 862-1302
~~HC Good Neighbor~~Grove Pharmacy	~~1071 Route 37 West, Unit 10~~123 Grove Street	~~Toms River~~Montclair	New Jersey	~~08755~~07042	650-867-1408
~~FLOYD'S FAMILY PHARMACY #2~~Mayson's Pharmacy	~~28471 HIGHWAY 22~~4199 F1 Winchester Road	~~PONCHATOULA~~Marshall	~~Louisiana~~Virginia	~~70454-6143~~20115-3269	(540) 364-8291
~~FLOYD'S FAMILY PHARMACY~~Kennebec Pharmacy & Home Care	~~1625 HIGHWAY 51 STE K~~839 Commercial Street	~~PONCHATOULA~~Rockport	~~Louisiana~~ Maine	~~70454-6594~~04856	(207) 594-0888
~~Castilla 87 Pharmacy~~RYALS DRUG STORE	~~890 Southwest 87th Avenue Suite 17~~12 S 2ND AVE	~~Miami~~MCRAE	~~Florida~~Georgia	~~33174-3245~~31055	(229) 868-6735
~~Homestead Pharmacy~~Ramsey Drug	~~601 Broadway~~401 College Dr S	~~Long Branch~~Devils Lake	~~New Jersey~~North Dakota	~~07740~~58301	(701) 662-3117
Seifert Drug #3	2102 N Main St Suite 100	Nappanee	Indiana	46550	(574) 773-8280
~~TABOR CITY MEDICINE MART INC~~Drugs America	~~220 South Main Street~~103 East 24Th St	~~Tabor City~~Lumberton	North Carolina	~~28463~~28358	(910)739-4196
Hanger Drugs	207 Sparks Avenue Suite 1	Jeffersonville	Indiana	47130	(812) 283-3591
~~True~~Greater Care Pharmacy	~~1628 Charleston Highway~~24800	~~West Columbia~~WAR	~~South Carolina~~Mi	~~29169~~48089-1965	(586) 486-5008

	HOOVER RD STE B	REN	chigan		
Playa Pharmacy	8131 West Manchester Avenue	Playa Del Rey	California	90293	(310) 823-4500
WilcoxWyandotte Pharmacy	140 East375 Eureka Road Suite A	DimondaleWyandotte	Michigan	4882148192-5839	(734) 720-0929
Davis Drugs Lone Oak	2855 Lone Oak Road	Paducah	Kentucky	42003	
Main StreetCucamonga Community Pharmacy	199 Main Street8237 Rochester Ave Suite 140	OrangeRancho Cucamonga	New JerseyCalifornia	07050-3728 91730-0717	(909) 948-8377
North WarrenKratzer?s Hometown Pharmacy and GiftMt Orab	155 Route 94North Point Drive	BlairstownMount Orab	New JerseyOhio	0782545154	(937) 444-0135
Grace CommunityElwyn Pharmacy	80 Pinnacles Drive Suite 9005075 Edgmont Ave	Palm CoastBrookhaven	FloridaPennsylvania	32164-2915 19015-1202	(610) 566-2226
MedipharmAalpha Pharmacy	1188 Bishop Street, Suite 802174 S Alvarado St	HonoluluLos Angeles	HawaiiCalifornia	9681390057-2211	(213) 483-8741
Happy DruggistSt. Mary's Pharmacy KRD	5770 Karl Road350 Boulevard	ColumbusPassaic	OhioNew Jersey	4322907055	(973) 365-7143
RoyalBest Care Pharmacy	5045 Turnpike Feeder Road1040 S Pendleton St Suite C	Fort PierceEasley	FloridaSouth Carolina	3495129642	(864) 644-8494
ScriptshopFriendly City Pharmacy on 2nd	4254 Erie Avenue Southwest717 2ND ST W	NavarreTIFTON	OhioGeorgia	4466231794-4201	(229) 382-3711
SPEEDY SCRIPTS PHARMACY INC	1115 45th Street Suite 3	West Palm Beach	Florida	33407	
Wallace CountyAR-EX Drug Store	107 West 2nd Street801 Broadway	Sharon SpringsMarysville	Kansas	6775866508	(785) 562-3196
MEDICINE CABINET PHARMACY	607 S MAYO TRL	PAINTSVILLE	Kentucky	41240	
Triple SRegions Pharmacy	1314 Highway AR 56999 N Tustin	Calico RockSanta Ana	ArkansasCalifornia	72519-0249 92705-6506	(714) 627-9190

	Ave Suite 216				
~~Hoffman Pharmacy~~Downtown Drug	~~1 7 Laurence Parkway~~8 2nd Street Northeast Suite 201B	~~Laurence Harbor~~Watertown	~~New Jersey~~South Dakota	~~08879~~57201-3622	(605) 753-7847
~~Rings~~Darlington Pharmacy	~~221 West~~1115 Main Street	~~Montpelier~~Darlington	~~Ohio~~Maryland	~~43543 109 9~~21034	(410) 457-5521
~~Roselle Park Rita Pharmacy~~	~~200 Chestnut Street~~	~~Roselle Park~~	~~New Jersey~~	~~07204~~	
~~Quick Mart Pharmacy~~	~~777 Washington Road~~	~~Parlin~~	~~New Jersey~~	~~08859~~	
~~South Gate~~Regions Mission Viejo Pharmacy~~ SF~~	~~8200 LONG BEACH BLVD UNIT D 2~~26024 Acero Suite 110	~~SOUTH GATE~~Mission Viejo	California	~~90280~~92691	(949) 755-6443
~~Holmdel Village Pharmacy~~	~~969 Holmdel Road~~	~~Holmdel~~	~~New Jersey~~	~~07733~~	
~~Southwood Rita Pharmacy~~	~~937 South Wood Avenue~~	~~Linden~~	~~New Jersey~~	~~07036~~	
~~Turnpike Chemist Corp~~	~~22421 Union Turnpike~~	~~Oakland Gardens~~	~~New York~~	~~11364-3631~~	
~~Black's Apothecary~~	~~1636 Memorial Boulevard~~	~~Murfreesboro~~	~~Tennessee~~	~~37129~~	
~~Foxcroft Pharmacy~~	~~1207 W MAIN ST~~	~~DOVER FOXCROFT~~	~~Maine~~	~~04426-3747~~	
~~Your Hometown~~Walter's Family Pharmacy ~~Taylorsville~~	~~913 Taylorsville Road~~604 South 12th Street	~~Taylorsville~~Murray	Kentucky	~~40071~~42071	(270) 753-7688
~~Rxbytel Pharmacy #1~~	~~425 Washington Street West~~	~~Charleston~~	~~West Virginia~~	~~25302-2130~~	
~~Kilgore Express Pharmacy #2~~	~~103 Greenhill Boulevard NorthWest~~	~~Fort Payne~~	~~Alabama~~	~~35968~~	
~~MANIFESTRX~~	~~1018 S. BATESVILLE RD BLDG #4A~~	~~GREER~~	~~South Carolina~~	~~29650~~	
~~GOREVILLE PROFESSIONAL PHARMACY~~Xpress Meds	~~901 South Broadway~~4201 West 95th Street Suite G	~~Goreville~~Oak Lawn	Illinois	~~62939~~60453-2615	(708) 459-1800
~~Drug Depot~~AHCS Specialty Care Sacramento	~~1588 UNIVERSITY~~	~~Bronx~~Sacramento	~~New York~~California	~~10453-699 1~~95815	(916) 518-0659

	AVE1820 Tribute Road Suite G				
Lifetime Pharmacy LLC	960 Ridgeview Drive Suite 120	Allen	Texas	75013-5402	
Pottstown DiscountAnderson Family Pharmacy	1501 East High1142 Jackson Street	PottstownAnderson	PennsylvaniaSouth Carolina	1946429625-2760	(864) 642-0200
Uni-ScriptSeaway Pharmacy	8250 Northwest 27th1707 Cherry Street Suite 301	DoralToledo	FloridaOhio	3312243608	(419) 214-5197
EZ PackHonest Pharmacy	933 Hilltop Drive Suite #1017740 Garvey Avenue Unit A	WeatherfordRosemead	TexasCalifornia	7608691770-3061	(626) 703-4750
NORTH GULFPORT DISCOUNT DRUGS	4723 TENNESSEE AVE	GULFPORT	Mississippi	39501-8130	
LYMAN PHARMACY	20006 HIGHWAY 53 STE B	GULFPORT	Mississippi	39503-7843	
Pharm-Aid LLC	12117 Pembroke Road	Pembroke Pines	Florida	33025	
Medicine ManHonest Pharmacy	13737 Artesia Boulevard210 North Garfield Avenue Suite 202101	CerritosMonterey Park	California	9070391754	(626) 545-2919
Rex Drug CoPattie Drugs	24 North Main Street868 Michigan Avenue	YeringtonBaldwin	NevadaMichigan	89447-0814449304	(231) 745-4697
Spence's Medical Center PharmacyFARMACIA AMERICA	215 Oak Drive South Suite MCALLE SALAS TORRES 3, ,ESQUINA MUNOZ RIVERA	Lake JacksonAGUAS BUENAS	TexasPuerto Rico	7756600703	(787) 732-2241
Spence's Medical Center Pharmacy	2301 East Mulberry	Angleton	Texas	77515	
Amphex Pharmacy, LLC	1459 East 3900 South	Millcreek	Utah	84124	
*J.BIRDS,INCHealthy Harlem Rx Corp	8551875 Lexington Avenue	New York	New York	10065-473310035	(212) 601-2661
North Rialto Drug	531 East Foothill Boulevard	Rialto	California	92376	(909) 875-2131
Nightingale Drug	1020 12th Avenue	Dyersville	Iowa	52040	(563) 875-7455

	South East				
~~Orchard Hills~~Fairmont Pharmacy	~~3816 W Chestnut Expressway~~50 Bellefontaine St Suite 103	~~Springfield~~Pasadena	~~Missouri~~California	~~65802~~91105	(626) 793-1188
~~FRANKLIN RX INC~~PRIME CARE DRUG & SURGICALS CORP	~~98B N FRANKLIN ST~~2066 FLATBUSH AVE	~~HEMPSTEAD~~BROOKLYN	New York	~~11550-3029~~11234	(718) 513-6644
~~Mauliola~~Grand Care Pharmacy ~~at Maui Medical Group~~Inc	~~2180 Main Street Suite 102~~6656 Grand Ave	~~Wailuku~~Maspeth	~~Hawaii~~New York	~~96793~~11378-0009	(718) 446-6656
Boies Medical Center Pharmacy	828 Delbon Avenue	Turlock	California	95382	(209) 634-8511
~~GoodPill~~Noubar's El Adobe Pharmacy~~, Inc.~~	~~17177 Pines~~2010 Wilshire Boulevard, Suite F-2010	~~Pembroke Pines~~Los Angeles	~~Florida~~California	~~33027~~90057	(213) 413-3999
~~Rx Discount~~Noubar's El Adobe Pharmacy Inc	~~12620 US Highway 301~~5207 Hollywood Boulevard	~~Dade City~~Los Angeles	~~Florida~~California	~~33525~~90027	(323) 461-9451
TYLERTOWN PHARMACY LLC	201 HOSPITAL DR	TYLERTOWN	Mississippi	39667-2019	(601) 222-1770
~~Cahuenga Blvd~~Medcare Medical Pharmacy	~~5503 Cahuenga Boulevard Suite 100~~1661 Golden Rain Rd	~~North Hollywood~~Seal Beach	California	~~91601-2920~~90740	(714) 557-2982
~~Key Drugs at Northwest~~ROTARY DRUG	~~2210 Barron Road~~1030 BARNUM AVE	~~Poplar Bluff~~STRATFORD	~~Missouri~~Connecticut	~~63901~~06614	(203) 378-9394
~~Nova~~WellCare Pharmacy	~~1330 South Mayo Trail~~2130 West Poplar Avenue Suite ~~102~~104	~~Pikeville~~Collierville	~~Kentucky~~Tennessee	~~41501~~38017	(901) 542-8001
Fisherville Pharmacy	219 Fisherville Rd Suite C	Penacook	New Hampshire	03303-2074	(603) 565-0210
Axtell's Pharmacy	1246 Highway 377 South Suite #100	Pilot Point	Texas	76258	(940) 686-2218
Drug Mart	1249 West 7th Street	South Plainfield	New Jersey	07080	(908) 561-5300
Town Pharmacy	4911 Bergenline Avenue	West New York	New Jersey	07093	(201) 766-1900
~~Abbeville Discount~~	~~201 West~~1221 Main Street	~~Abbeville~~Asbury Park	~~Georgia~~New Jersey	~~31001~~07712-5940	(732) 897-1500

~~Drugs~~Quick Med Pharmacy					
~~*FORSYTH PHARMACY INC~~Harlingen Pharmacy	~~16269 HWY 160~~1616 North Ed Carey Drive	~~FORSYTH~~Harlingen	~~Missouri~~Texas	~~65653-9805~~78550-8286	(956) 230-3200

Summary report: Litera Compare for Word 11.2.0.54 Document comparison done on 12/21/2025 10:53:59 AM	
Style name: Default Style	
Intelligent Table Comparison: Active	
Original filename: Exhibit D 2024-2025 Franchisee Lists [FINAL].docx	
Modified filename: Exhibit D 2025-2026 Franchisee List.docx	
Changes:	
Add	8470
~~Delete~~	8510
~~Move From~~	0
Move To	0
Table Insert	2471
~~Table Delete~~	772
Table moves to	0
~~Table moves from~~	0
Embedded Graphics (Visio, ChemDraw, Images etc.)	0
Embedded Excel	0
Format changes	0
Total Changes:	20223

EXHIBIT E
FINANCIAL STATEMENTS
AND CENCORA GUARANTY

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

	Page
Report of Independent Registered Public Accounting Firm	1
Consolidated Financial Statements:	
Consolidated Balance Sheets as of ~~September 30, 2024 and 2023~~ September 20, 2025, and 2024	4
Consolidated Statements of Operations for the fiscal years ended ~~September 30, 2024, 2023, and 2022~~ September 30, 2025, 2024, and 2023	5
Consolidated Statements of Comprehensive Income for the fiscal years ended September 30, 2025, 2024~~, 2023~~, ~~and 2022~~ 2023	6
Consolidated Statements of Changes in Stockholders' Equity for the fiscal years ended September 30, 2025, 2024~~, 2023~~, ~~and 2022~~ 2023	7
Consolidated Statements of Cash Flows for the fiscal years ended September 30, 2025, 2024, ~~2023,~~ and 20~~22~~23	8
Notes to Consolidated Financial Statements	9

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Stockholders and the Board of Directors of Cencora, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Cencora, Inc. and subsidiaries (the Company) as of September 30, 2024 and 2023, the related consolidated statements of operations, comprehensive income, changes in stockholders' equity and cash flows for each of the three years in the period ended September 30, 2024, and the related notes and financial statement schedule listed in the Index at Item 15(a) (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at September 30, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended September 30, 2024, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of September 30, 2024, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated November 26, 2024 expressed an unqualified opinion thereon.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosure to which they relate.

Legal Matters and Contingencies - Opioid Lawsuits and Investigations

Description of the Matter As discussed in Note 13 of the consolidated financial statements, the Company is involved in a significant number of lawsuits and government investigations relating to the distribution of prescription opioid pain medications and other controlled substances ("opioid litigation and investigations"). The Company recognizes a liability for those legal contingencies for which it is probable that a liability has been incurred at the date of the consolidated financial statements and the amount is reasonably estimable. As discussed in Note 4, in connection with the recognized liabilities for settled opioid lawsuits, the Company recognizes a related income tax benefit, which reflects an unrecognized tax benefit resulting from uncertainty in the amount that is more likely than not to be deductible for U.S. federal and state income tax purposes. The Company used significant judgment in measuring the amount of income tax benefit that may ultimately be deductible for U.S. federal and state purposes.

Auditing management's determination of whether the risk of loss related to opioid litigation and investigations is probable and reasonably estimable, and the related disclosures is highly subjective and requires significant judgment. Auditing management's judgments related to unsettled cases was challenging due to the significant judgment applied in determining the likelihood of resolution of matters through settlement or litigation and the magnitude of the liability. In addition, auditing management's estimate of the amount of income tax benefit related to the Company's uncertain tax positions is challenging because the evaluation of the technical merits of income tax benefits that qualify for a deduction related to the opioid litigation and investigations requires significant judgment.

How We Addressed the Matter in Our Audit

We tested the Company's internal controls that address the risks of material misstatement related to the completeness and presentation and disclosure of the opioid litigation and investigations liability and related uncertain tax position. This included testing controls related to the Company's process for identification, recognition, completeness, and disclosure of the opioid litigation and testing controls related to the Company's process to assess the technical merits of its tax position, including the Company's assessment as to the amount of benefit that is more likely than not to be realized upon ultimate settlement with taxing authorities. For example, we tested controls over management's review of the assessment of the completeness of the opioid litigation and investigations liability and whether a range of possible loss in excess of the amount accrued is reasonably estimable to determine the accuracy of the opioid litigation and investigations liability and the related financial statement disclosures.

To test the Company's opioid litigation and investigations liability, our substantive audit procedures included, among others, testing the completeness of the contingencies subject to evaluation by the Company and evaluating the Company's analysis of its assessment of the probability of outcome for each material legal contingency through inspection of responses to inquiry letters sent to both internal and external legal counsel, discussions with internal general counsel and external legal counsel to confirm our understanding of the allegations and any settlement discussions, inspection of proposed settlement agreements, and obtaining written representations from executives of the Company. We also compared the Company's assessment with its relevant history of similar legal contingencies that have been settled or otherwise resolved to evaluate the consistency of the Company's assessment for unsettled opioid litigation and investigations.

For those legal contingencies for which the Company has determined that a loss is probable and reasonably estimable and is therefore required to be recognized, we evaluated the method of measuring the amounts of the recorded and disclosed contingencies. For those legal contingencies for which the Company has determined that a loss is reasonably possible, and is therefore required to be disclosed, we evaluated the methods for determining whether a range of loss can be estimated and the related disclosures. We assessed the Company's estimate of the amount of the loss, for both contingencies that are probable and reasonably possible, through inspection of responses to inquiry letters sent to both internal and external legal counsel, discussions with internal general counsel and external legal counsel, inspection of proposed settlement agreements and obtaining written representations from executives of the Company. In addition, we evaluated the adequacy of the Company's financial statement disclosures.

To test the uncertain tax position, we involved our tax subject matter professionals in assessing the technical merits and measurement of the Company's tax positions related to the opioid litigation and investigation liability. We examined the Company's analyses and evaluated the underlying facts upon which the tax positions were based. We used our knowledge of historical settlement activity in similar matters involving legal settlements to evaluate the Company's measurement of the uncertain tax position associated with the opioid litigation and investigations. We also evaluated the adequacy of the Company's financial statement disclosures and obtained written representations from executives of the Company related to this income tax matter.

Goodwill Impairment Evaluation of the PharmaLex Reporting Unit

Description of the Matter

At September 30, 2024, the Company's consolidated goodwill balance was $9,318 million. As discussed in Note 2 to the consolidated financial statements, the Company's goodwill is tested for impairment at least annually, or whenever events or circumstances indicate that the value of goodwill may be impaired. If goodwill is determined to be impaired, an impairment loss is measured at the amount by which the reporting unit's carrying amount exceeds its fair value, not to exceed the carrying amount of goodwill. The Company performed a quantitative analysis of the PharmaLex reporting unit as of its annual goodwill impairment assessment date of July 1, 2024. Based on the Company's assessment, the estimated fair value of the reporting unit was determined to be less than its carrying value. As a result, a pre-tax goodwill impairment charge of $418 million was recognized.

Auditing the Company's goodwill impairment assessment for the PharmaLex reporting unit was complex and highly judgmental due to the significant judgments and estimation required by management in determining the fair value of the reporting unit, which is based on assumptions about future market or economic conditions and company-specific qualitative factors whose outcome is uncertain and will therefore be subject to change over time. In particular, the fair value estimate of the reporting unit involves the use of significant unobservable inputs and is sensitive to changes in significant assumptions, such as the revenue growth rate, discount rate and earnings before interest, taxes, depreciation and amortization ("EBITDA") margin.

How We Addressed the Matter in Our Audit

We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company's annual goodwill impairment assessment process, which included the PharmaLex reporting unit. For example, we tested controls over management's review of the fair value of the PharmaLex reporting unit including review of the valuation model, the significant assumptions described above, and the completeness and accuracy of the data used in the valuation.

To test the estimated fair value of the PharmaLex reporting unit, we performed audit procedures that included, among others, assessing the methodologies used to develop the estimated fair value, testing the significant assumptions discussed above, and evaluating the completeness and accuracy of the underlying data used by the Company in its analyses. We compared the significant assumptions used by the Company to forecasted industry and economic trends and peer company information. We performed sensitivity analyses of significant assumptions to evaluate the changes in the fair value of the reporting unit that would result from changes in the assumptions. We also involved valuation specialists to assist in our evaluation of the overall methodologies and significant assumptions used in the fair value estimate, including performing a comparative calculation of the discount rate.

/s/ Ernst & Young LLP

We have served as the Company's auditor since 1985.
Philadelphia, Pennsylvania
November 26, 2024

CENCORA, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)	September 30, 2024	September 30, 2023
ASSETS		
Current assets:		
Cash and cash equivalents	$ 3,132,648	$ 2,592,051
Accounts receivable, less allowances for returns and credit losses: 2024 — $1,308,018; 2023 — $1,433,396	23,871,815	20,911,081
Inventories	18,998,833	17,454,768
Right to recover assets	1,175,871	1,314,857
Income tax receivable	88,229	77,120
Prepaid expenses and other	450,417	448,949
Total current assets	47,717,813	42,798,826
Property and equipment, net	2,181,410	2,135,171
Goodwill	9,318,027	9,574,117
Other intangible assets	4,001,046	4,431,783
Deferred income taxes	246,348	200,667
Other assets	3,637,023	3,418,182
TOTAL ASSETS	$ 67,101,667	$ 62,558,746
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	$ 50,942,162	$ 45,836,037
Accrued expenses and other	2,758,560	2,353,817
Short-term debt	576,331	641,344
Total current liabilities	54,277,053	48,831,198
Long-term debt	3,811,745	4,146,113
Accrued income taxes	291,796	310,676
Deferred income taxes	1,643,746	1,657,944
Accrued litigation liability	4,296,902	5,061,795
Other liabilities	1,993,683	1,884,733
Commitments and contingencies (Note 13)		
Stockholders' equity:		
Common stock, $0.01 par value — authorized, issued, and outstanding: 2024 — 600,000,000 shares, 296,169,781 shares and 194,943,968 shares; 2023 — 600,000,000 shares, 294,822,962 shares and 200,814,804 shares	2,962	2,948
Additional paid-in capital	6,030,790	5,844,578
Retained earnings	5,417,139	4,324,187
Accumulated other comprehensive loss	(989,118)	(1,402,607)
Treasury stock, at cost: 2024 — 101,225,813 shares; 2023 — 94,008,158 shares	(9,815,835)	(8,247,103)
Total Cencora, Inc. stockholders' equity	645,938	522,003
Noncontrolling interest	140,804	144,284
Total stockholders' equity	786,742	666,287
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 67,101,667	$ 62,558,746

See notes to consolidated financial statements.

CENCORA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)	Fiscal Year Ended September 30, 2024	2023	2022
Revenue	$ 293,958,599	$ 262,173,411	$ 238,587,006
Cost of goods sold	284,048,570	253,213,918	230,290,639
Gross profit	9,910,029	8,959,493	8,296,367
Operating expenses:			
Distribution, selling, and administrative	5,661,106	5,309,984	4,848,962
Depreciation	428,500	410,341	386,595
Amortization	663,474	553,563	307,300
Litigation and opioid-related expenses (credit), net	227,070	(24,693)	123,191
Acquisition-related deal and integration expenses	103,001	139,683	119,561
Restructuring and other expenses	233,629	229,884	63,498
Goodwill impairment	418,000	—	75,936
Asset impairment	—	—	4,946
Operating income	2,175,249	2,340,731	2,366,378
Other loss (income), net	14,283	(49,036)	(27,352)
Interest expense, net	156,991	228,931	210,673
Income before income taxes	2,003,975	2,160,836	2,183,057
Income tax expense	484,702	428,260	516,517
Net income	1,519,273	1,732,576	1,666,540
Net (income) loss attributable to noncontrolling interests	(10,153)	12,717	32,280
Net income attributable to Cencora, Inc.	$ 1,509,120	$ 1,745,293	$ 1,698,820
Earnings per share:			
Basic	$ 7.60	$ 8.62	$ 8.15
Diluted	$ 7.53	$ 8.53	$ 8.04
Weighted average common shares outstanding:			
Basic	198,503	202,511	208,472
Diluted	200,284	204,591	211,210

See notes to consolidated financial statements.

CENCORA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands)	Fiscal Year Ended September 30, 2024	2023	2022
Net income	$ 1,519,273	$ 1,732,576	$ 1,666,540
Other comprehensive income (loss):			
Foreign currency translation adjustments	405,099	353,439	(1,426,741)
Other, net	(272)	33,395	4,910
Total other comprehensive income (loss)	404,827	386,834	(1,421,831)
Total comprehensive income	1,924,100	2,119,410	244,709
Comprehensive (income) loss attributable to noncontrolling interests	(1,491)	54,246	68,583
Comprehensive income attributable to Cencora, Inc.	$ 1,922,609	$ 2,173,656	$ 313,292

See notes to consolidated financial statements.

CENCORA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

(in thousands, except per share data)	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock	Non-controlling Interests	Total
September 30, 2021	$ 2,907	$ 5,465,104	$ 1,670,513	$ (445,442)	$ (6,469,728)	$ 361,057	$ 584,411
Net income (loss)	—	—	1,698,820	—	—	(32,280)	1,666,540
Other comprehensive loss	—	—	—	(1,385,528)	—	(36,303)	(1,421,831)
Cash dividends, $1.84 per share	—	—	(391,687)	—	—	—	(391,687)
Exercises of stock options	10	93,902	—	—	—	—	93,912
Share-based compensation expense	—	93,400	—	—	—	—	93,400
Purchases of common stock	—	—	—	—	(512,091)	—	(512,091)
Employee tax withholdings related to restricted share vesting	—	—	—	—	(38,076)	—	(38,076)
Divestiture of business	—	—	—	—	—	(3,544)	(3,544)
Other, net	10	6,327	—	—	—	(6,098)	239
September 30, 2022	2,927	5,658,733	2,977,646	(1,830,970)	(7,019,895)	282,832	71,273
Net income (loss)	—	—	1,745,293	—	—	(12,717)	1,732,576
Other comprehensive income (loss)	—	—	—	428,363	—	(41,529)	386,834
Cash dividends, $1.94 per share	—	—	(398,752)	—	—	—	(398,752)
Exercises of stock options	8	61,144	—	—	—	—	61,152
Share-based compensation expense	—	124,624	—	—	—	—	124,624
Purchases of common stock	—	—	—	—	(1,155,929)	—	(1,155,929)
Employee tax withholdings related to restricted share vesting	—	—	—	—	(71,279)	—	(71,279)
Divestiture of business	—	—	—	—	—	(76,957)	(76,957)
Other, net	13	77	—	—	—	(7,345)	(7,255)
September 30, 2023	2,948	5,844,578	4,324,187	(1,402,607)	(8,247,103)	144,284	666,287
Net income	—	—	1,509,120	—	—	10,153	1,519,273
Other comprehensive income (loss)	—	—	—	413,489	—	(8,662)	404,827
Cash dividends, $2.04 per share	—	—	(416,168)	—	—	—	(416,168)
Exercises of stock options	4	37,836	—	—	—	—	37,840
Share-based compensation expense	—	147,998	—	—	—	—	147,998
Purchases of common stock	—	—	—	—	(1,505,232)	—	(1,505,232)
Employee tax withholdings related to restricted share vesting	—	—	—	—	(63,500)	—	(63,500)
Other, net	10	378	—	—	—	(4,971)	(4,583)
September 30, 2024	$ 2,962	$ 6,030,790	$ 5,417,139	$ (989,118)	$ (9,815,835)	$ 140,804	$ 786,742

See notes to consolidated financial statements.

CENCORA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOW

(in thousands)	Fiscal Year Ended September 30, 2024	2023	2022
OPERATING ACTIVITIES			
Net income	$ 1,519,273	$ 1,732,576	$ 1,666,540
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation, including amounts charged to cost of goods sold	448,200	418,830	390,643
Amortization, including amounts charged to interest expense	670,642	562,018	319,192
Provision for credit losses	40,834	54,389	26,053
(Benefit) provision for deferred income taxes	(102,324)	(118,864)	196,184
Share-based compensation expense	147,998	124,624	93,400
LIFO (credit) expense	(52,168)	204,595	67,171
Impairment of assets, including goodwill	418,000	—	80,882
Gain on divestiture of businesses	—	(40,665)	(56,228)
Turkey highly inflationary impact	55,309	95,938	51,966
Loss (gain) on remeasurement of equity investments	16,201	(242)	(4,834)
Other, net	24,032	3,593	11,781
Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures:			
Accounts receivable	(2,784,339)	(2,711,786)	(1,659,525)
Inventories	(1,479,599)	(2,183,368)	(665,370)
Income tax receivable	(11,109)	102,201	49,307
Prepaid expenses and other assets	167,781	109,041	102,708
Accounts payable	4,968,093	6,103,451	3,320,725
Accrued expenses	148,533	51,112	(457,233)
Income taxes payable and other liabilities	(204,517)	(196,146)	(330,079)
Long-term accrued litigation liability	(506,155)	(399,963)	(500,195)
NET CASH PROVIDED BY OPERATING ACTIVITIES	3,484,685	3,911,334	2,703,088
INVESTING ACTIVITIES			
Capital expenditures	(487,173)	(458,359)	(496,318)
Cost of acquired companies, net of cash acquired	(69,771)	(1,409,835)	(133,814)
Cost of equity investments	(30,430)	(743,275)	(18,491)
Non-customer note receivable	(50,000)	—	—
Proceeds from divestiture of businesses	—	—	272,586
Other, net	19,278	9,004	7,600
NET CASH USED IN INVESTING ACTIVITIES	(618,096)	(2,602,465)	(368,437)
FINANCING ACTIVITIES			
Senior notes and other loan borrowings	688,321	157,547	155,189
Senior notes and other loan repayments	(662,525)	(811,353)	(1,238,954)
Borrowings under revolving and securitization credit facilities	69,703,045	78,218,439	4,832,605
Repayments under revolving and securitization credit facilities	(70,114,293)	(78,187,891)	(4,671,943)
Purchases of common stock	(1,491,367)	(1,180,728)	(483,704)
Exercises of stock options	37,840	61,152	93,912
Cash dividends on common stock	(416,168)	(398,752)	(391,687)
Employee tax withholdings related to restricted share vesting	(63,500)	(71,279)	(38,076)
Other, net	(12,347)	(9,413)	(10,122)
NET CASH USED IN FINANCING ACTIVITIES	(2,330,994)	(2,222,278)	(1,752,780)
EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	9,396	72,759	(57,850)
INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, INCLUDING CASH CLASSIFIED WITHIN ASSETS HELD FOR SALE	544,991	(840,650)	524,021
LESS: INCREASE IN CASH CLASSIFIED WITHIN ASSETS HELD FOR SALE	—	—	(610)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	544,991	(840,650)	523,411
Cash, cash equivalents, and restricted cash at beginning of year	2,752,889	3,593,539	3,070,128
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT END OF YEAR	$ 3,297,880	$ 2,752,889	$ 3,593,539

See notes to consolidated financial statements.

CENCORA, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2024

Note 1. Summary of Significant Accounting Policies

Cencora, Inc. and its subsidiaries, including a less-than-wholly-owned subsidiary in which Cencora, Inc. has a controlling financial interest (the "Company"), is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company delivers innovative programs and services designed to improve the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.

Basis of Presentation

The accompanying financial statements present the consolidated financial position, results of operations, and cash flows of the Company as of the dates and for the periods indicated. All significant intercompany accounts and transactions have been eliminated in consolidation.

The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ from these estimated amounts due to uncertainties inherent in such estimates. Management periodically evaluates estimates used in the preparation of the financial statements for continued reasonableness.

Recently Adopted Accounting Pronouncements

As of September 30, 2024, there were no recently-adopted accounting standards that had a material impact on the Company's financial position, results of operations, cash flows, or notes to the financial statements upon their adoption.

Recently Issued Accounting Pronouncements Not Yet Adopted

In November 2023, the Financial Accounting Standards Board ("FASB") issued ASU No. 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07")." ASU 2023-07 requires public entities to disclose significant segment expenses on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment's profit or loss that are currently required annually. ASU 2023-07 is effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. Early adoption is permitted. The guidance should be applied retrospectively to all periods presented in the financial statements. The Company is currently evaluating the impact of adopting this new accounting guidance.

In December 2023, the FASB issued ASU No. 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09")." ASU 2023-09 requires entities to provide additional information in their tax rate reconciliation and additional disclosures about income taxes paid by jurisdiction. ASU 2023-09 is effective for annual reporting periods beginning after December 15, 2024, with early adoption permitted. The guidance should be applied prospectively, but entities have the option to apply it retrospectively for each period presented. The Company is currently evaluating the impact of adopting this new accounting guidance.

Business Combinations

The assets acquired and liabilities assumed from an acquired business are recorded at estimated fair value, with the residual of the purchase price recorded as goodwill. The results of operations of an acquired businesses are included in the Company's operating results from the date of acquisition.

Cash, Cash Equivalents, and Restricted Cash

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value.

The Company is required to maintain certain cash deposits with banks mainly consisting of deposits restricted under contractual agency agreements and cash restricted by law and other obligations, including opioid-related legal settlements.

The following represents a reconciliation of cash and cash equivalents in the Consolidated Balance Sheets to cash, cash equivalents, and restricted cash in the Consolidated Statements of Cash Flows:

	September 30,			
(amounts in thousands)	2024	2023	2022	2021
Cash and cash equivalents	$ 3,132,648	$ 2,592,051	$ 3,388,189	$ 2,547,142
Restricted cash (included in Prepaid Expenses and Other)	98,596	97,722	144,980	462,986
Restricted cash (included in Other Assets)	66,636	63,116	60,370	60,000
Cash, cash equivalents, and restricted cash	$ 3,297,880	$ 2,752,889	$ 3,593,539	$ 3,070,128

Concentrations of Credit Risk and Allowance for Credit Losses

The Company has sales to a significant number of customers in the healthcare industry that include institutional and retail healthcare providers. Institutional healthcare providers include acute care hospitals, health systems, mail order pharmacies, long-term care and other alternate care pharmacies and providers of pharmacy services to such facilities, and physician offices. Retail healthcare providers include national and regional retail drugstore chains, independent community pharmacies, pharmacy departments of supermarkets and mass merchandisers, and veterinarians. The financial condition of the Company's customers can be affected by changes in government reimbursement policies as well as by other economic pressures in the healthcare industry.

The Company's trade accounts receivables are exposed to credit risk. Revenue from the various agreements and arrangements with the Company's largest customer in fiscal 2024, Walgreens Boots Alliance, Inc. ("WBA"), accounted for approximately 26% of revenue and represented approximately 37% of accounts receivable, net of incentives, as of September 30, 2024. Evernorth Health Services (formerly Express Scripts, Inc.), the Company's second largest customer in fiscal 2024, accounted for approximately 13% of revenue and represented approximately 5% of accounts receivable as of September 30, 2024. The Company generally does not require collateral for trade receivables. The Company evaluates its receivables for risk of loss by grouping its receivables with similar risk characteristics. Expected losses are determined based on a combination of historical loss trends, current economic conditions, and forward-looking risk factors. Changes in these factors, among others, may lead to adjustments in the Company's allowance for credit losses. The calculation of the required allowance requires judgment by Company management as to the impact of those and other factors on the ultimate realization of its trade receivables. The Company performs ongoing credit evaluations of its customers' financial condition and maintains reserves for expected credit losses for specific credit problems when they arise. There were no significant changes to this process during fiscal 2024, 2023, and 2022, and bad debt expense was computed in a consistent manner during these periods.

The Company maintains cash, cash equivalents, and restricted cash with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and, therefore, bear minimal credit risk. The Company seeks to mitigate such risks by monitoring the risk profiles of these counterparties. The Company also seeks to mitigate risk by monitoring the investment strategy of money market accounts in which it is invested, which are classified as cash equivalents.

Contingencies

Loss Contingencies: In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, government investigations, stockholder demands, and other disputes, including antitrust, commercial, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a liability when it is both probable that a loss has been incurred and the amount can be reasonably estimated. The Company also performs an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued. If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, the Company provides disclosure of the loss contingency in the notes to its financial statements. The Company reviews all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made. Among the loss contingencies that the Company considered in accordance with the foregoing in connection with the preparation of the accompanying financial statements were the opioid matters described in Note 13.

Gain Contingencies: The Company records gain contingencies when they are realized. Gains from antitrust litigation settlements are realized upon the receipt of cash and recorded as a reduction to cost of goods sold because they represent a

recovery of amounts historically paid to manufacturers to originally acquire the pharmaceuticals that were the subject of the antitrust litigation settlements (see Note 14).

Derivative Financial Instruments

The Company utilizes derivative financial instruments to manage exposures to foreign currency. The Company records all derivative financial instruments on the balance sheet at fair value and complies with established criteria for designation and effectiveness of hedging relationships. The Company's policy prohibits it from entering into derivative financial instruments for speculative or trading purposes.

Foreign Currency

When the functional currency of the Company's foreign operations is the applicable local currency, assets and liabilities are translated into U.S. dollars using the current exchange rates in effect at the balance sheet date, while revenues and expenses are translated at the weighted average exchange rates for the period. The resulting asset and liability translation adjustments are recorded as a component of Accumulated Other Comprehensive Loss within Stockholders' Equity.

During the quarter ended March 31, 2022, Turkey became a highly inflationary economy, as defined under U.S. GAAP. As a result, effective April 1, 2022, and until such time as the applicable economy is no longer considered highly inflationary, Turkish Lira-denominated assets and liabilities are remeasured using the Company's reporting currency in accordance with ASC 830, "Foreign Currency Matters." Turkish Lira denominated monetary assets and liabilities (primarily cash, accounts receivables, and accounts payables) are remeasured at each balance sheet date using the currency exchange rate then in effect, with currency remeasurement gains and losses recognized in Other Income in the Statement of Operations. Turkish Lira-denominated nonmonetary assets and liabilities (primarily inventories, goodwill, and other intangible assets) are translated at the currency exchange rate in effect prior to highly inflation accounting commencement or at the exchange rate in effect at their date of acquisition if subsequent to April 1, 2022. As such, nonmonetary assets and liabilities retain a higher historical basis when currencies are devalued. This higher historical basis results in incremental expense being recognized when nonmonetary assets are consumed (i.e., sale of inventory). During fiscal 2024, 2023, and 2022, the Company recorded incremental expenses of $54.1 million, $87.0 million, and $40.0 million, respectively, in Cost of Goods Sold related to the consumption of inventory and expenses of $1.2 million, $9.0 million, and $11.9 million, respectively, within Other Loss (Income), Net related to the currency remeasurement of monetary assets and liabilities.

Goodwill and Other Intangible Assets

Goodwill arises from acquisitions or consolidations of specific operating companies and is assigned to the reporting unit in which a particular operating company resides. The Company identifies its reporting units based upon the Company's management reporting structure, beginning with its operating segments. The Company aggregates two or more components within an operating segment that have similar economic characteristics. The Company evaluates whether the components within its operating segments have similar economic characteristics, which include the similarity of long-term gross margins, the nature of the components' products, services, and production processes, the types of customers and the methods by which products or services are delivered to customers, and the components' regulatory environment. As of September 30, 2024, the Company's reporting units include U.S. Pharmaceutical Distribution Services, U.S. Consulting Services, MWI Animal Health, Alliance Healthcare, Innomar, World Courier, PharmaLex, and Profarma.

Goodwill and other intangible assets with indefinite lives, such as certain trademarks and trade names, are not amortized; rather, they are tested for impairment at least annually. For the purpose of these impairment tests, the Company can elect to perform a qualitative assessment to determine if it is more likely than not that the fair values of its reporting units and indefinite-lived intangible assets are less than the respective carrying values of those reporting units and indefinite-lived intangible assets, respectively. Such qualitative factors can include, among others, industry and market conditions, overall financial performance, and relevant entity-specific events. If the Company concludes based on its qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, it performs a quantitative analysis. The Company elected to perform quantitative impairment assessments of goodwill for all its reporting units in fiscal 2024, 2023, and 2022 with the exception of its PharmaLex reporting unit in fiscal 2023 since it was acquired in fiscal 2023. The Company elected to perform qualitative impairment assessments of indefinite-lived intangible assets in fiscal 2024 and fiscal 2023 and a quantitative impairment assessment of indefinite-lived intangible assets in fiscal 2022.

The quantitative goodwill impairment test requires the Company to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit. If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized. If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.

When performing a quantitative impairment assessment, the Company utilizes an income approach or a weighted average of an income and market approach to value its reporting units. The income approach relies on a discounted cash flow analysis, which considers forecasted cash flows discounted at an appropriate discount rate, to determine the fair value of each reporting unit. The Company generally believes that market participants would use a discounted cash flow analysis to determine the fair value of the Company's reporting units in a sale transaction. The annual goodwill impairment test requires the Company to make several assumptions and estimates concerning future levels of revenue growth, earnings before interest, taxes, depreciation and amortization ("EBITDA"), EBITDA margins, capital expenditures, and working capital requirements, which are based upon the Company's long-range plan. The discount rate is an estimate of the overall after-tax rate of return required by a market participant whose weighted average cost of capital includes both debt and equity, including a risk premium. While the Company uses the best available information to prepare its forecasted cash flows and discount rate assumptions, actual future cash flows and/or market conditions could differ significantly resulting in future impairment charges related to recorded goodwill balances. While there are always changes in assumptions to reflect changing business and market conditions, the Company's overall methodology and the population of assumptions used have remained unchanged.

The quantitative impairment assessment for indefinite-lived intangibles other than goodwill (certain trademarks and trade names) consists of a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date. The Company estimates the fair value of its indefinite-lived intangibles using the relief from royalty method, which is a widely used valuation technique for such assets. The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.

The Company completed its required annual impairment assessments relating to goodwill and indefinite-lived intangible assets in fiscal 2024, 2023, and 2022 and, as a result, recorded a $418.0 million goodwill impairment in its PharmaLex reporting unit in fiscal 2024 (see Note 5) and a $75.9 million goodwill impairment in its Profarma reporting unit in fiscal 2022. No goodwill impairments were recorded in fiscal 2023 and no indefinite-lived intangible asset impairments were recorded in fiscal 2024, 2023, or 2022.

Finite-lived intangible assets are amortized using the straight-line method over the estimated useful lives of the assets. The Company performs a recoverability assessment of its long-lived assets when impairment indicators are present. The Company performed a recoverability assessment of PharmaLex's long-lived asset group as of July 1, 2024, and it was determined to be recoverable.

Income Taxes

The Company accounts for income taxes using a method that requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company's assets and liabilities (commonly known as the asset and liability method). In assessing the need to establish a valuation allowance on deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.

The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including settlements with tax authorities or resolutions of any related appeals or litigation processes, based upon the technical merits of the position. Tax benefits associated with uncertain tax positions that have met the recognition criteria are measured and recorded based upon the highest probable outcome that is more than 50% likely to be realized after full disclosure and resolution of a tax examination.

Inventories

Inventories are stated at the lower of cost or market. Cost for approximately 65% and 66% of the Company's inventories as of September 30, 2024 and 2023, respectively, has been determined using the last-in, first-out ("LIFO") method. If the Company had used the first-in, first-out method of inventory valuation, which approximates current replacement cost, inventories would have been approximately $1,535.8 million and $1,588.0 million higher than the amounts reported as of September 30, 2024 and 2023, respectively. The Company recorded a LIFO credit of $52.2 million in fiscal 2024 and LIFO expense of $204.6 million and $67.2 million in fiscal 2023 and 2022, respectively. The annual LIFO provision is affected by manufacturer pricing practices, which may be impacted by market and other external influences, changes in inventory quantities, and product mix, many of which are difficult to predict. Changes to any of the above factors can have a material impact to the Company's annual LIFO provision. Cost for the Company's inventory that is not determined using the LIFO method is stated at the lower of cost or market using the first-in, first-out method or moving average price method.

Investments

The Company first evaluates its investments in accordance with the variable interest model to determine whether it has a controlling financial interest in an investment. This evaluation is made as of the date on which the Company makes its initial investment, and subsequent evaluations are made if the structure of the investment changes. If it has determined that an investment is a variable interest entity ("VIE"), the Company evaluates whether the VIE is required to be consolidated. When the Company holds rights that give it the power to direct the activities of an entity that most significantly impact the entity's economic performance, combined with the obligation to absorb an entity's losses and the right to receive benefits, the Company consolidates a VIE. If it is determined that an investment is not a VIE, the Company then evaluates its investments under the voting interest model and generally consolidates investments in which it holds an ownership interest of greater than 50%. When the Company consolidates less-than-wholly-owned subsidiaries, it records its noncontrolling interest in its consolidated financial statements.

For equity securities without a readily determinable fair value, the Company uses the fair value measurement alternative and measures the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer. For investments in which the Company can exercise significant influence but does not control, it uses the equity method of accounting. The Company's share of earnings and losses of its investments is recorded in Other Income in the Consolidated Statements of Operations. The Company monitors its investments for impairment by considering factors such as the operating performance of the investment and current economic and market conditions.

Leases

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the facts and circumstances present. Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. At the lease commencement date, operating and finance lease liabilities and their corresponding right-of-use ("ROU") assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable and, as such, the Company uses its incremental borrowing rate to discount the lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term in a similar economic environment. Certain adjustments to the ROU asset may be required for items such as incentives received. The Company does not recognize on the balance sheet leases with terms of one year or less.

The Company has operating leases that are primarily comprised of buildings, office equipment, distribution center equipment, and vehicles. Some of the Company's leases include options to extend or early terminate the lease, which are included in the lease term when it is reasonably certain to exercise and there is a significant economic incentive to exercise that option. Certain lease agreements contain provisions for future rent increases. Lease payments included in the measurement of the lease liability comprise fixed payments. The Company combines lease and non-lease components as a single component. Operating lease cost is recognized over the expected lease term on a straight-line basis and is recorded in Distribution, Selling, and Administrative in the Company's Consolidated Statements of Operations. Variable lease payments, which are primarily comprised of maintenance, taxes, and other payments based on usage, are recognized when the expense is incurred. The Company's leases do not contain residual value guarantees.

Manufacturer Incentives

The Company considers fees and other incentives received from its suppliers relating to the purchase and distribution of inventory to represent product discounts, and, as a result, they are recognized within cost of goods sold upon the sale of the related inventory.

Property and Equipment

Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 40 years for buildings and improvements and from 3 to 10 years for machinery, equipment, and other. The costs of repairs and maintenance are charged to expense as incurred.

The Company capitalizes project costs relating to computer software developed or obtained for internal use when the activities related to the project reach the application development stage. Costs that are associated with preliminary stage activities, training, maintenance, and all other post-implementation stage activities are expensed as they are incurred. Software development costs are depreciated using the straight-line method over the estimated useful lives, which range from 3 to 10 years.

The following table summarizes the Company's property and equipment balances for the periods indicated:

(in thousands)	September 30, 2024	2023
Property and equipment, at cost:		
Land	$ 117,128	$ 116,465
Buildings and improvements	893,694	836,175
Machinery, equipment, and other	4,204,268	3,786,449
Total property and equipment	5,215,090	4,739,089
Less accumulated depreciation	(3,033,680)	(2,603,918)
Property and equipment, net	$ 2,181,410	$ 2,135,171

Revenue Recognition

The Company's revenues are primarily generated from the distribution of pharmaceutical products. The Company also generates revenues from global commercialization services, which include clinical trial support, post-approval and commercialization support, and global specialty transportation and logistics for the biopharmaceutical industry. See Note 15 for the Company's disaggregated revenue.

The Company recognizes revenue related to the distribution of products at a point in time when title and control transfers to customers and there is no further obligation to provide services related to such products. Service revenue is recognized over the period that services are provided to the customer. The Company is generally the principal in a transaction; therefore, revenue is primarily recorded on a gross basis. When the Company is the principal in a transaction, it has determined that it controls the ability to direct the use of the product or service prior to the transfer to a customer, it is primarily responsible for fulfilling the promise to provide the product or service to its customer, it has discretion in establishing pricing, and it controls the relationship with the customer. Revenue is recognized at the amount of consideration expected to be received. For the distribution business, revenue is primarily generated from a contract related to a confirmed purchase order with a customer in a distribution arrangement and is net of estimated sales returns and allowances, other customer incentives, and sales tax.

When the Company is the agent in a transaction, the fee received from a manufacturer customer is recognized within revenue as the service is performed.

The Company's customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit. The Company records an accrual for estimated customer sales returns at the time of sale to the customer based upon historical return trends. As of September 30, 2024 and 2023, the Company's accrual for estimated customer sales returns was $1,175.9 million and $1,314.9 million, respectively.

Share-Based Compensation

The Company accounts for the compensation cost of all share-based payments at fair value. The fair value of restricted stock units and performance stock units is based upon the grant date market price of the Company's common stock.

Share-based compensation expense is recognized over the requisite service period within Distribution, Selling, and Administrative in the Consolidated Statements of Operations to correspond with the same line item as the cash compensation paid to employees. Compensation expense associated with nonvested performance stock units is dependent upon the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued.

The income tax effects of awards are recognized when the awards vest or are settled and are recognized in Income Tax Expense in the Company's Consolidated Statements of Operations.

Shipping and Handling Costs

Shipping and handling costs include all costs to warehouse, pick, pack, and deliver inventory to customers. These costs, which were $1,265.7 million, $1,200.0 million, and $1,040.8 million for fiscal 2024, 2023, and 2022, respectively, are included in Distribution, Selling, and Administrative in the Company's Consolidated Statements of Operations.

Supplier Reserves

The Company establishes reserves against amounts due from its suppliers relating to various price and rebate incentives, including deductions or billings taken against payments otherwise due to them from the Company. These reserve estimates are established based upon the judgment of Company management after carefully considering the status of current outstanding claims, historical experience with the suppliers, the specific incentive programs, and any other pertinent information available to the Company. The Company evaluates the amounts due from its suppliers on a continual basis and adjusts the reserve estimates when appropriate based upon changes in factual circumstances. The ultimate outcome of any outstanding claim may be different than the Company's estimate.

Note 2. Acquisition and Equity Method Investment

PharmaLex Acquisition

The Company acquired and assumed control of PharmaLex Holding GmbH ("PharmaLex") effective January 1, 2023 for $1.473 billion, subject to customary adjustments, including a $29.3 million cash holdback. PharmaLex is a leading provider of specialized services for the life sciences industry. PharmaLex's services include regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality management and compliance. PharmaLex is headquartered in Germany and operates in over 30 countries. The acquisition advances the Company's role as a partner of choice for biopharmaceutical partners across the pharmaceutical development and commercialization journey. PharmaLex is a component of the Company's International Healthcare Solutions reportable segment.

The Company completed the purchase price allocations as of December 31, 2023. The purchase price was allocated to the underlying assets acquired, including $37.4 million of cash and cash equivalents, and liabilities assumed based upon their estimated fair values as of the date of the acquisition.

The purchase price exceeded the current estimated fair value of the net tangible and intangible assets acquired by $1,010.2 million, which was allocated to goodwill. Goodwill resulting from this acquisition is not deductible for income tax purposes.

The estimated fair value of the intangible assets acquired of $558.9 million, and the estimated useful lives are as follows:

(in thousands, except useful lives)	Fair Value	Useful Lives
Customer relationships	$ 522,634	12
Trade names	30,931	5
Software technology	5,333	6
Total	$ 558,898	

The Company established an estimated deferred tax liability of $146.0 million primarily in connection with the intangible assets acquired.

Investment in OneOncology

In June 2023, the Company and TPG, a global alternative asset management firm, acquired OneOncology, LLC ("OneOncology"), a network of leading oncology practices. Including all direct transaction costs, the Company invested $718.4 million (representing 34.9%) in a joint venture formed to acquire OneOncology for approximately $2.1 billion, and TPG acquired the majority interest in the joint venture. The Company accounts for its interest in the joint venture as an equity method investment, which is included in Other Assets on its Consolidated Balance Sheet.

Beginning on the third anniversary of the closing of the joint venture's acquisition of OneOncology and ending on the day before the fourth anniversary of that closing, TPG will have a put option under which TPG may require the Company to purchase all of the other interests in the joint venture, including TPG's interest, at a price equal to 19 times OneOncology's adjusted earnings before interest, taxes, depreciation and amortization for the most recently ended 12-month period prior to TPG's exercise of the put option, all of which is subject to various other adjustments and qualifications. In addition, on the date that is the third anniversary of the closing and again beginning on the fourth anniversary of the closing and ending on the day before the fifth anniversary of the closing, the Company will have a call option to purchase all of the other interests in the joint venture, including TPG's, also at the price set forth above. The fair value of the net put option, which is a Level 3 measurement, was determined using a Monte Carlo simulation, which relies on assumptions, including cash flow projections, risk-free rates, volatility, and details specific to the put and call options. The Company recorded the net fair value of the net put option of $872.9 million, which is recorded within Other Liabilities with a corresponding offset in Other Assets in the Company's

Consolidated Balance Sheets. Given the Company has elected to not mark the net put option to market, the fair value of the net put option at the time of the investment will remain on the balance sheet until its final resolution.

Upon the joint venture's acquisition of OneOncology, it was determined that there was a $625.2 million difference between the carrying value of the Company's investment in OneOncology and its underlying equity in net assets, which has been allocated to intangible assets of $305.6 million, a related deferred tax liability of $20.5 million, and goodwill of $340.0 million. The intangible assets and related deferred tax liability are being amortized over a weighted-average life of 23 years.

Note 3. Variable Interest Entity

The Company has substantial governance rights that allow it to direct the activities that significantly impact Profarma's economic performance. As such, the Company consolidates the operating results of Profarma in its consolidated financial statements. The Company is not obligated to provide future financial support to Profarma.

The following assets and liabilities of Profarma are included in the Company's Consolidated Balance Sheet for the periods indicated:

	September 30,	
(in thousands)	2024	2023
Cash and cash equivalents	$ 58,082	$ 33,256
Accounts receivables, net	236,930	253,419
Inventories	259,299	255,801
Prepaid expenses and other	68,612	63,327
Property and equipment, net	49,869	42,759
Other intangible assets	58,116	62,384
Other long-term assets	83,765	77,889
Total assets	$ 814,673	$ 788,835
Accounts payable	$ 307,201	$ 300,875
Accrued expenses and other	56,597	56,280
Short-term debt	76,308	73,650
Long-term debt	91,246	74,132
Deferred income taxes	19,227	22,701
Other long-term liabilities	61,690	54,691
Total liabilities	$ 612,269	$ 582,329

Profarma's assets can only be used to settle its obligations, and its creditors do not have recourse to the general credit of the Company.

Note 4. Income Taxes

Income Before Income Taxes

The following table summarizes the Company's income before income taxes for the periods indicated:

(in thousands)	Fiscal Year Ended September 30, 2024	2023	2022
Domestic	$ 1,288,983	$ 1,418,457	$ 1,351,696
Foreign	714,992	742,379	831,361
Total	$ 2,003,975	$ 2,160,836	$ 2,183,057

Income Tax Expense

The components of the Company's consolidated income tax expense are summarized in the following table for the periods indicated:

(in thousands)	Fiscal Year Ended September 30, 2024	2023	2022
Current provision:			
Federal	$ 309,380	$ 259,126	$ 126,969
State and local	80,040	42,933	39,282
Foreign	197,606	245,065	154,082
Total current provision	587,026	547,124	320,333
Deferred (benefit) provision:			
Federal	(17,934)	(15,600)	150,328
State and local	1,392	19,445	31,129
Foreign	(85,782)	(122,709)	14,727
Total deferred (benefit) provision	(102,324)	(118,864)	196,184
Income tax expense	$ 484,702	$ 428,260	$ 516,517

Tax Rate Reconciliation

A reconciliation of the statutory U.S. federal income tax rate to the Company's consolidated effective income tax rate is as follows for the periods indicated:

	Fiscal Year Ended September 30, 2024	2023	2022
Statutory U.S. federal income tax rate	21.0%	21.0%	21.0%
State and local income tax rate, net of federal tax benefit	3.0	2.3	2.5
Tax effect of foreign operations	(2.9)	(2.4)	(1.9)
Goodwill impairment	4.9	—	0.7
Change in valuation allowance	(4.2)	0.1	0.6
Other, net	2.4	(1.2)	0.8
Effective income tax rate	24.2%	19.8%	23.7%

Deferred Tax Liabilities and Assets

Deferred income taxes reflect the future tax consequences of differences between the tax bases of assets and liabilities and their financial reporting amounts. Significant components of the Company's deferred tax liabilities (assets) are as follows:

	September 30,	
(in thousands)	**2024**	**2023**
Inventories	$ 1,537,057	$ 1,475,467
Property and equipment	103,959	145,308
Goodwill and other intangible assets	1,143,962	1,242,466
Right-of-use assets	285,434	255,221
Other	31,416	51,490
Gross deferred tax liabilities	3,101,828	3,169,952
Net operating loss and tax credit carryforwards	(530,024)	(532,851)
Allowance for credit losses	(18,949)	(18,221)
Accrued expenses	(9,419)	(18,108)
Accrued litigation liability	(855,962)	(909,256)
Employee and retiree benefits	(26,960)	(22,927)
Goodwill and other intangible assets	(401,822)	(425,898)
Lease liabilities	(312,357)	(280,550)
Share-based compensation	(23,161)	(23,087)
Other	(128,136)	(119,180)
Gross deferred tax assets	(2,306,790)	(2,350,078)
Valuation allowance for deferred tax assets	602,361	637,403
Deferred tax assets, net of valuation allowance	(1,704,429)	(1,712,675)
Net deferred tax liabilities	$ 1,397,399	$ 1,457,277

As of September 30, 2024, the Company had $106.3 million of potential tax benefits from state net operating loss carryforwards and $443.1 million of potential tax benefits from foreign loss carryforwards, which have varying expiration dates. The Company had $4.7 million of federal tax credit carryforwards, $4.6 million of state tax credit carryforwards, and $3.1 million of foreign alternative minimum tax credit carryforwards.

The Company assesses the available positive and negative evidence to determine whether deferred tax assets are more likely than not to be realized. As a result of this assessment, valuation allowances have been recorded on certain deferred tax assets. For fiscal 2024, the Company decreased the valuation allowance on deferred tax assets by $35.0 million primarily due to the change in the valuation allowance against tax deductible goodwill. For fiscal 2023, the Company increased the valuation allowance on deferred tax assets by $20.1 million primarily due to the increase in the valuation allowance against foreign net operating loss carryforwards.

In fiscal 2024, 2023, and 2022, tax benefits of $15.0 million, $24.6 million, and $13.4 million, respectively, related to the exercise of employee stock options and lapses of restricted stock units were recorded in Income Tax Expense in the Company's Consolidated Statements of Operations. The tax benefits recognized in fiscal 2024, 2023, and 2022 are not necessarily indicative of amounts that may arise in future periods.

Income tax payments, net of refunds, were $603.9 million, $463.1 million, and $244.4 million in fiscal 2024, 2023, and 2022, respectively.

Cumulative undistributed earnings of international subsidiaries were $3.9 billion as of September 30, 2024, $2.1 billion of which is considered permanently reinvested. It is not practicable to estimate the taxes that would be due if such earnings were to be repatriated in the future.

The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various states and foreign jurisdictions. The Company is currently undergoing certain state and local income tax audits for various years. With few exceptions, the Company is no longer subject to U.S. federal, state and local, or foreign income tax examinations by tax authorities for years before 2020. The Company believes it has adequate tax reserves to cover potential federal, state or foreign tax exposures.

Unrecognized Tax Benefits

As of September 30, 2024 and 2023, the Company had unrecognized tax benefits, defined as the aggregate tax effect of differences between tax return positions and the benefits recognized in the Company's financial statements, of $545.0 million and $551.9 million, respectively ($498.0 million and $482.7 million, net of federal tax benefit, respectively). If recognized in fiscal 2024 and 2023, $488.1 million and $464.4 million, respectively, of these benefits would have reduced income tax expense and the effective tax rate. As of September 30, 2024 and 2023, included in the unrecognized tax benefits are $43.9 million and $25.9 million of interest and penalties, respectively, which the Company records in Income Tax Expense in the Company's Consolidated Statements of Operations.

A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, for the periods indicated is as follows:

	Fiscal Year Ended September 30,		
(in thousands)	**2024**	**2023**	**2022**
Unrecognized tax benefits at beginning of period	$ 525,933	$ 526,522	$ 500,399
Additions of tax positions of the current year	13,636	22,646	21,074
Additions to tax positions of the prior years	—	11,875	5,073
Reductions of tax positions of the prior years	(37,520)	(31,110)	—
Settlements and expiration of statutes of limitations	(2,410)	(3,457)	(24)
Effects of foreign currency translation	1,425	(543)	—
Unrecognized tax benefits at end of period	$ 501,064	$ 525,933	$ 526,522

During the next 12 months, it is reasonably possible that tax audit resolutions and the expiration of statutes of limitations could result in a reduction of unrecognized tax benefits by approximately $13.5 million.

A significant portion of the Company's unrecognized tax benefits as of September 30, 2024 relates to the legal accrual for litigation related to the Distributor Settlement Agreement, as well as other opioid-related litigation, as disclosed in Note 13. The Company has applied significant judgment in estimating the amount of the opioid settlements that will be deductible for U.S. federal and state purposes. In estimating the amount that would be deductible, the Company considered prior U.S. tax case law, the amount and character of the damages sought in litigation, and other relevant factors.

Note 5. Goodwill and Other Intangible Assets

The following is a summary of the changes in the carrying value of goodwill, by reportable segment, for fiscal 2024 and 2023:

(in thousands)	**U.S. Healthcare Solutions**	**International Healthcare Solutions**	**Total**
Goodwill as of September 30, 2022	$ 6,280,240	$ 2,223,646	$ 8,503,886
Goodwill recognized in connection with acquisitions	—	1,026,440	1,026,440
Goodwill derecognized in connection with divestiture	—	(14,424)	(14,424)
Foreign currency translation	2,177	56,038	58,215
Goodwill as of September 30, 2023	6,282,417	3,291,700	9,574,117
Purchase accounting adjustments	—	(12,904)	(12,904)
Goodwill recognized in connection with acquisitions	—	18,712	18,712
Goodwill impairment	—	(418,000)	(418,000)
Foreign currency translation	2,748	153,354	156,102
Goodwill as of September 30, 2024	$ 6,285,165	$ 3,032,862	$ 9,318,027

The Company has experienced a weakening in demand for specialized services in the life sciences industry, which has negatively impacted the operating results of PharmaLex. In the fourth quarter of fiscal 2024 and in connection with the Company's annual budgeting process, the Company revised PharmaLex's long-range forecast. In connection with the Company's annual goodwill impairment assessment, it recorded a goodwill impairment of $418.0 million in the PharmaLex reporting unit. The fair value of the reporting unit was determined based on a weighted average of income and market approaches. The income approach includes the Company's forecasted cash flows in its long-range plan as well as discount rate and income tax rate assumptions. This represents a Level 3 nonrecurring fair value measurement. The Company believes that its assumptions are representative of market participant assumptions; however, the forecasted cash flows used to estimate fair value and measure the related impairment are inherently uncertain and include assumptions that could differ from actual results in future periods.

The carrying values of goodwill as of September 30, 2024 and 2023 are net of the following accumulated impairments:

(in thousands)	U.S. Healthcare Solutions	International Healthcare Solutions
Accumulated impairment losses as of September 30, 2024	$ —	$ 493,936
Accumulated impairment losses as of September 30, 2023	$ —	$ 75,936

The Company performed a recoverability assessment of PharmaLex's long-lived assets as of July 1, 2024 using its revised long-range forecast. The recoverability assessment compared PharmaLex's undiscounted cash flows to the carrying value of the PharmaLex asset group, including goodwill, and it was determined to be recoverable.

The following is a summary of other intangible assets:

		September 30, 2024			September 30, 2023		
(dollars in thousands)	Weighted Average Remaining Useful Life	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
Indefinite-lived trade name		$ 17,000	$ —	$ 17,000	$ 17,000	$ —	$ 17,000
Finite-lived:							
Customer relationships	13 years	5,090,864	(1,536,081)	3,554,783	4,845,091	(1,213,200)	3,631,891
Trade names and other	5 years	1,259,954	(830,691)	429,263	1,224,795	(441,903)	782,892
Total other intangible assets		$ 6,367,818	$ (2,366,772)	$ 4,001,046	$ 6,086,886	$ (1,655,103)	$ 4,431,783

Amortization expense for finite-lived intangible assets was $663.5 million, $553.6 million, and $307.3 million in fiscal 2024, 2023, and 2022, respectively. Amortization expense for finite-lived intangible assets is estimated to be $548.9 million in fiscal 2025, $372.4 million in fiscal 2026, $314.6 million in fiscal 2027, $302.8 million in fiscal 2028, $291.1 million in fiscal 2029, and $2,154.2 million thereafter.

Note 6. Debt

Debt consisted of the following:

(in thousands)	September 30, 2024	2023
Multi-currency revolving credit facility due 2029	$ —	$ —
Receivables securitization facility due 2027	—	350,000
Money market facility	—	—
$500,000, 3.400% senior notes due 2024	—	499,677
$500,000, 3.250% senior notes due 2025	499,738	499,026
$750,000, 3.450% senior notes due 2027	747,308	746,464
$500,000, 2.800% senior notes due 2030	496,564	495,959
$1,000,000, 2.700% senior notes due 2031	992,718	991,600
$500,000, 5.125% senior notes due 2034	494,514	—
$500,000, 4.250% senior notes due 2045	495,574	495,378
$500,000, 4.300% senior notes due 2047	493,821	493,554
Alliance Healthcare debt	286	68,017
Nonrecourse debt	167,553	147,782
Total debt	4,388,076	4,787,457
Less current portion of senior notes	499,738	499,677
Less Alliance Healthcare current portion	286	68,017
Less nonrecourse current portion	76,307	73,650
Total, net of current portion	$ 3,811,745	$ 4,146,113

Multi-Currency Revolving Credit Facility

The Company has a $2.4 billion multi-currency senior unsecured revolving credit facility ("Multi-Currency Revolving Credit Facility") with a syndicate of lenders, which was scheduled to expire in October 2028. In October 2024, the Company amended and restated the Multi-Currency Revolving Credit Facility to extend the expiration to October 2029. Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based upon the Company's debt rating. The Company pays facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based on its debt rating. The Company may choose to repay or reduce its commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which the Company was compliant as of September 30, 2024.

Commercial Paper Program

The Company has a commercial paper program whereby it may from time to time issue short-term promissory notes in an aggregate amount of up to $2.4 billion at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary but may not exceed 365 days from the date of issuance. The notes will bear interest, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does not increase the Company's borrowing capacity as it is fully backed by the Company's Multi-Currency Revolving Credit Facility. There were no borrowings outstanding under the commercial paper program as of September 30, 2024 and 2023.

Receivables Securitization Facility

The Company has a $1,450 million receivables securitization facility ("Receivables Securitization Facility"), which was scheduled to expire in October 2026. In October 2024, the Company amended the Receivables Securitization Facility to extend the expiration to October 2027. The Company has available to it an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters. Interest rates are based on prevailing market rates for short-term commercial paper or 30-day Term SOFR, plus a program fee. The Company pays a customary unused fee at prevailing market rates, monthly, to maintain the availability under the Receivables Securitization Facility. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which the Company was compliant as of September 30, 2024.

In connection with the Receivables Securitization Facility, AmerisourceBergen Drug Corporation and a specialty distribution subsidiary sell on a revolving basis certain accounts receivable to Amerisource Receivables Financial Corporation, a wholly-owned special purpose entity, which in turn sells a percentage ownership interest in the receivables to financial institutions and commercial paper conduits sponsored by financial institutions. AmerisourceBergen Drug Corporation is the servicer of the accounts receivable under the Receivables Securitization Facility. As sold receivables are collected, additional receivables may be sold up to the maximum amount available under the facility. The Company uses the facility as a financing vehicle because it generally offers an attractive interest rate relative to other financing sources. The Company securitizes its trade accounts, which are generally non-interest bearing, in transactions that are accounted for as borrowings. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which the Company was compliant as of September 30, 2024.

Revolving Credit Note, Overdraft Facility, and Money Market Facility

The Company had a $75 million uncommitted, unsecured line of credit available to it pursuant to a revolving credit note that was terminated in April 2024. The Company also had a £10 million uncommitted U.K. overdraft facility, which expired in February 2024, to fund short-term normal trading cycle fluctuations related to its MWI Animal Health business. The Company has an uncommitted, unsecured line of credit available to it pursuant to a money market credit agreement ("Money Market Facility"). The Money Market Facility provides the Company with the ability to request short-term, unsecured revolving credit loans from time to time in a principal amount not to exceed $100 million. The Money Market Facility may be decreased or terminated by the bank or the Company at any time without prior notice.

Senior Notes

In fiscal 2022, the Company elected to repay $850 million of its senior notes that were due in March 2023. In fiscal 2023, the remaining balance of $675 million of these senior notes matured and was repaid.

In February 2024, the Company issued $500 million of 5.125% senior notes due in February 2034 (the "2034 Notes"). The 2034 Notes were sold at 99.867% of the principal amount with an effective yield of 5.132%. Interest on the 2034 Notes is payable semi-annually in arrears on February 15 and August 15 beginning on August 15, 2024. The Company used the proceeds from the 2034 Notes to repay the $500 million of 3.400% senior notes that matured in May 2024.

The senior notes discussed above and also illustrated in the above debt table are collectively referred to as the "Notes." Interest on the Notes is payable semiannually in arrears. Most of the Notes were sold at small discounts to the principal amounts and, therefore, have effective yields that are greater than the stated interest rates in the table above. Costs incurred in connection with the issuance of the Notes were deferred and are being amortized over the terms of the Notes. The indentures governing the Notes contain restrictions and covenants, which include limitations on additional indebtedness; distributions to stockholders; the repurchase of stock and the making of other restricted payments; issuance of preferred stock; creation of certain liens; transactions with subsidiaries and other affiliates; and certain corporate acts such as mergers, consolidations, and the sale of substantially all assets. An additional covenant requires compliance with a financial leverage ratio test. The Company was compliant with all covenants as of September 30, 2024.

Alliance Healthcare Debt

Alliance Healthcare debt is comprised of uncommitted revolving credit facilities in various currencies with various rates. These facilities are used to fund its working capital needs.

Nonrecourse Debt

Nonrecourse debt is comprised of short-term and long-term debt belonging to the Brazil subsidiaries and is repaid solely from the Brazil subsidiaries' cash flows and such debt agreements provide that the repayment of the loans (and interest thereon) is secured solely by the capital stock, physical assets, contracts, and cash flows of the Brazil subsidiaries.

Other Information

Scheduled future principal payments of debt are $566.9 million in fiscal 2025, $34.8 million in fiscal 2026, $24.5 million in fiscal 2027, $767.1 million in fiscal 2028, $7.6 million in fiscal 2029, and $3,007.8 million thereafter.

Interest paid on the above indebtedness during fiscal 2024, 2023, and 2022 was $250.1 million, $271.3 million, and $219.8 million, respectively.

Total amortization of financing fees and the accretion of original issue discounts, which are recorded as components of Interest Expense, Net on the Consolidated Statements of Operations, were $7.2 million, $8.5 million, and $11.9 million, for fiscal 2024, 2023, and 2022, respectively.

Note 7. Stockholders' Equity and Weighted Average Common Shares Outstanding

The authorized capital stock of the Company consists of [illegible] shares of common stock, par value $0.01 per share (the "common stock"), and 10,000,000 shares of preferred stock, par value $0.01 per share (the "preferred stock").

The holders of the Company's common stock are entitled to one vote per share and have the exclusive right to vote for the Board of Directors and for all other purposes as provided by law. Subject to the rights of holders of the Company's preferred stock, holders of common stock are entitled to receive ratably on a per share basis such dividends and other distributions in cash, stock, or property of the Company as may be declared by the Board of Directors from time to time out of the legally available assets or funds of the Company.

The following illustrates the components of Accumulated Other Comprehensive Loss, net of income taxes:

	September 30,	
(in thousands)	**2024**	**2023**
Foreign currency translation	$ (988,484)	$ (1,402,245)
Other, net	(634)	(362)
Total accumulated other comprehensive loss	$ (989,118)	$ (1,402,607)

The decrease in total accumulated other comprehensive loss from foreign currency translation primarily relates to the translation of Alliance Healthcare's goodwill and intangible assets balances.

In May 2020, the Company's Board of Directors authorized a share repurchase program allowing the Company to purchase up to $500 million of its outstanding shares of common stock, subject to market conditions. During fiscal 2022, the Company purchased 3.3 million shares of its common stock for $473.4 million to complete its authorization under this program.

In May 2022, the Company's Board of Directors authorized a share repurchase program allowing the Company to purchase up to $1.0 billion of its outstanding shares of common stock, subject to market conditions. During fiscal 2022, the Company purchased 0.3 million shares of its common stock for $38.7 million, which included $28.4 million of September 2022 purchases that cash settled in October 2022. During fiscal 2023, the Company purchased 6.0 million shares of its common stock for $961.3 million, including 5.5 million shares from WBA for $882.5 million, to complete its authorization under this program.

In March 2023, the Company's Board of Directors authorized a share repurchase program allowing the Company to purchase up to $1.0 billion of its outstanding shares of common stock, subject to market conditions. During fiscal 2023, the Company purchased 1.0 million shares of its common stock for $191.0 million, including 0.9 million shares from WBA for $167.5 million. During fiscal 2024, the Company purchased 3.9 million shares of its common stock for $809.0 million, including 2.5 million shares from WBA for $522.6 million, to complete its authorization under this program.

In March 2024, the Company's Board of Directors authorized a new share repurchase program allowing the Company to purchase up to $2.0 billion of its outstanding common stock, subject to market conditions. During fiscal 2024, the Company purchased 3.0 million shares of its common stock for $682.3 million, including 1.9 million shares from WBA for $427.4 million. As of September 30, 2024, the Company had $1,317.7 million availability under this program. From October 1, 2024 through November 22, 2024, the Company purchased 1.7 million shares of its common stock for a total of $385.4 million.

Common Shares Outstanding

Basic earnings per share is computed by dividing net income attributable to Cencora, Inc. by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed by dividing net income attributable to Cencora, Inc. by the weighted average number of shares of common stock outstanding, plus the dilutive effect of stock options and restricted stock units during the periods presented.

The following illustrates the components of diluted weighted average shares outstanding:

(in thousands)	Fiscal Year Ended September 30, 2024	2023	2022
Weighted average common shares outstanding - basic	198,503	202,511	208,472
Effect of dilutive securities - stock options and restricted stock units	1,781	2,080	2,738
Weighted average common shares outstanding - diluted	200,284	204,591	211,210

The potentially dilutive stock options and restricted stock units that were antidilutive were 85 thousand, 94 thousand, and 101 thousand for fiscal 2024, 2023 and 2022, respectively.

Note 8. Related Party Transactions

WBA owns more than 10% of the Company's outstanding common stock and is, therefore, considered a related party. The Company operates under various agreements and arrangements with WBA, including a pharmaceutical distribution agreement pursuant to which the Company distributes pharmaceutical products to WBA and an agreement that provides the Company the ability to access favorable economic pricing and generic products through a generic purchasing services arrangement with Walgreens Boots Alliance Development GmbH (both through 2029) as well as a distribution agreement pursuant to which it will supply branded and generic pharmaceutical products to WBA's Boots UK Ltd. subsidiary (through 2031).

Revenue from the various agreements and arrangements with WBA was $76.5 billion, $68.7 billion, and $64.1 billion in fiscal 2024, 2023, and 2022, respectively. The Company's receivable from WBA, net of incentives, was $9.0 billion and $8.1 billion as of September 30, 2024 and 2023, respectively.

Note 9. Retirement and Other Benefit Plans

The Company sponsors various retirement benefit plans and a deferred compensation plan covering eligible employees.

The Compensation and Succession Planning Committee ("Compensation Committee") of the Company's Board of Directors has delegated the administration of the Company's retirement and other benefit plans to its Benefits Committee, an internal committee, comprised of senior finance, human resources, and legal executives. The Benefits Committee is responsible for the investment options under the Company's savings plans, as well as performance of the investment advisers and plan administrators.

Retirement Benefit Plans

The Company sponsors the Cencora, Inc. Employee Investment Plan (the "Plan"), which is a defined contribution 401(k) plan covering salaried and certain hourly employees. Eligible participants may contribute to the plan from 1% to 50% of their regular compensation before taxes. The Company contributes $1.00 for each $1.00 invested by the participant up to the first 3% of the participant's salary and $0.50 for each additional $1.00 invested by the participant of up to an additional 2% of salary. An additional discretionary contribution, in an amount not to exceed the limits established by the Internal Revenue Code ("IRC"), may also be made depending upon the Company's performance. Based on the Company's performance in fiscal 2024, 2023, and 2022, the Company recognized expenses for discretionary contributions to the Plan in fiscal 2024, 2023, and 2022. All contributions are invested at the direction of the employee in one or more funds. All company matching contributions vest immediately except for the discretionary contributions made by the Company, which vest in full after five years of credited service.

The Company's international businesses sponsor various country-specific retirement plans.

Costs of above retirement benefit plans charged to expense for fiscal 2024, 2023, and 2022 were $99.8 million, $89.4 million, and $90.1 million, respectively.

Deferred Compensation Plan

The Company sponsors the Cencora, Inc. Deferred Compensation Plan. This unfunded plan allows eligible officers, directors and key management employees to defer a portion of their annual compensation and provides for a benefit restoration feature to selected key management. The benefit restoration feature provides certain eligible participants, including the Company's executive officers, with an annual amount equal to 4% of the participant's total cash compensation to the extent that an employee's compensation exceeds the annual compensation limit established by Section 401(a) (17) of the IRC. Prior to fiscal 2024, account balances associated with the benefit restoration feature were included in a separate account at the Company's plan administrator. In fiscal 2024, the benefit restoration account balances were combined with the Cencora, Inc. Deferred Compensation Plan. The Company's liability relating to its deferred compensation plan, including the benefit restoration feature, as of September 30, 2024 and 2023 was $57.9 million and $46.5 million, respectively.

Note 10. Share-Based Compensation

The Company's stockholders approved the AmerisourceBergen Corporation 2022 Omnibus Incentive Plan (the "2022 Plan"). As of September 30, 2024, there were 20.1 million shares available to be granted for employee and non-employee director stock restricted stock units, performance stock units, and stock options under the 2022 Plan.

Restricted Stock Units

The majority of restricted stock units granted vest ratably over a three-year period. The estimated fair value of restricted stock units under the Company's restricted stock unit plans is determined by the product of the number of shares granted and the closing grant date market price of the Company's common stock. The estimated fair value of restricted stock units is expensed on a straight-line basis over the requisite service period, net of estimated forfeitures. During fiscal 2024, 2023, and 2022, the Company recognized restricted stock unit expense of $98.9 million, $84.3 million, and $71.3 million, respectively.

A summary of the status of the Company's nonvested restricted stock units as of September 30, 2024 and changes during fiscal 2024 are presented below:

(in thousands, except grant date fair value)	Restricted Stock Units	Weighted Average Grant Date Fair Value
Nonvested as of September 30, 2023	1,295	$139
Granted	630	$201
Vested	(636)	$131
Forfeited	(81)	$165
Nonvested as of September 30, 2024	1,208	$173

During fiscal 2024, 2023, and 2022, the total fair values of restricted stock units vested were $83.2 million, $103.0 million, and $58.1 million, respectively. Expected future compensation expense relating to the 1.2 million restricted stock units outstanding as of September 30, 2024 is $84.6 million, which will be recognized over a weighted average period of 1.4 years.

Performance Stock Units

Performance stock units are granted to certain executive employees under the Plan and represent common stock potentially issuable in the future. Performance stock units vest at the end of a three-year performance period based upon achievement of specific performance goals. Based upon the extent to which the targets are achieved, vested shares may range from 0% to 230% of the target award amount. The fair value of performance stock units is determined by the grant date market price of the Company's common stock. Compensation expense associated with nonvested performance stock units is recognized over the requisite service period and is dependent on the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued. During fiscal 2024, 2023, and 2022, the Company recognized performance stock expense of $48.7 million, $40.4 million, and $19.7 million, respectively.

A summary of the status of the Company's nonvested performance stock units as of September 30, 2024 and changes during fiscal 2024 is presented below (based upon target award amounts).

(in thousands, except grant date fair value)	Performance Stock Units	Weighted Average Grant Date Fair Value
Nonvested as of September 30, 2023	251	$142
Granted	137	$197
Vested	(126)	$126
Forfeited	(14)	$183
Nonvested as of September 30, 2024	248	$178

Shares that vested over the three-year performance period ended September 30, 2024 were distributed to employees in November 2024.

Stock Options

The Company has not granted any stock options since fiscal 2020, and it does not expect to grant any stock options in fiscal 2025.

In fiscal 2024, employees exercised 503 thousand stock options at a weighted average exercise price of $84 per stock option. There were 533 thousand stock options outstanding as of September 30, 2024, all of which are exercisable, with a weighted average exercise price of $87 per option. The weighted average remaining contractual term for outstanding stock options is 1.6 years as of September 30, 2024.

Note 11. Leases

The Company has long-term leases for facilities and equipment. In the normal course of business, leases are generally renewed or replaced by other leases. Certain leases include escalation clauses.

The following illustrates the components of lease cost for the periods presented:

	Fiscal Year Ended September 30,		
(in thousands)	2024	2023	2022
Operating lease cost	$ 245,415	$ 234,567	$ 220,935
Short-term lease cost	18,459	9,799	11,257
Variable lease cost	35,539	25,598	25,108
Total lease cost	$ 299,413	$ 269,964	$ 257,300

The following summarizes balance sheet information related to operating leases:

	September 30,	
(in thousands, except for lease term and discount rate)	2024	2023
Right of use assets		
Other assets	$ 1,141,622	$ 1,019,368
Lease liabilities		
Accrued expenses and other	$ 204,767	$ 182,462
Other long-term liabilities	1,029,978	924,247
Total lease liabilities	$ 1,234,745	$ 1,106,709
Weighted-average remaining lease term	7.34 years	7.85 years
Weighted-average discount rate	4.18%	4.66%

Other cash flow information related to operating leases is as follows:

(in thousands)	Fiscal Year Ended September 30, 2024	2023	2022
Cash paid for amounts included in the measurement of lease liabilities			
Operating lease cash payments	$ 247,862	$ 229,203	$ 214,793
Right-of-use assets obtained in exchange for lease liabilities			
New operating leases	$ 305,882	$ 271,096	$ 179,214

Future minimum rental payments under noncancellable operating leases were as follows:

Payments Due by Fiscal Year (in thousands)	As of September 30, 2024
2025	$ 248,556
2026	231,499
2027	206,003
2028	176,871
2029	156,543
Thereafter	460,097
Total future undiscounted lease payments	1,479,569
Less: Future payments for leases that have not yet commenced [1]	(15,018)
Less: Imputed interest	(229,806)
Total lease liabilities	$ 1,234,745

[1] The Company has certain leases that it has executed of which it does not control the underlying assets; therefore, liabilities and ROU assets related to these leases were not recorded on the Company's Consolidated Balance Sheet as of September 30, 2024.

Note 12. Restructuring and Other Expenses

The following illustrates the expenses incurred by the Company relating to Restructuring and Other Expenses for the periods indicated:

(in thousands)	Fiscal Year Ended September 30, 2024	2023	2022
Restructuring and employee severance costs	$ 69,968	$ 105,220	$ 35,316
Business transformation efforts	130,069	82,117	27,990
Other, net	33,592	42,547	192
Total restructuring and other expenses	$ 233,629	$ 229,884	$ 63,498

Restructuring and employee severance costs in fiscal 2024 primarily included expenses incurred related to facility closures in connection with the Company's office optimization plan and workforce reductions in both of its reportable segments. Restructuring and employee severance costs in fiscal 2023 primarily included expenses incurred in connection with workforce reductions in both of the Company's reportable segments. Restructuring and employee severance costs in fiscal 2022 included costs primarily related to the write down of assets with respect to the Company's office optimization plan and restructuring activities within certain businesses in the U.S. Healthcare Solutions reportable segment.

Business transformation efforts in fiscal 2024 and 2023 included rebranding costs associated with the Company's name change to Cencora and non-recurring expenses related to significant strategic initiatives to improve operational efficiency, including certain technology initiatives. The majority of these costs related to services provided by third-party consultants. Business transformation efforts in fiscal 2022 primarily related to costs associated with reorganizing the Company to further align the organization to its customers' needs, including certain technology initiatives. The majority of these costs related to services provided by third-party consultants.

In March 2024, the Company experienced a cybersecurity event where data from its information systems was exfiltrated. In connection with this event, the Company incurred costs that were recorded in Other, net in the above table. The majority of the costs included in Other, net in fiscal 2024 related to this cybersecurity event.

In fiscal 2023, one of the Company's foreign business units experienced a cybersecurity event that impacted a standalone legacy information technology platform in one country and the foreign business unit's ability to operate in that country for approximately two weeks. In connection with this event, the Company incurred costs to restore the foreign business unit's operations in that country, which were recorded in Other, net in the above table. The majority of the costs included in Other, net in fiscal 2023 related to this cybersecurity event.

Note 13. Legal Matters and Contingencies

In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, government investigations, stockholder demands, and other disputes, including antitrust, commercial, product liability, intellectual property, regulatory, data privacy and security, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a reserve for these matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.

For those matters for which the Company has not recognized a liability, the Company cannot predict the outcome of their impact on the Company as uncertainty remains with regard to whether such matters will proceed to trial, whether settlements will be reached, and the amount and terms of any such settlements. Outcomes may include settlements in significant amounts that are not currently estimable, limitations on the Company's conduct, the imposition of corporate integrity agreement obligations, consent decrees, and/or other civil and criminal penalties. From time to time, the Company is also involved in disputes with its customers, which the Company generally seeks to resolve through commercial negotiations. If negotiations are unsuccessful, the parties may litigate the dispute or otherwise attempt to settle the matter.

With respect to the specific legal proceedings and claims described below, unless otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition.

Opioid Lawsuits and Investigations

A significant number of counties, municipalities, and other governmental entities in a majority of U.S. states and Puerto Rico, as well as numerous states and tribes, filed lawsuits in various federal, state and other courts against pharmaceutical wholesale distributors (including the Company and certain subsidiaries, such as AmerisourceBergen Drug Corporation ("ABDC") and H.D. Smith, LLC ("H.D. Smith")), pharmaceutical manufacturers, retail pharmacy chains, medical practices, and physicians relating to the distribution of prescription opioid pain medications.

Starting in December 2017, more than 2,000 cases were transferred to Multidistrict Litigation ("MDL") proceedings before the United States District Court for the Northern District of Ohio (the "MDL Court"). Since then, several cases filed by government and tribal plaintiffs that were selected as bellwether cases in the MDL have been resolved through trial or settlement. Following trial in two consolidated cases in West Virginia federal court, the court entered judgment in favor of the defendants, including the Company. The plaintiffs filed an appeal of the court's decision on August 2, 2022, which remains pending.

On July 21, 2021, the Company announced that it and the two other national pharmaceutical distributors had negotiated a Distributor Settlement Agreement that, if all conditions were satisfied, would result in the resolution of a substantial majority of opioid lawsuits filed by state and local governmental entities. The Distributor Settlement Agreement became effective on April 2, 2022, and as of September 30, 2024, it included 48 of 49 eligible states (the "Settling States") as well as 99% by population of the eligible political subdivisions in the Settling States. The Distributor Settlement Agreement requires the Company to comply with certain requirements, including the establishment of a clearinghouse that will consolidate data from all three national pharmaceutical distributors. West Virginia and its subdivisions and Native American tribes are not a part of the Distributor Settlement Agreement, and the Company has reached separate agreements with those groups. The State of Alabama also did not participate in the Distributor Settlement Agreement and was pursuing a case against the Company (and another national pharmaceutical distributor) in Alabama state court. On February 28, 2024, the Company and another national distributor executed an agreement with the State of Alabama and all its participating subdivisions to resolve opioid-related claims. Pursuant to the agreement, the two distributors will pay approximately $245 million, including attorneys' fees and costs, to the State of Alabama and its participating subdivisions, of which the Company's portion is 50%. On July 1, 2024, the Court entered a Final Consent Judgment and Dismissal with Prejudice pursuant to the terms of the settlement agreement. In Maryland, a trial commenced on September 16, 2024 in a case filed by the Mayor and City Council of Baltimore. On November 12, 2024,

the jury returned a verdict finding ABDC (and another national distributor) liable for public nuisance and assessing approximately $274 million total in compensatory damages, approximately $74 million of which was assessed against ABDC. A second phase of the trial is scheduled to commence on December 11, 2024 related to the City of Baltimore's request for an abatement remedy, which will proceed as a bench trial. While the judgment is not yet final, the Company is evaluating next steps, including a possible appeal. The $74 million is a component of the Company's $4.9 billion litigation liability as of September 30, 2024 as described below.

The MDL Court selected four cases filed by third-party payors to serve as additional litigation bellwethers. On May 31, 2024, the MDL Court severed and stayed these four cases against the Company and the two other national pharmaceutical distributors, pursuant to ongoing settlement discussions to resolve litigation filed by a putative class of third-party payors. On August 29, 2024, the Company and two other national pharmaceutical distributors entered into a proposed class action settlement agreement to resolve the opioid-related claims of a proposed settlement class of third-party payors. Pursuant to the agreement, the Company recorded a $93.0 million litigation expense accrual in Litigation and Opioid-Related Expenses (Credit), Net in its fiscal 2024 Consolidated Statement of Operations. On September 3, 2024, the MDL Court granted a motion for preliminary approval of the proposed class action settlement. Federal law imposes additional requirements before the class settlement can become final, including notice to class members, a time period for submission of any objections to the settlement or requests to be excluded from the settlement, and a fairness hearing, among other procedural steps, as described in the MDL Court's September 3, 2024 order. The MDL Court has scheduled a fairness hearing for January 13, 2025.

On September 26, 2024, the Company and two other national pharmaceutical distributors entered into a proposed class action settlement agreement to resolve the opioid-related claims of a proposed settlement class of hospitals. The Company recorded a $120.9 million litigation expense accrual in Litigation and Opioid-Related Expenses (Credit), Net in its fiscal 2024 Consolidated Statement of Operations, representing the Company's expected share of the potential class action settlement. Pursuant to these settlement discussions, a case in Alabama that involved up to eight plaintiff hospitals, and that was scheduled to begin trial on July 8, 2024, has now been severed and stayed as to the Company. On October 30, 2024, the United States District Court for the District of New Mexico granted a motion for preliminary approval of the proposed class action settlement. Federal law imposes additional requirements before the class settlement can become final, including notice to class members, a time period for submission of any objections to the settlement or requests to be excluded from the settlement, and a fairness hearing, among other procedural steps, as described in the Court's October 30, 2024 order. The Court has scheduled a fairness hearing for March 4, 2025.

In January 2024, the Company prepaid the net present value of a future obligation as permitted under its settlement agreements. The discount on the future obligation resulted in a $0.1 billion reduction of its accrued litigation liability. The Company's accrued litigation liability related to the Distributor Settlement Agreement, including the State of Alabama and an estimate for non-participating government subdivisions (with whom the Company has not reached a settlement agreement), as well as other opioid-related litigation for which it has reached settlement agreements, as described above, was $4.9 billion as of September 30, 2024 and $5.5 billion as of September 30, 2023. The $4.9 billion liability will be paid over 14 years. The Company currently estimates that $630.2 million will be paid prior to September 30, 2025, which is recorded in Accrued Expenses and Other on the Company's Consolidated Balance Sheet. The remaining long-term liability of $4.3 billion is recorded in Accrued Litigation Liability on the Company's Consolidated Balance Sheet. While the Company has accrued its estimated liability for opioid litigation, it is unable to estimate the range of possible loss associated with the matters that are not included in the accrual. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. The Company regularly reviews opioid litigation matters to determine whether its accrual is adequate. The amount of ultimate loss may differ materially from the amount accrued to date. Until such time as otherwise resolved, the Company will continue to litigate and prepare for trial and to vigorously defend itself in all such matters. Since these matters are still developing, the Company is unable to predict the outcome, but the result of these lawsuits could include excessive monetary verdicts and/or injunctive relief that may affect the Company's operations. Additional lawsuits regarding the distribution of prescription opioid pain medications have been filed and may continue to be filed by a variety of types of plaintiffs, including lawsuits filed by non-governmental or non-political entities and individuals, among others. The Company is vigorously defending itself in the pending lawsuits and intends to vigorously defend itself against any threatened lawsuits or enforcement proceedings.

Since July 2017, the Company has received subpoenas from several U.S. Attorney's Offices, including grand jury subpoenas from the U.S. Attorney's Office for the District of New Jersey ("USAO-NJ") and the U.S. Attorney's Office for the Eastern District of New York ("USAO-EDNY"). Those subpoenas requested the production of a broad range of documents pertaining to the Company's distribution of controlled substances through its various subsidiaries, including ABDC, and its diversion control programs. The Company produced documents in response to the subpoenas and engaged in discussions with the various U.S. Attorney's Offices, including the Health Care and Government Fraud Unit of the Criminal Division of the USAO-NJ, the U.S. Department of Justice Consumer Protection Branch and the U.S. Drug Enforcement Administration, in an attempt to resolve these matters. On December 29, 2022, the Department of Justice filed a civil Complaint against the

Company, ABDC, and Integrated Commercialization Services, LLC ("ICS"), a subsidiary of the Company, alleging violations of the Controlled Substances Act. Specifically, the Complaint alleges that the Company negligently failed to report suspicious orders to the Drug Enforcement Administration. In the Complaint, the Department of Justice seeks civil penalties and injunctive relief. This Complaint relates to the aforementioned and previously-disclosed investigations. On March 30, 2023, the Company filed a motion to dismiss the Complaint in its entirety on behalf of itself, ABDC, and ICS. On November 6, 2023, the United States District Court for the Eastern District of Pennsylvania granted in part and denied in part the motion, dismissing with prejudice all claims for civil penalties for Defendants' alleged violations of the suspicious order reporting requirement prior to October 24, 2018, but otherwise denying the motion. On December 18, 2023, the Company, ABDC and ICS filed an Answer and Affirmative Defenses to the Complaint. On January 23, 2024, the Court entered a Scheduling Order setting the fact discovery deadline as January 9, 2026 and the expert discovery deadline as September 18, 2026. The Company denies the allegations in the Complaint and intends to defend itself vigorously in the litigation.

Shareholder Securities Litigation

On October 11, 2019, Teamsters Local 443 Health Services & Insurance Plan, St. Paul Electrical Construction Pension Plan, St. Paul Electrical Construction Workers Supplemental Pension Plan (2014 Restatement), Retirement Medical Funding Plan for the St. Paul Electrical Workers, and San Antonio Fire & Police Pension Fund filed a complaint for a purported derivative action in the Delaware Court of Chancery against the Company and certain of its current and former officers and directors (collectively, "Defendants"). The complaint alleges that the Defendants breached their fiduciary duties by failing to oversee the compliance by certain of the Company's subsidiaries (including the Company's former subsidiary Medical Initiatives, Inc. ("MII")) with federal regulations, allegedly resulting in the payment of fines and penalties in connection with the settlements with the USAO-EDNY in fiscal 2017 and 2018 that resolved claims arising from MII's pre-filled syringe program. In December 2019, Defendants filed a motion to dismiss the complaint. After briefing and oral argument, on August 24, 2020 the Delaware Court of Chancery denied Defendants' motion to dismiss. On September 24, 2020, the Company's Board of Directors established a Special Litigation Committee to conduct an investigation concerning the plaintiffs' allegations, and on November 10, 2020, the Delaware Court of Chancery granted the Special Litigation Committee's motion to stay the litigation pending its investigation. On September 22, 2021, the Special Litigation Committee filed its report under seal and moved to dismiss the case. The Delaware Court of Chancery granted the Special Litigation Committee's motion to dismiss on November 17, 2023, and entered an Order and Final Judgement on December 8, 2023. On January 5, 2024, the plaintiffs filed a notice of appeal to the Delaware Supreme Court from the Delaware Court of Chancery's November 17, 2023 decision granting the motion to dismiss and December 8, 2023 Order and Final Judgement. On September 20, 2024, the Delaware Supreme Court affirmed the Court of Chancery's judgment on the basis of and for the reasons stated in the Court of Chancery's November 17, 2023 Memorandum Opinion and there is no further right of appeal.

On December 30, 2021, Lebanon County Employees' Retirement Fund and Teamsters Local 443 Health Services & Insurance Plan filed a complaint for a purported derivative action in the Delaware Court of Chancery against the Company and certain of its current officers and directors. The complaint alleges claims for breach of fiduciary duty allegedly arising from the Board's and certain officers' oversight of the Company's controlled substance diversion control programs. The defendants moved to dismiss the complaint on March 29, 2022. On December 22, 2022, the Delaware Court of Chancery granted the motion to dismiss. On January 9, 2023, the Plaintiffs filed a Motion for Relief from Judgment and Order Pursuant to Rule 60(b) from the Delaware Chancery Court's judgment. On January 20, 2023, the Plaintiffs also appealed the ruling to the Delaware Supreme Court. On March 21, 2023, the Delaware Court of Chancery denied the Plaintiffs' Motion for Relief from Judgement and Order Pursuant to Rule 60(b). On December 18, 2023, the Delaware Supreme Court reversed the dismissal and remanded the case to the Delaware Court of Chancery for further proceedings. On January 12, 2024, the Company's Board of Directors established a Special Litigation Committee ("SLC") and delegated to the SLC the Board's full authority with respect to the litigation. On March 4, 2024, the Delaware Court of Chancery granted the SLC's consented-to motion to stay the action pending its investigation of the allegations of the complaint.

Subpoenas, Ongoing Investigations, and Other Contingencies

From time to time, the Company receives subpoenas or requests for information from various government agencies relating to the Company's business or to the business of a customer, supplier, or other industry participant. The Company's responses often require time and effort and can result in considerable costs being incurred. Most of these matters are resolved without incident; however, such subpoenas or requests can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the healthcare industry, as well as to substantial settlements.

In January 2017, U.S. Bioservices Corporation, a former subsidiary of the Company, received a subpoena for information from the USAO-EDNY relating to its activities in connection with billing for products and making returns of potential overpayments to government payers. A filed qui tam complaint related to the investigation was unsealed in April 2019 and the relator filed an amended complaint under seal in the U.S. District Court for the Eastern District of New York. In

December 2019, the government filed a notice that it was declining to intervene. The court ordered that the relator's complaint against the Company and other defendants, including AmerisourceBergen Specialty Group, LLC, be unsealed. The relator's complaint alleged violations of the federal False Claims Act and the false claims acts of various states. The relator filed a second amended complaint, removing one state false claims act count. The Company filed a motion to dismiss the second amended complaint and all briefs on the motion were filed with the court on October 9, 2020. The motion to dismiss was granted on December 22, 2022. The False Claims Act claims were dismissed with prejudice, and the state claims were dismissed without prejudice. On January 24, 2023, the relator filed Motions to Reconsider Dismissal and For Leave to Amend the Complaint. Response briefs on those motions were filed by the Company and all briefing was completed on February 15, 2023.

In December 2019, Reliable Pharmacy, together with other retail pharmacies and North Sunflower Medical Center, filed a civil antitrust complaint against multiple generic drug manufacturers, and also included claims against ABDC and H.D. Smith, and other drug distributors and industry participants. The case is filed as a putative class action and plaintiffs purport to represent a class of drug purchasers including other retail pharmacies and healthcare providers. The case has been consolidated for multidistrict litigation proceedings before the United States District Court for the Eastern District of Pennsylvania. The complaint alleges that ABDC, H.D. Smith, and others in the industry participated in a conspiracy to fix prices, allocate markets and rig bids regarding generic drugs. In March 2020, the plaintiffs filed a further amended complaint. On July 15, 2020, the defendants filed a motion to dismiss the complaint. On May 25, 2022, the Court granted the motion to dismiss without prejudice. On July 1, 2022, the plaintiffs filed an amended complaint, again including claims against ABDC, H.D. Smith, and other drug distributors and industry participants. On August 21, 2022, the Company and other industry participants filed a motion to dismiss the amended complaint. All briefs on the motion were filed with the court on November 22, 2022.

On March 3, 2022, the United States Attorney's Office for the Western District of Virginia notified the Company of the existence of a criminal investigation into MWI Veterinary Supply Co. ("MWI"), the Company's animal health subsidiary, in connection with grand jury subpoenas to which MWI previously responded relating to compliance with state and federal regulatory requirements governing wholesale shipments of animal health products to customers. In October 2024, the Company reached an agreement in principle to resolve these claims. Pursuant to the agreement in principle, the Company recorded a $49.1 million litigation expense accrual in Litigation and Opioid-Related Expenses (Credit), Net in its fiscal 2024 Consolidated Statement of Operations. This liability was recorded in Accrued Expenses and Other on the Company's Consolidated Balance Sheet as of September 30, 2024.

Note 14. Litigation Settlements

Antitrust Settlements

Numerous lawsuits have been filed against certain brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. These lawsuits are generally brought as class actions. The Company has not been named a plaintiff in any of these lawsuits but has been a member of the direct purchasers' class (i.e., those purchasers who purchase directly from these pharmaceutical manufacturers). None of the lawsuits has gone to trial, but some have settled in the past with the Company receiving proceeds from the settlement funds. During fiscal 2024, 2023, and 2022, the Company recognized gains relating to these lawsuits of $170.9 million, $239.1 million, and $1.8 million, respectively. These gains, which are net of attorney fees and estimated payments due to other parties, were recorded as reductions to cost of goods sold in the Company's Consolidated Statements of Operations.

Note 15. Business Segment Information

The Company is organized geographically based upon the products and services it provides to its customer and reports its results under two reportable segments: U.S. Healthcare Solutions and International Healthcare Solutions.

Prior to October 1, 2024, the chief operating decision maker ("CODM") of the Company was the Executive Vice President and Chief Operating Officer ("COO") of the Company, whose function is to allocate resources to, and assess the performance of, the Company's operating segments. Effective October 1, 2024, the COO was promoted to President & Chief Executive Officer of the Company and remains the CODM. The CODM does not review assets by operating segment for the purpose of assessing performance or allocating resources.

The U.S. Healthcare Solutions reportable segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The U.S. Healthcare Solutions reportable segment also provides pharmaceutical distribution (including plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty pharmaceutical products) and additional services

to physicians who specialize in a variety of disease states, especially oncology, and to other healthcare providers, including hospitals and dialysis clinics. Additionally, the U.S. Healthcare Solutions reportable segment provides data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The U.S. Healthcare Solutions reportable segment also provides pharmacy management, staffing and additional consulting services, and supply management software to a variety of retail and institutional healthcare providers. It also provides a full suite of integrated manufacturer services that ranges from clinical trial support to product post-approval and commercialization support. Additionally, it delivers packaging solutions to institutional and retail healthcare providers. Through its animal health business, the U.S. Healthcare Solutions reportable segment sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. It also offers demand-creating sales force services to manufacturers.

The International Healthcare Solutions reportable segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services. The International Healthcare Solutions reportable segment distributes pharmaceuticals, other healthcare products, and related services to healthcare providers, including pharmacies, doctors, health centers and hospitals primarily in Europe. It is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. It also is a provider of specialized services, including regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality management and compliance, for the life sciences industry. In Canada, the business drives innovative partnerships with manufacturers, providers, and pharmacies to improve product access and efficiency throughout the healthcare supply chain.

The following illustrates reportable and operating segment disaggregated revenue as required by ASC 606, "Revenue from Contracts with Customers," for the periods indicated:

	Fiscal Year Ended September 30,		
(in thousands)	**2024**	**2023**	**2022**
U.S. Healthcare Solutions			
Human Health	$ 259,973,909	$ 229,716,669	$ 207,284,444
Animal Health	5,365,518	5,042,549	4,815,758
Total U.S. Healthcare Solutions	265,339,427	234,759,218	212,100,202
International Healthcare Solutions			
Alliance Healthcare	23,061,721	22,349,278	21,890,402
Other Healthcare Solutions	5,565,821	5,069,401	4,601,271
Total International Healthcare Solutions	28,627,542	27,418,679	26,491,673
Intersegment eliminations	(8,370)	(4,486)	(4,869)
Revenue	$ 293,958,599	$ 262,173,411	$ 238,587,006

The following illustrates reportable segment operating income information for the periods indicated:

	Fiscal Year Ended September 30,		
(in thousands)	**2024**	**2023**	**2022**
U.S. Healthcare Solutions	$ 2,934,877	$ 2,596,559	$ 2,456,972
International Healthcare Solutions	713,379	692,562	706,458
Total segment operating income	$ 3,648,256	$ 3,289,121	$ 3,163,430

The following reconciles total segment operating income to income before income taxes for the periods indicated:

(in thousands)	Fiscal Year Ended September 30, 2024	2023	2022
Total segment operating income	$ 3,648,256	$ 3,289,121	$ 3,163,430
Gains from antitrust litigation settlements	170,904	239,092	1,835
LIFO credit (expense)	52,168	(204,595)	(67,171)
Turkey highly inflationary impact	(54,087)	(86,967)	(40,033)
Acquisition-related intangibles amortization	(660,292)	(551,046)	(304,551)
Litigation and opioid-related (expenses) credit, net	(227,070)	24,693	(123,191)
Acquisition-related deal and integration expenses	(103,001)	(139,683)	(119,561)
Restructuring and other expenses	(233,629)	(229,884)	(63,498)
Goodwill impairment	(418,000)	—	(75,936)
Asset impairment	—	—	(4,946)
Operating income	2,175,249	2,340,731	2,366,378
Other loss (income), net	14,283	(49,036)	(27,352)
Interest expense, net	156,991	228,931	210,673
Income before income taxes	$ 2,003,975	$ 2,160,836	$ 2,183,057

Segment operating income is evaluated by the CODM of the Company and excludes gains from antitrust litigation settlements; LIFO credit (expense); Turkey highly inflationary impact; acquisition-related intangibles amortization; litigation and opioid-related (expenses) credit, net; acquisition-related deal and integration expenses; restructuring and other expenses; goodwill impairment; and impairment of assets. All corporate office expenses are allocated to the operating segment level.

Litigation and opioid-related (expenses) credit, net in fiscal 2024 includes $263.1 million of litigation expense accruals (see Note 13), offset in part by a net $92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as permitted under its opioid settlement agreements.

Litigation and opioid-related (expenses) credit, net in fiscal 2023 includes the receipt of $83.4 million from the H.D. Smith opioid litigation indemnity escrow.

Included in other loss (income), net, the Company recognized net gains of $40.7 million and $56.2 million from the divestiture of non-core businesses in fiscal 2023 and 2022, respectively.

The following illustrates depreciation and amortization by reportable segment for the periods indicated:

(in thousands)	Fiscal Year Ended September 30, 2024	2023	2022
U.S. Healthcare Solutions	$ 298,683	$ 292,814	$ 274,554
International Healthcare Solutions	132,999	120,044	114,790
Acquisition-related intangibles amortization	660,292	551,046	304,551
Total depreciation and amortization	$ 1,091,974	$ 963,904	$ 693,895

Depreciation and amortization related to property and equipment and intangible assets but excludes amortization of deferred financing costs and other debt-related items, which are included in interest expense, net.

The following illustrates capital expenditures by reportable segment for the periods indicated:

(in thousands)	Fiscal Year Ended September 30, 2024	2023	2022
U.S. Healthcare Solutions	$ 273,715	$ 268,069	$ 295,406
International Healthcare Solutions	213,458	190,290	200,912
Total capital expenditures	$ 487,173	$ 458,359	$ 496,318

Note 16. Fair Value of Financial Instruments

The recorded amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable as of September 30, 2024 and 2023 approximate fair value based upon the relatively short-term nature of these financial instruments. Within Cash and Cash Equivalents, the Company had $1,190.0 million and $1,489.0 million of investments in money market accounts as of September 30, 2024 and 2023, respectively. The fair value of the money market accounts was determined based upon unadjusted quoted prices in active markets for identical assets, otherwise known as Level 1 inputs.

The recorded amount of long-term debt (see Note 6) and the corresponding fair value as of September 30, 2024 were $3,811.7 million and $3,588.0 million, respectively. The recorded amount of long-term debt and the corresponding fair value as of September 30, 2023 were $4,146.1 million and $3,572.6 million, respectively. The fair value of long-term debt was determined based upon inputs other than quoted prices, otherwise known as Level 2 inputs.

Note 17. Subsequent Events

Announced Acquisition

On November 5, 2024, the Company entered into an agreement to acquire Retina Consultants of America ("RCA"). Under the terms of the agreement, the Company will acquire RCA for cash based on an enterprise value of approximately $4.6 billion, subject to a customary working capital and net-debt adjustment. RCA's affiliated practices, physicians, and management will rollover a portion of their equity in RCA. After giving effect to the rollover, a cash capitalization of RCA that the Company intends to make, and the payment of transaction fees and expenses, the Company's expected cash outlay at closing would be approximately $4.3 billion. At closing, the Company expects to hold approximately 85% ownership in RCA. The agreement also provides for the potential payment of up to $500 million in aggregate contingent consideration in fiscal 2027 and fiscal 2028, subject to the successful completion of certain predefined business objectives. The Company expects to fund the transaction through a combination of cash on hand and new debt financing and has obtained $3.3 billion in bridge financing commitments in connection with the transaction. The transaction is subject to the satisfaction of closing conditions, including receipt of required regulatory approvals.

Dividend Increase

In November 2024, the Company's Board of Directors increased the quarterly dividend paid on common stock by 8% and declared a regular quarterly cash dividend of $0.55 per share, payable on November 29, 2024 to shareholders of record on November 15, 2024.

GUARANTEE OF PERFORMANCE

For value receive Cencora, Inc., a Delaware corporation (the "Guarantor"), located at 1 West First Avenue, Conshohocken, PA 19428, absolutely and unconditionally guarantees to assume the duties and obligations of AmerisourceBergen Drug Corporation, located at 1 West First Avenue Conshohocken, PA 19428 (the "Franchisor"), under its franchise registration in each state where the franchise is registered, and under its Franchise Agreement identified in the Franchise Disclosure Document issued _____, as it may be amended, and as that Franchise Agreement may be entered into with franchisees and amended, modified or extended from time to time. This guarantee continues until all such obligations of the Franchisor under its franchise registrations and the Franchise Agreement are satisfied or until the liability of Franchisor to its franchisees under the Franchise Agreement has been completely discharged, whichever first occurs. The Guarantor is not discharged from liability if a claim by a franchisee against the Franchisor remains outstanding. Notice of acceptance is waived. The Guarantor does not waive receipt of notice of default on the part of the Franchisor. This guarantee is binding on the Guarantor and its successors and assigns.

The Guarantor executes this guarantee at Conshohocken, Pennsylvania on the 15th day of October, 2024.

Guarantor: Cencora, Inc.

By: _____

Name: Elizabeth Campbell

Title: Executive Vice President and Chief legal Officer

CENCORA, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)	September 30, 2025	September 30, 2024
ASSETS		
Current assets:		
Cash and cash equivalents	$ 4,356,138	$ 3,132,648
Accounts receivable, less allowances for returns and credit losses: 2025 — $1,796,172; 2024 — $1,308,018	25,225,299	23,871,815
Inventories	20,492,480	18,998,833
Right to recover assets	1,625,817	1,175,871
Prepaid expenses and other	539,339	538,646
Total current assets	52,239,073	47,717,813
Property and equipment, net	2,539,076	2,181,410
Goodwill	13,676,520	9,318,027
Other intangible assets	3,774,181	4,001,046
Deferred income taxes	208,810	246,348
Other assets	4,152,452	3,637,023
TOTAL ASSETS	$ 76,590,112	$ 67,101,667
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	$ 54,719,761	$ 50,942,162
Accrued expenses and other	2,982,993	2,758,560
Short-term debt	117,785	576,331
Total current liabilities	57,820,539	54,277,053
Long-term debt	7,542,988	3,811,745
Accrued income taxes	337,631	291,796
Deferred income taxes	1,620,724	1,643,746
Accrued litigation liability	3,881,283	4,296,902
Other liabilities	3,639,862	1,993,683
Commitments and contingencies (Note 12)		
Stockholders' equity:		
Common stock, $0.01 par value — authorized, issued, and outstanding: 2025 — 600,000,000 shares, 297,401,863 shares and 193,937,673 shares; 2024 — 600,000,000 shares, 296,169,781 shares and 194,943,968 shares	2,974	2,962
Additional paid-in capital	6,204,302	6,030,790
Retained earnings	6,534,227	5,417,139
Accumulated other comprehensive loss	(901,378)	(989,118)
Treasury stock, at cost: 2025 — 103,464,190 shares; 2024 — 101,225,813 shares	(10,332,106)	(9,815,835)
Total Cencora, Inc. stockholders' equity	1,508,019	645,938
Noncontrolling interests	239,066	140,804
Total stockholders' equity	1,747,085	786,742
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 76,590,112	$ 67,101,667

See notes to consolidated financial statements.

CENCORA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)	Fiscal Year Ended September 30, 2025	2024	2023
Revenue	$ 321,332,819	$ 293,958,599	$ 262,173,411
Cost of goods sold	309,854,280	284,048,570	253,213,918
Gross profit	11,478,539	9,910,029	8,959,493
Operating expenses:			
Distribution, selling, and administrative	6,493,842	5,661,106	5,309,984
Depreciation	494,141	428,500	410,341
Amortization	556,934	663,474	553,563
Litigation and opioid-related expenses (credit), net	60,671	227,070	(24,693)
Acquisition-related deal and integration expenses	291,044	103,001	139,683
Restructuring and other expenses	229,422	233,629	229,884
Goodwill impairment	723,884	418,000	—
Operating income	2,628,601	2,175,249	2,340,731
Other loss (income), net	78,717	14,283	(49,036)
Interest expense, net	291,548	156,991	228,931
Income before income taxes	2,258,336	2,003,975	2,160,836
Income tax expense	690,522	484,702	428,260
Net income	1,567,814	1,519,273	1,732,576
Net (income) loss attributable to noncontrolling interests	(13,645)	(10,153)	12,717
Net income attributable to Cencora, Inc.	$ 1,554,169	$ 1,509,120	$ 1,745,293
Earnings per share:			
Basic	$ 8.02	$ 7.60	$ 8.62
Diluted	$ 7.96	$ 7.53	$ 8.53
Weighted average common shares outstanding:			
Basic	193,820	198,503	202,511
Diluted	195,214	200,284	204,591

See notes to consolidated financial statements.

CENCORA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands)	Fiscal Year Ended September 30, 2025	2024	2023
Net income	$ 1,567,814	$ 1,519,273	$ 1,732,576
Other comprehensive income:			
Foreign currency translation adjustments	91,788	405,099	353,439
Other, net	6,027	(272)	33,395
Total other comprehensive income	97,815	404,827	386,834
Total comprehensive income	1,665,629	1,924,100	2,119,410
Comprehensive (income) loss attributable to noncontrolling interests	(23,720)	(1,491)	54,246
Comprehensive income attributable to Cencora, Inc.	$ 1,641,909	$ 1,922,609	$ 2,173,656

See notes to consolidated financial statements.

CENCORA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

(in thousands, except per share data)	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock	Non-controlling Interests	Total
September 30, 2022	$ 2,927	$ 5,658,733	$ 2,977,646	$ (1,830,970)	$ (7,019,895)	$ 282,832	$ 71,273
Net income (loss)	—	—	1,745,293	—	—	(12,717)	1,732,576
Other comprehensive income (loss)	—	—	—	428,363	—	(41,529)	386,834
Cash dividends, $1.94 per share	—	—	(398,752)	—	—	—	(398,752)
Exercises of stock options	8	61,144	—	—	—	—	61,152
Share-based compensation expense	—	124,624	—	—	—	—	124,624
Purchases of common stock	—	—	—	—	(1,155,929)	—	(1,155,929)
Employee tax withholdings related to restricted share vesting	—	—	—	—	(71,279)	—	(71,279)
Divestiture of business	—	—	—	—	—	(76,957)	(76,957)
Other, net	13	77	—	—	—	(7,345)	(7,255)
September 30, 2023	2,948	5,844,578	4,324,187	(1,402,607)	(8,247,103)	144,284	666,287
Net income	—	—	1,509,120	—	—	10,153	1,519,273
Other comprehensive income (loss)	—	—	—	413,489	—	(8,662)	404,827
Cash dividends, $2.04 per share	—	—	(416,168)	—	—	—	(416,168)
Exercises of stock options	4	37,836	—	—	—	—	37,840
Share-based compensation expense	—	147,998	—	—	—	—	147,998
Purchases of common stock	—	—	—	—	(1,505,232)	—	(1,505,232)
Employee tax withholdings related to restricted share vesting	—	—	—	—	(63,500)	—	(63,500)
Other, net	10	378	—	—	—	(4,971)	(4,583)
September 30, 2024	2,962	6,030,790	5,417,139	(989,118)	(9,815,835)	140,804	786,742
Net income	—	—	1,554,169	—	—	13,645	1,567,814
Other comprehensive income	—	—	—	87,740	—	10,075	97,815
Cash dividends, $2.20 per share	—	—	(437,081)	—	—	—	(437,081)
Exercises of stock options	4	29,129	—	—	—	—	29,133
Share-based compensation expense	—	147,963	—	—	—	—	147,963
Purchases of common stock	—	—	—	—	(438,488)	—	(438,488)
Employee tax withholdings related to restricted share vesting	—	—	—	—	(77,783)	—	(77,783)
Acquisitions	—	—	—	—	—	74,711	74,711
Other, net	8	(3,580)	—	—	—	(169)	(3,741)
September 30, 2025	$ 2,974	$ 6,204,302	$ 6,534,227	$ (901,378)	$ (10,332,106)	$ 239,066	$ 1,747,085

See notes to consolidated financial statements.

CENCORA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)	Fiscal Year Ended September 30, 2025	2024	2023
OPERATING ACTIVITIES			
Net income	$ 1,567,814	$ 1,519,273	$ 1,732,576
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation, including amounts charged to cost of goods sold	501,310	448,200	418,830
Amortization, including amounts charged to interest expense	567,106	670,642	562,018
Provision for credit losses	63,306	40,834	54,389
Provision (benefit) for deferred income taxes	59,864	(102,324)	(118,864)
Share-based compensation expense	147,963	147,998	124,624
LIFO (credit) expense	(76,875)	(52,168)	204,595
Impairment of assets, including goodwill	837,378	418,000	—
Loss (gain) on divestiture of businesses	35,539	—	(40,665)
Turkey highly inflationary impact	55,519	55,309	95,938
Adjustments to RCA equity units (Note 2)	121,666	—	—
Adjustments to contingent consideration (Note 2)	19,550	—	—
(Gain) loss on remeasurement of equity investment	(14,058)	16,201	(242)
Gain on divestiture of equity investment	(12,838)	—	—
Other, net	(33,548)	24,032	3,593
Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures:			
Accounts receivable	(1,923,411)	(2,784,339)	(2,711,786)
Inventories	(1,269,429)	(1,479,599)	(2,183,368)
Prepaid expenses and other assets	173,857	156,672	211,242
Accounts payable	3,693,364	4,968,093	6,103,451
Accrued expenses	(21,131)	148,533	51,112
Income taxes payable and other liabilities	(213,724)	(204,517)	(196,146)
Long-term accrued litigation liability	(404,102)	(506,155)	(399,963)
NET CASH PROVIDED BY OPERATING ACTIVITIES	3,875,120	3,484,685	3,911,334
INVESTING ACTIVITIES			
Capital expenditures	(667,981)	(487,173)	(458,359)
Cost of acquired companies, net of cash acquired	(4,095,630)	(69,771)	(1,409,835)
Cost of equity investments	(196,242)	(30,430)	(743,275)
Non-customer note receivable	(34,814)	(50,000)	—
Other, net	17,374	19,278	9,004
NET CASH USED IN INVESTING ACTIVITIES	(4,977,293)	(618,096)	(2,602,465)
FINANCING ACTIVITIES			
Senior notes and loan borrowings	4,508,482	688,321	157,547
Senior notes and loan repayments	(1,280,615)	(662,525)	(811,353)
Borrowings under revolving and securitization credit facilities	132,134,224	69,703,045	78,218,439
Repayments under revolving and securitization credit facilities	(132,166,423)	(70,114,293)	(78,187,891)
Purchases of common stock	(435,471)	(1,491,367)	(1,180,728)
Exercises of stock options	29,133	37,840	61,152
Cash dividends on common stock	(437,081)	(416,168)	(398,752)
Employee tax withholdings related to restricted share vesting	(77,783)	(63,500)	(71,279)
Other, net	(25,352)	(12,347)	(9,413)
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	2,249,114	(2,330,994)	(2,222,278)
EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	(50,272)	9,396	72,759
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	1,096,669	544,991	(840,650)
Cash, cash equivalents, and restricted cash at beginning of year	3,297,880	2,752,889	3,593,539
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT END OF YEAR	$ 4,394,549	$ 3,297,880	$ 2,752,889

See notes to consolidated financial statements.

CENCORA, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2025

Note 1. Summary of Significant Accounting Policies

Cencora, Inc. and its subsidiaries, including less-than-wholly-owned subsidiaries in which Cencora, Inc. has a controlling financial interest (the "Company"), is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company delivers innovative programs and services designed to improve the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.

Basis of Presentation

The accompanying financial statements present the consolidated financial position, results of operations, and cash flows of the Company as of the dates and for the periods indicated. All significant intercompany accounts and transactions have been eliminated in consolidation.

The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ from these estimated amounts due to uncertainties inherent in such estimates. Management periodically evaluates estimates used in the preparation of the financial statements for continued reasonableness. Certain reclassifications have been made to prior-period amounts to conform to the current year presentation.

Recently Adopted Accounting Pronouncements

In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07")." ASU 2023-07 requires public entities to disclose significant segment expenses on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment's profit or loss that are currently required annually. ASU 2023-07 is effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company adopted ASU 2023-07 and retrospectively reflected segment cost of goods sold and segment operating expenses in Note 14. The adoption of ASU 2023-07 had no impact on the Company's Consolidated Financial Statements.

Recently Issued Accounting Pronouncements Not Yet Adopted

In December 2023, the FASB issued ASU No. 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09")." ASU 2023-09 requires entities to provide additional information in their tax rate reconciliation and additional disclosures about income taxes paid by jurisdiction. ASU 2023-09 is effective for annual reporting periods beginning after December 15, 2024, with early adoption permitted. The guidance should be applied prospectively, but entities have the option to apply it retrospectively for each period presented. The Company is evaluating the impact of adopting this new accounting guidance.

In November 2024, the FASB issued ASU No. 2024-03, "Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03")." ASU 2024-03 requires disaggregated disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. Expense captions should be disaggregated to include expenses related to purchases of inventory, employee compensation, depreciation, and intangible asset amortization. ASU 2024-03 applies to public entities and is effective for annual periods beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The guidance should be applied prospectively with the option for retrospective application. The Company is evaluating the impact of adopting this new accounting guidance.

Business Combinations

The assets acquired and liabilities assumed from an acquired business are recorded at estimated fair value, with the residual of the purchase price recorded as goodwill. The results of operations of an acquired businesses are included in the Company's operating results from the date of acquisition.

Cash, Cash Equivalents, and Restricted Cash

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value.

The Company is required to maintain certain cash deposits with banks mainly consisting of deposits restricted under contractual agency agreements and cash restricted by law and other obligations.

The following represents a reconciliation of cash and cash equivalents in the Consolidated Balance Sheets to cash, cash equivalents, and restricted cash in the Consolidated Statements of Cash Flows:

	September 30,			
(amounts in thousands)	**2025**	**2024**	**2023**	**2022**
Cash and cash equivalents	$ 4,356,138	$ 3,132,648	$ 2,592,051	$ 3,388,189
Restricted cash (included in Prepaid Expenses and Other)	38,411	98,596	97,722	144,980
Restricted cash (included in Other Assets)	—	66,636	63,116	60,370
Cash, cash equivalents, and restricted cash	$ 4,394,549	$ 3,297,880	$ 2,752,889	$ 3,593,539

Concentrations of Credit Risk and Allowance for Credit Losses

The Company has sales to a significant number of customers in the healthcare industry that include institutional and retail healthcare providers. Institutional healthcare providers include acute care hospitals, health systems, mail order pharmacies, long-term care and other alternate care pharmacies and providers of pharmacy services to such facilities, and physician offices. Retail healthcare providers include national and regional retail drugstore chains, independent community pharmacies, pharmacy departments of supermarkets and mass merchandisers, and veterinarians. The financial condition of the Company's customers can be affected by changes in government reimbursement policies as well as by other economic pressures in the healthcare industry.

The Company's trade accounts receivables are exposed to credit risk. Revenue from the various agreements and arrangements with Walgreens and Boots UK Ltd. collectively accounted for approximately 25% of revenue and represented approximately 38% of accounts receivable, net of incentives, as of September 30, 2025. Evernorth Health Services, the Company's second largest customer in fiscal 2025, accounted for approximately 13% of revenue and represented approximately 5% of accounts receivable as of September 30, 2025. The Company generally does not require collateral for trade receivables. The Company evaluates its receivables for risk of loss by grouping its receivables with similar risk characteristics. Expected losses are determined based on a combination of historical loss trends, current economic conditions, and forward-looking risk factors. Changes in these factors, among others, may lead to adjustments in the Company's allowance for credit losses. The calculation of the required allowance requires judgment by Company management as to the impact of those and other factors on the ultimate realization of its trade receivables. The Company performs ongoing credit evaluations of its customers' financial condition and maintains reserves for expected credit losses for specific credit problems when they arise. There were no significant changes to this process during fiscal 2025, 2024, and 2023, and bad debt expense was computed in a consistent manner during these periods.

The Company maintains cash, cash equivalents, and restricted cash with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and, therefore, bear minimal credit risk. The Company seeks to mitigate such risks by monitoring the risk profiles of these counterparties. The Company also seeks to mitigate risk by monitoring the investment strategy of money market accounts in which it is invested, which are classified as cash equivalents.

Contingencies

Loss Contingencies: In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, government investigations, stockholder demands, and other disputes, including antitrust, commercial, data privacy and security, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a reserve for these matters when it is both probable that a loss has been incurred and the amount can be reasonably estimated. The Company also performs an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued. If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, the Company provides disclosure of the loss contingency in the notes to its financial statements. The Company reviews all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made. Among the loss contingencies that the Company considered in accordance with the foregoing in connection with the preparation of the accompanying financial statements were the opioid matters described in Note 12.

Gain Contingencies: The Company records gain contingencies when they are realized. Gains from antitrust litigation settlements are realized upon the receipt of cash and recorded as a reduction to cost of goods sold because they represent a recovery of amounts historically paid to manufacturers to originally acquire the pharmaceuticals that were the subject of the antitrust litigation settlements (see Note 13).

Derivative Financial Instruments and Nonderivative Hedges

The Company utilizes derivative financial instruments to manage exposures to foreign currency. The Company records all derivative financial instruments on the balance sheet at fair value and complies with established criteria for designation and effectiveness of hedging relationships. The Company's policy prohibits it from entering into derivative financial instruments for speculative or trading purposes.

The Company uses foreign currency denominated debt held at the parent level to offset a portion of its foreign currency exchange rate exposure on its net investments in Euro-denominated subsidiaries. The Company's €1.0 billion of senior notes (Note 6**)** are designated as nonderivative hedging instruments that are remeasured each reporting period to reflect changes in the foreign currency exchange spot rate, with changes since the last remeasurement date recorded as foreign currency translation adjustments as a component of other comprehensive income/loss. The Company recorded losses on its nonderivative hedges of $55.3 million in Foreign Currency Translation Adjustments in the Consolidated Statement of Comprehensive Income in fiscal 2025.

Foreign Currency

When the functional currency of the Company's foreign operations is the applicable local currency, assets and liabilities are translated into U.S. dollars using the current exchange rates in effect at the balance sheet date, while revenues and expenses are translated at the weighted average exchange rates for the period. The resulting asset and liability translation adjustments are recorded as a component of Accumulated Other Comprehensive Loss within Stockholders' Equity.

During the quarter ended March 31, 2022, Turkey became a highly inflationary economy, as defined under GAAP. As a result, effective April 1, 2022, and until such time as the applicable economy is no longer considered highly inflationary, Turkish Lira-denominated assets and liabilities are remeasured using the Company's reporting currency in accordance with Accounting Standards Codification ("ASC") 830, "Foreign Currency Matters." Turkish Lira denominated monetary assets and liabilities (primarily cash, accounts receivables, and accounts payables) are remeasured at each balance sheet date using the currency exchange rate then in effect, with currency remeasurement gains and losses recognized in Other Income in the Statement of Operations. Turkish Lira-denominated nonmonetary assets and liabilities (primarily inventories, goodwill, and other intangible assets) are translated at the currency exchange rate in effect prior to highly inflation accounting commencement or at the exchange rate in effect at their date of acquisition if subsequent to April 1, 2022. As such, nonmonetary assets and liabilities retain a higher historical basis when currencies are devalued. This higher historical basis results in incremental expense being recognized when nonmonetary assets are consumed (i.e., sale of inventory). During fiscal 2025, 2024, and 2023, the Company recorded incremental expenses of $49.6 million, $54.1 million, and $87.0 million, respectively, in Cost of Goods Sold related to the consumption of inventory and expenses of $5.9 million, $1.2 million, and $9.0 million, respectively, within Other Loss (Income), Net related to the currency remeasurement of monetary assets and liabilities.

Goodwill and Other Intangible Assets

Goodwill arises from acquisitions or consolidations of specific operating companies and is assigned to the reporting unit in which a particular operating company resides. The Company identifies its reporting units based upon the Company's management reporting structure, beginning with its operating segments. The Company evaluates whether the components within its operating segments have similar economic characteristics, which include the similarity of long-term gross margins, the nature of the components' products, services, and production processes, the types of customers and the methods by which products or services are delivered to customers, and the components' regulatory environment and aggregates two or more components within an operating segment that have similar economic characteristics. As of September 30, 2025, the Company's reporting units included U.S. Pharmaceutical Distribution Services, U.S. Consulting Services, MWI Animal Health, Alliance Healthcare, Innomar, World Courier, PharmaLex, and Profarma.

Goodwill and other intangible assets with indefinite lives, such as certain trademarks and trade names, are not amortized; rather, they are tested for impairment at least annually. For the purpose of these impairment tests, the Company can elect to perform a qualitative assessment to determine if it is more likely than not that the fair values of its reporting units and indefinite-lived intangible assets are less than the respective carrying values of those reporting units and indefinite-lived intangible assets, respectively. Such qualitative factors can include, among others, industry and market conditions, overall financial performance, and relevant entity-specific events. If the Company concludes based on its qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, it performs a quantitative analysis. The Company elected to perform quantitative impairment assessments of goodwill for all its reporting units in fiscal 2025, 2024, and 2023 with the exception of its PharmaLex reporting unit in fiscal 2023 since it was acquired in fiscal 2023. The Company elected to perform qualitative impairment assessments of indefinite-lived intangible assets in fiscal 2025, 2024, and 2023.

The quantitative goodwill impairment test requires the Company to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit. If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized. If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.

When performing a quantitative impairment assessment, the Company utilizes an income approach or a weighted average of an income and market approach to value its reporting units. The income approach relies on a discounted cash flow analysis, which considers forecasted cash flows discounted at an appropriate discount rate, to determine the fair value of each reporting unit. The Company generally believes that market participants would use a discounted cash flow analysis to determine the fair value of the Company's reporting units in a sale transaction. The annual goodwill impairment test requires the Company to make several assumptions and estimates concerning future levels of revenue growth, earnings before interest, taxes, depreciation and amortization ("EBITDA"), EBITDA margins, capital expenditures, and working capital requirements, which are based upon the Company's long-range plan. The discount rate is an estimate of the overall after-tax rate of return required by a market participant whose weighted average cost of capital includes both debt and equity, including a risk premium. While the Company uses the best available information to prepare its forecasted cash flows and discount rate assumptions, actual future cash flows and/or market conditions could differ significantly resulting in future impairment charges related to recorded goodwill balances. While there are always changes in assumptions to reflect changing business and market conditions, the Company's overall methodology and the population of assumptions used have remained unchanged.

The Company completed its required annual impairment assessments relating to goodwill and indefinite-lived intangible assets in fiscal 2025, 2024, and 2023 and, as a result, recorded goodwill impairments (see Note 5**)** of $723.9 million and $418.0 million in its PharmaLex reporting unit in fiscal 2025 and 2024, respectively. No goodwill impairments were recorded in fiscal 2023 and no indefinite-lived intangible asset impairments were recorded in fiscal 2025, 2024, or 2023.

Finite-lived intangible assets are amortized using the straight-line method over the estimated useful lives of the assets. The Company performs a recoverability assessment of its long-lived assets when impairment indicators are present. The Company performed a recoverability assessment of PharmaLex's long-lived asset group as of July 1, 2025, and it was determined to be recoverable.

Income Taxes

The Company accounts for income taxes using a method that requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company's assets and liabilities (commonly known as the asset and liability method). In assessing the need to establish a valuation allowance on deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.

The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including settlements with tax authorities or resolutions of any related appeals or litigation processes, based upon the technical merits of the position. Tax benefits associated with uncertain tax positions that have met the recognition criteria are measured and recorded based upon the highest probable outcome that is more than 50% likely to be realized after full disclosure and resolution of a tax examination.

Inventories

Inventories are stated at the lower of cost or market. Cost for approximately 63% and 65% of the Company's inventories as of September 30, 2025 and 2024, respectively, has been determined using the last-in, first-out ("LIFO") method. If the Company had used the first-in, first-out method of inventory valuation, which approximates current replacement cost, inventories would have been approximately $1,458.9 million and $1,535.8 million higher than the amounts reported as of September 30, 2025 and 2024, respectively. The Company recorded LIFO credits of $76.9 million and $52.2 million in fiscal 2025 and 2024, respectively, and LIFO expense of $204.6 million in fiscal 2023. The annual LIFO provision is affected by manufacturer pricing practices, which may be impacted by market and other external influences, changes in inventory quantities, and product mix, many of which are difficult to predict. Changes to any of the above factors can have a material impact on the Company's annual LIFO provision. Cost for the Company's inventory that is not determined using the LIFO method is stated at the lower of cost or market using the first-in, first-out method or moving average price method.

Investments

The Company first evaluates its investments in accordance with the variable interest model to determine whether it has a controlling financial interest in an investment. This evaluation is made as of the date on which the Company makes its initial investment, and subsequent evaluations are made if the structure of the investment changes. If it has determined that an investment is a variable interest entity ("VIE"), the Company evaluates whether the VIE is required to be consolidated. When the Company holds rights that give it the power to direct the activities of an entity that most significantly impact the entity's economic performance, combined with the obligation to absorb an entity's losses and the right to receive benefits, the Company consolidates a VIE. If it is determined that an investment is not a VIE, the Company then evaluates its investments under the voting interest model and generally consolidates investments in which it holds an ownership interest of greater than 50%. When the Company consolidates less-than-wholly-owned subsidiaries, it records its noncontrolling interest in its consolidated financial statements.

For equity securities without a readily determinable fair value, the Company uses the fair value measurement alternative and measures the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer. For investments in which the Company can exercise significant influence but does not control, it uses the equity method of accounting. The Company's share of earnings and losses of its investments is recorded in Other Loss (Income), Net in the Consolidated Statements of Operations. The Company monitors its investments for impairment by considering factors such as the operating performance of the investment and current economic and market conditions. In fiscal 2025, the Company recorded a $113.5 million impairment of an equity investment that was made in fiscal 2021 in Other Loss (Income), Net in its Consolidated Statement of Operations.

Leases

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the facts and circumstances present. Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. At the lease commencement date, operating and finance lease liabilities and their corresponding right-of-use ("ROU") assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable and, as such, the Company uses its incremental borrowing rate to discount the lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term in a similar economic environment. Certain adjustments to the ROU asset may be required for items such as incentives received. The Company does not recognize on the balance sheet leases with terms of one year or less.

The Company has operating leases that are primarily comprised of buildings, office equipment, distribution center equipment, and vehicles. Some of the Company's leases include options to extend or early terminate the lease, which are included in the lease term when it is reasonably certain to exercise and there is a significant economic incentive to exercise that option. Certain lease agreements contain provisions for future rent increases. Lease payments included in the measurement of the lease liability comprise fixed payments. The Company combines lease and non-lease components as a single component. Operating lease cost is recognized over the expected lease term on a straight-line basis and is recorded in Distribution, Selling, and Administrative in the Company's Consolidated Statements of Operations. Variable lease payments, which are primarily comprised of maintenance, taxes, and other payments based on usage, are recognized when the expense is incurred. The Company's leases do not contain residual value guarantees.

Manufacturer Incentives

The Company considers fees and other incentives received from its suppliers relating to the purchase and distribution of inventory to represent product discounts, and, as a result, they are recognized within cost of goods sold upon the sale of the related inventory.

Property and Equipment

Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 40 years for buildings and improvements and from 3 to 10 years for machinery, equipment, and other. The costs of repairs and maintenance are charged to expense as incurred.

The Company capitalizes project costs relating to computer software developed or obtained for internal use when the activities related to the project reach the application development stage. Costs that are associated with preliminary stage activities, training, maintenance, and all other post-implementation stage activities are expensed as they are incurred. Software development costs are depreciated using the straight-line method over the estimated useful lives, which range from 3 to 10 years.

The following table summarizes the Company's property and equipment balances for the periods indicated:

	September 30,	
(in thousands)	**2025**	**2024**
Property and equipment, at cost:		
Land	$ 124,999	$ 117,128
Buildings and improvements	1,128,433	893,694
Machinery, equipment, and other	4,479,886	4,204,268
Total property and equipment	5,733,318	5,215,090
Less accumulated depreciation	(3,194,242)	(3,033,680)
Property and equipment, net	$ 2,539,076	$ 2,181,410

Revenue Recognition

The Company's revenues are primarily generated from the distribution of pharmaceutical products. The Company also generates revenues from global commercialization services, which include clinical trial support, post-approval and commercialization support, and global specialty transportation and logistics for the biopharmaceutical industry. See Note 14 for the Company's disaggregated revenue.

The Company recognizes revenue related to the distribution of products at a point in time when title and control transfers to customers and there is no further obligation to provide services related to such products. Service revenue is recognized over the period that services are provided to the customer. The Company is generally the principal in a transaction; therefore, revenue is primarily recorded on a gross basis. When the Company is the principal in a transaction, it has determined that it controls the ability to direct the use of the product or service prior to the transfer to a customer, it is primarily responsible for fulfilling the promise to provide the product or service to its customer, it has discretion in establishing pricing, and it controls the relationship with the customer. Revenue is recognized at the amount of consideration expected to be received. For the distribution business, revenue is primarily generated from a contract related to a confirmed purchase order with a customer in a distribution arrangement and is net of estimated sales returns and allowances, other customer incentives, and sales tax.

When the Company is the agent in a transaction, the fee received from a manufacturer customer is recognized within revenue as the service is performed.

The Company's customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit. The Company records an accrual for estimated customer sales returns at the time of sale to the customer based upon historical return trends. As of September 30, 2025 and 2024, the Company's accrual for estimated customer sales returns was $1,625.8 million and $1,175.9 million, respectively.

Share-Based Compensation

The Company accounts for the compensation cost of all share-based payments at fair value. The fair value of restricted stock units and performance stock units is based upon the grant date market price of the Company's common stock.

Share-based compensation expense is recognized over the requisite service period within Distribution, Selling, and Administrative in the Consolidated Statements of Operations to correspond with the same line item as the cash compensation paid to employees. Compensation expense associated with nonvested performance stock units is dependent upon the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued.

The income tax effects of awards are recognized when the awards vest or are settled and are recognized in Income Tax Expense in the Company's Consolidated Statements of Operations.

Shipping and Handling Costs

Shipping and handling costs include all costs to warehouse, pick, pack, and deliver inventory to customers. These costs, which were $1,294.4 million, $1,265.7 million, and $1,200.0 million for fiscal 2025, 2024, and 2023, respectively, are included in Distribution, Selling, and Administrative in the Company's Consolidated Statements of Operations.

Supplier Reserves

The Company establishes reserves against amounts due from its suppliers relating to various price and rebate incentives, including deductions or billings taken against payments otherwise due to them from the Company. These reserve estimates are established based upon the judgment of Company management after carefully considering the status of current outstanding claims, historical experience with the suppliers, the specific incentive programs, and any other pertinent information available to the Company. The Company evaluates the amounts due from its suppliers on a continual basis and adjusts the reserve estimates when appropriate based upon changes in circumstances. The ultimate outcome of any outstanding claim may be different than the Company's estimate.

Note 2. Acquisitions and Equity Method Investment

RCA Acquisition

On January 2, 2025, the Company acquired an 85% interest in Retina Consultants of America ("RCA") for $4,042.0 million in cash, $694.4 million of contingent consideration related to equity units for certain RCA physicians and members of management that retained the remaining 15% interest in RCA, $545.7 million for the settlement of a net receivable resulting from a pre-existing commercial relationship between the Company and RCA, and $393.1 million for contingent consideration payable to the sellers associated with RCA's achievement of certain predefined business objectives in fiscal 2027 and fiscal 2028. The Company funded the cash purchase price through a combination of cash on hand and new debt financing (see Note 6). The Company believes the acquisition of RCA allows it to broaden its relationships with community providers and to build on its leadership in specialty pharmaceuticals within its U.S. Healthcare Solutions reportable segment.

As part of the acquisition, certain RCA physicians and members of management retained equity in RCA. The Company evaluated the equity unit arrangements to determine if the contingent payments were part of the purchase price or post-acquisition compensation expense, which would be recognized over any future service period. The $694.4 million of contingent consideration for the retained equity units was concluded to be a part of the purchase price and initially recorded at its fair value at the time of the acquisition based on the unit price that the Company paid to acquire RCA times the number of equity units retained by RCA physicians and members of management, and represents a Level 3 fair value measurement. The equity units retained by RCA physicians have an embedded option feature that is a liability classified compensation arrangement and is being expensed ratably over a period of 1.5 years. The fair value of the embedded option feature was determined using a Black-Scholes model that included assumptions for the equity unit value, expected life, and volatility and represents a Level 3 fair value measurement. During fiscal 2025, the Company recognized an expense of $121.7 million related to this embedded option feature and other incentive units granted in conjunction with the acquisition of RCA in Acquisition-Related Deal and Integration Expenses in its Consolidated Statement of Operations. The liability and associated future expenses may vary based on the change in the estimated fair value and payments made. The Company's estimated liability related to the equity units is $815.2 million and is recorded in Other Liabilities on the Company's Consolidated Balance Sheet, as of September 30, 2025.

The $393.1 million of contingent consideration represented an initial estimate for RCA's achievement of certain predefined business objectives in fiscal 2027 and fiscal 2028 and provides for the potential payment to the sellers of up to $500 million in the aggregate. The fair value of this liability was determined based on a weighted probability of the achievement of these objectives and represents a Level 3 fair value measurement. During the fourth quarter of fiscal 2025, the Company increased the estimated fair value of the liability related to the achievement of the predetermined business objectives from the initial estimated value and recorded an expense of $19.6 million in Acquisition-Related Deal and Integration Expenses in its Consolidated Statement of Operations. The Company's estimated liability related to the achievement of the predetermined business objectives is $412.6 million and is recorded in Other Liabilities on the Company's Consolidated Balance Sheet, as of September 30, 2025.

The purchase price has been preliminarily allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values at the date of the acquisition in the table that follows. The allocation as of September 30, 2025 is pending the finalization of working capital and tax account balances. There can be no assurance that the estimated amounts recorded will represent the final purchase price allocation.

(in thousands)		
Consideration		
Cash	$	4,042,007
Total estimated contingent consideration		1,087,450
Settlement of a net receivable resulting from a pre-existing commercial relationship		545,738
Estimated fair value of total consideration	$	5,675,195
Recognized amounts of identifiable assets acquired and liabilities assumed		
Cash and cash equivalents	$	143,312
Accounts receivable		450,744
Inventories		110,564
Prepaid expenses and other		12,866
Property and equipment		173,098
Goodwill		4,774,338
Other intangible assets		178,000
Deferred income taxes		46,380
Other assets		182,307
Total assets acquired	$	6,071,609
Accounts payable	$	72,385
Accrued expenses and other		163,272
Accrued income taxes		4,258
Other liabilities		156,164
Total liabilities assumed	$	396,079
Net assets acquired	$	5,675,530
Total estimated contingent consideration		(1,087,450)
Settlement of a net receivable resulting from a pre-existing commercial relationship		(545,738)
Noncontrolling interest		(335)
Total cash paid		4,042,007
Cash acquired		(143,312)
Net cash paid	$	3,898,695

The estimated fair value of the trade name acquired is $178.0 million and the estimated useful life is 15 years.

Goodwill reflects the intangible assets that do not qualify for separate recognition. Approximately $1,071 million of goodwill resulting from this acquisition is expected to be deductible for income tax purposes.

The Company incurred $65.1 million of acquisition-related costs in connection with this acquisition. These costs are included in Acquisition-Related Deal and Integration Expenses in the Company's Consolidated Statements of Operations.

The Company's consolidated results of operations since the acquisition date include RCA revenue of $2.1 billion. RCA's results of operations are included in the U.S. Healthcare Solutions reportable segment within the Company's business segment information (see Note 14).

Investment in OneOncology

In June 2023, the Company and TPG, a global alternative asset management firm, acquired OneOncology, LLC ("OneOncology"), a network of leading oncology practices. Including all direct transaction costs, the Company invested $718.4 million (representing 34.9%) in a joint venture formed to acquire OneOncology for approximately $2.1 billion, and TPG acquired the majority interest in the joint venture. The Company accounts for its interest in the joint venture as an equity method investment, which is included in Other Assets on its Consolidated Balance Sheet.

The Company and TPG Inc. ("TPG") are party to a series of put and call options governing the remaining interests in the joint venture, including TPG's interest. The Company owns a call option that, on the date that is the third anniversary of the closing, allows it to purchase the remaining interests in the joint venture at the greater of 19 times OneOncology's adjusted earnings before interest, taxes, depreciation and amortization for the most recently ended 12-month period ("OneOncology EBITDA") or 2.5 times a Multiple on Invested Capital, all of which is subject to various adjustments and qualifications. TPG owns a put option that, beginning on the third anniversary of the closing and ending on the day before the fourth anniversary of the closing, allows it to require the Company to purchase the remaining interests in the joint venture at a price equal to 19 times OneOncology EBITDA, subject to various adjustments and qualifications. The Company owns a call option that, beginning on the fourth anniversary of the closing and ending on the day before the fifth anniversary of the closing, allows it to purchase the remaining interests in the joint venture, also at a price equal to 19 times OneOncology EBITDA. The fair value of the net put option, which is a Level 3 fair value measurement, was determined using a Monte Carlo simulation, which relies on assumptions, including cash flow projections, risk-free rates, volatility, and details specific to the put and call options. The Company recorded the net fair value of the net put option of $872.9 million, which is recorded within Other Liabilities with a corresponding offset in Other Assets in the Company's Consolidated Balance Sheets. Given the Company has elected to not mark the net put option to market, the fair value of the net put option at the time of the investment will remain on the balance sheet until its final resolution.

Upon the joint venture's acquisition of OneOncology, it was determined that there was a $625.2 million difference between the carrying value of the Company's investment in OneOncology and its underlying equity in net assets, which has been allocated to intangible assets of $305.6 million, a related deferred tax liability of $20.5 million, and goodwill of $340.0 million. The intangible assets and related deferred tax liability are being amortized over a weighted-average life of 23 years.

PharmaLex Acquisition

The Company acquired and assumed control of PharmaLex Holding GmbH ("PharmaLex") effective January 1, 2023 for $1.473 billion, subject to customary adjustments, including a $29.3 million cash holdback. PharmaLex is a component of the Company's International Healthcare Solutions reportable segment.

The Company completed the purchase price allocations as of December 31, 2023. The purchase price was allocated to the underlying assets acquired, including $37.4 million of cash and cash equivalents, and liabilities assumed based upon their estimated fair values as of the date of the acquisition.

The purchase price exceeded the estimated fair value of the net tangible and intangible assets acquired by $1,010.2 million, which was allocated to goodwill. Goodwill resulting from this acquisition is not deductible for income tax purposes.

The estimated fair value of the intangible assets acquired of $558.9 million, and the estimated useful lives are as follows:

(in thousands, except useful lives)		Fair Value	Useful Lives
Customer relationships	$	522,634	12
Trade names		30,931	5
Software technology		5,333	6
Total	$	558,898	

The Company established an estimated deferred tax liability of $146.0 million primarily in connection with the intangible assets acquired.

Note 3. Variable Interest Entity

The Company has substantial governance rights that allow it to direct the activities that significantly impact Profarma's economic performance. As such, the Company consolidates the operating results of Profarma in its consolidated financial statements. The Company is not obligated to provide future financial support to Profarma.

The following assets and liabilities of Profarma are included in the Company's Consolidated Balance Sheet for the periods indicated:

	September 30,	
(in thousands)	**2025**	**2024**
Cash and cash equivalents	$ 70,796	$ 58,082
Accounts receivables, net	260,759	236,930
Inventories	303,480	259,299
Prepaid expenses and other	55,981	68,612
Property and equipment, net	65,410	49,869
Other intangible assets	53,861	58,116
Other long-term assets	99,519	83,765
Total assets	$ 909,806	$ 814,673
Accounts payable	$ 349,876	$ 307,201
Accrued expenses and other	71,383	56,597
Short-term debt	116,361	76,308
Long-term debt	65,390	91,246
Deferred income taxes	11,986	19,227
Other long-term liabilities	75,132	61,690
Total liabilities	$ 690,128	$ 612,269

Profarma's assets can only be used to settle its obligations, and its creditors do not have recourse to the general credit of the Company.

Note 4. Income Taxes

Income Before Income Taxes

The following table summarizes the Company's income before income taxes for the periods indicated:

(in thousands)	Fiscal Year Ended September 30, 2025	2024	2023
Domestic	$ 1,611,725	$ 1,288,983	$ 1,418,457
Foreign	646,611	714,992	742,379
Total	$ 2,258,336	$ 2,003,975	$ 2,160,836

Income Tax Expense

The components of the Company's consolidated income tax expense are summarized in the following table for the periods indicated:

(in thousands)	Fiscal Year Ended September 30, 2025	2024	2023
Current provision:			
Federal	$ 331,272	$ 309,380	$ 259,126
State and local	99,084	80,040	42,933
Foreign	200,302	197,606	245,065
Total current provision	630,658	587,026	547,124
Deferred provision (benefit):			
Federal	57,967	(17,934)	(15,600)
State and local	24,335	1,392	19,445
Foreign	(22,438)	(85,782)	(122,709)
Total deferred provision (benefit)	59,864	(102,324)	(118,864)
Income tax expense	$ 690,522	$ 484,702	$ 428,260

Tax Rate Reconciliation

A reconciliation of the statutory U.S. federal income tax rate to the Company's consolidated effective income tax rate is as follows for the periods indicated:

	Fiscal Year Ended September 30, 2025	2024	2023
Statutory U.S. federal income tax rate	21.0%	21.0%	21.0%
State and local income tax rate, net of federal tax benefit	3.4	3.0	2.3
Tax effect of foreign operations	(2.7)	(2.4)	(2.3)
Foreign-derived intangible income	(4.0)	(0.5)	(0.1)
Unrecognized tax benefits	3.4	0.9	(0.4)
Impairment of assets, including goodwill	8.2	4.9	—
RCA contingent consideration adjustments	1.3	—	—
Change in valuation allowance	0.2	(4.2)	0.1
Other, net	(0.2)	1.5	(0.8)
Effective income tax rate	30.6%	24.2%	19.8%

Deferred Tax Liabilities and Assets

Deferred income taxes reflect the future tax consequences of differences between the tax bases of assets and liabilities and their financial reporting amounts. Significant components of the Company's deferred tax liabilities (assets) are as follows:

	September 30,	
(in thousands)	**2025**	**2024**
Inventories	$ 1,578,513	$ 1,537,057
Property and equipment	109,649	103,959
Goodwill and other intangible assets	1,081,544	1,143,962
Right-of-use assets	384,884	285,434
Other	37,266	31,416
Gross deferred tax liabilities	3,191,856	3,101,828
Net operating loss carryforwards and other tax attributes	(623,370)	(530,024)
Allowance for credit losses	(25,670)	(18,949)
Accrued expenses	(17,047)	(9,419)
Accrued litigation liability	(771,912)	(855,962)
Employee and retiree benefits	(31,466)	(26,960)
Goodwill and other intangible assets	(379,401)	(401,822)
Lease liabilities	(416,718)	(312,357)
Share-based compensation	(27,247)	(23,161)
Other	(149,001)	(128,136)
Gross deferred tax assets	(2,441,832)	(2,306,790)
Valuation allowance for deferred tax assets	661,890	602,361
Deferred tax assets, net of valuation allowance	(1,779,942)	(1,704,429)
Net deferred tax liabilities	$ 1,411,914	$ 1,397,399

As of September 30, 2025, the Company had $168.2 million of potential tax benefits from federal and state net operating loss and other tax attribute carryforwards and $491.6 million of potential tax benefits from foreign loss carryforwards, both of which have varying expiration dates. The Company had $1.5 million of federal tax credit carryforwards, $1.0 million of state tax credit carryforwards, and $3.1 million of foreign alternative minimum tax credit carryforwards.

The Company assesses the available positive and negative evidence to determine whether deferred tax assets are more likely than not to be realized. As a result of this assessment, valuation allowances have been recorded on certain deferred tax assets. For fiscal 2025, the Company increased the valuation allowance on deferred tax assets by $59.5 million primarily due to the change in the valuation allowance against foreign net operating loss carryforwards. For fiscal 2024, the Company decreased the valuation allowance on deferred tax assets by $35.0 million primarily due to the increase in the valuation allowance against tax deductible goodwill.

In fiscal 2025, 2024, and 2023, tax benefits of $16.0 million, $15.0 million, and $24.6 million, respectively, related to the exercise of employee stock options and lapses of restricted stock units were recorded in Income Tax Expense in the Company's Consolidated Statements of Operations. The tax benefits recognized in fiscal 2025, 2024, and 2023 are not necessarily indicative of amounts that may arise in future periods.

Income tax payments, net of refunds, were $571.2 million, $603.9 million, and $463.1 million in fiscal 2025, 2024, and 2023, respectively.

Cumulative undistributed earnings of international subsidiaries were $4.3 billion as of September 30, 2025, $2.3 billion of which is considered permanently reinvested. It is not practicable to estimate the taxes that would be due if such earnings were to be repatriated in the future.

The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various states and foreign jurisdictions. The Company is currently undergoing certain state and local income tax audits for various years. With few exceptions, the Company is no longer subject to U.S. federal, state and local, or foreign income tax examinations by tax authorities for years before 2020. The Company believes it has adequate tax reserves to cover potential federal, state or foreign tax exposures.

Unrecognized Tax Benefits

As of September 30, 2025 and 2024, the Company had unrecognized tax benefits, defined as the aggregate tax effect of differences between tax return positions and the benefits recognized in the Company's financial statements, of $640.5 million and $545.0 million, respectively ($583.8 million and $498.0 million, net of federal tax benefit, respectively). If recognized in fiscal 2025 and 2024, $574.0 million and $488.1 million, respectively, of these benefits would have reduced income tax expense and the effective tax rate. As of September 30, 2025 and 2024, included in the unrecognized tax benefits are $72.3 million and $43.9 million of interest and penalties, respectively, which the Company records in Income Tax Expense in the Company's Consolidated Statements of Operations.

A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, for the periods indicated is as follows:

	Fiscal Year Ended September 30,		
(in thousands)	**2025**	**2024**	**2023**
Unrecognized tax benefits at beginning of period	$ 501,064	$ 525,933	$ 526,522
Additions to tax positions of the current year	41,433	13,636	22,646
Additions to tax positions of the prior years	37,611	—	11,875
Reductions of tax positions of the prior years	—	(37,520)	(31,110)
Settlements and expiration of statutes of limitations	(12,406)	(2,410)	(3,457)
Effects of foreign currency translation	457	1,425	(543)
Unrecognized tax benefits at end of period	$ 568,159	$ 501,064	$ 525,933

During the next 12 months, the Company does not anticipate any material change in unrecognized tax benefits due to tax audit resolutions and the expiration of statutes of limitations.

A significant portion of the Company's unrecognized tax benefits as of September 30, 2025 relates to the legal accrual for litigation related to the Distributor Settlement Agreement, as well as other opioid-related litigation, as disclosed in Note 12. The Company has applied significant judgment in estimating the amount of the opioid settlements that will be deductible for U.S. federal and state purposes. In estimating the amount that would be deductible, the Company considered prior U.S. tax case law, the amount and character of the damages sought in litigation, and other relevant factors.

Note 5. Goodwill and Other Intangible Assets

The following is a summary of the changes in the carrying value of goodwill, by reportable segment, for fiscal 2025 and 2024:

(in thousands)	**U.S. Healthcare Solutions**	**International Healthcare Solutions**	**Total**
Goodwill as of September 30, 2023	$ 6,205,774	$ 3,368,343	$ 9,574,117
Purchase accounting adjustments	—	(12,904)	(12,904)
Goodwill recognized in connection with acquisitions	—	18,712	18,712
Goodwill impairment	—	(418,000)	(418,000)
Foreign currency translation	2,748	153,354	156,102
Goodwill as of September 30, 2024	6,208,522	3,109,505	9,318,027
Goodwill recognized in connection with acquisitions	4,896,085	123,112	5,019,197
Goodwill impairment	—	(723,884)	(723,884)
Foreign currency translation	383	62,797	63,180
Goodwill as of September 30, 2025	$ 11,104,990	$ 2,571,530	$ 13,676,520

The Company continued to experience weakening demand for specialized services in the life sciences industry, which has negatively impacted the operating results of PharmaLex. In the fourth quarter of fiscal 2025 and in connection with the Company's annual budgeting process, the Company revised PharmaLex's long-range forecast. In connection with the Company's annual goodwill impairment assessment, it recorded a full impairment of the remaining goodwill of $723.9 million in the PharmaLex reporting unit. The fair value of the reporting unit was determined based on a weighted average of income and market approaches. The income approach includes the Company's forecasted cash flows in its long-range plan as well as discount rate and income tax rate assumptions. This represents a Level 3 nonrecurring fair value measurement. The Company believes that its assumptions are representative of market participant assumptions; however, the forecasted cash flows used to estimate fair value and measure the related impairment are inherently uncertain and include assumptions that could differ from actual results in future periods.

The carrying values of goodwill as of September 30, 2025 and 2024 are net of the following accumulated impairments:

(in thousands)	U.S. Healthcare Solutions	International Healthcare Solutions
Accumulated impairment losses as of September 30, 2025	$ —	$ 1,217,820
Accumulated impairment losses as of September 30, 2024	$ —	$ 493,936

The Company performed a recoverability assessment of PharmaLex's long-lived assets as of July 1, 2025 using its revised long-range forecast. The recoverability assessment compared PharmaLex's undiscounted cash flows to the carrying value of the PharmaLex asset group, including goodwill, and it was determined to be recoverable.

The following is a summary of other intangible assets:

		September 30, 2025			September 30, 2024		
(dollars in thousands)	Weighted Average Remaining Useful Life	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
Indefinite-lived trade name		$ 17,000	$ —	$ 17,000	$ 17,000	$ —	$ 17,000
Finite-lived:							
Customer relationships	12 years	5,250,912	(1,860,484)	3,390,428	5,090,864	(1,536,081)	3,554,783
Trade names and other	11 years	1,457,176	(1,090,423)	366,753	1,259,954	(830,691)	429,263
Total other intangible assets		$ 6,725,088	$ (2,950,907)	$ 3,774,181	$ 6,367,818	$ (2,366,772)	$ 4,001,046

Amortization expense for finite-lived intangible assets was $556.9 million, $663.5 million, and $553.6 million in fiscal 2025, 2024, and 2023, respectively. Amortization expense for finite-lived intangible assets is estimated to be $401.0 million in fiscal 2026, $341.9 million in fiscal 2027, $330.0 million in fiscal 2028, $314.9 million in fiscal 2029, $294.1 million in fiscal 2030, and $2,075.3 million thereafter.

Note 6. Debt

Debt consisted of the following:

(in thousands)	September 30, 2025	2024
Multi-currency revolving credit facility due in 2030	$ —	$ —
Receivables securitization facility due in 2028	—	—
Term loan due in 2027	799,043	—
Money market facility due in 2027	—	—
Working capital credit facility due in 2026	—	—
$500,000, 3.250% senior notes due 2025	—	499,738
$750,000, 3.450% senior notes due 2027	748,150	747,308
$500,000, 4.625% senior notes due 2027	497,309	—
€500,000, 2.875% senior notes due 2028	583,903	—
$600,000, 4.850% senior notes due 2029	596,603	—
$500,000, 2.800% senior notes due 2030	497,174	496,564
$1,000,000, 2.700% senior notes due 2031	993,838	992,718
€500,000, 3.625% senior notes due 2032	581,685	—
$500,000, 5.125% senior notes due 2034	495,104	494,514
$700,000, 5.150% senior notes due 2035	694,909	—
$500,000, 4.250% senior notes due 2045	495,792	495,574
$500,000, 4.300% senior notes due 2047	494,088	493,821
Alliance Healthcare debt	1,424	286
Nonrecourse debt	181,751	167,553
Total debt	7,660,773	4,388,076
Less current portion of senior notes	—	499,738
Less Alliance Healthcare current portion	1,424	286
Less nonrecourse current portion	116,361	76,307
Long-term debt	$ 7,542,988	$ 3,811,745

Multi-Currency Revolving Credit Facility

The Company had a $2.4 billion multi-currency senior unsecured revolving credit facility (“Multi-Currency Revolving Credit Facility”) with a syndicate of lenders, which was scheduled to expire in October 2029. In June 2025, the Company amended and restated the Multi-Currency Revolving Credit Facility to extend the expiration to June 2030 and increase the aggregate amount of the commitments under this facility to $4.5 billion. Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based upon the Company’s debt rating. The Company pays facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based on its debt rating. The Company may choose to repay or reduce its commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which the Company was compliant as of September 30, 2025. There were no borrowings outstanding under the Multi-Currency Revolving Credit Facility as of September 30, 2025 and 2024.

Commercial Paper Program

The Company had a $3.4 billion commercial paper program. In September 2025, the Company increased its commercial paper program to $4.5 billion. The commercial paper program does not increase the Company’s borrowing capacity, and it is fully backed by its Multi-Currency Revolving Credit Facility. The Company may, from time to time, issue short-term promissory notes in an aggregate amount of up to $4.5 billion at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary but may not exceed 365 days from the date of issuance. The notes will bear interest, if interest bearing, or will be sold at a discount from their face amounts. There were no borrowings outstanding under the commercial paper program as of September 30, 2025 and 2024.

364-Day Revolving Credit Facility

In November 2024, the Company entered into an agreement pursuant to which it obtained a $1.0 billion senior unsecured revolving credit facility (the "364-Day Revolving Credit Facility") with a syndicate of lenders, which was scheduled to expire 364 days after the January 2, 2025 closing of the RCA acquisition, the date on which borrowings under this facility became available to the Company. In June 2025, in conjunction with the amendment to the Multi-Currency Revolving Credit Facility, the Company terminated the 364-Day Revolving Credit Facility.

Receivables Securitization Facility

The Company had a $1.45 billion receivables securitization facility ("Receivables Securitization Facility"), which was scheduled to expire in October 2027. In June 2025, the Company amended the Receivables Securitization Facility to extend the expiration to June 2028, increase the size of the facility to $1.5 billion, and increase its accordion feature to $500 million from $250 million. This accordion feature allows the Company to increase the commitment on the Receivables Securitization Facility up to $500 million, subject to lender approval. Interest rates are based on prevailing market rates for short-term commercial paper or 30-day Term SOFR, plus a program fee. The Company pays a customary unused fee at prevailing market rates, monthly, to maintain the availability under the Receivables Securitization Facility. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which the Company was compliant as of September 30, 2025. There were no borrowings outstanding under the Receivables Securitization Facility as of September 30, 2025 and 2024.

In connection with the Receivables Securitization Facility, AmerisourceBergen Drug Corporation and a specialty distribution subsidiary sell on a revolving basis certain accounts receivable to Amerisource Receivables Financial Corporation, a wholly-owned special purpose entity, which in turn sells a percentage ownership interest in the receivables to financial institutions and commercial paper conduits sponsored by financial institutions. AmerisourceBergen Drug Corporation is the servicer of the accounts receivable under the Receivables Securitization Facility. As sold receivables are collected, additional receivables may be sold up to the maximum amount available under the facility. The Company uses the facility as a financing vehicle because it generally offers an attractive interest rate relative to other financing sources. The Company securitizes its trade accounts, which are generally non-interest bearing, in transactions that are accounted for as borrowings.

Money Market Facility

The Company has an uncommitted, unsecured line of credit available to it pursuant to a money market credit agreement ("Money Market Facility"). In September 2025, the Company entered into an amendment to the Money Market Facility pursuant to which it may request short-term unsecured revolving credit loans in a principal amount not to exceed $500 million on or after April 1 and before December 1 of any year and increases to $750 million on or after December 1 and before March 31 of any year. The Money Market Facility may be decreased or terminated by the bank or the Company at any time without prior notice. There were no borrowings outstanding under the Money Market Facility as September 30, 2025 and 2024.

Working Capital Credit Facility

In July 2025, the Company entered into an uncommitted, unsecured line of credit to support its working capital needs ("Working Capital Credit Facility"). The Working Capital Credit Facility provides the Company with the ability to request short-term, unsecured revolving credit loans from time to time in a principal amount not to exceed $500 million. The Working Capital Credit Facility expires in July 2026 and may be decreased or terminated by the bank or the Company at any time without prior notice. There were no borrowings outstanding under the Working Capital Credit Facility as of September 30, 2025.

Term Loan

In January 2025, the Company borrowed $1.5 billion on a variable-rate term loan ("Term Loan") that was scheduled to mature in December 2027. In September 2025, the Company amended the Term Loan to shorten the maturity to October 2027. The Term Loan was used to finance a portion of the acquisition of RCA (see Note 2). The Term Loan bears interest at a rate equal to either an adjusted SOFR plus an applicable margin or an alternate base rate plus an applicable margin. The margins are based on the Company's public debt ratings. The Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility. The Company has the right to prepay the borrowings under the Term Loan at any time, in whole or in part and without premium or penalty. Through September 30, 2025, the Company elected to make early principal payments of $700 million on the Term Loan.

Senior Notes

In December 2024, the Company issued $500 million of 4.625% senior notes due in December 2027 (the "2027 Notes"), $600 million of 4.850% senior notes due in December 2029 (the "2029 Notes"), and $700 million of 5.150% senior notes due in February 2035 (the "2035 Notes"). The 2027 Notes were sold at 99.815% of the principal amount with an effective yield of 4.634%. The 2029 Notes were sold at 99.968% of the principal amount with an effective yield of 4.852%. The 2035 Notes were sold at 99.945% of the principal amount with an effective yield of 5.153%. Interest on the 2027 Notes and the 2029 Notes is payable semi-annually in arrears on June 15 and December 15, which began on June 15, 2025. Interest on the 2035 Notes is payable semi-annually in arrears on February 15 and August 15, which began on February 15, 2025. The Company used the proceeds from the 2027 Notes, the 2029 Notes, and the 2035 Notes to finance a portion of the acquisition of RCA.

In May 2025, the Company issued €500 million of 2.875% senior notes due in May 2028 (the "2028 Notes") and €500 million of 3.625% senior notes due in May 2032 (the "2032 Notes"). The 2028 Notes were sold at 99.960% of the principal amount with an effective yield of 2.876%. The 2032 Notes were sold at 99.757% of the principal amount with an effective yield of 3.634%. Interest on the 2028 Notes and the 2032 Notes is payable annually in arrears beginning on May 22, 2026. The Company used the proceeds from the 2028 Notes and the 2032 Notes for general corporate purposes.

The senior notes discussed above and also illustrated in the above debt table are collectively referred to as the "Notes." Interest on the Notes is payable semiannually in arrears, with the exception of the 2028 Notes and the 2032 Notes, which are paid annually in arrears. Most of the Notes were sold at small discounts to the principal amounts and, therefore, have effective yields that are greater than the stated interest rates in the table above. Costs incurred in connection with the issuance of the Notes were deferred and are being amortized over the terms of the Notes. The indentures governing the Notes contain restrictions and covenants, which include limitations on additional indebtedness; distributions to stockholders; the repurchase of stock and the making of other restricted payments; issuance of preferred stock; creation of certain liens; transactions with subsidiaries and other affiliates; and certain corporate acts such as mergers, consolidations, and the sale of substantially all assets. An additional covenant requires compliance with a financial leverage ratio test. The Company was compliant with all covenants as of September 30, 2025.

In March 2025, the Company's $500 million of 3.250% senior notes matured and was repaid.

Alliance Healthcare Debt

Alliance Healthcare debt is comprised of uncommitted revolving credit facilities in various currencies with various rates. These facilities are used to fund its working capital needs.

Nonrecourse Debt

Nonrecourse debt is comprised of short-term and long-term debt belonging to the Brazil subsidiaries and is repaid solely from the Brazil subsidiaries' cash flows and such debt agreements provide that the repayment of the loans (and interest thereon) is secured solely by the capital stock, physical assets, contracts, and cash flows of the Brazil subsidiaries.

Other Information

Scheduled future principal payments of debt are $115.2 million in fiscal 2026, $24.9 million in fiscal 2027, $2.7 billion in fiscal 2028, $8.7 million in fiscal 2029, $1.1 billion in fiscal 2030, and $3.8 billion thereafter.

Interest paid on the above indebtedness during fiscal 2025, 2024, and 2023 was $356.5 million, $250.1 million, and $271.3 million, respectively.

Total amortization of financing fees and the accretion of original issue discounts, which are recorded as components of Interest Expense, Net on the Consolidated Statements of Operations, were $10.2 million, $7.2 million, and $8.5 million, for fiscal 2025, 2024, and 2023, respectively.

Note 7. Stockholders' Equity and Weighted Average Common Shares Outstanding

The authorized capital stock of the Company consists of 600,000,000 shares of common stock, par value $0.01 per share (the "common stock"), and 10,000,000 shares of preferred stock, par value $0.01 per share (the "preferred stock").

The holders of the Company's common stock are entitled to one vote per share and have the exclusive right to vote for the Board of Directors and for all other purposes as provided by law. Subject to the rights of holders of the Company's preferred stock, holders of common stock are entitled to receive ratably on a per share basis such dividends and other distributions in cash, stock, or property of the Company as may be declared by the Board of Directors from time to time out of the legally available assets or funds of the Company.

The following illustrates the components of Accumulated Other Comprehensive Loss, net of income taxes:

(in thousands)	September 30, 2025	2024
Foreign currency translation	$ (903,078)	$ (988,484)
Other, net	1,700	(634)
Total accumulated other comprehensive loss	$ (901,378)	$ (989,118)

In May 2022, the Company's Board of Directors authorized a share repurchase program allowing the Company to purchase up to $1.0 billion of its outstanding shares of common stock, subject to market conditions. During fiscal 2023, the Company purchased 6.0 million shares of its common stock for $961.3 million to complete its authorization under this program.

In March 2023, the Company's Board of Directors authorized a share repurchase program allowing the Company to purchase up to $1.0 billion of its outstanding shares of common stock, subject to market conditions. During fiscal 2023, the Company purchased 1.0 million shares of its common stock for $191.0 million under this program. During fiscal 2024, the Company purchased 3.9 million shares of its common stock for $809.0 million to complete its authorization under this program.

In March 2024, the Company's Board of Directors authorized a share repurchase program allowing the Company to purchase up to $2.0 billion of its outstanding common stock, subject to market conditions. During fiscal 2024, the Company purchased 3.0 million shares of its common stock for $682.3 million under this program. During fiscal 2025, the Company purchased 1.9 million shares of its common stock for $435.4 million under this program. As of September 30, 2025, the Company had $882.2 million availability under this program.

Common Shares Outstanding

Basic earnings per share is computed by dividing net income attributable to Cencora, Inc. by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed by dividing net income attributable to Cencora, Inc. by the weighted average number of shares of common stock outstanding, plus the dilutive effect of restricted stock units and stock options during the periods presented.

The following illustrates the components of diluted weighted average shares outstanding:

(in thousands)	Fiscal Year Ended September 30, 2025	2024	2023
Weighted average common shares outstanding - basic	193,820	198,503	202,511
Effect of dilutive securities - restricted stock units and stock options	1,394	1,781	2,080
Weighted average common shares outstanding - diluted	195,214	200,284	204,591

The potentially dilutive restricted stock units and stock options that were antidilutive were 69 thousand, 85 thousand, and 94 thousand for fiscal 2025, 2024 and 2023, respectively.

Note 8. Retirement and Other Benefit Plans

The Company sponsors various retirement benefit plans and a deferred compensation plan covering eligible employees.

The Compensation and Succession Planning Committee ("Compensation Committee") of the Company's Board of Directors has delegated the administration of the Company's retirement and other benefit plans to its Benefits Committee, an internal committee, comprised of senior finance, human resources, and legal executives. The Benefits Committee is responsible for the investment options under the Company's savings plans, as well as performance of the investment advisers and plan administrators.

Retirement Benefit Plans

The Company sponsors the Cencora, Inc. Employee Investment Plan (the "Plan"), which is a defined contribution 401(k) plan covering salaried and certain hourly employees. Eligible participants may contribute to the plan from 1% to 50% of their regular compensation before taxes. The Company contributes $1.00 for each $1.00 invested by the participant up to the first 3% of the participant's salary and $0.50 for each additional $1.00 invested by the participant of up to an additional 2% of salary. An additional discretionary contribution, in an amount not to exceed the limits established by the Internal Revenue Code of 1986, as amended (the "IRC"), may also be made depending upon the Company's performance. Based on the Company's performance in fiscal 2025, 2024, and 2023, the Company recognized expenses for discretionary contributions to the Plan in fiscal 2025, 2024, and 2023. All contributions are invested at the direction of the employee in one or more funds. All company matching contributions vest immediately except for the discretionary contributions made by the Company, which vest in full after five years of credited service.

The Company's international businesses sponsor various country-specific retirement plans.

Costs of above retirement benefit plans charged to expense for fiscal 2025, 2024, and 2023 were $125.3 million, $99.8 million, and $89.4 million, respectively. The increase in the cost of the retirement benefit plans from fiscal 2024 to fiscal 2025 is primarily due to the January 2025 acquisition of RCA.

Deferred Compensation Plan

The Company sponsors the Cencora, Inc. Deferred Compensation Plan. This unfunded plan allows eligible officers, directors and key management employees to defer a portion of their annual compensation and provides for a benefit restoration feature to selected key management. The benefit restoration feature provides certain eligible participants, including the Company's executive officers, with an annual amount equal to 4% of the participant's total cash compensation to the extent that an employee's compensation exceeds the annual compensation limit established by Section 401(a) (17) of the IRC. The Company's liability relating to its deferred compensation plan, including the benefit restoration feature, as of September 30, 2025 and 2024 was $63.1 million and $57.9 million, respectively.

Note 9. Share-Based Compensation

The Company's stockholders approved the AmerisourceBergen Corporation 2022 Omnibus Incentive Plan (the "2022 Plan"). As of September 30, 2025, there were 17.9 million shares available to be granted for employee and non-employee director stock restricted stock units, performance stock units, and stock options under the 2022 Plan.

Restricted Stock Units

The majority of restricted stock units granted vest ratably over a three-year period. The estimated fair value of restricted stock units under the Company's restricted stock unit plan is determined by the product of the number of shares granted and the closing grant date market price of the Company's common stock. The estimated fair value of restricted stock units is expensed on a straight-line basis over the requisite service period, net of estimated forfeitures. During fiscal 2025, 2024, and 2023, the Company recognized restricted stock unit expense of $108.7 million, $98.9 million, and $84.3 million, respectively.

A summary of the status of the Company's nonvested restricted stock units as of September 30, 2025 and changes during fiscal 2025 are presented below:

(in thousands, except grant date fair value)	Restricted Stock Units	Weighted Average Grant Date Fair Value
Nonvested as of September 30, 2024	1,208	$173
Granted	522	$242
Vested	(588)	$159
Forfeited	(64)	$206
Nonvested as of September 30, 2025	1,078	$213

During fiscal 2025, 2024, and 2023, the total fair values of restricted stock units vested were $93.6 million, $83.2 million, and $103.0 million, respectively. Expected future compensation expense relating to the 1.1 million restricted stock units outstanding as of September 30, 2025 is $89.4 million, which will be recognized over a weighted average period of 1.4 years.

Performance Stock Units

Performance stock units are granted to certain executive employees under the Plan and represent common stock potentially issuable in the future. Performance stock units vest at the end of a three-year performance period based upon achievement of specific performance goals. Based upon the extent to which the targets are achieved, vested shares may range from 0% to 230% of the target award amount. The fair value of performance stock units is determined by the grant date market price of the Company's common stock. Compensation expense associated with nonvested performance stock units is recognized over the requisite service period and is dependent on the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued. During fiscal 2025, 2024, and 2023, the Company recognized performance stock expense of $38.9 million, $48.7 million, and $40.4 million, respectively.

A summary of the status of the Company's nonvested performance stock units as of September 30, 2025 and changes during fiscal 2025 is presented below (based upon target award amounts).

(in thousands, except grant date fair value)	Performance Stock Units	Weighted Average Grant Date Fair Value
Nonvested as of September 30, 2024	248	$178
Granted	125	$243
Vested	(120)	$158
Forfeited	(7)	$211
Nonvested as of September 30, 2025	246	$220

Shares that vested over the three-year performance period ended September 30, 2025 were distributed to employees in November 2025.

Stock Options

The Company has not granted any stock options since fiscal 2020.

In fiscal 2025, employees exercised 387 thousand stock options at a weighted average exercise price of $87 per stock option. There were 147 thousand stock options outstanding as of September 30, 2025, all of which are exercisable, with a weighted average exercise price of $87 per option. The weighted average remaining contractual term for outstanding stock options was one year as of September 30, 2025.

Note 10. Leases

The Company has long-term leases for facilities and equipment. In the normal course of business, leases are generally renewed or replaced by other leases. Certain leases include escalation clauses.

The following illustrates the components of lease cost for the periods presented:

	Fiscal Year Ended September 30,		
(in thousands)	2025	2024	2023
Operating lease cost	$ 303,822	$ 245,415	$ 234,567
Short-term lease cost	9,571	18,459	9,799
Variable lease cost	37,573	35,539	25,598
Total lease cost	$ 350,966	$ 299,413	$ 269,964

The following summarizes balance sheet information related to operating leases:

(in thousands, except for lease term and discount rate)	September 30, 2025	September 30, 2024
Right of use assets		
Other assets	$ 1,548,478	$ 1,141,622
Lease liabilities		
Accrued expenses and other	$ 253,770	$ 204,767
Other long-term liabilities	1,416,633	1,029,978
Total lease liabilities	$ 1,670,403	$ 1,234,745
Weighted-average remaining lease term	7.55 years	7.34 years
Weighted-average discount rate	4.63%	4.18%

Other cash flow information related to operating leases is as follows:

(in thousands)	Fiscal Year Ended September 30, 2025	2024	2023
Cash paid for amounts included in the measurement of lease liabilities			
Operating lease cash payments	$ 294,430	$ 247,862	$ 229,203
Right-of-use assets obtained in exchange for lease liabilities			
New operating leases	$ 655,991	$ 305,882	$ 271,096

Future minimum rental payments under noncancellable operating leases were as follows:

Payments Due by Fiscal Year (in thousands)	As of September 30, 2025
2026	$ 319,915
2027	295,076
2028	269,676
2029	237,780
2030	190,742
Thereafter	668,804
Total future undiscounted lease payments	1,981,993
Less: Future payments for leases that have not yet commenced [1]	(13,071)
Less: Imputed interest	(298,519)
Total lease liabilities	$ 1,670,403

[1] The Company has certain leases that it has executed of which it does not control the underlying assets; therefore, liabilities and ROU assets related to these leases were not recorded on the Company's Consolidated Balance Sheet as of September 30, 2025.

Note 11. Restructuring and Other Expenses

The following illustrates the expenses incurred by the Company relating to Restructuring and Other Expenses for the periods indicated:

	Fiscal Year Ended September 30,		
(in thousands)	2025	2024	2023
Restructuring and employee severance costs	$ 101,562	$ 69,968	$ 105,220
Business transformation efforts	122,286	130,069	82,117
Other, net	5,574	33,592	42,547
Total restructuring and other expenses	$ 229,422	$ 233,629	$ 229,884

Restructuring and employee severance costs in fiscal 2025 primarily included expenses incurred related to workforce reductions in both of the Company's reportable segments. Restructuring and employee severance costs in fiscal 2024 primarily included expenses incurred related to facility closures in connection with the Company's office optimization plan and workforce reductions in both of its reportable segments. Restructuring and employee severance costs in fiscal 2023 primarily included expenses incurred in connection with workforce reductions in both of the Company's reportable segments.

Business transformation efforts in fiscal 2025, 2024, and 2023 included rebranding costs associated with the Company's name change to Cencora and non-recurring expenses related to significant strategic initiatives to improve operational efficiency, including certain technology initiatives. The majority of these costs related to services provided by third-party consultants.

In fiscal 2024, the Company experienced a cybersecurity event where data from its information systems was exfiltrated. In connection with this event, the Company incurred costs that were recorded in Other, net in the above table. The majority of the costs included in Other, net in fiscal 2024 related to this cybersecurity event.

In fiscal 2023, one of the Company's foreign business units experienced a cybersecurity event that impacted a standalone legacy information technology platform in one country and the foreign business unit's ability to operate in that country for approximately two weeks. In connection with this event, the Company incurred costs to restore the foreign business unit's operations in that country, which were recorded in Other, net in the above table. The majority of the costs included in Other, net in fiscal 2023 related to this cybersecurity event.

Note 12. Legal Matters and Contingencies

In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, government investigations, stockholder demands, and other disputes, including antitrust, commercial, data privacy and security, employment discrimination, intellectual property, product liability, regulatory, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a reserve for these matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.

For those matters for which the Company has not recognized a liability, the Company cannot predict the outcome of their impact on the Company as uncertainty remains, including with regard to whether such matters will proceed to trial, whether settlements will be reached, and the amount and terms of any such settlements. Outcomes may include settlements in significant amounts that are not currently estimable, limitations on the Company's conduct, the imposition of corporate integrity agreement obligations, consent decrees, and/or other civil and criminal penalties. From time to time, the Company is also involved in disputes with its customers, which the Company generally seeks to resolve through commercial negotiations. If negotiations are unsuccessful, the parties may litigate the dispute or otherwise attempt to settle the matter.

With respect to the specific legal proceedings and claims described below, unless otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition.

Opioid Lawsuits and Investigations

A significant number of counties, municipalities, and other governmental entities in a majority of U.S. states and Puerto Rico, as well as numerous states and tribes, filed lawsuits in various federal, state and other courts against pharmaceutical wholesale distributors (including the Company and certain subsidiaries, such as AmerisourceBergen Drug

Corporation (“ABDC”) and H.D. Smith, LLC (“H.D. Smith”)), pharmaceutical manufacturers, retail pharmacy chains, medical practices, and physicians relating to the distribution of prescription opioid pain medications.

Starting in December 2017, more than 2,000 cases were transferred to Multidistrict Litigation (“MDL”) proceedings before the United States District Court for the Northern District of Ohio (the “MDL Court”). Since then, several cases filed by government and tribal plaintiffs that were selected as bellwether cases in the MDL have been resolved through trial or settlement. Following trial in two consolidated cases in the United States District Court for the Southern District of West Virginia, the Court entered judgment in favor of the defendants, including the Company. The plaintiffs filed an appeal of the Court’s decision in the United States Court of Appeals for the Fourth Circuit on August 2, 2022. On October 28, 2025, the Fourth Circuit issued its opinion in the case, vacated the District Court’s judgment, and remanded the case back to the District Court for further proceedings consistent with the Fourth Circuit’s opinion.

On July 21, 2021, the Company announced that it and the two other national pharmaceutical distributors had negotiated a Distributor Settlement Agreement that, if all conditions were satisfied, would result in the resolution of a substantial majority of opioid lawsuits filed by state and local governmental entities. The Distributor Settlement Agreement became effective on April 2, 2022, and as of September 30, 2025, it included 48 of 49 eligible states (the “Settling States”) as well as 99% by population of the eligible political subdivisions in the Settling States. The Distributor Settlement Agreement requires the Company to comply with certain requirements, including the establishment of a clearinghouse that will consolidate data from all three national pharmaceutical distributors. The States of Alabama and West Virginia and their subdivisions and Native American tribes are not a part of the Distributor Settlement Agreement, and the Company has reached separate agreements with those groups.

The MDL Court selected four cases filed by third-party payors to serve as additional litigation bellwethers. On May 31, 2024, the MDL Court severed and stayed these four cases against the Company and the two other national pharmaceutical distributors, pursuant to ongoing settlement discussions to resolve litigation filed by a putative class of third-party payors. On August 29, 2024, the Company and two other national pharmaceutical distributors entered into a proposed class action settlement agreement to resolve the opioid-related claims of a proposed settlement class of third-party payors. Pursuant to the agreement, the Company recorded a $93.0 million litigation expense accrual in Litigation and Opioid-Related Expenses (Credit), Net in its fiscal 2024 Consolidated Statement of Operations. The MDL Court granted a motion for preliminary approval of the proposed class action settlement on September 3, 2024. Following a time period for submission of any objections or requests to be excluded from the settlement, the MDL granted final approval of the settlement during a fairness hearing held on January 13, 2025 and entered a final approval order on January 15, 2025. On February 13, 2025, the sole objector to the settlement filed a notice of appeal of the final approval order. A settlement agreement with the sole objector was entered into on June 12, 2025. On June 16, 2025, the MDL Court ruled that it would approve the settlement with the sole objector if remanded for that purpose. On July 25, 2025, the United States Court of Appeals for the Sixth Circuit granted a motion for limited remand. The MDL Court approved the settlement with the sole objector on August 8, 2025. The class action settlement became effective as of September 9, 2025.

In Maryland, a trial commenced on September 16, 2024 in a case filed by the Mayor and City Council of Baltimore in the Circuit Court for Baltimore City. On November 12, 2024, the jury returned a verdict finding ABDC (and another national distributor) liable for public nuisance and assessing approximately $274 million total in compensatory damages, approximately $74 million of which was assessed against ABDC. A second phase of the trial began on December 11, 2024 related to the City of Baltimore’s request for an abatement remedy and proceeded as a bench trial. On June 12, 2025, the Court issued a ruling on the defendants’ post-trial motions relating to the first phase of the trial. The Court upheld the jury’s finding of liability, but granted the defendants a new trial on the extent of damages to correct certain errors and due to the excessive nature of the jury’s damages award. In the alternative, the Court granted remittitur, through which the Court reduced the compensatory damages assessed against ABDC to approximately $14.4 million. The Court issued its ruling regarding the City of Baltimore’s request for abatement on August 8, 2025, assessing approximately $28 million against ABDC for abatement measures, bringing the overall monetary award assessed against ABDC to approximately $42.5 million. On August 14, 2025, the City of Baltimore informed the Court that it would accept the reduced damages award as reflected in the Court’s post-trial ruling, in lieu of a new trial. On September 2, 2025, the Court entered final judgment. In October 2025, ABDC (and the other national distributor) filed a notice of appeal to the Appellate Court of Maryland, and the City of Baltimore filed a notice of cross-appeal. In November 2025, both the City of Baltimore and ABDC (and the other national distributor) filed petitions for a writ of certiorari (bypass) with the Supreme Court of Maryland. If the Court grants the petitions, then the appeal will proceed directly in that Court, instead of in the Appellate Court. The $42.4 million is a component of the Company’s $4.3 billion litigation liability as of September 30, 2025, as described above.

On September 26, 2024, the Company and two other national pharmaceutical distributors entered into a proposed class action settlement agreement to resolve the opioid-related claims of a proposed settlement class of hospitals. The Company recorded a $120.9 million litigation expense accrual in Litigation and Opioid-Related Expenses (Credit), Net in its fiscal 2024

Consolidated Statement of Operations, representing the Company's expected share of the potential class action settlement. On October 30, 2024, the United States District Court for the District of New Mexico granted a motion for preliminary approval of the proposed class action settlement. Following notice to class members, a time period for submission of any objections to the settlement or requests to be excluded from the settlement, and a fairness hearing on March 4, 2025, the Court granted final approval of the settlement and entered a final approval order. The settlement became effective on April 4, 2025.

The Company's accrued litigation liability related to the Distributor Settlement Agreement, including the State of Alabama and an estimate for non-participating government subdivisions (with whom the Company has not reached a settlement agreement), as well as other opioid-related litigation for which it has reached settlement agreements, as described above, was $4.3 billion as of September 30, 2025 and $4.9 billion as of September 30, 2024. The $4.3 billion liability will be paid over 13 years. The Company currently estimates that $416.0 million will be paid prior to September 30, 2026, which is recorded in Accrued Expenses and Other on the Company's Consolidated Balance Sheet. The remaining long-term liability of $3.9 billion is recorded in Accrued Litigation Liability on the Company's Consolidated Balance Sheet. While the Company has accrued its estimated liability for opioid litigation, it is unable to estimate the range of possible loss associated with the matters that are not included in the accrual. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. The Company regularly reviews opioid litigation matters to determine whether its accrual is adequate. The amount of ultimate loss may differ materially from the amount accrued to date. Until such time as otherwise resolved, the Company will continue to litigate and prepare for trial and to vigorously defend itself in all such matters. Since these matters are still developing, the Company is unable to predict the outcome, but the result of these lawsuits could include excessive monetary verdicts and/or injunctive relief that may affect the Company's operations. Additional lawsuits regarding the distribution of prescription opioid pain medications have been filed and may continue to be filed by a variety of types of plaintiffs, including lawsuits filed by non-governmental or non-political entities and individuals, among others. The Company is vigorously defending itself in the pending lawsuits and intends to vigorously defend itself against any threatened lawsuits or enforcement proceedings.

Since July 2017, the Company has received subpoenas from several U.S. Attorney's Offices, including grand jury subpoenas from the U.S. Attorney's Office for the District of New Jersey ("USAO-NJ") and the U.S. Attorney's Office for the Eastern District of New York ("USAO-EDNY"). Those subpoenas requested the production of a broad range of documents pertaining to the Company's distribution of controlled substances through its various subsidiaries, including ABDC, and its diversion control programs. The Company produced documents in response to the subpoenas and engaged in discussions with the various U.S. Attorney's Offices, including the Health Care and Government Fraud Unit of the Criminal Division of the USAO-NJ, the U.S. Department of Justice Consumer Protection Branch and the U.S. Drug Enforcement Administration, in an attempt to resolve these matters. On December 29, 2022, the Department of Justice filed a civil complaint (the "Complaint") against the Company, ABDC, and Integrated Commercialization Services, LLC ("ICS"), a subsidiary of the Company, alleging violations of the Controlled Substances Act. Specifically, the Complaint alleges that the Company negligently failed to report suspicious orders to the Drug Enforcement Administration. In the Complaint, the Department of Justice seeks civil penalties and injunctive relief. This Complaint relates to the aforementioned and previously-disclosed investigations. On March 30, 2023, the Company filed a motion to dismiss the Complaint in its entirety on behalf of itself, ABDC, and ICS. On November 6, 2023, the United States District Court for the Eastern District of Pennsylvania granted in part and denied in part the motion, dismissing with prejudice all claims for civil penalties for Defendants' alleged violations of the suspicious order reporting requirement prior to October 24, 2018, but otherwise denying the motion. On December 18, 2023, the Company, ABDC and ICS filed an Answer and Affirmative Defenses to the Complaint. On July 15, 2025, the Court entered an Amended Scheduling Order setting the fact discovery deadline as June 12, 2026 and the expert discovery deadline as January 15, 2027. The Company denies the allegations in the Complaint and intends to defend itself vigorously in the litigation.

Shareholder Securities Litigation

On December 30, 2021, the Lebanon County Employees' Retirement Fund and Teamsters Local 443 Health Services & Insurance Plan filed a complaint for a purported derivative action in the Delaware Court of Chancery against the Company and certain of its current officers and directors. The complaint alleges claims for breach of fiduciary duty allegedly arising from the Board's and certain officers' oversight of the Company's controlled substance diversion control programs. The defendants moved to dismiss the complaint on March 29, 2022. On December 22, 2022, the Delaware Court of Chancery granted the motion to dismiss. On January 9, 2023, the Plaintiffs filed a Motion for Relief from Judgment and Order Pursuant to Rule 60(b) from the Delaware Chancery Court's judgment. On January 20, 2023, the Plaintiffs also appealed the ruling to the Delaware Supreme Court. On March 21, 2023, the Delaware Court of Chancery denied the Plaintiffs' Motion for Relief from Judgment and Order Pursuant to Rule 60(b). On December 18, 2023, the Delaware Supreme Court reversed the dismissal and remanded the case to the Delaware Court of Chancery for further proceedings. On January 12, 2024, the Company's Board of Directors established a Special Litigation Committee ("SLC") and delegated to the SLC the Board's full authority with respect to the litigation. On March 4, 2024, the Delaware Court of Chancery granted the SLC's consented-to motion to stay the action pending its investigation of the allegations of the complaint. On July 28, 2025, the SLC notified the Court of Chancery that the parties had reached an agreement in principle to settle all claims in the action following a successful mediation conducted on June 24, 2025, and filed a stipulation to stay the action pending the presentation of a stipulation of settlement for the Court's approval. The Court granted the stay on July 29, 2025. The parties filed a stipulation of settlement with the Court on August 15, 2025, and the Court held a fairness hearing on November 13, 2025. During the fairness hearing, the Court approved the settlement and dismissed the action with prejudice. Under this settlement, insurance carriers will pay the Company $111.3 million, less $24.8 million in attorneys' fees and expenses awarded by the court to plaintiffs' counsel.

Subpoenas, Ongoing Investigations, and Other Contingencies

From time to time, the Company receives subpoenas or requests for information from various government agencies relating to the Company's business or to the business of a customer, supplier, or other industry participant. The Company's responses often require time and effort and can result in considerable costs being incurred. Most of these matters are resolved without incident; however, such subpoenas or requests can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the healthcare industry, as well as to substantial settlements.

In January 2017, U.S. Bioservices Corporation, a former subsidiary of the Company, received a subpoena for information from the USAO-EDNY relating to its activities in connection with billing for products and making returns of potential overpayments to government payers. A filed qui tam complaint related to the investigation was unsealed in April 2019 and the relator filed an amended complaint under seal in the U.S. District Court for the Eastern District of New York. In December 2019, the government filed a notice that it was declining to intervene. The court ordered that the relator's complaint against the Company and other defendants, including AmerisourceBergen Specialty Group, LLC, be unsealed. The relator's complaint alleged violations of the federal False Claims Act and the false claims acts of various states. The relator filed a second amended complaint, removing one state false claims act count. The Company filed a motion to dismiss the second amended complaint and all briefs on the motion were filed with the Court on October 9, 2020. The motion to dismiss was granted on December 22, 2022. The False Claims Act claims were dismissed with prejudice, and the state claims were dismissed without prejudice. On January 24, 2023, the relator filed Motions to Reconsider Dismissal and For Leave to Amend the Complaint. Response briefs on those motions were filed by the Company and all briefing was completed on February 15, 2023. On October 17, 2025, the Court denied the relator's motions. On November 13, 2025, the relator filed a notice of appeal of such denial to the United States Court of Appeals for the Second Circuit.

On March 3, 2022, the United States Attorney's Office for the Western District of Virginia notified the Company of the existence of a criminal investigation into MWI Veterinary Supply Co. ("MWI"), the Company's animal health subsidiary, in connection with grand jury subpoenas to which MWI previously responded relating to compliance with state and federal regulatory requirements governing wholesale shipments of animal health products to customers. In October 2024, the Company reached an agreement in principle to resolve these claims. While no agreement has been finalized, pursuant to the agreement in principle the Company recorded a $49.1 million litigation expense accrual in Litigation and Opioid-Related Expenses (Credit), Net in its fiscal 2024 Consolidated Statement of Operations. This liability is included in Accrued Expenses and Other on the Company's Consolidated Balance Sheet as of September 30, 2025.

Note 13. Antitrust Litigation Settlements

Numerous lawsuits have been filed against certain brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. These lawsuits are generally brought as class actions. The Company has not been named a plaintiff in any of these lawsuits but has been a member of the direct purchasers' class (i.e., those purchasers who purchase directly from these pharmaceutical manufacturers). None of the lawsuits has gone to trial, but some have settled in the past with the Company receiving proceeds from the settlement funds. During fiscal 2025, 2024, and 2023, the Company recognized gains relating to these lawsuits of $236.4 million, $170.9 million, and $239.1 million, respectively. These gains, which are net of attorney fees and estimated payments due to other parties, were recorded as reductions to cost of goods sold in the Company's Consolidated Statements of Operations.

Note 14. Business Segment Information

The Company is organized geographically based upon the products and services it provides to its customer and reports its results under two reportable segments: U.S. Healthcare Solutions and International Healthcare Solutions.

The chief operating decision maker ("CODM") of the Company is its President & Chief Executive Officer, whose function is to allocate resources to, and assess the performance of, the Company's operating segments. The CODM does not review assets by operating segment for the purpose of assessing performance or allocating resources.

The U.S. Healthcare Solutions reportable segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The U.S. Healthcare Solutions reportable segment also provides pharmaceutical distribution (including plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty pharmaceutical products) and additional services to physicians who specialize in a variety of disease states, especially oncology and retina, and to other healthcare providers, including hospitals, specialty retinal practices, and dialysis clinics. The U.S. Healthcare Solutions reportable segment also provides pharmacy management, staffing and additional patient access and adherence support, and supply management software to a variety of retail and institutional healthcare providers. Additionally, it delivers packaging solutions to institutional and retail healthcare providers. Through its animal health business, the U.S. Healthcare Solutions reportable segment sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. It also offers demand-creating sales force services to manufacturers.

The International Healthcare Solutions reportable segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services. The International Healthcare Solutions reportable segment distributes pharmaceuticals and other healthcare products and provides related services to healthcare providers, including pharmacies, doctors, health centers and hospitals primarily in Europe. It is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. It also is a provider of specialized services, including regulatory affairs, market access, pharmacovigilance, development consulting and scientific affairs, and quality management and compliance, for the life sciences industry. In Canada, the business drives innovative partnerships with manufacturers, providers, and pharmacies to improve product access and efficiency throughout the healthcare supply chain.

The following illustrates reportable segment and disaggregated revenue as required by ASC 606, "Revenue from Contracts with Customers," for the periods indicated:

(in thousands)	Fiscal Year Ended September 30, 2025	2024	2023
U.S. Healthcare Solutions			
Human Health	$ 285,287,506	$ 259,973,909	$ 229,716,669
Animal Health	5,694,517	5,365,518	5,042,549
Total U.S. Healthcare Solutions	290,982,023	265,339,427	234,759,218
International Healthcare Solutions			
Alliance Healthcare	24,394,833	23,061,721	22,349,278
Other Healthcare Solutions	5,971,490	5,565,821	5,069,401
Total International Healthcare Solutions	30,366,323	28,627,542	27,418,679
Intersegment eliminations	(15,527)	(8,370)	(4,486)
Revenue	$ 321,332,819	$ 293,958,599	$ 262,173,411

The following illustrates reportable segment cost of goods sold information for the periods indicated:

(in thousands)	Fiscal Year Ended September 30, 2025	2024	2023
U.S. Healthcare Solutions	$ 283,076,597	$ 258,916,313	$ 228,938,102
International Healthcare Solutions	27,050,982	25,306,564	24,227,832
Intersegment eliminations	(9,622)	(5,322)	(4,486)
Total segment cost of goods sold	$ 310,117,957	$ 284,217,555	$ 253,161,448

The following illustrates reportable segment operating expenses information for the periods indicated:

(in thousands)	Fiscal Year Ended September 30, 2025	2024	2023
U.S. Healthcare Solutions	$ 4,330,727	$ 3,488,237	$ 3,224,557
International Healthcare Solutions	2,667,067	2,607,599	2,498,285
Intersegment eliminations	(5,905)	(3,048)	—
Total segment operating expenses	$ 6,991,889	$ 6,092,788	$ 5,722,842

The following illustrates reportable segment operating income information for the periods indicated:

(in thousands)	Fiscal Year Ended September 30, 2025	2024	2023
U.S. Healthcare Solutions	$ 3,574,699	$ 2,934,877	$ 2,596,559
International Healthcare Solutions	648,274	713,379	692,562
Total segment operating income	$ 4,222,973	$ 3,648,256	$ 3,289,121

The following reconciles total segment operating income to income before income taxes for the periods indicated:

(in thousands)	Fiscal Year Ended September 30, 2025	2024	2023
Total segment operating income	$ 4,222,973	$ 3,648,256	$ 3,289,121
Gains from antitrust litigation settlements	236,372	170,904	239,092
LIFO credit (expense)	76,876	52,168	(204,595)
Turkey highly inflationary impact	(49,571)	(54,087)	(86,967)
Acquisition-related intangibles amortization	(553,028)	(660,292)	(551,046)
Litigation and opioid-related (expenses) credit, net	(60,671)	(227,070)	24,693
Acquisition-related deal and integration expenses	(291,044)	(103,001)	(139,683)
Restructuring and other expenses	(229,422)	(233,629)	(229,884)
Goodwill impairment	(723,884)	(418,000)	—
Operating income	2,628,601	2,175,249	2,340,731
Other loss (income), net	78,717	14,283	(49,036)
Interest expense, net	291,548	156,991	228,931
Income before income taxes	$ 2,258,336	$ 2,003,975	$ 2,160,836

Segment operating income is evaluated by the CODM of the Company and excludes gains from antitrust litigation settlements; LIFO credit (expense); Turkey highly inflationary impact; acquisition-related intangibles amortization; litigation and opioid-related (expenses) credit, net; acquisition-related deal and integration expenses; restructuring and other expenses; and goodwill impairment. All corporate office expenses are allocated to the operating segment level.

Litigation and opioid-related (expenses) credit, net in fiscal 2024 includes $263.1 million of litigation expense accruals (see Note 12), offset in part by a net $92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as permitted under its opioid settlement agreements.

Litigation and opioid-related (expenses) credit, net in fiscal 2023 includes the receipt of $83.4 million from the H.D. Smith opioid litigation indemnity escrow.

Other loss (income), net includes a $113.5 million impairment of an equity investment that was made in fiscal 2021 and a $35.5 million loss on the divestiture of non-core businesses, offset in part by the Company's portion of an equity method investment's gain on the sale of a business of $39.7 million and a $14.1 million gain on the remeasurement of an equity investment in fiscal 2025.

Other loss (income), net, includes a $40.7 million net gain on the divestiture of non-core businesses in fiscal 2023.

The following illustrates depreciation and amortization by reportable segment for the periods indicated:

(in thousands)	Fiscal Year Ended September 30, 2025	2024	2023
U.S. Healthcare Solutions	$ 352,602	$ 298,683	$ 292,814
International Healthcare Solutions	145,445	132,999	120,044
Acquisition-related intangibles amortization	553,028	660,292	551,046
Total depreciation and amortization	$ 1,051,075	$ 1,091,974	$ 963,904

Depreciation and amortization related to property and equipment and intangible assets excludes amortization of deferred financing costs and other debt-related items, which are included in interest expense, net.

The following illustrates capital expenditures by reportable segment for the periods indicated:

(in thousands)	Fiscal Year Ended September 30, 2025	2024	2023
U.S. Healthcare Solutions	$ 399,518	$ 273,715	$ 268,069
International Healthcare Solutions	268,463	213,458	190,290
Total capital expenditures	$ 667,981	$ 487,173	$ 458,359

Note 15. Fair Value of Financial Instruments

The recorded amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable as of September 30, 2025 and 2024 approximate fair value based upon the relatively short-term nature of these financial instruments. Within Cash and Cash Equivalents, the Company had $1,864.0 million and $1,190.0 million of investments in money market accounts as of September 30, 2025 and 2024, respectively. The fair value of the money market accounts was determined based upon unadjusted quoted prices in active markets for identical assets, otherwise known as Level 1 inputs.

The recorded amount of long-term debt (see Note 6) and the corresponding fair value as of September 30, 2025 were $7,543.0 million and $7,361.4 million, respectively. The recorded amount of long-term debt and the corresponding fair value as of September 30, 2024 were $3,811.7 million and $3,588.0 million, respectively. The fair value of long-term debt was determined based upon inputs other than quoted prices, otherwise known as Level 2 inputs.

Note 16. Subsequent Events

Dividend Increase

In November 2025, the Company's Board of Directors increased the quarterly dividend paid on common stock by 9% and declared a regular quarterly cash dividend of $0.60 per share, payable on December 1, 2025 to shareholders of record on November 14, 2025.

Reportable Segments (revised as of October 1, 2025)

Recently, the Company undertook a strategic review of its business to ensure alignment with its growth priorities and strategic drivers. As a result of this review, the Company has reorganized certain business components within its reporting structure. Beginning in the first quarter of fiscal 2026, the Company's reporting structure will be comprised of U.S. Healthcare Solutions, International Healthcare Solutions, and Other. The U.S. Healthcare Solutions reportable segment will consist of U.S. Human Health (excluding legacy U.S. Consulting Services). The International Healthcare Solutions reportable segment will consist of Alliance Healthcare, Innomar, World Courier, and strategic components of PharmaLex. Other, which is not considered a reportable segment, will consist of businesses for which the Company has begun to explore strategic alternatives and includes MWI Animal Health, Profarma, U.S. Consulting Services and the other components of PharmaLex.

GUARANTEE OF PERFORMANCE

For value receive Cencora, Inc., a Delaware corporation (the "Guarantor"), located at 1 West First Avenue, Conshohocken, PA 19428, absolutely and unconditionally guarantees to assume the duties and obligations of AmerisourceBergen Drug Corporation, located at 1 West First Avenue Conshohocken, PA 19428 (the "Franchisor"), under its franchise registration in each state where the franchise is registered, and under its Franchise Agreement identified in the Franchise Disclosure Document issued 12/18/2025, as it may be amended, and as that Franchise Agreement may be entered into with franchisees and amended, modified or extended from time to time. This guarantee continues until all such obligations of the Franchisor under its franchise registrations and the Franchise Agreement are satisfied or until the liability of Franchisor to its franchisees under the Franchise Agreement has been completely discharged, whichever first occurs. The Guarantor is not discharged from liability if a claim by a franchisee against the Franchisor remains outstanding. Notice of acceptance is waived. The Guarantor does not waive receipt of notice of default on the part of the Franchisor. This guarantee is binding on the Guarantor and its successors and assigns.

The Guarantor executes this guarantee at Conshohocken, Pennsylvania on the 10th day of October, 2025.

Guarantor: Cencora, Inc.

By: _____

Name: Elizabeth Campbell

Title: Executive Vice President and Chief legal Officer

EXHIBIT F
STATE SPECIFIC ADDENDA TO AMERISOURCEBERGEN DRUG CORPORATION DISCLOSURE DOCUMENT
FOR THE STATE OF CALIFORNIA

1. Item 3 is amended to reflect that:

   Neither AmerisourceBergen Drug Corporation nor any person identified in Item 2 of the Disclosure Document is subject to any current effective order of any national securities association or national securities exchange as defined in the Securities Exchange Act of 1934, U.S.C.A. 78a et seq., suspending or expelling such persons from membership in such association or exchange.

2. Item 5 is amended by the addition of the following language:

   The release from claims does not include a release of any claims arising under the California Franchise Investment Act with respect to the offer or sale of the GNP Premier Agreement and the Premier Candidate Agreement.

3. Item 6 is amended by the addition of the following language:

   The highest interest rate allowed in California may be 10% annually.

4. Item 17 is amended by the addition of the following language:

   California Business and Professions Code Sections 20000 through 20043 provide rights to you concerning termination or nonrenewal of a franchise. If the GNP Premier Agreement contains a provision that is inconsistent with the law, the law will control.

   The GNP Premier Agreement provides for termination upon bankruptcy. This provision may not be enforceable under federal bankruptcy law (11 U.S.C.A. Sec. 101 et seq.).

   The GNP Premier Agreement does not contain any covenant not to compete which extend beyond expiration or termination of the Agreement but, to the extent it did, these provisions may not be enforceable under California law.

   The California Corporations Code, Section 31125 requires AmerisourceBergen Drug Corporation to give you a Disclosure Document, approved by the Department of Corporations, prior to a solicitation of a proposed material modification of an existing franchise.

   If the GNP Premier Agreement contains a liquidated damages clause, under California Civil Code Section 1671, certain liquidated damages clauses are unenforceable.

   The GNP Premier Agreement requires the application of the laws of Pennsylvania. This provision may be unenforceable under California Law.

   If you must sign a general release to renew or transfer your franchise, California Corporations Code Sec. 31512 voids a waiver of your rights under the Franchise Investment Law (California Corporations Code Sections 31000 through 31516). California Business and Professions Code Sec. 20010 voids a waiver of your rights under the Franchise Relations Act (Business and Professions Code Sections 20000 through 20043).

5. THE CALIFORNIA FRANCHISE INVESTMENT LAW REQUIRES THAT A COPY OF ALL PROPOSED AGREEMENTS RELATING TO THE SALE OF THE FRANCHISE BE DELIVERED TOGETHER WITH THE DISCLOSURE DOCUMENT.

6. OUR WEBSITE HAS NOT BEEN REVIEWED OR APPROVED BY THE CALIFORNIA DEPARTMENT OF BUSINESS OVERSIGHT. ANY COMPLAINTS CONCERNING THE CONTENT OF THIS WEBSITE MAY BE DIRECTED TO THE CALIFORNIA DEPARTMENT OF BUSINESS OVERSIGHT at **WWW.DFPI.CA.GOV**.

7. No statement, questionnaire, or acknowledgment signed or agreed to by a franchisee in connection with the commencement of the franchise relationship shall have the effect of (i) waiving any claims under any applicable state franchise law, including fraud in the inducement, or (ii) disclaiming reliance on any statement made by any franchisor, franchise seller, or other person acting on behalf of the franchisor. This provision supersedes any other term of any document executed in connection with the franchise.

ADDENDUM TO AMERISOURCEBERGEN DRUG CORPORATION
DISCLOSURE DOCUMENT
FOR THE STATE OF HAWAII

THESE FRANCHISES HAVE BEEN FILED UNDER THE FRANCHISE INVESTMENT LAW OF THE STATE OF HAWAII. FILING DOES NOT CONSTITUTE APPROVAL, RECOMMENDATION OR ENDORSEMENT BY THE DIRECTOR OF REGULATORY AGENCIES OR A FINDING BY THE DIRECTOR OF REGULATORY AGENCIES THAT THE INFORMATION PROVIDED HEREIN IS TRUE, COMPLETE AND NOT MISLEADING.

THE FRANCHISE INVESTMENT LAW MAKES IT UNLAWFUL TO OFFER OR SELL ANY FRANCHISE IN THIS STATE WITHOUT FIRST PROVIDING TO THE PROSPECTIVE FRANCHISEE, OR SUBFRANCHISOR, AT LEAST SEVEN (7) DAYS PRIOR TO THE EXECUTION BY THE PROSPECTIVE FRANCHISEE OF ANY BINDING FRANCHISE OR OTHER AGREEMENT, OR AT LEAST SEVEN (7) DAYS PRIOR TO THE PAYMENT OF ANY CONSIDERATION BY THE FRANCHISEE, OR SUBFRANCHISOR, WHICHEVER OCCURS FIRST, A COPY OF THE FRANCHISE DISCLOSURE DOCUMENT, TOGETHER WITH A COPY OF ALL PROPOSED AGREEMENTS RELATING TO THE SALE OF THE FRANCHISE.

THIS FRANCHISE DISCLOSURE DOCUMENT CONTAINS A SUMMARY ONLY OF CERTAIN MATERIAL PROVISIONS OF THE FRANCHISE AGREEMENT. THE CONTRACT OR AGREEMENT SHOULD BE REFERRED TO FOR A STATEMENT OF ALL RIGHTS, CONDITIONS, RESTRICTIONS AND OBLIGATIONS OF BOTH THE FRANCHISOR AND THE FRANCHISEE.

NOTWITHSTANDING ANYTHING CONTAINED IN THE FRANCHISE AGREEMENT OR AREA DEVELOPMENT AGREEMENT TO THE CONTRARY, YOU DO NOT HAVE TO PAY US THE INITIAL FRANCHISE FEE UNTIL WE PERFORM OUR PRE-OPENING OBLIGATIONS UNDER THE FRANCHISE AGREEMENT AND YOUR FIRST FRANCHISED BUSINESS IS OPEN. ONCE WE COMPLETE THIS OBLIGATION AND YOU ARE OPEN, YOU MUST IMMEDIATELY PAY US ALL INITIAL FEES WE DEFERRED.

ADDENDUM TO AMERISOURCEBERGEN DRUG CORPORATION
DISCLOSURE DOCUMENT
FOR THE STATE OF ILLINOIS

1. Illinois law governs the agreement(s) between the parties to this franchise.

2. Section 4 of the Illinois Franchise Disclosure Act provides that any provision in a franchise agreement that designates jurisdiction or venue outside the State of Illinois is void. However, a franchise agreement may provide for arbitration in a venue outside of Illinois.

3. Section 41 of the Illinois Franchise Disclosure Act provides that any condition, stipulation or provision purporting to bind any person acquiring any franchise to waive compliance with Illinois Franchise Disclosure Act or any other law of Illinois is void.

4. Your rights upon termination and non-renewal of a Franchise Agreement are set forth in sections 19 and 20 of the Illinois Franchise Disclosure Act.

No statement, questionnaire, or acknowledgment signed or agreed to by a franchisee in connection with the commencement of the franchise relationship shall have the effect of (i) waiving any claims under any applicable state franchise law, including fraud in the inducement, or (ii) disclaiming reliance on any statement made by any franchisor, franchise seller, or other person acting on behalf of the franchisor. This provision supersedes any other term of any document executed in connection with the franchise.

While the Franchisor's Parent company has guaranteed to assume the duties and obligations of the Participation (Franchise) Agreement if the Franchisor is unable to do so, the Parent company's financial condition calls into question its ability to fulfill such a guarantee.

There is no training program for this franchise opportunity.

ADDENDUM TO AMERISOURCEBERGEN DRUG CORPORATION
DISCLOSURE DOCUMENT
FOR THE STATE OF MARYLAND

1. Item 5 of the Disclosure Document is amended to reflect that, Based upon the financial information submitted, the Commissioner has determined that all fees paid to the franchisor by the franchisee, including payment for goods and services received from the franchisor before the business opens, shall be deferred pending satisfaction of all of the franchisor's pre-opening obligations to the franchisee.

2. Item 17 of the Disclosure Document is amended to reflect that, pursuant to the Code of Maryland Regulations, any general release required as a condition of renewal, sale and/or assignment/transfer will not apply to any liability or claims under the Maryland Franchise Registration and Disclosure Law resulting from the offer or sale of the franchise.

3. Item 17 of the Disclosure Document is amended to reflect that any claims arising under the Maryland Franchise Registration and Disclosure Law must be brought within 3 years after the grant of the franchise.

4. Item 17 of the Disclosure Document is amended to state that you may sue in Maryland for any claims arising under the Maryland Franchise Registration and Disclosure Law.

5. No statement, questionnaire, or acknowledgment signed or agreed to by a franchisee in connection with the commencement of the franchise relationship shall have the effect of (i) waiving any claims under any applicable state franchise law, including fraud in the inducement, or (ii) disclaiming reliance on any statement made by any franchisor, franchise seller, or other person acting on behalf of the franchisor. This provision supersedes any other term of any document executed in connection with the franchise.

ADDENDUM TO AMERISOURCEBERGEN DRUG CORPORATION
DISCLOSURE DOCUMENT
FOR THE STATE OF MICHIGAN

NOTICE TO PROSPECTIVE FRANCHISEES IN THE STATE OF MICHIGAN

THE STATE OF MICHIGAN PROHIBITS CERTAIN UNFAIR PROVISIONS THAT ARE SOMETIMES FOUND IN FRANCHISE DOCUMENTS. IF ANY OF THE FOLLOWING PROVISIONS ARE IN THESE FRANCHISE DOCUMENTS, THE PROVISIONS ARE VOID AND CANNOT BE ENFORCED AGAINST YOU.

(A) A prohibition on the right of a franchisee to join an association of franchisees.

(B) A requirement that a franchisee assent to release, assignment, novation, waiver, or estoppel which deprives a franchisee of rights and protections provided in the Michigan Franchise Investment Law. This shall not preclude a franchisee, after entering into a franchise agreement, from settling any and all claims.

(C) A provision that permits a franchisor to terminate a franchise prior to the expiration of its term except for good cause. Good cause shall include the failure of the franchisee to comply with any lawful provision of the franchise agreement and to cure such failure after being given written notice thereof and a reasonable opportunity, which in no event need be more than 30 days, to cure such failure.

(D) A provision that permits a franchisor to refuse to renew a franchise without fairly compensating the franchisee by repurchase or other means for the fair market value at the time of expiration of the franchisee's inventory, supplies, equipment, fixtures, and furnishings. Personalized materials which have no value to the franchisor and inventory, supplies, equipment, fixtures and furnishings not reasonably required in the conduct of the franchise business are not subject to compensation. This subsection applies only if: (1) the term of the franchise is less than 5 years and (2) the franchisee is prohibited by the franchise or other agreement from continuing to conduct substantially the same business under another trademark, service mark, trade name, logotype, advertising, or other commercial symbol in the same area subsequent to the expiration of the franchise or the franchisee does not receive at least 6 months advance notice of the franchisor's intent not to renew the franchise.

(E) A provision that permits the franchisor to refuse to renew a franchise on terms generally available to other franchisees of the same class or type under similar circumstances. This section does not require a renewal provision.

(F) A provision requiring that arbitration or litigation be conducted outside this state. This shall not preclude the franchisee from entering into an agreement, at the time of arbitration, to conduct arbitration at a location outside this state.

(G) A provision which permits a franchisor to refuse to permit a transfer of ownership of a franchise, except for good cause. This subdivision does not prevent a franchisor from exercising a right of first refusal to purchase the franchise. Good cause shall include, but is not limited to:

(1) the failure of the proposed transferee to meet the franchisor's then current reasonable qualifications or standards.
(2) the fact that the proposed transferee is a competitor of the franchisor or subfranchisor.
(3) the unwillingness of the proposed transferee to agree in writing to comply with all lawful obligations.
(4) the failure of the franchisee or proposed transferee to pay any sums owing to the franchisor or to cure any default in the franchise agreement existing at the time of the proposed transfer.

(H) A provision that requires the franchisee to resell to the franchisor items that are not uniquely identified with the franchisor. This subdivision does not prohibit a provision that grants to a franchisor a right of first refusal to purchase the assets of a franchise on the same terms and conditions as a bona fide third party willing and able to purchase those assets, nor does this subdivision prohibit a provision that grants the franchisor the right to acquire the assets of a franchise for the market or appraised value of such assets if the franchisee has breached the lawful provision of the franchise agreement and has failed to cure the breach in the manner provided in subdivision (C).

(I) A provision which permits the franchisor to directly or indirectly convey, assign, or otherwise transfer its obligations to fulfill contractual obligations to the franchisee unless provision has been made for providing the required contractual services.

THE FACT THAT THERE IS A NOTICE OF THIS OFFERING ON FILE WITH THE ATTORNEY GENERAL DOES NOT CONSTITUTE APPROVAL, RECOMMENDATION, OR ENDORSEMENT BY THE ATTORNEY GENERAL.

ANY QUESTIONS REGARDING THIS NOTICE SHOULD BE ADDRESSED TO:
DEPARTMENT OF ATTORNEY GENERAL
CONSUMER PROTECTION DIVISION
670 LAW BUILDING, 525 W. OTTAWA STREET
LANSING, MICHIGAN 48913
Telephone (517) 373-7117

ADDENDUM TO AMERISOURCEBERGEN DRUG CORPORATION DISCLOSURE DOCUMENT
FOR THE STATE OF MINNESOTA

1. The Commissioner of Commerce for the State of Minnesota requires that certain provisions in franchise documents be amended to be consistent with Minnesota Franchise Act, Minn. Stat. Section 80.01 et seq., and of the Rules and Regulations promulgated under the Act (collectively the “Minnesota Act”). To the extent that the Franchise Agreement and Franchise Disclosure Document have provisions that are inconsistent with the following, such provisions are hereby amended:

a. The Minnesota Department of Commerce requires that ABDC indemnify Minnesota franchisees against liability to third parties resulting from claims by third parties that a franchisee's use of the Marks infringes trademark rights of the third party. ABDC does not indemnify against the consequences of Customer's use of the Marks except in accordance with the requirements of the Franchise Agreement, and, as a condition to indemnification, Customer must provide notice to ABDC of any such claim within ten (10) days after the earlier of (i) actual notice of the claim or (ii) receipt of written notice of the claim, and must therein tender the defense of the claim to ABDC. If ABDC accepts the tender of defense, ABDC has the right to manage the defense of the claim including the right to compromise, settle or otherwise resolve the claim, and to determine whether to appeal a final determination of the claim. If either the Franchise Agreement or the Franchise Disclosure Document has a provision that is inconsistent with the Minnesota Act, such provision will be superseded by the Minnesota Act's requirements and will have no force or effect.

b. Minnesota Act, Sec. 80C.14, Subd. 4., requires, except in certain specified cases, that Customer be given written notice of ABDC's intention not to renew 180 days prior to expiration of the franchise and that Customer be given sufficient opportunity to operate the franchise in order to enable Customer the opportunity to recover the fair market value of the franchise as a going concern. If either the Franchise Agreement or the Franchise Disclosure Document has a provision that is inconsistent with the Minnesota Act, such provision will be superseded by the Minnesota Act's requirements and will have no force or effect.

c. Minnesota Act, Sec. 80C.14, Subd. 3., requires, except in certain specified cases, that Customer be given 90 days' notice of termination (with 60 days to cure). If either the Franchise Agreement or the Franchise Disclosure Document has a provision that is inconsistent with the Minnesota Act, such provision will be superseded by the Minnesota Act's requirements and will have no force or effect.

d. Minn. Rule 2860.4400(D) prohibits ABDC from requiring Customer to assent to a general release. If either the Franchise Agreement or the Franchise Disclosure Document requires Customer to execute a release of claims or to acknowledge facts that would negate or remove from judicial review any statement, misrepresentation or action that would violate the Franchise Act, such release will exclude claims arising under the Minnesota Act, and such acknowledgments will be void with respect to claims under the Minnesota Act.

e. Minnesota Statutes, Section 80C.21 and Minn. Rule 2860.4400(J) prohibit ABDC from requiring litigation to be conducted outside Minnesota, requiring waiver of a jury trial or requiring Customer to consent to liquidated damages, termination penalties or judgment notes. In addition, nothing in the Franchise Agreement or the Franchise Disclosure Document can abrogate or reduce Customer's rights under Minnesota Statutes, Chapter 80C or Customer's rights to any procedure, forum or remedies provided for by the laws of the jurisdiction.

No statement, questionnaire, or acknowledgment signed or agreed to by a franchisee in connection with the commencement of the franchise relationship shall have the effect of (i) waiving any claims under any applicable state franchise law, including fraud in the inducement, or (ii) disclaiming reliance on any statement made by any franchisor, franchise seller, or other person acting on behalf of the franchisor. This provision supersedes any other term of any document executed in connection with the franchise.

Notwithstanding anything contained in the franchise agreement or area development agreement to the contrary, you do not have to pay us the initial franchise fee until we perform our pre-opening obligations under the franchise agreement, and your first franchised business is open. Once we complete this obligation and you are open, you must immediately pay us all initial fees we deferred.

ADDENDUM TO AMERISOURCEBERGEN DRUG CORPORATION DISCLOSURE DOCUMENT FOR THE STATE OF NEW YORK

1. Item 3 of the Disclosure Document is supplemented by the following language: Except as described in Item 3:

   Neither we nor any person identified in Item 2 above, has pending any administrative, criminal or material civil action (or a significant number of civil actions irrespective of materiality) alleging a violation of any franchise law, securities law, fraud, embezzlement, fraudulent conversion, restraint of trade, unfair or deceptive practices, misappropriation of property or comparable allegations.

   Neither we nor any person identified in Item 2 above, has been convicted of a felony or pleaded nolo contendere to a felony charge or, within the ten-year period immediately preceding the date of this Disclosure Document, has been convicted of a misdemeanor or pleaded nolo contendere to a misdemeanor charge or been held liable in a civil action by final judgment or been the subject of a material complaint or other legal proceeding if such misdemeanor conviction or charge or civil action, complaint or other legal proceeding involved a violation of any franchise law, securities law, fraud, embezzlement, fraudulent conversion, restraint of trade, unfair or deceptive practices, misappropriation of property or comparable allegations.

   Neither we nor any person identified in Item 2 above, is subject to any injunctive or restrictive order or decree relating to franchises or under any Federal, State or Canadian franchise, securities, antitrust, trade regulation or trade practice law as a result of a concluded or pending action or proceeding brought by a public agency, is subject to any currently effective order of any national securities association or national securities exchange, as defined in the Securities and Exchange Act of 1934, suspending or expelling such person from membership in such association or exchange; or is subject to a currently effective injunctive or restrictive order relating to any other business activity as a result of an action brought by a public agency or department, including, without limitation, actions affecting a license as a real estate broker or sales agent.

2. Item 4 of the Disclosure Document is supplemented by the following language:

   Neither we, nor any of our affiliates or predecessors described in Item 1, or officers or general partners described in Item 2 have within the 10-year period immediately before the date of this Disclosure Document: (a) filed as a debtor (or had filed against it) a petition to start an action under U.S. Bankruptcy Code; (b) obtained a discharge of its debts under the U.S. Bankruptcy Code; or (c) was a principal officer of a company or general partner in a partnership that either filed as a debtor (or that had filed against it)a petition to start an action under U.S. Bankruptcy Code or that obtained a discharge of its debts under the U.S. Bankruptcy Code during or within 1 year after the officer or general partner held the position with the company or partnership.

3. Item 17, “Renewal, Termination, Transfer and Dispute Resolution”, shall be supplemented under the categories entitled “Termination by Franchisee” and “Assignment of Contract by Franchisor” respectively, by the following language which shall be deemed an integral part thereof:

   Any general release required under the GNP Premier Agreement shall be limited by the following, “All rights arising in your favor from the provisions of General Business Law of the State of New York, Article 33 and regulations issued thereunder shall remain in force; it being the intent of this proviso that the non-waiver provisions of GBL, Sections 687.4 and 687.5 be satisfied.”

   You have whatever rights you may have under applicable law to terminate the GNP Premier Agreement.

   No assignment will be made except to an Assignee who, in our opinion, is willing and able to assume our obligations under the GNP Premier Agreement.

   The GNP Premier Agreement requires the application of Pennsylvania law~~,~~; however, the choice of law provision should not be considered a waiver of any right conferred on the franchisee by GBL, Article 33.

No statement, questionnaire, or acknowledgment signed or agreed to by a franchisee in connection with the commencement of the franchise relationship shall have the effect of (i) waiving any claims under any applicable state franchise law, including fraud in the inducement, or (ii) disclaiming reliance on any statement made by any franchisor, franchise seller, or other person acting on behalf of the franchisor. This provision supersedes any other term of any document executed in connection with the franchise.

ADDENDUM TO AMERISOURCEBERGEN DRUG CORPORATION DISCLOSURE DOCUMENT FOR THE STATE OF NORTH DAKOTA

1. Item 17(i) of the Disclosure Document is amended by the addition of the following language:

If the GNP Premier Agreement contains a liquidated damages clause, under Section 51-19-09 of the North Dakota Franchise Investment Law, certain liquidated damages clauses are unenforceable.

2. The State Cover Page and Item 17.w. are amended by the addition of the following language:

The GNP Premier Agreement requires the application of the laws of Pennsylvania. This provision may be unenforceable under North Dakota Law.

No statement, questionnaire, or acknowledgment signed or agreed to by a franchisee in connection with the commencement of the franchise relationship shall have the effect of (i) waiving any claims under any applicable state franchise law, including fraud in the inducement, or (ii) disclaiming reliance on any statement made by any franchisor, franchise seller, or other person acting on behalf of the franchisor. This provision supersedes any other term of any document executed in connection with the franchise.

ADDENDUM TO AMERISOURCEBERGEN DRUG CORPORATION
DISCLOSURE DOCUMENT
FOR THE STATE OF RHODE ISLAND

1. Item 17 of the Disclosure Document is amended to state that Section 19-28.1-14 of the Rhode Island Franchise Investment Act provides that any provision in the GNP Premier Agreement restricting jurisdiction or venue to a forum outside of Rhode Island or requiring the application of the laws of another state is void with respect to a claim otherwise enforceable under this Act.

ADDENDUM TO AMERISOURCEBERGEN DRUG CORPORATION
DISCLOSURE DOCUMENT
FOR THE STATE OF VIRGINIA

1. In recognition of the restrictions contained in Section 13.1-564 of the Virginia Retail Franchising Act, Items 17.e. and 17.h. of the Franchise Disclosure Document are supplemented by the following:

> "Under Section 13.1-564 of the Virginia Retail Franchising Act, it is unlawful for a franchisor to cancel a franchise without reasonable cause. If any ground for default or termination stated in the GNP Premier Agreement do not constitute "reasonable cause", as that term may be defined in the Virginia Retail Franchising Act or the laws of Virginia, that provision may not be enforceable."

No statement, questionnaire, or acknowledgment signed or agreed to by a franchisee in connection with the commencement of the franchise relationship shall have the effect of (i) waiving any claims under any applicable state franchise law, including fraud in the inducement, or (ii) disclaiming reliance on any statement made by any franchisor, franchise seller, or other person acting on behalf of the franchisor. This provision supersedes any other term of any document executed in connection with the franchise.

The Virginia State Corporation Commission's Division of Securities and Retail Franchising requires us to defer payment of the initial franchise fee and other initial payments owed by franchisees to the franchisor until the franchisor has completed its pre-opening obligations under the franchise agreement.

ADDENDUM TO AMERISOURCEBERGEN DRUG CORPORATION
DISCLOSURE DOCUMENT
FOR THE STATE OF WASHINGTON

In the event of a conflict of laws, the provisions of the Washington Franchise Investment Protection Act, Chapter 19.100 RCW will prevail.

RCW 19.100.180 may supersede the franchise agreement in your relationship with the franchisor including the areas of termination and renewal of your franchise. There may also be court decisions which may supersede the franchise agreement in your relationship with the franchisor, including the areas of termination and renewal of your franchise.

In any arbitration or mediation involving a franchise purchased in Washington, the arbitration or mediation site will be either in the state of Washington, or in a place mutually agreed upon at the time of the arbitration or mediation, or as determined by the arbitrator or mediator at the time of arbitration or mediation. In addition, if litigation is not precluded by the franchise agreement, a

franchisee may bring an action or proceeding arising out of or in connection with the sale of franchises, or a violation of the Washington Franchise Investment Protection Act, in Washington.

A release or waiver of rights executed by a franchisee may not include rights under the Washington Franchise Investment Protection Act or any rule or order thereunder except when executed pursuant to a negotiated settlement after the agreement is in effect and where the parties are represented by independent counsel. Provisions such as those which unreasonably restrict or limit the statute of limitations period for claims under the Act, or rights or remedies under the Act such as a right to a jury trial, may not be enforceable.

Transfer fees are collectable to the extent that they reflect the franchisor's reasonable estimated or actual costs in effecting a transfer.

Pursuant to RCW 49.62.020, a noncompetition covenant is void and unenforceable against an employee, including an employee of a franchisee, unless the employee's earnings from the party seeking enforcement, when annualized, exceed $100,000 per year (an amount that will be adjusted annually for inflation). In addition, a noncompetition covenant is void and unenforceable against an independent contractor of a franchisee under RCW 49.62.030 unless the independent contractor's earnings from the party seeking enforcement, when annualized, exceed $250,000 per year (an amount that will be adjusted annually for inflation). As a result, any provisions contained in the franchise agreement or elsewhere that conflict with these limitations are void and unenforceable in Washington.

RCW 49.62.060 prohibits a franchisor from restricting, restraining, or prohibiting a franchisee from (i) soliciting or hiring any employee of a franchisee of the same franchisor or (ii) soliciting or hiring any employee of the franchisor. As a result, any such provisions contained in the franchise agreement or elsewhere are void and unenforceable in Washington. The undersigned does hereby acknowledge receipt of this addendum.

In lieu of an impound of franchise fees, the Franchisor will not require or accept the payment of any initial franchise fees until the franchisee has (a) received all initial training that it is entitled to under the franchise agreement or offering circular, and (b) is open for business.

No statement, questionnaire, or acknowledgment signed or agreed to by a franchisee in connection with the commencement of the franchise relationship shall have the effect of (i) waiving any claims under any applicable state franchise law, including fraud in the inducement, or (ii) disclaiming reliance on any statement made by any franchisor, franchise seller, or other person acting on behalf of the franchisor. This provision supersedes any other term of any document executed in connection with the franchise.

ADDENDUM TO AMERISOURCEBERGEN DRUG CORPORATION DISCLOSURE DOCUMENT FOR THE STATE OF WISCONSIN

1. Item 17 of the Disclosure Document is amended to state that the Wisconsin Fair Dealership Law (the "Wisconsin Act") supersedes any provisions contained in the Disclosure Document or the GNP Premier Agreement that are inconsistent with the Wisconsin Act.

State Effective Dates

The following states have franchise laws that require that the Franchise Disclosure Document be registered or filed with the states, or be exempt from registration: California, Hawaii, Illinois, Indiana, Maryland, Michigan, Minnesota, New York, North Dakota, Rhode Island, South Dakota, Virginia, Washington, and Wisconsin.

This document is effective and may be used in the following states, where the document is filed, registered, or exempt from registration, as of the Effective Date stated below:

State	Effective Date
California	~~Exempt~~
Florida	~~Effective~~
Hawaii	~~Effective~~
Illinois	~~Exempt~~
Indiana	~~Exempt~~
Maryland	~~January 8, 2025~~
Michigan	~~Effective~~
Minnesota	~~Pending~~
New York	~~Exempt~~
North Dakota	~~Pending~~
Rhode Island	~~December 30, 2024~~
South Dakota	~~Effective~~
Utah	~~Effective~~
Virginia	~~January 8, 2025~~
Washington	~~Pending~~
Wisconsin	~~December 19, 2024~~

Other states may require registration, filing, or exemption of a franchise under other laws, such as those that regulate the offer and sale of business opportunities or seller-assisted marketing plans.

In all other states, the effective date of this Franchise Disclosure Document is the Issuance Date of: December ~~19, 2024~~18, 2025.

AmerisourceBergen

GOOD NEIGHBOR PHARMACY

ITEM 23
RECEIPT

This Disclosure Document summarizes provisions of the GNP Premier Agreement and other information in plain language. Read this Disclosure Document and all agreements carefully.

If AmerisourceBergen Drug Corporation offers you a franchise, AmerisourceBergen Drug Corporation must provide this Disclosure Document to you 14 calendar days before you sign a binding agreement or make any payment to AmerisourceBergen Drug Corporation or an affiliate in connection with the proposed franchise sale. Under Michigan and Wisconsin law, AmerisourceBergen Drug Corporation must provide this Disclosure Document to you 10 business days before you sign any contract or make any payment relating to the franchise relationship. Under Oklahoma, New York and Rhode Island law, AmerisourceBergen Drug Corporation must provide this Disclosure Document to you at the earliest of the first personal meeting or 10 business days before you sign any contract or make any payment relating to the franchise relationship.

If AmerisourceBergen Drug Corporation does not deliver this Disclosure Document on time, or if it contains a false or misleading statement, or a material omission, a violation of federal and state law may have occurred and should be reported to the Federal Trade Commission, Washington, D.C. 20590 or the appropriate state agency listed in Exhibit A.

The name and address of our registered agent authorized to receive service of process is shown in Exhibit A.

The franchise seller's name(s), business address(es) and telephone number(s) is(are):

_____

_____

I have received a Franchise Disclosure Document with an issuance date of December ~~19, 2024~~18, 2025. State registration effective dates are listed on the State Registrations Page. This Disclosure Document included the following Exhibits:

A. State Administrators/Agents for Service of Process
B. GNP Premier Agreement with Exhibits A-E and Term Sheets 1-10
C. Table of Contents of GNP Manual
D. List of Current, Transferred & Former Franchisees
E. Financial Statements and Cencora Guaranty
F. Addendum to Disclosure Document

PROSPECTIVE FRANCHISEE:

Signed by: _____

Print Name: _____

Date: _____

Please sign this Receipt and return it (fax or mail) to:

Good Neighbor Pharmacy Programs
1 West First Avenue, Conshohocken, PA, 19428
Fax 610-862-3718.

ITEM 23
RECEIPT

This Disclosure Document summarizes provisions of the GNP Premier Agreement and other information in plain language. Read this Disclosure Document and all agreements carefully.

If AmerisourceBergen Drug Corporation offers you a franchise, AmerisourceBergen Drug Corporation must provide this Disclosure Document to you 14 calendar days before you sign a binding agreement or make any payment to AmerisourceBergen Drug Corporation or an affiliate in connection with the proposed franchise sale. Under Michigan and Wisconsin law, AmerisourceBergen Drug Corporation must provide this Disclosure Document to you 10 business days before you sign any contract or make any payment relating to the franchise relationship. Under Oklahoma, New York and Rhode Island law, AmerisourceBergen Drug Corporation must provide this Disclosure Document to you at the earliest of the first personal meeting or 10 business days before you sign any contract or make any payment relating to the franchise relationship.

If AmerisourceBergen Drug Corporation does not deliver this Disclosure Document on time, or if it contains a false or misleading statement, or a material omission, a violation of federal and state law may have occurred and should be reported to the Federal Trade Commission, Washington, D.C. 20590 or the appropriate state agency listed in Exhibit A.

The name and address of our registered agent authorized to receive service of process is shown in Exhibit A.

The franchise seller's name(s), business address(es) and telephone number(s) is(are):

_____

_____

I have received a Franchise Disclosure Document with an issuance date of December ~~19, 2024~~18, 2025. State registration effective dates are listed on the State Registrations Page. This Disclosure Document included the following Exhibits:

A.	State Administrators/Agents for Service of Process
B	GNP Premier Agreement with Exhibits A-E and Exhibits 1-10
C.	Table of Contents of GNP Manual
D.	List of Current, Transferred & Former Franchisees
E.	Financial Statements and Cencora Guaranty
F.	Addendum to Disclosure Document

PROSPECTIVE FRANCHISEE:

Signed by: _____

Print Name: _____

Date: _____

Please retain this Receipt for your records.